<SEC-DOCUMENT>0001193125-13-410690.txt : 20131025
<SEC-HEADER>0001193125-13-410690.hdr.sgml : 20131025
<ACCEPTANCE-DATETIME>20131025080116
ACCESSION NUMBER:		0001193125-13-410690
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131025
DATE AS OF CHANGE:		20131025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORAGENICS INC
		CENTRAL INDEX KEY:			0001174940
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				593410522
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32188
		FILM NUMBER:		131169286

	BUSINESS ADDRESS:	
		STREET 1:		4902 EISENHOWER BLVD
		STREET 2:		SUITE 125
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33634
		BUSINESS PHONE:		8132867900

	MAIL ADDRESS:	
		STREET 1:		4902 EISENHOWER BLVD
		STREET 2:		SUITE 125
		CITY:			TAMPA
		STATE:			FL
		ZIP:			33634
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d594509d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended September&nbsp;30, 2013. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For
the transition period from <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: 001-32188 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ORAGENICS,
INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>FLORIDA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>59-3410522</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>4902 Eisenhower Blvd., Suite 125 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Tampa, Florida 33634 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>813-286-7900 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Issuer&#146;s telephone number) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such
reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer, &#147;accelerated filer,&#148; &#147;non-accelerated
filer,&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate the number of shares outstanding of each of the issuer&#146;s classes of common equity, as of the latest practicable date: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of October&nbsp;25, 2013, there were 30,506,685 shares of Common Stock, $.001 par value, outstanding. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="3" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><A NAME="toc"></A>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc594509_1"><U>PART I &#150; FINANCIAL INFORMATION</U></A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_2">Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_3">Balance Sheets as of September 30, 2013 (unaudited) and December 31, 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_4">Statements of Operations for the Three and Nine Months Ended September 30, 2013 and 2012
(unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_5">Statements of Cash Flows for the Nine Months Ended September 30, 2013 and 2012 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_6">Notes to Financial Statements (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_7">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_8">Quantitative and Qualitative Disclosures About Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_9">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><A HREF="#toc594509_10">PART II &#150; OTHER INFORMATION</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_11">Legal Proceedings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;1A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_12">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_13">Unregistered Sales of Equity Securities and Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_14">Defaults Upon Senior Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_15">Mine Safety Disclosures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_16">Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item&nbsp;6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_17">Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc594509_18">Signatures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_1"></A>PART I &#150; FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_2"></A>ITEM&nbsp;1. FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc594509_3"></A>Oragenics, Inc. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Balance Sheets </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,267,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,925,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivables, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,777,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,403,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,815,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,488,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Liabilities and Shareholders&#146; Equity</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,364,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,157,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term notes payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible note payable to shareholder</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,956,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,452,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,256,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, no par value; 20,000,000 shares authorized; none issued and outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.001 par value; 50,000,000 shares authorized; 30,168,613 and 27,382,830 shares issued and outstanding at
September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,408,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,290,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(67,075,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(54,086,362</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,362,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,231,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,815,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,488,132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc594509_4"></A>Oragenics, Inc. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Operations </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months Ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">253,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">264,248</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">597,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">901,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost of sales</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross profit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">333,459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,907,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,289,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,130,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,558,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,596,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,180,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,740,022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,465,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,470,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,870,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,325,465</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,096,573</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,136,857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,444,146</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(456,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,339</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(654,611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Local business tax</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,776</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,824</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,056</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,503</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(459,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(657,474</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,325,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,555,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,989,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,101,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,325,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,555,941</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,989,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,101,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.34</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.47</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used to compute basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,515,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,793,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,496,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,578,448</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc594509_5"></A>Oragenics, Inc. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Statements of Cash Flows </B></P>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Nine&nbsp;Months&nbsp;Ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,989,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,101,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology access fee paid in common stock and convertible note payable to shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,798,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of discount on notes payable to shareholder</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">483,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,624,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,057,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Write off of expired inventory</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(240,005</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:11.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:11.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Inventory, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">140,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:11.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:11.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280,353</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(104,556</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:11.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,545,205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,470,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings under note payable to shareholder</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings under convertible secured note payable to shareholder</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments on short-term notes payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(96,788</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of income taxes associated with stock based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,939,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,913,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash released</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,763</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,904,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,057,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,658,079</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,586,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,925,967</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,739</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,267,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,757,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Supplemental disclosure of cash flow information:</I></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:9.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Non-cash investing and financing activities:</I></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Borrowings under short term notes payable for prepaid expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">157,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">134,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Par value of common stock issued for cashless exercise of warrants</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of convertible note payable and accrued interest to common shares and warrants</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,275,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount on note payable to shareholder for warrants issued</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">483,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Par value of forfeited stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair market value of the 771,169 warrants issued to Griffin Securities, Inc. as a reduction in paid in capital from issuance of common
stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,850,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc594509_6"></A>Oragenics, Inc. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Organization </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oragenics, Inc. (formerly known as Oragen, Inc.) (the &#147;Company&#148; or &#147;we&#148;) was incorporated in November 1996; however,
operating activity did not commence until 1999. The Company is focused on the discovery, development and commercialization of a variety of technologies associated with broad spectrum antibiotics, oral health, and other general health benefits. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of Presentation </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim financial statements as of September&nbsp;30, 2013 and December&nbsp;31, 2012 (audited) and for the three
and nine months ended September&nbsp;30, 2013 and 2012 have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) for interim financial information and with the instructions to
Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements include all
adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the financial condition, results of operations and cash flows for the periods presented. The results of operations for the interim period September&nbsp;30,
2013 are not necessarily indicative of the results that may be expected for the year ending December&nbsp;31, 2013 or any future period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial
statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December&nbsp;31, 2012, which are included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on
March&nbsp;26, 2013. The Company has incurred recurring losses and negative cash flows from operations since inception. To date the Company has not generated significant revenues from operations. The Company generated revenues of $597,449, incurred
a net loss of $12,989,419, and used cash of $5,545,205 in its operating activities during the nine months ended September&nbsp;30, 2013. As of September&nbsp;30, 2013, the Company had an accumulated deficit of $(67,075,781). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2012 and 2011, a significant source of debt and equity funding was provided to the Company by its largest shareholder, the Koski Family Limited
Partnership (the &#147;KFLP&#148;). In 2012 the Company raised $13,000,000 in gross proceeds through the private placement sale of its common stock. In 2013 the company raised $3,900,000 in gross proceeds through the private placement of its common
stock. The Company expects to incur substantial expenditures to further develop each of its technologies. The Company believes the working capital at September&nbsp;30, 2013 will be sufficient to meet the business objectives as presently structured
through December 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s ability to continue operations after its current cash resources are exhausted depends on its ability to obtain
additional financing or achieve profitable operations, as to which no assurances can be given. Cash requirements may vary materially from those now planned because of changes in the Company&#146;s focus and direction of its research and development
programs, competitive and technical advances, or other developments. Additional financing will be required to continue operations after the Company exhausts its current cash resources and to continue its long-term plans for clinical trials and new
product development. There can be no assurance that any such financing can be realized by the Company, or if realized, what the terms thereof may be, or that any amount that the Company is able to raise will be adequate to support the Company&#146;s
working capital requirements until it achieves profitable operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to seek additional funding through sublicensing arrangements,
joint venturing or partnering, sales of rights to technology, government grants and public or private financings. The Company&#146;s future success depends on its ability to raise capital and ultimately generate revenue and attain profitability. The
Company cannot be certain that additional capital, whether through selling additional debt or equity securities or obtaining a line of credit or other loan, will be available to it or, if available, will be on terms acceptable to the Company. If the
Company issues additional securities to raise funds, these securities may have rights, preferences, or privileges senior to those of its common stock, and the Company&#146;s current shareholders may experience dilution. If the Company is unable to
obtain funds when needed or on acceptable terms, the Company may be required to curtail their current development programs, cut operating costs and forego future development and other opportunities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Significant Accounting Policies </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no new accounting pronouncements issued or effective during the second quarter of 2013 that have had or are expected to have an impact on the
Company&#146;s financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
estimates. The principal areas of estimation reflected in the financial statements are stock-based compensation, valuation of warrants, inventory obsolescence reserve, sales returns and allowances and the allowance for doubtful accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Financial Instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of
the Company&#146;s cash and cash equivalents, accounts payable and accrued expenses approximate their carrying values due to their short-term nature. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Guaranteed Rights of Return </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has granted
guaranteed rights of return to two dental distributors. The Company defers recognition of revenue on these accounts until either the distributor provides notification to the Company that the product has been sold to the end consumer or the
guaranteed right of return period expires. Once notification has been received and verified, the Company records revenue in that accounting period. The Company had $23,711 and $27,812 of revenue deferred under guaranteed rights of return
arrangements included in deferred revenue in the balance sheets as of September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Inventory
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inventory is stated at the lower of cost or market. Cost, which includes material, labor and overhead, is determined on a first-in, first-out basis.
On a quarterly basis, we analyze our inventory levels and reserve for inventory that is expected to expire prior to being sold, inventory that has a cost basis in excess of its expected net realizable value, inventory in excess of expected sales
requirements, or inventory that fails to meet commercial sale specifications. Expired inventory is disposed of and the related costs are written off to the reserve for inventory obsolescence. The inventory reserve was approximately $22,000 and
$253,000 as of September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Payment Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, all forms of stock-based payments, including stock option grants, warrants, and restricted stock grants are measured at their fair value on the
awards&#146; grant date typically using a Black-Scholes pricing model. Stock-based compensation awards issued to non-employees for services rendered are recorded at the fair value of the stock-based payment. The expense resulting from stock-based
payments are recorded in research and development expense or selling, general and administrative expense in the statement of operations, depending on the nature of the services provided. Stock-based payment expense is recorded over the requisite
service period in which the grantee provides services to us. To the extent the stock option grants, warrants, or restricted stock grants do not vest at the grant date they are subject to forfeiture. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GAAP requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their
fair values as of the grant date. Stock-based compensation expense is recorded over the requisite service period in which the grantee provides services to us, to the extent the options do not vest at the grant date and are subject to forfeiture. For
performance-based awards that do not include market-based conditions, we record share-based compensation expense only when the performance-based milestone is deemed probable of achievement. We utilize both quantitative and qualitative criteria to
judge whether milestones are probable of achievement. For awards with market-based performance conditions, we recognize the grant-date fair value of the award over the derived service period regardless of whether the underlying performance condition
is met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company used the Black Scholes
Option Pricing Model in calculating the relative fair value of any warrants that have been issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Net Loss Per Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During all periods presented, the Company had securities outstanding that could potentially dilute basic earnings per share in the future, but were excluded
from the computation of diluted net loss per share, as their effect would have been antidilutive. Because the Company reported a net loss for all periods presented, shares associated with the stock options and warrants are not included because they
are antidilutive. Basic and diluted net loss per share amounts are the same for the periods presented. Net loss per share is computed using the weighted average number of shares of common stock outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes revenues from
the sales of product when title and risk of loss pass to the customer, which is generally when the product is shipped. Grant revenues are recognized as the reimbursable expenses are incurred over the life of the related grant. Grant revenues are
deferred when reimbursable expenses have not been incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records allowances for discounts and product returns at the time of sale as a
reduction of revenues as such allowances can be reliably estimated based on historical experience or known trends. The Company maintains a return policy that allows customers to return product within a specified period of time prior to and
subsequent to the expiration date of the product. The estimate of the provision for returns is analyzed quarterly and is based upon many factors, including industry data of product return rates, historical experience of actual returns, analysis of
the level of inventory in the distribution channel, if any, and reorder rates. If the history or product returns changes, the reserve will be adjusted. While the Company believes that the reserves it has established are reasonable and appropriate
based upon current facts and circumstances, applying different judgments to the same facts and circumstances would result in the estimated amounts for sales returns and chargebacks to vary. Because the ProBiora3 products are still relatively new to
the market, the Company could experience different circumstances in the future and these differences could be material. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentrations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is dependent on key suppliers to provide probiotics, blending, warehousing and packaging of its EvoraPlus, EvoraKids, EvoraPro, and Teddy&#146;s
Pride products. The Company had four key suppliers during the three and nine months ended September&nbsp;30, 2013 and 2012. The majority of the Company&#146;s cost of sales are from these key suppliers during the three and nine months ended
September&nbsp;30, 2013 and 2012. Accounts payable and accrued expenses for these vendors totaled approximately $-0- and $99,000 as of September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively. As of September&nbsp;30, 2013, the Company had a
prepaid balance of approximately $27,000 with one of these vendors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stock-based Compensation </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognized stock-based compensation on all employee and non-employee awards as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>September&nbsp;30, 2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended<BR>September&nbsp;30, 2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">183,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">105,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,575</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">116,726</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Selling, general and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,355,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">693,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,465,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">940,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Stock based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,538,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">799,391</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,624,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,057,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company granted -0- and 35,000 stock options, with a weighted-average grant date fair value of -0- and $3.41 per share,
during the three and nine months ended September&nbsp;30, 2013, respectively. The Company granted -0- and 100,000 stock options, with a weighted-average grant date fair value of $0 and $1.03 per share, during the three and nine months ended
September&nbsp;30, 2012, respectively. During the nine months ended September&nbsp;30, 2013, 50,533 stock options previously granted have vested, 56,050 stock options were forfeited and 31,533 included in outstanding stock options were exercised.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Included in the results for the September&nbsp;30, 2013 quarter is a liability and expense in the amount of $1,487,801 relating to probable awards under
the Company&#146;s 2012 Equity Incentive Plan (&#147;2012 Plan&#148;) pursuant to the Company&#146;s long term performance based incentive programs for certain members of management and independent directors that were triggered by the Probiotic ECC.
The liability and expense amount represents the grant date fair value of the 422,359 shares expected to be awarded under the 2012 Plan. See Note 8 &#150; Subsequent Events. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Warrants </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of warrant activity for the year ended December&nbsp;31, 2012 and the nine months ended September&nbsp;30, 2013 is as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance &#150; December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,942,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6.00</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance &#150; December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,235,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(288,888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19.87</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance &#150; September&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,747,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;31, 2013 Griffin Securities Inc. exercised 200,000 of their previously issued warrants resulting in the
issuance of 106,250 shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants outstanding as of September&nbsp;30, 2013 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="40%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="40%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:48.60pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exercise&nbsp;Price</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Warrants<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration&nbsp;Dates</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7/30/17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">2.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,170,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/23/15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">10.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/15/14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,747,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>



<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Short-term Notes Payable </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013 and December&nbsp;31, 2012, the Company had $108,220 and $47,977 respectively, in short-term notes payable for
the financing of various insurance policies. On March&nbsp;8, 2013, the Company entered into a short-term note payable for $50,037 bearing interest at 6.57% to finance the product liability insurance. Principal and interest payments on this note
began April&nbsp;10, 2013 and are made evenly based on a straight line amortization over a 10-month period with the final payment due on January&nbsp;10, 2014. On June&nbsp;20, 2013, we entered into a short-term note payable for $106,994 bearing
interest at 4.64% to finance a portion of the directors&#146; and officers&#146; liability insurance and employment practices liability insurance premiums. Principal and interest payments on this note began August&nbsp;24, 2013 and are made evenly
based on a straight line amortization over an 11-month period with the final payment due on June&nbsp;24, 2014. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Convertible Note Payable To Shareholder </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September 30, 2013, the Company entered into an unsecured short-term Convertible Promissory Note in the principal amount of $1,956,000
bearing interest at 3.00% as partial consideration for the Technology Access Fees associated with the Probiotic ECC (discussed below) entered into with Intrexon Corporation. The Convertible Promissory Note is payable, at the Company&#146;s option,
in cash or shares of the Company&#146;s common stock. Principal and accrued interest are due on December 31, 2013. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and Contingencies </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The University of Florida Research Foundation Licenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company holds exclusive licenses from the University of Florida Research Foundation, Inc. (&#147;UFRF&#148;) for its SMaRT Replacement Therapy and MU1140
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>MU1140 &#150;</I> The Company has exclusively licensed the intellectual property for our MU1140 lantibiotic
technology from the UFRF. The original license agreement was dated June&nbsp;22, 2000 and was subsequently amended on September&nbsp;15, 2000,&nbsp;July&nbsp;10, 2002,&nbsp;September&nbsp;25, 2002,&nbsp;March&nbsp;17, 2003 and April&nbsp;19, 2013.
The amended license agreement provides the Company with an exclusive worldwide license to make, use and sell products and processes covered by Patent No.&nbsp;5,932,469 entitled &#147;Antimicrobial Polypeptide, Nucleic Acid and Methods of Use&#148;
and includes U.S. patent numbers 6,964,760; 7,067,125; 6,391,285; 6,475,771 and foreign patents. The Company&#146;s license is for the period of the patents, which expire from 2017 through 2019, subject to the performance of terms and conditions
contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>SMaRT Replacement Therapy &#150;</I> The Company has exclusively licensed the intellectual property for its
replacement therapy technology from the UFRF. The original license agreement was dated August&nbsp;4, 1998 and was subsequently amended on September&nbsp;15, 2000,&nbsp;July&nbsp;10, 2002,&nbsp;September&nbsp;25, 2002,&nbsp;March&nbsp;17, 2003 and
April&nbsp;19, 2013. The amended license agreement provides the Company with an exclusive worldwide license to make, use and sell products and processes covered by Patent No.&nbsp;5,607,672, entitled &#147;Replacement Therapy for Dental
Caries&#148;, which was filed in the U.S. PTO on June&nbsp;7, 1995 and made effective on March&nbsp;4, 1997. The patent will expire on June&nbsp;7, 2015. The Company&#146;s license is for the period of the patent, subject to the performance of terms
and conditions contained therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Additional Terms of UFRF License Agreements &#150; </I>In the amended license agreements for SMaRT
Replacement Therapy and MU1140, the Company is obligated to pay 5% of the selling price of any products developed from the licensed technologies that the Company may sell as royalty to the UFRF. In addition, if the Company sublicenses any rights
granted by the amended license agreements, the Company is obligated to pay the UFRF 22% of all revenues received from the sublicenses, excluding monies received solely for development costs. The Company is also obligated to make the following
payments to UFRF as follows: a one-time commercialization fee, post-commercialization minimum royalty payments, and a one-time cumulative royalty payment. The one-time commercialization fee would be due on the first anniversary of first commercial
sale and is calculated at $5,000 per month between May&nbsp;1, 2013 and the month of the first anniversary of a commercial sale. The post-commercialization minimum royalty payments of $50,000 annually would be due following payment of a
commercialization fee. The one-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed $2.0 million, upon which we would be obligated to make a one-time additional payment to UFRF of 10% of the total
royalties due to UFRF in the calendar year in which cumulative royalties exceeded $2.0 million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is required to make minimum annual maintenance payments to the UFRF for the term of the amended
license agreements in the amount of $10,000 for each license agreement and $20,000 in aggregate. The aggregate minimum annual payments are required to be paid in advance on a quarterly basis (i.e. $5,000 per quarter) for both licenses. The Company
must also pay all patent costs and expenses incurred by the UFRF for the preparation, filing, prosecution, issuance and maintenance of the patents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The Exclusive Channel Collaboration (&#147;ECC&#148;) Agreements with Intrexon Corporation (&#147;Intrexon&#148;) </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company entered into an ECC Agreement (the &#147;Probiotics ECC&#148;) with Intrexon that governs a &#147;channel
collaboration&#148; arrangement in which the Company will use Intrexon&#146;s proprietary technology relating to the identification, design and production of genetically modified cells, DNA vectors and in vivo control of expression (the
&#147;Technology&#148;) for the development and commercialization of probiotics, specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus,
including, but not limited to, aphthous stomatitis and Behcet&#146;s disease (collectively, the &#147;Probiotics Program&#148;). The Probiotics ECC establishes committees comprised of Company and Intrexon representatives that will govern activities
related to the Probiotics Program in the areas of project establishment, chemistry, manufacturing and controls matters, clinical and regulatory matters, commercialization efforts and intellectual property matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Probiotics ECC grants the Company an exclusive worldwide license to utilize Intrexon&#146;s Technology to develop and commercialize probiotics,
specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus (&#147;Company Products&#148;). Such license is exclusive with respect to any clinical
development, selling, offering for sale or other commercialization of Company Products, and otherwise is non-exclusive. Subject to limited exceptions, the Company may not sublicense the rights described without Intrexon&#146;s written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Probiotics ECC, and subject to certain exceptions, the Company is responsible for, among other things, funding the further anticipated development
of probiotics toward the goal of commercialization, conducting preclinical and clinical development of candidate probiotics, as well as for other aspects of manufacturing and the commercialization of the product(s). Among other things, Intrexon is
responsible for technology discovery efforts, cell-engineering development, and certain aspects of the manufacturing process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will pay
Intrexon 10% of the net sales derived from the sale of products developed from the exclusive channel collaboration relating to the Probiotics Program. The Company has likewise agreed to pay Intrexon a percentage of revenue obtained from a
sublicensee in the event of a sublicensing arrangement. The percentage of the revenue to be paid will be determined at the time that a sublicense agreement is negotiated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may voluntarily terminate the Probiotics ECC upon 90 days written notice to Intrexon. Intrexon may also terminate the Probiotics ECC if the
Company breaches the Probiotics ECC and fails to cure the breach within 60 days or the Company does not pursue development of the Superior Therapy under the probiotics identified by Intrexon that is a &#147;Superior Therapy&#148; as defined in the
Probiotics ECC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon termination of the Probiotics ECC, the Company may continue to develop and commercialize any Company Product that, at the time of
termination, satisfies at least one of the following criteria: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commercialized by the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approved by regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the subject of at least an ongoing Phase 1, Phase 2 or Phase 3 clinical trial in the field of the Probiotics Program. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in partial consideration for each party&#146;s execution and delivery of the Probiotics ECC, on
September&nbsp;30, 2013 the Company entered into a Stock Purchase and Issuance Agreement and a First Amendment to the Stock Purchase and Issuance Agreement (collectively the &#147;SPIA&#148;) with Intrexon. Pursuant to the SPIA, the Company paid
Intrexon an up-front technology access fee of $6,000,000 (the &#147;Technology Access Fee&#148;) in consideration for the execution of the Probiotics ECC. The Technology Access Fee was paid to Intrexon by the Company through the (i)&nbsp;issuance of
1,348,000 shares (at $3.00 per share) of the Company&#146;s common stock (the &#147;Technology Access Shares&#148;), and (ii)&nbsp;a convertible promissory note in the amount of $1,956,000 which is payable, at the Company&#146;s option, in cash or
shares of Company common stock (the &#147;Convertible Note&#148;). The Convertible Note matures on December&nbsp;31, 2013 and requires the Company to obtain shareholder approval prior to conversion of the Convertible Note. The conversion price is
equal to the closing price per share of the Company&#146;s common stock on the last trading day immediately prior to the date of conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
September&nbsp;30, 2013 the Company also sold to Intrexon 1,300,000 shares of the Company&#146;s common stock at a price per share of $3.00 for gross proceeds of $3,900,000. The Company intends to use the proceeds from this sale of common stock
towards development of the Company&#146;s key initiatives relating to the Probiotics Program, and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the SPIA and as part
of the Probiotics ECC, the Company has also agreed to make certain payments to Intrexon upon the Company&#146;s achievement of designated milestones. The milestone payments are each payable to Intrexon, at the Company&#146;s election (subject to an
election right of Intrexon if the milestone is achieved by a sublicensee), either in cash or in shares of Company common stock (using the fair market value of the shares to calculate the number of shares to be issued to Intrexon in lieu of cash).
The Commercialization Milestone Events and amounts payable are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$2,000,000 within thirty (30)&nbsp;days of the dosing of a patient by or on behalf of the Company, or an Affiliate (as that term is defined in the Probiotics ECC) or permitted sublicensee of the Company, in a phase II
clinical trial, whether such occurs in the United States of America under the jurisdiction of the United States Food and Drug Administration (&#147;FDA&#148;) or elsewhere under the jurisdiction of a foreign regulatory agency, for a Company Product;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$5,000,000 within thirty (30)&nbsp;days of the first meeting of the primary endpoint by or on behalf of the Company, or an Affiliate or permitted sublicensee of the Company, in a phase III clinical trial, whether such
occurs in the United States of America under the jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency, for a Company Product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$10,000,000 within thirty (30)&nbsp;days of the first to occur of (a)&nbsp;the First Commercial Sale (as that term is defined in the Probiotics ECC) of a Company Product, or (b)&nbsp;the approval of a New Drug
Application (as that term is defined in the Probiotics ECC) for a Company Product by the FDA or equivalent regulatory action in a foreign jurisdiction. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the Probiotic ECC milestones had been achieved as of September&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2012, the Company entered into an ECC Agreement (the &#147;Lantibiotic ECC&#148;) with Intrexon that governs a &#147;channel
collaboration&#148; arrangement in which the Company will use Intrexon&#146;s advanced transgene and cell engineering platforms for the development and production of lantibiotics, a class of peptide antibiotics that are naturally produced in
Gram-positive bacteria and contain the characteristic polycyclic thioether amino acids lanthionine and methyllanthonine (collectively, the &#147;Lantibiotics Program&#148;). The Lantibiotic ECC establishes committees comprised of Company and
Intrexon representatives that will govern activities related to the Lantibiotics Program in the areas of project establishment, chemistry, manufacturing and controls matters, clinical and regulatory matters, commercialization efforts and
intellectual property matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Lantibiotic ECC grants the Company an exclusive worldwide license to use patents and other intellectual property of
Intrexon in connection with the research, development, use, importing, exporting, manufacture, sale, and offer for sale of drug products involving the direct administration to humans or companion animals of a lantibiotic for the prevention or
treatment of infectious disease (&#147;Oragenics Products&#148;). Such license is exclusive with respect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to any clinical development, selling, offering for sale or other commercialization of Oragenics Products, and otherwise is non-exclusive. Subject to limited exceptions, the Company may not
sublicense the rights described without Intrexon&#146;s written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Lantibiotic ECC, and subject to certain exceptions, the Company is
responsible for, among other things, funding the further anticipated development of lantibiotics toward the goal of commercialization, conducting preclinical and clinical development of candidate lantibiotics, as well as for other aspects of
manufacturing and the commercialization of the product(s). Among other things, Intrexon is responsible for technology discovery efforts, cell-engineering development, certain aspects of the manufacturing process, and costs of filing, prosecution and
maintenance of Intrexon&#146;s patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain expense allocations and other offsets provided in the Lantibiotic ECC, the Company will pay
Intrexon on a quarterly basis 25% of gross quarterly profits derived in that quarter from the sale of products developed from the Lantibiotic ECC, calculated on an Oragenics Product-by-Oragenics Product basis. The Company has likewise agreed to pay
Intrexon on a quarterly basis 50% of revenue obtained in that quarter from a sublicensor in the event of a sublicensing arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the first 18
months of the agreement, neither the Company nor Intrexon may terminate the ECC Agreement, except under limited circumstances, including in the event of a material breach by the other party and Intrexon may terminate the Lantibiotic ECC under
certain circumstances if the Company assigns its rights under the Lantibiotic ECC without Intrexon&#146;s consent. Following the first 12 months of the agreement, Intrexon may also terminate the Lantibiotic ECC if the Company fails to use diligent
efforts to develop and commercialize Oragenics Products or if the Company elects not to pursue the development of a Lantibiotics Program identified by Intrexon that is a &#147;Superior Therapy&#148; as defined in the Lantibiotic ECC. Following the
first 18 months of the agreement, the Company may voluntarily terminate the Lantibiotic ECC at any time upon 90 days written notice to Intrexon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon
termination of the Lantibiotic ECC, the Company may continue to develop and commercialize any Oragenics Product that has been, at the time of termination: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commercialized by the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approved by regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the subject of at least an ongoing Phase 1, Phase 2 or Phase 3 clinical trial in the Field (in the case of a termination by Intrexon due to an uncured material breach by the Company or a voluntary termination by the
Company). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s obligation to pay 25% of gross profits or revenue described above with respect to these &#147;retained&#148;
products as well as to use diligent efforts to develop and commercialize these &#147;retained&#148; Oragenics Products will survive termination of the Lantibiotic ECC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in partial consideration for each party&#146;s execution and delivery of the Lantibiotic ECC, the Company entered into a Stock Issuance Agreement
with Intrexon. Pursuant to the Stock Issuance Agreement, the Company issued to Intrexon 4,392,425 shares of the Company&#146;s common stock as an initial technology access fee, in consideration for the execution and delivery of the Lantibiotic ECC
and granted Intrexon certain equity participation rights and registration rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Stock Issuance Agreement and as part of the Lantibiotic ECC,
the Company has also agreed to make certain payments to Intrexon upon the Company&#146;s achievement of designated milestones in the form of shares of Company common stock or, at the Company&#146;s option, make a cash payment to Intrexon (based upon
the fair market value of the shares otherwise required to be issued). The milestone events and amounts payable are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">upon filing of the first Investigational New Drug application with the U.S. Food and Drug Administration for an Oragenics Product, that number of shares equal to the number of shares of common stock comprising 1.0% of
the Base Shares (as defined below); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">upon the dosing of the first patient in the first Phase 2 clinical study with an Oragenics Product, that number of shares equal to the number of shares of common stock comprising 1.5% of the Base Shares;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">upon the dosing of the first patient in the first Phase 3 clinical study with an Oragenics Product, that number of shares equal to the number of shares of common stock comprising 2% of the Base Shares;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">upon the filing of the first New Drug Application (&#147;NDA&#148;) or Biologics License Application (&#147;BLA&#148;) with the U.S. Food and Drug Administration for an Oragenics Product, or alternatively the filing of
the first equivalent regulatory filing with a foreign regulatory agency, that number of shares equal to the number of shares of Common Stock comprising 2.5% of the Base Shares; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">upon the granting of the first regulatory approval of an Oragenics Product, that number of shares equal to the number of shares of Common Stock comprising 3% of the Base Shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Base Shares is defined in the Stock Issuance Agreement to mean (i)&nbsp;the number of shares of Company common stock together with any securities or
instruments convertible or exercisable for shares of common stock issued and outstanding at the time of the applicable milestone event, (ii)&nbsp;minus any shares issuable upon conversion of Capital Inducement Securities. Capital Inducement
Securities is defined in the Stock Issuance Agreement to mean warrants or other convertible securities of the Company issued to investors in connection with a debt or equity investment in the Company that are issued in addition to the primary
investment securities and in an amount not to exceed 10% of the overall number of shares issued in the investment (on an as-converted to common stock basis). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the Lantibiotic ECC milestones had been achieved as of September&nbsp;30, 2013. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Subsequent Events </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2013, the Compensation Committee of the Board of Directors (the &#147;Board&#148;) of the Company met and determined
that one of the performance goals established in the Company&#146;s Long Term Incentive Programs (&#147;LTIP&#148;) as part of executive compensation and non-employee director compensation had been achieved. The performance goal met was the goal
related to the broadening of the Intrexon relationship to include a new area outside of lantibiotics. As a result of the Compensation Committee&#146;s determination, and pursuant to the LTIP, Dr.&nbsp;John Bonfiglio, the Company&#146;s Chief
Executive Officer, Michael Sullivan, the Company&#146;s Chief Financial Officer, and Dr.&nbsp;Martin Handfield, the Company&#146;s Vice President of Research and Development, were entitled to awards of 0.50%, 0.18%, and 0.17% respectively of the
Company&#146;s common stock outstanding at the time of the Compensation Committee&#146;s determination that such goal had been met. Accordingly, Dr.&nbsp;Bonfiglio, Mr.&nbsp;Sullivan, and Dr.&nbsp;Handfield were awarded 150,843, 54,304 and 51,287
shares of Company common stock under the Company&#146;s 2012 Equity Incentive Plan (the &#147;2012 Plan&#148;), respectively. Also on October&nbsp;18, 2013 the Board met and determined that a similar performance goal under the previously established
Long Term Incentive Program for the compensation of non-employee directors had been met. As a result, the Board approved the award of 33,185 shares of common stock under the Plan, to each of the Company&#146;s directors who were not employed by the
Company, including Frederick Telling, Charles Pope, Alan Dunton, Christine Koski and Robert Koski. In addition, the Board determined to amend its non-employee director compensation program. In connection with each annual meeting of shareholders
commencing with the 2013 Annual Meeting, each continuing non-employee director will be granted an award of 10,000 fully vested shares of the Company&#146;s common stock under the Company&#146;s 2012 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate shares awarded under the 2012 Plan of 422,359 consisted of a total of 165,925 shares to non-employee directors and 256,434 shares to executive
officers. Of the aggregate 422,359 shares awarded under the LTIP, (i)&nbsp;150,843 shares were awarded to Dr.&nbsp;Bonfiglio of which 50,000 shares were retained by the Company for applicable tax withholding obligations, (ii)&nbsp;54,304 shares were
awarded to Mr.&nbsp;Sullivan of which 19,000 shares were retained by the Company for applicable tax withholding obligation, (iii)&nbsp;51,287 shares were awarded to Dr.&nbsp;Handfield of which 15,287 shares were retained by the Company for
applicable tax withholding obligation, and (iv)&nbsp;33,185 shares were awarded to each of the five non-employee directors. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_7"></A>ITEM&nbsp;2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following information should be read in conjunction with the Financial Statements, including the notes
thereto, included elsewhere in this Form 10-Q. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This 10-Q contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended and Section&nbsp;21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking statements include statements regarding, among other things, (a)&nbsp;our need for and availability of working capital, (b)&nbsp;our financing plans, (c)&nbsp;our strategies,
(d)&nbsp;our projected sales and profitability, (e)&nbsp;anticipated trends in our industry. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the
words &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;believe,&#148; &#147;intend,&#148; or &#147;project&#148; or the negative of these words or other variations on
these words or comparable terminology. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results,
performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations as well as in this 10-Q
generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks outlined under &#147;Risk Factors&#148; in our Form 10-K and in
this 10-Q. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this filing will in fact occur. In addition to the information expressly required to be included in this filing, we will
provide such further material information, if any, as may be necessary to make the required statements, in light of the circumstances under which they are made, not misleading. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a healthcare company focused primarily
on developing novel antibiotics and oral health products. Within oral health we are marketing our oral health probiotics blend, ProBiora3, to consumers and to dental professionals. We also maintain a suite of other technologies stemming from several
years of our research efforts in the oral health space. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Antibiotics </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of our scientific team discovered that a certain bacterial strain produces MU1140, a molecule belonging to the novel class of antibiotics known as
lantibiotics. Lantibiotics, such as MU1140, are highly modified peptide antibiotics made by a small group of Gram positive bacterial species. Approximately 60 lantibiotics have been discovered since 1927 when the first lantibiotic, Nisin, was
discovered. Lantibiotics are generally recognized to be potent antibiotic agents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have performed preclinical testing on MU1140, which has demonstrated
the molecule&#146;s novel mechanism of action. MU1140 has proven active preclinically against all Gram positive bacteria against which it has been tested, including those responsible for a number of healthcare associated infections, or HAIs. The
most common HAIs are caused by drug-resistant bacteria, including methicillin-resistant<I> Staphylococcus aureus</I>, or MRSA, vancomycin-resistant<I> Enterococcus faecalis</I>, or VRE; and<I> Clostridium difficile,</I> or<I> C. diff</I>. We believe
the need for novel antibiotics is increasing as a result of the growing resistance of target pathogens to existing Food and Drug Administration (&#147;FDA&#148;) approved antibiotics on the market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The challenge presented by lantibiotics is that they have been difficult to investigate for their clinical usefulness as a therapeutic agent in the treatment
of infectious diseases due to a general inability to produce or synthesize sufficient quantities of pure amounts of any of these molecules. Standard fermentation methods are used to make a variety of currently marketed antibiotics. When such
fermentation methods are used to make lantibiotics the result is the production of only minute amounts of the lantibiotic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to meet the challenge associated with producing sufficient quantities of MU1140 for our clinical trials
and ultimately our commercialization efforts, we are pursuing the following path: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In June 2012, we entered into a worldwide exclusive collaboration agreement with Intrexon Corporation (&#147;Intrexon&#148;) for the development and commercialization of the native strain of MU1140 using Intrexon&#146;s
advanced transgene and cell engineering platforms (the &#147;Lantibiotic ECC&#148;). We expect to pursue our research and development efforts with Intrexon in accordance with the terms of the ECC on the development of the MU1140 molecule and
potential derivatives of the molecule. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have previously performed preclinical testing on native MU1140 and such testing has demonstrated
the molecule&#146;s novel mechanism of action. We have begun limited preclinical activities on MU1140 developed under the Lantibiotic ECC with Intrexon, in the second half of 2013. These preclinical activities are expected to include toxicity
results, pharmacokinetic studies, and efficacy studies in animals. This work will be done solely by us through the use of outside contractors. Pursuit of clinical trials toward the goal of ultimately obtaining regulatory approval will depend upon
further successful advancements in our research collaboration efforts with Intrexon and our efforts to have additional product manufactured. Developments from these efforts will dictate our regulatory path. If our preclinical work is successful, we
would expect to file an Investigational New Drug application with the FDA by the first quarter of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through our work with Intrexon, we have been able
to produce an exponential increase in the fermentation titer of the target compound MU1140 and the discovery of a new purification process for MU1140. We believe these developments represent progress toward our goal of commercial production of
sufficient quantities of MU1140 and deliver a step in validating the lantibiotics platform targeting infectious diseases. Previously, the ability to manufacture MU1140 by fermentation was originally thought not to be commercially feasible due to low
titers and difficulties in purification. In addition to the optimization of fermentation and purification strategies, we are working to leverage Intrexon&#146;s genetic and cell engineering expertise to produce analogs of MU1140 toward the goal of
establishing a pipeline of new lantibiotics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing requirements and methods for producing MU1140, or an analog, will primarily be dependent upon
the end results of our efforts under the ECC with Intrexon. We are actively seeking a third party manufacturer to produce additional quantities of MU1140, or a designated analog, based upon the developments achieved from our work with Intrexon. The
additional quantities of MU1140, or a designated analog, are needed for the consummation and pursuit of our preclinical testing activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also
produced a synthetic version of MU1140 known as MU1140-S. We created MU1140-S using our patented, novel organic chemistry synthesis platform known as DPOLT (Differentially Protected Orthogonal Lanthionine Technology). We engaged Bachem Americas,
Inc. (&#147;Bachem&#148;), a peptide synthesis manufacturing company to assist us with research on producing greater amounts of MU1140-S. While the work performed by Bachem generated improvements in the yield of components necessary to synthesize
MU1140-S, further research was determined to be needed, which was beyond the scope of our initial agreement with Bachem. While we continue to pursue this research internally through the use of existing grant funds, at this time our primary focus is
with ongoing research and development efforts with Intrexon. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Probiotic Products </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are marketing a variety of probiotic products that we developed. Our probiotic products contain the active ingredient ProBiora3, a patented blend of oral
care probiotics that promote fresher breath, whiter teeth and support overall oral health. We have conducted scientific studies on ProBiora3 in order to market our products under self-affirmed Generally Recognized As Safe status (&#147;GRAS&#148;).
We sell our ProBiora3 products through multiple distribution channels. We continue to seek improvement in the performance of our oral care probiotics business and consistent with these efforts: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are focusing our efforts on our direct-to-consumer channel, including internet, as well as on our Dental channel, which entails distribution to dentists throughout the United States; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To better serve our customers, we continue to evaluate new delivery systems, which we believe will enable us to deliver ProBiora3 to new markets and end-users. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to better understand and define our customer base, we conducted detailed market research utilizing
outside consultants at the end of 2012. The goal of the research was to develop a plan to improve market awareness and sales of our oral probiotic product line. The effort produced strategic marketing and sales plans that we have begun to implement.
The initial implementation of our new sales approach commenced at the end of the quarter ended June&nbsp;30, 2013 and as such, continues to be in a roll-out mode. The results for the September&nbsp;30, 2013 quarter have not met expectations. While
more time is needed for the expected benefits of the marketing plan to materialize, we expect to review the results and efforts undertaken to date toward the goal of making changes to improve our results. Our quarter over quarter sales of our
probiotic product lines may fluctuate. We believe that the successful execution of our marketing plans can lead to improved probiotic sales on a year over year sales basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We initiated two, double blinded randomized, placebo controlled clinical studies, one at the University of Washington and the other at Loma Linda University
in California, that we believe could allow us to enhance the claims we can make about our ProBiora3 products and assist us in registering the product for commercial sale in the European Union. Review of the baseline clinical and microbial data from
these studies did not demonstrate support for enhanced claims. We believe the results were attributable to the enrollment of test subjects with better than average oral health, which created a situation where there was little or no room for
demonstrating an improvement in clinical indices. We have determined that it is more cost effective to terminate these studies and transition our clinical efforts and resources to a more standardized oral care clinical study design capable of
demonstrating a product benefit. We, however, continue supporting a two-year study in children in Scandinavia. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Product Candidates and
Technologies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also possess and have developed other product candidates and technologies that originated from the discoveries of our scientific team.
These other product candidates and technologies include our SMaRT Replacement Therapy, our weight loss agent, LPT3-04, and DPOLT, which was specifically designed as a methodology for synthesizing lantibiotics using traditional organic chemistry
techniques. We continue to consider and evaluate opportunities that could promote the advancement of our other product candidates and technologies. We believe our other product candidates and technologies could provide potential partnership
opportunities for us. For our product candidates and technologies, we expect to devote limited financial resources toward continued research and development while exploring the possibilities for outlicensing such product candidates or entering into
partnerships or collaborative arrangements for the further development of such product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our SMaRT Replacement Therapy.</I> Our SMaRT
Replacement Therapy is based on the creation of a genetically modified strain of bacteria that colonizes in the oral cavity and replaces native bacteria that cause tooth decay. Our SMaRT Replacement Therapy product candidate is designed to be a
painless, one-time, five-minute topical treatment applied to the teeth that has the potential to offer lifelong protection against dental caries, or tooth decay. While we commenced a Phase 1b clinical trial for SMaRT Replacement Therapy during the
first quarter of 2011, the very restrictive study enrollment criteria required by the FDA made the enrollment of candidates meeting the restrictive criteria difficult. Due to the enrollment difficulty we encountered with our initial Phase 1a
clinical trial and now with our phase 1b clinical trial, we determined to discontinue pursuit of our Phase 1b clinical trial and instead focus our efforts on possible partnering opportunities that may exist for our SMaRT Replacement Therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our Weight Loss Agent-LPT3-04.</I> LPT3-04 is a naturally occurring compound that is normally consumed in the human diet in small amounts. In the course of
our SMaRT Replacement Therapy research, our scientific team also discovered that consumption of a significant amount of LPT3-04 resulted in dose-dependent weight loss in experimental animal models. We have filed a patent application for use of
LPT3-04 for weight regulation with the United States Patent Office. We believe this product candidate is positioned for collaboration, or outlicensing opportunities, which we may pursue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Intrexon Transaction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the
Company entered into an ECC Agreement (the &#147;Probiotics ECC&#148;) with Intrexon that governs a &#147;channel collaboration&#148; arrangement in which the Company will use Intrexon&#146;s proprietary technology relating to the identification,
design and production of genetically modified cells, DNA vectors and in vivo control of expression (the &#147;Technology&#148;) for the development and commercialization of probiotics, specifically the direct administration to humans of genetically
modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus, including, but not limited to, aphthous stomatitis and Behcet&#146;s disease (collectively, the &#147;Probiotics Program&#148;). The Probiotics ECC
Agreement establishes committees comprised of Company and Intrexon representatives that will govern activities related to the Probiotics Program in the areas of project establishment, chemistry, manufacturing and controls matters, clinical and
regulatory matters, commercialization efforts and intellectual property matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Probiotics ECC grants the Company an exclusive worldwide license to
utilize Intrexon&#146;s Technology to develop and commercialize probiotics, specifically the direct administration to humans of genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus
(&#147;Company Products&#148;). Such license is exclusive with respect to any clinical development, selling, offering for sale or other commercialization of Company Products, and otherwise is non-exclusive. Subject to limited exceptions, the Company
may not sublicense the rights described without Intrexon&#146;s written consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Probiotics ECC, and subject to certain exceptions, the Company
is responsible for, among other things, funding the further anticipated development of probiotics toward the goal of commercialization, conducting preclinical and clinical development of candidate probiotics, as well as for other aspects of
manufacturing and the commercialization of the product(s). Among other things, Intrexon is responsible for technology discovery efforts, cell-engineering development, and certain aspects of the manufacturing process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will pay Intrexon 10% of the net sales derived from the sale of products developed from the exclusive channel collaboration relating to the
Probiotics Program. The Company has likewise agreed to pay Intrexon a percentage of revenue obtained from a sublicensee in the event of a sublicensing arrangement. The percentage of the revenue to be paid will be determined at the time that a
sublicense agreement is negotiated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may voluntarily terminate the Probiotics ECC upon 90 days written notice to Intrexon. Intrexon may also
terminate the Probiotics ECC if the Company breaches the Probiotics ECC and fails to cure the breach within 60 days or the Company does not pursue development of the Superior Therapy under the probiotics identified by Intrexon that is a
&#147;Superior Therapy&#148; as defined in the Probiotics ECC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon termination of the Probiotics ECC, the Company may continue to develop and commercialize any Company Product
that, at the time of termination, satisfies at least one of the following criteria: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">commercialized by the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approved by regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a subject of an application for regulatory approval that is pending before the applicable regulatory authority; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the subject of at least an ongoing Phase 1, Phase 2 or Phase 3 clinical trial in the field of the Probiotics Program. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in partial consideration for each party&#146;s execution and delivery of the Probiotcs ECC, the Company entered into a Stock Purchase and
Issuance Agreement and a First Amendment to the Stock Purchase and Issuance Agreement (collectively the &#147;SPIA&#148;) with Intrexon. Pursuant to the SPIA, the Company paid Intrexon an up-front technology access fee of $6,000,000 (the
&#147;Technology Access Fee&#148;) in consideration for the execution of the Probiotics ECC. The Technology Access Fee was paid to Intrexon by the Company through the (i)&nbsp;issuance of 1,348,000 shares of the Company&#146;s common stock (the
&#147;Technology Access Shares&#148;), and (ii)&nbsp;a convertible promissory note in the amount of $1,956,000 which is payable, at the Company&#146;s option, in cash or shares of Company common stock (the &#147;Convertible Note&#148;). The
Convertible Note matures on December&nbsp;31, 2013 and requires the Company to obtain shareholder approval prior to conversion of the Convertible Note. The conversion price is equal to the closing price per share of the Company&#146;s common stock
on the last trading day immediately prior to the date of conversion. The Company sold to Intrexon 1,300,000 shares of the Company&#146;s common stock at a price per share of $3.00 for gross proceeds of $3,900,000. The Company intends to use the
proceeds from this sale of common stock towards development of the Company&#146;s key initiatives relating to the Probiotics Program, and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the SPIA and as part of the Probiotics ECC, the Company has also agreed to make certain payments to Intrexon upon the Company&#146;s achievement of
designated milestones. The milestone payments are each payable to Intrexon, at the Company&#146;s election (subject to an election right of Intrexon if the milestone is achieved by a sublicensee), either in cash or in shares of Company common stock
(using the fair market value of the shares to calculate the number of shares to be issued to Intrexon in lieu of cash). The Commercialization Milestone Events and amounts payable are as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$2,000,000 within thirty (30)&nbsp;days of the dosing of a patient by or on behalf of the Company, or an Affiliate (as that term is defined in the Probiotics ECC) or permitted sublicensee of the Company, in a phase II
clinical trial, whether such occurs in the United States of America under the jurisdiction of the United States Food and Drug Administration (&#147;FDA&#148;) or elsewhere under the jurisdiction of a foreign regulatory agency, for a Company Product;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$5,000,000 within thirty (30)&nbsp;days of the first meeting of the primary endpoint by or on behalf of the Company, or an Affiliate or permitted sublicensee of the Company, in a phase III clinical trial, whether such
occurs in the United States of America under the jurisdiction of the FDA or elsewhere under the jurisdiction of a foreign regulatory agency, for a Company Product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$10,000,000 within thirty (30)&nbsp;days of the first to occur of (a)&nbsp;the First Commercial Sale (as that term is defined in the Probiotics ECC) of a Company Product, or (b)&nbsp;the approval of a New Drug
Application (as that term is defined in the Probiotics ECC) for a Company Product by the FDA or equivalent regulatory action in a foreign jurisdiction. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>About Us </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated in November 1996 and
commenced operations in 1999. We consummated our initial public offering in June 2003. We have devoted substantially all of our available resources to the commercialization of our ProBiora3 products as well as our discovery efforts comprising
research and development, clinical trials for our product candidates, protection of our intellectual property and the general and administrative support of these operations. We have generated limited revenues from grants and ProBiora3 product sales
through September&nbsp;30, 2013, and have principally funded our operations through the sale of debt and equity securities, including the exercise of warrants issued in connection with these financing transactions. Prior to 2008 our revenues were
derived solely from research grants. Since 2008, our revenues have also included sales of our ProBiora3 products, which we initiated in late 2008. Our net revenues were $597,449 and $901,182 for the nine months ended September&nbsp;30, 2013 and
2012, respectively, and $1,331,764 and $1,444,447 for the years ended December&nbsp;31, 2012 and 2011, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, we
had an accumulated deficit of $(67,075,781) and we have yet to achieve profitability. We incurred net losses of $12,989,419 and $11,101,620 for the nine months ended September&nbsp;30, 2013 and 2012, respectively, and $13,090,446 and $7,678,868 for
the years ended December&nbsp;31, 2012 and 2011, respectively. We expect to incur significant and increasing operating losses for the foreseeable future as we seek to advance our product candidates through preclinical testing and clinical trials to
ultimately obtain regulatory approval and eventual commercialization. We are continuing our efforts to raise additional capital. Adequate additional funding may not be available to us on acceptable terms, or at all. We expect that research and
development expenses will increase along with general and administrative costs, as we grow and operate our business. There can be no assurance that additional capital will be available to us on acceptable terms, if at all. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenues prior to 2008 consisted
exclusively of grant funding from government agencies under the National Science Foundation&#146;s, or NSF, and National Institutes of Health&#146;s, or NIH, Small Business Innovation Research, or SBIR, grants. Since the initial launch of our
ProBiora3 products in late 2008, our net revenues for the year ended December&nbsp;31, 2008 and thereafter, also included sales of our ProBiora3 products. Sales of our ProBiora3 products were $1,194,878 and $1,229,510 for the years ended
December&nbsp;31, 2012 and 2011, respectively and $574,272 for the nine months ended September 30, 2013. Because of our efforts to increase the distribution of our ProBiora3 products, we continue to expect net revenues to increase in the future.
However, our ability to achieve an increase in ProBiora3 product revenues will depend on a number of factors, including primarily the success of marketing efforts related to our ProBiora3 products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that our revenues will fluctuate from quarter to quarter as a result of the volume of sales of our products and the amount of license fees, research
and development reimbursements, milestone and other payments from any license or strategic partnerships we may enter into in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of
Goods Sold </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cost of goods sold includes the production and manufacture of our ProBiora3 products, as well as shipping and processing expenses
and scrap expense. Scrap expense represents product rework charges, inventory adjustments, inventory replacement reserves, and damaged inventory. Because our ProBiora3 products contain live organisms they have a limited shelf life. As such, we
attempt to manage the amount of production we request of our manufacturers and the amount of inventory we maintain. We expect our cost of goods sold would increase as we are successfully able to expand our distribution and sales efforts for our
ProBiora3 products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development consists of expenses incurred in connection with the discovery and development of our product candidates. These expenses consist
primarily of employee-related expenses, which include salaries and benefits and attending science conferences; expenses incurred under agreements with contract research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
organizations, investigative sites and consultants that conduct our clinical trials and a substantial portion of our preclinical studies; the cost of acquiring and manufacturing clinical trial
materials; facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities and equipment, and depreciation of fixed assets; license fees for and milestone payments related to
in-licensed products and technology; stock-based compensation expense; and costs associated with non-clinical activities and regulatory approvals. We expense research and development costs as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development expenses can be divided into (i)&nbsp;clinical research, and (ii)&nbsp;preclinical research and development activities. Clinical
research costs consist of clinical trials, manufacturing services, regulatory activities and related personnel costs, and other costs such as rent, utilities, depreciation and stock-based compensation. Preclinical research and development costs
consist of our research activities, preclinical studies, related personnel costs and laboratory supplies, and other costs such as rent, utilities, depreciation and stock-based compensation and research expenses we incur associated with our ECC
agreements with Intrexon. While we are currently focused on advancing our product development programs, our future research and development expenses will depend on the clinical success of our product candidates, as well as ongoing assessments of
each product candidate&#146;s commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree
such arrangements would affect our development plans, research expenses and capital requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development expenses were $8,289,614
and $7,130,780 for the nine months ended September&nbsp;30, 2013 and 2012, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current strategy is to increase our research and development
expenses in the future as we continue the advancement of preclinical product development programs for our MU1140 product candidate and with respect to our probiotic projects. The lengthy process of completing preclinical and clinical trials; seeking
regulatory approval for our product candidates; and expanding the claims we are able to make, requires expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a
delay in generating product revenues and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Our current MU1140 product development candidate is not expected to be commercially
available until sometime after 2016. For our other product candidates and technologies, our plan is to reduce expenditures in research and development. We expect to seek licensing or partnering opportunities with larger pharmaceutical companies with
respect to our other product candidates, and technologies while committing limited research and development expenditures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and
Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling, general and administrative expenses consist principally of salaries and related costs for personnel in executive,
finance, business development, marketing, information technology, legal and human resources functions. Other general and administrative expenses include facility costs not otherwise included in research and development expenses, patent filing, and
professional fees for legal, consulting, auditing and tax services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our quarter over quarter expenses relating to general and administrative costs
will fluctuate, we anticipate that our general and administrative expenses when considered from an annual basis will increase for, among others, the following reasons: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with the advertising and marketing of our ProBiora3 products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to support our research and development activities, which, subject to available capital, we expect to expand as we continue the development of our product candidates; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the increased payroll, expanded infrastructure and higher consulting, legal, accounting and investor relations costs associated with being a public company. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income and (Expense) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income and
expense includes local business taxes, as well as interest income and expense. Interest income </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consists of interest earned on our cash and cash equivalents. The primary objective of our investment policy is capital preservation. Interest income consists primarily of interest associated
with our cash balance and interest expense in the prior comparative period associated with our indebtedness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2012 and 2011, we have net operating loss carryforwards of approximately $48,822,000 and $36,480,000, respectively, to offset future
federal and state income taxes. We also have research and development and investment tax credit carryforwards of approximately $881,000 and $551,000 as of December&nbsp;31, 2012 and 2011, respectively, to offset future federal and state income
taxes. Our net operating loss and research and development tax credit carryforwards will expire if not used by 2033 and 2023, respectively. Our ability to utilize our net operating loss and tax credit carryforwards may be limited in the event a
change in ownership, as defined in Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, has occurred or may occur in the future. The private placement transaction with the KFLP in June 2009 (the &#147;June 2009 Private
Placement&#148;) constituted such an event and our historical loss carryforwards were limited. In each period since our inception, we have recorded a 100% valuation allowance for the full amount of our deferred tax asset, as the realization of the
deferred tax asset is uncertain. As a result, we have not recorded any federal tax benefit in our statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for
the Three Months Ended September&nbsp;30, 2013 and 2012 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenues.</I></B> We generated net revenues of $253,374 for the three months ended
September&nbsp;30, 2013 compared to $264,248 for the three months ended September&nbsp;30, 2012. Our ProBiora3 revenues increased from September&nbsp;30, 2012 due primarily to increased advertising which was offset by a decline in grant revenues.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Goods Sold.</I></B> Cost of goods sold was $113,384 for the three months ended September&nbsp;30, 2013 compared to $164,059 for the three
months ended September&nbsp;30, 2012, a decrease of $50,675. This decrease was due primarily to a decline in scrap expense and shipping and warehousing costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development.</I></B> Research and development expenses were $6,907,251 for the three months ended September&nbsp;30, 2013 compared to
$600,208 for the three months ended September&nbsp;30, 2012, an increase of $6,307,043 or 1051%. This increase in research and development expenses was primarily due to the payment of a $6.0 million technology access fee through the issuance of
common stock and a Convertible Note payable to Intrexon Corporation pursuant to the terms of the our new Probiotic ECC during the three months ended September&nbsp;30, 2013. There was no such payment of a Technology Access Fee to Intrexon
Corporation during the three month period ending September&nbsp;30, 2012. There were also increases in consulting costs, salary related costs, and stock-based compensation costs of $208,120, $18,949, and $77,309 respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative.</I></B> Selling, general and administrative expenses were $2,558,205 for the three months ended September&nbsp;30,
2013 compared to $1,596,554 for the three months ended September&nbsp;30, 2012, an increase of $961,651 or 60.2%. This increase was due to increases in salary and salary related costs, stock-based compensation costs, advertising and marketing costs
of $113,401, $661,649, and $296,968, respectively which were partially offset by a decrease in consulting costs of $90,029. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income
(Expense).</I></B> Other income (expense) was $41 for the three months ended September&nbsp;30, 2013 compared to $(459,368) for the three months ended September&nbsp;30, 2012, resulting in a net change of $459,409. The net change was primarily
attributable to a decrease in interest expense of $454,691 due to the conversion of the note payable with warrants to common stock and the write off of the remaining discount to interest expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations for the Nine Months Ended September&nbsp;30, 2013 and 2012 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Revenues.</I></B> We generated net revenues of $597,449 for the nine months ended September&nbsp;30, 2013 compared to $901,182 for the nine months
ended September&nbsp;30, 2012. Our ProBiora3 revenues decreased from September&nbsp;30, 2012 due primarily to a decline in revenues from sales to our international clients and a decline in grant revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cost of Goods Sold.</I></B> Cost of goods sold decreased by $210,536 to $263,990 for the nine months ended September&nbsp;30, 2013 compared to $474,526
for the nine months ended September&nbsp;30, 2012. This decrease was primarily attributable to a decline in revenues from sales to our international clients and a decrease in scrap expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development.</I></B> Research and development expenses were $8,289,614 for the nine months
ended September&nbsp;30, 2013 compared to $7,130,780 for the nine months ended September&nbsp;30, 2012, an increase of $1,158,834 or 16.2%. This increase in research and development expenses was primarily due to the increased expense associated with
the payment of consulting fees to Intrexon pursuant to the terms of Lantibiotic ECC for the Lantibiotics Program during the nine month period ending September&nbsp;30, 2013 of $919,960 when compared to the nine month period ending September&nbsp;30,
2012. In addition the Technology Access Fee for the Probiotic ECC for the Probiotics Program increased by $202,000 when compared to the Technology Access Fee for the Lantibiotic ECC for the Lantibiotics Program </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Selling, General and Administrative.</I></B> Selling, general and administrative expenses were $5,180,702 for the nine months ended September&nbsp;30,
2013 compared to $3,740,022 for the nine months ended September&nbsp;30, 2012; an increase of $1,440,608 or 38.5%. This increase was due to increases in advertising and marketing, stock-based compensation, salary and salary related costs, Board fees
and travel costs of $861,382, $525,590, $43,445, $25,784 and $75,479, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense).</I></B> Other income (expense) was
$147,438 for the nine months ended September&nbsp;30, 2013 compared to $(657,474) for the nine months ended September&nbsp;30, 2012, resulting in a net change of $804,912. The net change was primarily attributable to a decrease in interest expense
of $651,272 and an increase in other income of $146,002 due to the receipt of cash relating to the purchase of our membership interest in our mutual insurer by an unrelated third party. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our inception, we
have funded our operations primarily through the sale of equity securities in our initial public offering, the sale of equity securities and warrants in private placements, debt financing and grants. During the nine months ended September&nbsp;30,
2013 and 2012, our operating activities used cash of $5,545,205 and $3,470,975 respectively. The use of cash in all periods primarily resulted from our net losses adjusted for non-cash items and changes in operating assets and liabilities. We had a
working capital surplus of $4,324,193 and $9,147,055 at September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended
September&nbsp;30, 2013 and 2012, our investing activities used cash of $17,649 and $0 respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the nine months ended September&nbsp;30, 2013
and 2012, our financing activities provided cash of $3,904,775 and $15,057,011, respectively. The cash provided by financing activities during the three months ended September&nbsp;30, 2013 was primarily due to the release of restrictions on cash
offset by reductions in short term notes payable. The cash provided by financing activities during the nine months ended September&nbsp;30, 2013 was primarily due to the release of restrictions on cash that was offset by reductions in short term
notes payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional details of our
financing activities for the periods reflected in this report are provided below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Koski Family Limited Partnership Financing Activities
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;30, 2010, we entered into an unsecured revolving credit agreement (the &#147;Credit Facility&#148;) with the Koski Family Limited
Partnership (&#147;KFLP&#148;) an accredited investor and our largest shareholder. Pursuant to the Credit Facility, we were able to borrow up to $2,000,000 from the KFLP at LIBOR plus 6.0%. The term of the Credit Facility was initially for 12 months
commencing August&nbsp;1, 2010. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;24, 2011, we entered into a First Amendment to the Credit Facility (the &#147;First Amendment&#148;) to
increase the available borrowing from $2,000,000 to $2,500,000 and simultaneously therewith we drew on the Credit Facility as amended by the First Amendment to borrow the additional $500,000 in available funds and executed another revolving
unsecured promissory note (the &#147;January 2011 Promissory Note&#148;) initially due on July&nbsp;30, 2011. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;4, 2011, we entered into a Second Amendment (the &#147;Second Amendment&#148;) to the Credit
Facility. As a result of the Second Amendment, we are able to borrow up to an additional $2,500,000 from the KFLP. Future draws under the Credit Facility, as amended, were limited to $500,000 per month commencing no earlier than March 2011. Under
the Second Amendment, the due date of the amounts then outstanding under the Credit Facility was extended by one year from July&nbsp;30, 2011 to July&nbsp;30, 2012. The interest rate remained at LIBOR plus 6.0%. The Second Amendment further provided
for the automatic conversion of any amounts borrowed and outstanding under the Credit Facility into securities that we may issue in subsequent securities offerings. Any automatic conversion of amounts outstanding under the Credit Facility would be
on the same terms of any such offering. In addition, the Second Amendment provided the KFLP with the right to put any undrawn available amounts under the Credit Facility, as amended, to us and thereby have a note issued to the KFLP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On each of March&nbsp;15, 2011,&nbsp;April&nbsp;5, 2011,&nbsp;May&nbsp;5, 2011,&nbsp;June&nbsp;3, 2011, and July&nbsp;8, 2011 we borrowed an additional
$500,000 under the Credit Facility, as amended, and executed a revolving unsecured promissory note in such amounts that each matured on July&nbsp;30, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;29, 2011, we entered into a Third Amendment (the &#147;Third Amendment&#148;) to the Credit Facility. As a result of the Third Amendment, we
increased our availability under the Credit Facility by $2,000,000 from $5,000,000 to $7,000,000. Future draws of the $2,000,000 in increased availability provided by the Third Amendment to the Credit Facility were limited to $1,000,000 increments
beginning no earlier than August 2011 and October 2011, respectively. All other terms of the Credit Facility remained the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On each of August&nbsp;1,
2011 and October&nbsp;5, 2011, the Company borrowed an additional $1,000,000 under the Credit Facility, as amended by the Third Amendment, and executed a revolving unsecured promissory note in such amounts that matured on July&nbsp;30, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;9, 2011, we entered into a Fourth Amendment (the &#147;Fourth Amendment&#148;) to the Credit Facility. The Fourth Amendment increased the
available borrowing under the Credit Facility by $500,000 from $7,000,000 to $7,500,000. On December&nbsp;9, 2011, the Company drew down on the Credit Facility, as amended, to borrow $500,000 in the newly available funds. All other terms of the
Credit Facility remained the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;23, 2012, we entered into a Fifth Amendment (the &#147;Fifth Amendment&#148;) to the Credit Facility.
The Fifth Amendment increased the available borrowing under the Credit Facility by $750,000 from $7,500,000 to $8,250,000. On January&nbsp;23, 2012, we drew down on the Credit Facility, as amended, to borrow $750,000. All other terms of the Credit
Facility remained the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;23, 2012, we entered into an Exchange of Notes for Equity Agreement (the &#147;Debt Exchange Agreement&#148;)
with the KFLP. Pursuant to the terms of the Debt Exchange Agreement, we issued 6,285,619 shares of common stock and warrants to acquire 1,571,405 shares of common stock to the KFLP in exchange for the cancellation of an aggregate of $8,737,011 of
indebtedness owed to the KFLP under the Credit Facility. The outstanding indebtedness consisted of $8,250,000 in principal owed on twelve separate promissory notes previously issued by us to the KFLP under the Credit Facility and accrued interest
through March&nbsp;23, 2012 (the closing date) of $487,011. The Credit Facility was terminated and the previously issued promissory notes thereunder were cancelled. The warrants are exercisable immediately at a price per share of $2.00 and expire
three (3)&nbsp;years from the date of issuance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;23, 2012, we also entered into a new loan agreement (the &#147;Loan Agreement&#148;) with
the KFLP. It provided us with up to $2.5 million in secured funding in two advances of $1,250,000 each with the first advance occurring on March&nbsp;23, 2012 and the second advance able to be made within 30 days thereafter, subject to the continued
accuracy of representations and warranties made by us and that no material adverse events had occurred in connection with the our business. Borrowings under the Loan Agreement matured in three years with interest at the rate of 5.0% and are secured
by select assets of us relating to or connected with the ProBiora3, SMaRT Replacement Therapy, MU1140 and LPT3-04 technologies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The loan amount was subject to automatic conversion upon a subsequent qualified equity financing by the Company
of $5,000,000 (excluding any converted debt amount). Pursuant to the Loan Agreement we also issued a warrant to the KFLP to acquire 599,520 shares of our common stock. The warrants are exercisable immediately at a price per share of $2.00 and expire
three (3)&nbsp;years from the date of issuance. The fair value of the warrant using the Black Scholes Model is $599,520. The first funding has a fair value of $1,250,000. Using the relative fair value method, the first funding has an initial value
of $766,441 and the warrant had an initial value of $483,559. The value of the warrant was credited to Additional Paid-in Capital. This discount of $483,559 was being charged to interest expense over the life of the Loan Agreement until the loan was
terminated as disclosed below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The July 2012 Private Placement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;30, 2012, we entered into a Stock Purchase Agreement (the &#147;Purchase Agreement&#148;) with certain accredited investors (the
&#147;Purchasers&#148;) pursuant to which we: (i)&nbsp;sold to the Purchasers an aggregate of 8,666,665 shares of our Common Stock at a price per share of $1.50 (the &#147;Common Shares&#148;) for aggregate gross proceeds of approximately
$13,000,000 (the &#147;Offering&#148;). We intend to use the net proceeds from this Offering of approximately $12,046,000 to accelerate development of several of our key initiatives including the ECC with Intrexon relating to our lantibiotics
program and sales and marketing of our probiotic product lines and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Griffin Securities, Inc. (the &#147;Placement Agent&#148;)
served as the placement agent for the Offering. In consideration for services rendered as the Placement Agent in the Offering, we agreed to (i)&nbsp;pay to the Placement Agent cash commissions equal to $899,698, or 7.0% of the gross proceeds
received in the Offering, less certain excluded proceeds, (ii)&nbsp;issue to the Placement Agent, or its designee, a five-year warrant to purchase up to 771,169 shares of our common stock (representing 9% of the common shares sold in the Offering)
with an exercise price of $1.50 per share (the &#147;Agent Warrants&#148;); and (iii)&nbsp;reimburse the Placement Agent for its reasonable actual out-of-pocket expenses, incurred in connection with the Offering, including reasonable legal fees and
disbursements up to a maximum aggregate amount of $50,000. The determination of the Placement Agent&#146;s fees did not include any shares issued to the KFLP, (in connection with the automatic conversion of its secured debt with us described below)
or shares acquired by any officers or directors participating in the Offering. The Agent Warrants were valued at $2.40 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because the Offering
constituted a &#147;qualified financing&#148; under the terms of our Loan Agreement with the KFLP, our secured debt in the principal amount of $2.5 million, together with accrued but unpaid interest thereon, due to the KFLP was automatically
converted contemporaneously with the closing of the Offering into 1,692,123 shares of common stock issued to the KFLP at the same price of $1.50 per share paid by the Purchasers in the Offering. As a result of the conversion of the secured
indebtedness, the Loan Agreement together with the related Security Agreement was terminated and the unamortized discount was expensed and the full value of the $2.5 million borrowed under the Loan Agreement and accrued interest was converted into
common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The September 2013 Private Placement and Convertible Note Payable to Shareholder </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013, the Company entered into a Stock Purchase and Issuance Agreement and a First Amendment to the Stock Purchase and Issuance Agreement
(collectively the &#147;SPIA&#148;) with Intrexon. Pursuant to the SPIA, the Company sold to Intrexon 1,300,000 shares of the Company&#146;s common stock at a price per share of $3.00 for gross proceeds of $3,900,000. The Company intends to use the
proceeds from this sale of common stock towards development of the Company&#146;s key initiatives relating to the Probiotic program, and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;30, 2013 as partial consideration for the Technology Access Fee paid to Intrexon pursuant to the Probiotic ECC we issued a convertible
promissory note in the amount of $1,956,000 which is payable, at the Company&#146;s option, in cash or shares of Company common stock (the &#147;Convertible Note&#148;). The Convertible Note matures on December&nbsp;31, 2013 and requires the Company
to obtain shareholder approval prior to conversion of the Convertible Note. The conversion price is equal to the closing price per share of the Company&#146;s common stock on the last trading day immediately prior to the date of conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Financings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;3, 2011, we entered into a short-term note payable for $48,988 bearing interest at 5.48%&nbsp;per annum to finance product liability insurance.
Payments on this note were made evenly based on a straight line amortization over a ten-month period with the final payment due on January&nbsp;10, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;12, 2011, we entered into a short-term note payable for $77,751 bearing interest at 4.75%&nbsp;per annum to finance a portion of the
directors&#146; and officers&#146; liability insurance. Principal and interest payments on this note began August&nbsp;24, 2011 and were made evenly based on a straight line amortization over an 11-month period with the final payment due on
June&nbsp;24, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;10, 2012, we entered into a short-term note payable for $50,037 bearing interest at 6.17%&nbsp;per annum to finance the
product liability insurance. Principal and interest payments on this note began April&nbsp;10, 2012 and were made evenly based on a straight line amortization over a 10-month period with the final payment due on January&nbsp;10, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2013, we entered into a short-term note payable for $50,037 bearing interest at 6.57%&nbsp;per annum to finance the product liability
insurance. Principal and interest payments on this note began April&nbsp;10, 2013 and are made evenly based on a straight line amortization over a 10-month period with the final payment due on January&nbsp;10, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;20, 2013, we entered into a short-term note payable for $106,994 bearing interest at 4.64%&nbsp;per annum to finance a portion of the
directors&#146; and officers&#146; liability insurance and employment practices liability insurance premiums. Principal and interest payments on this note begin August&nbsp;24, 2013 and are made evenly based on a straight line amortization over an
11-month period with the final payment due on June&nbsp;24, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;10, 2010, we were awarded the matching $500,000 grant from the NSF to support an SBIR Phase II grant previously awarded in 2008 for further
development of our DPOLT platform. On each of June&nbsp;17, 2010,&nbsp;February&nbsp;28, 2011,&nbsp;September&nbsp;29, 2011 and March&nbsp;29, 2012, we received $125,000 related to this NSF awarded SBIR II Phase II grant for our DPOLT platform.
Proceeds from the financing were allocated to further the development of our DPOLT platform, essential to the production of our lead antibiotic, MU1140, subject to the goals set forth by the NSF SBIR Phase II grant received by us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future Capital Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our capital requirements for
the remainder of 2013 will depend on numerous factors, including the success of our commercialization efforts and of our research and development, the resources we devote to develop and support our technologies and our success in pursuing strategic
licensing and funded product development relationships with external partners. Subject to our ability to generate revenues and cash flow from our ProBiora3 products and our ability to raise additional capital including through possible joint
ventures and/or partnerships, we expect to incur substantial expenditures to further commercialize or develop our technologies including continued increases in costs related to research, preclinical testing and clinical studies, as well as costs
associated with our capital raising efforts and being a public company. We will require substantial funds to conduct research and development and preclinical and Phase 1 clinical testing of our licensed, patented technologies and to develop
sublicensing relationships for the Phase 2 and 3 clinical testing and manufacture and marketing of any products that are approved for commercial sale. Our plans include seeking both equity and debt financing, alliances or other partnership
agreements with entities interested in our technologies, or other business transactions that would generate sufficient resources to ensure continuation of our operations and research and development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our current available cash and cash equivalents are sufficient to satisfy our liquidity requirements. We believe our existing cash and cash equivalents will
allow us to fund our operating plan through December 2014. We will continue to seek additional funding for our operations. The sale of additional equity or debt securities may result in additional dilution to our shareholders. If we raise additional
funds through the issuance of debt securities or preferred stock, these securities could have rights senior to those of our common stock and could contain covenants that would restrict our operations. We also will likely require additional capital
beyond our currently forecasted amounts, for example, as we continue to work with Intrexon under the Lantibiotic ECC for the development of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
MU1140 and the Probiotic ECC for the development of Probiotics. Any such required additional capital may not be available on reasonable terms, if at all. If we are unable to obtain additional
financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned clinical testing, research and development and commercialization activities, which could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with sales of our ProBiora3 products as well as research, development and commercialization of
pharmaceutical products, we are unable to estimate the exact amounts of our working capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cash flow generated from our ProBiora3 product sales; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of the product candidates we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials including the research and development expenditures we expect to make in
connection with our collaboration with Intrexon Corporation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of manufacturing our ProBiora3 products and product candidates and any products we successfully commercialize; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of commercialization activities for our ProBiora3 products and, if any of our product candidates are approved for sale, including marketing, sales and distribution costs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain current research and development licensing agreements and to establish new strategic partnerships, licensing or other arrangements and the financial terms of such agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to achieve our milestones under licensing arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of sales of, or royalties on, our products and future products, if any. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have based our estimate on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private
sales of our shares or debt and other sources. We may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it
is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other securities convertible into common stock, the
ownership interest of our existing stockholders will be diluted. If we are not able to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit our operations and our business,
financial condition and results of operations would be materially harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Estimates and Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in
accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;). The preparation of financial statements in accordance with GAAP requires us to make estimates and assumptions that affect reported amounts
and related disclosures. We consider an accounting estimate to be critical if it requires assumptions to be made that were uncertain at the time the estimate was made; and changes in the estimate or different estimates that could have been made
could have a material impact on our results of operations or financial condition. The principal areas of estimation reflected in the financial statements are stock-based compensation, valuation of warrants, sales returns and allowances, inventory
obsolescence and allowance for doubtful accounts. For a detailed discussion of our critical accounting estimates, see our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012. There have been no material changes to our critical
accounting estimates during the nine months ended September&nbsp;30, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no new accounting pronouncements issued or effective during the nine months ended September&nbsp;30, 2013 that have had or are expected to have an
impact on our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_8"></A>ITEM&nbsp;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Oragenics, Inc. is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Act of 1934 and is not required to provide the
information required under this item. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_9"></A>ITEM&nbsp;4. CONTROLS AND PROCEDURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Evaluation of Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management&#146;s evaluation of the effectiveness of the Company&#146;s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the
Exchange Act was performed under the supervision and with the participation of our senior management, including our Chief Executive Officer and Chief Financial Officer. The purpose of disclosure controls and procedures is to ensure that information
required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms, and that such information is accumulated and
communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures. Based upon Management&#146;s evaluation, Management has concluded that our disclosure controls
are effective as of the end of the period covered by this report. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2011, we disclosed and identified several material weaknesses in our internal
controls. Since that time we have been working on remediation of the identified material weaknesses and have provided updates in our periodic reports. Management believes progress has been made during the year ended December&nbsp;31, 2012 and
thereafter to remediate material weaknesses in the internal control over financial reporting. Although the control environment has significantly improved during the year ended December&nbsp;31, 2012 and thereafter when compared to prior periods, a
material weakness still remains. Nevertheless, based on a number of factors, including the performance of additional procedures by management designed to ensure the reliability of our financial reporting, management believes that the financial
statements in our Quarterly Report of Form-10Q for the three month period ended September&nbsp;30, 2013 fairly present, in all material respects, our financial position, results of operations, and cash flows for the periods presented in conformity
with GAAP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed and referenced above, the matters involving internal controls and procedures that our management identified and
considered to be material weaknesses that have not yet been satisfactorily remediated is insufficient personnel to employ segregation of duties. While segregation of duties remains a challenge for the Company, management has taken steps to further
reduce this risk by continuing to limit access to the accounting system wherever possible. This risk will remain until such time as the Company expands and hires more staff. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Remediation Initiatives </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although
management has not fully remediated the material weakness mentioned above, management believes progress is being made as we continue the engagement with a consulting firm specializing in Sarbanes-Oxley Section&nbsp;404 compliance to assist us in the
implementation of internal controls for financial reporting and disclosure and our remediation efforts. During 2012, the consulting firm completed an analysis to identify the most critical controls in our environment and a design and operating
effectiveness evaluation of those controls was performed. Reasonable remediation activities were identified based on cost and reduction of risk. All planned remediation was completed prior to year-end. Management will continue to monitor and
evaluate risk factors affecting our internal controls as our resources and available liquidity permit. Management is responsible for and is committed to achieving and maintaining a strong control environment, high ethical standards, and financial
reporting integrity. This commitment continues to be communicated to, and reinforced with, our employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may
deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and
presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations
are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Controls over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as indicated in the preceding paragraphs about management&#146;s evaluation of disclosure controls and procedures and internal controls, our management,
with the participation of our Chief Executive Officer (CEO) and Chief Financial Officer (CFO), has concluded there were no other significant changes in our internal controls over financial reporting that occurred during our last fiscal quarter that
have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on the
Effectiveness of Controls </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, including our CEO and CFO, do not expect that our disclosure controls and internal controls will prevent all
errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact
that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control
issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake.
Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management or board override of the control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that
any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.
Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_10">
</A>PART II &#150; OTHER INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_11"></A>ITEM&nbsp;1. LEGAL PROCEEDINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not a party to any pending legal proceeding that is not in the ordinary course of business or otherwise material to our financial condition or business.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_12"></A>ITEM&nbsp;1A. RISK FACTORS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In addition to the other information set forth in this Form 10-Q, you should carefully consider the Risk Factors described below before making an investment
decision in our securities. These risk factors are effective as of the date of this Form 10-Q and shall be deemed to be modified or superseded to the extent that a statement contained in our future filings modifies or replaces such statement. All of
these risks may impair our business operations. The forward-looking statements in this Form 10-Q involve risks and uncertainties and actual results may differ materially from the results we discuss in the forward-looking statements. If any of the
following risks actually occur, our business, financial condition or results of operations could be materially adversely affected. In that case, the trading price of our stock could decline, and you may lose all or part of your investment. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since our inception and expect to continue to experience losses for the
foreseeable future. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred significant net losses and negative cash flow in each year since our inception, including net losses of
approximately $13.0 million and $11 million for the nine months ended September&nbsp;30, 2013, and 2012, and approximately $13.1 million and $7.7 million for the years ended December&nbsp;31, 2012, and 2011, respectively. As of September&nbsp;30,
2013 our accumulated deficit was approximately $67.1 million. We have devoted a significant amount of our financial resources to research and development, including our preclinical development activities and clinical trials, and currently we only
have our ProBiora3 products available for commercial sale which to date has not generated significant revenue. We expect that the costs associated with our exclusive channel partnerships with Intrexon Corporation in the areas of lantibiotics
(&#147;Lantibiotics Program&#148;) and probiotics (&#147;Probiotics Program&#148;) and the development and commercialization of our product candidates under the Lantibiotics Program (which includes MU1140) and Probiotics Program using
Intrexon&#146;s advanced transgene and cell engineering platforms, as well as our expected increased marketing and sales efforts for our ProBiora3 products will increase the level of our overall expenses significantly going forward. As a result, we
expect to continue to incur substantial net losses and negative cash flow for the foreseeable future. These losses and negative cash flows have had, and will continue to have, an adverse effect on our shareholders&#146; equity and working capital.
Because of the numerous risks and uncertainties associated with product development and commercialization, we are unable to accurately predict the timing or amount of substantial expenses or when, or if, we will be able to achieve or maintain
profitability. The size of our future net losses will depend, in part, on the rate of growth of our expenses and the rate of growth of our revenues. If we are unable to develop and commercialize our other product candidates or if sales revenue from
ProBiora3 products is insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to raise additional capital in the future to complete the development and commercialization of our product candidates and operate our
business. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Developing and commercializing biopharmaceutical products, including conducting preclinical studies and clinical trials and
establishing manufacturing capabilities, is expensive. As a result of the approximately $15.9 million in net proceeds from our private placement of common stock in July 2012 and September 2013, we anticipate that our cash resources as of
September&nbsp;30, 2013 will be sufficient to fund our operations for at least the next 15 months. However, changes may occur that would consume our existing capital prior to that time, including the scope and progress of our efforts to develop and
commercialize our product candidates. Because we currently expect to devote a significant portion of our resources to develop and commercialize product candidates under our Lantibiotics Program and our Probiotics Program with Intrexon and for
ProBiora3 sales and marketing efforts further progress with the development of our other product candidates may be significantly delayed and may depend on the success of our development efforts involving our antibiotic candidates. Our actual costs,
as well as the actual revenues from sales of our ProBiora3 products, may ultimately vary from our current expectations, which could materially impact our use of capital and our forecast of the period of time through which our financial resources
will be adequate to support our operations. If our current cash, cash equivalents and short-term investments are not sufficient to fully implement our business strategy and sustain our operations, we will need to seek additional sources of financing
and such additional financing may not be available on favorable terms, if at all. Until we can generate a sufficient amount of product revenue, if ever, we expect to finance future cash needs through public or private equity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offerings, debt financings or corporate collaboration and licensing arrangements. If we do not succeed in raising additional funds on acceptable terms, we may be unable to complete planned
preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to discontinue product development and commercialization of one or more of our product
candidates, curtail or forego sales and marketing efforts, and/or forego licensing attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity or debt securities, which will have a dilutive
effect on our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ProBiora3 products are currently our only source of product revenue and have not generated substantial revenues to
date. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently our sole source of product revenues is from sales of our ProBiora3 products, which began in late 2008 and have generated only
modest revenues to date. Sales of our ProBiora3 products were $574,272, $790,166, and $587,557 for the nine months ended September&nbsp;30, 2013, 2012, and 2011, respectively, and $1,194,878, $1,229,510 and $1,128,895 for the years ended
December&nbsp;31, 2012, 2011 and 2010, respectively. While we plan to continue to increase the amount we spend on sales and marketing efforts for our ProBiora3 products, there can be no assurance that it will result in a significant increase in
sales. If we are unable to generate significant revenues from our ProBiora3 products our business, financial condition and results of operations will be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our success will depend on our ability to obtain regulatory approval of our product candidates under our Lantibiotics Program and our Probiotics Program
and their successful commercialization. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates under our Lantibiotics Program and Probiotics Program have not received regulatory
approval in any jurisdiction and they may never receive approval or, if approvals are obtained, may never be commercialized successfully. We have incurred and will continue to incur significant costs relating to the preclinical and clinical
development of our antibiotic product candidates including MU1140 or any analogs thereof we may develop. We have performed extensive preclinical testing using native MU1140 and have since entered into an Exclusive Channel Collaboration Agreement
with Intrexon Corporation. We expect to begin preclinical activities on native MU1140 in the second half of 2013. Those activities may include toxicity results, pharmacokinetic studies, and efficacy studies in animals. This work will be done solely
by us through the use of outside contractors. If our preclinical work is successful, we would expect to file an Investigational New Drug application with the FDA by the second quarter of 2015. Even if we are able to conduct successful clinical
trials or the required regulatory approvals are obtained, we may never be able to generate significant revenues from our product candidates. If our product candidates are unsuccessful, we may be unable to generate sufficient revenues to sustain and
grow our business, and our business, financial condition and results of operations will be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our exclusive channel
partnering arrangements with Intrexon are based on an early stage technology in the fields of lantibiotic and probiotics. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our exclusive channel
collaboration arrangement with Intrexon contemplates the use of Intrexon&#146;s advanced transgene and cell engineering platforms for the development and production of lantibiotics and probiotics<B>. </B>Such technologies have a limited history of
use in the design and development of active pharmaceutical ingredients and drug products involving direct administration and may therefore involve unanticipated risks or delays. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur additional expenses in connection with our exclusive channel collaboration arrangements with Intrexon. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our exclusive channel collaborations with Intrexon under our Lantibiotics Program and Probiotics Program, we are responsible for future research
and development expenses of product candidates developed under such collaborations, the effect of which we expect will increase the level of our overall research and development expenses going forward. Although all manufacturing, preclinical studies
and human clinical trials are expensive and difficult to design and implement, costs associated with the manufacturing, research and development of biologic product candidates are generally greater in comparison to small molecule product candidates.
We expect to add additional personnel to support our Lantibiotics Program and Probiotics Program with Intrexon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because our collaborations with Intrexon
are in the early stage and we have not yet identified a specific product candidate from the Intrexon collaborations, future development costs associated with this program may be difficult </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to anticipate and exceed our expectations. Our actual cash requirements may vary materially from our current expectations for a number of other factors that may include, but are not limited to,
unanticipated technical challenges, changes in the focus and direction of our development activities or adjustments necessitated by changes in the competitive landscape in which we operate. If we are unable to continue to financially support such
collaborations due to our own working capital constraints, we may be forced to delay our activities. If we are unable to obtain additional financing on terms acceptable to us or at all, we may be forced to seek licensing partners or discontinue
development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to retain the exclusive rights licensed to us by Intrexon to develop and commercialize lantibiotic products and
probiotic products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our exclusive channel collaboration agreements with Intrexon (the &#147;ECC&#146;s&#148;), we are responsible for,
among other things, funding the further anticipated development of lantibiotics and probiotics toward the goal of commercialization, conducting preclinical and clinical development of product candidate s, as well as for other aspects of
manufacturing and the commercialization of the product(s). During the first 18 months, neither we nor Intrexon may terminate the ECC&#146;s, except under limited circumstances. Intrexon may terminate such agreements if we do not perform certain
specified requirements, including developing therapies identified to us and considered superior by Intrexon. There can be no assurance that we will be able to successfully perform under the ECC&#146;s and if the ECC&#146;s are terminated it would
prevent us from achieving our business objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our success will depend on our ability to partner or sub-license our product candidates and
their subsequent successful commercialization. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our MU1140 and other product candidates are in early stage development and will require partners
with substantial financial resources to continue the development of each of these products to commercialization. In addition, none of these product candidates have received regulatory approval in any jurisdiction and they may never receive approval
or, if approvals are obtained, may never be commercialized successfully. We recently determined to cease pursuit of our second Phase 1 clinical trial. There can be no assurance that a new clinical trial for our SMaRT Replacement Therapy product
candidate will be commenced, by us in the future or that we will be able to establish a partner relationship or sublicense our Replacement Therapy technology for future development. In addition, we do not know whether any of our clinical trials will
be successful or can be completed within our current expected budget. For our MU1140 and other antibiotic product candidates, we have performed extensive preclinical testing using native MU1140 and expect to continue to pursue the preclinical
testing of our MU1140 and other antibiotic product candidates during the remainder of 2013. Even if we are able to partner and conduct successful clinical trials or the required regulatory approvals are obtained, we may never be able to generate
significant revenues from our MU1140 or other antibiotic product candidates or other product candidates. If our MU1140 product candidate or our other product candidates under the Lantibiotics Program and Probiotics Program or otherwise are
unsuccessful, we may be unable to generate sufficient revenues to sustain and grow our business, and our business, financial condition and results of operations will be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our financial results could vary significantly from quarter to quarter and are difficult to predict. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenues and operating results could vary significantly from quarter to quarter due to a variety of factors, many of which are outside of our control. As
a result, comparing our operating results on a period-to-period basis may not be meaningful. In addition, we may not be able to predict our future revenues or results of operations. We base our current and future expense levels on our internal
operating plans and sales forecasts, and our operating costs are to a large extent fixed. As a result, we may not be able to reduce our costs sufficiently to compensate for an unexpected shortfall in revenues, and even a modest shortfall in revenues
could disproportionately and adversely affect financial results for that quarter. Individual products represent meaningful portions of our revenues in any quarter. We may incur significant or unanticipated expenses associated with our research and
development efforts of our product candidates under development. In addition to other risk factors discussed in this section, factors that may contribute to the variability of our quarterly results include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of release of new products and services by us and our competitors, particularly those that may represent a significant portion of revenues in any given period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the popularity of new products, and products released in prior periods; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in pricing policies by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in the size and rate of growth of overall consumer and retailer demand for our ProBiora3 products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success in entering new geographic markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decisions by us to incur additional expenses, such as increases in marketing or research and development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the level of expenses associated with our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">accounting rules governing recognition of revenues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount we reserve against returns and allowances; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of compensation expense associated with equity compensation grants. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of these and other
factors, our quarterly and annual operating results could be materially adversely affected. Moreover, our operating results may not meet announced guidance or the expectations of research analysts or investors, in which case the price of our common
stock could decrease significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and future economic and market conditions could materially adversely affect our revenues, expense
levels and profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The U.S. economy and the global economy are recovering from a severe recession. Factors such as uncertainties in
consumer spending, a sustained regional and/or global economic downturn or slow recovery may reduce the demand for our ProBiora3 products. Furthermore, challenging economic conditions also may impair the ability of our customers to pay for our
commercial products. Because consumer spending for our ProBiora3 products can generally be considered a discretionary purchase, we may experience a more negative impact on our business due to these conditions than other companies that do not depend
on discretionary spending. If demand for our ProBiora3 products declines or our customers are otherwise unable to pay for our products, we may be required to offer extensive discounts or spend more on marketing than budgeted and our revenues,
expense levels, and liquidity position will be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to government regulation of the processing,
formulation, packaging, labeling and advertising of our consumer products. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Federal Food, Drug, and Cosmetic Act, or FDCA, companies
that manufacture and distribute foods, such as our ProBiora3 products, are limited in the claims that they are permitted to make about nutritional support on the product label without FDA approval. Any failure by us to adhere to the labeling
requirements could lead to the FDA&#146;s requiring that our products be repackaged and relabeled, which would have a material adverse effect on our business. In addition, companies are responsible for the accuracy and truthfulness of, and must have
substantiation for, any such statements. These claims must be truthful and not misleading. Statements must not claim to diagnose, mitigate, treat, cure or prevent a specific disease or class of disease. We are able to market our ProBiora3 products
in reliance on the self-affirmed Generally Recognized As Safe, or self-affirmed GRAS, status of our active ingredient, ProBiora3. No governmental agency or other third party has made a determination as to whether or not ProBiora3 has achieved GRAS
status. We make this determination based on independent scientific opinions that ProBiora3 is not harmful under its intended conditions of use. If the FDA, another regulatory authority or other third party denied our self-affirmed GRAS status for
ProBiora3, we could face significant penalties or be required to undergo the regulatory approval process in order to market our probiotic products, and our business, financial condition and results of operations will be adversely affected. We cannot
guarantee that in such a situation ProBiora3 would be approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s Good Manufacturing Practices, or GMPs, describe the methods, equipment,
facilities, and controls for producing processed food and set the minimum sanitary and processing requirements for producing safe and wholesome food. Those who manufacture, package, or hold human food must comply with the GMPs. If we or our
suppliers fail to comply with the GMPs, the FDA may take enforcement action against us or our suppliers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The processing, formulation, packaging, labeling
and advertising of our probiotic products are subject to regulation by one or more federal agencies including the FDA, the Federal Trade Commission and the Environmental Protection Agency. Our activities are also subject to regulation by various
agencies of the states and localities in which our probiotic products are sold. Any changes in the current regulatory environment could impose requirements that would limit our ability to market our probiotic products and make bringing new products
to market more expensive. In addition, the adoption of new regulations or changes in the interpretation of existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulations may result in significant compliance costs or discontinuation of product sales and may adversely affect our business, financial condition and results of operations. While our
ProBiora3 products are categorized as foods, it is possible that the FDA or a state regulatory agency could classify these products as a cosmetic or a drug. If the products are classified as cosmetics rather than a food, we would be limited to
making claims that the products cleanse and beautify, but we could not make structure or function claims. If our probiotic products are classified as drugs, we would not be able to market the ProBiora3 products without going through the drug
approval process. Either of these events would limit our ability to effectively market our products and would adversely affect our financial condition and results of operations. If the FDA or a state regulatory agency viewed the products as
cosmetics or drugs, they could claim that the products are misbranded and require that we repackage and relabel the products and impose civil and/or criminal penalties. Either or both of these situations could adversely affect our business and
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we undertake product recalls or incur liability claims with respect to our ProBiora3 products, such recalls or claims could increase
our costs and adversely affect our reputation, revenues and operating income. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ProBiora3 products are designed for human and animal
consumption and we may face product recalls or liability claims if the use of our products is alleged to have resulted in injury or death. ProBiora3 is classified as a food ingredient and is not subject to pre-market regulatory approval in the
United States. Our ProBiora3 products contain ingredients that do not have long histories of human or animal consumption. Previously unknown adverse reactions resulting from consumption of these ingredients could occur. We may have to undertake
various product recalls or be subject to liability claims, including, among others, that our ProBiora3 products include inadequate instructions for use or inadequate warnings concerning possible side effects and interactions with other substances. A
product recall or liability claim against us could result in increased costs and could adversely affect our reputation with our customers, which, in turn, could have a material adverse effect on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Product liability insurance is expensive, is subject to deductibles and coverage limitations, and may not be available in the future. While
we currently maintain product liability insurance coverage, we cannot be sure that such coverage will be adequate to cover any incident or all incidents. In addition, we cannot be sure that we will be able to obtain or maintain insurance coverage at
acceptable costs or in a sufficient amount, that our insurer will not disclaim coverage as to a future claim or that a product liability claim would not otherwise adversely affect our business, financial condition and results of operations. The cost
of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. Uncertainties resulting from the initiation and continuation of product liability litigation or other proceedings could have a material
adverse effect on our ability to compete in the marketplace. Product liability litigation and other related proceedings may also require significant management attention. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations in the agreements with the University of Florida Research Foundation, Inc., under which we license our rights
to MU1140 and to SMaRT Replacement Therapy, our license to these product candidates may be terminated and we will be unable to commercialize these product candidates. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hold our MU1140 and SMaRT Replacement Therapy product candidates under licenses from the University of Florida Research Foundation, Inc., or UFRF. We are
required to make minimum annual maintenance payments to the UFRF for the term of the amended license agreements in the amount of $10,000 for each license agreement and $20,000 in aggregate. The aggregate minimum annual payments are required to be
paid in advance on a quarterly basis (i.e. $5,000 per quarter) for both licenses. We are also required to pay all patent costs and expenses incurred by the UFRF for the preparation, filing, prosecution, issuance and maintenance of the patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UFRF may terminate our licenses to MU1140 and to SMaRT Replacement Therapy if we breach our obligations to timely pay these amounts, to submit development
reports as required under the license agreements or commit any other breach of any other covenants contained in the license agreements. There is no assurance that we will be able to comply with these conditions in a timely manner or at all. If our
license agreements are terminated, we will be unable to commercialize these product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are able to commercialize any product candidates,
we are obligated to pay 5% of the selling price of any products developed from the licensed technologies that we may sell as royalty to the UFRF. In addition, if we sublicense any rights granted by the amended license agreements, we are obligated to
pay the UFRF 22% of all </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenues received from the sublicenses, excluding monies received solely for development costs. We are also obligated to make the following payments to UFRF as follows: a one-time
commercialization fee, post-commercialization minimum royalty payments, and a one-time cumulative royalty payment. The one-time commercialization fee would be due on the first anniversary of first commercial sale and is calculated at $5,000 per
month between May&nbsp;1, 2013 and the month of the first anniversary of a commercial sale. The post-commercialization minimum royalty payments of $50,000 annually would be due following payment of a commercialization fee. The one-time additional
royalty payment would be due when total cumulative royalties paid to UFRF exceed $2.0 million, upon which we would be obligated to make a one-time additional payment to UFRF of 10% of the total royalties due to UFRF in the calendar year in which
cumulative royalties exceeded $2.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until commercial sale of any products developed from these licensed product candidates takes place, we will
not earn any revenues from these product candidates and will, therefore, need additional financing to fund our required royalty payments and development expenses, such as through the commercialization and sale of our ProBiora3 products, the sale of
our debt or equity securities, or otherwise. There can be no assurance that we will achieve sufficient sales of our ProBiora3 products or be able to raise the capital necessary to meet our obligations under our licenses. If we are unable to meet our
obligations under these licenses, we may lose the licenses to these product candidates and our business, financial condition and results of operations will be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on third-party manufacturers for our ProBiora3 products. The loss of any manufacturer or any interruptions in the supply of our ProBiora3
products would have a negative impact on our revenues and profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have no manufacturing facilities and are dependent upon
establishing relationships with independent manufacturers to supply our product needs. We currently have a one supplier that is able to produce two of the three strains of bacteria needed to produce ProBiora3 and one supplier that is able to produce
one of the strains of bacteria needed to produce ProBiora3. These suppliers use proprietary methodologies to produce these three strains of bacteria. We believe our arrangements with our contract manufacturers have the capacity to meet our current
and expected future manufacturing needs. Although we have qualified and used at least two contract manufacturers for each step in our manufacturing process, we do not have a long-term supply agreement or commitment with any of our manufacturers. If
our manufacturers are unable or unwilling to produce our ProBiora products in sufficient quantities, or at all, at acceptable pricing in accordance with specifications we establish from time to time we would need to find alternative manufacturers
that are qualified. If, in such instances, we are unsuccessful in obtaining alternative manufacturers, it could impair our ability to sell our ProBiora3 products and would have a negative impact on our revenues and profitability. In addition,
competitors who own their manufacturing facilities may have an advantage over us with respect to pricing, availability of product and in other areas through their control of the manufacturing process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The risks associated with the numerous factors that could cause interruptions in the supply of our products, including manufacturing capacity limitations,
regulatory inspections, changes in our sources for manufacturing, disputes with a manufacturer, our failure to timely locate and obtain replacement manufacturers as needed and conditions affecting the cost and availability of raw materials, are
magnified when the suppliers are limited in number. Any interruption in the supply of finished products could hinder our ability to timely distribute our products and satisfy customer demand. If we are unable to obtain adequate product supplies to
satisfy our customers&#146; orders, we may lose those orders, our customers may cancel other orders, and they may choose instead to stock and purchase competing products. This could result in a loss of our market share and negatively affect our
revenues and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our manufacturers in general fail to meet our requirements and the requirements of regulatory authorities, our revenues
may be materially adversely affected. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not have the internal capability to manufacture our ProBiora3 products or our LPT3-04 Weight Loss,
SMaRT Replacement Therapy, MU1140, or any other c product candidates under GMPs, as required by the FDA and other regulatory agencies. In order to continue to develop and commercialize our product candidates, apply for regulatory approvals for our
product candidates, and continue to commercialize our ProBiora3 products, we will need to contract with third parties that have, or otherwise develop, the necessary manufacturing capabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are a limited number of manufacturers that operate under GMPs that are capable of manufacturing our
ProBiora3 products. Furthermore, manufacturing MU1140 or our other potential product candidates on a commercial scale have not yet been undertaken, so there are additional technical skills needed for the manufacture of MU1140 that will further limit
the number of potential manufacturers. As such, if we are unable to enter into supply and processing contracts with any of these manufacturers or processors for our MU1140 and other product candidates, or ProBiora3 products we may incur additional
costs and delays in development and commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Problems with these manufacturing processes such as equipment malfunctions, facility
contamination, labor problems, raw material shortages or contamination, natural disasters, power outages, terrorist activities, or disruptions in the operations of our suppliers and even minor deviations from normal procedures, could result in
product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are
required to find an additional or alternative source of supply, there may be additional costs and delays in the development or commercialization of our product candidates. Additionally, the FDA and other regulatory agencies routinely inspect
manufacturing facilities before approving a New Drug Application, or NDA, or Biologic License Application, or BLA, for a drug or biologic manufactured at those sites. If any of our manufacturers or processors fails to satisfy regulatory
requirements, the approval and eventual commercialization of our commercial products and product candidates may be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our contract
manufacturers must comply with the applicable GMPs, which include quality control and quality assurance requirements as well as the corresponding maintenance of records and documentation. If our contract manufacturers do not comply with the
applicable GMPs and other FDA regulatory requirements, we may be subject to product liability claims, the availability of marketed products for sale could be reduced, our product commercialization could be delayed or subject to restrictions, we may
be unable to meet demand for our products and may lose potential revenues and we could suffer delays in the progress of preclinical testing and clinical trials for products under development. We do not have control over our third-party
manufacturers&#146; compliance with these regulations and standards. Moreover, while we may choose to manufacture our products ourselves in the future, we have no experience in the manufacture of pharmaceutical or biological products for clinical
trials or commercial purposes. If we decide to manufacture products, we would be subject to the regulatory requirements described above. In addition, we would require substantial additional capital and would be subject to delays or difficulties
encountered in manufacturing pharmaceutical or biological products. Regardless of the manufacturer of our products, we will be subject to continuing obligations regarding the submission of safety reports and other post-market information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to find a method to produce MU1140 in large-scale commercial quantities. If we cannot, we will be unable to generate significant
revenues from sales of our MU1140 product candidate. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our antibiotic product candidate, MU1140, is produced by our strain of <I>S. mutans</I>. To
date, it has been produced only in laboratory cultures. In March 2005 we successfully developed a methodology for producing MU1140 in quantities sufficient to undertake its preclinical testing. In addition, we developed the DPOLT synthetic chemistry
methodology to allow large-scale commercial production of, a synthetic version of MU1140, known as MU1140-S. However, this methodology may not be feasible for cost effective, large scale manufacture. In June of 2012 we entered into an exclusive
collaboration agreement with Intrexon Corporation to use its advanced transgene and cell engineering platforms to achieve sufficient production quantities of MU1140. While preliminary results from these efforts have demonstrated progress in the
increase in production of MU1140, we will need to contract with a third party manufacturer to produce additional quantities in order to be able to pursue further preclinical testing. If we are not able to utilize either of these methodologies for
large-scale manufacture, we will be unable to partner and generate revenues from this product candidate and our business, financial condition and results of operations will be materially adversely affected. The manufacturing of MU1140 or any other
possible antibiotic product candidates based on lantibiotics, is a highly exacting and complex process. Manufacturing MU1140 or any other antibiotic candidates derived from lantibiotics on a commercial scale has not yet been achieved so there are
additional risks that such efforts will not be successful. The Intrexon technology may not be feasible to efficiently develop methodologies to enable large scale manufacturing of MU1140 or other antibiotic product candidates. Third-party
manufacturers must have additional technical skills and must take multiple steps to attempt to control the manufacturing processes. If we are unable to produce MU1140 in large-scale commercial quantities, we will be unable to generate significant
revenues from sales of our MU1140 product candidate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ProBiora3 products and our product candidates face various forms of competition from other products in
the marketplace. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by intense competition, rapid product development and
technological change. Most of the competition that our ProBiora3 products and our product candidates face comes from companies that are large, well established and have greater financial, marketing, sales and technological resources than we have.
Our ProBiora3 products compete with a range of consumer and nutraceutical products. Our commercial success with product candidates will depend on our ability and the ability of any sub-licensees to compete effectively in marketing and product
development areas including, but not limited to, sales and branding, drug safety, efficacy, ease of use, patient or customer compliance, price, marketing and distribution. There can be no assurance that competitors will not succeed in developing and
marketing products that are more desirable or effective than our ProBiora3 products or the products developed from our product candidates or that would render our products obsolete and non-competitive. We anticipate that our SMaRT Replacement
Therapy technology would compete with other companies attempting to develop technologies in the oral health care market, including vaccines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
rely on the significant experience and specialized expertise of our senior management and scientific team and we have incurred significant turnover in key positions over the last several years. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our performance is substantially dependent on the continued services and on the performance of our senior management and scientific team, who have extensive
experience and specialized expertise in our business. Our performance also depends on our ability to retain and motivate our other key employees. In May 2011, we hired Dr.&nbsp;John Bonfiglio as Chief Executive Officer and in February 2012, we hired
Mr.&nbsp;Michael Sullivan, CPA as our Chief Financial Officer. The loss of the services of these key employees could harm our ability to develop and commercialize our product candidates. We have no key man life insurance policies. We have employment
agreements with Dr.&nbsp;Bonfiglio and Mr.&nbsp;Sullivan. The term of each of these employment agreements is for an indefinite period and will end when the employment relationship is terminated by either party for any or no reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We need to hire and retain additional qualified scientists and other highly skilled personnel to maintain and grow our business. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future success depends on our ability to identify, attract, hire, train, retain and motivate highly skilled technical, managerial and research personnel
in all areas within our organization. We plan to continue to grow our business and will need to hire additional personnel to support this growth. We believe that there are only a limited number of individuals with the requisite skills to serve in
many of our key positions, and we compete for key personnel with other biotechnology and nutraceutical companies, as well as universities and research institutions. It is often difficult to hire and retain these persons, and we may be unable to
replace key persons if they leave or be unable to fill new positions requiring key persons with appropriate experience. If we fail to attract, integrate and retain the necessary personnel, our ability to maintain and grow our business could suffer
significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any of our product candidates are shown to be ineffective or harmful in humans, we will be unable to generate revenues from these
product candidates. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through
preclinical testing and clinical trials that our products are safe and effective for use in humans. To date the testing of the antibiotic substance MU1140 has been undertaken solely in the laboratory and in animals. We have not yet conducted human
studies with any MU1140 or any analog thereof. It is possible that when these studies are conducted, they will show that our antibiotic candidates are ineffective or harmful in humans. If MU1140 or any analogs thereof are shown to be ineffective or
harmful in humans, we will be unable to commercialize and generate revenues from sales of this compound. If we are unable to generate revenues from MU1140 or any other product candidates, our business, financial condition and results of operations
will be materially adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We intend to rely on third parties to pay the majority of the costs associated with obtaining regulatory
approval for, and manufacturing and marketing of, our product candidates. If we are unable to obtain agreements with third parties to fund these costs, we will have to fund such costs ourselves or we may be unable to extract any value from these
technologies. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we continue our development of product candidates, we intend to either license these product candidates to, or partner with, one
or more major pharmaceutical companies at the earliest possible time in their product development. If we do so, we intend for these licensees or partners to pay the costs associated with any remaining development work, regulatory submissions,
clinical trials and the manufacturing and marketing of our product candidates. If we are unable to license our product candidates or otherwise partner with third parties, we will have to fund the costs of our clinical trials ourselves or we will be
unable to extract any value from these technologies. We will also have to establish our own manufacturing facilities and find our own distribution channels. This would greatly increase our future capital requirements and we cannot assure you that we
would be able to obtain the necessary financing to pay these costs or that we will be generating significant revenues from any of our products, such as ProBiora3, sufficient to cover the associated costs. If we do not generate sufficient revenues to
cover the associated costs or we cannot obtain financing on acceptable terms or at all, our business, financial condition and results of operations will be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our dependence on collaborative arrangements with third parties subjects us to a number of risks. These collaborative arrangements may not be on terms
favorable to us. Agreements with collaborative partners typically allow partners significant discretion in electing whether or not to pursue any of the planned activities. We cannot control the amount and timing of resources our collaborative
partners may devote to products based on the collaboration, and our partners may choose to pursue alternative products. Our partners may not perform their obligations as expected. Business combinations or significant changes in a collaborative
partner&#146;s business strategy may adversely affect a partner&#146;s willingness or ability to complete its obligations under the arrangement. Moreover, we could become involved in disputes with our partners, which could lead to delays or
termination of the collaborations and time-consuming and expensive litigation or arbitration. Even if we fulfill our obligations under a collaborative agreement, our partner may be able to terminate the agreement under certain circumstances. If any
collaborative partner were to terminate or breach our agreement with it, or otherwise fail to complete its obligations in a timely manner, our chances of successfully commercializing our product candidates would be materially and adversely affected.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to risks of doing business internationally as we attempt to expand our sales through international distributor relationships.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a number of international distributor agreements for our ProBiora3 products. As a result, we expect to increase our revenues
from international sales. A number of factors can slow or prevent international sales, or substantially increase the cost of international sales, and we may encounter certain risks of doing business internationally including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced protection and enforcement for our intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unexpected changes in, or impositions of, legislative or regulatory requirements that may limit our ability to sell our products and repatriate funds to the United States; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">political and economic instability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in foreign currency exchange rates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in developing and maintaining distributor relationships in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in negotiating acceptable contractual terms and enforcing contractual obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exposure to liabilities under the U.S. Foreign Corrupt Practices Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential trade restrictions and exchange controls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">creditworthiness of foreign distributors, customer uncertainty and difficulty in foreign accounts receivable collection; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the burden of complying with foreign laws and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Potential for fines for claimed violations of foreign laws and regulations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we attempt to expand our sales
internationally, our exposure to these risks could result in our inability to attain the anticipated benefits and our business could be adversely impacted. Our success will depend, in large part, on our ability to anticipate and effectively manage
these and other risks associated with our international operations. However, any of these factors could adversely affect our international operations and, consequently, our operating results. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our intellectual property rights do not adequately protect our products or product candidates, or if
third parties claim we are infringing their intellectual property rights, others could compete against us more directly or we could be subject to significant litigation. Such results could prevent us from marketing our products or product candidates
and hurt our profitability. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product and product candidates are protected by patents and patent applications, including patents exclusively
licensed from the University of Florida Research Foundation, Inc., or the UFRF. We are the exclusive worldwide licensee to the patents for SMaRT Replacement Therapy and MU1140, which are owned by the UFRF. Our success depends in part on our ability
to obtain patents or rights to patents, protect trade secrets, operate without infringing upon the proprietary rights of others, and prevent others from infringing on our patents, trademarks and other intellectual property rights. We will be able to
protect our intellectual property from unauthorized use by third parties only to the extent that it is covered by valid and enforceable patents, trademarks and licenses. Patent protection generally involves complex legal and factual questions and,
therefore, enforceability of patent rights cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. Thus, any patents that we own or license from others may not provide adequate protection against
competitors. In addition, any future patent applications may fail to result in patents being issued. Also, those patents that are issued may not provide us with adequate proprietary protection or competitive advantages against competitors with
similar product candidates. Moreover, the laws of certain foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to patents and trademarks, we rely on trade secrets and proprietary know-how. We seek protection of these rights, in part, through confidentiality
and proprietary information agreements. These agreements may not provide meaningful protection or adequate remedies for violation of our rights in the event of unauthorized use or disclosure of confidential and proprietary information. Failure to
protect our proprietary rights could seriously impair our competitive position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of an infringement or violation, we may face litigation and
may be prevented from pursuing product development or commercialization. We may receive in the future, notice of claims of infringement of other parties&#146; proprietary rights. We may not have the financial resources to defend against claims of
infringement by other parties. Infringement or other claims could be asserted or prosecuted against us in the future and it is possible that past or future assertions or prosecutions could harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA instituted numerous clinical holds with respect to our Phase 1 clinical trial program for our SMaRT Replacement Therapy product candidate.
Although the clinical holds were lifted with respect to the attenuated version of the SMaRT strain, a clinical hold remains in effect for our IND for the non-attenuated SMaRT strain. If the FDA does not lift the clinical hold on this IND, we will be
unable to conduct the clinical trials necessary to obtain marketing approval of our product candidate. The FDA&#146;s concerns that resulted in these clinical holds may lead to the imposition of a new clinical hold or holds or the failure of our
product candidates to obtain marketing approval. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 1998, the FDA imposed a clinical hold on the IND for our SMaRT strain. The FDA
expressed concerns about the potential for DNA transfer into or from the SMaRT strain; the possible creation of an organism with increased ability to colonize and produce dental caries; and the potential for the transfer of the strain between
humans. We met with the FDA to discuss proposed trials of an attenuated SMaRT strain to address the FDA&#146;s concerns, and the FDA informed us that such trials required a separate IND. We submitted an IND for the attenuated strain in March 2003.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA then imposed multiple clinical holds with respect to the Phase 1 clinical trials of the attenuated strain. Specifically, we received clinical
hold letters in May 2003,&nbsp;February 2004,&nbsp;June 2007 and August 2007. In connection with the clinical hold letter in May 2003, the FDA requested that we provide preclinical data on eradication of the attenuated version of the SMaRT strain
once it had been implanted and a plan for the eradication of the attenuated strain in the trial subjects and their spouse or partners. In an April 2004 meeting, the FDA suggested that we conduct two eradication trials: one in subjects without teeth,
and, if successful, another trial in subjects with teeth. We submitted revised protocols in accordance with FDA&#146;s suggestions, and in November 2004 the FDA lifted the clinical hold for the attenuated strain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We initiated our first Phase 1 clinical trial in April 2005, but we found it difficult to find subjects who fit the FDA&#146;s highly cautious inclusion and
exclusion criteria, particularly with respect to the subjects&#146; lack of dentition. We concluded this trial early after enrolling only two of the 15 planned subjects. The FDA then recommended that we revise the protocol for the evaluation of ten
healthy male subjects, ranging from 18 to 30 years old and with normal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dentition, in an institutionalized setting. After we submitted additional information, the FDA issued another clinical hold letter in June 2007 for the proposed trial with the attenuated strain,
citing the need for a plan with respect to serious adverse effects; a plan for the eradication of the attenuated strain in trial subjects&#146; offspring; and a required pregnancy test for female partners of subjects. We submitted additional
protocols in response to the FDA&#146;s concerns. In August 2007, the FDA issued another clinical hold letter with required revisions to the protocol for offspring of subjects. We submitted a response to the clinical hold letter in September 2007,
and the FDA removed the clinical hold for our Phase 1 trial in the attenuated strain in October 2007. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we commenced a Phase 1b clinical trial for
SMaRT Replacement Therapy during the first quarter of 2011, the very restrictive study enrollment criteria required by the FDA made the enrollment of candidates meeting the restrictive criteria difficult. Due to the enrollment difficulty we
encountered with our initial our Phase 1a clinical trial and now with our phase 1b clinical trial, we determined to discontinue pursuit of our Phase 1b clinical trial and instead focus our efforts on possible partnering opportunities that may exist
for our SMaRT Replacement Therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that future clinical trials for the attenuated strain will be successful, or that the FDA
will ever lift the clinical hold on the non-attenuated SMaRT strain. In addition, there can be no assurances that we will be able to locate a partner willing to pursue further development of our SMaRT Replacement Therapy technology. If the FDA does
not lift the clinical hold on the non-attenuated SMaRT strain, we or a partner would not be able to conduct the clinical trials necessary to pursue marketing approval of the SMaRT strain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may impose additional requirements that may significantly increase the time and expense of obtaining FDA approval. Although the FDA has removed the
clinical holds with respect to our Phase 1 trials for the attenuated strain, if the FDA has further concerns regarding the safety or risks associated with our trials, the FDA could implement another clinical hold on our ongoing trial or future
trials or raise concerns as a part of a future NDA review process for our SMaRT Replacement Therapy product candidate, which could delay or prevent marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates are subject to substantial government regulation, including the regulation of preclinical testing and clinical trials. If we are
unable to obtain regulatory approval for our product candidates we will be unable to generate revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The production and marketing of products
which may be developed from our MU1140 product candidate, our SMaRT Replacement Therapy product candidate or any other product candidates from our Lantibiotics Program and probiotics program or otherwise and our research and development, preclinical
testing and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities. Most of the product candidates we are developing must undergo rigorous preclinical testing and clinical trials and an
extensive regulatory approval process before they can be marketed in the United States or internationally. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we fail to obtain regulatory approval for
our product candidates, or if the FDA fails to lift the clinical hold on our IND for non-attenuated version of SMaRT, we may have to cease further development. Clinical trials on our product candidates are expected to take several years to fully
complete. The commencement or completion of preclinical studies or clinical trials can be delayed or prevented for a number of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our belief that SMaRT Replacement Therapy is one of the first genetically modified bacterial strains for use in humans, which may cause the FDA to proceed with additional caution; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in finding a partner with the resources to support large and expensive clinical development and commercialization costs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">findings in preclinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties obtaining regulatory approval to commence a clinical trial or complying with conditions imposed by a regulatory authority regarding the scope or term of a clinical trial; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and trial sites, the terms of which can be subject to extensive negotiation and may vary
significantly among different CROs and trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">insufficient or inadequate supply or quality of a product candidate or other materials necessary to conduct our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">challenges recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including the size and nature of patient population, proximity of patients to clinical sites, eligibility criteria
for the trial, nature of the trial protocol, the availability of approved effective treatments for the relevant condition and competition from other clinical trial programs for similar indications; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">severe or unexpected drug or biologic-related side effects experienced by patients in a clinical trial; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties retaining patients who have enrolled in a clinical trial but may be prone to withdraw due to rigors of the trial, lack of efficacy, side effects, or personal issues, or who are lost to further follow up.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials also may be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may
be suspended or terminated by us, the FDA, the IRBs at the sites where the IRBs are overseeing a trial, or a data safety monitoring board, or DSMB, overseeing the clinical trial at issue, or other regulatory authorities due to a number of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues or lack of effectiveness; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue the clinical trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that clinical trials will
demonstrate the safety or effectiveness of any of our product candidates, or will otherwise satisfy regulatory requirements. Our preclinical studies or clinical trials may produce negative or inconclusive results, there may be inconsistencies
between early clinical trial results and results obtained in later clinical trials, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials. Moreover, preclinical and clinical data are often
susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain FDA approval for their
products. If we are unable to resolve the FDA&#146;s concerns, we will not be able to obtain regulatory approval for these product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
pre-marketing approval process can be particularly expensive, uncertain and lengthy, and a number of products for which FDA or other governmental regulatory approval has been sought by other companies have never been approved for marketing. In
addition to testing and approval procedures, extensive regulations also govern marketing, manufacturing, distribution, labeling, and record-keeping procedures. If we do not comply with applicable regulatory requirements, such violations could result
in warning letters, non-approval, suspensions of regulatory approvals or ongoing clinical trials, civil penalties and criminal fines, product seizures and recalls, operating restrictions, injunctions, and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may encounter such delays and rejection of our product candidates by the FDA or other regulatory authority may also adversely affect our business. Such
delays or rejection may be encountered due to, among other reasons, government or regulatory delays, lack of efficacy during clinical trials, unforeseen safety issues, or changes in regulatory policy during the period of product development. More
stringent regulatory approval processes in product clearance and enforcement activities could result in our experiencing longer approval cycles, more uncertainty, greater risk, and higher expenses. Even if regulatory approval of a product is
granted, this approval may entail limitations on uses for which the product may be labeled and promoted. It is possible, for example, that we may not receive FDA approval to market products based on our licensed, patented product candidates for
different indications or to market updated products that represent extensions of our basic product candidates. In addition, we may not receive FDA approval to export our products based on our licensed, patented product candidates in the future, and
countries to which products are to be exported may not approve them for import. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, legislative or regulatory proposals are introduced
that could alter the review and approval process relating to our product candidates. It is possible that the applicable regulatory authority will issue additional regulations further restricting the sale of our product candidates. Any change in
legislation or regulations that govern the review and approval process relating to our future product candidates could make it more difficult and costly to obtain approval for new products based on our product candidates, or to produce, market, and
distribute such products if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot assure you that the market and consumers will accept our products or product candidates. If they
do not, we will be unable to generate significant revenues from our products or product candidates and our business, financial condition and results of operations will be materially adversely affected. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The commercial success of our ProBiora3 products our MU1140 antibiotic product candidate, and any of our other product candidates and technologies will depend
in part on market acceptance by consumers. Biopharmaceutical companies have received substantial support from the scientific community, regulatory agencies and many governmental officials in the United States and internationally. Future scientific
developments, media coverage and political events may diminish such support. Public attitudes may be influenced by claims that health products are unsafe for consumption or pose unknown risks to the environment or to traditional social or economic
practices. Securing governmental approvals for, and consumer confidence in, such products poses numerous challenges, particularly outside the United States. The market success of product candidates developed by biopharmaceutical companies could be
delayed or impaired in certain geographical areas as a result. Products based on our product candidates may compete with a number of traditional dental therapies and drugs manufactured and marketed by major pharmaceutical companies and biotechnology
companies. Market acceptance of products based on our product candidates will depend on a number of factors including potential advantage over alternative treatment methods. We can offer you no assurance that dentists, physicians, patients or the
medical and dental communities in general will accept and utilize products developed from our product candidates. If they do not, we may be unable to generate significant revenues from our product candidates and our business, financial condition and
results of operations will be materially adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our products do not receive favorable third-party reimbursement, or if new
restrictive legislation is adopted, market acceptance of our products may be limited and we may not generate significant revenues. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to
commercialize our products will depend in part on the extent to which appropriate reimbursement levels for the cost of our proposed formulations and products and related treatments are obtained by governmental authorities, private health insurers
and other organizations, such as Health Maintenance Organizations, or HMOs. Reimbursement from third parties depends greatly on our ability to present data which demonstrate positive outcomes and reduced utilization of other products or services as
well as cost data which show that treatment costs using the new product are equal to or less than what is currently covered for other products. If our products do not receive favorable third-party reimbursement and patients are unwilling or unable
to pay for our products out-of-pocket, it could limit our revenues and harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The continuing efforts of government and insurance companies,
health maintenance organizations and other payers of healthcare costs to contain or reduce costs of health care may affect our future revenues and profitability, and the future revenues and profitability of our potential customers, suppliers and
collaborative partners and the availability of capital. For example, in certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control. In the United States, recent federal and state government
initiatives have been directed at lowering the total cost of health care. In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, a sweeping law intended to broaden access to health insurance, reduce or
constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health
policy reforms. Federal and state legislatures will likely continue to focus on health care reform, controlling the cost of prescription pharmaceuticals and on the reform of the Medicare and Medicaid systems. While we cannot predict whether any such
legislative or regulatory proposals will be adopted, the announcement or adoption of such proposals could materially harm our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud which
could subject us to regulatory sanctions, harm our business and operating results and cause the trading price of our stock to decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective
internal controls required under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley Act, are necessary for us to provide reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or
prevent fraud, our business, reputation and operating results could be harmed. We have discovered, and may in the future discover, areas of our internal controls that need improvement. We cannot be certain that the measures we have taken or intend
to take will ensure that we maintain adequate controls over our financial processes and reporting in the future. Any failure to implement required new or improved controls or difficulties encountered in their implementation could subject us to
regulatory sanctions, harm our business and operating results or cause us to fail to meet our reporting obligations. Inferior internal controls could also harm our reputation and cause investors to lose confidence in our reported financial
information, which could have a negative impact on the trading price of our stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>KFLP, together with members of the Koski family, have a substantial interest in our outstanding shares of common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, the KFLP, together with members of the Koski family, beneficially own approximately 41.6% of our outstanding shares of common
stock, and includes outstanding warrants to acquire 2,170,925 shares of our common stock that were issued in connection with our Debt Exchange Agreement and Loan Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Christine L. Koski and Robert C. Koski, serve on our Board of Directors and they each share voting and investment powers with two other Koski family members
as general partners of the KFLP. As a result, the Koski family will be able to affect the outcome of, or exert significant influence over, all matters requiring shareholder approval, including the election and removal of directors and any change in
control. In particular, this concentration of ownership of our common stock could have the effect of delaying or preventing a change of control of us or otherwise discouraging or preventing a potential acquirer from attempting to obtain control of
us. This, in turn, could have a negative effect on the market price of our common stock. It could also prevent our shareholders from realizing a premium over the market price for their shares of common stock. Moreover, the interests of this
concentration of ownership may not always coincide with our interests or the interests of other shareholders, and, accordingly, the Koski family could cause us to enter into transactions or agreements that we would not otherwise consider. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain provisions of our articles of incorporation, bylaws, executive employment agreements and stock option plan may prevent a change of control of
our company that a shareholder may consider favorable. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions of our articles of incorporation, bylaws, executive employment agreements and
stock option plan may discourage, delay or prevent a change of control of our company that a shareholder may consider favorable. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorization of the issuance of &#147;blank check&#148; preferred stock that could be issued by our Board of Directors without shareholder approval and that may be substantially dilutive or contain preferences or
rights objectionable to an acquirer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability of our Board of Directors to amend the bylaws without shareholder approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vacancies on our Board may only be filled by the remaining directors and not our shareholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements that only our Board, our President or holders of more than 10% of our shares can call a special meeting of shareholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obligations to make certain payments under executive employment agreements in the event of a change of control and termination of employment; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">immediate vesting of all outstanding stock options. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, these provisions could discourage bids for
our common stock at a premium and limit the price that investors are willing to pay in the future for shares of our common stock. However, in our articles of incorporation we expressly elected not to be governed by Sections 607.0901 and 607.0902 of
the Florida Business Corporation Act, which are statutory anti-takeover provisions relating to affiliated transactions and control share acquisitions, respectively. As such, we do not have the protection of these statutes in connection with any
unwanted takeover attempts which could have the effect of encouraging an attempted change of control without first negotiating with our Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We cannot assure you that our new listing on the NYSE MKT will increase the liquidity of our common stock or that our shares will continue to be listed
on the NYSE MKT. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock commenced trading on the NYSE MKT (formerly the NYSE Amex and the American Stock Exchange) on April&nbsp;10,
2013, and we are subject to certain NYSE MKT continued listing requirements and standards. Historically the daily trading volume of our shares is relatively low which has made our common stock significantly less liquid and there can be no assurance
that liquidity will increase as a result of being listed on the NYSE MKT. We may also incur costs that we have not previously incurred for expenses for compliance with the rules and requirements of the NYSE MKT. We cannot provide any assurance that
we will be able to continue to satisfy the requirements of the NYSE&#146;s continued listing standards. A delisting of our common stock could negatively affect the price and liquidity of our common stock and could impair our ability to raise capital
in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price has historically been volatile and the trading volume of our stock has been low.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since our initial public offering in June 2003 and through September&nbsp;30, 2013 our stock price has fluctuated from $90.00 to $0.75 per share.
The trading price of our common stock has been, and may be, subject to wide fluctuations in response to a number of factors, many of which are beyond our control. These factors include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">quarter-to-quarter variations in our operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our perceived funding needs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of testing, technological innovations, or new commercial products by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">governmental regulations, rules, and orders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our level of, and expected future use of, working capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general conditions in the healthcare, dentistry, or biopharmaceutical industries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">comments, research reports and/or earnings estimates by securities analysts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments concerning patents or other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation or public concern about the safety of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of directors, officers and key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">release of transfer restrictions on our outstanding shares of common stock or sales of additional shares of common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential litigation initiated against us; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the additional sale of common stock by us in capital raising transactions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, the daily trading
volume of our common stock has been relatively low and on some days our stock does not trade at all. An order for the purchase or sale of a large number of our shares could significantly affect the price at which the order is executed. We cannot
guarantee that an active public market for our common stock will be sustained or that the average trading volume will increase. In addition, the stock market in general has experienced significant price and volume fluctuations. Volatility in the
market price for particular companies has often been unrelated or disproportionate to the operating performance of those companies. Broad market factors may seriously harm the market price of our common stock, regardless of our operating
performance. In addition, securities class action litigation has often been initiated following periods of volatility in the market price of a company&#146;s securities. A securities class action suit against us could result in substantial costs,
potential liabilities, and the diversion of management&#146;s attention and resources. To the extent our stock price fluctuates or remains low, it could impair our ability to raise capital through the offering of additional equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The issuance of additional equity securities by us in the future could result in dilution to our existing shareholders. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has authority, without action or vote of our shareholders, to issue all or a part of our authorized but unissued shares, except where
shareholder approval is required by law. Any issuance of additional equity securities by us in the future could result in dilution to our existing shareholders. Such issuances could be made at a price that reflects a discount or a premium to the
then-current trading price of our common stock. In addition, our business strategy may include expansion through internal growth by acquiring complementary businesses, acquiring or licensing additional products or brands, or establishing strategic
relationships with targeted customers and suppliers. In order to do so, or to finance the cost of our other activities, we may issue additional equity securities that could result in further dilution to our existing shareholders. These issuances
would dilute your percentage ownership interest, which would have the effect of reducing your influence on matters on which our shareholders vote, and might dilute the book value of our common stock. For example, we have recently issued a
significant number of shares of our common stock in connection with financings and establishing strategic relationships and as a result our outstanding shares have increased from 5,894,176 shares as of December&nbsp;31, 2011 to 30,168,613 shares as
of September&nbsp;30, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Lantibiotics ECC that we entered into on June&nbsp;20, 2012, we will a be required to issue additional
shares of our common stock of up to 4.5% of our then outstanding common stock to Intrexon upon meeting certain commercialization milestones. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the new Probiotics ECC we entered into on September&nbsp;30, 2013, we will be required, at our
option, to pay up to $17 Million cash to Intrexon or issue up to $17 Million of additional shares of our common stock to Intrexon upon meeting certain commercialization milestones. We also issued a convertible promissory note in the amount of
$1,956,000 which is payable, at our option, in cash or shares of our common stock (the &#147;Convertible Note&#148;). The Convertible Note matures on December&nbsp;31, 2013 and the conversion price is equal to the closing price per share of our
common stock on the last trading day immediately prior to the date of conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may also incur additional dilution if performance awards are made
pursuant to our long term incentive programs for executives and non-employee directors or holders of stock options, whether currently outstanding or subsequently granted, exercise their options, or if warrant holders exercise their warrants to
purchase shares of our common stock. For example, on October&nbsp;21, 2013 we issued an aggregate of 389,174 shares of our common stock to our executive officers and non-employee directors pursuant to performance awards under our long term incentive
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our common stock may depress our stock price. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market price of our common stock could decline as a result of sales of substantial amounts of our common stock in the public market, or the perception
that these sales could occur. In addition, these factors could make it more difficult for us to raise funds through future offerings of common stock. We have recently issued a significant number of shares of common stock and the number of
outstanding shares has increased from 5,894,176 shares as of December&nbsp;31, 2011 to 27,382,830 as of December&nbsp;31, 2012 and as of September&nbsp;30, 2013 has increased to 30,168,613 shares . In June of 2012 we issued to Intrexon 4,392,425
shares of our common stock which are subject to piggy &#150;back registration rights. On July&nbsp;31, 2012, we issued 8,666,665 shares of Common Stock to investors and Warrants to purchase an additional 771,169 shares of Common Stock to the
placement agent and pursuant to a Registration Rights Agreement we are required to register these shares and warrant shares for resale. On August&nbsp;31, we filed a Registration Statement on Form S-1 to register the resale of these shares by the
purchasers. The Registration Statement as amended was declared effective by the SEC on September&nbsp;26, 2012. Accordingly, these shares may be resold in the open market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, there were 30,168,613 shares of our common stock outstanding, with another 2,747,094 shares of common stock issuable upon
exercise of warrants to investors, 607,840 shares issuable upon exercise of options outstanding and an additional 2,689,711 shares available for option grants under our 2012 Equity Incentive Plan. The issuance of shares of our common stock under our
2012 Equity Incentive Plan is covered by Form S-8 registration statements we filed with the Securities and Exchange Commission, or SEC, and upon exercise of the options, such shares may be resold into the market. We have also issued shares of common
stock and warrants in connection with previous private placements. Such shares are available for resale as well as certain of the shares of common stock issuable upon exercise of the warrants. We have also issued shares of our common stock in the
private placement and financing transaction, which are deemed to be &#147;restricted securities,&#148; as that term is defined in Rule 144 promulgated under the Securities Act of 1933, as amended, or Securities Act, and such shares may be resold
pursuant to the provisions of Rule 144. For example, on September&nbsp;30, 2013 we issued 1,348,000 restricted shares of our common stock to Intrexon as part of the technology access fee for the Probiotic&#146;s ECC and on the same date we also sold
1,300,000 restricted shares of our common stock to Intrexon in a private placement, The resale of shares acquired from us in private transactions could cause our stock price to decline significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, from time to time, certain of our shareholders may be eligible to sell all or some of their restricted shares of common stock by means of
ordinary brokerage transactions in the open market pursuant to Rule 144, subject to certain limitations. In general, pursuant to Rule 144, after satisfying a six-month holding period: (i)&nbsp;affiliated shareholders, or shareholders whose shares
are aggregated, may, under certain circumstances, sell within any three-month period a number of securities which does not exceed the greater of 1% of the then-outstanding shares of common stock or the average weekly trading volume of the class
during the four calendar weeks prior to such sale and (ii)&nbsp;non-affiliated shareholders may sell without such limitations, in each case provided we are current in our public reporting obligations. Rule 144 also permits the sale of securities by
non-affiliates that have satisfied a one-year holding period without any limitation or restriction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are unable to estimate the number of shares that
may be sold because this will depend on the market price for our common stock, the personal or business circumstances of sellers and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The requirements of being a public company may strain our resources, divert management&#146;s attention and
affect our ability to attract and retain qualified members for our Board of Directors. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company, we are already subject to the
reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Sarbanes-Oxley Act. The requirements of these rules and regulations may increase our legal, accounting and financial compliance costs; may make
some activities more difficult, time-consuming and costly; and may also place undue strain on our personnel, systems and resources. Our management and other personnel need to devote a substantial amount of time to comply with these requirements.
Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. These rules and regulations could also make it more difficult for us to attract and retain qualified
persons to serve on our Board of Directors and Board committees or as executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a public company we are also required to assess our internal
control over financial reporting under Section&nbsp;404 of the Sarbanes-Oxley Act and file periodic reports with the SEC. If we are unable to comply with these requirements in a timely manner, or if material weaknesses or significant deficiencies
persist, the market price of our stock could decline and we could be subject to sanctions or regulatory investigations, which could harm our business. We must perform an assessment of our internal control over financial reporting to allow management
to report on the effectiveness of our internal control over financial reporting, as required by Section&nbsp;404 of the Sarbanes-Oxley Act. Our compliance with Section&nbsp;404 of the Sarbanes-Oxley Act requires that we incur substantial accounting
expense and expend significant management efforts. If we are unable to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act or the SEC reporting requirements in a timely manner, or if we continue to note or identify
deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities,
which would require additional financial and management resources. As a smaller reporting company, we do not have to have our independent registered public accounting firm report on the effectiveness of our internal control over financial reporting.
If in the future we no longer meet the requirements of a smaller reporting company, our independent registered public accounting firm will have to report on our internal controls over financial reporting. There can be no assurance that our
independent registered public accounting firm will not identify material weaknesses which could have an adverse effect on our stock price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_13"></A>ITEM&nbsp;2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_14"></A>ITEM&nbsp;3. DEFAULTS UPON
SENIOR SECURITIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_15"></A>ITEM&nbsp;4. MINE SAFETY DISCLOSURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not Applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_16"></A>ITEM&nbsp;5.
OTHER INFORMATION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_17"></A>ITEM&nbsp;6. EXHIBITS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Incorporated by reference to the Exhibit Index filed after signature page. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc594509_18"></A>SIGNATURES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized on this 25th day of October, 2013. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ORAGENICS, INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BY:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John N. Bonfiglio Ph.D.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">John N. Bonfiglio Ph.D., President, Chief Executive Officer and Principal Executive Officer</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BY:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Sullivan</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Michael Sullivan, Chief Financial Officer and Principal Accounting Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>Incorporated by Reference</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:27.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:65.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File no.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:19.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing<BR>date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:30.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed<BR>herewith</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive License Agreement between the Company and the University of Florida Research Foundation, Inc. effective August 4, 1998 for Replacement Therapy for Dental Caries (the &#147;Replacement Therapy License Agreement&#148;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/16/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Replacement Therapy License Agreement dated September&nbsp;15, 2000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/16/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Replacement Therapy License Agreement dated June 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/16/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Third Amendment to Replacement Therapy License Agreement dated September&nbsp;25, 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/16/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amendment to Replacement Therapy License Agreement dated March 2003</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2/A-3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4/9/03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Standard Exclusive License Agreement with Sublicensing Terms between the Company and the University of Florida Research Foundation, Inc. effective June&nbsp;22, 2000 (the &#147;MU1140 License Agreement&#148;)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/16/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to the MU1140 License Agreement dated September&nbsp;15, 2000</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/16/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amendment to the MU1140 License Agreement dated June&nbsp;10, 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/16/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Third Amendment to the MU1140 License Agreement dated September&nbsp;25, 2002</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/16/02</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amendment to the Antimicrobial Polypeptide License Agreement dated March 2003</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">SB-2/A-3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">333-100568</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.36</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4/9/03</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amendment to Replacement Therapy License Agreement dated April 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">001-32188</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4/23/13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amendment to the MU1140 License Agreement dated April 2013</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">001-32188</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">4/23/13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive Channel Collaboration Agreement by and between Oragenics, Inc. and Intrexon Corporation dated as of September&nbsp;30, 2013.**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">001-32188</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/1/13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stock Purchase and Issuance Agreement by and between Oragenics, Inc. and Intrexon Corporation dated as of September&nbsp;30, 2013.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">001-32188</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/1/13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to the Stock Purchase and Issuance Agreement dated September&nbsp;30, 2013.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">001-32188</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/1/13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Convertible Promissory Note dated September&nbsp;30, 2013.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">001-32188</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">10/1/13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been requested for the redacted portions of this exhibit pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><B>Incorporated by Reference</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:27.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:65.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:19.10pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Form</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File&nbsp;no.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:19.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filing<BR>date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Filed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:30.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>herewith</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Executive Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Principal Financial Officer pursuant to Rule 13a-14 and Rule 15d-14(a), promulgated under the Securities and Exchange Act of 1934, as amended.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer).</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">X</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d594509dex311.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
<TEXT>
<HTML><HEAD>
<TITLE>Certification of Principal Executive Officer</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, John N. Bonfiglio Ph.D., certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I have reviewed
this Quarterly Report on Form 10-Q of Oragenics, Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The
registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls
and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant&#146;s auditors and the audit committee of the registrant&#146;s Board of Directors: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and
material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated this 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of October, 2013 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John N. Bonfiglio Ph.D.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">John N. Bonfiglio Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d594509dex312.htm
<DESCRIPTION>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
<TEXT>
<HTML><HEAD>
<TITLE>Certification of Principal Financial Officer</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Michael Sullivan, certify that: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. I have reviewed this
Quarterly Report on Form 10-Q of Oragenics, Inc.; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit
to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. The
registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,
particularly during the period in which this report is being prepared; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Designed such internal control over financial reporting, or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Evaluated the effectiveness of the registrant&#146;s disclosure controls
and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the
registrant&#146;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to
the registrant&#146;s auditors and the audit committee of the registrant&#146;s Board of Directors: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All significant deficiencies and
material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record, process, summarize and report financial information; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s
internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated this 25<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day of October, 2013 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Sullivan</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Michael Sullivan</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d594509dex321.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (CHIEF EXECUTIVE OFFICER)
<TEXT>
<HTML><HEAD>
<TITLE>Certification pursuant to 18 U.S.C. Section 1350 (Chief Executive Officer)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section&nbsp;1350) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2013 (the &#147;Report&#148;) of Oragenics, Inc. (the
&#147;Registrant&#148;), as filed with the Securities and Exchange Commission on the date hereof, I, John N. Bonfiglio Ph.D., the Chief Executive Officer of the Registrant, hereby certify, to the best of my knowledge, that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as
amended; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Registrant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John N. Bonfiglio Ph.D.</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">John N. Bonfiglio Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">October 25, 2013</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d594509dex322.htm
<DESCRIPTION>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (CHIEF FINANCIAL OFFICER)
<TEXT>
<HTML><HEAD>
<TITLE>Certification pursuant to 18 U.S.C. Section 1350 (Chief Financial Officer)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 32.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Chief Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section&nbsp;1350) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2013 (the &#147;Report&#148;) of Oragenics, Inc. (the
&#147;Registrant&#148;), as filed with the Securities and Exchange Commission on the date hereof, I, Michael Sullivan, the Chief Financial Officer of the Registrant, hereby certify, to the best of my knowledge, that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1) The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, as
amended; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2) The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Registrant. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Sullivan</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Michael Sullivan</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">October 25, 2013</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>ogen-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 4 -->
<!-- Creation date: 2013-10-24T00:14:06Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:ogen="http://oragenics.com/20130930" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="ogen-20130930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE382471--1310-Q0005_STD_0_20130308_0_923847x1164788" unitRef="pure" decimals="INF" id="id_2113118_5DDDFA4B-A3AA-4BC0-906F-7B2505C269D9_1003_2">0.0657</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE382471--1310-Q0005_STD_0_20130308_0_923847x1164788" unitRef="iso4217_USD" decimals="0" id="id_2113118_5DDDFA4B-A3AA-4BC0-906F-7B2505C269D9_1003_1">50037</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE382471--1310-Q0005_STD_0_20130620_0_923847x931724" unitRef="pure" decimals="INF" id="id_2113118_5DDDFA4B-A3AA-4BC0-906F-7B2505C269D9_2004_4">0.0464</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE382471--1310-Q0005_STD_0_20130620_0_923847x931724" unitRef="iso4217_USD" decimals="0" id="id_2113118_5DDDFA4B-A3AA-4BC0-906F-7B2505C269D9_2004_3">106994</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE382471--1310-Q0005_STD_0_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2002_28">11757775</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <ogen:WarrantsIssued contextRef="eol_PE382471--1310-Q0005_STD_0_20120930_0_921954x1164725" unitRef="shares" decimals="INF" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_3002_38">771169</ogen:WarrantsIssued>
  <us-gaap:PreferredStockNoParValue contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" xsi:nil="true" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_19" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_27">30168613</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_26">30168613</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="shares" xsi:nil="true" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_22" />
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_8995EFA2-DC8A-466D-BFB1-5838B926FD2C_5001_9">2747094</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_20">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_25">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_24">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="shares" xsi:nil="true" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_21" />
  <us-gaap:PreferredStockValue contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_18" />
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_28">71408003</us-gaap:AdditionalPaidInCapital>
  <us-gaap:ShortTermNonBankLoansAndNotesPayable contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_13">108220</us-gaap:ShortTermNonBankLoansAndNotesPayable>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_16">4452899</us-gaap:LiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_30">4362391</us-gaap:StockholdersEquity>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_12">2364968</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_29">-67075781</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_15">23711</us-gaap:DeferredRevenueCurrent>
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_14">1956000</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_23">30169</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_31">8815290</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:InventoryValuationReserves contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_9B5DB620-63EF-4844-AC62-E027A1138E97_1_0">22000</us-gaap:InventoryValuationReserves>
  <us-gaap:AssetsCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_7">8777092</us-gaap:AssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_9">8815290</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_2">8267888</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_4">58878</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_5">223318</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_6">227008</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_1_8">38198</us-gaap:PropertyPlantAndEquipmentNet>
  <ogen:NumberOfVendorsWithPrepaidBalanceOfCompany contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="Vendor" decimals="INF" id="id_2113118_89691DAB-2E85-472A-9B3E-C3E01901801F_5_3">1</ogen:NumberOfVendorsWithPrepaidBalanceOfCompany>
  <ogen:ClassOfWarrantOutstandingWeightedAverageExercisePrice contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_7BA700F7-18C9-4C58-A5B7-E38249D660AB_5001_9">1.91</ogen:ClassOfWarrantOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharePrice contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_921954x1164727_928294x1220768" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_C4EA13DD-D7F3-48BD-BCCC-A0FB6A718486_2001_1">3.00</us-gaap:SharePrice>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_923847x954731" unitRef="pure" decimals="INF" id="id_2113118_2B8A5B8C-00DB-40CA-A720-7C4BA305C5ED_2001_1">0.0300</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_923847x954731" unitRef="iso4217_USD" decimals="0" id="id_2113118_2B8A5B8C-00DB-40CA-A720-7C4BA305C5ED_2001_0">1956000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_923847x954731_928294x1220768" unitRef="iso4217_USD" decimals="0" id="id_2113118_F8A2650B-D6E4-4639-9728-7095DE2B5BB5_4001_2">1956000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x1014875" unitRef="shares" decimals="INF" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_3_2">5000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x1014875" unitRef="iso4217_USD_per_Warrant" decimals="2" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_3_1">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <ogen:WarrantsExpirationDates contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x1014875" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_3_3">2014-04-15</ogen:WarrantsExpirationDates>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x960261" unitRef="shares" decimals="INF" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_1_2">571169</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x960261" unitRef="iso4217_USD_per_Warrant" decimals="2" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_1_1">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <ogen:WarrantsExpirationDates contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x960261" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_1_3">2017-07-30</ogen:WarrantsExpirationDates>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x975231" unitRef="shares" decimals="INF" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_2_2">2170925</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x975231" unitRef="iso4217_USD_per_Warrant" decimals="2" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_2_1">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <ogen:WarrantsExpirationDates contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x975231" id="id_2113118_A2E1889F-26E3-4384-B949-9CC8F8306CC6_2_3">2015-03-23</ogen:WarrantsExpirationDates>
  <us-gaap:DeferredRevenue contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_927059x1177511" unitRef="iso4217_USD" decimals="0" id="id_2113118_6752AD98-42C5-4508-9059-A6A77CAFF68D_1001_1">23711</us-gaap:DeferredRevenue>
  <ogen:TerminationNoticePeriod contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_928294x1220768" id="id_2113118_FB6366B5-CC42-4D44-87D3-77EC5BB941E9_2001_1">P90D</ogen:TerminationNoticePeriod>
  <ogen:TerminationNoticePeriod contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_928294x1220780" id="id_2113118_8E037B49-0714-4562-9683-391AEA2D4403_2001_4">P90D</ogen:TerminationNoticePeriod>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_930526x923447" unitRef="iso4217_USD" decimals="0" id="id_2113118_89691DAB-2E85-472A-9B3E-C3E01901801F_2001_1">0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20130930_0_930526x923447" unitRef="iso4217_USD" decimals="0" id="id_2113118_89691DAB-2E85-472A-9B3E-C3E01901801F_2001_2">27000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <ogen:PercentageOfShareGrantedUnderLongTermIncentiveProgram contextRef="eol_PE382471--1310-Q0005_STD_0_20131018_0_926607x927115_932504x931597" unitRef="pure" decimals="4" id="id_2113118_8E8A118C-DB4B-44DC-837E-AD9A0ED85567_1001_2">0.0017</ogen:PercentageOfShareGrantedUnderLongTermIncentiveProgram>
  <ogen:PercentageOfShareGrantedUnderLongTermIncentiveProgram contextRef="eol_PE382471--1310-Q0005_STD_0_20131018_0_926607x927612_932504x931597" unitRef="pure" decimals="4" id="id_2113118_8E8A118C-DB4B-44DC-837E-AD9A0ED85567_2001_1">0.0018</ogen:PercentageOfShareGrantedUnderLongTermIncentiveProgram>
  <ogen:PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram contextRef="eol_PE382471--1310-Q0005_STD_0_20131018_0_926607x931864_932504x931597" unitRef="pure" decimals="4" id="id_2113118_8E8A118C-DB4B-44DC-837E-AD9A0ED85567_3001_0">0.0050</ogen:PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram>
  <ogen:StockIssuedToEachDirectorDuringPeriodSharesOther contextRef="eol_PE382471--1310-Q0005_STD_0_20131018_0_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_5D88994B-4436-41EE-9382-99BDFB87E182_4002_3">33185</ogen:StockIssuedToEachDirectorDuringPeriodSharesOther>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20131025_0" unitRef="shares" decimals="INF" id="id_2113118_80C7FF39-E8B6-4B1E-B8F1-F42408367692_2_5">30506685</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20111231_0" unitRef="shares" decimals="INF" id="id_2113118_8995EFA2-DC8A-466D-BFB1-5838B926FD2C_1001_1">306388</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE382471--1310-Q0005_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_4001_27">171739</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <ogen:ClassOfWarrantOutstandingWeightedAverageExercisePrice contextRef="eol_PE382471--1310-Q0005_STD_0_20111231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_7BA700F7-18C9-4C58-A5B7-E38249D660AB_1001_1">19.14</ogen:ClassOfWarrantOutstandingWeightedAverageExercisePrice>
  <us-gaap:PreferredStockNoParValue contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" xsi:nil="true" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_19" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_27">27382830</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_26">27382830</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="shares" xsi:nil="true" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_22" />
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2113118_8995EFA2-DC8A-466D-BFB1-5838B926FD2C_3001_5">3235982</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_20">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_25">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_24">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="shares" xsi:nil="true" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_21" />
  <us-gaap:PreferredStockValue contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_18" />
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_28">63290625</us-gaap:AdditionalPaidInCapital>
  <us-gaap:ShortTermNonBankLoansAndNotesPayable contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_13">47977</us-gaap:ShortTermNonBankLoansAndNotesPayable>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_16">1256486</us-gaap:LiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_30">9231646</us-gaap:StockholdersEquity>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_12">1157520</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_29">-54086362</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_15">50989</us-gaap:DeferredRevenueCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_23">27383</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_31">10488132</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:InventoryValuationReserves contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_9B5DB620-63EF-4844-AC62-E027A1138E97_2_0">253000</us-gaap:InventoryValuationReserves>
  <us-gaap:AssetsCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_7">10403541</us-gaap:AssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_3">61763</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Assets contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_9">10488132</us-gaap:Assets>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_2">9925967</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_4">69795</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:InventoryNet contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_5">124178</us-gaap:InventoryNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_6">221838</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_AAA6156F-D756-4AED-B67F-F0CA7A286E21_2_8">84591</us-gaap:PropertyPlantAndEquipmentNet>
  <ogen:ClassOfWarrantOutstandingWeightedAverageExercisePrice contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_7BA700F7-18C9-4C58-A5B7-E38249D660AB_3001_5">3.53</ogen:ClassOfWarrantOutstandingWeightedAverageExercisePrice>
  <us-gaap:DeferredRevenue contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0_927059x1177511" unitRef="iso4217_USD" decimals="0" id="id_2113118_6752AD98-42C5-4508-9059-A6A77CAFF68D_1003_1">27812</us-gaap:DeferredRevenue>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE382471--1310-Q0005_STD_0_20121231_0_930526x923447" unitRef="iso4217_USD" decimals="0" id="id_2113118_89691DAB-2E85-472A-9B3E-C3E01901801F_2006_1">99000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x1032852_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_0B1D5008-4D08-4531-9C5E-11240E763D5E_1001_1">165925</us-gaap:StockIssuedDuringPeriodSharesOther>
  <ogen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x1032852_930809x1041243_932504x931597" unitRef="Non_Employee_Directors" decimals="INF" id="id_2113118_0B1D5008-4D08-4531-9C5E-11240E763D5E_1001_6">5</ogen:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x1057198_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_0B1D5008-4D08-4531-9C5E-11240E763D5E_2001_2">256434</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x927115_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_0B1D5008-4D08-4531-9C5E-11240E763D5E_3001_5">15287</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x927115_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_5D88994B-4436-41EE-9382-99BDFB87E182_1001_2">51287</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x927612_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_0B1D5008-4D08-4531-9C5E-11240E763D5E_4001_4">19000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x927612_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_5D88994B-4436-41EE-9382-99BDFB87E182_2001_1">54304</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x931864_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_0B1D5008-4D08-4531-9C5E-11240E763D5E_5001_3">50000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x931864_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_5D88994B-4436-41EE-9382-99BDFB87E182_3001_0">150843</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_0B1D5008-4D08-4531-9C5E-11240E763D5E_6001_0">422359</us-gaap:StockIssuedDuringPeriodSharesOther>
  <ogen:ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted contextRef="eol_PE382471--1310-Q0005_STD_18_20131018_0_930809x1041243_932504x931597" unitRef="shares" decimals="INF" id="id_2113118_5D88994B-4436-41EE-9382-99BDFB87E182_4001_4">10000</ogen:ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted>
  <dei:EntityRegistrantName contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_80C7FF39-E8B6-4B1E-B8F1-F42408367692_1_1">ORAGENICS INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_5A4DBA51-3F79-40D7-98F8-7776D0F7DB05_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_80C7FF39-E8B6-4B1E-B8F1-F42408367692_1_4">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_5A4DBA51-3F79-40D7-98F8-7776D0F7DB05_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_5A4DBA51-3F79-40D7-98F8-7776D0F7DB05_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_5A4DBA51-3F79-40D7-98F8-7776D0F7DB05_1_2">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_80C7FF39-E8B6-4B1E-B8F1-F42408367692_1_2">0001174940</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_80C7FF39-E8B6-4B1E-B8F1-F42408367692_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_5A4DBA51-3F79-40D7-98F8-7776D0F7DB05_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_C060BB29-BC7C-4300-BB81-61208A7A7ED0_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognized stock-based compensation on all employee and
 non-employee awards as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="46%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;183,168&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,858&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;158,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,726&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Selling, general and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,355,175&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;693,533&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,465,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;940,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total Stock based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,538,343&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;799,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,624,165&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,057,218&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company granted -0- and 35,000 stock options, with a
 weighted-average grant date fair value of -0- and $3.41 per share,
 during the three and nine months ended September&amp;#xA0;30, 2013,
 respectively. The Company granted -0- and 100,000 stock options,
 with a weighted-average grant date fair value of $0 and $1.03 per
 share, during the three and nine months ended September&amp;#xA0;30,
 2012, respectively. During the nine months ended September&amp;#xA0;30,
 2013, 50,533 stock options previously granted have vested, 56,050
 stock options were forfeited and 31,533 included in outstanding
 stock options were exercised.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Included in the results for the September&amp;#xA0;30, 2013 quarter is
 a liability and expense in the amount of $1,487,801 relating to
 probable awards under the Company&amp;#x2019;s 2012 Equity Incentive
 Plan (&amp;#x201C;2012 Plan&amp;#x201D;) pursuant to the Company&amp;#x2019;s long
 term performance based incentive programs for certain members of
 management and independent directors that were triggered by the
 Probiotic ECC. The liability and expense amount represents the
 grant date fair value of the 422,359 shares expected to be awarded
 under the 2012 Plan. See Note 8 &amp;#x2013; Subsequent Events.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_372E68FE-5BBF-4638-82B2-02CF1442C426_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 There are no new accounting pronouncements issued or effective
 during the second quarter of 2013 that have had or are expected to
 have an impact on the Company&amp;#x2019;s financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_2_2">50533</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_97BE6C38-889F-475C-95EA-14823D577705_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Stock-Based Payment Arrangements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Generally, all forms of stock-based payments, including stock
 option grants, warrants, and restricted stock grants are measured
 at their fair value on the awards&amp;#x2019; grant date typically using
 a Black-Scholes pricing model. Stock-based compensation awards
 issued to non-employees for services rendered are recorded at the
 fair value of the stock-based payment. The expense resulting from
 stock-based payments are recorded in research and development
 expense or selling, general and administrative expense in the
 statement of operations, depending on the nature of the services
 provided. Stock-based payment expense is recorded over the
 requisite service period in which the grantee provides services to
 us. To the extent the stock option grants, warrants, or restricted
 stock grants do not vest at the grant date they are subject to
 forfeiture.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_8C74E641-2162-4E61-B33C-71715074C9FD_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Commitments and
 Contingencies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;The University of Florida Research Foundation Licenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company holds exclusive licenses from the University of Florida
 Research Foundation, Inc. (&amp;#x201C;UFRF&amp;#x201D;) for its SMaRT
 Replacement Therapy and MU1140 product candidates.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;MU1140 &amp;#x2013;&lt;/i&gt; The Company has exclusively licensed the
 intellectual property for our MU1140 lantibiotic technology from
 the UFRF. The original license agreement was dated June&amp;#xA0;22,
 2000 and was subsequently amended on September&amp;#xA0;15,
 2000,&amp;#xA0;July&amp;#xA0;10, 2002,&amp;#xA0;September&amp;#xA0;25,
 2002,&amp;#xA0;March&amp;#xA0;17, 2003 and April&amp;#xA0;19, 2013. The amended
 license agreement provides the Company with an exclusive worldwide
 license to make, use and sell products and processes covered by
 Patent No.&amp;#xA0;5,932,469 entitled &amp;#x201C;Antimicrobial
 Polypeptide, Nucleic Acid and Methods of Use&amp;#x201D; and includes
 U.S. patent numbers 6,964,760; 7,067,125; 6,391,285; 6,475,771 and
 foreign patents. The Company&amp;#x2019;s license is for the period of
 the patents, which expire from 2017 through 2019, subject to the
 performance of terms and conditions contained therein.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;SMaRT Replacement Therapy &amp;#x2013;&lt;/i&gt; The Company has
 exclusively licensed the intellectual property for its replacement
 therapy technology from the UFRF. The original license agreement
 was dated August&amp;#xA0;4, 1998 and was subsequently amended on
 September&amp;#xA0;15, 2000,&amp;#xA0;July&amp;#xA0;10,
 2002,&amp;#xA0;September&amp;#xA0;25, 2002,&amp;#xA0;March&amp;#xA0;17, 2003 and
 April&amp;#xA0;19, 2013. The amended license agreement provides the
 Company with an exclusive worldwide license to make, use and sell
 products and processes covered by Patent No.&amp;#xA0;5,607,672,
 entitled &amp;#x201C;Replacement Therapy for Dental Caries&amp;#x201D;, which
 was filed in the U.S. PTO on June&amp;#xA0;7, 1995 and made effective
 on March&amp;#xA0;4, 1997. The patent will expire on June&amp;#xA0;7, 2015.
 The Company&amp;#x2019;s license is for the period of the patent,
 subject to the performance of terms and conditions contained
 therein.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Additional Terms of UFRF License Agreements &amp;#x2013;&lt;/i&gt; In the
 amended license agreements for SMaRT Replacement Therapy and
 MU1140, the Company is obligated to pay 5% of the selling price of
 any products developed from the licensed technologies that the
 Company may sell as royalty to the UFRF. In addition, if the
 Company sublicenses any rights granted by the amended license
 agreements, the Company is obligated to pay the UFRF 22% of all
 revenues received from the sublicenses, excluding monies received
 solely for development costs. The Company is also obligated to make
 the following payments to UFRF as follows: a one-time
 commercialization fee, post-commercialization minimum royalty
 payments, and a one-time cumulative royalty payment. The one-time
 commercialization fee would be due on the first anniversary of
 first commercial sale and is calculated at $5,000 per month between
 May&amp;#xA0;1, 2013 and the month of the first anniversary of a
 commercial sale. The post-commercialization minimum royalty
 payments of $50,000 annually would be due following payment of a
 commercialization fee. The one-time additional royalty payment
 would be due when total cumulative royalties paid to UFRF exceed
 $2.0 million, upon which we would be obligated to make a one-time
 additional payment to UFRF of 10% of the total royalties due to
 UFRF in the calendar year in which cumulative royalties exceeded
 $2.0 million.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company is required to make minimum annual maintenance payments
 to the UFRF for the term of the amended license agreements in the
 amount of $10,000 for each license agreement and $20,000 in
 aggregate. The aggregate minimum annual payments are required to be
 paid in advance on a quarterly basis (i.e. $5,000 per quarter) for
 both licenses. The Company must also pay all patent costs and
 expenses incurred by the UFRF for the preparation, filing,
 prosecution, issuance and maintenance of the patents.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;The Exclusive Channel Collaboration (&amp;#x201C;ECC&amp;#x201D;)
 Agreements with Intrexon Corporation
 (&amp;#x201C;Intrexon&amp;#x201D;)&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On September&amp;#xA0;30, 2013, the Company entered into an ECC
 Agreement (the &amp;#x201C;Probiotics ECC&amp;#x201D;) with Intrexon that
 governs a &amp;#x201C;channel collaboration&amp;#x201D; arrangement in which
 the Company will use Intrexon&amp;#x2019;s proprietary technology
 relating to the identification, design and production of
 genetically modified cells, DNA vectors and in vivo control of
 expression (the &amp;#x201C;Technology&amp;#x201D;) for the development and
 commercialization of probiotics, specifically the direct
 administration to humans of genetically modified probiotics for the
 treatment of diseases of the oral cavity, throat, sinus and
 esophagus, including, but not limited to, aphthous stomatitis and
 Behcet&amp;#x2019;s disease (collectively, the &amp;#x201C;Probiotics
 Program&amp;#x201D;). The Probiotics ECC establishes committees
 comprised of Company and Intrexon representatives that will govern
 activities related to the Probiotics Program in the areas of
 project establishment, chemistry, manufacturing and controls
 matters, clinical and regulatory matters, commercialization efforts
 and intellectual property matters.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Probiotics ECC grants the Company an exclusive worldwide
 license to utilize Intrexon&amp;#x2019;s Technology to develop and
 commercialize probiotics, specifically the direct administration to
 humans of genetically modified probiotics for the treatment of
 diseases of the oral cavity, throat, sinus and esophagus
 (&amp;#x201C;Company Products&amp;#x201D;). Such license is exclusive with
 respect to any clinical development, selling, offering for sale or
 other commercialization of Company Products, and otherwise is
 non-exclusive. Subject to limited exceptions, the Company may not
 sublicense the rights described without Intrexon&amp;#x2019;s written
 consent.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the Probiotics ECC, and subject to certain exceptions, the
 Company is responsible for, among other things, funding the further
 anticipated development of probiotics toward the goal of
 commercialization, conducting preclinical and clinical development
 of candidate probiotics, as well as for other aspects of
 manufacturing and the commercialization of the product(s). Among
 other things, Intrexon is responsible for technology discovery
 efforts, cell-engineering development, and certain aspects of the
 manufacturing process.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company will pay Intrexon 10% of the net sales derived from the
 sale of products developed from the exclusive channel collaboration
 relating to the Probiotics Program. The Company has likewise agreed
 to pay Intrexon a percentage of revenue obtained from a sublicensee
 in the event of a sublicensing arrangement. The percentage of the
 revenue to be paid will be determined at the time that a sublicense
 agreement is negotiated.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company may voluntarily terminate the Probiotics ECC upon 90
 days written notice to Intrexon. Intrexon may also terminate the
 Probiotics ECC if the Company breaches the Probiotics ECC and fails
 to cure the breach within 60 days or the Company does not pursue
 development of the Superior Therapy under the probiotics identified
 by Intrexon that is a &amp;#x201C;Superior Therapy&amp;#x201D; as defined in
 the Probiotics ECC.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upon termination of the Probiotics ECC, the Company may continue to
 develop and commercialize any Company Product that, at the time of
 termination, satisfies at least one of the following criteria:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;commercialized by the Company;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;approved by regulatory
 authorities;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;a subject of an application for
 regulatory approval that is pending before the applicable
 regulatory authority; or&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;the subject of at least an ongoing
 Phase 1, Phase 2 or Phase 3 clinical trial in the field of the
 Probiotics Program.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In addition, in partial consideration for each party&amp;#x2019;s
 execution and delivery of the Probiotics ECC, on September&amp;#xA0;30,
 2013 the Company entered into a Stock Purchase and Issuance
 Agreement and a First Amendment to the Stock Purchase and Issuance
 Agreement (collectively the &amp;#x201C;SPIA&amp;#x201D;) with Intrexon.
 Pursuant to the SPIA, the Company paid Intrexon an up-front
 technology access fee of $6,000,000 (the &amp;#x201C;Technology Access
 Fee&amp;#x201D;) in consideration for the execution of the Probiotics
 ECC. The Technology Access Fee was paid to Intrexon by the Company
 through the (i)&amp;#xA0;issuance of 1,348,000 shares (at $3.00 per
 share) of the Company&amp;#x2019;s common stock (the &amp;#x201C;Technology
 Access Shares&amp;#x201D;), and (ii)&amp;#xA0;a convertible promissory note
 in the amount of $1,956,000 which is payable, at the
 Company&amp;#x2019;s option, in cash or shares of Company common stock
 (the &amp;#x201C;Convertible Note&amp;#x201D;). The Convertible Note matures
 on December&amp;#xA0;31, 2013 and requires the Company to obtain
 shareholder approval prior to conversion of the Convertible Note.
 The conversion price is equal to the closing price per share of the
 Company&amp;#x2019;s common stock on the last trading day immediately
 prior to the date of conversion.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On September&amp;#xA0;30, 2013 the Company also sold to Intrexon
 1,300,000 shares of the Company&amp;#x2019;s common stock at a price per
 share of $3.00 for gross proceeds of $3,900,000. The Company
 intends to use the proceeds from this sale of common stock towards
 development of the Company&amp;#x2019;s key initiatives relating to the
 Probiotics Program, and general corporate purposes.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the SPIA and as part of the Probiotics ECC, the Company has
 also agreed to make certain payments to Intrexon upon the
 Company&amp;#x2019;s achievement of designated milestones. The milestone
 payments are each payable to Intrexon, at the Company&amp;#x2019;s
 election (subject to an election right of Intrexon if the milestone
 is achieved by a sublicensee), either in cash or in shares of
 Company common stock (using the fair market value of the shares to
 calculate the number of shares to be issued to Intrexon in lieu of
 cash). The Commercialization Milestone Events and amounts payable
 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;$2,000,000 within thirty
 (30)&amp;#xA0;days of the dosing of a patient by or on behalf of the
 Company, or an Affiliate (as that term is defined in the Probiotics
 ECC) or permitted sublicensee of the Company, in a phase II
 clinical trial, whether such occurs in the United States of America
 under the jurisdiction of the United States Food and Drug
 Administration (&amp;#x201C;FDA&amp;#x201D;) or elsewhere under the
 jurisdiction of a foreign regulatory agency, for a Company
 Product;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;$5,000,000 within thirty
 (30)&amp;#xA0;days of the first meeting of the primary endpoint by or
 on behalf of the Company, or an Affiliate or permitted sublicensee
 of the Company, in a phase III clinical trial, whether such occurs
 in the United States of America under the jurisdiction of the FDA
 or elsewhere under the jurisdiction of a foreign regulatory agency,
 for a Company Product;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;$10,000,000 within thirty
 (30)&amp;#xA0;days of the first to occur of (a)&amp;#xA0;the First
 Commercial Sale (as that term is defined in the Probiotics ECC) of
 a Company Product, or (b)&amp;#xA0;the approval of a New Drug
 Application (as that term is defined in the Probiotics ECC) for a
 Company Product by the FDA or equivalent regulatory action in a
 foreign jurisdiction.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 None of the Probiotic ECC milestones had been achieved as of
 September&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On June&amp;#xA0;5, 2012, the Company entered into an ECC Agreement
 (the &amp;#x201C;Lantibiotic ECC&amp;#x201D;) with Intrexon that governs a
 &amp;#x201C;channel collaboration&amp;#x201D; arrangement in which the
 Company will use Intrexon&amp;#x2019;s advanced transgene and cell
 engineering platforms for the development and production of
 lantibiotics, a class of peptide antibiotics that are naturally
 produced in Gram-positive bacteria and contain the characteristic
 polycyclic thioether amino acids lanthionine and methyllanthonine
 (collectively, the &amp;#x201C;Lantibiotics Program&amp;#x201D;). The
 Lantibiotic ECC establishes committees comprised of Company and
 Intrexon representatives that will govern activities related to the
 Lantibiotics Program in the areas of project establishment,
 chemistry, manufacturing and controls matters, clinical and
 regulatory matters, commercialization efforts and intellectual
 property matters.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Lantibiotic ECC grants the Company an exclusive worldwide
 license to use patents and other intellectual property of Intrexon
 in connection with the research, development, use, importing,
 exporting, manufacture, sale, and offer for sale of drug products
 involving the direct administration to humans or companion animals
 of a lantibiotic for the prevention or treatment of infectious
 disease (&amp;#x201C;Oragenics Products&amp;#x201D;). Such license is
 exclusive with respect to any clinical development, selling,
 offering for sale or other commercialization of Oragenics Products,
 and otherwise is non-exclusive. Subject to limited exceptions, the
 Company may not sublicense the rights described without
 Intrexon&amp;#x2019;s written consent.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the Lantibiotic ECC, and subject to certain exceptions, the
 Company is responsible for, among other things, funding the further
 anticipated development of lantibiotics toward the goal of
 commercialization, conducting preclinical and clinical development
 of candidate lantibiotics, as well as for other aspects of
 manufacturing and the commercialization of the product(s). Among
 other things, Intrexon is responsible for technology discovery
 efforts, cell-engineering development, certain aspects of the
 manufacturing process, and costs of filing, prosecution and
 maintenance of Intrexon&amp;#x2019;s patents.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Subject to certain expense allocations and other offsets provided
 in the Lantibiotic ECC, the Company will pay Intrexon on a
 quarterly basis 25% of gross quarterly profits derived in that
 quarter from the sale of products developed from the Lantibiotic
 ECC, calculated on an Oragenics Product-by-Oragenics Product basis.
 The Company has likewise agreed to pay Intrexon on a quarterly
 basis 50% of revenue obtained in that quarter from a sublicensor in
 the event of a sublicensing arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During the first 18 months of the agreement, neither the Company
 nor Intrexon may terminate the ECC Agreement, except under limited
 circumstances, including in the event of a material breach by the
 other party and Intrexon may terminate the Lantibiotic ECC under
 certain circumstances if the Company assigns its rights under the
 Lantibiotic ECC without Intrexon&amp;#x2019;s consent. Following the
 first 12 months of the agreement, Intrexon may also terminate the
 Lantibiotic ECC if the Company fails to use diligent efforts to
 develop and commercialize Oragenics Products or if the Company
 elects not to pursue the development of a Lantibiotics Program
 identified by Intrexon that is a &amp;#x201C;Superior Therapy&amp;#x201D; as
 defined in the Lantibiotic ECC. Following the first 18 months of
 the agreement, the Company may voluntarily terminate the
 Lantibiotic ECC at any time upon 90 days written notice to
 Intrexon.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upon termination of the Lantibiotic ECC, the Company may continue
 to develop and commercialize any Oragenics Product that has been,
 at the time of termination:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;commercialized by the Company;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;approved by regulatory
 authorities;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;a subject of an application for
 regulatory approval that is pending before the applicable
 regulatory authority; or&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;the subject of at least an ongoing
 Phase 1, Phase 2 or Phase 3 clinical trial in the Field (in the
 case of a termination by Intrexon due to an uncured material breach
 by the Company or a voluntary termination by the Company).&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s obligation to pay 25% of gross profits or
 revenue described above with respect to these
 &amp;#x201C;retained&amp;#x201D; products as well as to use diligent efforts
 to develop and commercialize these &amp;#x201C;retained&amp;#x201D; Oragenics
 Products will survive termination of the Lantibiotic ECC.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In addition, in partial consideration for each party&amp;#x2019;s
 execution and delivery of the Lantibiotic ECC, the Company entered
 into a Stock Issuance Agreement with Intrexon. Pursuant to the
 Stock Issuance Agreement, the Company issued to Intrexon 4,392,425
 shares of the Company&amp;#x2019;s common stock as an initial technology
 access fee, in consideration for the execution and delivery of the
 Lantibiotic ECC and granted Intrexon certain equity participation
 rights and registration rights.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Under the Stock Issuance Agreement and as part of the Lantibiotic
 ECC, the Company has also agreed to make certain payments to
 Intrexon upon the Company&amp;#x2019;s achievement of designated
 milestones in the form of shares of Company common stock or, at the
 Company&amp;#x2019;s option, make a cash payment to Intrexon (based upon
 the fair market value of the shares otherwise required to be
 issued). The milestone events and amounts payable are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="5%" align="left"&gt;(i)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;upon filing of the first
 Investigational New Drug application with the U.S. Food and Drug
 Administration for an Oragenics Product, that number of shares
 equal to the number of shares of common stock comprising 1.0% of
 the Base Shares (as defined below);&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="5%" align="left"&gt;(ii)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;upon the dosing of the first patient
 in the first Phase 2 clinical study with an Oragenics Product, that
 number of shares equal to the number of shares of common stock
 comprising 1.5% of the Base Shares;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="5%" align="left"&gt;(iii)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;upon the dosing of the first patient
 in the first Phase 3 clinical study with an Oragenics Product, that
 number of shares equal to the number of shares of common stock
 comprising 2% of the Base Shares;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="5%" align="left"&gt;(iv)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;upon the filing of the first New Drug
 Application (&amp;#x201C;NDA&amp;#x201D;) or Biologics License Application
 (&amp;#x201C;BLA&amp;#x201D;) with the U.S. Food and Drug Administration for
 an Oragenics Product, or alternatively the filing of the first
 equivalent regulatory filing with a foreign regulatory agency, that
 number of shares equal to the number of shares of Common Stock
 comprising 2.5% of the Base Shares; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="8%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="5%" align="left"&gt;(v)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;upon the granting of the first
 regulatory approval of an Oragenics Product, that number of shares
 equal to the number of shares of Common Stock comprising 3% of the
 Base Shares.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Base Shares is defined in the Stock Issuance Agreement to mean
 (i)&amp;#xA0;the number of shares of Company common stock together with
 any securities or instruments convertible or exercisable for shares
 of common stock issued and outstanding at the time of the
 applicable milestone event, (ii)&amp;#xA0;minus any shares issuable
 upon conversion of Capital Inducement Securities. Capital
 Inducement Securities is defined in the Stock Issuance Agreement to
 mean warrants or other convertible securities of the Company issued
 to investors in connection with a debt or equity investment in the
 Company that are issued in addition to the primary investment
 securities and in an amount not to exceed 10% of the overall number
 of shares issued in the investment (on an as-converted to common
 stock basis).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 None of the Lantibiotic ECC milestones had been achieved as of
 September&amp;#xA0;30, 2013.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_DB52742E-CA20-41AC-8735-077518B846B8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognizes revenues from the sales of product when
 title and risk of loss pass to the customer, which is generally
 when the product is shipped. Grant revenues are recognized as the
 reimbursable expenses are incurred over the life of the related
 grant. Grant revenues are deferred when reimbursable expenses have
 not been incurred.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company records allowances for discounts and product returns at
 the time of sale as a reduction of revenues as such allowances can
 be reliably estimated based on historical experience or known
 trends. The Company maintains a return policy that allows customers
 to return product within a specified period of time prior to and
 subsequent to the expiration date of the product. The estimate of
 the provision for returns is analyzed quarterly and is based upon
 many factors, including industry data of product return rates,
 historical experience of actual returns, analysis of the level of
 inventory in the distribution channel, if any, and reorder rates.
 If the history or product returns changes, the reserve will be
 adjusted. While the Company believes that the reserves it has
 established are reasonable and appropriate based upon current facts
 and circumstances, applying different judgments to the same facts
 and circumstances would result in the estimated amounts for sales
 returns and chargebacks to vary. Because the ProBiora3 products are
 still relatively new to the market, the Company could experience
 different circumstances in the future and these differences could
 be material.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_FD23D637-29E6-485C-A30E-3AB7AF20EFEA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The warrants outstanding as of September&amp;#xA0;30, 2013 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
 &lt;tr&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="40%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="40%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 48.6pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" align="center"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Warrants&lt;br /&gt;
 Outstanding&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Expiration&amp;#xA0;Dates&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;1.50&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;571,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7/30/17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;2.00&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,170,925&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3/23/15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;10.00&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4/15/14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,747,094&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="shares" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_18">27496676</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:LongTermDebtTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_9445A44E-FFBB-4A7E-81D2-BA9E288E43A0_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Convertible Note Payable To
 Shareholder&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On September 30, 2013, the Company entered into an unsecured
 short-term Convertible Promissory Note in the principal amount of
 $1,956,000 bearing interest at 3.00% as partial consideration for
 the Technology Access Fees associated with the Probiotic ECC
 (discussed below) entered into with Intrexon Corporation. The
 Convertible Promissory Note is payable, at the Company&amp;#x2019;s
 option, in cash or shares of the Company&amp;#x2019;s common stock.
 Principal and accrued interest are due on December 31, 2013.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:LongTermDebtTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_2_1">3.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:InventoryPolicyTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_43CCEEE4-7EDC-4FCF-8CBA-20940D39D05B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Inventory&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Inventory is stated at the lower of cost or market. Cost, which
 includes material, labor and overhead, is determined on a first-in,
 first-out basis. On a quarterly basis, we analyze our inventory
 levels and reserve for inventory that is expected to expire prior
 to being sold, inventory that has a cost basis in excess of its
 expected net realizable value, inventory in excess of expected
 sales requirements, or inventory that fails to meet commercial sale
 specifications. Expired inventory is disposed of and the related
 costs are written off to the reserve for inventory obsolescence.
 The inventory reserve was approximately $22,000 and $253,000 as of
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_14">-5545205</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_17">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_2_0">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_F9A146A1-1C66-4B60-803B-4193A1B5C844_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On October&amp;#xA0;18, 2013, the Compensation Committee of the Board
 of Directors (the &amp;#x201C;Board&amp;#x201D;) of the Company met and
 determined that one of the performance goals established in the
 Company&amp;#x2019;s Long Term Incentive Programs (&amp;#x201C;LTIP&amp;#x201D;)
 as part of executive compensation and non-employee director
 compensation had been achieved. The performance goal met was the
 goal related to the broadening of the Intrexon relationship to
 include a new area outside of lantibiotics. As a result of the
 Compensation Committee&amp;#x2019;s determination, and pursuant to the
 LTIP, Dr.&amp;#xA0;John Bonfiglio, the Company&amp;#x2019;s Chief Executive
 Officer, Michael Sullivan, the Company&amp;#x2019;s Chief Financial
 Officer, and Dr.&amp;#xA0;Martin Handfield, the Company&amp;#x2019;s Vice
 President of Research and Development, were entitled to awards of
 0.50%, 0.18%, and 0.17% respectively of the Company&amp;#x2019;s common
 stock outstanding at the time of the Compensation Committee&amp;#x2019;s
 determination that such goal had been met. Accordingly,
 Dr.&amp;#xA0;Bonfiglio, Mr.&amp;#xA0;Sullivan, and Dr.&amp;#xA0;Handfield were
 awarded 150,843, 54,304 and 51,287 shares of Company common stock
 under the Company&amp;#x2019;s 2012 Equity Incentive Plan (the
 &amp;#x201C;2012 Plan&amp;#x201D;), respectively. Also on October&amp;#xA0;18,
 2013 the Board met and determined that a similar performance goal
 under the previously established Long Term Incentive Program for
 the compensation of non-employee directors had been met. As a
 result, the Board approved the award of 33,185 shares of common
 stock under the Plan, to each of the Company&amp;#x2019;s directors who
 were not employed by the Company, including Frederick Telling,
 Charles Pope, Alan Dunton, Christine Koski and Robert Koski. In
 addition, the Board determined to amend its non-employee director
 compensation program. In connection with each annual meeting of
 shareholders commencing with the 2013 Annual Meeting, each
 continuing non-employee director will be granted an award of 10,000
 fully vested shares of the Company&amp;#x2019;s common stock under the
 Company&amp;#x2019;s 2012 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The aggregate shares awarded under the 2012 Plan of 422,359
 consisted of a total of 165,925 shares to non-employee directors
 and 256,434 shares to executive officers. Of the aggregate 422,359
 shares awarded under the LTIP, (i)&amp;#xA0;150,843 shares were awarded
 to Dr.&amp;#xA0;Bonfiglio of which 50,000 shares were retained by the
 Company for applicable tax withholding obligations,
 (ii)&amp;#xA0;54,304 shares were awarded to Mr.&amp;#xA0;Sullivan of which
 19,000 shares were retained by the Company for applicable tax
 withholding obligation, (iii)&amp;#xA0;51,287 shares were awarded to
 Dr.&amp;#xA0;Handfield of which 15,287 shares were retained by the
 Company for applicable tax withholding obligation, and
 (iv)&amp;#xA0;33,185 shares were awarded to each of the five
 non-employee directors.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_8E797D4A-999E-4BC5-8928-B5612AE916C2_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The accompanying unaudited interim financial statements as of
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012 (audited) and
 for the three and nine months ended September&amp;#xA0;30, 2013 and
 2012 have been prepared in accordance with accounting principles
 generally accepted in the United States of America
 (&amp;#x201C;GAAP&amp;#x201D;) for interim financial information and with the
 instructions to Form 10-Q and Article 10 of Regulation S-X.
 Accordingly, they do not include all of the information and
 footnotes required by GAAP for complete financial statements. In
 the opinion of management, the accompanying financial statements
 include all adjustments, consisting of normal recurring accruals,
 necessary for a fair presentation of the financial condition,
 results of operations and cash flows for the periods presented. The
 results of operations for the interim period September&amp;#xA0;30,
 2013 are not necessarily indicative of the results that may be
 expected for the year ending December&amp;#xA0;31, 2013 or any future
 period.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 These financial statements should be read in conjunction with the
 audited financial statements and notes thereto for the year ended
 December&amp;#xA0;31, 2012, which are included in our Annual Report on
 Form 10-K filed with the Securities and Exchange Commission on
 March&amp;#xA0;26, 2013. The Company has incurred recurring losses and
 negative cash flows from operations since inception. To date the
 Company has not generated significant revenues from operations. The
 Company generated revenues of $597,449, incurred a net loss of
 $12,989,419, and used cash of $5,545,205 in its operating
 activities during the nine months ended September&amp;#xA0;30, 2013. As
 of September&amp;#xA0;30, 2013, the Company had an accumulated deficit
 of $(67,075,781).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During 2012 and 2011, a significant source of debt and equity
 funding was provided to the Company by its largest shareholder, the
 Koski Family Limited Partnership (the &amp;#x201C;KFLP&amp;#x201D;). In 2012
 the Company raised $13,000,000 in gross proceeds through the
 private placement sale of its common stock. In 2013 the company
 raised $3,900,000 in gross proceeds through the private placement
 of its common stock. The Company expects to incur substantial
 expenditures to further develop each of its technologies. The
 Company believes the working capital at September&amp;#xA0;30, 2013
 will be sufficient to meet the business objectives as presently
 structured through December 2014.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s ability to continue operations after its
 current cash resources are exhausted depends on its ability to
 obtain additional financing or achieve profitable operations, as to
 which no assurances can be given. Cash requirements may vary
 materially from those now planned because of changes in the
 Company&amp;#x2019;s focus and direction of its research and development
 programs, competitive and technical advances, or other
 developments. Additional financing will be required to continue
 operations after the Company exhausts its current cash resources
 and to continue its long-term plans for clinical trials and new
 product development. There can be no assurance that any such
 financing can be realized by the Company, or if realized, what the
 terms thereof may be, or that any amount that the Company is able
 to raise will be adequate to support the Company&amp;#x2019;s working
 capital requirements until it achieves profitable operations.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company intends to seek additional funding through sublicensing
 arrangements, joint venturing or partnering, sales of rights to
 technology, government grants and public or private financings. The
 Company&amp;#x2019;s future success depends on its ability to raise
 capital and ultimately generate revenue and attain profitability.
 The Company cannot be certain that additional capital, whether
 through selling additional debt or equity securities or obtaining a
 line of credit or other loan, will be available to it or, if
 available, will be on terms acceptable to the Company. If the
 Company issues additional securities to raise funds, these
 securities may have rights, preferences, or privileges senior to
 those of its common stock, and the Company&amp;#x2019;s current
 shareholders may experience dilution. If the Company is unable to
 obtain funds when needed or on acceptable terms, the Company may be
 required to curtail their current development programs, cut
 operating costs and forego future development and other
 opportunities.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_2_4">31533</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_20FBB58B-C5F3-4FE3-9831-D6B82EAE7C66_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Concentrations&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company is dependent on key suppliers to provide probiotics,
 blending, warehousing and packaging of its EvoraPlus, EvoraKids,
 EvoraPro, and Teddy&amp;#x2019;s Pride products. The Company had four
 key suppliers during the three and nine months ended
 September&amp;#xA0;30, 2013 and 2012. The majority of the
 Company&amp;#x2019;s cost of sales are from these key suppliers during
 the three and nine months ended September&amp;#xA0;30, 2013 and 2012.
 Accounts payable and accrued expenses for these vendors totaled
 approximately $-0- and $99,000 as of September&amp;#xA0;30, 2013 and
 December&amp;#xA0;31, 2012, respectively. As of September&amp;#xA0;30,
 2013, the Company had a prepaid balance of approximately $27,000
 with one of these vendors.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_F9BE96EB-BAB4-4D89-ACA2-FC3F5450E9A4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 GAAP requires all share-based payments to employees, including
 grants of employee stock options, to be recognized in the financial
 statements based on their fair values as of the grant date.
 Stock-based compensation expense is recorded over the requisite
 service period in which the grantee provides services to us, to the
 extent the options do not vest at the grant date and are subject to
 forfeiture. For performance-based awards that do not include
 market-based conditions, we record share-based compensation expense
 only when the performance-based milestone is deemed probable of
 achievement. We utilize both quantitative and qualitative criteria
 to judge whether milestones are probable of achievement. For awards
 with market-based performance conditions, we recognize the
 grant-date fair value of the award over the derived service period
 regardless of whether the underlying performance condition is
 met.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_E60B3E72-542B-450F-AD86-4768E6294B08_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Significant Accounting
 Policies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 There are no new accounting pronouncements issued or effective
 during the second quarter of 2013 that have had or are expected to
 have an impact on the Company&amp;#x2019;s financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and disclosure of
 contingent assets and liabilities at the date of the financial
 statements, as well as the reported amounts of revenues and
 expenses during the reporting period. Actual results could differ
 from those estimates. The principal areas of estimation reflected
 in the financial statements are stock-based compensation, valuation
 of warrants, inventory obsolescence reserve, sales returns and
 allowances and the allowance for doubtful accounts.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The fair value of the Company&amp;#x2019;s cash and cash equivalents,
 accounts payable and accrued expenses approximate their carrying
 values due to their short-term nature.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Guaranteed Rights of Return&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has granted guaranteed rights of return to two dental
 distributors. The Company defers recognition of revenue on these
 accounts until either the distributor provides notification to the
 Company that the product has been sold to the end consumer or the
 guaranteed right of return period expires. Once notification has
 been received and verified, the Company records revenue in that
 accounting period. The Company had $23,711 and $27,812 of revenue
 deferred under guaranteed rights of return arrangements included in
 deferred revenue in the balance sheets as of September&amp;#xA0;30,
 2013 and December&amp;#xA0;31, 2012, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Inventory&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Inventory is stated at the lower of cost or market. Cost, which
 includes material, labor and overhead, is determined on a first-in,
 first-out basis. On a quarterly basis, we analyze our inventory
 levels and reserve for inventory that is expected to expire prior
 to being sold, inventory that has a cost basis in excess of its
 expected net realizable value, inventory in excess of expected
 sales requirements, or inventory that fails to meet commercial sale
 specifications. Expired inventory is disposed of and the related
 costs are written off to the reserve for inventory obsolescence.
 The inventory reserve was approximately $22,000 and $253,000 as of
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Stock-Based Payment Arrangements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Generally, all forms of stock-based payments, including stock
 option grants, warrants, and restricted stock grants are measured
 at their fair value on the awards&amp;#x2019; grant date typically using
 a Black-Scholes pricing model. Stock-based compensation awards
 issued to non-employees for services rendered are recorded at the
 fair value of the stock-based payment. The expense resulting from
 stock-based payments are recorded in research and development
 expense or selling, general and administrative expense in the
 statement of operations, depending on the nature of the services
 provided. Stock-based payment expense is recorded over the
 requisite service period in which the grantee provides services to
 us. To the extent the stock option grants, warrants, or restricted
 stock grants do not vest at the grant date they are subject to
 forfeiture.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 GAAP requires all share-based payments to employees, including
 grants of employee stock options, to be recognized in the financial
 statements based on their fair values as of the grant date.
 Stock-based compensation expense is recorded over the requisite
 service period in which the grantee provides services to us, to the
 extent the options do not vest at the grant date and are subject to
 forfeiture. For performance-based awards that do not include
 market-based conditions, we record share-based compensation expense
 only when the performance-based milestone is deemed probable of
 achievement. We utilize both quantitative and qualitative criteria
 to judge whether milestones are probable of achievement. For awards
 with market-based performance conditions, we recognize the
 grant-date fair value of the award over the derived service period
 regardless of whether the underlying performance condition is
 met.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company used the Black Scholes Option Pricing Model in
 calculating the relative fair value of any warrants that have been
 issued.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During all periods presented, the Company had securities
 outstanding that could potentially dilute basic earnings per share
 in the future, but were excluded from the computation of diluted
 net loss per share, as their effect would have been antidilutive.
 Because the Company reported a net loss for all periods presented,
 shares associated with the stock options and warrants are not
 included because they are antidilutive. Basic and diluted net loss
 per share amounts are the same for the periods presented. Net loss
 per share is computed using the weighted average number of shares
 of common stock outstanding.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognizes revenues from the sales of product when
 title and risk of loss pass to the customer, which is generally
 when the product is shipped. Grant revenues are recognized as the
 reimbursable expenses are incurred over the life of the related
 grant. Grant revenues are deferred when reimbursable expenses have
 not been incurred.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company records allowances for discounts and product returns at
 the time of sale as a reduction of revenues as such allowances can
 be reliably estimated based on historical experience or known
 trends. The Company maintains a return policy that allows customers
 to return product within a specified period of time prior to and
 subsequent to the expiration date of the product. The estimate of
 the provision for returns is analyzed quarterly and is based upon
 many factors, including industry data of product return rates,
 historical experience of actual returns, analysis of the level of
 inventory in the distribution channel, if any, and reorder rates.
 If the history or product returns changes, the reserve will be
 adjusted. While the Company believes that the reserves it has
 established are reasonable and appropriate based upon current facts
 and circumstances, applying different judgments to the same facts
 and circumstances would result in the estimated amounts for sales
 returns and chargebacks to vary. Because the ProBiora3 products are
 still relatively new to the market, the Company could experience
 different circumstances in the future and these differences could
 be material.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Concentrations&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company is dependent on key suppliers to provide probiotics,
 blending, warehousing and packaging of its EvoraPlus, EvoraKids,
 EvoraPro, and Teddy&amp;#x2019;s Pride products. The Company had four
 key suppliers during the three and nine months ended
 September&amp;#xA0;30, 2013 and 2012. The majority of the
 Company&amp;#x2019;s cost of sales are from these key suppliers during
 the three and nine months ended September&amp;#xA0;30, 2013 and 2012.
 Accounts payable and accrued expenses for these vendors totaled
 approximately $-0- and $99,000 as of September&amp;#xA0;30, 2013 and
 December&amp;#xA0;31, 2012, respectively. As of September&amp;#xA0;30,
 2013, the Company had a prepaid balance of approximately $27,000
 with one of these vendors.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:ShortTermDebtTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_AF69AAA9-430B-4583-9DC8-2BECC34DE71F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p&gt;&lt;!-- xbrl,n --&gt;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Short-term Notes Payable&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;!-- xbrl,body --&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As of September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012, the
 Company had $108,220 and $47,977 respectively, in short-term notes
 payable for the financing of various insurance policies. On
 March&amp;#xA0;8, 2013, the Company entered into a short-term note
 payable for $50,037 bearing interest at 6.57% to finance the
 product liability insurance. Principal and interest payments on
 this note began April&amp;#xA0;10, 2013 and are made evenly based on a
 straight line amortization over a 10-month period with the final
 payment due on January&amp;#xA0;10, 2014. On June&amp;#xA0;20, 2013, we
 entered into a short-term note payable for $106,994 bearing
 interest at 4.64% to finance a portion of the directors&amp;#x2019; and
 officers&amp;#x2019; liability insurance and employment practices
 liability insurance premiums. Principal and interest payments on
 this note began August&amp;#xA0;24, 2013 and are made evenly based on a
 straight line amortization over an 11-month period with the final
 payment due on June&amp;#xA0;24, 2014.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ShortTermDebtTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_2_3">56050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_9F6045F6-CEC3-48A8-B692-93420DD9EECB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognized stock-based compensation on all employee and
 non-employee awards as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="46%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;183,168&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,858&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;158,575&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116,726&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Selling, general and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,355,175&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;693,533&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,465,590&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;940,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total Stock based compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,538,343&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;799,391&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,624,165&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,057,218&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_94125766-6AE0-480D-8EFE-96F12B28AF4A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and disclosure of
 contingent assets and liabilities at the date of the financial
 statements, as well as the reported amounts of revenues and
 expenses during the reporting period. Actual results could differ
 from those estimates. The principal areas of estimation reflected
 in the financial statements are stock-based compensation, valuation
 of warrants, inventory obsolescence reserve, sales returns and
 allowances and the allowance for doubtful accounts.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_AD95D44D-A8EF-42CB-9317-C86A476F192B_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Organization&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Oragenics, Inc. (formerly known as Oragen, Inc.) (the
 &amp;#x201C;Company&amp;#x201D; or &amp;#x201C;we&amp;#x201D;) was incorporated in
 November 1996; however, operating activity did not commence until
 1999. The Company is focused on the discovery, development and
 commercialization of a variety of technologies associated with
 broad spectrum antibiotics, oral health, and other general health
 benefits.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_2910B728-CE83-4C51-A769-56CF757A3E09_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During all periods presented, the Company had securities
 outstanding that could potentially dilute basic earnings per share
 in the future, but were excluded from the computation of diluted
 net loss per share, as their effect would have been antidilutive.
 Because the Company reported a net loss for all periods presented,
 shares associated with the stock options and warrants are not
 included because they are antidilutive. Basic and diluted net loss
 per share amounts are the same for the periods presented. Net loss
 per share is computed using the weighted average number of shares
 of common stock outstanding.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_A6B14E53-E097-42DF-B4AE-6664414D2F5B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The fair value of the Company&amp;#x2019;s cash and cash equivalents,
 accounts payable and accrued expenses approximate their carrying
 values due to their short-term nature.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:RevenueRecognitionDeferredRevenue contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_CFBFF3F4-6EA1-41DB-A4C8-93CC7A94D200_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Guaranteed Rights of Return&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has granted guaranteed rights of return to two dental
 distributors. The Company defers recognition of revenue on these
 accounts until either the distributor provides notification to the
 Company that the product has been sold to the end consumer or the
 guaranteed right of return period expires. Once notification has
 been received and verified, the Company records revenue in that
 accounting period. The Company had $23,711 and $27,812 of revenue
 deferred under guaranteed rights of return arrangements included in
 deferred revenue in the balance sheets as of September&amp;#xA0;30,
 2013 and December&amp;#xA0;31, 2012, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
  <us-gaap:Revenues contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_0">597449</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_11">-151861</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:GrossProfit contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_2">333459</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_14">-12989419</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:RepaymentsOfShortTermDebt contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_21">96788</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:OtherNonoperatingIncome contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_12">144503</us-gaap:OtherNonoperatingIncome>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_9">15098</us-gaap:InvestmentIncomeInterest>
  <us-gaap:LiabilitiesAssumed1 contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_32">157031</us-gaap:LiabilitiesAssumed1>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_7">-13136857</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_30">3108</us-gaap:InterestPaid>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_9">-10917</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_13">147438</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_16">-12989419</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_10">-140865</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_16">17649</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_12">-280353</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_25">3904775</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:InventoryWriteDown contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_7">-240005</us-gaap:InventoryWriteDown>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_1">263990</us-gaap:CostOfGoodsSold>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_13">-27278</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_6">1624165</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_5">64042</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_26">-1658079</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_11">8824</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:InterestExpense contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_10">3339</us-gaap:InterestExpense>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_23">3939800</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_17">-17649</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_4">8289614</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_24">61763</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <us-gaap:OperatingExpenses contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_6">13470316</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_5">5180702</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_3_15" />
  <ogen:ClassOfWarrantExercised contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_8995EFA2-DC8A-466D-BFB1-5838B926FD2C_7001_7">200000</ogen:ClassOfWarrantExercised>
  <ogen:SummaryOfWarrantActivityTableTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_DDCF2CFA-9C72-4B91-B17B-61D9137E8668_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 A summary of warrant activity for the year ended December&amp;#xA0;31,
 2012 and the nine months ended September&amp;#xA0;30, 2013 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance &amp;#x2013; December&amp;#xA0;31, 2011&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;306,388&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,942,094&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance &amp;#x2013; December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,235,982&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(200,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(288,888&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance &amp;#x2013; September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,747,094&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ogen:SummaryOfWarrantActivityTableTextBlock>
  <ogen:ClassOfWarrantExercisedWeightedAverageExercisePrice contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_7BA700F7-18C9-4C58-A5B7-E38249D660AB_7001_7">1.50</ogen:ClassOfWarrantExercisedWeightedAverageExercisePrice>
  <ogen:ClassOfWarrantExpired contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_8995EFA2-DC8A-466D-BFB1-5838B926FD2C_7001_8">288888</ogen:ClassOfWarrantExpired>
  <ogen:ClassOfWarrantExpiredWeightedAverageExercisePrice contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_7BA700F7-18C9-4C58-A5B7-E38249D660AB_7001_8">19.87</ogen:ClassOfWarrantExpiredWeightedAverageExercisePrice>
  <ogen:CommonStockIssuedDuringPeriodParValueForWarrantsExercise contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_33">106</ogen:CommonStockIssuedDuringPeriodParValueForWarrantsExercise>
  <ogen:NumberOfDentalDistributorWithGuaranteedRightsOfReturns contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="Customer" decimals="INF" id="id_2113118_6752AD98-42C5-4508-9059-A6A77CAFF68D_1_0">2</ogen:NumberOfDentalDistributorWithGuaranteedRightsOfReturns>
  <ogen:NumberOfKeySuppliers contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="Supplier" decimals="INF" id="id_2113118_89691DAB-2E85-472A-9B3E-C3E01901801F_3_0">4</ogen:NumberOfKeySuppliers>
  <ogen:WarrantPolicyTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_7C3A1FC8-7FCB-4CD1-A545-B71EEC3C51A9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company used the Black Scholes Option Pricing Model in
 calculating the relative fair value of any warrants that have been
 issued.&lt;/p&gt;
 &lt;/div&gt;</ogen:WarrantPolicyTextBlock>
  <ogen:WarrantDisclosureTextBlock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" id="id_2113118_70C6F7AF-EF55-4D2A-A0A5-A264B48D77E1_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 A summary of warrant activity for the year ended December&amp;#xA0;31,
 2012 and the nine months ended September&amp;#xA0;30, 2013 is as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="77%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&lt;br /&gt;
 Average&lt;br /&gt;
 Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance &amp;#x2013; December&amp;#xA0;31, 2011&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;306,388&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19.14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,942,094&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance &amp;#x2013; December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,235,982&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.53&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(200,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(288,888&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(19.87&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance &amp;#x2013; September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,747,094&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On January&amp;#xA0;31, 2013 Griffin Securities Inc. exercised 200,000
 of their previously issued warrants resulting in the issuance of
 106,250 shares of our common stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The warrants outstanding as of September&amp;#xA0;30, 2013 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;
 &lt;tr&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="40%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="40%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom" colspan="2" nowrap="nowrap" align="center"&gt;
 &lt;p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 48.6pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" align="center"&gt;&lt;b&gt;Exercise&amp;#xA0;Price&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Warrants&lt;br /&gt;
 Outstanding&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Expiration&amp;#xA0;Dates&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;1.50&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;571,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7/30/17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;2.00&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,170,925&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3/23/15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;$&lt;/td&gt;
 &lt;td valign="top" align="right"&gt;10.00&lt;/td&gt;
 &lt;td valign="top" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,000&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4/15/14&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,747,094&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</ogen:WarrantDisclosureTextBlock>
  <ogen:TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1_3">6000000</ogen:TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForNoncashConsideration contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_921954x1164727_928294x1220768" unitRef="shares" decimals="INF" id="id_2113118_F8A2650B-D6E4-4639-9728-7095DE2B5BB5_1001_1">1348000</us-gaap:StockIssuedDuringPeriodSharesIssuedForNoncashConsideration>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_921954x1164727_928294x1220768" unitRef="shares" decimals="INF" id="id_2113118_C4EA13DD-D7F3-48BD-BCCC-A0FB6A718486_1001_0">1300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_921954x1164727_928294x1220768" unitRef="iso4217_USD" decimals="0" id="id_2113118_C4EA13DD-D7F3-48BD-BCCC-A0FB6A718486_1001_2">3900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x1164788" id="id_2113118_5DDDFA4B-A3AA-4BC0-906F-7B2505C269D9_1001_7">2014-01-10</us-gaap:DebtInstrumentMaturityDate>
  <ogen:DebtInstrumentAmortizationPeriod contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x1164788" id="id_2113118_5DDDFA4B-A3AA-4BC0-906F-7B2505C269D9_1001_5">P10M</ogen:DebtInstrumentAmortizationPeriod>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x931724" id="id_2113118_5DDDFA4B-A3AA-4BC0-906F-7B2505C269D9_2001_8">2014-06-24</us-gaap:DebtInstrumentMaturityDate>
  <ogen:DebtInstrumentAmortizationPeriod contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x931724" id="id_2113118_5DDDFA4B-A3AA-4BC0-906F-7B2505C269D9_2001_6">P11M</ogen:DebtInstrumentAmortizationPeriod>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x954731" id="id_2113118_2B8A5B8C-00DB-40CA-A720-7C4BA305C5ED_1001_2">2013-12-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x954731_928294x1220768" id="id_2113118_F8A2650B-D6E4-4639-9728-7095DE2B5BB5_2001_3">2013-12-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_1003_0">158575</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_927015x932414" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_2003_1">1465590</us-gaap:ShareBasedCompensation>
  <ogen:LicenseAgreementDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164756" id="id_2113118_1898E7B9-EB94-4D9D-B5BA-3FD015F34159_1001_0">2000-06-22</ogen:LicenseAgreementDate>
  <ogen:LicenseAgreementDateFifthAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164756" id="id_2113118_1898E7B9-EB94-4D9D-B5BA-3FD015F34159_1001_5">2013-04-19</ogen:LicenseAgreementDateFifthAmended>
  <ogen:LicenseAgreementDateFirstAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164756" id="id_2113118_1898E7B9-EB94-4D9D-B5BA-3FD015F34159_1001_1">2000-09-15</ogen:LicenseAgreementDateFirstAmended>
  <ogen:LicenseAgreementDateFourthAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164756" id="id_2113118_1898E7B9-EB94-4D9D-B5BA-3FD015F34159_1001_4">2003-03-17</ogen:LicenseAgreementDateFourthAmended>
  <ogen:LicenseAgreementDateSecondAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164756" id="id_2113118_1898E7B9-EB94-4D9D-B5BA-3FD015F34159_1001_2">2002-07-10</ogen:LicenseAgreementDateSecondAmended>
  <ogen:LicenseAgreementDateThirdAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164756" id="id_2113118_1898E7B9-EB94-4D9D-B5BA-3FD015F34159_1001_3">2002-09-25</ogen:LicenseAgreementDateThirdAmended>
  <ogen:PatentLicenseExpirationTerm contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164756" id="id_2113118_1898E7B9-EB94-4D9D-B5BA-3FD015F34159_1001_6">2017 through 2019</ogen:PatentLicenseExpirationTerm>
  <ogen:LicenseAgreementDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_0">1998-08-04</ogen:LicenseAgreementDate>
  <ogen:LicenseAgreementDateFifthAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_5">2013-04-19</ogen:LicenseAgreementDateFifthAmended>
  <ogen:LicenseAgreementDateFirstAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_1">2000-09-15</ogen:LicenseAgreementDateFirstAmended>
  <ogen:LicenseAgreementDateFourthAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_4">2003-03-17</ogen:LicenseAgreementDateFourthAmended>
  <ogen:LicenseAgreementDateSecondAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_2">2002-07-10</ogen:LicenseAgreementDateSecondAmended>
  <ogen:LicenseAgreementDateThirdAmended contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_3">2002-09-25</ogen:LicenseAgreementDateThirdAmended>
  <ogen:PatentRightEffectiveInceptionDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_7">1997-03-04</ogen:PatentRightEffectiveInceptionDate>
  <ogen:PatentRightExpireDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_8">2015-06-07</ogen:PatentRightExpireDate>
  <ogen:PatentRightFillingDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802" id="id_2113118_41C051E0-ECBA-4AD2-8CBF-2A6248B7A514_1001_6">1995-06-07</ogen:PatentRightFillingDate>
  <ogen:AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="pure" decimals="2" id="id_2113118_97C5EB3E-2CEC-4FC4-8427-BCD5329C09D5_1001_5">0.10</ogen:AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage>
  <ogen:AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="iso4217_USD" decimals="-5" id="id_2113118_97C5EB3E-2CEC-4FC4-8427-BCD5329C09D5_1001_4">2000000</ogen:AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum>
  <ogen:AnnualMinimumRoyaltyPaymentsPostCommercialization contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="iso4217_USD" decimals="INF" id="id_2113118_97C5EB3E-2CEC-4FC4-8427-BCD5329C09D5_1001_3">50000</ogen:AnnualMinimumRoyaltyPaymentsPostCommercialization>
  <ogen:PercentageOfSellingPricePayableAsRoyalty contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="pure" decimals="2" id="id_2113118_97C5EB3E-2CEC-4FC4-8427-BCD5329C09D5_1001_0">0.05</ogen:PercentageOfSellingPricePayableAsRoyalty>
  <ogen:PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="pure" decimals="2" id="id_2113118_97C5EB3E-2CEC-4FC4-8427-BCD5329C09D5_1001_1">0.22</ogen:PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty>
  <ogen:AggregateMinimumAnnualMaintenancePayment contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="iso4217_USD" decimals="INF" id="id_2113118_5526BFBA-587F-4BE8-9450-6C3A864673EB_1001_1">20000</ogen:AggregateMinimumAnnualMaintenancePayment>
  <ogen:MinimumQuarterlyMaintenancePayment contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="iso4217_USD" decimals="INF" id="id_2113118_5526BFBA-587F-4BE8-9450-6C3A864673EB_1001_2">5000</ogen:MinimumQuarterlyMaintenancePayment>
  <ogen:MonthlyCalculationOfCommercializationFee contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="iso4217_USD" decimals="0" id="id_2113118_97C5EB3E-2CEC-4FC4-8427-BCD5329C09D5_1001_2">5000</ogen:MonthlyCalculationOfCommercializationFee>
  <ogen:MinimumAnnualMaintenancePaymentsEachLicenseAgreement contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489" unitRef="iso4217_USD" decimals="INF" id="id_2113118_5526BFBA-587F-4BE8-9450-6C3A864673EB_1001_0">10000</ogen:MinimumAnnualMaintenancePaymentsEachLicenseAgreement>
  <ogen:PotentialFutureMilestonePaymentsThree contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768" unitRef="iso4217_USD" decimals="0" id="id_2113118_6B6C41FD-84B4-415C-B9C0-F8B346D541A0_1001_2">10000000</ogen:PotentialFutureMilestonePaymentsThree>
  <ogen:PotentialFutureMilestonePaymentsOne contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768" unitRef="iso4217_USD" decimals="0" id="id_2113118_6B6C41FD-84B4-415C-B9C0-F8B346D541A0_1001_0">2000000</ogen:PotentialFutureMilestonePaymentsOne>
  <ogen:LicenseAgreementDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768" id="id_2113118_32F65AF1-FF56-462D-8BB5-D35D66C279A9_1001_0">2013-09-30</ogen:LicenseAgreementDate>
  <ogen:TechnologyAccessFeeUpfrontPayment contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768" unitRef="iso4217_USD" decimals="0" id="id_2113118_F8A2650B-D6E4-4639-9728-7095DE2B5BB5_3001_0">6000000</ogen:TechnologyAccessFeeUpfrontPayment>
  <ogen:PotentialFutureMilestonePaymentsTwo contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768" unitRef="iso4217_USD" decimals="0" id="id_2113118_6B6C41FD-84B4-415C-B9C0-F8B346D541A0_1001_1">5000000</ogen:PotentialFutureMilestonePaymentsTwo>
  <ogen:MaximumPeriodToCureBreach contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768" id="id_2113118_FB6366B5-CC42-4D44-87D3-77EC5BB941E9_1001_2">P60D</ogen:MaximumPeriodToCureBreach>
  <ogen:MilestoneMeasurementPeriod contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768" id="id_2113118_6B6C41FD-84B4-415C-B9C0-F8B346D541A0_1001_3">P30D</ogen:MilestoneMeasurementPeriod>
  <ogen:PercentageOfNetSalesDerivedFromSaleOfProductsPayable contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768" unitRef="pure" decimals="INF" id="id_2113118_FB6366B5-CC42-4D44-87D3-77EC5BB941E9_1001_0">0.10</ogen:PercentageOfNetSalesDerivedFromSaleOfProductsPayable>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForNoncashConsideration contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780" unitRef="shares" decimals="INF" id="id_2113118_6BC40DD4-5E0D-4A20-ADF8-E4DB65AAF50E_1001_0">4392425</us-gaap:StockIssuedDuringPeriodSharesIssuedForNoncashConsideration>
  <ogen:LicenseAgreementDate contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780" id="id_2113118_8E7CB72D-E41D-43A0-A55A-25D540B3CB95_1001_0">2012-06-05</ogen:LicenseAgreementDate>
  <ogen:MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780" unitRef="pure" decimals="INF" id="id_2113118_C9CB52E1-9001-4567-9FA0-4A67778E3AB2_6_1">0.10</ogen:MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued>
  <ogen:PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780" unitRef="pure" decimals="2" id="id_2113118_8E037B49-0714-4562-9683-391AEA2D4403_1001_0">0.25</ogen:PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable>
  <ogen:PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780" unitRef="pure" decimals="2" id="id_2113118_8E037B49-0714-4562-9683-391AEA2D4403_1001_1">0.50</ogen:PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement>
  <ogen:PeriodDuringWhichCompanyCannotTerminateLicenseAgreement contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780" id="id_2113118_8E037B49-0714-4562-9683-391AEA2D4403_1001_3">P12M</ogen:PeriodDuringWhichCompanyCannotTerminateLicenseAgreement>
  <ogen:PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780" id="id_2113118_8E037B49-0714-4562-9683-391AEA2D4403_1001_2">P18M</ogen:PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily>
  <ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1164708" unitRef="pure" decimals="INF" id="id_2113118_C9CB52E1-9001-4567-9FA0-4A67778E3AB2_3_0">0.020</ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock>
  <ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1164709" unitRef="pure" decimals="INF" id="id_2113118_C9CB52E1-9001-4567-9FA0-4A67778E3AB2_2_0">0.015</ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock>
  <ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1164723" unitRef="pure" decimals="INF" id="id_2113118_C9CB52E1-9001-4567-9FA0-4A67778E3AB2_4_0">0.025</ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock>
  <ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1164724" unitRef="pure" decimals="INF" id="id_2113118_C9CB52E1-9001-4567-9FA0-4A67778E3AB2_5_0">0.030</ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock>
  <ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock contextRef="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1185488" unitRef="pure" decimals="INF" id="id_2113118_C9CB52E1-9001-4567-9FA0-4A67778E3AB2_1_0">0.010</ogen:PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="shares" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_18">14578448</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_4_1">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_14">-3470975</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_17">-0.76</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="shares" decimals="INF" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_4_0">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:Revenues contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_0">901182</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_11">-11843</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:GrossProfit contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_2">426656</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_14">-11101620</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:RepaymentsOfShortTermDebt contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_21">99514</us-gaap:RepaymentsOfShortTermDebt>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_9">7193</us-gaap:InvestmentIncomeInterest>
  <us-gaap:LiabilitiesAssumed1 contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_32">134914</us-gaap:LiabilitiesAssumed1>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_7">-10444146</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestPaid contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_30">2936</us-gaap:InterestPaid>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_22">127291</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_9">-20265</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_13">-657474</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_16">-11101620</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_10">-195643</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_34">11275196</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_12">-104556</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_25">15057011</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_1">474526</us-gaap:CostOfGoodsSold>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_13">112879</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_6">1057218</us-gaap:ShareBasedCompensation>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_5">55793</us-gaap:DepreciationAndAmortization>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_26">11586036</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_11">10056</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:InterestExpense contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_10">654611</us-gaap:InterestExpense>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_23">11913442</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_4">7130780</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromRepaymentsOfNotesPayable contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_19">2500000</us-gaap:ProceedsFromRepaymentsOfNotesPayable>
  <us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_24">120374</us-gaap:ProceedsFromRepaymentsOfRestrictedCashFinancingActivities>
  <us-gaap:OperatingExpenses contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_6">10870802</us-gaap:OperatingExpenses>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_4">483559</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_5">3740022</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_20">750000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_4_15" />
  <ogen:DiscountOnNotePayableToShareholderForWarrantsIssued contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_35">483559</ogen:DiscountOnNotePayableToShareholderForWarrantsIssued>
  <ogen:NumberOfKeySuppliers contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="Supplier" decimals="INF" id="id_2113118_89691DAB-2E85-472A-9B3E-C3E01901801F_4_0">4</ogen:NumberOfKeySuppliers>
  <ogen:ParValueOfRestrictedStockForfeited contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_36">5</ogen:ParValueOfRestrictedStockForfeited>
  <ogen:TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_2_3">5798001</ogen:TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0_921954x1164725" unitRef="iso4217_USD" decimals="0" id="id_2113118_F1DD6941-5EDF-44E5-84FC-85988221E6FF_1002_37">1850806</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_1004_0">116726</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_274_20120930_0_927015x932414" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_2004_1">940492</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="eol_PE382471--1310-Q0005_STD_31_20130131_0_921954x1164725" unitRef="shares" decimals="INF" id="id_2113118_2A18B179-924B-41BB-9BA7-CA3929E4A8D5_1_1">106250</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
  <ogen:ClassOfWarrantExercised contextRef="eol_PE382471--1310-Q0005_STD_31_20130131_0_921954x1164725" unitRef="shares" decimals="INF" id="id_2113118_2A18B179-924B-41BB-9BA7-CA3929E4A8D5_1_0">200000</ogen:ClassOfWarrantExercised>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE382471--1310-Q0005_STD_366_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_9E6EDC3F-89FA-42F8-B711-B13E74E500BF_2_0">13000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <ogen:ClassOfWarrantExpired contextRef="eol_PE382471--1310-Q0005_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_2113118_8995EFA2-DC8A-466D-BFB1-5838B926FD2C_4001_4">12500</ogen:ClassOfWarrantExpired>
  <ogen:ClassOfWarrantExpiredWeightedAverageExercisePrice contextRef="eol_PE382471--1310-Q0005_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_7BA700F7-18C9-4C58-A5B7-E38249D660AB_4001_4">6.00</ogen:ClassOfWarrantExpiredWeightedAverageExercisePrice>
  <ogen:ClassOfWarrantGrantedInPeriod contextRef="eol_PE382471--1310-Q0005_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_2113118_8995EFA2-DC8A-466D-BFB1-5838B926FD2C_4001_2">2942094</ogen:ClassOfWarrantGrantedInPeriod>
  <ogen:ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice contextRef="eol_PE382471--1310-Q0005_STD_366_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_7BA700F7-18C9-4C58-A5B7-E38249D660AB_4001_2">1.87</ogen:ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="shares" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_18">23793309</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_3_1">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_17">-0.11</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="shares" decimals="INF" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_3_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:Revenues contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_0">264248</us-gaap:Revenues>
  <us-gaap:GrossProfit contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_2">100189</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_14">-2555941</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_9">5645</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_7">-2096573</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_13">-459368</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_16">-2555941</us-gaap:NetIncomeLoss>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_1">164059</us-gaap:CostOfGoodsSold>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_2_2">799391</us-gaap:ShareBasedCompensation>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_11">8776</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:InterestExpense contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_10">456237</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_4">600208</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_6">2196762</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_5">1596554</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_2_15" />
  <ogen:NumberOfKeySuppliers contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0" unitRef="Supplier" decimals="INF" id="id_2113118_89691DAB-2E85-472A-9B3E-C3E01901801F_2_0">4</ogen:NumberOfKeySuppliers>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_1002_0">105858</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_92_20120930_0_927015x932414" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_2002_1">693533</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="shares" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_18">27515372</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_1_1">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_17">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="shares" decimals="INF" id="id_2113118_CAF62D36-2997-47F9-863E-D5A86125A48C_1_0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:Revenues contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_0">253374</us-gaap:Revenues>
  <us-gaap:GrossProfit contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_2">139990</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_14">-9325424</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_9">3611</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_7">-9325465</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_13">41</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_16">-9325424</us-gaap:NetIncomeLoss>
  <us-gaap:CostOfGoodsSold contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_1">113384</us-gaap:CostOfGoodsSold>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_1_2">1538343</us-gaap:ShareBasedCompensation>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_11">2024</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:InterestExpense contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_10">1546</us-gaap:InterestExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_4">6907250</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:OperatingExpenses contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_6">9465455</us-gaap:OperatingExpenses>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_5">2558205</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2113118_C8A32C03-AF91-4AF4-8FFB-B5ED9364CA90_1_15" />
  <ogen:NumberOfKeySuppliers contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0" unitRef="Supplier" decimals="INF" id="id_2113118_89691DAB-2E85-472A-9B3E-C3E01901801F_1_0">4</ogen:NumberOfKeySuppliers>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_1001_0">183168</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0_927015x932414" unitRef="iso4217_USD" decimals="0" id="id_2113118_8C8C1D42-ED6C-4877-B774-26C2211C8A40_2001_1">1355175</us-gaap:ShareBasedCompensation>
  <ogen:ExpensesRelatedToStockAwards contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0_930809x1041243" unitRef="iso4217_USD" decimals="0" id="id_2113118_E473EC1C-1D11-4B46-9CF2-0C894BCC2DE7_1001_0">1487801</ogen:ExpensesRelatedToStockAwards>
  <ogen:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded contextRef="eol_PE382471--1310-Q0005_STD_92_20130930_0_930809x1041243" unitRef="shares" decimals="INF" id="id_2113118_E473EC1C-1D11-4B46-9CF2-0C894BCC2DE7_1001_1">422359</ogen:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded>
  <context id="eol_PE382471--1310-Q0005_STD_92_20130930_0_930809x1041243">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ogen:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_92_20130930_0_927015x932414">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_92_20130930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_92_20120930_0_927015x932414">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_92_20120930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_31_20130131_0_921954x1164725">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ogen:GriffinSecuritiesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_274_20120930_0_927015x932414">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_274_20120930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_274_20120930_0_921954x1164725">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ogen:GriffinSecuritiesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_274_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1185488">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ogen:InvestigationalNewDrugApplicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:LantibioticEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1164724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ogen:FirstRegulatoryApprovalOfOragenicsProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:LantibioticEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1164723">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ogen:FilingOfFirstInvestigationalNewDrugApplicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:LantibioticEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1164709">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ogen:ClinicalStudyPhaseTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:LantibioticEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780_931737x1164708">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ogen:ClinicalStudyPhaseThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:LantibioticEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220780">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:LantibioticEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1220768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:ProbioticsEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1185489">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:UniversityOfFloridaResearchFoundationLicensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:SmartReplacementTherapyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_928294x1164756">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:MuOneOneFourZeroMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_927015x932414">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x954731_928294x1220768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ogen:ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:ProbioticsEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x954731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ogen:ConvertiblePromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x931724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:DirectorsAndOfficersLiabilityInsuranceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_923847x1164788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ogen:ProductLiabilityInsuranceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0_921954x1164727_928294x1220768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ogen:IntrexonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:ProbioticsEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_18_20131018_0_930809x1041243_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ogen:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-18</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x931864_930809x1041243_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ogen:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-18</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x927612_930809x1041243_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ogen:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-18</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x927115_930809x1041243_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ogen:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:VicePresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-18</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x1057198_930809x1041243_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ogen:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ogen:ExecutiveOfficersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-18</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_18_20131018_0_926607x1032852_930809x1041243_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ogen:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ogen:NonEmployeeDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-18</endDate>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20121231_0_930526x923447">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20121231_0_927059x1177511">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">ogen:GuaranteedRightsOfReturnMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20131025_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <instant>2013-10-25</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20131018_0_930809x1041243_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ogen:TwoThousandTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-18</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20131018_0_926607x931864_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-18</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20131018_0_926607x927612_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-18</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20131018_0_926607x927115_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:VicePresidentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-18</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_930526x923447">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_928294x1220780">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:LantibioticEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_928294x1220768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:ProbioticsEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_927059x1177511">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">ogen:GuaranteedRightsOfReturnMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x975231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">ogen:RangeTwoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x960261">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">ogen:RangeOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_926437x1014875">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">ogen:RangeThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_923847x954731_928294x1220768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ogen:ConvertiblePromissoryNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:ProbioticsEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_923847x954731">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ogen:ConvertiblePromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0_921954x1164727_928294x1220768">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ogen:IntrexonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ogen:ProbioticsEccMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20120930_0_921954x1164725">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ogen:GriffinSecuritiesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130620_0_923847x931724">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:DirectorsAndOfficersLiabilityInsuranceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-06-20</instant>
    </period>
  </context>
  <context id="eol_PE382471--1310-Q0005_STD_0_20130308_0_923847x1164788">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001174940</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">ogen:ProductLiabilityInsuranceMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-03-08</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Vendor">
    <measure>ogen:Vendor</measure>
  </unit>
  <unit id="iso4217_USD_per_Warrant">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>ogen:Warrant</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Non_Employee_Directors">
    <measure>ogen:Non_Employee_Directors</measure>
  </unit>
  <unit id="Customer">
    <measure>ogen:Customer</measure>
  </unit>
  <unit id="Supplier">
    <measure>ogen:Supplier</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ogen-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 4 -->
<!-- Creation date: 2013-10-24T00:14:06Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
  xmlns:us-types="http://fasb.org/us-types/2013-01-31"
  xmlns:ogen="http://oragenics.com/20130930"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://oragenics.com/20130930"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/StatementOfIncome" id="Role_StatementOfIncome">
        <link:definition>105 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>106 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical" id="Role_StatementOfCashFlowsIndirectParen">
        <link:definition>107 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>108 - Disclosure - Organization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" id="Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
        <link:definition>109 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>110 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock" id="Role_NotesToFinancialStatementsWarrantDisclosureTextBlock">
        <link:definition>112 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsShortTermDebtTextBlock" id="Role_NotesToFinancialStatementsShortTermDebtTextBlock">
        <link:definition>113 - Disclosure - Short-Term Notes Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock" id="Role_NotesToFinancialStatementsLongTermDebtTextBlock">
        <link:definition>114 - Disclosure - Convertible Note Payable to Shareholder</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>115 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>117 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>118 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsWarrantDisclosureTextBlockTables">
        <link:definition>119 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation" id="DisclosureBasisOfPresentationAdditionalInformation">
        <link:definition>120 - Disclosure - Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>121 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized">
        <link:definition>122 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation" id="DisclosureStockBasedCompensationAdditionalInformation">
        <link:definition>123 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantActivity" id="DisclosureWarrantsSummaryOfWarrantActivity">
        <link:definition>124 - Disclosure - Warrants - Summary of Warrant Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation" id="DisclosureWarrantsAdditionalInformation">
        <link:definition>125 - Disclosure - Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstanding" id="DisclosureWarrantsSummaryOfWarrantsOutstanding">
        <link:definition>126 - Disclosure - Warrants - Summary of Warrants Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureShorttermNotesPayableAdditionalInformation" id="DisclosureShorttermNotesPayableAdditionalInformation">
        <link:definition>127 - Disclosure - Short-term Notes Payable - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureConvertibleNotePayableToShareholderAdditionalInformation" id="DisclosureConvertibleNotePayableToShareholderAdditionalInformation">
        <link:definition>128 - Disclosure - Convertible Note Payable to Shareholder - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>129 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://oragenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>130 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="ogen-20130930_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="ogen-20130930_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="ogen-20130930_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="ogen-20130930_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage" id="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum" id="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AggregateMinimumAnnualMaintenancePayment" id="ogen_AggregateMinimumAnnualMaintenancePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AnnualMinimumRoyaltyPaymentsPostCommercialization" id="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" id="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" id="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="ClassOfWarrantExercised" id="ogen_ClassOfWarrantExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantExercisedWeightedAverageExercisePrice" id="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantExpired" id="ogen_ClassOfWarrantExpired" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantExpiredWeightedAverageExercisePrice" id="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantGrantedInPeriod" id="ogen_ClassOfWarrantGrantedInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice" id="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOutstandingWeightedAverageExercisePrice" id="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalStudyPhaseThreeMember" id="ogen_ClinicalStudyPhaseThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalStudyPhaseTwoMember" id="ogen_ClinicalStudyPhaseTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentAndContingenciesLineItems" id="ogen_CommitmentAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommitmentAndContingenciesTable" id="ogen_CommitmentAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="CommonStockIssuedDuringPeriodParValueForWarrantsExercise" id="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePromissoryNotesMember" id="ogen_ConvertiblePromissoryNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DebtInstrumentAmortizationPeriod" id="ogen_DebtInstrumentAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DiscountOnNotePayableToShareholderForWarrantsIssued" id="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="ogen_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExecutiveOfficersMember" id="ogen_ExecutiveOfficersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ExpensesRelatedToStockAwards" id="ogen_ExpensesRelatedToStockAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FilingOfFirstInvestigationalNewDrugApplicationMember" id="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FirstRegulatoryApprovalOfOragenicsProductMember" id="ogen_FirstRegulatoryApprovalOfOragenicsProductMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GriffinSecuritiesIncMember" id="ogen_GriffinSecuritiesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GuaranteedRightsOfReturnMember" id="ogen_GuaranteedRightsOfReturnMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IntrexonMember" id="ogen_IntrexonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestigationalNewDrugApplicationMember" id="ogen_InvestigationalNewDrugApplicationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LantibioticEccMember" id="ogen_LantibioticEccMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDate" id="ogen_LicenseAgreementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDateFifthAmended" id="ogen_LicenseAgreementDateFifthAmended" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDateFirstAmended" id="ogen_LicenseAgreementDateFirstAmended" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDateFourthAmended" id="ogen_LicenseAgreementDateFourthAmended" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDateSecondAmended" id="ogen_LicenseAgreementDateSecondAmended" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementDateThirdAmended" id="ogen_LicenseAgreementDateThirdAmended" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued" id="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumPeriodToCureBreach" id="ogen_MaximumPeriodToCureBreach" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MilestoneMeasurementPeriod" id="ogen_MilestoneMeasurementPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumAnnualMaintenancePaymentsEachLicenseAgreement" id="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumQuarterlyMaintenancePayment" id="ogen_MinimumQuarterlyMaintenancePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MonthlyCalculationOfCommercializationFee" id="ogen_MonthlyCalculationOfCommercializationFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MuOneOneFourZeroMember" id="ogen_MuOneOneFourZeroMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonEmployeeDirectorsMember" id="ogen_NonEmployeeDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfDentalDistributorWithGuaranteedRightsOfReturns" id="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfKeySuppliers" id="ogen_NumberOfKeySuppliers" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfVendorsWithPrepaidBalanceOfCompany" id="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ParValueOfRestrictedStockForfeited" id="ogen_ParValueOfRestrictedStockForfeited" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentLicenseExpirationTerm" id="ogen_PatentLicenseExpirationTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentRightEffectiveInceptionDate" id="ogen_PatentRightEffectiveInceptionDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentRightExpireDate" id="ogen_PatentRightExpireDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentRightFillingDate" id="ogen_PatentRightFillingDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock" id="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram" id="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfNetSalesDerivedFromSaleOfProductsPayable" id="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable" id="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement" id="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfSellingPricePayableAsRoyalty" id="ogen_PercentageOfSellingPricePayableAsRoyalty" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfShareGrantedUnderLongTermIncentiveProgram" id="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty" id="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodDuringWhichCompanyCannotTerminateLicenseAgreement" id="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily" id="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialFutureMilestonePaymentsOne" id="ogen_PotentialFutureMilestonePaymentsOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialFutureMilestonePaymentsThree" id="ogen_PotentialFutureMilestonePaymentsThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PotentialFutureMilestonePaymentsTwo" id="ogen_PotentialFutureMilestonePaymentsTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProbioticsEccMember" id="ogen_ProbioticsEccMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProductLiabilityInsuranceMember" id="ogen_ProductLiabilityInsuranceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeOneMember" id="ogen_RangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeThreeMember" id="ogen_RangeThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RangeTwoMember" id="ogen_RangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors" id="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded" id="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted" id="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SmartReplacementTherapyMember" id="ogen_SmartReplacementTherapyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedToEachDirectorDuringPeriodSharesOther" id="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfWarrantActivityTableTextBlock" id="ogen_SummaryOfWarrantActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" id="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TechnologyAccessFeeUpfrontPayment" id="ogen_TechnologyAccessFeeUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TerminationNoticePeriod" id="ogen_TerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandTwelveEquityIncentivePlanMember" id="ogen_TwoThousandTwelveEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UniversityOfFloridaResearchFoundationLicensesMember" id="ogen_UniversityOfFloridaResearchFoundationLicensesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantDisclosureTextBlock" id="ogen_WarrantDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantPolicyTextBlock" id="ogen_WarrantPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsExpirationDates" id="ogen_WarrantsExpirationDates" type="xbrli:dateItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantsIssued" id="ogen_WarrantsIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ogen-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 4 -->
<!-- Creation date: 2013-10-24T00:14:06Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DocumentandEntityInformation" roleURI="http://oragenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfIncome" roleURI="http://oragenics.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureBasisOfPresentationAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized" roleURI="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsSummaryOfWarrantActivity" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantActivity"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsSummaryOfWarrantsOutstanding" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureShorttermNotesPayableAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureShorttermNotesPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureConvertibleNotePayableToShareholderAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureConvertibleNotePayableToShareholderAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlockTables" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsShortTermDebtTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsShortTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermNonBankLoansAndNotesPayable" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsSold" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.1000" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1.0600" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" xlink:label="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="1.1700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0700" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstanding">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureShorttermNotesPayableAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureConvertibleNotePayableToShareholderAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsShortTermDebtTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ogen-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 4 -->
<!-- Creation date: 2013-10-24T00:14:06Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DocumentandEntityInformation" roleURI="http://oragenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfIncome" roleURI="http://oragenics.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureBasisOfPresentationAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized" roleURI="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsSummaryOfWarrantActivity" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantActivity"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsSummaryOfWarrantsOutstanding" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureShorttermNotesPayableAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureShorttermNotesPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureConvertibleNotePayableToShareholderAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureConvertibleNotePayableToShareholderAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlockTables" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsShortTermDebtTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsShortTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfIncome">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise" xlink:label="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_DiscountOnNotePayableToShareholderForWarrantsIssued" xlink:label="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GriffinSecuritiesIncMember" xlink:label="ogen_GriffinSecuritiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ParValueOfRestrictedStockForfeited" xlink:label="ogen_ParValueOfRestrictedStockForfeited"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" xlink:label="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_LiabilitiesAssumed1" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ogen_ParValueOfRestrictedStockForfeited" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ogen_GriffinSecuritiesIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0200" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GriffinSecuritiesIncMember" xlink:label="ogen_GriffinSecuritiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantsIssued" xlink:label="ogen_WarrantsIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ogen_GriffinSecuritiesIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ogen_WarrantsIssued" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GuaranteedRightsOfReturnMember" xlink:label="ogen_GuaranteedRightsOfReturnMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns" xlink:label="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfKeySuppliers" xlink:label="ogen_NumberOfKeySuppliers"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfVendorsWithPrepaidBalanceOfCompany" xlink:label="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ogen_NumberOfKeySuppliers" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="ogen_GuaranteedRightsOfReturnMember" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ExpensesRelatedToStockAwards" xlink:label="ogen_ExpensesRelatedToStockAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="ogen_TwoThousandTwelveEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ogen_ExpensesRelatedToStockAwards" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ogen_TwoThousandTwelveEquityIncentivePlanMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantActivity">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExercised" xlink:label="ogen_ClassOfWarrantExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GriffinSecuritiesIncMember" xlink:label="ogen_GriffinSecuritiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ogen_ClassOfWarrantExercised" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ogen_GriffinSecuritiesIncMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeOneMember" xlink:label="ogen_RangeOneMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeThreeMember" xlink:label="ogen_RangeThreeMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeTwoMember" xlink:label="ogen_RangeTwoMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantsExpirationDates" xlink:label="ogen_WarrantsExpirationDates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ogen_WarrantsExpirationDates" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="ogen_RangeOneMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="ogen_RangeTwoMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="ogen_RangeThreeMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureShorttermNotesPayableAdditionalInformation">
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_DebtInstrumentAmortizationPeriod" xlink:label="ogen_DebtInstrumentAmortizationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorsAndOfficersLiabilityInsuranceMember" xlink:label="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ProductLiabilityInsuranceMember" xlink:label="ogen_ProductLiabilityInsuranceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermNonBankLoansAndNotesPayable" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="ogen_DebtInstrumentAmortizationPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="ogen_ProductLiabilityInsuranceMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureConvertibleNotePayableToShareholderAdditionalInformation">
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ConvertiblePromissoryNotesMember" xlink:label="ogen_ConvertiblePromissoryNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="ogen_ConvertiblePromissoryNotesMember" order="1.0400" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage" xlink:label="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum" xlink:label="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AggregateMinimumAnnualMaintenancePayment" xlink:label="ogen_AggregateMinimumAnnualMaintenancePayment"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization" xlink:label="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClinicalStudyPhaseThreeMember" xlink:label="ogen_ClinicalStudyPhaseThreeMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClinicalStudyPhaseTwoMember" xlink:label="ogen_ClinicalStudyPhaseTwoMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommitmentAndContingenciesLineItems" xlink:label="ogen_CommitmentAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommitmentAndContingenciesTable" xlink:label="ogen_CommitmentAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ConvertiblePromissoryNotesMember" xlink:label="ogen_ConvertiblePromissoryNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_FilingOfFirstInvestigationalNewDrugApplicationMember" xlink:label="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_FirstRegulatoryApprovalOfOragenicsProductMember" xlink:label="ogen_FirstRegulatoryApprovalOfOragenicsProductMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_IntrexonMember" xlink:label="ogen_IntrexonMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_InvestigationalNewDrugApplicationMember" xlink:label="ogen_InvestigationalNewDrugApplicationMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LantibioticEccMember" xlink:label="ogen_LantibioticEccMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDate" xlink:label="ogen_LicenseAgreementDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFifthAmended" xlink:label="ogen_LicenseAgreementDateFifthAmended"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFirstAmended" xlink:label="ogen_LicenseAgreementDateFirstAmended"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFourthAmended" xlink:label="ogen_LicenseAgreementDateFourthAmended"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateSecondAmended" xlink:label="ogen_LicenseAgreementDateSecondAmended"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateThirdAmended" xlink:label="ogen_LicenseAgreementDateThirdAmended"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_2"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued" xlink:label="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MaximumPeriodToCureBreach" xlink:label="ogen_MaximumPeriodToCureBreach"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MilestoneMeasurementPeriod" xlink:label="ogen_MilestoneMeasurementPeriod"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement" xlink:label="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MinimumQuarterlyMaintenancePayment" xlink:label="ogen_MinimumQuarterlyMaintenancePayment"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MonthlyCalculationOfCommercializationFee" xlink:label="ogen_MonthlyCalculationOfCommercializationFee"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MuOneOneFourZeroMember" xlink:label="ogen_MuOneOneFourZeroMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentLicenseExpirationTerm" xlink:label="ogen_PatentLicenseExpirationTerm"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightEffectiveInceptionDate" xlink:label="ogen_PatentRightEffectiveInceptionDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightExpireDate" xlink:label="ogen_PatentRightExpireDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightFillingDate" xlink:label="ogen_PatentRightFillingDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock" xlink:label="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable" xlink:label="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable" xlink:label="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement" xlink:label="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfSellingPricePayableAsRoyalty" xlink:label="ogen_PercentageOfSellingPricePayableAsRoyalty"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty" xlink:label="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsOne" xlink:label="ogen_PotentialFutureMilestonePaymentsOne"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsThree" xlink:label="ogen_PotentialFutureMilestonePaymentsThree"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsTwo" xlink:label="ogen_PotentialFutureMilestonePaymentsTwo"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ProbioticsEccMember" xlink:label="ogen_ProbioticsEccMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_SmartReplacementTherapyMember" xlink:label="ogen_SmartReplacementTherapyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TechnologyAccessFeeUpfrontPayment" xlink:label="ogen_TechnologyAccessFeeUpfrontPayment"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TerminationNoticePeriod" xlink:label="ogen_TerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_UniversityOfFloridaResearchFoundationLicensesMember" xlink:label="ogen_UniversityOfFloridaResearchFoundationLicensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_MuOneOneFourZeroMember" order="1.4000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_SmartReplacementTherapyMember" order="1.4400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_UniversityOfFloridaResearchFoundationLicensesMember" order="1.4600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_LantibioticEccMember" order="1.4800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_ProbioticsEccMember" order="1.5000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_CommitmentAndContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateFirstAmended" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateSecondAmended" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateThirdAmended" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateFourthAmended" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateFifthAmended" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PatentLicenseExpirationTerm" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PatentRightFillingDate" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PatentRightEffectiveInceptionDate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PatentRightExpireDate" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfSellingPricePayableAsRoyalty" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MonthlyCalculationOfCommercializationFee" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_AggregateMinimumAnnualMaintenancePayment" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MinimumQuarterlyMaintenancePayment" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_TerminationNoticePeriod" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MaximumPeriodToCureBreach" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_TechnologyAccessFeeUpfrontPayment" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_SharePrice" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PotentialFutureMilestonePaymentsOne" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PotentialFutureMilestonePaymentsTwo" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PotentialFutureMilestonePaymentsThree" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MilestoneMeasurementPeriod" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement" order="1.3700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock" order="1.3800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued" order="1.3900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="dei_LegalEntityAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ogen_IntrexonMember" order="1.4100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_InvestigationalNewDrugApplicationMember" order="1.4300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_ClinicalStudyPhaseTwoMember" order="1.4500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_ClinicalStudyPhaseThreeMember" order="1.4700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember" order="1.4900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_FirstRegulatoryApprovalOfOragenicsProductMember" order="1.5100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="ogen_ConvertiblePromissoryNotesMember" order="1.4200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ExecutiveOfficersMember" xlink:label="ogen_ExecutiveOfficersMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NonEmployeeDirectorsMember" xlink:label="ogen_NonEmployeeDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram" xlink:label="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram" xlink:label="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_StockIssuedToEachDirectorDuringPeriodSharesOther" xlink:label="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="ogen_TwoThousandTwelveEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VicePresidentMember" xlink:label="us-gaap_VicePresidentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ogen_TwoThousandTwelveEquityIncentivePlanMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ChiefFinancialOfficerMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_VicePresidentMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ogen_NonEmployeeDirectorsMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ogen_ExecutiveOfficersMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsShortTermDebtTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ogen-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 4 -->
<!-- Creation date: 2013-10-24T00:14:06Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_2113118_928978_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_2113118_928978_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_2113118_935297_1_1">Accounts Payable And Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_2113118_935297_2_1">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_2113118_938700_1_1">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_2113118_938700_2_1">Accounts receivables, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_2113118_933723_1_1">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_2113118_933723_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage" xlink:label="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage_lbl" xml:lang="en-US" id="id_2113118_1164691_3_1">Additional royalty payment condition aggregate royalty percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage_lbl" xml:lang="en-US" id="id_2113118_1164691_1_1">Additional Royalty Payment Condition Aggregate Royalty Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage_lbl" xml:lang="en-US" id="id_2113118_1164691_2_1">Total royalties due to UFRF</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage" xlink:to="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum" xlink:label="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum_lbl" xml:lang="en-US" id="id_2113118_1164692_3_1">Additional royalty payment condition royalty paid minimum.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum_lbl" xml:lang="en-US" id="id_2113118_1164692_1_1">Additional Royalty Payment Condition Royalty Paid Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum_lbl" xml:lang="en-US" id="id_2113118_1164692_2_1">One-time additional royalty payment would be due when total cumulative royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum" xlink:to="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="id_2113118_934148_1_1">Adjustments To Additional Paid In Capital Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="id_2113118_934148_2_1">Fair market value of the 771,169 warrants issued to Griffin Securities, Inc. as a reduction in paid in capital from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2113118_929248_1_1">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2113118_929248_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AggregateMinimumAnnualMaintenancePayment" xlink:label="ogen_AggregateMinimumAnnualMaintenancePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_AggregateMinimumAnnualMaintenancePayment_lbl" xml:lang="en-US" id="id_2113118_1177273_3_1">Aggregate minimum annual maintenance payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_AggregateMinimumAnnualMaintenancePayment_lbl" xml:lang="en-US" id="id_2113118_1177273_1_1">Aggregate Minimum Annual Maintenance Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_AggregateMinimumAnnualMaintenancePayment_lbl" xml:lang="en-US" id="id_2113118_1177273_2_1">Aggregate minimum annual maintenance payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_AggregateMinimumAnnualMaintenancePayment" xlink:to="ogen_AggregateMinimumAnnualMaintenancePayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_2113118_921947_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_2113118_921947_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_2113118_940746_1_1">Amortization Of Debt Discount Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="id_2113118_940746_2_1">Accretion of discount on notes payable to shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization" xlink:label="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization_lbl" xml:lang="en-US" id="id_2113118_1164696_3_1">Annual minimum royalty payments post commercialization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization_lbl" xml:lang="en-US" id="id_2113118_1164696_1_1">Annual Minimum Royalty Payments Post Commercialization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization_lbl" xml:lang="en-US" id="id_2113118_1164696_2_1">Post-commercialization minimum royalty payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization" xlink:to="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_2113118_930670_1_1">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_2113118_930670_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_2113118_938186_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_2113118_938186_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_2113118_928450_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_2113118_928450_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_2113118_937150_1_1">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_2113118_937150_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_2113118_926145_1_1">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_2113118_926145_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_2113118_1031744_3_1">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_2113118_1031744_1_1">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_2113118_1031744_2_1">Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_2113118_1137132_3_1">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_2113118_1137132_1_1">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_2113118_1137132_2_1">Basis Of Presentation And Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="id_2113118_929561_1_1">Business Description And Basis Of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" id="id_2113118_929561_2_1">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2113118_938283_1_1">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2113118_938283_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2113118_938283_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2113118_938283_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_2113118_938600_1_1">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_2113118_938600_6_1">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_2113118_925504_1_1">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="id_2113118_925504_2_1">Non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="id_2113118_931864_1_1">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="id_2113118_931864_2_1">Dr. John Bonfiglio [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChiefFinancialOfficerMember_lbl" xml:lang="en-US" id="id_2113118_927612_1_1">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChiefFinancialOfficerMember_lbl" xml:lang="en-US" id="id_2113118_927612_2_1">Michel Sullivan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefFinancialOfficerMember" xlink:to="us-gaap_ChiefFinancialOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExercised" xlink:label="ogen_ClassOfWarrantExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClassOfWarrantExercised_lbl" xml:lang="en-US" id="id_2113118_977687_3_1">Number of warrants exercised in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClassOfWarrantExercised_lbl" xml:lang="en-US" id="id_2113118_977687_1_1">Class Of Warrant Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ClassOfWarrantExercised_lbl" xml:lang="en-US" id="id_2113118_977687_2_1">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ogen_ClassOfWarrantExercised_lbl" xml:lang="en-US" id="id_2113118_977687_14_1">Warrants, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClassOfWarrantExercised" xlink:to="ogen_ClassOfWarrantExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164701_3_1">Weighted average exercise price of warrants exercised in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164701_1_1">Class Of Warrant Exercised Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164701_2_1">Weighted Average Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice" xlink:to="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExpired" xlink:label="ogen_ClassOfWarrantExpired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClassOfWarrantExpired_lbl" xml:lang="en-US" id="id_2113118_1164702_3_1">Number of warrants expired in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClassOfWarrantExpired_lbl" xml:lang="en-US" id="id_2113118_1164702_1_1">Class Of Warrant Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ogen_ClassOfWarrantExpired_lbl" xml:lang="en-US" id="id_2113118_1164702_14_1">Warrants, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClassOfWarrantExpired" xlink:to="ogen_ClassOfWarrantExpired_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164703_3_1">Weighted average exercise price of warrants expired in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164703_1_1">Class Of Warrant Expired Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164703_14_1">Weighted Average Price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice" xlink:to="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantGrantedInPeriod" xlink:label="ogen_ClassOfWarrantGrantedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClassOfWarrantGrantedInPeriod_lbl" xml:lang="en-US" id="id_2113118_1164704_3_1">Number of warrants granted in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClassOfWarrantGrantedInPeriod_lbl" xml:lang="en-US" id="id_2113118_1164704_1_1">Class Of Warrant Granted In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ClassOfWarrantGrantedInPeriod_lbl" xml:lang="en-US" id="id_2113118_1164704_2_1">Warrants, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClassOfWarrantGrantedInPeriod" xlink:to="ogen_ClassOfWarrantGrantedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164705_3_1">Weighted average exercise price of warrants granted in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164705_1_1">Class Of Warrant Granted In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1164705_2_1">Weighted Average Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice" xlink:to="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_2113118_932954_1_1">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_2113118_932954_2_1">Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_2113118_931483_1_1">Class Of Warrant Or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_2113118_931483_2_1">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_2113118_929417_1_1">Class Of Warrant Or Right Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_2113118_929417_4_1">Warrants, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_2113118_929417_5_1">Warrants, Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="id_2113118_929417_2_1">Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_2113118_928347_1_1">Class Of Warrant Or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_2113118_928347_2_1">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1221405_3_1">Weighted average exercise price of warrants outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1221405_1_1">Class Of Warrant Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1221405_4_1">Weighted Average Price, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2113118_1221405_5_1">Weighted Average Price, Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice" xlink:to="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClinicalStudyPhaseThreeMember" xlink:label="ogen_ClinicalStudyPhaseThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClinicalStudyPhaseThreeMember_lbl" xml:lang="en-US" id="id_2113118_1164708_3_1">Clinical study phase three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClinicalStudyPhaseThreeMember_lbl" xml:lang="en-US" id="id_2113118_1164708_1_1">Clinical Study Phase Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ClinicalStudyPhaseThreeMember_lbl" xml:lang="en-US" id="id_2113118_1164708_2_1">Clinical Study Phase 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClinicalStudyPhaseThreeMember" xlink:to="ogen_ClinicalStudyPhaseThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClinicalStudyPhaseTwoMember" xlink:label="ogen_ClinicalStudyPhaseTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ClinicalStudyPhaseTwoMember_lbl" xml:lang="en-US" id="id_2113118_1164709_3_1">Clinical study phase two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ClinicalStudyPhaseTwoMember_lbl" xml:lang="en-US" id="id_2113118_1164709_1_1">Clinical Study Phase Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ClinicalStudyPhaseTwoMember_lbl" xml:lang="en-US" id="id_2113118_1164709_2_1">Clinical Study Phase 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ClinicalStudyPhaseTwoMember" xlink:to="ogen_ClinicalStudyPhaseTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommitmentAndContingenciesLineItems" xlink:label="ogen_CommitmentAndContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_CommitmentAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_2113118_1026379_3_1">Commitment And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_CommitmentAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_2113118_1026379_1_1">Commitment And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_CommitmentAndContingenciesLineItems_lbl" xml:lang="en-US" id="id_2113118_1026379_2_1">Commitment And Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_CommitmentAndContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommitmentAndContingenciesTable" xlink:label="ogen_CommitmentAndContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_CommitmentAndContingenciesTable_lbl" xml:lang="en-US" id="id_2113118_1017599_3_1">Commitment And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_CommitmentAndContingenciesTable_lbl" xml:lang="en-US" id="id_2113118_1017599_1_1">Commitment And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_CommitmentAndContingenciesTable_lbl" xml:lang="en-US" id="id_2113118_1017599_2_1">Commitment And Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="ogen_CommitmentAndContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_2113118_930041_1_1">Commitments And Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_2113118_930041_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2113118_923990_1_1">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2113118_923990_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise" xlink:label="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise_lbl" xml:lang="en-US" id="id_2113118_1164711_3_1">Common stock issued during period par value for warrants exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise_lbl" xml:lang="en-US" id="id_2113118_1164711_1_1">Common Stock Issued During Period Par Value For Warrants Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise_lbl" xml:lang="en-US" id="id_2113118_1164711_2_1">Par value of common stock issued for cashless exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise" xlink:to="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_2113118_931741_1_1">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_2113118_931741_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_2113118_930676_1_1">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_2113118_930676_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_2113118_925763_1_1">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_2113118_925763_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2113118_923588_1_1">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2113118_923588_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_2113118_935685_1_1">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_2113118_935685_2_1">Common stock, $0.001 par value; 50,000,000 shares authorized; 30,168,613 and 27,382,830 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_930849_1_1">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_930849_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="id_2113118_930526_1_1">Concentration Risk By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="id_2113118_930526_2_1">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_2113118_930739_1_1">Concentration Risk Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_2113118_930739_2_1">Concentrations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="id_2113118_927911_1_1">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="id_2113118_927911_2_1">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US" id="id_2113118_935612_1_1">Convertible Notes Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US" id="id_2113118_935612_2_1">Convertible note payable to shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ConvertiblePromissoryNotesMember" xlink:label="ogen_ConvertiblePromissoryNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" id="id_2113118_954731_3_1">Convertible promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" id="id_2113118_954731_1_1">Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" id="id_2113118_954731_2_1">Convertible Promissory Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ConvertiblePromissoryNotesMember" xlink:to="ogen_ConvertiblePromissoryNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" id="id_2113118_937862_1_1">Cost Of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US" id="id_2113118_937862_2_1">Cost of sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_2113118_922004_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_2113118_922004_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_2113118_938754_1_1">Current State And Local Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_2113118_938754_14_1">Local business tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="id_2113118_935911_1_1">Debt Conversion Converted Instrument Amount 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" id="id_2113118_935911_2_1">Conversion of convertible note payable and accrued interest to common shares and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_2113118_928741_1_1">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_2113118_928741_2_1">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_DebtInstrumentAmortizationPeriod" xlink:label="ogen_DebtInstrumentAmortizationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_DebtInstrumentAmortizationPeriod_lbl" xml:lang="en-US" id="id_2113118_1001969_3_1">Debt instrument amortization period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_DebtInstrumentAmortizationPeriod_lbl" xml:lang="en-US" id="id_2113118_1001969_1_1">Debt Instrument Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_DebtInstrumentAmortizationPeriod_lbl" xml:lang="en-US" id="id_2113118_1001969_2_1">Short-term notes payable amortization period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_DebtInstrumentAmortizationPeriod" xlink:to="ogen_DebtInstrumentAmortizationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_2113118_935575_1_1">Debt Instrument Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_2113118_935575_2_1">convertible promissory note issued to pay technology access fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="id_2113118_935575_12_1">Short-term note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_2113118_924352_1_1">Debt Instrument Interest Rate Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_2113118_924352_2_1">Interest rate on short-term note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_2113118_924921_1_1">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_2113118_924921_2_1">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_2113118_926342_1_1">Debt Instrument Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_2113118_926342_2_1">Final payment date of short-term note payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="id_2113118_926342_12_1">Maturity date of convertible note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_2113118_924143_1_1">Debt Instrument [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_2113118_924143_2_1">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_2113118_935260_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_2113118_935260_2_1">Revenue deferred under guaranteed rights of return arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US" id="id_2113118_927059_1_1">Deferred Revenue Arrangement Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US" id="id_2113118_927059_2_1">Deferred Revenue Arrangement Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US" id="id_2113118_927287_1_1">Deferred Revenue Arrangement Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xml:lang="en-US" id="id_2113118_927287_2_1">Deferred Revenue [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_2113118_935460_1_1">Deferred Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_2113118_935460_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="id_2113118_938558_1_1">Depreciation And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="id_2113118_938558_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorsAndOfficersLiabilityInsuranceMember" xlink:label="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember_lbl" xml:lang="en-US" id="id_2113118_931724_1_1">Directors And Officers Liability Insurance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember_lbl" xml:lang="en-US" id="id_2113118_931724_2_1">Directors' and Officers' Liability Insurance Financing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember" xlink:to="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_2113118_930617_1_1">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_2113118_930617_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_2113118_923166_1_1">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_2113118_923166_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_DiscountOnNotePayableToShareholderForWarrantsIssued" xlink:label="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued_lbl" xml:lang="en-US" id="id_2113118_1164720_3_1">Discount on note payable to shareholder for warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued_lbl" xml:lang="en-US" id="id_2113118_1164720_1_1">Discount On Note Payable To Shareholder For Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued_lbl" xml:lang="en-US" id="id_2113118_1164720_2_1">Discount on note payable to shareholder for warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued" xlink:to="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_DocumentAndEntityInformationAbstract" xlink:label="ogen_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_2113118_951207_3_1">Document and entity information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_2113118_951207_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_2113118_951207_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="ogen_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_2113118_922019_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_2113118_922019_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_2113118_921974_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_2113118_921974_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_2113118_921989_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_2113118_921989_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_2113118_921984_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_2113118_921984_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_2113118_929231_1_1">Earnings Per Share Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" id="id_2113118_929231_2_1">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_931897_1_1">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_931897_2_1">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_2113118_932976_1_1">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_2113118_932976_2_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_2113118_921997_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_2113118_921997_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2113118_922042_1_1">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2113118_922042_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_2113118_921970_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_2113118_921970_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_2113118_921955_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_2113118_921955_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_2113118_921937_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_2113118_921937_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_2113118_932367_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_2113118_932367_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ExecutiveOfficersMember" xlink:label="ogen_ExecutiveOfficersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ExecutiveOfficersMember_lbl" xml:lang="en-US" id="id_2113118_1057198_3_1">Executive officers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ExecutiveOfficersMember_lbl" xml:lang="en-US" id="id_2113118_1057198_1_1">Executive Officers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ExecutiveOfficersMember_lbl" xml:lang="en-US" id="id_2113118_1057198_2_1">Executive Officers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ExecutiveOfficersMember" xlink:to="ogen_ExecutiveOfficersMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ExpensesRelatedToStockAwards" xlink:label="ogen_ExpensesRelatedToStockAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ExpensesRelatedToStockAwards_lbl" xml:lang="en-US" id="id_2113118_1220764_3_1">Expenses related to stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ExpensesRelatedToStockAwards_lbl" xml:lang="en-US" id="id_2113118_1220764_1_1">Expenses Related To Stock Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ExpensesRelatedToStockAwards_lbl" xml:lang="en-US" id="id_2113118_1220764_2_1">Liability and expense related to equity incentive plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ExpensesRelatedToStockAwards" xlink:to="ogen_ExpensesRelatedToStockAwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_2113118_931938_1_1">Fair Value Of Financial Instruments Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_2113118_931938_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_FilingOfFirstInvestigationalNewDrugApplicationMember" xlink:label="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember_lbl" xml:lang="en-US" id="id_2113118_1164723_3_1">Filing of first investigational new drug application.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember_lbl" xml:lang="en-US" id="id_2113118_1164723_1_1">Filing Of First Investigational New Drug Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember_lbl" xml:lang="en-US" id="id_2113118_1164723_2_1">Filing of First Investigational New Drug Application [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember" xlink:to="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_FirstRegulatoryApprovalOfOragenicsProductMember" xlink:label="ogen_FirstRegulatoryApprovalOfOragenicsProductMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_FirstRegulatoryApprovalOfOragenicsProductMember_lbl" xml:lang="en-US" id="id_2113118_1164724_3_1">First regulatory approval of oragenics product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_FirstRegulatoryApprovalOfOragenicsProductMember_lbl" xml:lang="en-US" id="id_2113118_1164724_1_1">First Regulatory Approval Of Oragenics Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_FirstRegulatoryApprovalOfOragenicsProductMember_lbl" xml:lang="en-US" id="id_2113118_1164724_2_1">First Regulatory Approval of Oragenics Product [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_FirstRegulatoryApprovalOfOragenicsProductMember" xlink:to="ogen_FirstRegulatoryApprovalOfOragenicsProductMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GriffinSecuritiesIncMember" xlink:label="ogen_GriffinSecuritiesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_GriffinSecuritiesIncMember_lbl" xml:lang="en-US" id="id_2113118_1164725_3_1">Griffin securities inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_GriffinSecuritiesIncMember_lbl" xml:lang="en-US" id="id_2113118_1164725_1_1">Griffin Securities Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_GriffinSecuritiesIncMember_lbl" xml:lang="en-US" id="id_2113118_1164725_2_1">Griffin Securities Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_GriffinSecuritiesIncMember" xlink:to="ogen_GriffinSecuritiesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" id="id_2113118_933395_1_1">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" id="id_2113118_933395_6_1">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GuaranteedRightsOfReturnMember" xlink:label="ogen_GuaranteedRightsOfReturnMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_GuaranteedRightsOfReturnMember_lbl" xml:lang="en-US" id="id_2113118_1177511_3_1">Guaranteed rights of return.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_GuaranteedRightsOfReturnMember_lbl" xml:lang="en-US" id="id_2113118_1177511_1_1">Guaranteed Rights Of Return [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_GuaranteedRightsOfReturnMember_lbl" xml:lang="en-US" id="id_2113118_1177511_2_1">Guaranteed Rights of Return [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_GuaranteedRightsOfReturnMember" xlink:to="ogen_GuaranteedRightsOfReturnMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_2113118_933538_1_1">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" id="id_2113118_933538_6_1">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_2113118_927850_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_2113118_927850_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_2113118_927015_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_2113118_927015_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_2113118_931901_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_2113118_931901_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_2113118_940829_1_1">Income Tax Expense Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="id_2113118_940829_2_1">Income tax benefit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="id_2113118_936903_1_1">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="id_2113118_936903_2_1">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_2113118_935454_1_1">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_2113118_935454_14_1">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_2113118_938117_1_1">Increase Decrease In Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_2113118_938117_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="id_2113118_935750_1_1">Increase Decrease In Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="id_2113118_935750_14_1">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_2113118_924543_1_1">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_2113118_924543_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_2113118_933216_1_1">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_2113118_933216_14_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_2113118_938923_1_1">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_2113118_938923_14_1">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_2113118_935259_1_1">Interest Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US" id="id_2113118_935259_2_1">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_IntrexonMember" xlink:label="ogen_IntrexonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_IntrexonMember_lbl" xml:lang="en-US" id="id_2113118_1164727_3_1">Intrexon.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_IntrexonMember_lbl" xml:lang="en-US" id="id_2113118_1164727_1_1">Intrexon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_IntrexonMember_lbl" xml:lang="en-US" id="id_2113118_1164727_2_1">Intrexon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_IntrexonMember" xlink:to="ogen_IntrexonMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_2113118_938714_1_1">Inventory Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="id_2113118_938714_2_1">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_928546_1_1">Inventory Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_928546_2_1">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US" id="id_2113118_935813_1_1">Inventory Valuation Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US" id="id_2113118_935813_2_1">Inventory reserve FIFO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" id="id_2113118_937732_1_1">Inventory Write Down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" id="id_2113118_937732_2_1">Write off of expired inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_InvestigationalNewDrugApplicationMember" xlink:label="ogen_InvestigationalNewDrugApplicationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_InvestigationalNewDrugApplicationMember_lbl" xml:lang="en-US" id="id_2113118_1185488_3_1">Investigational new drug application.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_InvestigationalNewDrugApplicationMember_lbl" xml:lang="en-US" id="id_2113118_1185488_1_1">Investigational New Drug Application [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_InvestigationalNewDrugApplicationMember_lbl" xml:lang="en-US" id="id_2113118_1185488_2_1">Investigational New Drug Application [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_InvestigationalNewDrugApplicationMember" xlink:to="ogen_InvestigationalNewDrugApplicationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_2113118_934440_1_1">Investment Income Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="id_2113118_934440_2_1">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LantibioticEccMember" xlink:label="ogen_LantibioticEccMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_LantibioticEccMember_lbl" xml:lang="en-US" id="id_2113118_1220780_3_1">Lantibiotic ECC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_LantibioticEccMember_lbl" xml:lang="en-US" id="id_2113118_1220780_1_1">Lantibiotic Ecc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_LantibioticEccMember_lbl" xml:lang="en-US" id="id_2113118_1220780_2_1">Lantibiotic ECC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_LantibioticEccMember" xlink:to="ogen_LantibioticEccMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_2113118_921954_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_2113118_921954_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_2113118_935778_1_1">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_2113118_935778_6_1">Total liabilities and shareholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_2113118_924388_1_1">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_2113118_924388_2_1">Liabilities and Shareholders' Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US" id="id_2113118_934819_1_1">Liabilities Assumed 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAssumed1_lbl" xml:lang="en-US" id="id_2113118_934819_2_1">Borrowings under short term notes payable for prepaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAssumed1" xlink:to="us-gaap_LiabilitiesAssumed1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_2113118_934201_1_1">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_2113118_934201_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_2113118_929787_1_1">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_2113118_929787_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDate" xlink:label="ogen_LicenseAgreementDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_2113118_1080434_3_1">License agreement date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_2113118_1080434_1_1">License Agreement Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_LicenseAgreementDate_lbl" xml:lang="en-US" id="id_2113118_1080434_2_1">License Agreement, Original Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_LicenseAgreementDate" xlink:to="ogen_LicenseAgreementDate_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFifthAmended" xlink:label="ogen_LicenseAgreementDateFifthAmended"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_LicenseAgreementDateFifthAmended_lbl" xml:lang="en-US" id="id_2113118_1164732_3_1">License agreement date fifth amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_LicenseAgreementDateFifthAmended_lbl" xml:lang="en-US" id="id_2113118_1164732_1_1">License Agreement Date Fifth Amended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_LicenseAgreementDateFifthAmended_lbl" xml:lang="en-US" id="id_2113118_1164732_2_1">License agreement date fifth amended</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_LicenseAgreementDateFifthAmended" xlink:to="ogen_LicenseAgreementDateFifthAmended_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFirstAmended" xlink:label="ogen_LicenseAgreementDateFirstAmended"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_LicenseAgreementDateFirstAmended_lbl" xml:lang="en-US" id="id_2113118_1164733_3_1">License agreement date first amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_LicenseAgreementDateFirstAmended_lbl" xml:lang="en-US" id="id_2113118_1164733_1_1">License Agreement Date First Amended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_LicenseAgreementDateFirstAmended_lbl" xml:lang="en-US" id="id_2113118_1164733_2_1">License agreement, first amendment date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_LicenseAgreementDateFirstAmended" xlink:to="ogen_LicenseAgreementDateFirstAmended_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFourthAmended" xlink:label="ogen_LicenseAgreementDateFourthAmended"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_LicenseAgreementDateFourthAmended_lbl" xml:lang="en-US" id="id_2113118_1164734_3_1">License agreement date fourth amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_LicenseAgreementDateFourthAmended_lbl" xml:lang="en-US" id="id_2113118_1164734_1_1">License Agreement Date Fourth Amended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_LicenseAgreementDateFourthAmended_lbl" xml:lang="en-US" id="id_2113118_1164734_2_1">License agreement, fourth amendment date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_LicenseAgreementDateFourthAmended" xlink:to="ogen_LicenseAgreementDateFourthAmended_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateSecondAmended" xlink:label="ogen_LicenseAgreementDateSecondAmended"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_LicenseAgreementDateSecondAmended_lbl" xml:lang="en-US" id="id_2113118_1164735_3_1">License agreement date second amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_LicenseAgreementDateSecondAmended_lbl" xml:lang="en-US" id="id_2113118_1164735_1_1">License Agreement Date Second Amended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_LicenseAgreementDateSecondAmended_lbl" xml:lang="en-US" id="id_2113118_1164735_2_1">License agreement, second amendment date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_LicenseAgreementDateSecondAmended" xlink:to="ogen_LicenseAgreementDateSecondAmended_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateThirdAmended" xlink:label="ogen_LicenseAgreementDateThirdAmended"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_LicenseAgreementDateThirdAmended_lbl" xml:lang="en-US" id="id_2113118_1164736_3_1">License agreement date third amended.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_LicenseAgreementDateThirdAmended_lbl" xml:lang="en-US" id="id_2113118_1164736_1_1">License Agreement Date Third Amended</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_LicenseAgreementDateThirdAmended_lbl" xml:lang="en-US" id="id_2113118_1164736_2_1">License agreement, third amendment date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_LicenseAgreementDateThirdAmended" xlink:to="ogen_LicenseAgreementDateThirdAmended_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" id="id_2113118_928185_1_1">Long Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" id="id_2113118_928185_2_1">Convertible Note Payable to Shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xml:lang="en-US" id="id_2113118_931737_1_1">Loss Contingencies By Nature Of Contingency [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xml:lang="en-US" id="id_2113118_931737_2_1">Loss Contingency Nature [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xml:lang="en-US" id="id_2113118_923163_1_1">Loss Contingency Nature [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xml:lang="en-US" id="id_2113118_923163_2_1">Loss Contingency, Nature [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued" xlink:label="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued_lbl" xml:lang="en-US" id="id_2113118_1164743_3_1">Maximum percentage of primary investment securities to investment of shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued_lbl" xml:lang="en-US" id="id_2113118_1164743_1_1">Maximum Percentage Of Primary Investment Securities To Investment Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued_lbl" xml:lang="en-US" id="id_2113118_1164743_2_1">Maximum percentage of primary investment securities to investment of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued" xlink:to="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MaximumPeriodToCureBreach" xlink:label="ogen_MaximumPeriodToCureBreach"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_MaximumPeriodToCureBreach_lbl" xml:lang="en-US" id="id_2113118_1220769_3_1">Maximum period to cure breach.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_MaximumPeriodToCureBreach_lbl" xml:lang="en-US" id="id_2113118_1220769_1_1">Maximum Period To Cure Breach</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_MaximumPeriodToCureBreach_lbl" xml:lang="en-US" id="id_2113118_1220769_2_1">Maximum period to cure the breach</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_MaximumPeriodToCureBreach" xlink:to="ogen_MaximumPeriodToCureBreach_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MilestoneMeasurementPeriod" xlink:label="ogen_MilestoneMeasurementPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_MilestoneMeasurementPeriod_lbl" xml:lang="en-US" id="id_2113118_1220779_3_1">Milestone measurement period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_MilestoneMeasurementPeriod_lbl" xml:lang="en-US" id="id_2113118_1220779_1_1">Milestone Measurement Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_MilestoneMeasurementPeriod_lbl" xml:lang="en-US" id="id_2113118_1220779_2_1">Milestone measurement period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_MilestoneMeasurementPeriod" xlink:to="ogen_MilestoneMeasurementPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement" xlink:label="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement_lbl" xml:lang="en-US" id="id_2113118_1221401_3_1">Minimum annual maintenance payments each license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement_lbl" xml:lang="en-US" id="id_2113118_1221401_1_1">Minimum Annual Maintenance Payments Each License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement_lbl" xml:lang="en-US" id="id_2113118_1221401_2_1">Minimum annual maintenance payment per license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement" xlink:to="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MinimumQuarterlyMaintenancePayment" xlink:label="ogen_MinimumQuarterlyMaintenancePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_MinimumQuarterlyMaintenancePayment_lbl" xml:lang="en-US" id="id_2113118_1177274_3_1">Minimum quarterly maintenance payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_MinimumQuarterlyMaintenancePayment_lbl" xml:lang="en-US" id="id_2113118_1177274_1_1">Minimum Quarterly Maintenance Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_MinimumQuarterlyMaintenancePayment_lbl" xml:lang="en-US" id="id_2113118_1177274_2_1">Quarterly maintenance payment to UFRF under installment plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_MinimumQuarterlyMaintenancePayment" xlink:to="ogen_MinimumQuarterlyMaintenancePayment_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MonthlyCalculationOfCommercializationFee" xlink:label="ogen_MonthlyCalculationOfCommercializationFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_MonthlyCalculationOfCommercializationFee_lbl" xml:lang="en-US" id="id_2113118_1221400_3_1">Monthly calculation of commercialization fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_MonthlyCalculationOfCommercializationFee_lbl" xml:lang="en-US" id="id_2113118_1221400_1_1">Monthly Calculation Of Commercialization Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_MonthlyCalculationOfCommercializationFee_lbl" xml:lang="en-US" id="id_2113118_1221400_2_1">One-time commercialization fee would be due on the first anniversary of first commercial sale</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_MonthlyCalculationOfCommercializationFee" xlink:to="ogen_MonthlyCalculationOfCommercializationFee_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MuOneOneFourZeroMember" xlink:label="ogen_MuOneOneFourZeroMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_MuOneOneFourZeroMember_lbl" xml:lang="en-US" id="id_2113118_1164756_3_1">MU1140.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_MuOneOneFourZeroMember_lbl" xml:lang="en-US" id="id_2113118_1164756_1_1">Mu One One Four Zero [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_MuOneOneFourZeroMember_lbl" xml:lang="en-US" id="id_2113118_1164756_2_1">MU1140 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_MuOneOneFourZeroMember" xlink:to="ogen_MuOneOneFourZeroMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_2113118_937453_1_1">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_2113118_937453_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2113118_924600_1_1">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2113118_924600_2_1">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_2113118_939292_1_1">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_2113118_939292_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2113118_924425_1_1">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2113118_924425_2_1">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_2113118_928832_1_1">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_2113118_928832_2_1">Cash used in operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_2113118_928832_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2113118_930909_1_1">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2113118_930909_2_1">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_2113118_935636_1_1">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_2113118_935636_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_2113118_935636_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_923522_1_1">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_923522_2_1">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NonEmployeeDirectorsMember" xlink:label="ogen_NonEmployeeDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_NonEmployeeDirectorsMember_lbl" xml:lang="en-US" id="id_2113118_1032852_3_1">Non-employee directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_NonEmployeeDirectorsMember_lbl" xml:lang="en-US" id="id_2113118_1032852_1_1">Non Employee Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_NonEmployeeDirectorsMember_lbl" xml:lang="en-US" id="id_2113118_1032852_2_1">Non- employee Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_NonEmployeeDirectorsMember" xlink:to="ogen_NonEmployeeDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_2113118_935626_1_1">Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_2113118_935626_6_1">Total other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_2113118_927496_1_1">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="id_2113118_927496_2_1">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns" xlink:label="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns_lbl" xml:lang="en-US" id="id_2113118_1164761_3_1">Number of dental distributor with guaranteed rights of returns.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns_lbl" xml:lang="en-US" id="id_2113118_1164761_1_1">Number Of Dental Distributor With Guaranteed Rights Of Returns</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns_lbl" xml:lang="en-US" id="id_2113118_1164761_2_1">Number of dental distributor with guaranteed rights of returns</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns" xlink:to="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfKeySuppliers" xlink:label="ogen_NumberOfKeySuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_NumberOfKeySuppliers_lbl" xml:lang="en-US" id="id_2113118_1164764_3_1">Number of key suppliers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_NumberOfKeySuppliers_lbl" xml:lang="en-US" id="id_2113118_1164764_1_1">Number Of Key Suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_NumberOfKeySuppliers_lbl" xml:lang="en-US" id="id_2113118_1164764_2_1">Number of key suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_NumberOfKeySuppliers" xlink:to="ogen_NumberOfKeySuppliers_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfVendorsWithPrepaidBalanceOfCompany" xlink:label="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany_lbl" xml:lang="en-US" id="id_2113118_1220761_3_1">Number of vendors with prepaid balance of company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany_lbl" xml:lang="en-US" id="id_2113118_1220761_1_1">Number Of Vendors With Prepaid Balance Of Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany_lbl" xml:lang="en-US" id="id_2113118_1220761_2_1">Number of vendors with prepaid balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany" xlink:to="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_2113118_940683_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_2113118_940683_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_2113118_927909_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_2113118_927909_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_2113118_934856_1_1">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_2113118_934856_6_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_2113118_927825_1_1">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_2113118_927825_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2113118_931858_1_1">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2113118_931858_2_1">Organization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="id_2113118_934300_1_1">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" id="id_2113118_934300_2_1">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ParValueOfRestrictedStockForfeited" xlink:label="ogen_ParValueOfRestrictedStockForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ParValueOfRestrictedStockForfeited_lbl" xml:lang="en-US" id="id_2113118_1164771_3_1">Par value of restricted stock forfeited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ParValueOfRestrictedStockForfeited_lbl" xml:lang="en-US" id="id_2113118_1164771_1_1">Par Value Of Restricted Stock Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ParValueOfRestrictedStockForfeited_lbl" xml:lang="en-US" id="id_2113118_1164771_2_1">Par value of forfeited stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ParValueOfRestrictedStockForfeited" xlink:to="ogen_ParValueOfRestrictedStockForfeited_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentLicenseExpirationTerm" xlink:label="ogen_PatentLicenseExpirationTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PatentLicenseExpirationTerm_lbl" xml:lang="en-US" id="id_2113118_1164773_3_1">Patent license expiration term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PatentLicenseExpirationTerm_lbl" xml:lang="en-US" id="id_2113118_1164773_1_1">Patent License Expiration Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PatentLicenseExpirationTerm_lbl" xml:lang="en-US" id="id_2113118_1164773_2_1">Patents license expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PatentLicenseExpirationTerm" xlink:to="ogen_PatentLicenseExpirationTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightEffectiveInceptionDate" xlink:label="ogen_PatentRightEffectiveInceptionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PatentRightEffectiveInceptionDate_lbl" xml:lang="en-US" id="id_2113118_1164774_3_1">Patent right effective inception date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PatentRightEffectiveInceptionDate_lbl" xml:lang="en-US" id="id_2113118_1164774_1_1">Patent Right Effective Inception Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PatentRightEffectiveInceptionDate_lbl" xml:lang="en-US" id="id_2113118_1164774_2_1">Patent effective date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PatentRightEffectiveInceptionDate" xlink:to="ogen_PatentRightEffectiveInceptionDate_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightExpireDate" xlink:label="ogen_PatentRightExpireDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PatentRightExpireDate_lbl" xml:lang="en-US" id="id_2113118_1164775_3_1">Patent right expire date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PatentRightExpireDate_lbl" xml:lang="en-US" id="id_2113118_1164775_1_1">Patent Right Expire Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PatentRightExpireDate_lbl" xml:lang="en-US" id="id_2113118_1164775_2_1">Patent right expire date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PatentRightExpireDate" xlink:to="ogen_PatentRightExpireDate_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightFillingDate" xlink:label="ogen_PatentRightFillingDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PatentRightFillingDate_lbl" xml:lang="en-US" id="id_2113118_1164776_3_1">Patent right filling date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PatentRightFillingDate_lbl" xml:lang="en-US" id="id_2113118_1164776_1_1">Patent Right Filling Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PatentRightFillingDate_lbl" xml:lang="en-US" id="id_2113118_1164776_2_1">Patent right filling date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PatentRightFillingDate" xlink:to="ogen_PatentRightFillingDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_2113118_935396_1_1">Payments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_2113118_935396_14_1">Payment of income taxes associated with stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_2113118_936514_1_1">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_2113118_936514_14_1">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock" xlink:label="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock_lbl" xml:lang="en-US" id="id_2113118_1164780_3_1">Percentage of base shares equal to number of shares for common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock_lbl" xml:lang="en-US" id="id_2113118_1164780_1_1">Percentage Of Base Shares Equal To Number Of Shares For Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock_lbl" xml:lang="en-US" id="id_2113118_1164780_2_1">Percentage of number of shares of common stock equal to Base Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock" xlink:to="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram" xlink:label="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram_lbl" xml:lang="en-US" id="id_2113118_1221403_3_1">Percentage of common stock outstanding earned under long term incentive program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram_lbl" xml:lang="en-US" id="id_2113118_1221403_1_1">Percentage Of Common Stock Outstanding Earned Under Long Term Incentive Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram_lbl" xml:lang="en-US" id="id_2113118_1221403_2_1">Percentage of share granted under long term incentive program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram" xlink:to="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable" xlink:label="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable_lbl" xml:lang="en-US" id="id_2113118_1220823_3_1">Percentage of net sales derived from sale of products payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable_lbl" xml:lang="en-US" id="id_2113118_1220823_1_1">Percentage Of Net Sales Derived From Sale Of Products Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable_lbl" xml:lang="en-US" id="id_2113118_1220823_2_1">Percent of company pay out of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable" xlink:to="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable" xlink:label="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable_lbl" xml:lang="en-US" id="id_2113118_1164781_3_1">Percentage of quarterly profit derived from sale of products payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable_lbl" xml:lang="en-US" id="id_2113118_1164781_1_1">Percentage Of Quarterly Profit Derived From Sale Of Products Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable_lbl" xml:lang="en-US" id="id_2113118_1164781_2_1">Percentage company pay on quarterly basis out of gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable" xlink:to="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement" xlink:label="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement_lbl" xml:lang="en-US" id="id_2113118_1164782_3_1">Percentage of quarterly revenue in case of sublicensor agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement_lbl" xml:lang="en-US" id="id_2113118_1164782_1_1">Percentage Of Quarterly Revenue In Case Of Sublicensor Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement_lbl" xml:lang="en-US" id="id_2113118_1164782_2_1">Company's obligation to make payment from all revenue received from sublicensing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement" xlink:to="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfSellingPricePayableAsRoyalty" xlink:label="ogen_PercentageOfSellingPricePayableAsRoyalty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PercentageOfSellingPricePayableAsRoyalty_lbl" xml:lang="en-US" id="id_2113118_1164783_3_1">Percentage of selling price payable as royalty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PercentageOfSellingPricePayableAsRoyalty_lbl" xml:lang="en-US" id="id_2113118_1164783_1_1">Percentage Of Selling Price Payable As Royalty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PercentageOfSellingPricePayableAsRoyalty_lbl" xml:lang="en-US" id="id_2113118_1164783_2_1">Company's obligation to pay from percentage of selling price of product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PercentageOfSellingPricePayableAsRoyalty" xlink:to="ogen_PercentageOfSellingPricePayableAsRoyalty_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram" xlink:label="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram_lbl" xml:lang="en-US" id="id_2113118_1220790_3_1">Percentage of share granted under long term incentive program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram_lbl" xml:lang="en-US" id="id_2113118_1220790_1_1">Percentage Of Share Granted Under Long Term Incentive Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram_lbl" xml:lang="en-US" id="id_2113118_1220790_2_1">Percentage of share granted under long term incentive program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram" xlink:to="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty" xlink:label="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty_lbl" xml:lang="en-US" id="id_2113118_1164784_3_1">Percentage of sublicenses revenue payable in addition of royalty.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty_lbl" xml:lang="en-US" id="id_2113118_1164784_1_1">Percentage Of Sublicenses Revenue Payable In Addition Of Royalty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty_lbl" xml:lang="en-US" id="id_2113118_1164784_2_1">Company's obligation to pay from all revenue received from sublicenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty" xlink:to="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement_lbl" xml:lang="en-US" id="id_2113118_1164785_3_1">Period during which company cannot terminate license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement_lbl" xml:lang="en-US" id="id_2113118_1164785_1_1">Period During Which Company Cannot Terminate License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement_lbl" xml:lang="en-US" id="id_2113118_1164785_2_1">Period during which company cannot terminate license agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement" xlink:to="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily_lbl" xml:lang="en-US" id="id_2113118_1164786_3_1">Period during which company cannot terminate license agreement voluntarily.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily_lbl" xml:lang="en-US" id="id_2113118_1164786_1_1">Period During Which Company Cannot Terminate License Agreement Voluntarily</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily_lbl" xml:lang="en-US" id="id_2113118_1164786_2_1">Period during which company cannot terminate license agreement voluntarily</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily" xlink:to="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_2113118_930809_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_2113118_930809_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_2113118_931386_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_2113118_931386_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsOne" xlink:label="ogen_PotentialFutureMilestonePaymentsOne"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PotentialFutureMilestonePaymentsOne_lbl" xml:lang="en-US" id="id_2113118_1040838_3_1">Potential future milestone payments one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PotentialFutureMilestonePaymentsOne_lbl" xml:lang="en-US" id="id_2113118_1040838_1_1">Potential Future Milestone Payments One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PotentialFutureMilestonePaymentsOne_lbl" xml:lang="en-US" id="id_2113118_1040838_2_1">Milestone amount payable one</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PotentialFutureMilestonePaymentsOne" xlink:to="ogen_PotentialFutureMilestonePaymentsOne_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsThree" xlink:label="ogen_PotentialFutureMilestonePaymentsThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PotentialFutureMilestonePaymentsThree_lbl" xml:lang="en-US" id="id_2113118_1004208_3_1">Potential future milestone payments three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PotentialFutureMilestonePaymentsThree_lbl" xml:lang="en-US" id="id_2113118_1004208_1_1">Potential Future Milestone Payments Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PotentialFutureMilestonePaymentsThree_lbl" xml:lang="en-US" id="id_2113118_1004208_2_1">Milestone amount payable three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PotentialFutureMilestonePaymentsThree" xlink:to="ogen_PotentialFutureMilestonePaymentsThree_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsTwo" xlink:label="ogen_PotentialFutureMilestonePaymentsTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_PotentialFutureMilestonePaymentsTwo_lbl" xml:lang="en-US" id="id_2113118_1138087_3_1">Potential future milestone payments two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_PotentialFutureMilestonePaymentsTwo_lbl" xml:lang="en-US" id="id_2113118_1138087_1_1">Potential Future Milestone Payments Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_PotentialFutureMilestonePaymentsTwo_lbl" xml:lang="en-US" id="id_2113118_1138087_2_1">Milestone amount payable two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_PotentialFutureMilestonePaymentsTwo" xlink:to="ogen_PotentialFutureMilestonePaymentsTwo_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" id="id_2113118_923464_1_1">Preferred Stock No Par Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockNoParValue_lbl" xml:lang="en-US" id="id_2113118_923464_2_1">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNoParValue" xlink:to="us-gaap_PreferredStockNoParValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_2113118_929540_1_1">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_2113118_929540_2_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_2113118_932934_1_1">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_2113118_932934_2_1">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2113118_926142_1_1">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2113118_926142_2_1">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_2113118_933055_1_1">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_2113118_933055_2_1">Preferred stock, no par value; 20,000,000 shares authorized; none issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_2113118_939595_1_1">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_2113118_939595_2_1">Prepaid balance of vendors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_2113118_939595_12_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ProbioticsEccMember" xlink:label="ogen_ProbioticsEccMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ProbioticsEccMember_lbl" xml:lang="en-US" id="id_2113118_1220768_3_1">Probiotics ECC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ProbioticsEccMember_lbl" xml:lang="en-US" id="id_2113118_1220768_1_1">Probiotics Ecc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ProbioticsEccMember_lbl" xml:lang="en-US" id="id_2113118_1220768_2_1">Probiotics ECC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ProbioticsEccMember" xlink:to="ogen_ProbioticsEccMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_2113118_940825_1_1">Proceeds From Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="id_2113118_940825_2_1">Borrowings under convertible secured note payable to shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_2113118_938994_1_1">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_2113118_938994_2_1">Gross proceeds from private placement of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_2113118_938994_12_1">Net proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_2113118_940409_1_1">Proceeds From Repayments Of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="id_2113118_940409_2_1">Borrowings under note payable to shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities_lbl" xml:lang="en-US" id="id_2113118_940616_1_1">Proceeds From Repayments Of Restricted Cash Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities_lbl" xml:lang="en-US" id="id_2113118_940616_2_1">Restricted cash released</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ProductLiabilityInsuranceMember" xlink:label="ogen_ProductLiabilityInsuranceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ProductLiabilityInsuranceMember_lbl" xml:lang="en-US" id="id_2113118_1164788_3_1">Product liability insurance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ProductLiabilityInsuranceMember_lbl" xml:lang="en-US" id="id_2113118_1164788_1_1">Product Liability Insurance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ProductLiabilityInsuranceMember_lbl" xml:lang="en-US" id="id_2113118_1164788_2_1">Product Liability Insurance [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ProductLiabilityInsuranceMember" xlink:to="ogen_ProductLiabilityInsuranceMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_2113118_940861_1_1">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_2113118_940861_2_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_2113118_926437_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_2113118_926437_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_2113118_930818_1_1">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_2113118_930818_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeOneMember" xlink:label="ogen_RangeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_RangeOneMember_lbl" xml:lang="en-US" id="id_2113118_960261_3_1">Range one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_RangeOneMember_lbl" xml:lang="en-US" id="id_2113118_960261_1_1">Range One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_RangeOneMember_lbl" xml:lang="en-US" id="id_2113118_960261_2_1">Range 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_RangeOneMember" xlink:to="ogen_RangeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeThreeMember" xlink:label="ogen_RangeThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_RangeThreeMember_lbl" xml:lang="en-US" id="id_2113118_1014875_3_1">Range three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_RangeThreeMember_lbl" xml:lang="en-US" id="id_2113118_1014875_1_1">Range Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_RangeThreeMember_lbl" xml:lang="en-US" id="id_2113118_1014875_2_1">Range 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_RangeThreeMember" xlink:to="ogen_RangeThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeTwoMember" xlink:label="ogen_RangeTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_RangeTwoMember_lbl" xml:lang="en-US" id="id_2113118_975231_3_1">Range two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_RangeTwoMember_lbl" xml:lang="en-US" id="id_2113118_975231_1_1">Range Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_RangeTwoMember_lbl" xml:lang="en-US" id="id_2113118_975231_2_1">Range 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_RangeTwoMember" xlink:to="ogen_RangeTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_2113118_932122_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_2113118_932122_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_2113118_926607_1_1">Related Party Transactions By Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_2113118_926607_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" id="id_2113118_933669_1_1">Repayments Of Short Term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xml:lang="en-US" id="id_2113118_933669_14_1">Payments on short-term notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_2113118_939407_1_1">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_2113118_939407_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_2113118_928963_1_1">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_2113118_928963_2_1">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2113118_937648_1_1">Restricted Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2113118_937648_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_2113118_935451_1_1">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_2113118_935451_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xml:lang="en-US" id="id_2113118_932120_1_1">Revenue Recognition Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xml:lang="en-US" id="id_2113118_932120_2_1">Guaranteed Rights of Return</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_924259_1_1">Revenue Recognition Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_924259_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_2113118_933119_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_2113118_933119_2_1">Revenue, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_2113118_933119_12_1">Revenues generated by company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_2113118_925602_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_2113118_925602_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_2113118_931816_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_2113118_931816_2_1">Stock-Based Compensation Expense Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" id="id_2113118_931763_1_1">Schedule Of Short Term Debt [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" id="id_2113118_931763_2_1">Schedule of Short-term Debt [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" id="id_2113118_924972_1_1">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" id="id_2113118_924972_2_1">Summary of Warrants Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_2113118_940817_1_1">Selling General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_2113118_940817_2_1">Selling, general and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="id_2113118_932414_1_1">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="id_2113118_932414_2_1">Selling, General and Administrative Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_2113118_938471_1_1">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_2113118_938471_2_1">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_2113118_938471_12_1">Total Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_2113118_931512_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_2113118_931512_2_1">Stock options forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_2113118_929506_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_2113118_929506_2_1">Stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors_lbl" xml:lang="en-US" id="id_2113118_1220784_3_1">Share based compensation arrangement by share based payment award options grants in period to number of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors_lbl" xml:lang="en-US" id="id_2113118_1220784_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period To Number Of Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors_lbl" xml:lang="en-US" id="id_2113118_1220784_2_1">Number of non-employee directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_2113118_928357_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_2113118_928357_2_1">Weighted-average grant date fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" id="id_2113118_923631_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" id="id_2113118_923631_2_1">Stock options vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded_lbl" xml:lang="en-US" id="id_2113118_1221399_3_1">Share-based compensation arrangement by share based payment award shares expected to be awarded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded_lbl" xml:lang="en-US" id="id_2113118_1221399_1_1">Share Based Compensation Arrangement By Share Based Payment Award Shares Expected To Be Awarded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded_lbl" xml:lang="en-US" id="id_2113118_1221399_2_1">Grant date fair value, shares expected to be awarded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted_lbl" xml:lang="en-US" id="id_2113118_1221494_3_1">Share based compensation arrangement by share based payment award to be granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted_lbl" xml:lang="en-US" id="id_2113118_1221494_1_1">Share Based Compensation Arrangement By Share Based Payment Award To Be Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted_lbl" xml:lang="en-US" id="id_2113118_1221494_2_1">Number of fully vested shares granted as award to non-employee director</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_2113118_923943_1_1">Share Based Compensation Option And Incentive Plans Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="id_2113118_923943_2_1">Stock-Based Payment Arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_2113118_928548_1_1">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_2113118_928548_2_1">Per shares price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_2113118_926902_1_1">Shares Paid For Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="id_2113118_926902_2_1">Retained by the Company for applicable tax withholding obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" id="id_2113118_929236_1_1">Short Term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" id="id_2113118_929236_2_1">Short-term Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US" id="id_2113118_931189_1_1">Short Term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US" id="id_2113118_931189_2_1">Short-Term Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" id="id_2113118_923847_1_1">Short Term Debt Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" id="id_2113118_923847_2_1">Short-term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" id="id_2113118_923877_1_1">Short Term Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" id="id_2113118_923877_2_1">Short-term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermNonBankLoansAndNotesPayable_lbl" xml:lang="en-US" id="id_2113118_933950_1_1">Short Term Non Bank Loans And Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermNonBankLoansAndNotesPayable_lbl" xml:lang="en-US" id="id_2113118_933950_2_1">Short term notes payable for financing insurance policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermNonBankLoansAndNotesPayable_lbl" xml:lang="en-US" id="id_2113118_933950_12_1">Short-term notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermNonBankLoansAndNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_2113118_931089_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_2113118_931089_2_1">Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_SmartReplacementTherapyMember" xlink:label="ogen_SmartReplacementTherapyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_SmartReplacementTherapyMember_lbl" xml:lang="en-US" id="id_2113118_1164802_3_1">Smart replacement therapy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_SmartReplacementTherapyMember_lbl" xml:lang="en-US" id="id_2113118_1164802_1_1">Smart Replacement Therapy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_SmartReplacementTherapyMember_lbl" xml:lang="en-US" id="id_2113118_1164802_2_1">Smart Replacement Therapy [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_SmartReplacementTherapyMember" xlink:to="ogen_SmartReplacementTherapyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_2113118_926570_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_2113118_926570_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_2113118_932756_1_1">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_2113118_932756_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_2113118_924693_1_1">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_2113118_924693_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_2113118_926771_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_2113118_926771_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_2113118_934682_1_1">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_2113118_934682_6_1">Total shareholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_2113118_925186_1_1">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_2113118_925186_2_1">Shareholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US" id="id_2113118_931845_1_1">Stock Issued During Period Shares Conversion Of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US" id="id_2113118_931845_2_1">Shares of common stock issued upon exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration_lbl" xml:lang="en-US" id="id_2113118_925842_1_1">Stock Issued During Period Shares Issued For Noncash Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration_lbl" xml:lang="en-US" id="id_2113118_925842_2_1">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_2113118_932873_1_1">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_2113118_932873_2_1">Company's common stock shares sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" id="id_2113118_928209_1_1">Stock Issued During Period Shares Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US" id="id_2113118_928209_2_1">Common stock awarded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_2113118_930668_1_1">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_2113118_930668_2_1">Stock options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_StockIssuedToEachDirectorDuringPeriodSharesOther" xlink:label="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther_lbl" xml:lang="en-US" id="id_2113118_1221402_3_1">Stock issued to each director during period shares other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther_lbl" xml:lang="en-US" id="id_2113118_1221402_1_1">Stock Issued To Each Director During Period Shares Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther_lbl" xml:lang="en-US" id="id_2113118_1221402_2_1">Award approved by the board</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther" xlink:to="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_2113118_924078_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_2113118_924078_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_2113118_931597_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_2113118_931597_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_2113118_925770_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_2113118_925770_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_2113118_929519_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_2113118_929519_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_2113118_930713_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_2113118_930713_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_2113118_932504_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_2113118_932504_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_2113118_929873_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_2113118_929873_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_SummaryOfWarrantActivityTableTextBlock" xlink:label="ogen_SummaryOfWarrantActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_SummaryOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US" id="id_2113118_1107718_3_1">Summary of warrant activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_SummaryOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US" id="id_2113118_1107718_1_1">Summary Of Warrant Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_SummaryOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US" id="id_2113118_1107718_2_1">Summary of Warrant Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_SummaryOfWarrantActivityTableTextBlock" xlink:to="ogen_SummaryOfWarrantActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_2113118_930441_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_2113118_930441_2_1">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US" id="id_2113118_923447_1_1">Supplier Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US" id="id_2113118_923447_2_1">Supplier Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" xlink:label="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder_lbl" xml:lang="en-US" id="id_2113118_1221480_3_1">Technology access fee paid in common stock and convertible note payable to shareholder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder_lbl" xml:lang="en-US" id="id_2113118_1221480_1_1">Technology Access Fee Paid In Common Stock And Convertible Note Payable To Shareholder</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder_lbl" xml:lang="en-US" id="id_2113118_1221480_2_1">Technology access fee paid in common stock and convertible note payable to shareholder</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" xlink:to="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TechnologyAccessFeeUpfrontPayment" xlink:label="ogen_TechnologyAccessFeeUpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_TechnologyAccessFeeUpfrontPayment_lbl" xml:lang="en-US" id="id_2113118_1133400_3_1">Technology access fee upfront payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_TechnologyAccessFeeUpfrontPayment_lbl" xml:lang="en-US" id="id_2113118_1133400_1_1">Technology Access Fee Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_TechnologyAccessFeeUpfrontPayment_lbl" xml:lang="en-US" id="id_2113118_1133400_2_1">Up-front technology access fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_TechnologyAccessFeeUpfrontPayment" xlink:to="ogen_TechnologyAccessFeeUpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TerminationNoticePeriod" xlink:label="ogen_TerminationNoticePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_TerminationNoticePeriod_lbl" xml:lang="en-US" id="id_2113118_1116170_3_1">Termination notice period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_TerminationNoticePeriod_lbl" xml:lang="en-US" id="id_2113118_1116170_1_1">Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_TerminationNoticePeriod_lbl" xml:lang="en-US" id="id_2113118_1116170_2_1">Termination notice period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_TerminationNoticePeriod" xlink:to="ogen_TerminationNoticePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_2113118_931202_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_2113118_931202_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="ogen_TwoThousandTwelveEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_TwoThousandTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_2113118_1041243_3_1">Two thousand twelve equity incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_TwoThousandTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_2113118_1041243_1_1">Two Thousand Twelve Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_TwoThousandTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_2113118_1041243_2_1">2012 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_TwoThousandTwelveEquityIncentivePlanMember" xlink:to="ogen_TwoThousandTwelveEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_2113118_928294_1_1">Type Of Arrangement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_2113118_928294_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_UniversityOfFloridaResearchFoundationLicensesMember" xlink:label="ogen_UniversityOfFloridaResearchFoundationLicensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_UniversityOfFloridaResearchFoundationLicensesMember_lbl" xml:lang="en-US" id="id_2113118_1185489_3_1">UFRF license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_UniversityOfFloridaResearchFoundationLicensesMember_lbl" xml:lang="en-US" id="id_2113118_1185489_1_1">University Of Florida Research Foundation Licenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_UniversityOfFloridaResearchFoundationLicensesMember_lbl" xml:lang="en-US" id="id_2113118_1185489_2_1">UFRF License Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_UniversityOfFloridaResearchFoundationLicensesMember" xlink:to="ogen_UniversityOfFloridaResearchFoundationLicensesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_2113118_931855_1_1">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_2113118_931855_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VicePresidentMember" xlink:label="us-gaap_VicePresidentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VicePresidentMember_lbl" xml:lang="en-US" id="id_2113118_927115_1_1">Vice President [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VicePresidentMember_lbl" xml:lang="en-US" id="id_2113118_927115_2_1">Dr. Martin Handfield [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VicePresidentMember" xlink:to="us-gaap_VicePresidentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantDisclosureTextBlock" xlink:label="ogen_WarrantDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_WarrantDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2113118_1177535_3_1">Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_WarrantDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2113118_1177535_1_1">Warrant Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_WarrantDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2113118_1177535_2_1">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_WarrantDisclosureTextBlock" xlink:to="ogen_WarrantDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantPolicyTextBlock" xlink:label="ogen_WarrantPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_WarrantPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_1177275_3_1">Warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_WarrantPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_1177275_1_1">Warrant Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_WarrantPolicyTextBlock_lbl" xml:lang="en-US" id="id_2113118_1177275_2_1">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_WarrantPolicyTextBlock" xlink:to="ogen_WarrantPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantsExpirationDates" xlink:label="ogen_WarrantsExpirationDates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_WarrantsExpirationDates_lbl" xml:lang="en-US" id="id_2113118_1164820_3_1">Warrants expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_WarrantsExpirationDates_lbl" xml:lang="en-US" id="id_2113118_1164820_1_1">Warrants Expiration Dates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_WarrantsExpirationDates_lbl" xml:lang="en-US" id="id_2113118_1164820_2_1">Expiration Dates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_WarrantsExpirationDates" xlink:to="ogen_WarrantsExpirationDates_lbl"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantsIssued" xlink:label="ogen_WarrantsIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ogen_WarrantsIssued_lbl" xml:lang="en-US" id="id_2113118_985904_3_1">Warrants issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ogen_WarrantsIssued_lbl" xml:lang="en-US" id="id_2113118_985904_1_1">Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ogen_WarrantsIssued_lbl" xml:lang="en-US" id="id_2113118_985904_2_1">Warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ogen_WarrantsIssued" xlink:to="ogen_WarrantsIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_2113118_927104_1_1">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" id="id_2113118_927104_2_1">Shares used to compute basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ogen-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 4 -->
<!-- Creation date: 2013-10-24T00:14:06Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DocumentandEntityInformation" roleURI="http://oragenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfIncome" roleURI="http://oragenics.com/taxonomy/role/StatementOfIncome"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureBasisOfPresentationAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureSignificantAccountingPoliciesAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized" roleURI="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsSummaryOfWarrantActivity" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantActivity"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureWarrantsSummaryOfWarrantsOutstanding" roleURI="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstanding"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureShorttermNotesPayableAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureShorttermNotesPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureConvertibleNotePayableToShareholderAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureConvertibleNotePayableToShareholderAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://oragenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlockTables" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsShortTermDebtTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsShortTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsLongTermDebtTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="ogen-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_DocumentAndEntityInformationAbstract" xlink:label="ogen_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermNonBankLoansAndNotesPayable" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockNoParValue" xlink:label="us-gaap_PreferredStockNoParValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockNoParValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfGoodsSold" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise" xlink:label="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_DiscountOnNotePayableToShareholderForWarrantsIssued" xlink:label="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GriffinSecuritiesIncMember" xlink:label="ogen_GriffinSecuritiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAssumed1" xlink:label="us-gaap_LiabilitiesAssumed1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ParValueOfRestrictedStockForfeited" xlink:label="ogen_ParValueOfRestrictedStockForfeited"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfNotesPayable" xlink:label="us-gaap_ProceedsFromRepaymentsOfNotesPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" xlink:label="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" xlink:label="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_LiabilitiesAssumed1" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ogen_DiscountOnNotePayableToShareholderForWarrantsIssued" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ogen_ParValueOfRestrictedStockForfeited" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ogen_GriffinSecuritiesIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.2800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="1.2900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.3000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfNotesPayable" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="1.3500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.3600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.2600" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GriffinSecuritiesIncMember" xlink:label="ogen_GriffinSecuritiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantsIssued" xlink:label="ogen_WarrantsIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ogen_GriffinSecuritiesIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ogen_WarrantsIssued" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_Revenues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GuaranteedRightsOfReturnMember" xlink:label="ogen_GuaranteedRightsOfReturnMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns" xlink:label="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfKeySuppliers" xlink:label="ogen_NumberOfKeySuppliers"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NumberOfVendorsWithPrepaidBalanceOfCompany" xlink:label="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryValuationReserves" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ogen_NumberOfKeySuppliers" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ogen_NumberOfVendorsWithPrepaidBalanceOfCompany" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="ogen_GuaranteedRightsOfReturnMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ExpensesRelatedToStockAwards" xlink:label="ogen_ExpensesRelatedToStockAwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="ogen_TwoThousandTwelveEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ogen_ExpensesRelatedToStockAwards" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ogen_TwoThousandTwelveEquityIncentivePlanMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantActivity">
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExercised" xlink:label="ogen_ClassOfWarrantExercised"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExpired" xlink:label="ogen_ClassOfWarrantExpired"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantGrantedInPeriod" xlink:label="ogen_ClassOfWarrantGrantedInPeriod"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice" xlink:label="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ogen_ClassOfWarrantGrantedInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ogen_ClassOfWarrantExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ogen_ClassOfWarrantExpired" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice_2" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClassOfWarrantExercised" xlink:label="ogen_ClassOfWarrantExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_GriffinSecuritiesIncMember" xlink:label="ogen_GriffinSecuritiesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ogen_ClassOfWarrantExercised" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ogen_GriffinSecuritiesIncMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstanding">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeOneMember" xlink:label="ogen_RangeOneMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeThreeMember" xlink:label="ogen_RangeThreeMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_RangeTwoMember" xlink:label="ogen_RangeTwoMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantsExpirationDates" xlink:label="ogen_WarrantsExpirationDates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ogen_WarrantsExpirationDates" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="ogen_RangeOneMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="ogen_RangeTwoMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="ogen_RangeThreeMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureShorttermNotesPayableAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_DebtInstrumentAmortizationPeriod" xlink:label="ogen_DebtInstrumentAmortizationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DirectorsAndOfficersLiabilityInsuranceMember" xlink:label="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ProductLiabilityInsuranceMember" xlink:label="ogen_ProductLiabilityInsuranceMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermNonBankLoansAndNotesPayable" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="ogen_DebtInstrumentAmortizationPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="ogen_ProductLiabilityInsuranceMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_DirectorsAndOfficersLiabilityInsuranceMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureConvertibleNotePayableToShareholderAdditionalInformation">
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ConvertiblePromissoryNotesMember" xlink:label="ogen_ConvertiblePromissoryNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="ogen_ConvertiblePromissoryNotesMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage" xlink:label="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum" xlink:label="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AggregateMinimumAnnualMaintenancePayment" xlink:label="ogen_AggregateMinimumAnnualMaintenancePayment"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization" xlink:label="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClinicalStudyPhaseThreeMember" xlink:label="ogen_ClinicalStudyPhaseThreeMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ClinicalStudyPhaseTwoMember" xlink:label="ogen_ClinicalStudyPhaseTwoMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommitmentAndContingenciesLineItems" xlink:label="ogen_CommitmentAndContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_CommitmentAndContingenciesTable" xlink:label="ogen_CommitmentAndContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ConvertiblePromissoryNotesMember" xlink:label="ogen_ConvertiblePromissoryNotesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_FilingOfFirstInvestigationalNewDrugApplicationMember" xlink:label="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_FirstRegulatoryApprovalOfOragenicsProductMember" xlink:label="ogen_FirstRegulatoryApprovalOfOragenicsProductMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_IntrexonMember" xlink:label="ogen_IntrexonMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_InvestigationalNewDrugApplicationMember" xlink:label="ogen_InvestigationalNewDrugApplicationMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LantibioticEccMember" xlink:label="ogen_LantibioticEccMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDate" xlink:label="ogen_LicenseAgreementDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFifthAmended" xlink:label="ogen_LicenseAgreementDateFifthAmended"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFirstAmended" xlink:label="ogen_LicenseAgreementDateFirstAmended"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateFourthAmended" xlink:label="ogen_LicenseAgreementDateFourthAmended"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateSecondAmended" xlink:label="ogen_LicenseAgreementDateSecondAmended"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_LicenseAgreementDateThirdAmended" xlink:label="ogen_LicenseAgreementDateThirdAmended"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued" xlink:label="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MaximumPeriodToCureBreach" xlink:label="ogen_MaximumPeriodToCureBreach"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MilestoneMeasurementPeriod" xlink:label="ogen_MilestoneMeasurementPeriod"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement" xlink:label="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MinimumQuarterlyMaintenancePayment" xlink:label="ogen_MinimumQuarterlyMaintenancePayment"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MonthlyCalculationOfCommercializationFee" xlink:label="ogen_MonthlyCalculationOfCommercializationFee"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_MuOneOneFourZeroMember" xlink:label="ogen_MuOneOneFourZeroMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentLicenseExpirationTerm" xlink:label="ogen_PatentLicenseExpirationTerm"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightEffectiveInceptionDate" xlink:label="ogen_PatentRightEffectiveInceptionDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightExpireDate" xlink:label="ogen_PatentRightExpireDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PatentRightFillingDate" xlink:label="ogen_PatentRightFillingDate"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock" xlink:label="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable" xlink:label="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable" xlink:label="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement" xlink:label="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfSellingPricePayableAsRoyalty" xlink:label="ogen_PercentageOfSellingPricePayableAsRoyalty"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty" xlink:label="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily" xlink:label="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsOne" xlink:label="ogen_PotentialFutureMilestonePaymentsOne"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsThree" xlink:label="ogen_PotentialFutureMilestonePaymentsThree"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PotentialFutureMilestonePaymentsTwo" xlink:label="ogen_PotentialFutureMilestonePaymentsTwo"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ProbioticsEccMember" xlink:label="ogen_ProbioticsEccMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_SmartReplacementTherapyMember" xlink:label="ogen_SmartReplacementTherapyMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TechnologyAccessFeeUpfrontPayment" xlink:label="ogen_TechnologyAccessFeeUpfrontPayment"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TerminationNoticePeriod" xlink:label="ogen_TerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_UniversityOfFloridaResearchFoundationLicensesMember" xlink:label="ogen_UniversityOfFloridaResearchFoundationLicensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_MuOneOneFourZeroMember" order="1.4000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_SmartReplacementTherapyMember" order="1.4400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_UniversityOfFloridaResearchFoundationLicensesMember" order="1.4600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_LantibioticEccMember" order="1.4800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ogen_ProbioticsEccMember" order="1.5000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateFirstAmended" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateSecondAmended" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateThirdAmended" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateFourthAmended" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_LicenseAgreementDateFifthAmended" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PatentLicenseExpirationTerm" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PatentRightFillingDate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PatentRightEffectiveInceptionDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PatentRightExpireDate" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfSellingPricePayableAsRoyalty" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MonthlyCalculationOfCommercializationFee" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_AggregateMinimumAnnualMaintenancePayment" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MinimumQuarterlyMaintenancePayment" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_TerminationNoticePeriod" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MaximumPeriodToCureBreach" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_TechnologyAccessFeeUpfrontPayment" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_SharePrice" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PotentialFutureMilestonePaymentsOne" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PotentialFutureMilestonePaymentsTwo" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PotentialFutureMilestonePaymentsThree" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MilestoneMeasurementPeriod" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement" order="1.3700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock" order="1.3800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesLineItems" xlink:to="ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued" order="1.3900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="dei_LegalEntityAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ogen_CommitmentAndContingenciesTable" xlink:to="ogen_CommitmentAndContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ogen_CommitmentAndContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ogen_IntrexonMember" order="1.4100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_InvestigationalNewDrugApplicationMember" order="1.4300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_ClinicalStudyPhaseTwoMember" order="1.4500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_ClinicalStudyPhaseThreeMember" order="1.4700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_FilingOfFirstInvestigationalNewDrugApplicationMember" order="1.4900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ogen_FirstRegulatoryApprovalOfOragenicsProductMember" order="1.5100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="ogen_ConvertiblePromissoryNotesMember" order="1.4200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ChiefFinancialOfficerMember" xlink:label="us-gaap_ChiefFinancialOfficerMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ExecutiveOfficersMember" xlink:label="ogen_ExecutiveOfficersMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_NonEmployeeDirectorsMember" xlink:label="ogen_NonEmployeeDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram" xlink:label="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram" xlink:label="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted" xlink:label="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_StockIssuedToEachDirectorDuringPeriodSharesOther" xlink:label="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_TwoThousandTwelveEquityIncentivePlanMember" xlink:label="ogen_TwoThousandTwelveEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_VicePresidentMember" xlink:label="us-gaap_VicePresidentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ogen_TwoThousandTwelveEquityIncentivePlanMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ChiefExecutiveOfficerMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_ChiefFinancialOfficerMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_VicePresidentMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ogen_NonEmployeeDirectorsMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ogen_ExecutiveOfficersMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_StockIssuedToEachDirectorDuringPeriodSharesOther" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantPolicyTextBlock" xlink:label="ogen_WarrantPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ogen_WarrantPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_WarrantDisclosureTextBlock" xlink:label="ogen_WarrantDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="ogen_WarrantDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <loc xlink:type="locator" xlink:href="ogen-20130930.xsd#ogen_SummaryOfWarrantActivityTableTextBlock" xlink:label="ogen_SummaryOfWarrantActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="ogen_SummaryOfWarrantActivityTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsShortTermDebtTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense Recognized</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognized stock-based compensation on all employee and
 non-employee awards as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
 <tr>
 <td width="46%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;Months&#xA0;Ended<br />
 September&#xA0;30, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;Months&#xA0;Ended<br />
 September&#xA0;30, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br />
 September&#xA0;30, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br />
 September&#xA0;30, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">183,168</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">105,858</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">158,575</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,726</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Selling, general and administrative</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,355,175</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">693,533</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,465,590</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">940,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total Stock based compensation</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,538,343</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">799,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,624,165</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,057,218</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0`E!5Y>V0$```04```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F-%NVC`4AN\G[1TBWT[$
MV-LZ-A&X8-UEA[3N`3S[0"(<V[(-A;?O26A153$0*E+/#1'$/O^'+SXE_WBZ
M;6VQ@9@:[RHFRB$KP&EO&K>LV-_[7X,1*U)6SBCK'51L!XE-)Q\_C.]W`5*!
MNUVJ6)US^,%YTC6T*I4^@,,["Q];E?%K7/*@]$HM@<OA\(9K[S*X/,C=##89
M_X2%6MM<W&[QYSU)!)M8,=LO[+(JID*PC5892?G&F5<I@Z>$$G?V:U+=A/0)
M,1@_FM#=^7_`T[[?>#2Q,5#,5<QWJD4,OK7\P<?5/^]7Y>DA1RC]8M%H,%ZO
M6SR!,H4(RJ0:(+>V[*]EJQKWS'TBOU^<>'\15P;I_E\_^$(.283C,Q&.+T0X
MOA+AN"'"\8T(QX@(QW<B'&)(!82*4045I0HJ3A54I"JH6%50T:J@XE5!1:R"
MBEDE%;-**F:55,PJJ9A54C&KI&)62<6LDHI9)16SRO<R:\:.`WC_^7:5]6/.
MO&2GO+.0KOQ@O!]Z+KE6$<R?'+$-NCK`R]EG.+2R>E9C+7+E0SC,/96/7<T\
M^I"PM8IP.<!S+=7M'@0<!#$W<"BFCA4\AT1LO"X/?-4P0=>I&3!'LGG?X4T>
M`0``__\#`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R96QS+RYR
M96QS(*($`BB@``(`````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````(R2ST[#,`S&[TB\0^3[ZFY(
M"*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?'&(O3L.Z
M*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+BQJZE/PC
M8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J/OH\^;*W
M-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C`YXFVEQ/
M]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/5%\```#_
M_P,`4$L#!!0`!@`(````(0"]%IRJS0$``-<2```:``@!>&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;',@H@0!**```0``````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````"\6$UO@S`,O4_:?T"YK\&F[=JIM(=-DWK=NA\000JH$%"2??3?
M+^HZ6*7-NR!?D.((\W@V[SFL-A]-';UIZZK6I`(FL8BTR=J\,D4J7G:/-PL1
M.:],KNK6Z%0<M1.;]?75ZDG7RH>;7%EU+@I9C$M%Z7UW)Z7+2MTH-VD[;<+.
MOK6-\F%I"]FI[*`*+3&.Y]+^S"'6%SFC;9X*N\TA$='NV(5'_Y^\W>^K3#^T
MV6NCC?_E&?*]M0=7:NU#4F4+[5/1AYP\[4`R"9B%_`-.X(,7SH*"@W-F.#BG
MX'#7BBP5`C<W0'%SRXSFE@(#R(P&D(3#30Z0[.",F1V<4>PDHWY6F:JS^U)5
M)KSC60+[$(6"NV/HAN'6/2!U#X-MLKH"QF2IEMQPEA0<;ATF99B[<<B^`79J
M2&YPRMTW4ZIODE$EQY7*ZOS9VS#:ND'[+L(4&FY/("T!N-$`"0='=:A^(A^J
MU(?.0SK2DQ_WD([DD`[<[@"D.P"W.P#I#LFH&NC\L0Y'U'ZT^5I3WS6WYI&2
MQUT:LC+`30V0W."H=M`KRM`K?>A;9,@1%+G/+$B>69)11<:''SAZ8.:TE*<K
M.4!PZVXON_+B=]3Z$P``__\#`%!+`P04``8`"````"$`=.K!?2P#``"*"0``
M#P```'AL+W=O<FMB;V]K+GAM;(Q634_C,!"]K[3_(<I]R2?E0[0(6-!R@4KI
MPM$RB=M8)';6=BC=7[_CA(9IW*TXM78RSS/OO1GGXO*]KKPWIC278NI'1Z'O
M,9'+@HO5U/^]N/MQZGO:4%'02@HV]3=,^Y>S[]\NUE*]ODCYZ@&`T%._-*8Y
M#P*=EZRF^D@V3,"3I50U-;!4JT`WBM%"EXR9N@KB,)P$->7"[Q'.U5<PY'+)
M<_93YFW-A.E!%*NH@?1UR1OMSRZ6O&)/?44>;9H'6D/>[Y7O552;VX(;5DS]
M8UC*-=O94&USW?(*GIXE8>('LZ'(N?(*MJ1M9190WA8=^(K3.)[8-RT53YRM
M]6>077KOSUP4<FU?!6HWPRJ!!-;=HV=>F!*>AV$X[/UB?%6:[2;`!PB_8Q#.
MZ7X]T96W982`4N16&&XVY%[T[',)$EK6[Z&RR/?4.8<_ZKZ(;.(8Y9I65.2,
M9/9MC:)B%!4?CB)SJD":DAF>4R!].#E!&!VY^.3,4`/$"J.)7)+'AJE>4A2?
MHOATG,-N_`W5);D#?7$-0.Y0^?%7X_MJ4!83A-()CZMX5"LJ^-\N=123@/+#
MT2?CHZ^IYEW5<\4T,.!$8\E.Q]$97PD./4&%(5=Y+EO07JS(7%8\YPPG@34\
M<V",S%\A$U:0&UE#[VHG#:Q?%(X!GJE2D`,F/,&*18[9LE(JLV"J)@_2,`U,
M;^A+M9,REBQR?'<C!0PNPR&H@]@B$"/!P;AT+%KD>`\*KKGIS6?;!W`MAS`&
M.0P[9.`3)&/D6K!]T>Q/"PJ2VS?K9!P*4W1P0.2Z[Z"(H/]G$YUA(,>`V7X9
MR<(RBQ-*L24CQY-;-?<$8C=&CAWWFIE<%3!U84*C0J*=0EP_'F0$K#PPDF)?
MPXP=C;3_,=+O(YP8%P:++^+TI6&<G7P<TP[,9FU=4[6QX^YC#_H7XR1(Z=@Q
M[8"SY996^P=^NH/CN';`<?/1Y!'G@YLQ=BULN]DXW?PA/<))\53H[TX\0@\W
M-6Z%&+<C+$:"'>QJ@A**<6_"8H23C=MZ<+-E'.-@1\>=HX.N,KBJX2;,X1O"
M_G27<'H\Z2T6;#^C9O\```#__P,`4$L#!!0`!@`(````(0"E=*H'V04``"P6
M```8````>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE)AM;Z,X$,??GW3?`?&^
MB6UL'J*FJ^6A=ROM2:?3/;RFA"2H(41`M[O?_L:8@&>RK>B;W<;\&,]_9NPQ
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M[:R_G>[8O/[65KNOU;F$:$.>=`:>FN99HU]V>@A>7M^\_3ADX,_6V97[_.74
M_]6\_EY6AV,/Z5:@2`O;['ZD95=`1,',2BAMJ6A.X`#\Z]25+@V(2/Y]^/^U
MVO7'K>OY*Q4PCP/N/)5=_UAIDZY3O'1]4_]G(#Z:,D;$:,0#[\?G8B5"Q97_
M`2MRM`+SSE86NK(VLH8HI7F?/]RWS:L#I0>.=Y=<%S+?@.%K>(R8*6!OQ0L"
MI8U\UE:V;N`Z$(H.DOSM0<G[]3?(2S$B\4\0A9'DBN@L:+/I=6`VR_$KV970
M)0"*)ED0<5O6S[-]]5[#VOOKO+$9`-N3'('G36X)Y6,DO46(D>R6L(P@.5`X
MR^5H&,K4\EX%V+?8(')2G-"!E`YDU@!R#:IRN6L:WKJ@>PJL"HEK!@F'(A+*
M\P)22`D"?"DDL9#:@(H"*2,\168#$>,\G!.#I,%Z6"Y-PT0:F3<VB#](X]SS
M0BH-`;YDBEA(;4#X7A0Q(LT&9""5F*L22?,_(DW#6)I/YHT-,DH#OZAC"0(8
MXR&59@.>YTFJ/;,!*7S_K;4"N]#RK&D8KQ6?;#&Q0:RU0@=2.I!9`RCJ^E!A
M;;;O[TH:)E&?ZW38'V.#F*C[$0N$(GE)$,&88'2QV$`HPLCGI"@SFPBXQX)P
MG@2IBSZB3L-$G8=K.3:(42>4"@6C#<,FN(I\1;M.:A.*ARQ@)(:93<!F`S&:
M"22/P]EC>?8&F@@DD8U'QBB,I*^DH@H1(GCD!_[LWM@DM5];][KVI#Z;S*M^
M8#)DAK,P8*$5""Q3M]3%1<I-`[9W=)]HB$?&.'@7>4*!5)SK!#."02X#4@\I
M9KC'/3^DG2TC$)-2<CF'`TO5#7BY5-.NH0].S<N?#9L%R0UC;18W(^G-2&:/
M8`=UTUWNH&G1*!>T\7/#F%QX/B>;78*>*U^2/*7H.5<L(OM)AH"`1W,2L3+=
M@Y<K,QT;*2,3Q]PP8Y5QJ#%:8@B0</3V2'12;`.Z$&E2&09@P=H1Q`)U)UXN
MT/1M))#,'>NOEFF=WPDFR':28"`,`A*!E``AM9!A@#/V5H_ENADO5V=:MZTN
MF'O(N'(,8Z\<.I(.LTX[G92*S=4U[G/6.S@=NB4O=]@T<.0P62DQOS9Y_;4C
MR=-D?#I6(QQF8*_"]9@BA,-AS2-$AH@[V!$!FHQ@>;I)+Y=G6CJ21[I*S.VV
M;S9M6BX)9J!%JX@&(L4,%U$(#"GMC$"<,^Z+N4*P5-VPETLU[1U))443<\/`
M]C!M[#05R0(F7<!D[S-(J/C0>6.@\7G#*A:SQD;&?%N]D5/,_#RGF'DCIP1Z
M-Z?B0V>.@29229^*1R8:OK7NV,J;%\X0BX0"M!.F%)"D6604L+9;G$<H/KM@
M]16+![E]__0/=V+T@&Q-,.;3,&:3$0%<)WD!6<?):&=DO"#R/$:67XJ90$8^
M'#.GC<;LK(CA4@6AM#Z\C6!S"6>NE^JR/91)>3IU3M&\Z`LV#W(QC4Z7?Y^'
MNS\R'O,-7`;!=0P93^&R<!A?3P_@KNZ2'\H_\O90G3OG5.YA*K8*H%FVYK;/
M_.B;RW#9]=3T<$LW_'F$6]D2KIG8"N!]T_37'_HR:;KG??@?``#__P,`4$L#
M!!0`!@`(````(0#/;D_KM`,``*P+```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(V+GAM;)166X^B3!1\WV3_`^%]@.:B8M3-*,)N\GW)9K.79X16R0!-Z':<
M^?=[FA9LCK.S[CPX4M8INJIO9_'II2J-9]KR@M5+DUB.:=`Z8WE1'Y;FC^_Q
MP\PTN$CK/"U939?F*^7FI]7'#XLS:Y_XD5)A@$+-E^91B&9NVSP[TBKE%FMH
M#;_L65NE`A[;@\V;EJ9Y5U25MNLX$[M*B]I4"O/V'@VVWQ<9C5AVJF@ME$A+
MRU3`^/FQ:'BO5F7WR%5I^W1J'C)6-2"Q*\I"O':BIE%E\R^'FK7IK@3?+\1/
MLUZ[>[B1KXJL99SMA05RMAKHK>?0#FU06BWR`AS(V(V6[I?F(YDG,]->+;I\
M?A;TS+7O!C^R<](6^7]%32%LF"8Y`3O&GB3U2RXA*+9OJN-N`KZV1D[WZ:D4
MW]CY,RT.1P&S'8`AZ6N>OT:49Q`HR%AN()4R5L(`X-.H"KDR()#TI?M_+G)Q
M7)K>Q`JFCD>`;NPH%W$A)4TC.W'!JE^*1"Y22L2]B'@P^LOOKN7.`A),_D'%
MOZC`>_NA^-:4.*$WO7\HDXO(]"IRMQ];9=-%':4B72U:=C9@^8)[WJ1R,Y`Y
M"/<9JT2&U/\4.J0M11ZERM*$>LB3PT)Y7GE.L+"?87:S"V=]RW''C,T;#&=,
MB10%/H<7(9'M+<-SIF.5^):#5));AN>$@XH-X0T)P@K!"7JPUM]>I7U@LD@&
M)E>M3'"-@0T&(@7HUCUG,@RI4]G>P8G?XLS&.LG[G)%]V!BZ_?=M2S)L0VWZ
M/(*F>*TX_A#-!@,1!K88B#&0:,!H]+`Q]='+Y?_WR9-%2Q,R&A:A1\@XP;7B
MS+J]0)R9ZR*;&YW@3\,I6J.1^OT:PQ8#,082#1B9A"-&-_G^%$DR-H=VQUIQ
MKF/;8"#"P%8!*H_`<3QD-\8%B5Y`G$D8^D/"(W-P*MYO3I*Q.6_053M1<31S
M&(@PL%5`X'2S#6<RC%;["[8/*,`8*R0C!=^:>%I]&$YUA9%[.')U]_>M7UF$
M4[BFJU)0'"T%#$0]H.\"=.9O>TY_S,4]H!>A0RSI.;(WT`]:V=:AJ^KO>U46
M8:]H[:T51_.*@4@!03>_/IGXUZM`G;NX(!X7S`B*%]HF.:SNE<JCZH+4U5S1
M]D`WM"RYD;&3['`\>/.`#LW7HRL/282OR1PNDUM\0^9PI\A,AP)HEIKT0/]/
MVT-1<Z.D>WB58\F6I%7MEGH0K.D:A1T3T"9U7X_0%5.XMQP+R'O&1/\@7S#T
MV:O?````__\#`%!+`P04``8`"````"$`XMC7M>D#```,#@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970R-2YX;6R45UUOHS@4?1]I_P/B?0#SD80HR6@"ZLY(
ML])JM1_/!)P$%3#";M/^^[GV):EMLE/ZTH;KXY-S/SAV-E]>VL9YI@.O6;=U
MB1>X#NU*5M7=:>O^\_?#YY7K<%%T5=&PCF[=5\K=+[O?/FTN;'CD9TJ%`PP=
MW[IG(?JU[_/R3-N">ZRG':P<V=`6`AZ'D\_[@1:5VM0V?A@$"[\MZLY%AO4P
MAX,=CW5)<U8^M;032#+0IA"@GY_KGE_9VG(.75L,CT_]YY*U/5`<ZJ86KXK4
M==IR_?W4L:$X-)#W"XF+\LJM'B;T;5T.C+.C\(#.1Z'3G%,_]8%IMZEJR$"6
MW1GH<>M^)>N<K%Q_MU$%^K>F%ZY]=OB977X?ZNI'W5&H-O1)=N#`V*.$?J]D
M"#;[D]T/J@-_#DY%C\53(_YBEV^T/IT%M#N!C&1BZ^HUI[R$B@*-%R:2J60-
M"("_3EO+T8"*%"_J_Z6NQ'GK1@LO6081`;ASH%P\U)+2=<HG+EC['X+(2(4D
MX4@2@_IQ/?3"54*2Q?LL/BI2">:%*':;@5T<F!KX3MX7<@;)&IAE9A'4YWYF
MD)+<\U5N4EL!S:$=S[LP76[\9RAA.6+V=S`F(KN#"$Q(?@>2KFX8'W*X)0+E
MT1/Y=0(2#(FZCI9`?.-52>X1$ZL>R*PS.Y!K`4,*\,Z7(L%;%Z@T*:DE!3$+
MK/0R7@:I)3;3$5$8)>DJ-#ER`Q$LHM7_U!&&8+YX"3;%1X'5PSUBM#K:@5P+
M&'6$=V.^%`E^KZ6(T:38@5P+&%(6'Y$BP795B-F./6)BU5+B)>9J=EV55B)G
M+]<"AJ[E1W1)L*DK3.U10PR.6K(D9&$!,@2\U3#7`H8T>?AISO+K%U*"36E1
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M=?_6QE&>%D%Y>)_'ZVY?G.@?Q7"J.^XT]`A#%'A+&(4!;_/X(%BOKK4')N`6
MKCZ>X5<7A1,X\`!\9$Q<'Z!I_NUWW.XG````__\#`%!+`P04``8`"````"$`
M;K<+`;@"```*!P``&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6R455UO
MFS`4?9^T_V#YO7PX@0044C54W2IMTC3MX]DQ!JP"1K;3M/]^US@A7U67\@#X
M<GQ\[KGV97'[TC;HF2LM9)?AT`LPXAV3A>BJ#/_^]7`SQT@;VA6TD1W/\"O7
M^';Y^=-B*]63KCDW"!@ZG>':F#[U?<UJWE+MR9YW\*64JJ4&AJKR=:\X+89)
M;>.3((C]EHH..X947<,ARU(P?B_9IN6=<22*-]2`?EV+7N_96G8-74O5TZ:_
M8;+M@6(M&F%>!U*,6I8^5IU4=-U`WB_AE+(]]S"XH&\%4U++TGA`YSNAESDG
M?N(#TW)1",C`VHX4+S-\%Z9YC/WE8O#GC^!;??2.="VW7Y0HOHF.@]E0)EN`
MM91/%OI8V!!,]B]F/PP%^*%0P4NZ:<Q/N?W*154;J'8$"=F\TN+UGFL&A@*-
M1R++Q&0#`N".6F%W!AA"7X;G5A2FSO`D]J)9,`D!CM9<FP=A*3%B&VUD^]>!
MPAV5(R$[$GCN2,+(FY)H-O\(RV3'`L\="TF\>11-X_GLOUI\E]=@TSTU=+E0
M<HM@ZX%RW5.[D<,4F-_V!0RQV#L+SO`,(TA90RV?ER0)%_XS%(#M,"N'@?N(
M.4/DEPB2D)'%!V&C.G#L>G46;-79*EJYJWW@(.6PS(#('>)8+$DF;TL!<ZZ7
M8L$G4LX#N0L<KQR&P=LK3S^RL@7#)CVRGR33D=?YXC#3T:C\*'!B/VRKZW.V
MX`R#HV/A21*=K>PPL=LZ@;U.`?D[@!-E\:DR>ZPGT!S>W[YVTKG"^%3`RF&.
MO'$!)SD,8A(=)#M%KO>X0]5R5?&<-XU&3&YL7R&0ZQ@=6][=Q)I_%E^1=#7$
M_?$#M**>5OP[597H-&IX"92!9\^[<LW,#8SLAZ.\E@::T/!:PS^'PRD(/`"7
M4IK]P+;+\2^V_`<``/__`P!02P,$%``&``@````A`%FZ?J26`P``/PL``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULE%9=CYLX%'VOM/\!^3U\Y@.B
MD&J2T>Q6:J6JVFV?'7`2:P`CVYG,_/N]Y@(!9UHQ>0A@'Q\?GWM][<WGU[)P
M7IA47%0I"5R?.*S*1,ZK4TK^^_=I%A-':5KEM!`52\D;4^3S]J]/FZN0S^K,
MF':`H5(I.6M=KSU/96=64N6*FE70<Q2RI!H^Y<E3M60T;P:5A1?Z_M(K*:\(
M,JSE%`YQ//*,/8KL4K)*(XED!=6@7YUYK3JV,IM"5U+Y?*EGF2AKH#CP@NNW
MAI0X9;;^<JJ$I(<"UOT:S&G6<3<?=_0ESZ10XJA=H/-0Z/V:$R_Q@&F[R3FL
MP-CN2'9,R4.PW@<1\;:;QJ"?G%W5X-U19W']6_+\*Z\8N`UQ,A$X"/%LH%]R
MTP2#O;O13TT$ODLG9T=Z*?0/<?V'\=-90[@7L"*SL'7^]LA4!HX"C1LN#%,F
M"A``_T[)36J`(_2U>5YYKL\IB9;N8N5'`<"=`U/ZB1M*XF07I47Y"T%!2X4D
M84L"SY8D6+CS<+&*/\(2M2SP[%B6DUD\7%=CTR/5=+N1XNI`[H%R55.3R<$:
MF#M_<#6]8[\S#)PR)`^&)24KXH`7"J+\L@U7R<9[@<AD+6:'&/CO,<$8L;]'
MA/.XQWB@N)<-5@YEOQ_.3IT!&W4FO$;N#AN&4L)^F@:Q?P?A]Y"1$C!MNA(#
MAA0:>!#&-UX4AYAYKW8_:!C-//_(S`:<$EA6[WX86_[O$+-LXA>%T2*);5M&
M"'\9Q;\)#^R-Z:88L"W-FGB'F($IV(!:PV0>^LG\_?@L/R+%@&TI4<^+\4$,
MSCR#<@Z_,6*/B$;L*&"P/Z:[8L"VE-L240IB.BFQ^5E21@BH-@.M(VGFO!N4
M@3_O)P.VI2W&$^\0T\9G-5\-XX-;;(BPLVVD+1EK,R4J@H/@SQK-(%OCTM*(
MF`3SW5U8@=X/NX/$#6[NC^0%H&6Z=PW:%K:RA+6@0;JW+:@U<./;B+$64T(G
MQS'`@CLN"E8&[5I0-[,5YWW;?9_L@2FATZ5@P1U+N3M!$(129A"2@0V84\VD
M*8F;D,YN\1Z;9`KJ0-FTA();REU&)=;.W[6@SJS$JK#FJF-(L#\:IAPJQ'L,
M'M`EDR>V9T6AG$Q<S!TE@&7UK?W]Z2$T1X77=\#UI:8G]HW*$Z^44[`C#/7=
M%51,B1<@_-"B;H[_@]!P<6E>SW!197!`^BZ`CT+H[L-,T%]]M_\#``#__P,`
M4$L#!!0`!@`(````(0":^?/-O@,``#H,```9````>&PO=V]R:W-H965T<R]S
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M?G.#-!NXNX<)?55D+67TP"V@LX70J>>EO;2!:;O."W"`:3=:<MB83^XJ<3W3
MWJZ[!/TLR(5)OPUVHI=/;9%_+6H"V88Z807VE+X@]$N.(=AL3W8_=Q7XMS5R
M<DC/)?]&+Y])<3QQ*'<(CM#8*G^/"<L@HT!C>2$R9;0$`?#7J`IL#<A(^M;]
MOQ0Y/VU,?V:%<\=W`6[L">//!5*:1G9FG%;_"9#;4PD2KR>!'3V)ZUG>(G3#
MV9]9;*&H,QBG/-VN6WHQH&O@G:Q)L0?=%3`/SH2.T>OOK()')'E"EHTY-PUP
MP:`^KUMO[JSM5\AIUF.B*28,5<AN@&`&D3<>`E=>5]V2#`@L'U@:?4&V9%^_
MKM0@'\$H?WAO)`+`??6COG<W180S%1)/(9Z*2*8(B42QXZMVL$S!;QMPL(6;
MH-5D%[.Y*B$2F&"TOM,#L1Y(I("B,5`UWDXY@C<F).":X;E6VTA@@JZ?M&[:
MW5B+Q=JLV^>'CJ/M3>1U%Y8E@&(($GQ_#R%8-Z35.Q*8Q2\-W5B+Q=I2&+("
M+4^)O`RWD#^66'$S^X@;!.MNKKS=QQD)C-0Z>B`6`5&(T`E]C2&1-BA2X2"Y
M/_$(UJ4&8PJ$5(&1I.J!6`1ZJ3,GU'M&VJ!(Q2M>.C]O-SV"=:G:&1@)C"15
M#\0BT+>W.\VJM$&1NOR(5`3K4K4#+A(82:H>B/5`(@44;2[<R7(>[SO@NEU_
M.N%ZD"1S$HDGD42.J$KQQI$JCDI]4'^[\JZXI]3S3C^+>Y`X']Q@,5\XVJ>^
MZR%7,_$DDL@153K>-Q^7+FXI5?I"^\!@^L)^$4T9>)X?+E7$KD?(RL6>:P1G
M.&3I(D*Y&,G$Q%*1]DAVI"R9D=$SCEL^G(AC=!P%G[I)4(M'[@K&"[C@M7B,
MHR/&[7$!)K<F/9)_TO98U,PHR0%>Y5AS.&9;,?N)!TZ;;G[:4PXS6_?S!#,Z
M@<'%L0!\H)0/#_B"<>K?_@\``/__`P!02P,$%``&``@````A`#W>E$Z"`P``
MYPH``!@```!X;"]W;W)K<VAE971S+W-H965T,2YX;6R45EUOHS@4?5]I_P/R
M>P)."&FBD%%#U9F1=J75[GP\.V`2JX!9VVG:?S_W8J#@C"KZPH=]./?XW'N-
M=Y]>RL)[YDH+6<6$S@/B\2J5F:A.,?G^[7%V1SQM6)6Q0E8\)J]<DT_[/__8
M7:5ZTF?.C0<,E8[)V9AZZ_LZ/?.2Z;FL>04SN50E,_"J3KZN%6=9\U%9^(L@
MB/R2B8I8AJV:PB'S7*3\0::7DE?&DBA>,`/Z]5G4NF,KTRET)5-/EWJ6RK(&
MBJ,HA'EM2(E7IMNOITHJ=BQ@W2\T9&G'W;S<T)<B55++W,R!SK=";]>\\3<^
M,.UWF8`5H.V>XGE,[NDVH4OB[W>-03\$O^K!LZ?/\OI9B>PO47%P&_)DV/$_
M7O#4\`PR1SS,R%'*)_ST*PP%$$0W``RB_^_"W"\PBM^'&3YW(1^;M/VCO(SG
M[%*8?^7U"Q>GLX%(*[`!W=AFKP]<IY`&B#5?K)`UE050P-4K!=83V,A>K#J1
MF7-,EM%\M0Z6%.#>D6OS*)"2>.E%&UG^M"#:4EF214L"]ZN=7T1S&@;1!SB6
M+0?<6PX*=.\+\.UB&I\>F&'[G9)7#ZH4Y.J:8<W3+1#^W@QP`;'W"([)&M(5
M$PT9>=X'._\9/$];Q,$BX-HCZ!B1=`A,&VCHA<`2I@M!,`K!+*&R@QT8QETX
M<6\1RQXQ$@(N#(5@F2RA0M]W!C\"W&#=8<]N%5I$V$M.!@.C^.$X_OMQ$1P3
M6%OO]\J):Q%P[1'1&)%T"#<C4-5#(]X7@N"QD/4XS,$BK)#C[XHGZ1"ND.@C
M0A`\%G+G"+&(52,AI*O0$9K8^293H\1`W4_W`\%C&1M'AD6$C8Q%0-^JL:F7
MI)MVS<!_V.2&1?!8!74[UD*&]4'=ENT@KI3-1Z0@V)'BM.C!0D927%<ZB"N%
M0H=.MZ5!.V+<?FTQ-C^4KL--Z%B7])`;-;C)34X2M5OBL(FIV\4M!M7D^]F,
M+F9+R%*.6_",.I65].`;7;@)3M=EM\R1+F?O.."?!](ZRIG;3SWF1@YN@0,Y
MT[9:.%C<5)+;XBUFL-NV(U'3;LM@%431W9O)ML_M,<+^'DNN3CSA1:&]5%[P
M6$#ATWZT/^>T!Y!^`DX,-3OQOYDZB4I[!<_ATV"^AKU-V3.'?3&R;GZ^1VG@
MK-`\GN%`R>%G%LP!G$MINA?TK3^B[G\!``#__P,`4$L#!!0`!@`(````(0#A
M;4CWIP(``*D&```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)1576^;
M,!1]G[3_8/F]@"'D2R%5NJI;I4V:IGT\.\:`58R1[33MO]^UG9"OKLI>`)MS
MS[GGWHM9W+[(%CUS;83J"DRB!"/>,56*KB[PKY\/-U.,C*5=25O5\0*_<H-O
MEQ\_++9*/YF&<XN`H3,%;JSMYW%L6,,E-9'J>0=O*J4EM;#4=6QZS6GI@V0;
MITDRCB45'0X,<WT-AZHJP?B]8AO).QM(-&^IA?Q-(WJS9Y/L&CI)]=.FOV%*
M]D"Q%JVPKYX4(\GFCW6G-%VWX/N%C"C;<_O%!;T43"NC*AL!71P2O?0\BV<Q
M,"T7I0`'KNQ(\ZK`*S*_F^!XN?#U^2WXUAP](].H[6<MRJ^BXU!L:)-KP%JI
M)P=]+-T6!,<7T0^^`=\U*GE%-ZW]H;9?N*@;"]W.P9#S-2]?[[EA4%"@B=+<
M,3'50@)P15*XR8""T!=_WXK2-@7.QE$^23("<+3FQCX(1XD1VQBKY)\`(CNJ
M0)+N2."^(R%Y-$KSR?0*ECADY`W>4TN7"ZVV"(8&-$U/W0B2.3`[9R/(*>0Q
M>/V75?#H2%:.I<`3C"#<0'N>EQF9+N)GJ"G;8>X"!JX#A@R(&+(94H(TCE-Z
MN\A[90=VRJ[H+I6[L'$LD[XMDYW*..<93,;[<BZHP*`QF,C(;.`/&03,R$_4
ML:_1J>#[0@X,"1T+I<F94,!<"D'_KB^@`Y\[.E0L.`J8J6\LF>7C)#FD<M*Z
M\?\H._"Y<G9F,6#RQ$LG47)X?Z(+DW?L^+I>NJ!S_<F9?L#D7GY$QMFAUT$_
M'!GABY)<U_P3;UN#F-JXXX!`W+`[G%2KU(_&\`).BI[6_!O5M>@,:GD%H4DT
M@:KK<-:$A56]_U[7RL(9X1\;^"5PF/HD`G"EE-TOW&DV_&26?P$``/__`P!0
M2P,$%``&``@````A`)_8>-3K"@``8CD``!D```!X;"]W;W)K<VAE971S+W-H
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MLBI?+C,SW1Q`_6->S5=S,]/3XVYOCL"F?7(N7M;3K\&#7B;3^=.C2]!_]\5G
M1?X_J=[*S[^?][M_[D^%R;99)[L"SV7YW4I_W]F0&3SW1G]S*_#O\V17O&P^
M#I?_E)__*/:O;Q>SW(DY(GM@#[M?NJBV)J-FFEGH,+;EP0"8?R?'O=T:)B.;
MG^[GYWYW>5M/HW269(LH,/+)<U%=ONWME-/)]J.ZE,?_@2BP4,TD(4YB?N(D
M039X<(2#S<]Z<#@+ETF0I",08IS%_*QG26=QF&3+`0<RAZ2X'.O-9?/T>"X_
M)V;CFL.NWC>V#((',W.=7$A%D^YKV389LI-\M;.LIR8C)I&5V2(_GJ(P>)S_
M,,NZ14WN:X1"U0J;>#NMAH#YMYDVC)?-M'-S",UQF(6AQ]&].6I<*[:X]0?E
M$&`?U'R,0U&^(DFY1/N2<-%(&*S9"!36)CTR=7$;V@XR.I*,*`R;^1UE#IJX
M.3`E`YH$&))9^_%(=M!Z:HZ[79]$(H%F"9MB%:V6BS8ID%JJ"()5$,6QF$0S
M2;1PK^;0V7&8DAY_''80/XXH6#7S0VI!0U(K`YH$&%)Z#Y(=U+?:H"%(,J!)
M@"&92AV?)3M(9"F,1)9`D[K5#E9):E:**Q0H6FA-`HS1^C?I3+>+PXHE6\P_
M.0=-XMCB((W$"BMXGY"1`"-;C2&S8DF6"#+0M)^L9$"3`$,)3-N@61K62MRH
MOMV%(D+E132-<"[;N@>O7@"-GC:2*!3M-4<1K%^4IBNY?BAH@36-<#S;JPG>
MP+1!A^>8F5C+`$0U9K84VU"A@&+"$!?AF+9;C\>$'L\Q6]N$=A:`"#&S.!;'
MH5!`,:]Y1V#;\WA,:.H<4ZQI[J9>3VO,)/2R";-03!+AV;0->CPFM'6&&8FF
MEMOS45/E-6:Z\K))S,$M@,8A'8MNFS;!O-WX`FCQ'$^<6.4H`KPXB):B;2L4
MT"Q>LPY[WCL"#[H[QQ/NGKLIUU.S;LUY1!1YB,0G,(,DPA?:-N[A&80VSQ'%
M-LL#X@7NTY47T33">6SW)CP#NPWT?%-T;5:\$[Z`&`-RR8BF&L85"O.XO=.<
M6CJ9;-(HPD)(%X'8B@H%9*?1",<3'C(L;6&7EXARS%%48_I-&@44$^;UZS4T
M.V?\ZKI1,INR2:.H;BM^DT8!Q;0TMI;L)36[0++=>_0F#*'GL^((99-&48WI
M-VD44,QK7A+:[CT>$WH^P_2:M)OZ5I-&`<6\YB7VNIUB]I1.EX>(RLC=E#5>
M5Y-&`<4CKL(7>Y2'A%T>(L]1482+'"\345,*!13OFH>$HSS$J46I1%[C`3-`
MO"1>2?_`62C>-?\(1_F'4TL\D9P<18`7AT$J/%"A@.(1R^&+*^RD9^^!'_#2
M\!J--`T5RHBF$<9C;UW06AC6I]VHOFL0%+5945Y$TPCGNLL_H@[_D)>*.8J2
MA;N87,P6HEH4"EIP32,<TW;LT1TOLJ/$KHOE:2F*&DQY^J!00#%A7A?AF!W^
M$9O^<WOW11W^$<O.AR*X:Y#XMPSP?4IYS3ZBN^S#C9+)%!6:HZBE%-E6**"8
MU^PC$O9A2V9`,CML)!9]+G=3KZ>`:?Y485_\$E6AA()>,Y)HE)$XM<RC/)5&
M4;,IQ6Y0^#ZEN^8CD?"1@9T'^C[KB+$HX-Q-7:<QZ$HB<0^X'L$A#IR7CO"3
M@9C0_SFFM+T(1&2UY5H3%T%,$N&8PE<&8G;XB[R9D$<@:FM'4GIN@R/\9,;"
M;6[W'Z>6.U*Z'XK:':>\B*81EK7X+I=QH_K<#T64BUR$P&I2#>>RC9S82D^>
MH.VSS>;=@8M!A"<QP2(51:-0T`)K&N%XPDYZ\+IL1%Z&Q+4ID`OF1/:^1E3_
M[4?3"$<47M*#"+V>93`1O2V/001U$$>KT/S]3I0"2F@.K[F(=0RZQ,,*UHT2
M)>'_U08,H6G2/B9Q#-R)),+S*#S$8O:;70Q-G^=3FAV*&DPOF<0YD))$.&6'
MEPR@[/"21#I>7%L%W9@>:BUJ-R:)<%3;P4EI#UQWZ/L\H=)/XMH<**JXF%&-
MJ$6MA\F[#G&'IPS(:H>G)%[7!E&S]J+6E/MHO!.":T]<AB74S.$EM)_2C9*%
M))L2BMIR5EY$TPCGNLM;$C`)TPUOW#A$$>7RO(5J.)<U@M$;,+&C1+Y2T9]S
M%)F4V&\1F"LKN:PH:,$UC7!,X3'#ZB3I\)I44.0H:BF4%]$TPKF$L0SD`AOH
M65;B%6[3JT1&-(UPKKO\)(&^S_J*OZP@PF4-9O&*O_[V15QN*9RVS;"F$<[=
M83#VKL!MPTXZ#$;>ELE1U%(H+Z)IA'/9!CZ^3*#M]ZPS\09<9QG1"8EPKKO\
M(^GP#W^=0=26K[>LQ"F@*^.\+L4<\R[O2#J\(Y7G#2BBRTJ\`;E(A'&E'6[1
MO]W<J+XS?A01+B^B:81SW>46*;3]V^6+(ES6<&9OTI!7X)<OCFB/1-,(Y^YP
MDW[W3;O<1)YYH:BE4%Y$TPCGNLL^4K"/V^6+(LH%P]J(IAK.=9=]I.`#/>L,
MHK9\1>$HG(5B$G_AF,)-;G?CM,M%Q#ERCJ+VTY47T33">>YRB11<HF<Y042Y
M9$3C1$[#N6R;)B[1DR=HZFP9O0OU%$3UA7HB[\<H%+3`FD8XWEUFD7:9A;S8
M0%&SV\1)EL+W*25Q#TXIO*(GB1T>$<LS][3N_^0TVKN=T(B:2R$:88B9L(W;
MB$XM3Y;%A5B.(E.![9E^*JZ35"-J$&F$(PH'Z4'L<@Z9Q0Q$<,?#?AW0O,0=
M#Y209:81#BBLH@>PPR(R\>EY!B)R!]4'!`D%)!$.:-OXX&+.H.F;R=KURT05
MY"AJ[YUV9-`S#QSDD#F@;=?#`:&Y<T!Q2I=G(`)`=ZN\@Q`T-(4DP@E'^4;6
MX1N9<*T<1>8329[%N8)J1&V=P-P=2;S+2C+P!)Y,:7$H:A.EO(BF$9XZ827#
M+BPS<(O;%H<BR@7#VHBF&LXE/*2G;#N\P[N3FH$(-UT4FZ^5B\I6**&`U^PC
M&V4?3BUZ<R;-#44UH,'S`6N':7<<B;`,+D>9AU-+0&D>*,)OYHN>C&^2W-$(
M1Q.F,6S3+7WS"+V[T"B"'$:KKARBA(+"S"["06W3)JUO(*@=)7,I/#9?@JBE
M4%Y$TPCG$IXQD`MZ_NVJ78*(<LF(IAK.93OT^'Q!7V==SGM,8`DBV'O=SPF@
MI$77-,)!1SF&>5;-6U#YM>(<1?49=,?#`L0;X'X!#B'[#AYI@\>MCL7YM5#%
MX5!-MN6'?5PM-'<XFVCS*-W7T'YS3\3SX$&YY]'FS1OF";?WS6OQK\WY=7^J
M)H?BQ4RYF%D3.\,S<O#+I7QW#WD]EQ?S;)O[[YMYEK$PCU<M9D;\4I:7^A?S
MP?/FZ<BG_P,``/__`P!02P,$%``&``@````A`"*:59ZI!```GA,``!D```!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&ULG%C;CJLV%'VOU']`O`]@`PE$(4<S
MG4Y[I%.IJGIY)L1)T`".@)G,_'VWO1TNAB0P>4A"LKS7OBZ,U]\^\LQX9V65
M\B(RB>68!BL2ODN+0V3^\_?+0V`:51T7NSCC!8O,3U:9WS8__[0^\_*U.C)6
M&V"AJ"+S6->GE6U7R9'E<67Q$RO@GSTO\[B&R_)@5Z>2Q3NY*,]LZC@+.X_3
MPD0+JW**#;[?IPE[YLE;SHH:C90LBVOPOSJFI^IB+4^FF,OC\O7M])#P_`0F
MMFF6UI_2J&GDR>K[H>!EO,T@[@_BQ<G%MKP8F,_3I.05W]<6F+/1T6',H1W:
M8&FSWJ40@4B[4;)]9#Z2U9/KF_9F+1/T;\K.5>>[41WY^;<RW?U("P;9ACJ)
M"FPY?Q70[SOQ$RRV!ZM?9`7^+(T=V\=O6?T7/__.TL.QAG+[$)$(;+7[?&95
M`AD%,Q:5;B0\`P?@W<A3T1J0D?A#?I[377V,3'=A^4O')0`WMJRJ7U)ATC22
MMZKF^7\((L*IQ@A51N!3&2&^Y5%_&4RP8J-',L#GN(XWZY*?#>@:X*Q.L>A!
ML@++(C(7\H-^-+%>"Q7<$T8>A97(7)H&+*^@/N\;=QFN[7?(::(P3XB!]P9#
M0]I@;/"G<0H<Z3HUGN8+MP`+;I$KX<P3_M`E<@-GG,B=0R3`D0G6VP"6B\8N
M<B/&D]W4C<B;0R3`4(8.D1L0C0@Q0R+HI^FI$^!^1&[0E@0C0LQ"%M6CU/7;
MNO9JMIA#+,`ZL:M%B!@D=ET2^,W_/5YHNF[`EP:^W3-BD<[O-?8Q<,0@/W'@
MU?S?XQ<:WQF@V[P"K/.V<2$O8H:5#><0"?"]%D+,D(C`_'=#FI92N4J/31\/
M!?(=V4Z^)=+:>9%?']HNZ&69"/7HI'FB3Z@YW9%U@V531\RW-!V9(WD00M+A
MO%U:@K)S>VH5:(1+",=T+I29?ESZX!($J0;VG<"[EEM-G";F%A6H[T.@YQ9!
MZ(,O*MT`^N6=)5OBUCL8HU:65%D1-)+J64I%4(;NE!5!(UQ?4B<R)D^#44*0
M&B5B!==G1Y.HB?4=T:JP+9]*\C6Q(K/42J+OR94"#9-,-;VZ/:<2K>N4/CL*
MI/K6<YWVYM#K6_HE69*K=!?TT5$@-;[AU=&ALU1*HC7J4-];*-!(IF>I%$4!
MNCTZ"C3"]255HF.JI(^.`C6CLPC[KZN3)';K796>-DERE9[S0<==DRLZ2ZXD
M^MXD*=!(SC6YNC-)8S(UB`M!:I(([=Q^^Y/T)9&B(R(5#"8)06J2_.LN:)HU
ML;JXC>K=!\/V3HLZ2:_MM<2S5K>C;F=<HN]55X&&U74UL;K#-;9WTJLK34:F
M2NW"#VF[F^V5UYVE4A*M3TPKP9A3!?)P*SF^KW`UP9I64KE*IV\#4_2H;B-I
MUH3K3II1L&Z+I(N@$2Y-D.YPH<;T6G7PO`?G*&)SA26E_L)SV\1C2?&8!$\1
M<E8>V"\LRRHCX6_B"(1`/9I?F^.91RH?B9L_X'3D%!_8'W%Y2(O*R-@>ECK6
M$LA+/%_!BYJ?Y!G%EM=P+B*_'N$<C,%SOF,!>,]Y?;D0)SC-R=KF?P```/__
M`P!02P,$%``&``@````A``@IIOBJ!```Z1```!@```!X;"]W;W)K<VAE971S
M+W-H965T,BYX;6R4F%UOHS@4AN]7VO^`N&_`-A\F2C*:I.KN2#O2:K4[<TT)
M25`#CH`V[;_?8XZ#/^BTR4T;X.7X\3D^K^,LOKS61^^E;+M*-$N?S$+?*YM"
M;*MFO_3_^_?ACOM>U^?--C^*IESZ;V7G?UG]_MOB+-JG[E"6O0<1FF[I'_K^
M-`^"KCB4==[-Q*ELX,E.M'7>PV6[#[I36^;;X:7Z&-`P3((ZKQH?(\S;:V*(
MW:XJRGM1/-=ETV.0MCSF/?!WA^K47:+5Q37AZKQ]>C[=%:(^08C'ZECU;T-0
MWZN+^;=](]K\\0CS?B517EQB#Q>3\'55M*(3NWX&X0($G<XY"[(`(JT6VPIF
M(-/NM>5NZ7\E\PUE?K!:#`GZ497GSOCL=0=Q_J.MMG]530G9ACK)"CP*\22E
MW[;R%KP<3-Y^&"KP=^MMRUW^?.S_$><_RVI_Z*'<,<Q(3FR^?;LONP(R"F%F
M-):1"G$$`/CKU95<&I"1_'7X?ZZV_6'ILV06IR$C(/<>RZY_J&1(WRN>NU[4
M/U%$5"@,0E40!O3J.9U1'I,X^3Q*@$3#!._S/E\M6G'V8-7`F-TIEVN0S"'R
M^S."J4CM5RD>7@'8#LKPLB+9(GB!S!5*LIY*J*W8O*,(1TD`6",;S/AZ-BF&
MO/K>R$;)&';`7Z,D&K(JY[,Q;E@#0Y3K!Y;BI0^A],#.E-<HX4/&.$U2SKF-
MMC$564;C+$E'A846W8(FQ0X:&\-B3E!BY`1O)`-K0M)$OV!QP+J]/D52['!$
M#@=*<-B8\]1-D/D\R=(L'M^WL));L*38P=)A,3TH02Q*&2,NERD@-"(&N`66
MVF#201CXT,?])E]R`)-QW@B(D@M@&H8NH"T@G&F!!2CWJJN-0(H=,+U>$0PE
M",;3-`TSIRLVIH*$4<CB2'>LQ9;=PB;%#IN>,K*A!-D8)YGS?&,^YU&<_0*+
M0`&OS]F@=L`F[BDC+GV5-4YBFFEO'-@W*@Q*(&V<$Z8S:Z6-W&;N:,S@1*.1
M,6?P]1!QZ1MV8=ZQ!Y?F:BRHZU8\04LVW93I[&/UE`8S0%D298E;0$M"2)S&
M5$_%QI3.:V!^W)`$?=K"T\E7>*BY%(A38VA50E,1I5FJ>\=F<\S^RA1.79]I
M$U>,ILN3+$["4.='0:)D*+5-=9/URZ])3CLRU_N5YE+0E#@5WUB".,RX[AL;
M[2;[)U/_9Z[_*PVB15%,>:;'5HFRMX`XB;@V:1O/V00^66OHW+!6=#_JP*J.
MJ#'[T;AC#^X8O%Q,$13G$XBITS.]6A4$:F"]:-!)0WZHL4$=MY>@Z>>@4]MG
M3J76Q/1U%I+$$6PL`4T9UWUC(=*;C']0V\8?.=VV5AI<9RF)0AZ&>G!<:)8F
M8;`UP!?_\>N`#7B3\U-T?M/5C)T8BZPT"'B7I&$:I]SM4UL4PRP2EFA_M!&E
MTU]MO%2JG1SJP`H1-:I786!F;-PJA:8DHXPDD6XI&T]ZM(%WG??"(72"Z91Q
MK33J-/#N'F])?K''XV$5SW*G?%]^S]M]U73>L=Q!PX0SV3(M'E7QHA>GX>SV
M*'HX8@X?#_"30@D'H7`&XIT0_>5"'H;''RE6_P,``/__`P!02P,$%``&``@`
M```A`%\?RN3D`@``*@D``!@```!X;"]W;W)K<VAE971S+W-H965T,RYX;6R4
MEEUOVC`4AN\G[3]8OF\^2?@04#5TW29MTC3MX]HD#K&:Q)%M2OOO=VQ3P*'-
M@`L@Y,GKYQP[,?/;YZ9&3U1(QML%#KT`(]KFO&#M9H%__WJXF6`D%6D+4O.6
M+O`+E?AV^?'#?,?%HZPH50@26KG`E5+=S/=E7M&&2(]WM(4S)1<-47`H-K[L
M!"6%N:BI_2@(4K\AK,4V828NR>!ER7)ZS_-M0UME0P2MB0)_6;%.OJ8U^25Q
M#1&/V^XFYTT'$6M6,_5B0C%J\MG73<L%6==0]W,X(OEKMCDXBV]8+KCDI?(@
MSK>BYS5/_:D/2<MYP:`"W78D:+G`=^%L%0;87\Y-@_XPNI,GWY&L^.ZS8,4W
MUE+H-LR3GH$UYX\:_5KHG^!B_^SJ!S,#/P0J:$FVM?K)=U\HVU0*ICN!BG1A
ML^+EGLH<.@HQ7I3HI)S7(`#OJ&%Z:4!'R+/YW+%"50L<IUXR#N(0<+2F4CTP
M'8E1OI6*-W\M%.ZC;$BT#XG!?G\^\J))$B;I_U-\:V0*O">*+.>"[Q"L&AA3
M=D2OP7`&R6]7!*5H]D[#YA*0E3`-3\O1:.X_0>?R/9*=(Y%+K-X@@@/B@];!
M#2H^==-=CV'NAAWU1<!A='1,#O&FC,PB(]-=7=?JY`='`%).!88'UO`"0]1Q
MX+0WL$5&)T@\<9'5(.+(0<SE<AKNR8W=D3.+I&9:X?EB7BZR&D0<.5C6E\MI
MN"?7:TMF$1C_T-RSS@TBCEQZC9R&>W)3MRV910;E!A%';GR-G(9=N>1X+]G%
M;I&IF=;PTTWLNJ_>/>U(Z8WLXJ>$AGM2H3MJ9A&[UI*WU]H@XLA-KY'3<$^N
M]X#*+&+EXB!,)VG8[]HI$HWC232)CWUWY&!;NJ)UAN[I]<;.]LR@G\.\(VAW
M.[L9=&1#OQ.Q8:U$-2WA)@N\,=Q0PNYU]D#QSCS\UUS!'F6^5O"?A,(3-/``
M+CE7KP=Z-SW\RUG^`P``__\#`%!+`P04``8`"````"$`:2Q-G%)!``#.T```
M%````'AL+W-H87)E9%-T<FEN9W,N>&UL[)W9;B1'EJ;O!YAW<"2R,!0027')
MM:12@[EILJ3,9">IU@P:<^&,<)(A!<.C8\D4ZZK>8>:F@6E`F$?1H]23S/>?
M8V9NO@1S:4G3W1B@%F:$N]FQLV]VXLN_^^EJ5KRMEJMI/?_3K?W=O5M%-1_7
MD^G\XD^WOCM]?N?AK6*U+N>3<E;/JS_=NJY6M_[NJ__\G[Y<K=8%[\Y7?[IU
MN5XO_OCYYZOQ9755KG;K137GF_-Z>56N^>?RXO/58EF5D]5E5:VO9I\?[.W=
M__RJG,YO%>-Z,U__Z=;#^X>WBLU\^D^;ZHE_<OCH_JVOOEQ-O_IR_=73>KRY
MJN;K`C"*9_/U='U=O)C[^H#]Y>?KK[[\7(_ZXX^*E_5\?;GBT4DUZ7Y[4BUV
MB\.]47&PMW_8_?+U>+U;'-P;_C*!<30(1O&/1V>K];(<K_]'=]GTYNGUHNI^
MN;]WY^^[GQUQW(D=^?FLO.A^FY8[KI;36BB9%$_+=6_E]-SSZ6I<SHK_7I7+
MXCG(7&U=,3P9%AY\]N][6`LD>5-=3(4`"/6JO.I!\_K-T=?/7KUX<E*\>/6D
M"T!8X@E47@+I"RCW4_%-==U][LEFN>29(C_1MN.'-9]/9]6R>`)^+NIE;\&3
MJW*F[]]4BWJYANN+)_75HISW'HP0UE=7];PX6=?C'T?%R66YK%;%Z\W:9(37
MNP`_+F?E?%SQ)+R_*G:^.WE:W/ZL^]33:@Q3[AO?'72_C&<N5RN6^&/OZW)U
M:9(QUA_5/VVF;\L9..H1^4T%=:;C=34I]&AWG:.Q">.J6%;CBC7.9M5J5,RK
M=??!%_.W+`\N![\]7E:+<CHIJI]0`RN0(Z&MUY?@>!R(YP?I+GM:KZ'\S<\<
M+U$N2\1?B^JH"PG)(!R^W/!6$:.S:7DVG4W7TZJ/UH2.17DM7-B6Y7B\W("_
M>+CN&4XN8:([ZVIY5<SK-8</+W>?>U*#0]A-Z^K!^%RQKHN5>.JRGDVJ9?>U
MI]5Y!?]/(!$DV/1$K(W"['3=A8QO?8_5?S%$KJ][C`4EPW8KY_9Y#9S+`O;:
M5%^@/T=[>_9?!QE*;]:<?_J7:O(%IYI7Q72U$K:,`[:+R"\___)S%T"$4&(6
M-KZ]M[NWMY]O?N_&S5'O^_<?CN[O']K>!P]&AP\/1@\/]R*DPX`5Y;K`/*RK
MJS.X-=H(6P(!#9\&(1U!@]6B&J^G;ZM93UD<329P53V'H24,=Z9S1&XQA<&[
M!X7--E>;&=II4DRJ\^EXVI,WIVK&%HEDW<7\R8SN!ON'O-E54\?P(#:T6D\Q
M')]M4ULG:^`V,_7Z')4\1]--.?)QO;+3WV`1>[R5&*M[IMZ3=IR<V3[T#2?Z
MASY=;V?8-G-NA;S]V'O!'GQ\&.;!1V\`.-%I5=3GQ6M4:"GNW&J.#C_8@^H9
MJQ<XCU>8N\09V[VB-Z[$!K7WDQKW$EA7F+*>(?MZ6:]0K<OZO"\LX7#8\:BC
M>WH-.X@C-':C.0&(66UFI,L9)]5LAD4?%1?5'(S-3)C*R=5T;FZ.)+_[B@N@
M;!0(SF#H/O>M#G"^K*^*\"S$Z#[SVFSFU/&Y$T[S6>\T+^:8&RQ[X4]V5TE?
MAP6ZWW];RS,\VZRF\PJ8UN5/W2=R.+K?A?,.0CI(5SOX687OCG7PH[%EG\2!
MC?BN.`/[`X1^5:V+&6CL@O2X7$W'1JK)=+:16L6%L2<+R.(&H/O.B;MQFQ5/
M8X'AX`5O%F>?LE1D?!.U)W+)GL_J=UM%S9XXMR=R?H!W""2F;[?X)I,?-JNU
M%"\4J[%$XQK-*U\B'I5/];>YA'8L+%##EC<L?5J-+^?UK+[`QQJ/Q1+GE=P3
M/#H9L<PL&X[9^%,<&:S>$MN"A4?&)T0G"OH*_CG/O:;W>D,+3CXU5>:R>247
M_B_V08_$<F'N0%%(+/KBF_J+6^3B^^44#JC/SP4ASTSE=DVCY]M=_<EE.;_`
MW6MCV?QU@RPSR3T!!A<Z?>YW#XJ.&/Z]].P!)@;,V$LG6)EJNH$'CC=H1S"E
MHZ-E!SSN[C8]V(;VZ;[49?US=R!N9OW']7)9OT.WKL@7X")_C/O<>S?GWE5%
MZ"%M\>'N^'%Y[3(H3_4#/?_PCE";Z[^"0*46+P/!N^GZTCU?::`.OW:1*,Q#
MHW%538)%D<M@(2=;Y/+:?;,3#J)%9I6VZSZ7:,LV;Z<3X#F[+H9H-?0B9R3S
M`ROM3"K_ZS/3(V)+A07&T#?$K,8C0P_*5S\CX3"?R\Z*42T7TH7AQO?)L6Q_
M\V2S6,S,N<4^2D5A;&`0O6!`2Z@X2LI"]>0Z65XISRY<K^KY'5LF$Q2@&4)K
M;^$>&QOO%?VHLP`XF*,5CW<!P='W@,X.EJOW$"-I#4&*'[9"$5;+\=0UP[MR
MJ5Q/SP![;*M\HB^YQ4"(J%@8"Z>GT8=QXVN1GYMD/;5MHZ<=NX&5\DB=5<S;
M]@#7L!#7""'IC5C@Q.<5VG_B0MA]]NOE]!PZ%2=2&&:?25>1OOG'EQ8A]I)_
MS\OILK@JES\BJ18Z"RUX3,6#!_N$J8_2^6*X#/C]/4:^24G@@Z1.-C@'(!@P
MDFGV^-*]R@_5`<E-[WDKW0"P#U'[U+V4UO>!/;9@_/7RHIQOL=7!(DJPC^L9
M(3&6=7L8\7I9XJ!/QZN`HAV)9+6<71<_SNMW<S1KX8_X]P2S0O[?_OJ_GWBB
M[V]__9<"'N>#=Q5_?P8]9,C']9*,H"EDL/RJ?NOQ__ZC1_>_*"[K=\0-RU'?
MI[I&5Y@1,=U+*KW"3JVGLX(7'^T6IVP=]@4QL";)6!@-4@HH\X18E\Q:%I<$
M1^N*0RF\#D@3%Y4PU'):D0\32T7/3>CJFI.S95W"STI8+#=7K$CN:5H3W8,U
M3CDK+JMRMKX<V5Z>K8M1CW\3W?#5;E<>Y'`;^QP3AN"2#KI?.C?2[A@783?S
M<D..A+.;\$^OHNX#EE7C0T,*CI:2,K_\/)B5X>.0EBEVPK*?V4FDO(38]>42
M+U;*!'-1%2@8U0?0_^R_;7'J`P?%9?F6.*"JD#/I47<"[23+B1E9,]8ZF:C,
MN19+6&>*Y5C%L!%&Y'NEE<R%%CC?S>WD)GUV0/+]9&;+8@<N_/KHZ-CX4,#W
MD9.9'#N0`:!%IW/2NZX7+"IXCA@4*B[88T=XQF,BA/T](914O7).4B$G=_[;
M;B&)6TZ`?P;KL1A<3`!1KR4'L\T$U,UFQF.VCP3,7Q9&S^MZS:,<>"E#+A3A
M(.@4IGE%\UF%+QUL6XN^NR@1(U"](*IVBW%5SA%HS^OJ7"VV&5JD!639A$8C
M1'`.;QI=./1<8,^`$KT-E11A87[*V4KNMD*=<HEC`]++XEPZ&XHG?HZ';_9G
M;<_Q629P,\.!9X\FG#>L)T]!HNZLZ'Z*TA>V>C5QI<"_!M:(+T4V\)>'61;?
M1!2+1YG"=U-`'$,I>!C8A,RXS?H2_^FJO(:W+5%B58&XV[7J1`B'<!03GTG$
M#J4LJ8\4YYNU_"$'J:<53B\YWB#-Y2IO9C")H$$IH5W!Y0^;N9NTQ,]1/S0H
MS_6"1-F8CE,12M8)OQ%XV+`'^\&H>'<Y5>8'P`-K&P#U9ED<S><P`Z*!VK=8
M]'D0H&\XQHSE$F29Y9<`//N):(GP3XK]"LMK?#PO7BK'],O/!_>]FMC6_817
M`D`%$67S(T<JH2'MK=-5%TZYG(?:&:."I`WV1?^SD"RS15U,,%E&ZFAFM)48
MP_6YN373B_F45+,J=:&2$&*'AGW;X#;OIN=AJ-OW'CT8W;W[:-0<I;2T@XXA
MCKN]?S!Z]/#1Z.X^S^A0&PMGY/S;ZZ-[=^^-#O;N\7XQE0#!3!S:1#,F/XH)
M7A:?B'L_2'FCS6SS`;UNNBW9WTN8K\0_Z&?@#;J=^P]&>P_NC1X\W/^LQ]Y/
M'2BS$3H8?V"!2BC2H'8%5T$>3CJISM9V?BE(K/4YH:O.)$\C157PL,X8R88.
M%4IFY9+$PCIW:/T4W]2K'Z?%\_)*@O[M],HL"E[;FESEZG*Z2&[.-\^_-7MB
MNM8`SK=9EKCS$RAUF*HY$.,B9E@]KL1\UIN+2X,/`_=6++:8E91$L/>6H]4I
M!2[:/M5MXH:']A[?+*0VXH:'HT>A>O2Q^PUN=9JA3BF=,<"`49.Q8K6A,B^?
M!_FV?`^:&]UE3YQOEN!C&1VNHBK1#V&+W*5J"\19-9OB`;("^[ZKES^*G*'$
MTRHC91[+NRE&%*VWVA`_X-2".B"\HBYLJZ0<;'WV`^"CM.7&13L!D=V\`S=)
MRD"0J.'$?W=[3)KAY&]__6=6LV+GM79%XR)G&[C314[%@/*<$-*I&`JUIGK`
MDS$R#Z`UJY\N2W*/P#"I2*)-$#67W6SQ^FQ=0M2R*8(%'0Z.9#S&E\*=.)^\
MKM56&R@0(B.+ZVDJCGBR&^),[#/XG0M_%Z`&7?=$:B2X')Z&D3W#(;[&L'$2
MB`W2+*E*61)C1#0@KIW/`?ZL&G,,C^:;W)V(&>3/$&;NN0GN!+_&[5-@#;`R
M6$30J2Z6Y15.A3B>)*>97^D(XR;5T\#,6SN1?.]0&\_\_14:;`AUD7^2FW4C
M';.S1*)A<B2B6X@K"#/&,.53SR^\FBV\N0\SIB9BAZ"7`-_)L#.OP.RR5E0:
MY4@4,9&!9P+=<F+"P3@@T@>K#?+6\$=X%L^`0$>$@ET;JAC"IN=R'.QKV7/6
MT1-*?Y@X+BM(Y*Z-/9YV*J\LRVS_SM94'&9,R.E-.6'H75#+"?K:S"D)!=)!
M\@NR%XU%NK+?8L@-0C8#Z9'E8]&JP_,W"2X:;&UB!G2KJOJQ)57!C$1M@)HC
M6B:S;194V1GWH^'%'VK6H<]KCM[3M_`=T8QL!?\:>9E-6F\YO;ATS9ET'Q'!
M!='O<F[*'MY6KEK\O+#M;*E@$Q(98>'3AFHN2^XN0FZK*FS7'DZ#I$O9",=X
M*I%&G*,C$OT6`Z1<F[Z)^D0='=<M`,2!<H%0'F/:+J2<G"L:,0O[B:$J:"Q?
MW6W>RJN`.=[-G(/!8,TM<^R)((FS*3^C0(&HN(I!9\,%2=AG=3EGI\AF;\OI
M+'*@/89#17`?/VZ>5)K`V!R?!9<OOI/Q)#;7'?V@QCS[`KV:DV;@)HZ70P*7
ML!`Z,7M`8F0AL//%2-;H''];ZMB$2]X`SK%J'\1*4T[(FJYN@Z)$"R:/P)W`
M#%SCC*B0LIS=R@18IIKTAGQ<J^69B]L[GU()ZJ-AXV!X[#0B)/4D\N)H$6'>
M/+V$-:&Q[0Z&:*BE7?$-H(WP0CP8X<Q4=:[M-Q`X^:]CZM<N)015-)[%:"E_
M5S+DJ9;:=`O]C^I$ZFF#D\RG/&HR#3$U]F6G_?$-L>Q\C:R\\.Z;_)5E/4<'
MNM_62]R>*I(R(X^FEDJ'RYJT1OYFR.D)K=7YN3LKN9\.!Q$=%RC/I5P*.`'_
MY!`THJN-G>1Z\[([%'+6H!'TL^\P\E-<14R)V+VK15*321,,]A#VG1OV9T3^
M4AM#!Q4CHP`]BP%\@T$F:H)S0$"<ZVL/_[Y66B.PB)@TIBH$_57Y(_Y1W-0U
M$R2XLMA,IDD6S]!EQP(`#`H'=[MD,8NWJ]FK6<G0_MTI09C_AC9DR<$RHYQ0
M(<_"00ZHOX<.:?[6.W2<^5T\-`16"OK$LN9`*TK-`C-_24I/$EN3TS@:KQ5-
MQWP#C$3(/R%S#C]D/EE"E^OKD#WC15@#1Q#`PQ,*JM$],^<54^##!S*FLKZQ
M@6KOR#+PB>JQ*J``-O0THD-6-=D[9`BU(R]O^;:*!I)$PV8I3QDTX%W6[]PO
MU3^%W_21)2,F]>9L?;[A*"Y&?<&VRL`_J)M.!WV>6/N%9?+,I^T*]ZG(J.14
MJY*0^ZSFLPLB^T,FBD?A$[1=!"052NP<G9;&HEQ@2'\RR=&II/A(Y5^+N+:I
M"&_:UK_,"Y^EHJJ>.'Z-&L!I0!,7;]R]X+1O#)5#QXN62WD+\S9X[Z)9(G@H
M+.'4,(/SCKP'9X1O$!,<T[,-_:EM)X0'X#VKLM?$Z+'Y(+!VT#4HCH2DC3EO
M%(+<&[#L?%Q:>E^U4,NL6"K%UC/;ET((L!>$,/K&.I(EDV$Q4WBLK42;U`R*
M0JK2DX3=\YIK9A@+`B8I)"3AB*_%IS@W#11I%T(6&GFE8=@"#XY'JDG;Z/$(
MB5]AQ1I*E8AQ/96I_B#1I\#:T(:4P<'AZ,'^OBU^FQ;+AZ3+C2J^DJ%;L2JN
M!0?KGLAD.U#0*D7!557$KHRSI>72&BWPU)CC3=5VH0!QM,4&\CT&6XR14P:3
M+""82[V;/7Y]$75!ESO3%PH9S/Z`6E>SZ`(W=#+\HJ(7_(A2^;><2F4=P]%D
M-S"+1$\CTCMGLH/01RXVI1;HP^(3$N98'46J\EO0W,O5FB[24?B+7C_K3C+Z
M\WVPM!A]]2PAZN]@9+I/K_^":MFHC!#5VPQ"AZ@M*#=35LT#1GY`D)J/=MF9
M#:8/#MY9)6T@)LXUI[TIYBOA9[!@H(BCJI_,Y8<Y%%2FA><D/CR0,__-E$N^
M7NO-])9U!/*>E1I,1WI0F$YH8*`C.:6,LM(K\D&]>.;)*A$_R0LX?-;M[S$:
M3%<+T@90`%\<`DE6Z9&`=))7<^]PE]Y1`B9`XR%LK&?PAO&:VQ4W=@W.XQO*
M!V;J%W+>/CA07LX`N'UPSY)TOS:_VUV&.Y3Q.%AL3SG*HL>N&'SM[9`J%6'Q
MQ#X$WB`I-[J4X@-MG.F-7]2"A8]LJM+C2!@UE(E9"QR#B'A%P59S`P!2P/05
M#H$EOUSDL$NY(717L62YR8JHPE\,R?#KA1(68%-=CI1]BL?D+G^\<S*F00`5
M#EN/]?E5/:EFNWZU8\!W*'SQZ/M";'K<[U14M^KKBF7``S'0\BT1N/2IM!X(
M%>2N9/4/5Q8YW.Z9#:#.>41LSRT*(491,%":\S3PO",I;87PB*N&^EQ-`K6H
M`?S>'M?TN-D&PL-8G17-\\2=A_2",3CN<_,'])AD)^$FV$Z<Q).L*2]P3+.;
MF^JE3(%T8Y`_Q)[F\K1:-(?`YCI6.[G78`E&-])I:XBVD5O@@EK]A.0Z29S;
MMO(FF-K&FA,OE*JM+M+7]D^%&,J_\`"Y&65UI2-@%/67#+E*CA`71=G:V*78
M$\%6&"(IM.`Y<&T4/FV6^%.:5995]''A$V'BURZ\03BQ'[QYYHR+KZ0\7"#^
M4`@A12\BF0BVQ!*>-,V0B&)(:=,=W9R.^3L0WXXF>#+B.]FQNC>24OII.R6Y
M5T=*K5I*&RHJ"*0(.L-L4E@^>`'!0TB*)E23W7:[&+>(.HBG>HY6LT2'CM3?
MGN(0?.E7<7`JJ->0MEO69V9P(7](Q4M5[Q;?TZI"OA)R%V?D)>14X`(C[:H?
MZ_1\0&K-_SU6?RP^C#CEA\V$ZF=,G*4]72-MW4X("^BQRJI[3)&%&TS*.29[
M1@#8X,:8TC2"L?(=BW+[:M66;[0'&MG<X:`.HNX@/X/5`%'&J_$80JBYKC,+
M?3+<-@#)3;BJUCT/\OM@U+IB>\J:$FOEO3>2&6UBQJB(QNBUF\?C8)->RB9)
M^#!@8VO90'SUEGDB(DS[U%HYFE2>P^`T'2S>T-<#5OV=WZI@>XR2/5';71?L
MIQMOET#-@`;"^U25ZH83RNMDZ</L2HH#XVF`!85[.,M,LB7V8JL]YDKMG"P/
M**;1DMZQ[/&(BPIK?%OT*3ZEAPDAF4!F%\1NQ)TH(EC;%U8=O=O]CZMAA0)4
ME6>O*.`I.]%@2GSO&<>WU6[Q.-2*A/9(O29+TFR`Z)M#-(`C.XNT8;O)5ROF
MEH<G$+-$/VF;>=.$0S&D@<2M2@?0#[BOD+)-6MSVYZJN^2[Z1P_TW4+L8?7\
MC"96Y]45"57T95#T[KM*P3T?T3*EEKQBOK%[=-`B')^_(%+*!A.9I&NS/:Y\
M$P+2-P2H(5SOLN5IBQ[VV%_,];(`-'0T^!'EYK%[C,-=8T[79(W-ZYRN\$O/
MPS$ADI2:7J0Y;\UM)OK\0@"7-W4U:C=4OA044GA?J*7G:V4\$-(`BI`MG1Z,
MJ?,?GTROSC;+E6GCX.FYTL1&>&M(\GQFTW/+$@FL&(68[AO<*P7.!N3P/L;N
M8B_+2,0=>X3H8EG9`B0WYK[$]-:V2+K$V3<B.27+W,,B%VL'4/PF`<S;6,%]
M@RJPJ))@MD>J"2HGBL'#I%EZ"H&(GL<E:1^NGJ(ES8<(50-@\Q[0M?QQ.7X9
MRV@`@4I!#HH2>\5"W:8J.*(W;7]52YT%C"="OB*>4&8+U4S7A\>3,JZF'\5,
M=MX4,8O-U(5`V&HN9W1`2>*XQC(+IM>`,*P?(H!P6%O3OWR+"XR2$^HCDN&]
M$.^GM#N(TJY\XUC:+'@'WX2:.,EUTF.Y1TBG&`>E=`X<92XJX<AJA.6%+6B6
M(Q'2O<(C#QHPH2]41[*T@]9M@M[@4::$G8XTIA8_K\B+J/XU5X#)"2CH$@5P
M5L&0"EP."IVON%U!`",RM`H5*<]T*0HBA=M4VZQ!4#+Z_:6N3`FZJ-6SKHX0
MJH6W53G'/I"\(/JAR$KBR9U!9:FYYIONAR^`!:(#:8[U6#D2XEU(QM,E]WY9
M#%=1Z.*N@;D9GB$7B\BILA`Z*J.5*>KA%8(%`UJBQ&@S&S&)%09QC.1/H941
MRO`+NN@Q.B,D-B97!T7;Z!TOZ\=D?LK#B&G.@$*#,?$(HB,"NZEF%#2G.W/M
M7*,;?^FY5-13.4"';:$CPA\:#,4"$(EX-2)'`;8O=D9:`%PKE]937$^X$\?:
M+E^#-:!(=D3$8U>!`A?^2/^KZOVT^)`PYD0058&D_O\L=DU#<FOBLA0&]_5#
M;@%@%V"RY&:*74M1QNO96Y!W/-M`:/OSFZF*K?[ILG8F/ZTFDVLKA^+Z^59J
MI^CH+/E7YTKHM4&<;%*+'&7K3^IT=F5S5?Z`%@W]Y(U@>)G6,IOA2JXQ0'2]
M(,UO`,]1*)O<7*T02SMW8&HG:#7H11U`XBE9]#H&O'G[SMX=X_;;CQYY1LT\
M@D].&G]4DR&,XY=P8N(:1=@!CP2Z\GP6"2E><U,`9L.Q>NS]M+F2]/K<-%A,
M%A1O0I92N>>5N_1N`D)V[Z;;%"=92D;R$1?](.<+&Y>]CJ^77I=885&;?(.D
M.L^?Q5`0'7M>R[WH3^0X%6O_\O-+:][_Y>=GZM[O@C5`S_<_TKO$_HK,^WLV
MNMU=UJ]"&_J"ZL_/WWNZ$:Z0KIH4D4,/[QDK&"J;C(QQ1IF\[#O1RS8GT)--
M[5`P+G?[</<NLS-B1,75DD_6%IW"2<N=,C@0N[CM?IP-DF5]T7H??8S;(?G-
M:"KLSZ]PBF[YIWC:X..#&HQ'!=-'[AT>=D(W9/SM%#.`LHFX,!=;F4'%R??N
MC_;N,8$DQX?'LNBP<.%,4L%5%BT>TD26><L"I:'WXZV\24])O,B*:7)TW$'P
M7+7^/2`NL98DQ[&D@RGV=0JTF(T.KEMHJ$-5W=X?W7U("9`A+>X/*"8TN^FI
MII#GV5@I4!L'TVN&Q7J2GWEG-`!CA)77.*;$9_=A[&O]RR[%+(B7E)>*CD:^
M$!/*V);"F?@$I%HB+@@CZ`P+8Q6@#R4+F8YQ:`>[LMM=9A*RI@Z=&<_8&EWE
M&W@7J!D9A0B6B*!><7%AJ?[0JG@<G83BV9,G;E:'L1C0AVF0EZGP29C9*L_Z
M\B[EH,-[CV)`+7K$&AVND&$9$6S0G'!'SA6WX)7N-C_DJMO_+$Z:8.09)@9'
MHZ>BR)`6CV>JV6R_?'>$HW2%LV<WT$+B0L&`)A<0:+AQ+FZ\DV%668?[(.$S
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M?JH`N?O`B0TF.)56?&47IG`"%:]VGWNJ.RJ94[E=YGU%T[,WKGBT'1OHU9YD
M89<SRT"TK5LI>P]'!P?!`[C[8/3HP0/9,&D];(0JT%`T[T"R$U+_LH@\JI]0
MM/*`3#=FL=*\2#79F,"R/FJ\I)<FWMIZZ)>VVB"A)DW1DS?B7D)WWQ2G:-O;
M&E!V^(#<&ML9X^E5+Q'>W[WWX`^R7PZ7IR"P2M8^WYB*!.!N`5/H4FDY,UVI
MCG!;*]7Y<*[)1%DS$GD'RAGSXFBQG,Y^^7D_#+JT%Q6T7]'47B@MB9N2LF><
MA3A9Z5MO6<8RI4$J7CXI=9,4B:`LI/"=H9/FR(E@.H7&G%G!WWK#`">)=`#@
MKB'WSQOYU0R.LWY0G$%U/WTX3B6JCQ[='43JW=W[=UM(+<GF<0A@<171&&^U
M!\BRT[*!]E]:N\``VNT9KX\J#X."D5U3[F'H8=3/U92,SJ<1:W.Q6:W!S%W'
MS+^:6O-B?_^CR.6$\>W[%XE(I6`_?5RA1%YM(B9A,/&)].;PN,*MKYW>^!I2
MF%1HFL)WDR3.\7BLZH3ODRF#?'N<,EW-9&BE.T'!$"`D4;#\<@B\@B_[2+XZ
MT?B0]!YB9O^@!/:"YF;R3I@*+EQ,[.(BS!9USFF\C7^MR]6J+3Y7D\A0!:CE
M,#(HA<!^0T^ORCW$P9^U1<3$[@5IK>HG=GL2AA3`YC&YW5"J=V;!;'0CY>1)
M^=Q[]BJX:51K'46+-38QT\PA&939QXY^HH.R/=5#>D<]HP`<M7X<=GK8,ZZ`
M1+NU9SXEI5!1?2^TXZ*BNT8K?_BH^_"'6;-35!CW\>%O^DK,C65>%RFXDC1*
MZ)]Y3A<\>7'IDF]1`)IJV@5$JP1D,AQB-E&;&P7*E2(9OY,#\6.^[,/WBR,M
M&`OPW?,WSYNQ`,KKO"S?G`(D5[/"14R`6)8+3_N__&Y__^X>2LO-"B44YE)8
M`KT-^E(#EL/#.+S^)1_J/\?\S^HOZOIE,O3>K<^_^G+,9##+MUTQ"GI?GRR?
M0Q]_Y)0*SXIZX;OB34T0I6_/_7JJKZ`//K=%;7+T'U<D2EG&HA\R]+>^:N43
M+-L><8BQ"EBT7##&F]M`Z@57CSEGQ":%<$/.6S@.(6.<<N%W[WRL64,%,.I2
M`[W)U[)4V*0H+T@UF=972Y[P-BF"\<)-P?=TET1?-E4=@"1%KZR4.#VI,(RP
M#93&8?WEYS]O9OBY;A3W#O@@>\SG3MNG+_WN^/X#V^S0[$&TZ(_<1CCD<<,^
MX&#%FY\RT0W9%^O(#,S)_;79Y)TRSG$)=+IN,HS4H6`;ZP949"0T&&+&VE)I
M4'NL`J54U34VP;JI7M6[O_Q\;_3H\&!T]_XC*2_562>:KW+$WU?3L>)C<,W]
M%:9AT^XP8:]7&X93,+?O:,ST%&WQDEM8:C1`(7^WTEP6^Q1MK:K_JOAN]V07
M;68[>IUY5>`<W+\[>G!_[XN"9"JWM_</[GW!IX>/]D<'#^W/N[K/_<![EM'4
M!(L:H*-5,-R9#)N.BPC!L8I:/?@^P:,(;\;J,-$X+=DNY03>#_#)_`H9_X!H
M60>82)*G*+2>+B39&;$GH=U%ID452K#'&T`[#]H2N4SSSOE[_=5V7?`?0:95
M0R%+DO2<D"$]MVYL[*<*]5'PO/!\&-#ST`CP_Z5ZJU3?WWLPNO\`%9B+]9`)
MDL`\Y2'D_(E&%.%D_TN4$^'7)VH$+\R$^?CTM=2F:UGT'N2X9^3PB"5=,^.9
MH!V=9@]<<(,NL#N501#SU1#!>Y\LX;^M[&9WO4]-"4CE89JBKU$<16.T4N;N
M_ZV%?A'ZK(.=BRHRV4M7E=O5D:EV<TW:#CTZMJ:NSL@3*3O-&;\N[OTAAF[Q
M#B[NNB=MU,407!O5;FV$+R\F+1#@8JFH(F!!E&C;[<7.4>@-=]^6]343L&PX
M@M2S*&`#+.+-6>M)T#?1S4.?AVVDMQELX7>;8NX_9(.W&NC5^Q$0X2@.#@P5
M*J"E/AG:B?QR3SIT!A`":OUQ2CT0M>OPZ7E=;\-5D83FMU'M2D-+1"S5.EOI
M6FU&&;OE*,B\3*<=0NQOI7+C7`EX*.*1)Z&<><>Z8<;I&D:<8<9LV1%Q.G=;
M^M]ISO(5L\HB8>(N7B_/E_4!ZG*U.\_Z<6[>/[1.G*40Q<ZF^S90U>."D-ZV
M2SB6&<SODHBCX=[8GPD7PF2WO82'C?=98X1RZW>:(O:RE/N71?G:S?,JP:GP
M73I;ZT9-ZPI+4'H?ASF)DR6FS'W5M"/XP'L?P_%[--4K^>89X3K(C7*"QN]0
MH;V%M\V%WWJPR?<-X<2G-L\0#6",I)M#8/3VP>Y>05_QC!`,OW2!9O>&/!)(
M"?X^EV8\DD$7^$A:QO;@A/M[2=58]T`X@<`)=QWMR6"N(#5>/B.RK*S!APX+
M_3S6H)O84*_[`3I'&/#BUE^=9JH%?LJOH9O(17&`,Q3T6/=:I8G[N))Q#BU'
M$C\9L-%EE6,9]>AV910SXWE)SQ/L6L=FXO1TO5GGV_XS$'J_O,!028,[9Z1_
M0CF7Y`!Z`E=Y@?R<,&&<9ADFI,@CZ-UN*W:FN^R1R5BX_O:9*37K78^:V4&)
M*ON*+!MM"*@T8+!^A.`VA/M<B#*^@P7X'"BT8`9%WD+J`G<TW![7E3P?$[]@
M:!*3O)0GP%C$$H/T0TZL(.8A=@BLT/QXD=C@60Q[BR?>#X?-F=E-04]":$H@
MM47+!F3.P=;4D)518\Y(;[53`.NO7K?"U3ABL6V@<.8LTB/T)OD]5W&S\4S2
ML*GC6/RDZRE`V`;+;+#/$\%L*BH<AS.26VC.:`%?<P=-[.52)OZ.Y#1G3U%J
M<[9_1H%8!UZUEM9.YA_SK*886:L@)(2=A*.:@N8$(ZI4-"ARL4(<L`JU-'*$
MO*\I2ZZ(V25:ZL8SS0U\^NJ(!IVQNBGM3<!\.WWK4W26]4QR!T.1K+>&S3AX
M]#0Z)31\,6\T2FINC05&H_*CUF4Y8$LM:.D:H_2X$./U:89]2.*4TK><%0>^
MW)"0L6!Z\#3-H@D8$HRE9>%T!E*2&N)L"V@?FQ@Z+E7C%9,P6W2-C\P\*<<"
M`Z,6ER4I;243PYTC;]V?TVX\"[/*UNI\6UP2YO,:71$T\G'+PU=X7%V.J[5%
MX6'O8D?\T=1]!`;,<YS001+2ZOI"J4M]]IV8E>H+.6NU;BIMH20C5]+M3]Q*
MN\#D;53RY83^R%1PCBBH8$9%I^!&&N\Y'\=ZMWM9<!GJ/C!9!D(`3YPLV-%]
M>$E.4+L8EL!3VHGA4?R6FD@(@B'=1IVCWJ;BG$$"N.:"*SA#*L%SFLJDK]'"
MLD1*=C</)/\A,A-W'RB01+X=RJ>%EP=U5'8R(=>\7F]@B-*)CC`GU'*@@VFF
M>-LH8MKHW0B'D!ADP@B2RT.[%_/?O""8!HZ(`776VNF<>K*AV3W:5M@_PYGF
MP,-YJG8*%V+,1.=,62!Z:"-4&Q>AU5`K)2>=HDY?M4?[C)D<>ZX78+XN2.Y;
MVPOO-.8;>*Q)+QHDVDB:>XQ1D.7CV*TE^%"L'1=5="6!;^(2^SK$2>A;[I"=
M(2LR$%31D\`9&\1[U:JN(!`]'OPNM1*U.=%/P);QMF7L\-D&)4<4CE7$41<W
MB&,)/'*Z=SF,DMW@DY/%F8TZ89P9J`2SZK*2^(P@0:R#GH9T-`N@$GCQHB[-
M*/2(H6EQM.!38%0\1:P6IZR9N,=_=/9(2?V654"MQ'DNX@(_16E<9`JGKTX$
M60\B'4)?+)Q;=U9HU:,!O$3A%:]T$)F;7U6UE"OF]H;K'4X,U]ZIYF3>*V?:
M['A.QDB[#'J!U#X!`"H9W>.04YZ,K&C:6CY?@C9S^75#3+*B3()?$&Q":A.A
M='%H,-?0".R@)P-2VHY'QJ_\B>*\<G,5857A8S;]L3(!M,2*F9,6]!2WB4%E
MDKAG!:%"5B`,P((;[024]5..0F-BC9ZJ_=/EKK`N?2NFRX9P.#SM'83WN`NZ
M*+KJAEC^D0VL"#D6B_C])DVS$78O)K-,MS`9BQHJXG,C]:1(WM:S#<>EJ4%>
MG69C\)H=*,.G+)%%AX_V*-I<(PAA.@-J2)DC`(\,H-Q.**)J>0L*;ER7&RG"
M0:32&?8;&^TFKP."9)9>7!]`013A</H;INT@Q?T`(1*:+SNI65)*T_H<A=?T
M\U11(/EA"MB4]V!P2X-3G#0]E=O$(KJW\`(!3#JK$01)-<^[NY(YW>)Q6CIX
M+S!,^W`]0GVG:#QB3B72H#?:K_4M@VH;-H'T1BLOFQ=1SHK6(J,SH!^PB=##
MV$Q;!IZPX$L_[;-BV`WGQ-_$T=*U#A,4O=(D.>(EYMY/;/SMK__GR\Y8M7'F
M0#E2,[I]T7W:NOLU>@?D9^Y8^(5$C7GKOR(Q,:LEX202T044CT[,G.?++!94
M]S`ED9S$K!,)<?AE+4$67I=-R]_TGVA<7W^!9]`%6J_E,$3<`0SVD`F2_!X#
MVHDA\J/P!Q-_EN'/P\8WH246V`+[0`;NUO:9`FJ:[NL"\8*3AV&%"A^(U+>U
M65A60E_[O1EZ`SWX-F>1:],XZYB;_LYH"3REP9"W)8OHR2SB]6$51?IM)`GY
MBQCDIRC<]BZ9Y:7\X9&RY'+GI7B$W!/K_7[?$JU(Q]XCT#DY?G%DT6(KG*;;
MJ-,/K>?:PF8IE:0`H.5F<0?S(*A2'$H((QMJO_4%PFY;^XNUP/1CUJR?Q0""
M1G+24#@AWI37H=,V!!FD@5N9S-UO^F3HKFP2@0ET1$G+1G40JZOZ;&=*1VQ*
MN;#=_NCP[D._1N%]G3O*RJIW1Y;3&UL^B[P15C2_4V(.;WB7_O;#G]BJ.K][
M*CM30:!,:=-_@XS&GJ.YFJ:"0.0IMM1IY,D-%#-F7IU52;_EL-W8H1/1,GB`
M)QE8KX!%@$>OHP%8WRABQ&+A*3;-.EECKH>7-GNI'>W!X6'ZYJII"),2<D5%
MB"VNL,P(8AE_'<CIV8;`X7)$VG->]0$W7)Z5S@MWL[F4[LZR+'LBZGMIRKFT
MZTQ&@0R)J4U\!69.,AQ#O@@.1H)63ZK[0ZLV$/5LX.OW*Q-S,"B]3'(G1&P:
MK\DXFP9)R:G>(BA<C.]G9;#6D9VU)7F=T>TL>/LPCEJ/)/<)%%/TFP9X@U`E
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M4NH@D7\T)YD3'U4;DTE`2XHL%LAB@NME1#Q7;8V(4EZN?9.>)>S!56K*E5UO
MY+:-7S-#(L-K*GRJ7K.=PST4O@49@<\FKH_X%Q(*P\ON8[)`''0ZJR[+F?V6
M9,8X>"&:_5<<T8A,3S%LO@,HYM/)G56$=*,OC@&SF4.6RJ3U-0OV`DR!2N9(
M`94Y;R]>=#PU]67XS&L;O%#S>QBDLX.UVOI319LD>#]LR)].^&'YS/MOO_:\
MIF%<V'^ZW%PPW+Z5GE8UX_E3=VXX#],)*^"!+-MW8"!B:-[*75OUB)(NE1(L
MDY>`]"MHZ'G;7CWZ(,)Z15:#!&5O`F;1P7;M"0VZL-GJ'TOJ3R/=[T$[B"'&
M^KT(03,D_90?00ET@?&H2+%3(H42*?>XX?<XZ/%$J9N/EB<);U1M@75,2G?.
MPC[)HS$Y5[.K\W06K'WLIH,,*]5AYPK$P.4BX)-.R5G>90Y1;20BE\:>H\+/
M3J8P.-E%*^4EN["RFS<V$R:9![02Q\U:56.)L+<!GI!W<-VS'H?.G1[`SR*J
M;37$;[.^72QV/^IQ%?F;%A%#_1G#PQVAE?P1TU]*6=+[UJ0L:4I<0[]PFU0$
MRS,V4GD+5T!!-V8]R2LL.YI8XX9`;NB$99?8LQPL@0R4#5*T`J2OAD&$YE^3
M.KR#5X1_1<\!\SM`+@/9M"F^JAI'C8/&>);^W8HDF&;<7(^OR2^/^79:N^*G
M35N_SD'SK7YQB%L^@$L.R-9BP-GE-:59/O4/6_&IQYJH\(QJC!+KUN*R;XW=
M4K6+2&.,T/X>Q;@,A@1A-'/_WLMQV=D,OY]6CR,*P'-)OI*7#J8(;;_7'I;-
M'3(8CA^>,P_`$A22!*)(;K^-^5')3":LK1Q_Y&JAVUFJ65$@CW\VB7T"8`4>
M'@Y85<OL>@Q&)O(C@F3)52$[_%;&V030?JKGAB*XW>Y<\.NC^&7\+[\):!+(
M9?=&^&PWK;:PI+>[-@2P>56<7V*T(V]PT[Q`;F6^U_'W2"4%_U8*?7V@`FHY
MX_+?3:FOP^5^A"P"BF';[USKR_A&D>)O7NW+]P,'_S'J?9%V'U+K<\)[TQ:*
M:*`!RRT7)A!M%F]Z1WUE\7K0<ST'YF2H<FPM8>H7JST?3^2,D77UB'):560(
MT$:Z;Y/*)CU>E3:)KF6_'BE=%$=OD('B:B[1WX&W0'M*)S2Y67I*/YRFX-#+
ME6;HR0R%)YHVZ*@NDZ8,BA@H4XFS!^<XAN6<4`HR_'HR/Q4<%=J=L^L[/87B
M(+<S3,2;[RUE#A[\WMX?Y!3%@J-G%B-NNR?-,A>$+<'K^9`R9S?8SP;!>,RW
M_]![<\T^B'ZI>JF?C"4?$.IND:S\PFQC%5565!C?5"I5GDR5`FO1IF\BA+FQ
MF:(U"4UQ>^B?&C@7F5HY?+,B5!9#Q.!L:7418]/(]F1VNP!U:!]`B9+8`B7F
MC^)1<5MIE\/VPH>AHZ.)U[OK#G9XX#)89P>3DS7O*9KO@/F#[9AO'6B@<-O=
MO5.Y3959)3V9\CK%NU_'K@0EFH*0&/+DFWJWM\8B]Y@>QH#C/+,6,6,Y."_B
MLAB)2Q)8[IBT:[EED0&:.:2A+Q%NAZ#IK+'2]Q&%VVQY^82[PXB^@<5SC75S
M#;ZSE<JNJMQ:<?9#"_)=:=Q66.[LU2YV"4P%/Q]66>[1$SH!NM26`F#,##4"
MQ'Z@R-PK&>NYZ(J@NGC3"\\HT$\OGCZWXNE.C.14>]7:2:_(A<VY)'2KLR>_
M\D491ZW'@THB,BOLRX_(A]Z*1CV$=3,&Z/\$[FECS\RBAOY[O2J^AQ`M\X4-
M,J/%CE&M-RU@_`H*(:Q%#NHAPJW6&FS/@8DMF5:)*:\FI`(:KS_S>WCVXX5Y
M</4>1^!<:<KE:L,/.P!B5.@Z)900@CK\V/,H7F!$?X."=F?;MABT$RVA[CQ0
MK3:,1QTS4$RV>G7_O?9F`RGZNURZY?[OP;VL8B!<!;;K5UHA)DSKM:+9<&':
MDM@R&C=5FN67=4O_'4R97K?X&/&(9T^#P/2[,J3W93Z]M4^4#@9.BY-]:SJK
M_?,>Q;]+J7$O^/<1:#!PYKQ.U0&SC6.II-^O4!6=#66VQ.;O*?M8RZ1KRIS`
ML5QM%35272HCA9*7I#NA?B>;3RPF>5_IR!P<BUD[ET><$4,]*"4T;=H-7HJH
M]Y'5']H*NE;)K)D''%$!N,?R@BHV"3;]:#L#@6<V!\%2PWD?3\J-V)77&\LB
MEA4><+[%%QB77KFL51SO?0L1QWEG`_^@@F$%=`8KFK,MU#^6A3GQ4K32V+'\
MY)-(>D44=3T,(DAK-?4P(ZIUQ!!U65TL&#3'G/<4'315J=5Z,PF_MXA2Z*GD
MWP`#S573#`-#Q_WUSIOU2_W>Y_7;I!UZ#YSV[7;B#DG`<#$$\_VJJ>X]GFH(
MAV+);WV22G&45TYX^/&W69^38/S7B(K<FQDVFP0ZUENMH](O=E^K+;U2^_WZ
M2GC2I+:IL.0%F%!S_$211%NJV<BM1":2![O##"D=UI6WG1NH9%8N*UJZO.7P
M+Y2V0%O)J_PU16W;R0Z'5$W/@&9".%`$WVI4,2K\2!A-$>K%$J6'U""0+>PF
M1:X.U_6%%T*<U(0N^:^8**G`51Q^H%&M(+@@=##Y,"SX*XPD3`/G&EL)09M6
MLN`DR0BU)@9V`@R`#O9"C9L=&S;B9#H:*05RSCI$V$R+&P!FG1S`V&+UI%SP
MFSTSS"VY:)]I<T*C)(W1-*'N,IWAAJ\_!?G-8,1X]R!'6([6=M@<$`0-]1,!
M]-]Y#P(OMPH+)3:)085"O'MJ_K1U(`6K$BEL0JGR65B:KZ,C'J(+@@FOXF>+
M9!"*6'J)__ATL#F-V0"H]#*^8W:%0#<;2`_V&:[96OR8;;.#W&OA%3??C9]8
MD*5;/(-?-.7:15?B\R)NQVEL..9?5\8E"QI_JL)[9[HP]!ZX84;L:Q3+>%V?
M54NNOO<&*\8!XXH-O`P8-?/C6M=FT$Q/K:(CAH@-F?:5%8;Y6IB--*=8"5H5
M`WBD)JS*7<KJWO3-R:^UK+#NX]!7F&X&INQM6,\"E6]U&>A4#3DOTA#A8R]P
M`I%*GZ<OC@V8S*,/S:^$C)!4^6/S"PVVUMCS.%*X_9B&7[9*\)Y7[8*N'Y^R
M7EFAP.X668>=LY(^.^-J)OFDS`0DK]M[\0BG^,D:<9YG&E$_]C,.JH>:HB+8
M$@EF36D,I7&$]B$2LA^;R`B03IE(:?B+M#`,>.K>LF(L&>50&.0V[9+147^N
M+^?%8WYV>WK!=?]6%&2K/;F<5N=<D;9F;]#[VJ<XCHJ7_,1J6<VXH<9EN+<E
MV9N,,;)7GY.099@<*C&]*HZQS9DL0^JH^*]\8'WK_37^0=VFQYP=Q``_IW\3
MRIQ&VZ=-CD_C+5$^/.4#L,!Q&(/-2WN[I+A'_-_^0_Y/^_,G4T%#]L.=E0RU
M*'L[`LS4V)3W&!+Q\(>0Q"7$>K^,AQ+SP5W0FI]A6$[@($U;-21EQ'DIBC4(
M3WA,"'0<Q,'4^TQ%?7CWD%GH)`CV[MJY[VDXUX-HR3BRP.X9Z":W'+XV;-AX
MZV=N!S+9A%F3IK!'COE$`MJ=7W]DTTT&U).QCNN?;1J%J@,7F6>,@>A)90/L
M@E17F`F?*YD;-$HJ/$/IAGJ@95!K9%K>B=4(IK.NG\&;EDP7(N!6GV3%P\/1
M_L,\0\.6#7,UAQ#V6`V[1T-05,XY&:(.(U=V63O%92G#;TM:'CL3Q;RH\9P4
M)34,1HR?TF,`DXV*)T2?NHMWS%"_47$D6C[=,',`$)Y<$K(BGU7Q3;WZ<6KL
M\T9V9>T?=.;U:$\_?]1`KAAM"H85+@9QVM;$^,=XT5>V=-<7,7S$>1Q->Z`Y
M93X1U9M;-+L2$Y*"?WCRL#CR.1XO_3VJ04(N.RAUK:>'88OW[6+^2BY$I*<W
MTG$Y5>,`_%<',K'**-#7)`VQ<[HFV>FY(*>@MIGO$;S0*.7-8FD!<4V<7<\9
M<6O4&<V'^OU(>:?\N7^?J8%-QA!^&T2!)W(.F-!Z]_!N/)^8,UD$*K(H:?W\
M^VMW#AI((PQ;(79#9`%$4%9Q"U/F\8CLUU:%.H#?X=#@9VZ9A!WLK9B^CCU]
M`<?>J>KAK[S]=?F3\8A81QS0)-17T?,/>C-?/`.II8T;B!@^^*M#9``I%FFK
M[T$D-<8@(8F)F)G2_W60Y&9T9_H6J-JJK0M5KL?.E=4?9K0>UY]0\;2)(1A^
MF474DNC$($M2Q:BLG?A7+V]B(6OXB6U1/YGEG5/%;:L/?^%9^$'H-^G7!+NN
M^??AQT>+K6O_7]+.K2>N(X;C7^4\5"*5@(KDO1*"@I!8H-#T)<I#0C<)$ET0
M"TU;]</W9\]XSAS/92^\[L[QW#P>V_.W/59LB&V9#?X1_-Z>UDW1=#ETDM%C
MMX-:8)=%04+Q"3KO'HCOD-&2@WZV4.5;`55OCN5=Y_['X<W[F^/AAV(1#MX.
M,P3B-W+)X%$O/!^73R0Z-[#_$5*%?2!81QSVARA4DS$@"4:][X:!J27<*X1T
M+0B"%W95P)\2@Z+WV&U03OPZ'8EOFR<HM1_&FMB^V2D9@A0ID@798(+^!?7A
M,:6W9/WH)MW$GL@J+MQZN0D')N)T7H2%_CZ7PEI^&$<OV.B\C?O?`P^PWI/U
MEPTQ9N*_57/X<"ZW_!F[M/SH.[A(945%`X>E`-\1<4IE6)P">L=^I9H$QH78
MZ/'EAB6-%>\\M3.,;[2+)PG376JAP).SDTO?:NQS4NC,-V/*&FWY.580H5NH
MLWA%ONB18&P01OXX)>#IGXX3NP[9!NGA6DOY#1]F6L*F6*[(Q^+*GS_)BW"X
MGCMK1$P,R_<UG!`_!&,2U'0UAF/,Y[644&T-H2G]]H+KLR882SDWK!(7O_SY
M>/_PSYP'#/91S+0;><B(!:5SJ2MJI4&Y1%J-LE1J($MQ@U`YK<>%+:L/RU2D
M^[R]&*;HGL8@-S&:\I`8[J-(`_'4V-3.BFXI:Y6B51NS`E9^\ZVZ3K_XF/]J
M2CHHIOTV7!&A(%:_672]EC>#ZIUUN["UHN=WM4)7F3LEN1LE[88H#0CLA1_?
MJ<B=$#&JKYBXUE^P8J*^-J^6:_(TTOW-Z2BNWW13KSX-P2QNEW&Q?G8I<$U`
M@SJ)HN!J#6E78@X0K,55/-+",?-T*^FTVC3@;AQZO08QF4&0H@4AJS,=:SIQ
MT7#8UYE%X\/6G!K-VS-L?E"?;ZMY?_:FW:V\YOVZ'725*0JV[*>B#/[3(XM2
M,7V1FU8OH*$G(HTI[(FDW'(5T*HPY@J/^>OU,</.N)HS<>Y^>*FCVHF9**SI
MU'@2Q_/;-/VBQ%>BWU%]K^7&'`Z:$MNX)G"K[UZ/1%!=CU$&"W4A4'_;I![^
M?]?\OU6R:5C)12W='`>X)F,9Y>99*JC4DK%X5_<'*CII]1^_!,G)OZ-^G>B;
M7>[P4&R2>>PAZO(87ZV^B$+;IY]Z7]ER:-FK'A=K6\5]82:R-0)A28]]7X(O
MF7&D:DVAB#CFH)]@UJD0,CJ^&0YZW,8D)]"X=VR9I1;PDN<,'8!O[\B.X^/-
M"F?VOX&K\%&BU_AO#\BJJP96\<=!XP]9^*S8DQ@N*%!NB*VIH3*FE],+68*K
M:AFA=9@R)P4K6IX-I6HLL3O4S<IUOO4+HFP"_\57X*[<0]7D(2M&]J/<T9_X
M"4(%FW4FUQJVD57S=DJUQ\&WV;+CSK2U6L@.C*^N`MBL)H3Q2S&3!"&"D</6
MUMW/Z0O1XH-0BL:VQ?^=@""6&6P7R$^LQR+"L-4^P^('7(/Z=?4A6$:VQF<\
M]9)TC\==;+1-OB,\DH?)C3^3PMUD=-SPNZA-WGVQ3\MK](KI"C(!-Y2:'NB9
M=]$NJY][].-I=1*_6#?$MC]C%XU."3R^FFRLM8MA#,'>%H2-./-UZ)YT;$@6
M0`F>0X^N;=:$FDZGWDZ3,A<,U+:;Q`KD;6D'G2/DM!=G$<Y<87Z-B&&]1+^/
M:?5B7DV!"6!.(N@X/G+K^3FM)"O8`$,]IT3\VB&0\;AMQ85QV<V;/R8^CZ6U
MQ,$?#\(:>>O]%*XV2R7O/T]C-80%M\1KTL![^J&Z=J`HKM8L+;MO.@-%+'4#
M[&'FTUT*`F.;]9RSR^FP)#'BZ1Q:.G-`%:LH^F]_Q5'#C<T[3)[ZV[J'X91Q
M@R<&S0$OUGT86,6F/,?BN@L9;#2TMW4"?XNQ1L+2BY#OL'[Z8W)$/V:YMD3=
M4,QWN!=\DZOQ=-R&DZ0GAZ_&X#0%K0AT0,Y+2D8$]-\3:QT:A0O;4ND96>/T
M(&T\?08KKIP_N*P013%'?QPUF5,7@N5)X5DF.A,WI*`($DYZRBDLS/_QNBX]
M-=S?=>UL]NEOY7"V-Q-6""G-2)*!C#(L$SR7_:$Z&\XQXK<TOX[ONL5SPW\X
M\!LXYQS(V>+1C($80@V>!U^-7(C/!3G"T'$J&RYY@Z$>6=[<&P44&\ZX-;C.
MI*N4VN96A]))`I^>*"+Z5<O9[4<R$%Z/F<#9G@3U+"#533/J:I(\J]TL<*(<
M^8E@"%(@)=CU>Y<QLAQ5-EJ"EA1\$6(:_0<Q:ZK_^7TWHZ%O/4MYH2*L#V&C
M%AT@L;7;/G]_6+_M-ZH)MEN#626\*$`S.=(5.^U=2!;K230V1P]IS&W;XO51
M^$X.7'142IZZHC-+FR@/6*A#Q?]U3F$P6"K)[&/(9G]<B/W1&E^)+US#4^$_
M2M2+ET7PB/N#81']3$HRG=<H%G*45_$MWA,\_"Y`Q@3"B7&ZGP7>Z)N.[T(U
M&$="?0""4)J<F.K;M2<+6&&8`NO2VOBF4Q&M#&'/`1:J+'A(]4>`&31G>(#)
M>&*=?F&,+=ST/':ASX6WV`S1L@&4P@]18(,9:K"Y+JUVV\U#%L:##9M==QMO
MU__%PV+/`%KS#&!KYW%+JNEIMLJ5A86#4U12]F($FKLOK<&F`_AIN7S^^7\`
M``#__P,`4$L#!!0`!@`(````(0`(U/]G2PL``%9A```-````>&PO<W1Y;&5S
M+GAM;,Q=;6_CQA'^7J#_@>"U10+4)XFD+,FQ')QDLSG@Z@8Y%RW0%`4E439K
MOJ@4=6>GZ'_OS/)M5A+)I;74)D;.$J6=>>:9V=G9%]+7W[\$OO;%C;=>%$[U
MP?N^KKGA,EIYX>-4_^N#?3'6M6WBA"O'CT)WJK^Z6_W[F]_^YGJ;O/KNYR?7
M3300$6ZG^E.2;*YZO>WRR0V<[?MHXX;PR3J*`R>!M_%C;[N)76>UQ4:!WS/Z
M_<M>X'BAGDJX"I8B0@(G?MYM+I91L'$2;^'Y7O+*9.E:L+SZ^!A&L;/P`>K+
MP'*6N6SVYD!\X"WC:!NMD_<@KA>MU][2/40YZ4UZ(.GF.MP%=I!LM66T"Y.I
M;A27M/23CZNI?JEKJ<GS:`4@_O"?791\][OTU[L_OGO7_]>WW_WC)W?USY^_
M.?SLYV_U7JZ&R`0?U,M\WZ\5"Q^GDGN9!3?7ZR@DAHR`)F3KZCF,OH8V?@;!
M`.;AUVZNM[]H7QP?K@P0WC+RHUA+P,M@'[L2.H&;?F/N^-XB]O!K:R?P_-?T
MLH$76&!DWPL\<!->[*4:SJMG@6ARF\8(@[/)Q"O4I@!,<O!BO4W.OX_8Q.D:
M-NLZA3].%[.BWBYIN@[CXH##4W05OB)ZXL?%5+=MR"&#?A]II0[K2-EDW@=]
M9U-V.3R;9:9MVB.IEG&Q>.@W5&C:,JEL4&A_&-V>C4[YRJJLR]+PN7H`=CBY
M+'K0=6OZ]\C&GW/$R9D'M&X\QJ1R29]UO3(W/GB!N]7NW:_:3U'@A$@L'=38
MM[DQF0L\^>(+UR.2.N"2*@M6B72OY["HD.D'^=*%W=`Z?KC^W5W\L+&K"[^R
MSK"%7N+Y?E'YFQ;6QG#EYAHF(8D;AS:\T;+7#Z\;J(Q#F"]A4/?2[S5\^S%V
M7@<&JP_%&FPCWULABL<YJ\>S>FA^>6?/[YA>@DP41850VYZ/.A!Z-YO,Y2.=
M3R:RA1HV_$@6^F&(/Y*%VO#?7!JGV8AHR0)9R-,2#^?/_?>CR60R'ER.Q^.)
M90XLBY&\R"+:"U?NBXM3:FDT'2(8`H*).9Y<&@"D;XV9JK,B,`'`:#@<#P<3
MPX+_V4#1/0+9G`YUU5XE"!1YE2!0Y%4V#/8D9/ZLI\!JEN*^2A`H\BI!H,BK
M(\D9&);[%'N5(%#D58)`D5=9%2^QK\(JL6*O$@2*O$H0*/*JM.(SR\`3Y5XE
M"!1YE2`XMU?S:=7\[LYFRU"'E5EU?<QF<C!W7$3Q"K;8\GVC@0GSMO3:S;7O
MKA.8)<;>XQ/^3J(-_+N(D@0VI&ZN5Y[S&(6.#R][>8O\=TU+V+*#W;FIGCQY
MRV=0QDV,4[RIBJXT%)G(P@K?&EG]D34T+M-)E"35@;OR=L&A=87NH[$"-"*W
MS883#L-"218.Y:ID#[V0N4^P!7,U\[1@`XB)/"0$6\BPL5RA%[61M!"SD300
MM)&T$+41NLZQSI4SN8IVL%N\[V#;'O?[Z6*HJ)YZ@03XD8@Y#H*T.>2SL<D1
M1AO;M+45\LM!WY@9^,,JUB.6-K0XM+.AP1$K&UJ(VLC'3>Y=3GBQG(#I^0B2
M/;ZYK[\-!BA*&^9X]I)@EI]PDR;=IA%.=\?-;11/K`8)[8:KW(8]F@YM:%:2
M#8XPUBY=W_^,H]_?U\6`"^M*-]<O:W*B`HZYX)$#/+"!+V'Q-GN9#J[I&S"H
MJI%1V4AS-AO_]7X7+-S89F=?F`IV%1>)RW<S5A64[S_XWF,8N&QE3$_%_!A'
MB;M,V-D<MG9>A<>LP#/(!(G@.46_5:$?>!+FXQ3]L/)RU(G`BU+]$%S"^F7&
M`YY"RH(:7$"#N@Z/3`0PO\X1@!-4(,!34QD'$)XJ$,"\)4<``5HB`#@U47%*
M/QB0;`8Q4*H$_5VIA!R36\FI[-#*JO0+^FNLM+GT>Q+-)-]"H)<TPYL:`">I
MK$JQJE(,<3OTM)(">%-#@0VCKIPA;U"5\Y410I(N8"@9@310QXB\J"0Y%W26
M`.H9F4FL0TA08"I2#0'@*(%`'#%0-/X.*`9%(S"-!D5#,(7`C<%G[!/4$]P(
MJ0@#X%'2*\HZ8<"-&&>D@4!0E2%)-!BJ4B3%H"I'EJXP5*5(`D%5AJ2>4)4B
M*095.9*X0E6*)!"`$249DGI"58JD&%3ER-(5IJH422"HRI#$$V;'*;)'ETW3
M152R?CK$6\&JEA[!0?GT?]]7+^O&A=1!U:0)9.7-T]E3.G,$7["Y%)E*(S@G
M7SO5GJ+8^P4FF7B_VA(64]U8Q_L;$V])KWR-G<V#^P)3T723YV5]DH$-F$K]
ML)*M:VV42^?G!"P"GFX@HM%R-JEO7)C?BPQ^<;LQ0AI!X.*.:@S(=89!>@A(
MZB+8<U73!(.D<@S453!@-B7#-V<SW$VEN:Q]+D&VLA5Q`,U5.&_*M8T]B5"#
M+X5T5V;V\VH[(4_B[%;,5AOZ#PY!IZ9-PO-`=@BVH5VI<IQ-JZ.]M<_K=I>A
MVOM56&+N3XOKTH3-%K(;@YF./HTI3<.;0-(^`GSUZLHTVNNZP-W8#TC9T`++
M\>*%3PQO8)8=I&E9:I(0?A.!-1%-"8%N>OK0(S6**CQ7#U3$<95C&87_!E<9
M-9N!=5VT$D]C<),1IE(Y/!YDKS+GPWB6;30UIHA6:$BN?%/42AQ[JYD!D'5^
MZ9R9^E#FW20G2+!/"=5[@LIIC\GG]:WBI`H0[E-*\<W)"*%?2*6L#3TT07?1
MC2@Y;TAX%)Z46*9XQ*L0]E0;X2I$.M`3B>O:KUWQV`5N2=.[+J#1T,P\_BM&
MRT,[6J0/L%K)%[/$BTR1`NO\E;&43LV3UFY!F!`H!4MWX28%'D]5J_BJUR\2
M7I6ET!'2VHRV1E4Q`I#K:A$A/%EU=)0JD'^L)]8S]88*K7$H:$('CT)15PP9
MLC>E&F.#G=M5L)C.]OU@IX_<-\'?-5'L"VKX#"EXYF7_]]J%]F&)059,]W#9
M;['S?+C]&#?\<,]VN=O"77:S]&*VRU8GJY@@8=>@LF#L:"L+)*2=R,!]?((+
M4F=;6:`^E66"M406W%+26A:$="8+3UF4N"P(M[:XH$DFB^=^*,B]=<R/[#Q2
MB0M-%L%%995^!.:(C2:8W%96Z4=P')4%)K>55?H1$!)9%BAI*ZOT(WB!RH)P
M:RNK\*.%.;CD'K;<A61='O4C'ZMX>$`$%Y55^I&/55,P5JFLTH]\K*+);7&5
M?@2IA"\+/F@KJ_0CGR<LP3Q!;2S]R',_%.1^/Z/R$6\(1GPJI?0=O"(<X61%
MA*-42NDU/LI-P2A/I93^XN/;$HSO5$KI*9!'+++@`W&+"A^9/+N6(+LS9Y5G
M73Y@<)P1@0'/,%SN?'AJ=83/O&:'8W#-E!B$1R&%)#VYRV=M#O<Z%H+X_H##
MJ(B@NY>-[X1.$L6O&AZ(*<3Q3A\*BOM3%!4<\1*PIA(!]`,\(1P>/JX!+RE#
M?`SC88@V8HJ^P-.#I^/;B('6*1H^_G!9JHT8:)V*X9,JUD\B8CZ&FUWA(3Z7
MXM`M(N*3%SZ[*SYR>(9Q$5M$TKV[2V*GB#^^2QF"Q-SC';*%##Y%I`^+S&_G
MS>K/>[@A-B<1#PN1OH,UM`CPO^P20B.[3:4<=PW!O/3@)?#4@+P3\S@`E@B.
MAP@.J14B]C**H(R_.7&(O87KNGLQ6F%1>>0/JO_52WFW-.,]P6?HL_NHB_D`
MT+MRU\[.3QZ*#Z=Z^?K/['D<$$S9MW[TOD0)$S'5R]>?\$$GT(MA`@CIYM,6
M'IX!O[5=[$WU_][-1I/;.]NX&/=GXPO+=(<7D^'L]F)HS6>WM_:D;_3G_P/*
M\`\.7,$3ZT]XH#_[PP-PZ&]@76U]>.Q_G!F;@?]<7IOJY$T*GSW=`&##EG1N
M1&];_$&$F_\#``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;```3````
M>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-
M&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*
MLAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]
M2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA
M,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&
M2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5
M"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!
M8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7
M\!O59GU[S<$;D,4WEO#USG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*
M/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB
M+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+>J^>?__J^5/TZOF3XX?/
MCA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\
M>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C
M<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMA
MY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X
M8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^
MF9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,
MR,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$
M[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P
M1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J2
M9_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;
MSCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?
M414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>
MSHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!
MY+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH
M9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.
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MV@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1J
MZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD
M%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG
M60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A
M-]0A/X#:BN#[A28&80-1?<DV'D@72#LX@L;)#MI@TJ2L:=/625LMVZPON-/-
M^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_
M9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*MOP```/__`P!02P,$%``&
M``@````A`$*>';D`!0``(A,``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N
M>&ULE%C;CJ,X$'U?:?\!\3XA)H%<E&34X;([TJRT6NWEF1`G00TX`KK3_?=;
MIC#XTIW0+S.=XU-%G7*Y"KSY_E;DUBNMZHR56YM,IK9%RY0=L_*\M?_Y._ZV
MM*VZ2<ICDK.2;NUW6MO?=[_^LKFQZKF^4-I8X*&LM_:E::YKQZG3"RV2>L*N
MM(25$ZN*I(&?U=FIKQ5-CJU1D3ON=.H[19*5-GI85V-\L-,I2VG(TI>"E@TZ
MJ6B>-!!_?<FNM?!6I&/<%4GU_'+]EK+B"BX.69XU[ZU3VRK2]8]SR:KDD(/N
M-S)/4N&[_6&X+[*T8C4[-1-PYV"@IN:5LW+`TVYSS$`!3[M5T=/6?B+KF*QL
M9[=I$_1O1F^U]+=57]CMMRH[_LQ*"MF&?>([<&#LF5-_'#D$QHYA';<[\&=E
M'>DI><F;O]CM=YJ=+PULMP>*N+#U\3VD=0H9!3<3U^.>4I9#`/"O562\-"`C
MR5O[_RT[-I>M/?,GWF(Z(T"W#K1NXHR[M*WTI6Y8\1^22.<*G;B=$Q^B[];=
MB;OTB.<_]N)@1*W`,&F2W:9B-PNJ!IY97Q->@V0-GH4RC*/7^IE4T,B=/'$O
M6WMA6Z"BAOUYW;G>;..\0D[3CK,W.9ZG4@)!X1GD?D,!#'Z):A()AC")$6A3
MYX#&7BBD3Q;Z\=8)/9S,]0BO>P3`]R!0#20P&9ZO4D*3XJJ,R&3H3F*D**F>
M]EX4Q;.O*.9D13$"BF)OWC^HW9Y@!"<<P8E&<&+DM%NBJ)Q_124G*RH14%7J
M52DXHAA"`4C%H&]3)#C"*$;`C!\:P/BZY&0E?@2P4?`3$^A`*``Y6$UA)#A]
ML`B8P4*'D(/EW6(.W/N'B1M!QY//CK=0*VF/G'E_X`(="'4@TH%8`I0*@;.B
M!SV#$7`_:&ZTM>&P#0?>6VI!(T<*6@="`;0=4;6.Q%J?=`E0XN=O$5*+OA\W
M)^MQK]0G[Y&SQ#X-KQ)#_\!CC>N#KO"!0:0;Q(J!-Y,?H4A;?44:)VO2?"WT
M/7+FK32]6]U9"^^L17?68K$&FZ@((U!@\J;QD_*XZ%HK5>),&WC[CN/C[LW\
M^<K7ZC+H*-(&/C:*#*-8,2+$6WCND&Y5+1^ZHTN4<+:JTO4-F4CJ9+J+Z=10
MB0Q9Y2.;J'OT8!-WB'@.6<Z&YZ@:^>"5-([<41S72A_QM:F_)TC"JM42$?2+
MHD^$/<*[BD:/^D5!CV5$5<1'JJ3H?F,A.(!5)<8['I*&_`:=V8"$!A(92"PC
M:LQ\C$HQCYM`!(?O_1'4D89(`P,)#20RD%A&U-CY5-5B']$3<!:K>==:VYY_
MC,"1$DUA0;2R"#K"("Y\9!(9)K%JLEB2H9!5H7P22T(?%!;.;56@]H:R)])P
MQR%E(*&!1`82RX@:,Y^^4LPC"PMG]H/"D@9[%[N.A$1'(@.)942-G8];+?81
MA85#6LZ[.6S$9.>M9FC^G0JQ*%I-2`3R`3WJ%P4][A"LVM7JT[<$^+17]#VH
M)YS)LJX/Q@N2NG<@F"Z&.&FRMW+#-HJM_:E)U!&&,\;O)/BQ;!'<,;QBP"_P
M@E9G&M`\KZV4O?#K`SX!>K2_VGAJKQ0T?$_6\+D,J=3PD*SAF]C$8W<=MWZ<
MW@!N**[)F?Z15.>LK*V<GB"$Z60!O:3".P[\T;!K>T]P8`W<3;1_7N`NBL+G
MQG0"Y!-CC?@!#W;ZVZW=_P```/__`P!02P,$%``&``@````A`-=6KI^6`P``
M#@L``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULC%;1CILZ$'V_4O\!
M\=Z``9,0):DV@;VW4BM55[?MLP-.@A8PLIW-[M_?,0X$FS;IRVXX.7,\9V9B
M9O7IK:Z<5\I%R9JUBV:^Z]`F9T79'-?N]_^>/RY<1TC2%*1B#5V[[U2XGS8?
M_EI=&'\1)TJE`PJ-6+LG*=NEYXG\1&LB9JRE#7QS8+PF$A[YT1,MIZ3H@NK*
M"WP_]FI2-JY66/(_T6"'0YG3E.7GFC92BW!:$0GYBU/9BEZMSO]$KB;\Y=Q^
MS%G=@L2^K$KYWHFZ3ITO/Q\;QLF^`M]O*")YK]T]3.3K,N=,L(.<@9RG$YUZ
M3KS$`Z7-JBC!@2J[P^EA[3ZA989\U]NLN@+]*.E%C#X[XL0N?_.R^%(V%*H-
M?5(=V#/VHJB?"P5!L#>)?NXZ\(T[!3V0<R7_99=_:'D\26@W!D?*V+)X3ZG(
MH:(@,PNP4LI9!0G`7Z<NU6A`1<A;]_]2%O*T=L-XAN=^B(#N[*F0SZ62=)W\
M+"2K?VH2NDIID>`J`A%7$13,@@5&.'ZLXNF,.H,ID62SXNSBP-3`F:(E:@;1
M$I25LQ#JH_,8O/[.*GA4(D]*9>W.70?"!?3G=1/$\<I[A9KF5\YVRL'8I.QZ
MBJJ@TDU[X*:+S)"L9ZCV@:7!%U1K[.O7G>K35V25?G_N5@.@??-CGKN;,K!E
M.)U2`E,DFS)&(H:=T+2CVA3]=@![6RH(VCEV$<_-%+::$PW6=S:0VD`V`HP<
M(S/'^R57Y+4+!1@JC.QQV&K.HILGA,-%&(5F]KLQ8YXD86*-1SHFH#B(4&S-
M7&8P?#P/T&(XQ+`'Y1Y/5/]+N6]3!9DV@_BFWPWY5G-&+;"!U`:R$6#D&$]S
M?#PF*NC1F&C.*$<;2&T@&P%&CG!+C.MXOWZ*;-9O.B::$^LQ683(+O#.(/AX
M@:T.I`8!OI_;0V(04#P/;K]UPYMZX?_B-KWO4069'H,X&690SXCFC.IO`ZD-
M9"/`R#&9YOAX1E30HQG1G%&.-I#:0#8"C!SA96X4\GX!.[99P>F47$G7VR3$
M&-E=WAF4.`EQ:-TWJ<%`48QQXIN=4GN(*I4^)XG\*+G=^MJC7C/T6[BF_$AW
MM*J$D[.S6B%"F.,!'=:;IT#=T!:^14MX94[Q5*U#"O>&`-A&6G*D7PD_EHUP
M*GJ`H_S9'"X2KO<9_2!9V^T$>R9A#^D^GF#OI/`R]F=`/C`F^P=UP+#);OX'
M``#__P,`4$L#!!0`!@`(````(0`>H6?KPPH``&XQ```9````>&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;*R;76_B2A*&[U?:_X"X/X!MP&`E.0K^-JRT6IW=
MO2;$2=``CH!,9O[]5KNKW!^%38CVYC#SN*JZ^^WJ[FJ/S]V?O_:[WL_R>-I6
MA_N^,QCU>^5A4SUO#Z_W_7__E?PQZ_=.Y_7A>;VK#N5]_W=YZO_Y\/>_W7U6
MQQ^GM[(\]R#"X73??SN?WX/A\+1Y*_?KTZ!Z+P_PY*4Z[M=G^.OQ=7AZ/Y;K
MY]IIOQNZH]%TN%]O#WT9(3A^)4;U\K+=E%&U^=B7A[,,<BQWZS/T__2V?3]1
MM/WF*^'VZ^./C_<_-M7^'4(\;7?;\^\Z:+^WWP3YZZ$ZKI]V,.Y?SGB]H=CU
M7UCX_79SK$[5RWD`X8:RHWS,\^%\")$>[IZW,`(A>^]8OMSW'YU@Y;G]X<-=
M+=!_MN7G2?MS[_16?:;'[?-J>RA!;9@G,0-/5?5#F.;/`H'SD'DG]0S\\]A[
M+E_6'[OSOZK/K-R^OIUANB<P(C&PX/EW5)XVH"B$&;@3$6E3[:`#\-_>?BM2
M`Q19_ZI_/[?/Y[?[/O2V]U2>SLE6A.KW-A^G<[7_KWSH8`CI#):U,_R2\W0P
M\4>>`VUU.7KH"+_H.!FXLXDSF5YQ'*,C_**C._"=T=SSNQN$IW5/X1?]'&<P
MFTS&T]D5SREZPB^-L7-H/MK#[XTMP9*L^PB_-XUMCG[PBWZS@3,>79/2@5R3
M4R^2#N>^<VA.DRSP!QJ<^[6)<RA7Q!^^,KRA3-0Z[Z/U>?UP=ZP^>["90-NG
M][78FIQ`!*.,EWG:K(&V)0"Y+Z(\BC#W?9@ER/(3K-N?#^YX?#?\"6MM@S8+
M;N.8%B%9B(4EPD8VB&V0V""U06:#W`:%#98V6&E@",(UZH%@_P_U1!BA'HU[
M04"3TY**+,@ELD%L@\0&J0TR&^0V*&RPM,%*`X94L#D94EW>4BF?A#5LGEH^
M.9.9*<%"VD#2D@8A(Q$C,2,)(RDC&2,Y(P4C2T96.C'D@2WX!GF$-:Q8B*:M
MMXFE#QK!3V/D3.:F4=@8D8@1(S$C"2,I(QDC.2,%(TM&5CHQ)(/3QY!,;ET#
M<0)U)Y=PK-6C,2\D\3R52HQ$C,2,)(RDC&2,Y(P4C"P96>G$T`7.5D.7;C&$
MM2D&$EF<B&TX9"1B)&8D821E)&,D9Z30B3%0.&YN&*BP-@<JB5>7A/5Y$S9$
M+1G/VG8BM($C02TKVRANC"C%DB8TD921K/'20D]'YHK-&R,*5.B!#('$M40_
MW+LS05B;`DFB"\1(A$1E2\Q(PKQ21K+&2Q^[52#DC5$S=CV0,7:HWXRQ:[O#
M^6V[^;&H8/I@$B]HXD$!(\L:$<241!)=$D8B).I@BAE)F%?*2-9XZ9*X5CHT
M1HTD>B!#$E&C&II<&#O<&&CPM;DY>D0N!%+)/_7,+H5DI2\1>X5$RH@Z'A-R
MZP+2&TV]F;7X$C+13SX[=$I&*B<SA;2.3ZP*-4<K;UQWP)E#X6\.K:`X+>V;
M<HNJ\>O+3]P'K&1#Y,%6K\EM]2DDQVZY,;K2)$:_>L:A7I^/W='<BIU0;%AF
M30^XWBQV1GZJN1R1-Y7B#F:^K2V&:6G+U%:4F3=H*ZM2*)@HV1;BL@-R>[!Y
M-B-SIE8-%:*5VZVM#`5&%#VFZ%"\:-&GYH@3BMZ23?4>E)*1BIYQE'^IP8(<
M6QHT)08C0^)O[:"B1K6S6B(KJZUL",FQ6WF,KK2)T0_23%>>[2/HJ.>:,[6*
MXU3U@28VXRB_V*)O'=L%.;:U:&HOBMX;TAMK9#V])7*G34Z&3H.4,O9:CLA(
M749CCA)"*GK*4<91SE%A(%,%4>+>H(*LB$%HFJV%>'<'V6>>5[Y5581DI4\-
M%P9#Z:F&",\KUYO,9];QG%!LR+=F([!CIV0T:WJ>$5+-Y8CP=/(&$^O<+<BG
MI2U36U%5WZ`M%N&ZMA)9R]@Z0$('':$H:1U_1$9JL#$B:QFS#12C=\U<2M'G
MFKKHIQK,O]1@0;%:&C0E%G7Y#1++,MY(7ZSLKYQ1TLIMZ1.^24,C->+8P>BP
M+313X_@L@=%13ZH+.V73!UI[&8;73L5<M2C>$#H#Z[0MR$5O2ULLIKHP7$/=
M[QU/(HI5XTIDY34[GM"Q.Z_12!<=HT,":J);*SEQT!%^E!4_GM!*3VQ$JL4<
M8YDKR;?6:7&M15-[<<6X(;/EC<3(;(F,XZE!:LS:Y&,:HY%^/#&4.$THRL:4
MHXRCG*/"0(8*XE0Q5/A6!M91S`Q$9)U:UF()R4K/$:87&:E\B`G)4\OUQSXO
M^\FF92'*PI2,M%.+D%ZT.>R:A59TS1K,K0.YH#`MS9NS(&X->B[:L_!7]0[R
M7KSH:Y==4>%;&P$B/4<5ZLA1,E++,N8H(:254!QE'.4<%08RU;GMGN0V]R0U
M/G=LG;H+LC(/#GN'5%:T""..8HX2CE*.,HYRC@J.EARM#&3J!RG8EEW=;T]<
MX6FM:XGTU\QHI:&(HYBCA*.4HXRCG*."HR5'*P.9(HF+A;X$KR@C[R'Z<>`B
M4MM4R%'$4<Q1PE'*4<91SE'!T9*CE8%,9<0-X09EY(7"4$:BL5DO6-?9$#8R
MD6Q@I=::1-J;RABM`*G5;9\8"1D96[AME2HK:C`CI%ZGYPJU-UB0D='@S+H^
M+Y45-;@B)#_I,/Y95I3WNNSVF?"EE[^P\;,5+)&F<XA6&HH0&=)+1PTE9`5;
MKJKQ?/L5A+*B<6>$=*%9^(*LU%OH)4<K0A<T%!6]KN&512TO`$;J2N3I!0HK
M!D(7K>;X6M`J<R)\/NY*VAB-Q#G8:&GG;**,2,J4D*R%)K[#;C89F;34(G4I
ME)-15_N%,J+VEXC&3CWX,;R#M<[:%3FU-&_N-J+XOV'*\*Z@W>G%'5+L(T9.
MVO5;2%;BWTG@Q;'Y4C.BIWIU8,]%C$;BG7#'A&$'U:F0HA\L_;II!VI7U\J8
MC&*#=VOLG(RZ.E`H(S5CJ)#L`+PRG[$9PUZW-&_.F+BHZ#/VO8U*7G>,M2?1
MM;6'5KCVK#TW<N7C*TM/&EU9>HT1"9EB<"B]Q$Q.1B.K]8P,6C(?%UX3N'VN
M"XJD\FA)0\.%Y_CVUTHK<FIIWIA&<:(:T]B]5];F9FF("+9C$BCD*.(H5JA=
M@(2,U*TYY2@CI/J0*]0>O5!&U/<E1RL#F>K!&C34^]8B\$042U2)8#>CCH5H
MI:&(HYAB07*U[B`)&:FL2A'1[G3I:IV16\OV(-.:C+HZ4)"1ZL"2HY6!3-WM
MNZ&M^]=NSN(+5UMXB8QL9BA"1\TJ5JA+>`RE[M<I^2F4$=*SN>E#>_2"^RTY
M$A\ABT'+ODM5Y4?%\N/*?7E\+<-RMSOU-M6'^&`8CI*'NP;+KYFA@@U$!0;9
M:3V![YP?ZZRU^`*^?ZZGV^8N!+H09^'!]](7^.,8XE\,-`[@@RO>H07TM/[@
MV6KXT76#1Q#C@@<\$1=K_J3P@Z*>*"O6`N00Y33WB.")J*KY$[C3!/'%)W"1
M"<0UA?M`Y0U/+D6#.TP@RFON`U>9(+_X!.XO@:BLN<_"!?7AUGSAB1\L+BD0
M^D%XB4=^`)^0\#B)'\"'))RG?@"?DW">^0%\/G2!SP+XM.8"GP=Y'6?83!5\
M[?Z^?BW_L3Z^;@^GWJY\@>0>U1_='>7W\O(O9WSK]E2=X7OW^@7<&_Q_#25\
M3C8:P-7TI:K.]!=H>-C\GQ(/_P,``/__`P!02P,$%``&``@````A`-"-I194
M!0``XA4``!@```!X;"]W;W)K<VAE971S+W-H965T.2YX;6RL6,F.XS80O0?(
M/PBZCV71\@K;@[8;G0R0`$&0Y:R6:5MHRS0D]3)_GU<4M;"HZ6X;N7BI*A:?
M7A4?*2Z_OF4G[T7F1:K.*S\<#'U/GA.U2\^'E?_W7P]?9KY7E/%Y%Y_46:[\
M[[+POZY__FGYJO*GXBAEZ2'#N5CYQ[*\+(*@2(XRBXN!NL@S/'N59W&)O_DA
M*"ZYC'=Z4'8*Q'`X";(X/?M5AD7^F1QJOT\3>:^2YTR>RRI)+D]Q"?S%,;T4
M=;8L^4RZ+,Z?GB]?$I5=D.(Q/:7E=YW4][)D\>UP5GG\>,)SOX51G-2Y]1\G
M?98FN2K4OAP@75`!=9]Y'LP#9%HO=RF>@&CW<KE?^7?A8BMF?K!>:H+^2>5K
MT?GM%4?U^DN>[GY+SQ)LHTY4@4>EGBCTVXY,&!PXHQ]T!?[(O9W<Q\^G\D_U
M^JM,#\<2Y1[CB>C!%KOO][)(P"C2#,28,B7J!`#X]+*46@.,Q&_Z^S7=E<>5
M+V:#2(RGLQ#QWJ,LRH>4<OI>\ER4*ONWB@I-KBJ+,%GP76<9C*?#D<[QSKB1
M&8=O,VX4#<1L'(XG-+L[,JC@:S;NXS)>+W/UZJ'%@*^XQ-2PX0+9:AJJ#`TQ
M/^(%A%"2.\JR\J>^AR<N4,R7=2A&R^`%!4A,S*8GQH[8UA%4-\!K,(*=_P$C
M92&,5$L"O:D-+6C!`-41'!"(Z@+J[YF:&PI>^?ALN0G']D2;*B84#;AMUV*1
M$5TS-P6CLM;D3F%,T%#7C55MVS@[\#L9+&CHO,_30L$:6E,/8YETF1*1S=2V
M">(UP;#NY-3(8S34E8U,66Q4Q@(>VOH)5K]M$\1184ET4;W?*11L3VXL2-^9
M?,(H:8+XY+17\;4]#TG/KJ6%,MG(C,6F9<J0-4$<V=Q&]CXM%&Q/;BPV+3,V
M>1/$)P^Q67!>;F@5G<;&59ML5N8,6!OE(",%[%3L?5["2B^QNI&GDK3:9#$S
M&G(`9N"$!EHK&`ID`=#;P6TMHU,Q>BH]#2UZ1B%'UT0YZ$@4/T^/D=`N/<9D
MT\-5G^22&JZ''B#O`B!ZQ!#&*U6&&&`M79ML;K@:MU$.-R2,G^?&R&B7FT99
M.UHSXO)+1Z0?<`-2NP`T-Y&X16W`O$./,=GT<!FN!T9N8U\EQ*&KQ+6I/3]L
M+9.]C)CR?K".774-C<EN5"[\;933#4Q@=3$FT\$4Y;NV5UWY#8W)+@87_S:*
MHQ-,@-^G1T?;0E*;;'KX!M!&.0"8SA(]H]DMK2I<#:Y--CM\$VBC''!,@S]@
MQZAE9R4+8[+8B?@FT$8Y`)C,$COA=#:XOG>$*\&UR6(GXGM`&^6`P\"NS'S`
M#D6SWC$FFQV^!X@FR@%`"M@16LW.$)1?N:[H%,:A&1/F;H][$=\#ZH&NR`D\
M$X<VBO!B>$/E*!4CSIAL='R#T!@PL`?=51(L7`FN37;E^![01CF58ZJL13&<
MW"**N)EPZ#$FFQXNV?7`#CW5%47U4I[)_""W\G0JO$0]T_6#F..UK#%7=R,;
M,:LO1QR/@$>_1CJ>$3Q:)1Q/!(\&Y'C&\.C;#\<S@4<?D!S/%!Z]2W)/B#'5
MH<KQ8`QV4Q3,\>!)L<WU>>;PS/L\8@@$^O:'9Q-TJ:1O8+@GQ!B<R_OFP1@<
MJ_L\X+IZ97>R@>OJ6.YXP'6U-AP/N,;IRIT'-V%WO14E8#WQ&VJ!/CM`]=7_
M+D+^7HJ!J`_0!G7L+3VJV%M$U+`W/RJH"Q@T7."&[1(?Y.]Q?DC/A7>2>RR!
MH5ZA>75'5_TIU04:@VLV5>)J3?\\XBY5XEIG2/O47JFR_@-&@^9V=OT?````
M__\#`%!+`P04``8`"````"$`@69\#S,#``"P"0``&````'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;*R676^;,!2&[R?M/R#?EZ^$A*"0*J'J5FF3IFD?UPZ8
M8!4PLIVF_?<[YL,%)YO2:C<A'(Y?'K_']F%]^UR5UA/A@K(Z1I[M(HO4*<MH
M?8C1SQ_W-R&RA,1UADM6DQB]$(%N-Q\_K$^,/XJ"$&F!0BUB5$C91(XCTH)4
M6-BL(34\R1FOL(1;?G!$PPG.VD%5Z?BNNW`J3&O4*43\&@V6YS0E=RP]5J26
MG0@G)9;`+PK:B$&M2J^1JS!_/#8W*:L:D-C3DLJ75A1951H]'&K&\;Z$>3][
M<YP.VNW-F7Q%4\X$RZ4-<DX'>C[GE;-R0&FSSBC,0-EN<9+':.M%R0HYFW7K
MSR]*3F+TWQ(%.WWB-/M":P)F0YE4`?:,/:K4ATR%8+!S-OJ^+<`W;F4DQ\=2
M?F>GSX0>"@G5#F!":EY1]G)'1`J&@HSM!THI924`P*]54;4RP!#\W%Y/-)-%
MC/RE'0;!?!$N069/A+RG2A-9Z5%(5OWNLKQ>JU/Q>Q6X]BJ![8>!%RS@I?\:
M..L'PK4?.%O8P=*=>9<'.AU^Z\8=EGBSYNQDP0H#/M%@M5Z]",0&&SIF;<S?
M?`%#E,A6J<1HB2R8L8!:/FT\;[EVGJ``:9^SNY`SS4B&#%4WP-.,X,Y_8%0J
MBE'54D'OAL`KM&\`#1DF$!@U!KJ\9@9O5'*,X'?D33!]T:[+\7P-EXPC$S/F
M;WFW2H;*3E]N%J9/<MNZF1;HAV/\5X4)&BS9L2UJ+?F!7L=7+R8ETT+K2O41
M8!EY&$X]3'226:W%.9:W\M2V[G?8U61*:4K61Z9D*X-,)YEDL&%,P[QE:+\=
M3`E-P?K(!,QW#3"=9(*I)F><"O[<?X]E2FE*UD>F9)Y!II-,LM4%LG>L,24S
MQ>HC4RQS-^@DC=4UF.Y(K0@_D(24I;!2=E3-PU.;2H=U8]NV&]V([Z#AM=W!
MC/M1<C%_%L$I`2!&_G8>;=O&:<1W001[Y#Q_MXB2Q:7X,DK:T]+4":,DO)2_
MZANVHP=`PVSP@7S%_$!K894D!T]<6S5(WK7<[D:R!KR"KLDD=,KV;P%?1@1.
M:5?MAIPQ.=PHY_6WUN8/````__\#`%!+`P04``8`"````"$`P=0(S+H"``#K
M!@``&````'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*Q576^;,!1]G[3_8/F]
M?"4D*0JIDE3=*JW2-.WCV3$&K&*,;*=I__VNS4<)S:9.V@O@R_'AW'.O+^N;
M9U&A)Z8TEW6*0R_`B-549KPN4OSC^]W5"B-M2)V12M8LQ2],XYO-QP_KDU2/
MNF3,(&"H=8I+8YK$]S4MF2#:DPVKX4TNE2`&EJKP=:,8R=PF4?E1$"Q\07B-
M6X9$O8=#YCFG[%;2HV"U:4D4JX@!_;KDC>[9!'T/G2#J\=A<42D:H#CPBIL7
M1XJ1H,E]44M%#A7D_1S.">VYW>(-O>!422USXP&=WPI]F_.U?^T#TV:=<<C`
MVHX4RU.\#9-]C/W-VOGSD[.3'CTC7<K3)\6S+[QF8#:4R1;@(.6CA=YG-@2;
M_3>[[UP!OBJ4L9P<*_--GCXS7I0&JAU#0C:O)'NY99J"H4#C14X&E14(@"L2
MW'8&&$*>W?W$,U.F.%IZJSB>+U9+H#DP;>ZXY<2('K61XE>+"JVJ@27J6.#>
ML:R\<!XLX)-_VS;KML&]VS9;>/$RF(67-_JM>.?%+3%DLU;RA*"_0)UNB.W6
M,`&RWH16\6#+GUR!1"S)UK*D>(D1Y*NADD^;,)RO_2>PGW:8W07,.6+?(VS5
M0-Z@$;SY#QHMB]5HW;>B=WW@570T$=0CIH+`J+&@RQW3>V/!*8;KR)OX_$.[
M%A-&@[C].')FQOQ?OFW!4-GSCT\+TX&"MF[GRO;#R['\5X8S:="R8UML+ZVN
M[>'I.OG=[62)G.RA5ET$U(Q<7$RT#J"A7NWA;QM>,%6P/:LJC:@\VH.]@(R'
MZ#!SMJX*D_@.9I$[N--XE.POXF<)E!!T3/#;>;)UPV02W\7=K/.'%S!K&E*P
M!Z(*7FM4L1PD!YZ=+:J=5NW"R,8=XX,T,&3<8PD_%08M'G@`SJ4T_<(:,_RF
M-K\!``#__P,`4$L#!!0`!@`(````(0`'W#,N)`(``(T$```8````>&PO=V]R
M:W-H965T<R]S:&5E=#8N>&ULE)3=CMHP$(7O*_4=+-]OG`02EHBP6H1H5VJE
M5=6?:^,XB44<1[8A\/8=VX#0TJK;FR1.SGPS<V9@\724'3IP;83J2YQ$,4:\
M9ZH2?5/B']\W#X\8&4O[BG:JYR4^<8.?EA\_+$:E=Z;EW"(@]*;$K;5#08AA
M+9?41&K@/7RIE9;4PE$WQ`R:T\H'R8ZD<9P3246/`Z'0[V&HNA:,KQ7;2][;
M`-&\HQ;J-ZT8S(4FV7MPDNK=?GA@2@Z`V(I.V).'8B19\=+T2M-M!WT?DREE
M%[8_W.&E8%H95=L(<"04>M_SG,P)D):+2D`'SG:D>5WBYZ1833!9+KP_/P4?
MS<TS,JT:/VE1?1$]![-A3&X`6Z5V3OI2N5<03.ZB-WX`KQI5O*;[SGY3XV<N
MFM;"M#-HR/555*<U-PP,!4R49H[$5`<%P!5)X38##*%'?Q]%9=L23_(HF\63
M!.1HRXW="(?$B.V-5?)7$"5G5("D9PC<SY`DC=+'+,GR?U-(J,@WN*:6+A=:
MC0B6!G*:@;H53`H@N\ZF?^T,6G(QSR[(AX+:P#0.RR1)%^0`%K*S9G6OR?*K
MA$#V:PF0]K:$/YMZ2>W$)8;K3>KXRO7EK8)FZD=ZFVCR/XF<^&VBR9M$09-[
M!V:S),GG5T'H,&Q4,'R@#?]*=2-Z@SI>0_UQ-`.K==BG<+!J\,9NE84]\(\M
M_.PYN!Y'(*Z5LI>#V]CK'\GR-P```/__`P!02P,$%``&``@````A`!S8!WFN
M!@```QP``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R<6=MNVS@0?5]@
M_T'0NVV2N@=QBDI%=PML@<5B+\^*+=M";<N0E*;]^QUR:&DX2AP[>4ABZG!X
M.)<SM'C_X<=A[WVOVJYNCDM?SH7O5<=5LZZ/VZ7_S]^?9ZGO=7UY7)?[YE@M
M_9]5YW]X^/67^^>F_=;MJJKWP,*Q6_J[OC_=+1;=:E<=RF[>G*HC/-DT[:'L
MX6.[772GMBK79M)AOU!"Q(M#61]]M'#77F.CV6SJ5?6I63T=JF./1MIJ7_;`
MO]O5I^YL[;"ZQMRA;+\]G6:KYG`"$X_UONY_&J.^=UC=?=D>F[9\W,.^?\BP
M7)UMFP\3\X=ZU39=L^GG8&Z!1*=[SA;9`BP]W*]KV(%VN]=6FZ7_4=X5H?(7
M#_?&0?_6U7-'_O>Z7?/\6UNO_ZB/%7@;XJ0C\-@TWS3TRUH/P>3%9/9G$X$_
M6V]=;<JG??]7\_Q[56]W/80[@AWIC=VM?WZJNA5X%,S,5:0MK9H]$(#?WJ'6
MJ0$>*7^8O\_UNM\M_2">1XD(),"]QZKK/]?:I.^MGKJ^.?R'(&E-H1%EC03`
MWCY7UQI9("&SOT]E7S[<M\VS!TD#2W:G4J>@O`/#YXTAC6&KK^T4MJB-?-16
MEG[B>[")#L+S_2%)[A??P:,K"\FG$.DBBC-"!P+8#11AWY3BRSX_,]%@S43'
M0%/+<0!L#]046W>*B.(!XC`!!UW/1(,ASF3A)!W,(C>$A`/9@@PX"X>W+*S!
M2Q]V->PX"=G""$E-I&9296D6RLS%%"Y&2B%C)0:,0P]RF/I%)U$`-78Y4GH2
M\P^CD".$^(<,.`3B*8$0L)<)Z$FNG])Q?Q@@A,3&3[$P/X,'#**@B"C)4B'&
MM'8H0G'<[B,]B5$<S2-%A!`?X0!R#M,@BD:O.H1T;R*5?]E7&LR(L#+*$6)]
M%8J0/2_H\PA<%0R>=&AEM]#28$9K-(O^00C2@@P.91P-"V,('82($B7'.G6H
M2<CIZUUFT(P<KT.+078S%4*&<7868@+LLM%Z20)X7=5)5%DJ2RE;,K<8DE-T
MQ"6AQ9.0N)Q%$J662E,Z2BW&RV)LP$0F62,I'(`2BL33I:;%]'IJ*+V4FIKX
M!3&66BA2LC2FDG00612'8SJZY)BB7QF\J;2KB?\08TE&,HV98A320<CT58Y:
M;8D#K^2(&DT=&3`&N3XZ0=V>TSX5033ZR7K2@4@11J\U9<G$_XT4G*I^,*E*
M*NHSE2C>N`NSYGD#4JHT>45D)9/]-\B]H/<L_7-C\;ST+(K"2$TU@_:`61`F
M(DO&9'83\:8V(%'$(<N'LT4ZBJ4M8,10]2`C[N(WB;U\0>U'M]O%J9C/9!*'
M#%%8*U,]53>INT&[ZI[QTX/%V#1_B8Q%O$"&B?OEO%%34<]XS5D,"0L=<<*B
MM$S?7/AF%O,(.P/D%D-)Z+7.Z:PB]XCELM+:>CLK5&0J1^3D@4FC$$-9X0A&
M+C&LAD.#2XKI^!MQFNIWQL5'476>97'""ZQ@B"R2HPV7W+L$7'\C98>J;!0/
MZS'$4(^Y>@VB23+09<7T^KJVHJ:ZG?'69S$8M2`+]&E\")LA7C@0*3,9A.2@
MZO*\2;K55+HS+MT6@_QBT`/>]!R`5"(@7]Q<;DRUK_0AZK!3"UR]%6+./A1A
M0CJ']2&%R`A.S$*.:N/R9`)_)<^IT&=,QG/E"GT<I8+T8$N48J2,TE@$8\XX
M1/77U=O%Q<QR)4_RE,LM"#V:92J"FF99Z4!D(I-@W*Y+D[6%Z_P98'N@<8=O
M\RZ'W(*09JJT[K#<*!R(E$F4T.1PB6I9OUFL`SW+?2<@!>\A%D2TAXZX+%C+
MN*S.P;152,%*-+<@6Q]23'Q$.X?*7LTWUC>N#"3V!EAB.'[!R9@'$D'4/V3$
M]<^[&D0P;1"2'T%S"T(_2?.JT^59N(@@S%YK8\&[&H:9Q6MSK'[L8Q84FA<\
M4K#'Q?"8OY(,6&_0X7O[A9.9Q2DQ+<@MB(:/GN;ART822=+ZW("^JR\$T[XP
M2>S<@B@OV@<NO6D*6!=XHPRGZB_%J(<V<`BB;'`$WVF.YQ7'/2%3^<M$#)J%
M2[(#16Y!A`@=<5=_EWB'T[/]M.8MB++`:6;$9?&",L?@ES=\@<H,OT?E(4T?
M@P(W,%J^*0L<P:#(-!(IJ3&DA7<N>"=QJ-IM553[?>>MFB=]GZ*@,H?1X:[G
MH[GJ8>,YW`&9"Y/%\`"N8$[EMOI:MMOZV'G[:@,FQ3P!`6OQ$@<_],W)W(0\
M-CU<OIA_=W#95L']@9@#>-,T_?F#EH+A^N[A?P```/__`P!02P,$%``&``@`
M```A`,`5D&^T`P``_PH``!D```!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
ME%9=CZLV$'VOU/^`>%_`8/,1);G:A-!>Z5:JJGX\$W`2M(`1=C:[_[YC'`@V
MO5?I/B1A]LSQG#-C[/67CZ:VWFG/*]9N;.1XMD7;@I55>][8?_V9O<2VQ47>
MEGG-6KJQ/RFWOVQ__FE]8_T;OU`J+&!H^<:^"-&M7)<7%]KDW&$=;>$_)]8W
MN8#'_NSRKJ=Y.20UM>M[7N@V>=7:BF'5/\/!3J>JH"DKK@UMA2+I:9T+J)]?
MJHZ/;$WQ#%V3]V_7[J5@30<4QZJNQ.=`:EM-L?IZ;EF?'VO0_8%P7HS<P\."
MOJF*GG%V$@[0N:K0I>;$35Q@VJ[+"A1(VZV>GC;V*UIEL>UNUX,_?U?TQF>_
M+7YAMU_ZJOQ6M13,AC;)!AP9>Y/0KZ4,0;*[R,Z&!OS>6R4]Y==:_,%NO]+J
M?!'0;0*"I*Y5^9E27H"A0./X1#(5K(8"X--J*CD98$C^,7S?JE)<-G80.B3R
M`@1PZTBYR"I):5O%E0O6_*-`Z$ZE2/P["63<29#O^#%!)/P?+.&=!;Y'EM#!
M/HGB)VIQE:[!IC07^7;=LYL%HP>5\RZ7@XQ6P#SZH]1,CGW/,'!*DKQ*EHT=
MV19XP:')[UL?1VOW'3I3W#&[)880';(?(;(/DC<=`P]>I*<<1L28DJD`?,Y*
MB:<D%V1/VJ$O<^W_/1.C1`F6$L>%=BJ@+30M,U2_7R)(J$/2)<37$8<EPB3)
MEA#?FU@TQ8&N6'8;?W<WC,IE$LR]YF@R\0]2=PJ#)W?V9B`U`P<SD,T"6M%8
M+_K';9+@C0V./-I/'F:H8A4F5G-*@B#"NIJ]!@BQCQ\#I.9R#B!)A+'AQV$.
M2#R$8J.MF0(,AFEBH1O/SZ0$ZV)-*3L%"0>M+TG@$U!CJ-4@/B$DP<8N2S4(
M\I,8(*9D'8.0A\+9&`Z^90JS5`UOGN=52["NVB=&P3N%F<VC&4A5X&X,(9CX
MGO$Z.FB0`$=>$AF0;$:KM1%>A<\+DF!=D-F`G8+<JPTC+Y*O?:./"O/0G#Z1
M=#"3,BV)8"\.@_`QO)I(>4<RSHX`3N@?;U"9I(OUR8-?;5"%>2C9FX%4!=06
M#I(@B3UCDQ_F"(02%&!L+`/W#EF*(D&!-_Q-GBJEZF*A3LR&]F>ZIW7-K8)=
MY:4A@&TU1:?[S*LO7X-&?(=6<+PMXRE:P1D&<7=*@/M'EY_I;WE_KEINU?0$
M2WE.!)NG5S<8]2!8-YS?1R;@YC'\O,!%D\+!Z3D`/C$FQ@>YP'1UW?X+``#_
M_P,`4$L#!!0`!@`(````(0!,X_++'0@``!4D```9````>&PO=V]R:W-H965T
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MQS8ZGDGB)3R$R8]4M%X[;NWQVRFZ;%X.=-_?C<YFR]KI!Y`_AMM+%$>OR1W)
M-;)`\9Y[C5Z#E)X>=B'=@>CVVB5X?:P_&_;:Z-8;3P]I!_T=!A]QZ?]:O(\^
M1I=P-PM/`?4VY4EDX"6*O@K3\4X@<FZ`MYMFP+_4=L'KYOV0K*,/+PC?]@FE
MVZ0[$C=F[WXX0;RE'B69NY8IE+;1@0*@O[5C*(8&]<CF>WK]"'?)_K'>[MZ9
M]\VV0>:UER!.W%!(UFO;]SB)CO]D1D8NE8FT<I$V18\B%8Z=W)&NN>-]94,4
M4AHM7;DAZK&*!KJY`UUO:H":3QN@*S=`;54T0/,H=:#K30WT<GNZYO8M\\[H
M-+NBNRO:,>@^LT2)(9)U<G5?&45JZ9_;;L;@1(I_;FN$4IZ%5<I]=4H,3KKX
MY[9&..UB8-]X)YQXFGOL\I/NXM0;I=S_Y$XX^<9/LM_()ETZAYU-LGEZN$0?
M-2J,E)GXO!%EUK"%",_>;"`4\_FSZ4SS6*@\"YG'.L5-,S6F&O3MR6AW'QK?
MJ&YL<YO^%1O58L`6HD@(64<'0QVX.ACIP-/!6`<3'4QU,-/!7`<+'2QUX.M@
MI8-U"30H/46.:"K\'SD2,B)'W+M]!C)I+2TA;,$NC@Z&.G!U,-*!IX.Q#B8Z
MF.I@IH.Y#A8Z6.K`U\%*!^L24!)"E082TJ:9>OV1QW-$>-'#K3Q'.O=JA_<S
M&RI^W.,#(`Z0(1`7R`B(!V0,9`)D"F0&9`YD`60)Q`>R`K(N$R4E5,F5E%2G
M0EA3Q2.UBGJ5&S73<M91$S4HOBPI=*S"2(F-GAF_$)NP3F/C(=#/"34IH^WT
MBK;24CDHC-C-`3($X@(9`?&`C(%,@$R!S(#,@2R`+('X0%9`UF6BY((>QDHN
MLN?=W3TY5`\9X:BF)2/MMIRK0!P@0R`ND!$0#\@8R`3(%,@,R!S(`L@2B`]D
M!61=)DH.:)F@Y*"ZXX6UVO$YR78`8ITP`.(`&0)Q@8R`>$#&0"9`ID!F0.9`
M%D"60'P@*R#K,E$ZGM9WO]#QPEKM^(S0DXYKS`"(DQ-:R\AB93;58C4LC%C(
M!:$1$*_PJI`>%T8L/0&A*9!9X566;JM1SPLCEEZ`T!*(7WA52*\*(Y9>EX64
M)-*^34EBJ8(E^W#[M1]1QU/W7YE5;7J49>MU(:+F-B/EW`)Q<D++HE)N#;67
MAH41WXH+0B,@7N%5EM:6H^/"B*4G(#0%,BN\RM):U//"B*47(+0$XA=>96DM
MZE5AQ-+KLI"26[''5I)[)8FT3><LIN9J&G/4(J$B1UTMH@$;R0KJ2"3]#%-;
M]0S9JI5M\:RVT95KGG1DN6Q27ENU-:,1&\D`/(DJ`ABS51Y`T[1,37O")E4!
M3-E(!C"3J"*`.5OE`5#[]Z8Z`19L4A7`DHUD`+Y$%0&LV"H/P.C>M[2-]II-
M/@E`'7%BTXD'`.F"Z/9R(DYZM'J2HU9YU=K5*NJ`_60O.(B&+"4&OCA8,$U#
M[W27W:AL%N,>AUT>IFS.8S^)QFISW5[;;&MQ3]BKJK4I&TGI&:*YVIK1Z9IF
M3WM<+MBMJKDE&\GF?$0KM;E>I]GI:=5AS5Z?M*8.'[%%+@^?GQ2L;$=-&R^N
MA7UQT$=#IY6>4&=;&40.(WEZ,43D,I):(T0>(ZDU1C1A)+6FB&:,I-8<T8*1
MU%HB\AE)K16B-:-42\T%S7<E%_]I92`VQ?I4SI#R3#%,K>P-<L>65>368433
MKIB45QXJN3R7U+;5[F@3SF4E,BV4<'KG0C("C_TJ(QBS51;!?:_7[FGK@PF;
M5`4P92,9P(Q190!SMLJ[H-OJ&%VM?Q=L4Q7!DHUD!#ZCR@A6;)5'T#3O6X;V
M9%VSS2<1J(-1')"4"X,^&+]$Y\^6J>453G[.4BX8&5(*!B!''.V+LM(K1N,0
MD<M(3LP1(H^1U!HCFC"26E-$,T92:XYHP4AJ+1'YC*36"M&:T96"(4Y)]!S1
MRR#"OWK\GY^WE-.4(\I#,6,-4UNJ#,3[%%%M.D6:'$1#1"ZB$2(/T1C1!-$4
MT0S1'-$"T1*1CVB%:*T@=7:)LY7_)W/9*0U-;?E$SI&:.>VD>B!>:^F9`S1$
M*Q?1")&':(QH@FB*:(9HCFB!:(G(1[1")-ZWR\[),I>]/\_>O1V#RULP"`Z'
MN+:-WL6[<:IF3P\%SE[<]TV;SC$I+3KOVG2V=H4;Y$!CYMHWY$(QX3<+RZ:-
M+O*E9=-V%[EOV716<87W;-KG(E];-NUVD=./$I[3EQSZO8D?*URQ[[=L>AN#
M.OVV3>\$D#]W[.>K-^Q9-AT1H8/7L^EX`?G$LNF0`?G4LNFH`?G,LNF<Z`KO
MV73&@+QOV?UK?&#9@VO<L6PZ/4,=IV?3R0MRU[+I_`7YR++I%(9XH\@`_2CC
MO'D+YIO+6WB*:X?@E09F,]T)7K*?=60?DOS)_1(E]'.,]"&^IY_?!'00VQ3/
MCM<H2OB#:*#X0<_3OP```/__`P!02P,$%``&``@````A`#TUN/_L`@``[P<`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK%7);MLP$+T7Z#\0O$>;
M93L1+`>V@K0!6J`HNIQIB9*(B*)`TG'R]QU22R0Y+1R@%RVCQ\<W;X:CS>TS
MK]`3E8J).L:^XV%$ZU1DK"YB_//'_=4U1DJ3.B.5J&F,7ZC"M]N/'S8G(1]5
M2:E&P%"K&)=:-Y'KJK2DG"A'-+2&+[F0G&AXE86K&DE)9A?QR@T\;^5RPFK<
M,D3R$@Z1YRRE=R(]<EKKED32BFC0KTK6J)Z-IY?0<2(?C\U5*G@#%`=6,?UB
M23'B:?10U$*20P5Y/_LA27MN^W)&SUDJA1*Y=H#.;86>YWSCWKC`M-UD##(P
MMB-)\QCO_"A98W>[L?[\8O2D1L](E>+T2;+L"ZLIF`UE,@4X"/%HH`^9"<%B
M]VSUO2W`-XDRFI-CI;^+TV?*BE)#M9>0D,DKRE[NJ$K!4*!Q@J5A2D4%`N"*
M.#.=`8:09WL_L4R7,0Y"9[GV%C[`T8$J?<\,)4;I46G!?[<@OZ-J28*.!.X=
M2>CXH;<R%/]8MNB6P;U;MEB][GV^T&VU6RONB";;C10G!.T%ZE1#3+/Z$9#U
M'K0,@RM_,P7<,"0[PQ+C-4:0KX)"/FW]:W_C/H'[:8?9OX&9(I(>88H&\@:-
MX,U_T&A8C$932"-ZWP=>10<S03UB+@B,&@MZNV%Z;PPXQG`=>3/;:-]B_&`0
MEXPC$S/"]^QMP%#9Z>;SPG2@5V>2<62R.33EY8D;L-U\<+R+C-(<1R8[K=ZS
MDP%/=^HBGNW%U:RLP\=Q218#:*(#>GJ<L3D?01B8@=`=SXO/B&&:BNPBX/:H
M-<)!A^U2&(!V66A:HU76#K3V%',J"YK0JE(H%4<SK*XAY2$ZS-&=]7P6W\-\
MM=-H'@^BY$W\(H*^!!TS_"Z,=K9[9O%]&$$KG>/WRRBQ`W6.7W?SWAT^P+QM
M2$&_$EFP6J&*YI"BYZS!?ME.[/9%BP:\A:DK-$Q:^UC"CY7".?<<`.="Z/[%
M&#G\JK=_````__\#`%!+`P04``8`"````"$`H@5)3E\'``#)'P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6RLF5USHE@0AN^W:O^#Y?VH@(A2B5-1
MQ&]%:G;WFB!&*BH6D&3FWT\?H`^<TX8R4WLSF&?ZO-UTGV\>OO\\GQKO09R$
MT>6QJ;0ZS49P\:-]>'EY;/[SP_[6;S:2U+OLO5-T"1Z;OX*D^7WX]U\/'U'\
MFAR#(&V`PB5Y;![3]&JVVXE_#,Y>THJNP07^YQ#%9R^%/^.7=G*-`V^?-3J?
MVFJGTVN?O?#2S!7,^!Z-Z'`(_<"*_+=S<$ESD3@X>2G$GQS#:X)J9_\>N;,7
MO[Y=O_G1^0H2S^$I3']EHLW&V3?G+Y<H]IY/\-X_E:[GHW;V!Y$_AWX<)=$A
M;8%<.P^4OO.@/6B#TO!A'\(;L+0WXN#PV'Q23%?1FNWA0Y:@?\/@(ZG\;B3'
MZ&,:A_M5>`D@VU`G5H'G*'IEIO,]0]"X35K;606<N+$/#M[;*76CCUD0OAQ3
M*+<.;\1>S-S_LH+$AXR"3$O5F9(?G2``^+=Q#EG7@(QX/[/G1[A/CX]-K=?2
MC8ZF@'GC.4A2.V22S8;_EJ31^;_<2"FD<A&U$(%G(:+V6WU=[_;ZQOTJW4(%
MGAA*K5=0SD*'9V$/B:X+LU<T@"<V^'J4,'`RK_#$*%M=53?Z6<)JDC0H&L(3
MO:MEIFL:*M`I\AJQWE'D_^N!*U@E]J.042LR=1%`7O,(X`=&H-[WV@J6E?W`
MMA6W=W8Q!8O'?GPQ>@.CAQ\8P;W18[F5LM[*W=&W\\&6C5W+2[WA0QQ]-&!"
MA.&47#TVO2HF4\91F]>`C^//AC&,7Z;RQ&0>F_!6,$(3F'O>AVI7?6B_PWSA
M%S8C:J.(%F.T8),#D[5D,)&!+8.I#&8RF,M@(8.E#%8R6,M@(X.M#!P9[&3@
M5D`;RL-K!*/D_Z@1DV$UPNR.$%2*)A4$+;"))8.)#&P93&4PD\%<!@L9+&6P
MDL%:!AL9;&7@R&`G`[<"A(+`W$,*HL&4>'NIPS'"6L&B5ADC2M<0$S[*;6!>
MQ(R/";$(F1!B$S(E9$;(G)`%(4M"5H2L"=D0LB7$(61'B%LE0DE@2A=*4E\*
M9@TS'JA5YBM-JD5A!`]NI'0'HM&8&V'!+$(FA-B$3`F9$3(G9$'(DI`5(6M"
M-H1L"7$(V1'B5HE0'M@9">7)EYD6VY/55XHUS"J%^1WE1,MVLMDJ,2;$(F1"
MB$W(E)`9(7-"%H0L"5D1LB9D0\B6$(>0'2%NE0@U@.V*4(/ZQ#-K,?$%R3?<
M;'D>$V(1,B'$)F1*R(R0.2$+0I:$K`A9$[(A9$N(0\B.$+=*A,3#MN@+B6?6
M8N)S`@L,CH$Q(59!8`M13E9Z1YRL)MP(A6PB-"5DQEO52,^Y$4HOB-"2D!5O
M5966YN$U-T+I#1':$N+P5C72.VZ$TFY52"@B[(V%(E9FL/08^J^C"!(/Z;\Q
MJC38$.?;9"8BUC8GU=H28A4$=B.5VDI[YPDWPE>QB="4D!EO5966-NYS;H32
M"R*T)&3%6U6EI:C7W`BE-T1H2XC#6U6EI:AWW`BEW:J04%LX"`NUO5%#N(/`
M(C)KL8@Y46$'R`O4D\(9%S;E[&EQ4K92]*XT9`LC-3M3*7U-Z?5%"[NPJ.YE
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M@3:0-@,+-*D+8(E&90`K1+4!K-&J2$%/[2H]*;\;M*F+8(M&900.HMH(=FA5
M1-#1#561%E07;3Z)0.R,8%3;&7]$U\_VI)7]#+L&D38T!1(FC-RJ@BRT&O#>
M.*'(1E0.S"E%,T2EUIRB!:)2:TG1"E&IM:9H@ZC4VE+D("JU=A2Q[VK9N*Q,
M&/EWLORN_1S$+\$X.)V2AA^]L6]@L&0/'SC./]"-NB9<H,`^1>:Z"8=ZRC>&
M";MERK>&"7MFRAW#A`//#=XW8;-,N6N8L&6F'#XD/F47E'*<[`/C#?N1:L)-
M*M49:2;<YU'^U#6?(*'T/V:&">?,&[QOPAF%\H5APDF%\J5APGF%\I5APF'S
M!N^;<%"A?&28HUM\;)CC6]PR3#B"4QVK;\+QC7+;,.$01_G4,.$H![S-*P`?
M4J_>2[#VXI?PDC1.P0$Z62>[7XOS3['Y'VDQ(SQ'*7Q"S2:'(WPR#^`VI]."
MFZ-#%*7X!W/`/\(/?P,``/__`P!02P,$%``&``@````A`.'9DQM?!```OA``
M`!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&ULE%A=CZLV$'VOU/^`>+\!
M&T@V49*KW:ZVO5(K554_GEEP$K2`$2:;W7_?&6,^!LB&O$3!/IXY9\8<,-OO
M'UEJO8M2)3+?V6SAVI;((QDG^7%G__/WR[<'VU)5F,=A*G.QLS^%LK_O?_YI
M>Y'EFSH)45D0(5<[^U15Q<9Q5'026:@6LA`YS!QDF8457)9'1Q6E"&.]*$L=
M[KI+)PN3W*XC;,HY,>3AD$3B64;G3.15':04:5@!?W5*"M5$RZ(YX;*P?#L7
MWR*9%1#B-4F3ZE,'M:TLVOPXYK(,7U/0_<'\,&IBZXM1^"R)2JGDH5I`.*<F
M.M:\=M8.1-IOXP048-FM4AQV]B/;//&E[>RWND#_)N*B>O\M=9*77\LD_CW)
M!50;^H0=>)7R#:$_8AR"Q<YH]8ONP)^E%8M#>$ZKO^3E-Y$<3Q6T.P!%*&P3
M?SX+%4%%(<R"!Q@IDBD0@%\K2W!K0$7"CYW-(7$25Z>=[2T7P<KU&,"M5Z&J
MEP1#VE9T5I7,_JM!3).J8VEJSV$5[K>EO%C0;T"K(L3=PS80>)H+D$#L(X)W
M]LJV((V"`K[ON<^VSCN(C@SFJ<;`;XOI$`XD;3-#MOF9$8R9L2I(Y:D>Z*?A
M+1&2QKLG#8*AK'WR+&CCUIEKC*^KVM?CTT387;[$3IIVM"V_564,!.T@++@_
M8&%`$+VK<P]$2@"@?J61V=)?P.C7W<9EFD=;=#/2KSKLO9892;JD2;].A>"1
MY&4;N"Z\`0&)GN0.1++#'AU*YJZ_6-T4C0NI:#-"1:]:;B0M6O7LNPG!(]$/
M;>!:M`%1T1V(9%_3[-CG@,W0C.NH9C-"-:];:B0K`R.<+UJCAZH]MPU=JVY0
M1'8/10D`S3X![:OKVV:&RZAL9H:(;N^*?[&[#$RC1[H[SS*ZC:U1W1V*ZD8G
MZNTV[3AL=?O&1FL9*C=#5+G7MH4F'EC=U_<VF_(S;^AG#8HJ[U"4`*!&RH-@
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M<&-,1.,<9O1[_C`:#V!&GQ2',PPFIF(!Y4G&0'B2+]"=9,N`+;RE3+!EP!8>
M[##CM*3@]%B$1_%'6!Z37%FI.$!-7;V1R_K\65]4LH!:PQE25G!NU']/\)U`
MP$'+Q?OM(&757&""]LO#_G\```#__P,`4$L#!!0`!@`(````(0!&@R=M*@L`
M`$TS```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*R;6V_B2A+'WU?:
M[X!X/X!MKE:2HPF^PTJKU=G=9X8X"9J`(V`F9[[]J7)7N2]E$YC=EY#\7%7=
M_G=U=[5Q[G[_<__6^U$>3[OJ<-_W!J-^KSQLJZ?=X>6^_^\_DM_F_=[IO#D\
M;=ZJ0WG?_UF>^K\__/UO=Q_5\=OIM2S//8AP.-WW7\_G]W`X/&U?R_WF-*C>
MRP-<>:Z.^\T9_CR^#$_OQW+S5#OMWX;^:#0=[C>[0U]%"(_7Q*B>GW?;,JJV
MW_?EX:R"',NWS1GZ?WK=O9\XVGY[3;C]YOCM^_MOVVK_#B&^[MYVYY]UT'YO
MOPWSET-UW'Q]@_O^TQMOMAR[_D.$W^^VQ^I4/9\'$&ZH.BKO>3%<#"'2P]W3
M#NX`9>\=R^?[_A<O7`?C_O#AKA;H/[ORXV3\WCN]5A_I<?>TWAU*4!O&"4?@
M:U5]0]/\"1$X#X5W4H_`/X^]I_)Y\_WM_*_J(RMW+Z]G&.X)W!'>6/CT,RI/
M6U`4P@S\"4;:5F_0`?C9V^\P-4"1S9_UY\?NZ?P*ORT&8W\RFWM@W_M:GL[)
M#F/V>]OOIW.U_R]942P5Q:<H\$E1@NE@,AL%=9`+C@$YPB<W#ZU><!B3`WQR
M2P-O/)IB9R^XP=7Z-N&3VPFNZN"4'.&S:<^?3[S)9RW.R!$^;VL19F;=5?AL
M6KSB#A?D!I_DMAA<U5$/<DZE`":?&MW@2M<F>^`7OLOQ->/A<<;@+TVCW;<Y
M5&E;SX)H<]X\W!VKCQXL+=#PZ7V#"Y478BS.?Y4+S8SHFA`P$S#*%PQSWX>Q
M@E0_P2S^\>`%\[OA#YAY6[)Y;+&Q+99L@=,,PT8NB%V0N"!U0>:"W`6%"U8N
M6!M@",(UZH%@_P_U,`RJQ_?]R$#+Z3M2L06[1"Z(79"X('5!YH+<!84+5BY8
M&\"2"E8H2ZKV!9;S":WO^_!3Y]/$S2=E`TG+&BP%B02)!4D$207)!,D%*019
M";(VB24/K,<WR(/6,&,AFM9'S#<R&M73<>+D3W.Q/8+5-UCT;^@;6M=]XV%Y
M)`)-ZMY.%DZ'&B-VBP2)!4D$207)!,D%*019";(VB:4/[&V6/FH-'<S`X7*6
MHZ,ME2)!H'-:D$B06)!$D%203)!<D$*0E2!KDUBZP'9@Z7)9#+2VQ2#B:3$$
MB02)!4D$207)!,D%*4QBW2@>!LQ-]/*-HK5]HXH$=:5:;WS+AN@IX\[OB&Q@
M;]+3RC6*&R.>5DD3FDDJ2-9X&:&G(WO&YHT1!RK,0)9`4%3=(!!:VP(I8@HD
M2$1$9TLL2"*\4D&RQLN\=\^Y]\:HN7<SD'7O6!]:-V\L#^?7W?;;8P7C!Z/8
MDC4!K-U48&$46Y0Z,&R21MI(%#'2VV0L4<)(QTHERAC!'J]3;NJ4)KFV:L1A
MI,YB9@7E86EU_=RIS1T95''F@T!&IP)[P);DZ)NSQ9TLD3;BGL>,_'H7#4;3
M8.[4(0F;F+NQ&SIE(YV>F49&QR=CN^,Y6<$9N*ZJ%W`ZL"T*CM/1OIV,6)[=
M(+>JYJ#08$$>\9``B1C`YF;([?1I25;8M<;*U2321AP])@2G4;Q;?S'V1PLG
M=L)NL-ITQD[9R-2;;D:CG*R"J1)W,)^YVI)/1UNVMEC<W:`MFCNIK%``&TUS
M9][4+=VP[`/'3U*Y,=+:4G2K#IM.[3M..#H8-WUP1RYE(RUE)E%."%)7A_+<
M!@MV[&C0EAC+5E/B7UM+,8JCO$).5CO9L/3(\7)6-T9:>8H.E5*CJ3<5ZP@Y
MFKGF39TZ.=5]X/"91#DA2&RCQ9FS@Q?LV-6BK3W6OZ;V+?M5/6]IPZ)RV5PZ
M%/*GS6JRQ$=MF,MF/]ULB]A('Y!CB1)&.GHJ4291+E%A(5L%K'9O4`'-G513
MR-ZO9DZ!L?3(RAP:*0P9Z6D8LQ_M5WXP6<R=#3IAFXX95X]?RD;S9K`R1KJY
MG!#M3O!(T-EW"_;I:,O6%@OL&[2E>MS,,(6<:>QL($N/'*%D:Z:CU):,],W&
MY&=/*G<]2SCZI9%+V6AAJ"L:S*]JL.!8'0W:$H/1+1*CN9.^"GVV1RDK'SXN
M2$Q&IL04'9;"QL^;B00F1S.I6E9*LC(S6+28>TV+=7TU<';;@J[[9EM&LMCJ
MXB'`3.!?VY[440+V15[A'STZ7<!JJ669BNV)'.&CL3*Z6L_KB$)!9<;18XX.
MJTGCY\V<F9RP(^BEK>3VU/2!PV?LJ%O,VUMTYFG!CETM6MKC>FII?WE[JLWM
MS"9D;D\:Z7L6BK*1L3U)E#`RMB>),HERB0H+V2K@8>A_SD`L+9UI3PA;UJ,_
M<R;+DJW,$9-ZJ>A@RRD2LY_:M?S9>";+?K;IF(AJUV(C8\XS,HLV3QRSR(J/
M68.%LR$7'*:C>7L4\-1P:13^J-XA]UJ/_$8)Y=/APU@("%DYJJPNEU#LI_>;
M6**$D9FC370>K$Q:Y1(5%K+5`0F%.OYD`(O;C=\ZX:+LYBDA>P-Q#CE+=JR_
M6%;KHD2Q1(E$J4291+E$A40KB=86LG7$\X*999^L>'2\,+.)D"V6NZWXC16G
M0"11+%$B42I1)E$N42'12J*UA6RQ\*!ABF5LS9_HIHXHYG8,<Q3SSGQ,+U$D
M42Q1(E$J4291+E$AT4JBM85LD?`\88KTB3+J^&$I0TBO[4M<F'"2:A1)%$N4
M2)1*E$F42U1(M))H;2%;&2S.;U"&:GESKBDT!C6,#=1Y!K#T&RL]UQ0R'O/&
M9`5(QW*WV82-K'W/M4JU%3>8,=+/@G.-NALLV,AJ<.X\<UAI*VYPS4@^'<;S
M@R6[,6NO?W9>1W%J/0Q\WX?1X%XLR<I`$2%+>N5HH(2M8*<T1M9];J.MN,6,
MD2FT"%^PE7Z`OY)HS:A%0ZS(;TA=*N#-U%4H@+[I&W0KJ*5/5@MZENK4AA%=
M'U]*VIB,L-AJFG)S-M%&+&7*2!60DYDGCH,9FW04<'45D+/1I?8+;<3MKPB-
MO?KFQ_#@VBDYUNS4T;RUVN#$OF'(:G,[OPF-K9P40\96^#43/&VWGP1'?-6L
M#MRQB+GM2X(EVH@%2PG!7E0W[4'![SL9D[&;F7=N!W(VNM2!0AMQ!U:$QJH#
M\#W#W!TQ=NIHWAXQ:-X:L5]:J`*,X@RD0I_,/7(,:.XY:VY$ER]//3*Z//6T
M$0N9,J*I-QHYK6=LT)'Y:N*QT>5A5&)`%[GU%?GQQ/-F8^<IPIHC=S1O#R.>
M=JY?*P-U.#(+($)027`7EQ)%$L4:75CYV$@_:D@ERACI/N0:=4<OM!'W?271
MVD*V>B"QI=ZO30*,XDP"A6`UXXXMH?:N-W"-(HEB0O@@J7L[82.=52DA7IW:
MGD=D[-:Q/%!:T\U<ZD#!D70'5A*M+63KC@<T,VM=W:][W(#?T[G"*V1ELT`1
M.1I6L4:7A*=0^J%$RGX:98S,;&[ZT!V]D'XKB?#=<KQIU7>EJGI77+TENR^/
M+^6R?'L[];;5=WP/'`JMA[L&JY?4H8(-L0*#['2NP.OK7^H4=?@CO-9>#[?+
M?0C4$N<Q@-?@6_B7<?@%;D$V_#@)X86U%CX-X86M%NY#"_"LH>W*&*ZTM5',
MPP+>[&ASF8583\LK$2B%9;6\`H>:,&Z]`B>9$,\IT@=*;[C2%@T.,2'6U]('
MSC)AWGH%#C`AEM;2Y]$'-6$Q:+DR#Q];)5C.PV7KA6@>X@LX,E0R#_$U''DA
MA9MLO9#-0W@)2SIDBS"O)Y"37/#^3HAOYX#'L+D$_\SPOGDI_[$YONP.I]Y;
M^0Q)/JI?7CRJ?X=0?YSID>77Z@S_Q0#K,[PK#O^V4L)KVB-\=/=<56?^`QMH
M_A'FX2\```#__P,`4$L#!!0`!@`(````(0!K*?`[M`(``/P&```9````>&PO
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M@AYJ^TT=/W)15A:J/8>$7%YI_GS'#0-#@2::>!E,U2``?I$4KC/`$/KDGT>1
MVRK#TT4T7\;3!.!HSXV]%XX2(W8P5LE?'2AQH@+)I">!9T\";W_!3WL\/(=#
MYU$RBQ?NS,M]I-/L+;BCEJY76AT1M!6H,BUU39JDP#7DWC$$-_YD!B3@2#:.
M)<-+C"!/`P5\7"?7\Q5Y!-=9C]F^@CE'[`:$*Q;("QK!B?^@T;$XC<YU)WH[
M!%Y$3T:"!L18$!AU*NCU1AF\<6!HB3-O1@=M.TPR">)VIY$S,V;G9_]CP1P+
ME/Q<U;AB/2CV!5V.O`D?7^Q+KA<!=*896O+4+Z]YYF]3WZIO;C3'Y'6'*O81
MD'/2>V.Q`10JV4V#[BI(KDN^XW5M$%,'=],7D'*(AB&T\?49Q;<PG/Q5'L<G
MZ>Y5_#2%XH*.$7XS2S=^NHSBVWD__$CX`,.GI27_0G4I&H-J7H#D.%I"EKH;
M7]W"JM9?\+VR,';\:P7_,AR:/XX`7"AEAX4S)OQOK7\#``#__P,`4$L#!!0`
M!@`(````(0!/%[YCW`(``)X'```9````>&PO=V]R:W-H965T<R]S:&5E=#$U
M+GAM;*Q576^;,!1]G[3_8/F]?"4A#0JI$JINDS9IFO;Q[!@#5@$CVVG:?[]K
M\U$@W91)>\'X<GQ\?.[U97OW7)7HB4G%11UCW_$P8C45*:_S&/_X_G!SBY'2
MI$Y)*6H6XQ>F\-WN_;OM6<A'53"F$3#4*L:%UDWDNHH6K"+*$0VKX4LF9$4T
M3&7NJD8RDMI%5>D&GA>Z%>$U;ADB>0V'R#).V;V@IXK5NB61K"0:]*N"-ZIG
MJ^@U=!61CZ?FAHJJ`8HC+[E^L:08533ZE-="DF,)YW[VEX3VW'9R05]Q*H42
MF7:`SFV%7IYYXVY<8-IM4PXG,+8CR;(8[_TH";&[VUI_?G)V5J-WI`IQ_B!Y
M^IG7#,R&-)D$'(5X--!/J0G!8O=B]8--P%>)4I:14ZF_B?-'QO-"0[97<"!S
MKBA]N6>*@J%`XP0KPT1%"0+@B2IN*@,,(<]V//-4%S$.ULYJ[2U\@*,C4_J!
M&TJ,Z$EI4?UJ07Y'U9($'0F,'4GH!+<K?Q4:DK\L7'0+8>P6+L+7W2\7NJUZ
M:\8]T62WE>*,H,!`GVJ(*5<_`K+>A99A\.5/MH`?AF1O6&*\Q@A.K""53[M@
ML=ZZ3^`_[3"'2XP_120]PJ0-Y`T:P9W_H-&P&(TFE4;TH0^,1,\$]8BY(#!J
M+.CMDNF],>`8PW/DS>UTHT.+\8-!7#*.3,Q8_LO>!@R9G6X^3TP'\FS>-E-E
MR?!Q+/^582(-2G9LBZFEI;=QPKZ2KRXG0V1E#[GJ(J!FY.)<ZP":YPL4S(7Y
M&]_<Z^Z.7:W,,$V5=9&)LJ4W<W$`#<K:OM1>Q8K)G"6L+!6BXF1ZSAIR,42'
M=KBW]3&+'Z!-VJ8RCP=1\B9^$4%Q@8X9?K^,]K;=SN*'5938_C>/AUU[=H</
MT!X;DK,O1.:\5JAD&1S%<]9@LVP;;#O1H@$/H4D*#8W1OA;P'V1P*3T'P)D0
MNI\8PX8_Z^XW````__\#`%!+`P04``8`"````"$`?QD"1Y`*``"[-0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6RL6]ENXSH2?1]@_L'P^XVMQ<Z"
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MYPWB_IZ5RY7WW?VCW&_7JWW3-L^'"[B;6*(ZYNO)]02>[F^?UHB`TC[:U\]W
MXX?LQLQGX\G];9>@_Z[K]Y;]/6I?F_>_[==/?ZYW-;*-<:(1^-PT7\CTCR>"
MT'FB>G_J1N"?^]%3_;S\NCG\JWG_>[U^>3U@N&>(B`*[>?I1U>T*&86;B[RC
ML6HV(("?H^V:I@8RLOS>_7Y?/QU>[\;%_&)V.2TRF(\^U^WATYI<CD>KK^VA
MV?[/&F5$JG>2.R?X[9S@KP_L"V>/W][^\B*_FF6S.3WU@YZEZPFKD^E.;.A=
M)JOE87E_NV_>1YB>"*Y]6])DSV[@V*?0TNB3^K.<(@_DY(&\W(TOQR.DJ\5$
M^':?75W=3KYA\%;.YC%A(RT6WH+22VZK&#`,F""`/@JD_!=$05XH"O_\1P^$
ML/*(LK?P7:H8,`P0E#'^,>4"*R`]=WV>J1-FJ<CSM:3T:&VRO`]CH9!*(88C
M@B=F'>?Y,3\RQDR"LP\F@C.:=O,DFB6+OC'M05##?#V>&AEWU/Q0/5JDA!H$
MLM=3F<U%;^2[50HQ'!$$YY(@+:Y\=@'S$Y<7^9'<'8)L,>Y9Q+TWZKDKQ'!$
M<,=BYLDE[E?7M(^>2IX<2?(6B1(?KZS>J">O$,,109X4/MK5SB-/CB1YBT3D
MBRCSO5%/7B&&(X+\M2:?E9V$G9IZ\B396R1B7T;L>Z.>O4(,1P3[#)L8S_W'
M&T9G+2EZ*.S#"PU5&C("DIQ(-Z+Y,`-VXC+,K/Q@>_.)>?207(BS**'!RG>L
M-&0$)/F3B##^`SFUDB-H6B@:]WE,L[<*-!5DH"PTJ^`+5I(FB0BCV1434YB?
MFF<G1CS/#I)YOHP#Z*U"``HR)$^T+$H=`*E/%,"\N+@\?=.#\WCI>4B&$.M?
ML`HA.%\=WZXP,L)*C@&)T:\)@3Q%2]-!,H2H`%E0"=[GUQ5R"C+"2H9`FA2%
M<,YJ==+&9U&O=D$V\<X6SZ+>*@R!@DS&(<F?9.D7\+?J)I:Q@WC^\VDL^UEO
M%?@KR`@KR9^4*>)_5MF268D3$3A(1A!KO^\89GRE(2,@&0&I$XM@8+^T6B9H
M.GF[[G?Z1::@2D-&0()3?I(N=M9R\7G(OG[2^]'"025&MR\#\VE4C%3>*KP1
M&`_)CJ$.D,PC]?PXF[D620>5+)L:JC1D!"0YD0@=/<*YE2P^PA[BV73")I.B
MLNFL>#:3'4,1()F3^AS/W&D5V\1R"XEL*JC25D9`DA,I#.-$PEU<=<7^P&!3
MQVB:.H@GUD)#T]19\<0F.X:R109!&L."&&#N%(DGUD(BL0JJZ`T((3,K(R#)
MB42"<3H^L4Y=.#T'\<1::"BQSHHG-MDQE%,R"!(/%L1`8LDZFA(.8A5]KJ!*
M0T9`DE-"H[+\\HQWZUR+E(<P^]BV&E=JP:J760T9`<D0(I%B<^/$>CG7`N8A
M&4)<J06K$(+S%:37""L1`AU8\9E!(9Q7+W>>Y*SQD`@ABXNU8-6'H"$C(!G"
M2>)6:'%S$-L/%AJJ-&0$)#F1GK`%1VGU)P`?+[["*A$7.@^Q;<-!`]N&MV+;
MAH>P>,/"R$+]*:,X2>@*+70.$IG50J>MC(`D)Q*4.+-9V;WA#626>D83U$$\
MLQ8:RJRSXIE-=<Q"72RC(`EB40PPMX(EYH32L$6AH$I#1D"2$RD*X]3-67KW
M'R!GA4B0<Q!/:U*NXLJL<%8\K:F.6>@H0R!-8B$,,'<*QA2Z<!#&DBV/4%5W
M[\*+8!5VK+ZCAXRPDC03TG?>X6:AI<]#,H10RKH07,<@$E7H&$+@5C*$A/1=
MXJ.WDT^*"JU\'I(1A)K11:!DK@H=0P3<2D10_C+EZSS)C<5#,H10G=D0@I7G
M6VG("$B&$"D?K=@SCEE*+8D>DOSC^BE8!?[.5YA71EA)_@F5/&\=E%HU/21#
MB.NG8!5"<+YX"!R2(40224-PUDE+J=730R*"/"Z?@E6(P/GB$7!(1@#WQ^^9
M)5E'<]U"7.2=%8,J#1D!24XD94?OXZ45/JY`'F(*Y*`!8?=63($\A!T^:,(T
M:()D3G)U/',K;H*YTSMVTE(JJ-*0$9#D1-IT/">G9$P5*6<TZ#R;%AK*IK/B
MV4QV#/(DF4="^;&>TV<C\=RT$)N("V?%H$I#1D"24T+YCCIIP1,5/0?QQ%IH
M*+'.BB<VV3&HI@AB%HG?QXGMK.6B=Q#+XD)#E8:,@"2GA)JY5]$!>EJ_2`6C
M&>N@@<1Z*Y98#V'BAO6?_^25:9:0-#<[3CP2Z#Q%2>]EB#,)KQBVJO`=P^Y?
M:<@(2(Y#0M(H!Z?RUX(VZT6(\P^UO./?6_6"%CIZR`A(\H\$[<RJ:*:5SD-H
M83,A*('C[SKR_"O(!%\(2?(_2?QF6OP<)-:FM6)0I:V,@"2G2-8HIZY2&UB;
M6N%F#F*;GH/DVLR#*'2)K=)6/]OA2&>8Z!'CXW83*U!<DV<.XHPM%#&."OS*
M=8RL0ADM<WR2V,VTV#F(#?)"0Y6&C(`D)Q*5L[)HU4ADT4$\BRG-RJ,:O9JE
MK(I0!PO&\Y.4K;.6FZR#>!8U5&G("$AR2BB;.^K^>/7,M;)YB&7107*6%4&@
M[.I)6P7QD(PC&1N@Z72)E8QS"XDL*JC25D9`DE-"EXY:T7.M1![B6;16418C
M<:I<Q\@J2(!D3-M^M'K.>[^=.P'A&>XUA8E1$>V9"]^1B9&&C(!D"">)$:Z*
MQR6NA\`V:&81-FVKF<'*"WRE(;J)WKGO@K$T[<UR>Q]Z6^]?ZD6]V;2C5?.5
M;HVCV+R_[6%[I?UQ/L6=]NY:NFK)T=)5?JJE1$OW6-4R\S?DXY89G@,""$BU
MX#FHOU(M!5JZ059]P``U0ZH/&$"Y4RU7:.DN><7>2MSKQ[E,HD\);C@42;6`
M&PX;4BW@AI?Y5,L<+?-D"[CA)2O1I\!S</Z?:D&D.+].M5RBI?MP,HZTP'-P
MLIGJ<XV6[C4[[E-BY'#JENB3@P$^*TZU@`$^[$RU@`$^0TRU@`$^FDNT%&"`
M3[Q2+1@Y?.Z4:,F0:UQI2K6`&RX+I5K`#9=P4BW@AJLPB98<#'"M(]6"D<,5
MA41+AGAPN3/5`F_V8"$>A0PST=Z!5RUXCJTL5`MF(F[6I9Z#D<.%-=V"K[@\
M).<[$4O8/X)6TIZF;<+^H;QYP,:E'_Q(ZS:%8QR3PXA13`XBQC`YA!C!;@`G
M?9;PU9FWY4O]C^7^9;UK1YOZ&9ODM/OL;&^_?&/_.31O*(KP!9KF@"_-='^^
MXDM2-6XL3>F,_[EI#OX?!#;IOW9U_W\```#__P,`4$L#!!0`!@`(````(0!#
M5A'%E@```*H````0````>&PO8V%L8T-H86EN+GAM;#R.00H",1`$[X)_"'-W
M9]>#B"194/`%^H"0'4T@F2R9(/I[X\5+0]%0W7I^YZ1>5"46-C`-(RAB7Y;(
M3P/WVW5W!"7-\>)283+P(8'9;C?:N^0OP456W<!B(+2VGA#%!\I.AK(2]^91
M:G:M8WVBK)7<(H&HY83[<3Q@[@*PVJMJX#Q-H&(_`2K]$JW&_XK]`@``__\#
M`%!+`P04``8`"````"$`G:'O8;\"```U"```$``(`61O8U!R;W!S+V%P<"YX
M;6P@H@0!**```0``````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````````"<5E%/
MVS`0?I^T_Q#E'5(Z-&TH#8("8M*V5DJ!1\LXE\8BL3/[VE%^_<X)*>GJ9F)O
MCN^[\W=WG\^)SY^K,EB#L5*K27AR/`H#4$)G4BTGX=WBYNA+&%CD*N.E5C`)
M-V##\^3CAWAN=`T&)=B`0B@["0O$^BR*K"B@XO:8S(HLN3851_HTRTCGN11P
MI<6J`H71>#3Z',$S@LH@.ZJW`<,VXMD:_S=HIH7C9^\7FYH()_%%79=2<*0L
MDQ]2&&UUCL'ULX`RCOK&F-BE(%9&XB89Q5'_,TX%+V%*@9.<EQ;BZ&TCO@7N
MBC;GTM@D7N/9&@1J$UCY0F4;A\$CM^#H3,(U-Y(K)%H.UGXTZ[*V:)(';9YL
M`8`VC@C0;C;+/K:_EJ?)^&N#H-4NTD5HF9!AE^-"8@EVEL^Y01_EKWW.#8N6
M<4NHZR(C;;!KA50O]DVUW9:ZSWR;PR4ON1+`TKWD#D`842.A%(#4.VK4%N8*
MU])(D2,X-5FF<S8C239-WBG=`?"4VX+=E/KW^\`M*2^9F5ER)5\:!E[`);>R
M(3HW8(GT860JETK2;2&=L`LA](HJK)9LKDG&DI2WS:E?"BV>Z`3(V%17=/OL
MX?`/W!@*?2#S0AM<@*G83XU@*>$-?RS]ATZUHNF!DNP-N@,SU-1G+T\B5TEL
M>^;$0R%<;C1V:)AX/=+5HX5?*RH8NUZ[7OM1@R4[\?N@MV9LX1+V'].5;@CC
M[3.[R#+I)I"?R2#[L=_G`/NTV7^72\O-Z[)-.%U5%3<;=]%>]TB:PRY=RKS\
MUW`8.,6RF?>4U.D4]W3Z6F>OR[!<_1H9U"OS'K,GV&WO72'Z+COS^:^)_%VJ
M)WM7+_05S;CNR=G=C-."1F1&P[BSOVW$M_3:F-(%F1:<+EC68?8-[H&\;_\"
MDI/3X]&G$;U]O;TX>GOODS\```#__P,`4$L#!!0`!@`(````(0#ZW19)-`$`
M`$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**```0``````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````"4D4%/PR`8AN\F_H>&>TMI,S-)RQ(U.[G$
MQ!F--X1O*[%0`FBW?R_KNCJC%X_D?7EXOH]JL=-M\@G.J\[4B&0Y2L"(3BJS
MK='3>IG.4>(#-Y*WG8$:[<&C!;N\J(2EHG/PX#H++BCP22093X6M41."I1A[
MT8#F/HL-$\--YS0/\>BVV'+QSK>`BSR_PAH"ESQP?`"F=B*B$2G%A+0?KAT`
M4F!H08,)'I.,X.]N`*?]GQ>&Y*RI5=C;.-.H>\Z6XAA.[9U74['O^ZPO!XWH
M3_#+ZOYQ&#55YK`K`8@=]M-R'U9QE1L%\F;/=F^N3;QO*OP[JZ08[*APP`/(
M)+Y'CW:GY+F\O5LO$2MR4J8D3XO9FA0T)W0V?ZWPJ37>9Q-0CP+_(EZ?$4\`
M-GC__'/V!0``__\#`%!+`0(M`!0`!@`(````(0`E!5Y>V0$```04```3````
M``````````````````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&``@`
M```A`+55,"/U````3`(```L`````````````````$@0``%]R96QS+RYR96QS
M4$L!`BT`%``&``@````A`+T6G*K-`0``UQ(``!H`````````````````.`<`
M`'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&``@````A`'3J
MP7TL`P``B@D```\`````````````````10H``'AL+W=O<FMB;V]K+GAM;%!+
M`0(M`!0`!@`(````(0"E=*H'V04``"P6```8`````````````````)X-``!X
M;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"+0`4``8`"````"$`SVY/Z[0#
M``"L"P``&0````````````````"M$P``>&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;%!+`0(M`!0`!@`(````(0#BV->UZ0,```P.```9````````````````
M`)@7``!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!`BT`%``&``@````A
M`&ZW"P&X`@``"@<``!D`````````````````N!L``'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"+0`4``8`"````"$`6;I^I)8#```_"P``&0``````
M``````````"G'@``>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+`0(M`!0`
M!@`(````(0":^?/-O@,``#H,```9`````````````````'0B``!X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L!`BT`%``&``@````A`#W>E$Z"`P``YPH`
M`!@`````````````````:28``'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M`0(M`!0`!@`(````(0#A;4CWIP(``*D&```9`````````````````"$J``!X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`BT`%``&``@````A`)_8>-3K
M"@``8CD``!D`````````````````_RP``'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"+0`4``8`"````"$`(II5GJD$``">$P``&0``````````````
M```A.```>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(M`!0`!@`(````
M(0`(*:;XJ@0``.D0```8``````````````````$]``!X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"+0`4``8`"````"$`7Q_*Y.0"```J"0``&```````
M``````````#A00``>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&
M``@````A`&DL39Q200``SM```!0`````````````````^T0``'AL+W-H87)E
M9%-T<FEN9W,N>&UL4$L!`BT`%``&``@````A``C4_V=+"P``5F$```T`````
M````````````?X8``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`^V*E
M;90&``"G&P``$P````````````````#UD0``>&PO=&AE;64O=&AE;64Q+GAM
M;%!+`0(M`!0`!@`(````(0!"GAVY``4``"(3```9`````````````````+J8
M``!X;"]W;W)K<VAE971S+W-H965T,C`N>&UL4$L!`BT`%``&``@````A`-=6
MKI^6`P``#@L``!D`````````````````\9T``'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q02P$"+0`4``8`"````"$`'J%GZ\,*``!N,0``&0``````````
M``````"^H0``>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(
M````(0#0C:465`4``.(5```8`````````````````+BL``!X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`@69\#S,#``"P"0``&```
M``````````````!"L@``>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!`BT`
M%``&``@````A`,'4",RZ`@``ZP8``!@`````````````````J[4``'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0`'W#,N)`(``(T$
M```8`````````````````)NX``!X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"+0`4``8`"````"$`'-@'>:X&```#'```&`````````````````#UN@``
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`,`5D&^T
M`P``_PH``!D`````````````````V<$``'AL+W=O<FMS:&5E=',O<VAE970Q
M.2YX;6Q02P$"+0`4``8`"````"$`3./RRQT(```5)```&0``````````````
M``#$Q0``>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+`0(M`!0`!@`(````
M(0`]-;C_[`(``.\'```9`````````````````!C.``!X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L!`BT`%``&``@````A`*(%24Y?!P``R1\``!D`````
M````````````.]$``'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4
M``8`"````"$`X=F3&U\$``"^$```&0````````````````#1V```>&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(````(0!&@R=M*@L``$TS
M```9`````````````````&?=``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L!`BT`%``&``@````A`&LI\#NT`@``_`8``!D`````````````````R.@`
M`'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"+0`4``8`"````"$`3Q>^
M8]P"``">!P``&0````````````````"SZP``>&PO=V]R:W-H965T<R]S:&5E
M=#$U+GAM;%!+`0(M`!0`!@`(````(0!_&0)'D`H``+LU```9````````````
M`````,;N``!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@`
M```A`$-6$<66````J@```!``````````````````C?D``'AL+V-A;&-#:&%I
M;BYX;6Q02P$"+0`4``8`"````"$`G:'O8;\"```U"```$```````````````
M``!1^@``9&]C4')O<',O87!P+GAM;%!+`0(M`!0`!@`(````(0#ZW19)-`$`
M`$`"```1`````````````````$;^``!D;V-0<F]P<R]C;W)E+GAM;%!+!08`
1````)P`G`'H*``"Q``$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EROAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue, net</a></td>
        <td class="nump">$ 253,374<span></span></td>
        <td class="nump">$ 264,248<span></span></td>
        <td class="nump">$ 597,449<span></span></td>
        <td class="nump">$ 901,182<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
        <td class="nump">113,384<span></span></td>
        <td class="nump">164,059<span></span></td>
        <td class="nump">263,990<span></span></td>
        <td class="nump">474,526<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump">139,990<span></span></td>
        <td class="nump">100,189<span></span></td>
        <td class="nump">333,459<span></span></td>
        <td class="nump">426,656<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">6,907,250<span></span></td>
        <td class="nump">600,208<span></span></td>
        <td class="nump">8,289,614<span></span></td>
        <td class="nump">7,130,780<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
        <td class="nump">2,558,205<span></span></td>
        <td class="nump">1,596,554<span></span></td>
        <td class="nump">5,180,702<span></span></td>
        <td class="nump">3,740,022<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">9,465,455<span></span></td>
        <td class="nump">2,196,762<span></span></td>
        <td class="nump">13,470,316<span></span></td>
        <td class="nump">10,870,802<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(9,325,465)<span></span></td>
        <td class="num">(2,096,573)<span></span></td>
        <td class="num">(13,136,857)<span></span></td>
        <td class="num">(10,444,146)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">3,611<span></span></td>
        <td class="nump">5,645<span></span></td>
        <td class="nump">15,098<span></span></td>
        <td class="nump">7,193<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(1,546)<span></span></td>
        <td class="num">(456,237)<span></span></td>
        <td class="num">(3,339)<span></span></td>
        <td class="num">(654,611)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Local business tax</a></td>
        <td class="num">(2,024)<span></span></td>
        <td class="num">(8,776)<span></span></td>
        <td class="num">(8,824)<span></span></td>
        <td class="num">(10,056)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">144,503<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
        <td class="nump">41<span></span></td>
        <td class="num">(459,368)<span></span></td>
        <td class="nump">147,438<span></span></td>
        <td class="num">(657,474)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
        <td class="num">(9,325,424)<span></span></td>
        <td class="num">(2,555,941)<span></span></td>
        <td class="num">(12,989,419)<span></span></td>
        <td class="num">(11,101,620)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (9,325,424)<span></span></td>
        <td class="num">$ (2,555,941)<span></span></td>
        <td class="num">$ (12,989,419)<span></span></td>
        <td class="num">$ (11,101,620)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
        <td class="num">$ (0.34)<span></span></td>
        <td class="num">$ (0.11)<span></span></td>
        <td class="num">$ (0.47)<span></span></td>
        <td class="num">$ (0.76)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute basic and diluted net loss per share</a></td>
        <td class="nump">27,515,372<span></span></td>
        <td class="nump">23,793,309<span></span></td>
        <td class="nump">27,496,676<span></span></td>
        <td class="nump">14,578,448<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostOfGoodsSold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CurrentStateAndLocalTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GrossProfit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxExpenseBenefit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386349&amp;loc=d3e3636-108311<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SellingGeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><b>4.</b></td>
 <td valign="top" align="left"><b>Stock-based Compensation</b></td>
 </tr>
 </table>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognized stock-based compensation on all employee and
 non-employee awards as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="46%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;Months&#xA0;Ended<br />
 September&#xA0;30, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Three&#xA0;Months&#xA0;Ended<br />
 September&#xA0;30, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br />
 September&#xA0;30, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Nine&#xA0;Months&#xA0;Ended<br />
 September&#xA0;30, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">183,168</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">105,858</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">158,575</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">116,726</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Selling, general and administrative</p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,355,175</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">693,533</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,465,590</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">940,492</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total Stock based compensation</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,538,343</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">799,391</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,624,165</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,057,218</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company granted -0- and 35,000 stock options, with a
 weighted-average grant date fair value of -0- and $3.41 per share,
 during the three and nine months ended September&#xA0;30, 2013,
 respectively. The Company granted -0- and 100,000 stock options,
 with a weighted-average grant date fair value of $0 and $1.03 per
 share, during the three and nine months ended September&#xA0;30,
 2012, respectively. During the nine months ended September&#xA0;30,
 2013, 50,533 stock options previously granted have vested, 56,050
 stock options were forfeited and 31,533 included in outstanding
 stock options were exercised.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Included in the results for the September&#xA0;30, 2013 quarter is
 a liability and expense in the amount of $1,487,801 relating to
 probable awards under the Company&#x2019;s 2012 Equity Incentive
 Plan (&#x201C;2012 Plan&#x201D;) pursuant to the Company&#x2019;s long
 term performance based incentive programs for certain members of
 management and independent directors that were triggered by the
 Probiotic ECC. The liability and expense amount represents the
 grant date fair value of the 422,359 shares expected to be awarded
 under the 2012 Plan. See Note 8 &#x2013; Subsequent Events.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-13-410690-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-13-410690-xbrl.zip
M4$L#!!0````(`#!`64/N#TS,+W(``+R5`P`1`!P`;V=E;BTR,#$S,#DS,"YX
M;6Q55`D``YQ=:E*<76I2=7@+``$$)0X```0Y`0``[%UK<^,VLOU^J^Y_X%5V
M4[M5@@R`X,N3F2V^E'7=B3UK>Y/L?G'1(FRSEB(5DO+C_OK;`"F)>LLR*6N2
M2:9LBP3`/HV#1@/HIG[XV_,P5AYYED=I\K%#>KBC\&20AE%R_[$SSE&0#Z*H
MH^1%D(1!G";\8^>%YYV_??KO__KA?Q!2+B\5+TT2'L?\1?EUP&.>!057SA)1
M8\#AYF`\Y$G156Z#G(=*FBB_.I>?%=HCBO)0%*/3DY.GIZ=>EH639GJ#='BB
M(#1YQ,^E=*>*HO<H2%B[=9F.D_!48;5+;L:#`HHK(<AQJE!,5$0PHNP:XU/"
M3K'^[WKI=/221?</A?*7P5^A,-:0J*%<]BY[-6#?*U=IDD/IX2A(7A0[CI5+
M42M7+GG.LT<>]JI&GV^S6`&=)OG'3@V>N-Q+L_L3>(1Z$E7:Z90E3\7=>$/Y
M.$K^(]0W+2\NS)5_4F5I8EG6B;P[*1KE*:/$V"1,66+:=AZM:AF*DI-??_I\
M-7C@PP`M(@"FW`?!:%KS+LAO9;WJQHGL!TR02B950CY[D)0HYX/>??IX`C=6
M%$_O>3(MGV8!?(P&N>2**(PM%=>$*5Y&/%\IC;RSHGTA0EC,2U0!UT[*FW-%
MHY5%];)H-"F:%Z-L-4IQ1XA!YL48`*.+[&5UG>KF"ND'XRR#<;NN7G575*3S
M%?GSX&%U)7%GQ9.BY)'GQ>HJY;T5E9+Q<#4#PR([$3UR`B5X%@VF%6#H;:^3
M)FBAWKC(UE+=.H&['1BDBB*':7R:2S)?\CM%CIE3T>K'3AX-1[%@MKP69(,L
MC?ENHU/6>,CXW<>.X"N:,+/WG(=[#-[=[<))":L:;:<>ORV$"<ZD[3U+"IY!
MQUR"1;PJX$?XA6<#N`&#2!FD</>YN!0R\S2^^>*K)F4&08BH8#?_@8'_-U?7
MW@V^D6A4;,*?%E5-9CP3HC/#-#O*.(G*)D;C#,0)^2`:!C&,P+/S?D>)PH^=
M*+RA!)HDYHWF>5[?9@ZR5=M&S'$QLK#>1X9#-:RY5+<\ZX8`P!O:^81[6->,
M'TY>#VV32OK!@-M#,9R:5D!E3F_^>>75]8#?H`72^:3![[5*F($Y&`MTBF=*
ML%1B4-8&"8#E[(9)$C"='1$)-N-OE@-2"6KG$\&Z9:U5PCH2N$'^8">A^.7_
M-HX>@Q@*YW;A!EGV`E[>ST$\?FW_4V'3;O`^B/O$\W2+$:3Y7A\QYFO(9'T7
MF9IEFI027^_W!6)Z0TV`3`S-,`QM!GHG.*4&A`4^_06N!U#B+,_'X'[NA1/Z
MF5@:*P<[U6JP\X<`B+>-ZCMA5@5F%3`;!CS'^N%DA?CS/?L%YAD.$WMX5:2#
M_YRG7X)LG\Y4-W7FS8AG-Q.4X!J>)A%,2$`YOH32MFV=:$!>S]!TQ&S?0XYN
M]%$?N[9A4U/W*;F!_ZVEV0K<ZF&:2!17\E$7XT(N.*`_WPQFMR[:47AJ=#ZI
MF.BF3M0:)S?(OP7I7K1L&Z2^$\CME&RO,QMA(J7+3(R#/+^XJT;=1287>8=G
MHVE9FM^W*?)<$Z8%70<`?0?LAZF:CD7UOD?=&W`)R(W5^40-9N#ZO+`-Q/8N
ML\?%0YI%_W=TS,0`%Y?_S?!N1K!E`!XM5$TZ?0M0-XB_%B=,"Q=9Z1;)Z0%\
M(UFWM6FB&?REUX?)2O#K,&VG=L,&MQE#1)8,T;SHC4_K3<WEYI+@=AA&8OLM
MB+\$47B6N,$H*H*X6>$W.9B[ZEQX6H1A$Q96,XJMD7X>XA6,N.*:9\/S-'&"
MY#^?TR#)P2<]3PN>?PE>@MNXX<YJ`"^1"PCP-FO69!<@\]`_1\%M%(.*>.[*
M/:77KYQ:!PK>"V,:A3ETAG19[H4N%:/L(8U#GN5B65&\'!TN%>8^INI4M6HF
M<5GNA=$XD%N&D\Z$OH4K,.##KZ$C*4SVJLXLW:P-T-T!S6OBDA=!E/#0#[($
M?*`<JHV'XUC,(!Z_BP;1\2F`@G.'=`/#$MBL]?EV)(M['N5,<LD?>3+F1]O=
MFNAN6/O6-SA62;[HZ"2//"LB($/=;!TM2G!KB*7I"U[=)@QK';L6O((F6*N6
MJT=KI>-6VYY989MA.'\-EIAT/IDFT:B%5\XP*U',8SZ##D^*-'L1^I#'E=4Y
M8GXXM):C>8Y.,=)5OX^8R1BR79TB'U/#AC*F;QF`5BRYZ!Q=UPN_,/GD.2^.
M=GHQH!,-`U;.M#:[U"5>!>;H4%@KJ%B*VOXN\`%L":"CNF&:YEX;P(M.PR4?
M<*@@S"POCI67,$%HIFFL\'E6B;_&K$"!HP,FYG>JJL1<84E`WJ7U[PA68/[S
MB">Y</,NB@>>';=%T05``V-S;FMJ&XQ%W.D(7(&7+W&0%%!>4'PDCG>.L4=A
M":V:Q)K#NU[\VJ',^7AXR[.+NY]Y$J99_DM4/%2:<H)8A)5<W$U";=Z*N7S$
M]@U7W2*>[2#JFQIB!K61Y:@^<E4?$PL3$Y/^C28/X:J#F=TAU'`O[,S.MF1_
MX6*/EH<V^('!/?>?>3:(<OXEBP:'V*>C2PHQ'!N8W#<0,5T+,5<SD:TY!I*/
MMCQ=Q[8SW8$F/6NBEKT0+FZO@'AO0#Y_6F?`1Y-:\!&\&$-?<U*_LUY<YMM$
M]3P8&7T5G"8'1H;KNLC&?4>W#6(R4Q?'ET0<VJL]/+?;,L%UL%/ZB3[*4VJ-
M&2(BYU6G]-0QH=]-%V'L.8C!^$>V`3ZCX3+'5K'F:KXWQ8M[6*TC?O=3^LWX
M=S:'NRL!KUC=[1.KT2SFG8;`EF-[TZ:ZAAWDZ3Y#3%<M9!G41.`_:YY/'<UQ
MM!LF5$#W5D$[AV\`7F>J\4PP8:;Q^L-[F_K$-*T^HKH/(Q[4BAR+`7S7-?NF
MBG77U6]DI)(VOZA_U2G<RM)S1G)Z,Z_N[KD86:^/17M8/6^S0=Q1/43L/O>V
MZF<+XA5Q'>!:19E<A'I@4IK2R7X@57$Z21C"#!%M(8!C0<Y#,M_2,=5).\27
MXUVK(E:^%NHO*:0]YLMYD?2T(R?^1"/[02QY;R!L(!4?$>\-C:HM\9X*W@-E
ML$6UKXCXBQIIC_A4$)\>O<6?:&0_B"7Q-8151-77$'_A9&-O#`;6+%CH&(9&
M]O)L=8!O>Y:)&'5AW:MA$UG0)+)A+6.X=K^OFYZ(099F;//I3*VGQ)%RE$CL
MYVD!_0J.?I3N&72QY+PN>J:.KNJZHR'7910QCS%D&IZ*#,-WP2NU&/&MZ0KE
MBX6]JI_6"'D0&.9R3Y@^5@T'*(8-\""8IE-DZ::*5(O8ODT!E@B'%S#8[C`.
M=@Q\`S\UJC_#LH,Q8Q\F[K0#,UUH-G`@W-H.XR%U(28A8S$8;K<=1\F>V0K\
MXD[N3_PH;!</_YF$//N<)O>"7F>)*!,]@HU.[[-@^%JU@%==9DSH.@:+2\&*
M:*`DJF$F0N<UR]BP*<%6C!33AM\N\AP&JW'FN<A4#1^!';.Q[YF:IANES:)5
M")E1C96]T+Z[MG1"V]96;0,'B_WYQK55.P&NN4,B@J%=[:G$U%G;VE.KG1^A
M/0VOT-[>Z&O:E+7+X,7KU`\&#UZ4\4&19MXX@\9*JU\%7(L1OZ_B5&QB<"DP
M(Y2I:S6WFR>M>>!#65)QJHY@(O:1!4(@RW*\OF,:X&-1L6DD'2EQ,C19-+\6
M;*FGD$>G/JBO>&DRH8!@JNT3PHU=H]]7+>2;#F!WB(\<LT]0GU&&354W=`O6
M$.)0#&8+K.L"^VX`6EU"$0+N<%L1ZQ-'$OQG=>Y(]W7+IA:.LI=A-YO05.Z,
M&IU/Q""&:NUUFGVP$Z2-RFCV!&G""&+U"&ON"*FAS"BZLR(:B*:F+6=&+8-I
M,%Z?2G)3`P0PU4WY"BUG1K4-4M\)9/N94>MQ-L+$]C.C]NVHG>89Z9")F96J
M8(3IOA--HYE1;3/SB#*CVH9Z;)E1NT\3S>`_ILRHM@U1&YE1&_NKJ;F\K<RH
M+<*_.:JKS+O756IAO7ZT\5Z94>WC%9E1S+`,HQZJ<_#$J`/@!.>%4$UGIG[`
MQ*CV<8G$*`L>HK,:KO=+C#I`1XH0&Z(9&FUB'[SQQ*@#6"B1&*4Q;.JJ7O/N
MWB4QZ@#=+?T=R[36'KVUD2AT@%Y4R\74ZG=,M)\H=`#+)*.>F&D2E:XTN8?,
M%'H#W)TRA:C,%-+4@Z<*M=^/ANQ&K&JLYG-O".('C$46#<#NM/+RI?9Y"PX@
M,72U;EI?A:B!U*GV45JK!N>A<J<.8%[!*[*H9NG&7KO-+>1.M8\95L:Z95C:
MLEO4:NY4^\`TX;HS8KQ3[E3[`&7N%#'5(\F=:A\P++)-IM7?Y;!C[M0A3H#V
MV=':\P1HNE?;T]3F#H#>%E]7P3]@?)T,D*>&2>B6^+J#K5\/%\6D"^R6-><W
M[KV:K44.O#DP0F3^+(64$*Q24Z/-!DI@AW@:!G(P3_S05((L5_,1@;:Q#YZ8
MI_FSLU)=FPLZW@ZY'D8BKCKB3>PB.Q$,JW3*;3'2[KDP-L[+K`AH7URRGX(L
MO!B)@OF/Y=LHD_(9U^DD#7(2H/$*-Z\)]9ZGR8T_',7I"^<W4QF:4S=,2].8
ME+8U=W`B:P:QS'<@\C1R4=.9REY/Y+F$REQL1_?3[#IX%CFX8B4-->'"ZOYZ
MH]*FP8N'UMEDFB0:-><VJE^O@@/SK`V5[118-@D!U<B\RKX*EI5!GX=F&:OB
MR\G\;/QUL*QQE>W$LDGHK,94_)79LDEP[*%9)E\;H%:'^%\7RUI0V4XLFX08
M$UA!,/4--&M/0P>GD5[IA%$1YG-H?_@Z=28!\4>ALEUCK4O[7HZ\QC2P&']]
MR>^CO!#WSH/A*U;?U%#G7F&R3TRUM,87E_:/_OF9>Z6<G;OUP.IYR69RVP`K
ME"\GB(-7Q+)M$5BSF>?8&D%JW[`0PYZ!++-O(L,P=`_W#<^!=J3`=]"QO!1T
M3I1%S?:CF&=N4/#[-'O%@5<SB@7F7`$#00+EDH_2K!!Q?]5;;NI*GA-RAF#R
M56#]*!\$\;]XD/7ARBM6C,UHNTS:5$N!U\BT+/3URZ@Y(N\HJ3#XT.J\I$*0
M9?%*&^<GH4@V/;2<M-0HPI;,_UXKUU*:!A3(@O@L"?GS__*#TUFDAX%!)`:S
M&)[+OIB7:R9VM>4T(TO3"M]1<J`PM$R12DJQU\FU;NR5O?(NHP]LR#]6CKV:
M3`M[N7`[3O-Q5KU2:S)%77(9VN&F>9$OS5#Y-6!R8O`$&@/H8AT[#K60XQHN
M`G<?(\<Q"8)U!S9MPS9\#Y>#]ONX^!!&C]_?%Q\`B?A4R,BWO'@17R3F7%QZ
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M8WY,3H;Y=V6:A$)&A9*G<11VEO0*@Q;&6R(/<%</*&E^KQ\RSF<R_`23ZD,^
M^PP.!P]EX4PYJ22[XJ."BT..63$5=^4W\NXX9WQ36*4P^@=0V'F4?"/8.^FK
M87[-VU`Q(8,XR]/QJMG:67+6]C#!E5=Q#YI,P:WXSG5]O]]?8Y6%8[K*A;KV
M?[U&9^>>?WY]JB#"ASMZAY_]/E28E5_V#44,;)`-'H23IX3\D<>I#/19<K?:
MX>V?=IIOJX_RR]%E-6*J7:*;.U5.TJ=,?!MX^7M1SJ9'6H,8L=8UM=\Y1LWL
M:H;V^\9(]*Y!]78QOME3K-N$=S=*5[#0@D565[GG"<^"6!JG(!Q&B=PP%V^E
M.9!]>EV-%9W?536M2[X6BK\5KFZI74U5_QA@29?I6E>S\!\#KL5PEUGT'>U8
M92A&SSNL:5M3XZ(5K'QJN;LU<ZB?*X=ZQ3->:[1:?>`AJ/1-:]^T]DUK;6FM
M&<_O>!>HUZEX,84\DU&6SRKV<P/ASEV:%"LFE\F&Z8+&1>G73"O[+A7`>3*[
M*GL?!^I8M6)85E>UR#>=S#%%IZQ+]/=95QRO5K!F="EI>=/D]^&DJC`CA>GX
M-N:'F@/W?^(QN0[?]/9-;]_TUH2S.G\84SMM*8LNQ-"LC"<1L2(M1<K<5Q'5
M"".Y_ZAJ7:$<&36CI&4B75=YBHH')8"J3U5",`K*C."ROA**D+R[(,I$9XRY
MDMY-&_R3VF-$&7&8/T3(6!<:"660N%*`&(4XLY7EDBCARE">J2E<'*5M.FP4
MK60\'_&!V"6-7WH;,1&,5X`2:"2L5X#Z$RXQD1Y6!29HHT3U-DS0C#@2["Y@
M\F9MOJXEM:MH6&Q1SD-61AE_C-)Q'L]T]`"8E4>>P]]020?7`@M0<]6>>`:*
M2+,['HDJDB9$-A\E@W@LI(D2)9VEC:]N@5?9XV%O:80=@O5G-5F%2D'7X[@0
MH5V9_+R!;LIOXR`K@,)1#@T%2ESE1+](7?#R?0F3=H/R6P0%6TB7F4;7Q`0>
M%@<R>+M(H851EMY*:U`%F(W%*^EEY8K"E0CP;.M#+KFA5&]<FKZP'IH1[RU0
M_C(KZWZ0)<7EV47OPU^5T3C+QX+21;K^*7$J.PY@#@6U02U#\:VJU7(TFCQ7
M""_>E%\J;L`S\0HP92@UEP-J:`+J!64F@]1/!.A&@K1B3$VSEHN'H"AY48!K
M>P]_A,KMBQ!/(`,%1>++513?=<O!O5KGE;(S#M3.111JU<#:$2S@,TJ[JF:5
M0S>7;8D7[0CMW%9]PD4LX*Q;IGKM`4VX(MY*J)C*3'_J!^5J?)OSW\8"I"_>
M$Y+/L[S\)R]5@:JU]PZ\+=YV/G@7!D>5RR\2<;(T@3\'LC/R+VD<#5[*G\U'
MZZH&]76S[R/-<?KB"RM-9%*'(DS=/F&,NHSJZZ)U#Q`>*AXCPRW$BVF2`DQ@
M]?K5F;:4>77)SII%:&RU5XV'L\+8$._&35(E@2:"F9RC.3G!*DD@,!SYW5TY
M?<S/LCF'3@[_O[TO;6X;21;\[@C]!ZY?=X0[@I!Q']TSC@"O?IJQ+:WMGGZQ
M7QP0"4J8I@`.0,K6^_6;F54%%$"0!"5>DKDQ^]HBP4)E5E;>1\[%X!H05Z,K
M2`+@-J"?!\2E\]L`B]"WP&4B8!C#&>;,+N4?XR@&?A$%$\`-D.W=XAVHI_Y-
M";:FC/-Z?3'5]9(F`?\BT2=:`["2M<=?B0U+R+K^P-9[AJWHGN<HIC/P%-<V
M^DK/\EU;TRW?=+NLL92E@KBM5&YN&>H:O"X4J;&?^_&HF)L"3)&?T]8XB>=T
M^G87^0<.A#,=JZMX5M]7--/5C9[E.(XHUFG(231W-ZR$Y=`3EEH<RRWI$`[,
M07YG:063AS8ENJ-`1P%=RHB?<F'2YJH<<@SZ'G[/E#<F2M$&X&/VVB2`T[P_
M'5?UV&/$0N["`(49BE!@,,`P0`#+4ICK2:3[R#Q$EMJSAVDTQ,VWYAG3*(-6
M9Q+`QC\/;Y-)B,ILA#GKH!6/PLEYZ_.R/'_V'EB`LTF0\G*2/]-CL$5B-(0_
M4E144!=!0+",`'4!#@:LL:A,U&"3*2Q"16%Z)NYTG"9W0C6NX+_\.E"HTB49
M:_![L3!M>VT*244]I?=S]HP@8`>L@%MY3$W#G?(CBH,9G&,.*<<14V#O(]AI
M&>T<F.*-60%2<L]4*3+<0)7-P)00*Z*ZB6/^8(??;B.`&=_&#)10O"HKCH@$
MTSP#+#-M%E@.OC4_C.6$"Q@KZ#8W4CCECI`N9F0+\?,NT>-M^$"'E,VO_PT"
MDNV"&T6`I.;:WB,XZV*?V6A&9(.M!1,2G"&(WC`K-,GMZW=NUS'[MJDINF;K
M"OQ34SJ&T54<S=$LU3&[WJ#WXU5CN=NIQI+.E!<BE<YUU3N.NB@+7Q/AOY$C
M_A$#6:<9VG#`4@:3)(U&09&;.P#%;\1X]GNXZ,!!&-S1`57PW*>$?3'05`0A
MF2%7G?`=$E,G9E$+W=FK.OC::,:?ETWW/P:?!F6K'>52!/3P^4/PZ0LM-`4!
MR#@W6@?!E-G"'_[0-%-%1CF:`V,:H@\&>5:-]KW"SU**;9L_[X(&^$9EL[DX
MX#*V`PG7H`-P;(^X!(F`HTTFP(7G(/*FO(LCX2N9IP(?V-0QXEZ$63B\C9-)
M<O,@A#"=&*"<R6HXJQLP7R;B1:W@)@T9IK_!5A";H]8_YG+ZOZXS9YO*7(+X
M6):[`&#+P1WSTP$UUWB6-$O\NEU\^(_YY$%ZA)Q/JBX]4+.0+A:2G_N`]":M
MY-!*!FW4![UI(GWG,1<7PP/?-*RXB(A<$$L6(/>@QM+%^):DDQ%PSE!:!%2N
MN^"OL`U2FSE&46\1!$L,#_\`V9Z1\77/G4'H"`I(MG],SHLM6VW/T-NF[;50
M4,XF\*Q\D7SX\"X:H@<IF.`2R>1A"HB#+;5;'^?#20@$X0\CYLC\$,YNDQ'I
MQ7]DH7P!N>^*G(:H\_QQ_OD<5!S:3SQG[BZ[[=EFV['5WUI.6[6=-AAMO\&G
MAJ>U=9?^">9+VW$TSM6!1D,0`7R=K.2WKKCC..ZBPD/)U23RL='?;)$VUYI"
MG'\=,H:$T^'1$9W,;V[Q#SCE0G'AMTAV\J&*%Z)]@$"CLR!BCEM4'JC%/_X&
MMAX?&T\AYEC+&INQ&=*GZQG-"C:#;#DMWLG.@]Y:X32-^0Q&(W).X\]OYMFL
MH'BSW=(\SUW':,YJ"XZ`U:QE-(LLI)[5;,!H8,DFK&8-HR%%:"VK6<UHF+VR
MFM4L832VZK1MASA]+:^IHSNDCQX.HIVTND&*RIO$5/A=Y:<]CB9%/(+XR]67
M2Y0895'CT/%;M/F[`,"5W7SP=.44&+4X#,V<87V+L-2=,8BZ]6%SUGE9Y6G.
MCB1FA)@J,YK-V`R_24?(:(IQ3*TO(?>DX,46NFK+%P2<+6,]%\("7TK[#+G+
M>1J[5TS!:9<$,9Q+<@W61<`#&6"+MZR?"].=_`3D,PF9`,$?Y=>".QC@ISG3
M*CBAX&A1R*,VY7MY!V\B>0X$G28/P01X)#]ZQO@`[(`CK]V*QI6?`[7DNC2U
M;L!8;);')UE(J(HQW'^.L_6($'MIZ3JA)""FD+(VS^2D".$R2<!+FVHSAC-B
MKJ8XDIY'6D\F*#;PU"0G#=!S5A'NN*]@DB7ES2&SXL*<=9B@0Q(^(7B`=BWU
MGV@%<'U#!30<_-T0K$:,J8)9^;_,<!J'P/RF\'9E\3OT"MW-[\0A(5O,O7_D
M-\J7;O$Q/LADQ9&6?%OK]@"L>3X9831M5#C\QE&*KI68V4E!^L`(D7U<+-/*
M@@ECWH"R83`9LH%"Z)/YB24G8#(!Q<+A!;-O88B"[T,@2S0>ML5%\,WL87X7
MZK9!N0V5+7#^N2DN*?!KL80#>,F<?)@E="R<].(&)%26$9[?)-ADY610ILBO
M^78;`MXIKWCA.)&*L=5_3F)`XR$1]$_ZN0K0`;O`VSJ?)L(G]TTZU`4:+I.E
MM$<!H7@/0*JI.5MBNRNVA-LFOQH]R^7B$&=FC(*T]0!F=.$CK(6)@;$`2'-9
M\KU&.'PO"P<IYW%YRM#RMC`[\4Z0I_4_\RB5CD20*"-"^`S5V9C$L*!59#T%
MI\X%.Z4`\"-:(:JB0IP5&0^,\'&E,(!36M3N*']&9X]%,3%R^`ZIB>N%XL\J
M`!57>0'M-1DS2,T12II[IFG`/T7`$R[@=9`!CMY$Y_`6B8OP!\C7`HM<)[-\
MRQ7V?3='IH$,'`4*QE.X9D6LG@MF[OA&U`RQ05@NODKHG>*8C90[@D`%1`<^
MTU&S<#CG8C+#A(UAR'6^XNA*VE9C#\_VXU^Y4Z^?J^/=6SBI$+1>=.=>)PS"
MLI.KW^V6?%QH)!0$11K^13Q+P^_PPVZ23ODB\%AI&?%,::W#^@HO:]T\>;Y:
M246AUA*D^`/U@D4#6)$1T7J##\OPYNDP6:N*P0K24#_#]!<T;$"O#DK+#/D!
M#>4#*KL\BN!ESFFY?E*884#[:%XM'@+:"6@F@]$S0[E:V,*D;>494,RXQGR@
M:!P-^44`@P\=(]Q`0[64FG2AAH#!K1F/!MXE(_@1QOC0X=]N]3[ZK7N>4L0<
M-JW[Z#XABR)-)FP!N)<I6'Q$CE7<?LDWN>A]Q6=EM8[=\D4Q#9=RFA]1NX4Y
M?`09;IC6H*PGDHQ%:`Y/*VG=SH'22&FHA;)85FP(CR,-@YE0'$91%@;(<SAG
M2#`,.`SNH]E#FSQ`P0QV%,7SG$EER?0VN)G+,=]VZWH^H_#7)+J+F&`'I7!Z
M.[M-X(?9#.X#F+^16*,3W@[#6?GD^49:;Y"\1!(C(_QZ6CZC/"_,)2MAGO'=
M,LG#IC&N$66W9+5CK&06DE<.0[TI)A4B_()&D1#R*Y'GAI&R(!+/D(K9+<%C
MP=W2B!-&IDRNS,K;X'O-T_S@$'B^&QP2&;SY)O%LVJWA;7B'9PU(@#.>C^$M
M+"6'&[](GP@"H!;X`1S'$$0!$@`/L-^@?H--9XL'%B@O'`-9D"!GQ%_GL.(_
M/TS69<U9\GBKS%2:>)!!,@+8R_A.<8WQ67YI:RYLV.2F+MY36&7CFUJZI[#`
M9C>UN*=5Z2>0=L6M]\KM^3R7]*Y(CEFAJ#C+$Z=;)'P>"JJ3.%V[R"Q(QN.0
MJ);2)-`T(U4IX:W+:UAA=7_,NJ0??(MH3V>\SZ+8&6XZ]QD)#H2ZO,@_EVD%
M_0W`J9BC*:</3.AEG@,0),,TN@Y'!&\"?*V>8KZER$1BHH\8^<-A+L@?>9)I
M^9HPK$F^-)%J6\&+Y$HA*R`#DRV+,-P.!]9&W1SS.>BT9K<XI!=TSCG+\B!K
M>)[B=\1`X-71E+B?+/1*P@TV@NDT+#LB";A\72"#-CGW4(:3TRDL<;8Z@D.*
M&A>AR](E#3!_G/F7*,1'L`1$PT7"<86]DN%81YQ,`2?"?)/!;?'O6-IS&4.Y
M\%A$J>SAAQM-+F34;S@G;I-BHH3Q312'[.*4[A4A@)]D`0,_R#(<W$]].+Y=
M4OG0[,G1(MGPP`J)+>#%2TM>-+RAQ"_&*QV-!7^JU4]K5,=%H7R^$#V>1'^%
MQ&W(\APQ2[<$0X`6(.;:8,4'[)&[`UO)-8]XT0X#B<NPT#/;]+WPVQ3?$^T5
M"C3W'Y7>(1*@V)M8OCE9KH1B=-R$:'S3ZWD.$GE]2&>1MR([0)%(X_`&$()W
M]_#D@@SZ/IG,`>HT0KE*$/$DJJHR0!XF#VM.1L%#SI21P:.G&C`DSNN\.+D[
MLL#!%"^M?/:JNC;S->?[ND[1)<$#V)5'\5J.@VC"72)#3'O#Q]AO2)+`R=LJ
MVV52*M9HC1)8%)5GJK.@W.LR_\2'/\\I7I+FOORBND!BK\(J(HJ]?B@;=N1#
M+BG3U47+QAQ>MS'1$CE:%L$^D,3#(Q=')['EJORK"OTA940)%Z&DXE44/'R^
MHH,0^MJE*\6BZ,4N0.6!_V9C-`+@N0FH:ICOGGM<"J\M:!?PNRC88C-H^WGU
M@EZ71<<?LW[>I&!43KG3ZU+N!&WK>O.%M,VW4'UOB;ARCQXGL,WS\4XT\@)I
M))ABT@*CCL)P1R$]!Q,D)=?"B51.I(*DDMMTJ#V"&CJ=3K@3E$<A),\/HRLP
ME83X%PGZUR%FDC%'%%L`SK+R6TYZ#[^!OG*BO1/MP?>W88GZA)H3X#2,FX35
MV5S=HA=7:_-_Z*CMLG\:A>D^2S%,'HG`?C@9%>9-C7FV'?)[7O'9<MH+IGRF
M,T0:>IM`S4_S*\\BI?AU.>>*`A<\(LC+@":8L_"P3&&N3S4NN@*L"$+QUF-7
M\W1(1TT>=!Z#+,6F6*+(@'(H\KEIPC!OND@I1+`0(?A\=>&OB'%AFMI5I:`=
M?U(V&,BJ+FS]&`Q-!0QZEJM9>'""(;I8*&4%P]<V1H8I.KPB3H05P_`C6&@0
MAN6-1G'-\3(GASC(A;.#=?(B]X67X"LH55!D:^0@E?50,N]8MB]^^B;ZI2"`
M/):,R1=MPW19,PQ6ZOH&TVJ,<Q8//^/M+'X1NZQ-!42%&#;`BJ=6X`F/G`'!
M"DQ+J&*>L#>1O-$`D0<$/B-?&TB^.]@ZBC*PK27?2ZG!@F?1F?&D$)20;(!]
MNU5-5"L#P6K$Z&(.@^R6BND81B0/M@PI>N&KL':E[6)/@)HX5O41C,;,4PI=
MP<J]<%B]K7+N$L]R*,=*9@EW48G3PM(4](@*76%*'H%9PK&92517W8U(^92>
M9"F"&#?X#T:1^`7#JK(B@3#OYE(P_?64PK/`)BAP9FE`:LP(S/H(S*L1NJXF
ME$8E-D_1&'3MH%\XW]YA/!:K@_OE2!;ZI3(X$?FRPA)P\407FIS,FMTP\OSE
M>!>'3N1/]Q99S$V:9!ES&(>LF.$GH^VQ%Y9\HV>L>"8>47;AG$=.\A]RIRR<
MOO#<EK;"G/]9O8.K%I*_0CC@.$+7)`5?*Z[<6FV!L091T3KD:2`A>M>F2;9A
M6=,.XC0H;)@<S$AJ-_%?L4H#(@[FD,[3M$0P0,[ZS)D\>4=77#!0'"(XB3P7
M@'(H*()S%TU".+18Y#'E?Y^]*F=2<>6#F*;\[MQ;5O=B5$U(@&-&A12CPCBN
M^)S"<;BK(IC"\"1O)<IA(-NYY&T'&1%&%):1F#3\,[]`4NBK+).H9)RIIEBO
M?1>D?X6S2MDV6X1<B7F2*0MH4&T/%<J+9]`S7U2/%_#$K4D4SGD,##:8\_QJ
MX.F#`)GWAF'D0W(LEUA(']CQ8Q?#YDY&V?$:93_IN=+)PPSP?U+**7YCJ))Z
MQ$(/C'Q'3!Q3`&H*-(8,`.X/AD=!-0QO@\EX0393_3O<4'^,28=([F\"D=&/
M&9^1'"^H55)_P16FZ#.?4>.'XJY6A`#I5;`S,@,N+O!ZE"Q'+(,)Z6IGF*V0
M#(>@T.>%,#'%_S]CFP("&.P,$'^8(5W$3/X]3Z-L%`UEG;K\PT&2L!*_7CI'
MN]8OYW244BH&O8K%@5;9)`N_41.>_*VP2O6]05[2)[M>L&P;D("B.9!$+X]&
MG#R!IXN/%]]ZQ,5GU0MW83CC]Y_I;]$=)ER"7C=-(L$*F(E18@;+6<&RBWWV
M:O75OFARLPO;;=G=7G.SX7[B1FHOY497\NQ5^5*>KN3I2LI7DM4O/.I.HEV.
MU(Z?O@FD1XF`\1$FBD6-T6>TL)I+8"Y_J72O2KUTG=]<5]Z9.P3H3B!5"$DH
MA1PVW0#='DGQ%@%V[HZ"BTK7]#_SZ![K=F:E.\BN*/*/LZ(47KZ^VW,4;]/T
M^RBE`90Z4TI6%K70NP[#N+!G1'KP"M?!P=P9Y0)@J\W[SRYW$%.50N'"K?.&
MO9<:;C0H4RB*%`I.^(0RA4HNY)HR!5XF-$)/5)RAKX%GYE%EJ)R]-P7B9:W3
MEE0$+)0K2(U','L1!&20$:_@72A:TO<\LROEO;8PI?A,E*NS2_A[&MPI4U#W
MJ=3M&NX0YI[D.>2!J)(#6Y5]E\&ZN$8R>1@^@'`>(@M+F$P.0`6&PQQ&HXRV
M"5]09V&J,H)''B;T*7V(1[PZE?^]#,C25'Y8IT(92[+YE^;R4S"E83;_\ES^
M\CZ6YO,OR>9'$Z9)/G]]-G\Y,KL^GW\AFY\1Q9'D\U>/\[$)_5E>QU9DB"^I
M89#<2$R9!'S'W-%$K(42P'FGI78YY1;>T\8&IH!87FH7?A=_2"<9MLGIR;/5
M,>M=2GD?MT8@._,\5MK#?3*Y%WZF974#>=4`Y<H#:E@LCWJ",M4Z*#4JDFH$
MT5%$/"4M%_Q$,35_2*@P("^ZD>_E)38QCSF--R@1.'M5*1+8K$2`X%@L$EA5
M(K"X0URE6B:P>9'`6;DM`>9D-BP2D'A,;9G`L10)5.[>,54)3$IR;3]U`A59
M^Y(J!3:K$N"5!52,#$_RLF*YJ)C+H4HQ\9(JSLW*B[=+[)_KJ)FW>Y],$F:X
MR"(#N$\6SK*\*VGA;EBX+;*,6BQK2)AE4BT;UUDC%19D*[Z$UXVC65'W$.7E
MMZ+1=M%/I$$=A+17YFUMR]TO6!+#`M]4KA^4A0_9MBOM?.JJ(A9J(LI5\[``
M0X#%RCT6*B0XQ&5XI1@.Q6O.7C6NF#@(N4E3-I@AK[EBTH;H@2"LGG8KYA&I
M<NI%#("6JA/*)0\ERZG-63-W8'%!ALPQ2H?S.QRA,0Q+_9@72TY``PPI`8N7
M)^1S$]A]H%2B<A'LXJ:J2AQM![?!KUQI.]52"C!HP'3/6!\T)E%E)WEU[=6%
M>$*RM@9YBCU;AA^'OOPXUI>$5+=2`81J/H0R.@*F>4,-C+D6OJ;08%&+H0CE
MN$(=%!%E!2)XWZA&9,&0I'.MLT^0F>5%(4\O"2&`2AZ>"H8JQU!S)_B%EHY!
MQNC*ZI^:`T'S%[-:L":#%P,M*0625+3C*EQ9*67DRI6S5Y7BY)K*E45NSL<T
M9.1>(CVY5,8B[^@4,OXAW-2GDI03C9Q*4DZD<BI).='>,Z>]V6Y*4@94DO(F
M;U$WQ(=)QY;U-UF;9KT'J5(`F[=A"F79RCI[51&TE$.1Z[H/U96E)W\YSKBF
MY!VH),>S_H[<A8T>@I(+1#@^.&M@3H'"HQI<)S5^9$`'M2V0;94T9(Z$DHU2
M]&HNO'E+#+1U^C2]<_T;<Y7[[%5AR9%W*)NG]^@47Z_T'VJFY:YKC%;:-CQ$
M3/XVJ8I(U/Q(%3_E"IYJ_0XZ_9;\LMK<=R$)UVP;GMXV=>OLU>:I]1G-MJ/\
M]$FY75U1&-1N4M53@[HZ6Q?SVGECXQR`W,?)!GS2$9*'G3<_8>X5WA*LB"VQ
MSP\=CEAZX#7Y\34.SDJ*?-,$>3D@+%+D-TR01T]XD;PA"AD3UOAT=250BR(F
MC:J+>&]<2EZ76N'FFW_#!F<A#-RKLBYAO8B/+;1`99?CETJ^/_,;UF:<\WQS
M]+2=,LX;Z5SNHW4NJT;GPBJ]C14FHG<6WBGEG]&=P.%E7'(#0Q,I7R6%/H^6
MT[R!-4G28Y8FNN"3:C/MOUHJ@=)$KAI;**6H%A3QC`^$13NG(`._!C@?C9<-
M4HJ:\%E>@Z3_]LOF=NN/3FB/IK1RL4'A$.9%!T6HC7TL%/1<*\]F\U$QNV,)
M(6$(I4HJ&Q'2V:LR*163#R1".GD[CHTH]TN5QF&I4C_1Y#.@R?NGD&2-6%Z:
M=RU;I1]KRH\Z$<U<`:+,!\P4/S^KM(3MO*_KF%`OY6MD/-H[M=<`Q?\$;+PX
MD'HUU"L?]2G?_%EVTU:52CWZPG79A?M<<^&6B`'$Q.G:'=6U>]*M(XNZAB+K
MG-;,P;U-?5:F/YGZC)\+/X!$?<?I"935[<4:D*5&/IKH84#<**H4GRQ!U:(Q
M/4MN6&XZ[TY-,Z'"X9Q%J%C)-_"J.;/]Y08AZ-7ZCLZ^+!`9=_FQ50T-[CBB
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MR.\#CKY.V:;^ERIJ^,B\4F:K*)NA;"4<.X9L`X=E,J]UE/U%Z>$4.L)2*-%3
M:(YS1<*T731OXDU?*/64S2\KDK#Q^^PVFD[#T3E619&BR;?#1D+Q;1*ISWBG
M[>CN>IXR`9%/9R(&)"8T(9>@UTRB<7ZQ>.40K$#*1>W[@!>'M`)MM/Y-MP'-
MZ$0619=1O/7P3;H16^DHHXSJ;RS'DX888I[Z7/B+!>;3<#:G2CT^Z387F&Q4
M'Z8@`E!Y#9R$IXR5@4MO&9*^<$TXC@!;#UAH%=U1DC/SAL,:MQ'*&S+5$9<I
M&/5#$OA_Q<DW(J\4>QA51G1A9CO\?[8=W#$6P0%CX6*'7-PYU?'@H7A04"\K
M^@W$9!`<[%&,.46H\P95+)V^&,4KR)JFK#+32O2ODJB8;5F`7#@\*7<]$SY7
M@7`:N!-,'I"HB\1S/ANQ%#NX8]FL-`BIG#P\FF/-&NXED.\I!QP[*U'QS1*4
MC[&@#E5@OJ4VVQ!FA7/`)AA^98"@((U)X>:2=81F9G3-8F2\KI-F@%(C`1;3
M(A.%[0-3UB_8JFP[%&.O4B&N<Q/RJ2!8\Y52N)D:Z*/Z-OHW0(Q,XL_;:!*6
MM)IKH+DP+QN4?H^IS&(<=%Z<..)\)<B2F,5+,(8R92.N\/2*$VC1O08BP",0
MXW@J&=VH5SY0F4>$Y5+X]+_GHYN\ZQ-CIW?A\C7X!$;8\WPRR_/"\^LCPCNB
M""LC#LBO+JX%RL]->!T,_Z+WW8.:==[JA,-`]`$#:Z@#U!T84A`^I3D.,T0O
M:]Y%?H`8&!#?,@M6E6-Y0]IG04=GKR2@*YGEW'4RQQ(\49%#L7[V//$,7(YQ
M#9&4L<A!%Y64M8I&62_Y/(0CGT_"RS'IU:RM7M8GK1:;Y?W)5>G+]!/%7K>O
MKPQZNM&S#4?1O;ZMF*[557Q#[2N&WW'\@:[V!WU_,WUE^P*D,"AD.XJXP:H>
M>3L,-2*0S\G%XIJ%"V1(*10K'"ZY`ECQC6SZ>>Y+N4YF(/_RS9C<W;.-=QS?
MN\NNE5DJCK_Q&;ME9;T&%B`<.'/X0'\->MZW-)C^_37[[XI#GE;H4)#V?ZGT
M_UK:=(9-)*/1;ZT_+WI?_OO7ENF>-]#P*SNOV4!N<O29ZT3J`G&%/297F!WK
MCG4#AV#]+U;_MB'&7J\\H14($>R=/DA;;_G;+PLV5\'-RT9'/U=CBXWT4$G;
M+A:>?$,Y%[X!L!)@P__5[?;[@\&22XN.9/SFI\;N9DJSHM]HYY:Z_F<5%K#1
MD3Z%')Y,?(L`6X[6UFROT8]?$-C.6T-]JSF[!7L[9+]](M?/U1^+R/6VYJAM
M3[=^-#(WWNK&6VW'8#\C[J[^:)1/W2=_-*HW@>3?:N8!J7YQ2LER8)LB9=O/
M/>&`EA@X9,P7RNEWKIS6'.FF%L=.7[AC'?X@9[X/U6,M(]W.0Q4XQTD\J[EK
MPH9?>BSXN]U9=74ZAV,Z;=7;,1LZ`D0=EIA/K+9E`.<;)?/K2;@O7OOX-[Y\
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M;W>I-_*PJ9:(GZUNS3R/*4&.$E:RVR2=*=3-6\;553%-C=`6B=R:*,9BTTDQ
M50W6D.:J78=!RO((\)58F#]KX=BIGT5U9VVY\1E+:J@=9X=9(5DRI&'U19YZ
MJ:\V_/P-9J+,LRRO^2H#76XGW>4SHK"#.&\YO!+VA2EQRX8<K9P2UZC&F*85
M%DC&!(+A,&7)AP*CF$R$A9[%/+B6&`/7/".OEJ=5`MRX=4SU'>&VPS@CC/E%
M`[[.0_'(%2M7];&-YR7K)$I)4-E%?$49,15&3%]B@&`01.F_J'+UZ=(DRA)3
MUYRO?WSN?9V&Z==%Z:(O2A=_8.L]PU9TSW,4TQEXBFL;?:5G^:ZMZ<":W>Y7
M_:OV^IUQ;FJ2Y-TO=LI'<R$R9W:5"FD:Z#KKFXK3[W45<]`=*&ZWXRLZF"%J
MS_!ZJM4YBE3('!,5!K[G!,B+(I4I@[>Q_!K&*X`;L<QV[+:*+(%EP)P#,\AF
M/)GQ[!7/P0JS/&6EW:)V]BP)'<CB-@Q&;9;5S?I+\#:?K(!!B:C7&_LW-D]D
M33U1/`35#J7PTE`DBK62>5HD8L$*E)\E&@BP9*EQ(CV2-_+!=)TA3WBF)#:>
M[';VBI68HQC`R8;MZF^I<I]A@_4+Y?V'6=?[:,:Z3/#%XQ`SN;`_!XEMJG%O
MES/'BM^*7Z%<HT137O1..5/MUB(8>3]'G)`C=0.AG^,J+*V/]Y`];U&4DYBQ
M=-P@>G#0X(A5BXPJ&:&LQRXR;=&A,!F/13)4/8:3:\!;F`TQFTFT92V^S5/8
M$(V87?:=\KG@<'_2:388;>(GW3+8'^OSN%FMU[+9HCK2%>_,0ME<37*IEC&H
M,AO[&,ZZ(">O>"/>SL,?@,:+^')*ND%\XQ?-^;<J'%;;&P.MU[,]4U/`OA@H
MH)E;B@L<4'$MSW5U7>O;@P'P/LU\_4ZQ+-/25:L`O#E(953T@S3&%M$@#H38
MV+*I]2CAV-#T<@`5ZKGI%'A8`\\N-8W?J>O0+FS3BX^#Q^H/("D-"]ZY*P6"
M@*Y@-<\U9E,D=Y"`Z/F::?N:HG5M6S$[MJJXJ@%&K.89OM:QNJYI_GBFJ[<=
MT[4X/CX%]#F;J)?#65(2+II;M53%#6AUQ8B7O!HW`:H_HX*L'@W.P-JRA7E"
M]%2E+KI<I'87SG@:OJ1"D1X@%4D!:\2^/E0AAZ,(LE*&=[5$K6S)H5'50JL*
M]$%,DL)>8+PO<U:NP'[_Y>*JM%=84NI_Q#M%W=.L@0(S**=IR,7==)(\A&*.
M".E<I0<7RKE8'4$5-L+(M[S\A3XJ3\%I7:=),`ICJ5Y6FJTS87K1;31E)81<
MAP7M#A.^<40.I?WB$*/*P(?SEL_J+B@UO31Z=)$.RD@69\<G0E#AR4)_,,1O
MN]5+SPN*^T=R&P,IQ>/H9A(E[>7V>!=0-@95CQ\!$O`8=$"L//H`NGH03EJ?
MYY-)=!_$:U<91#@Z(:(RS7P55EHO;>T#.D;BUG_#%V/L1+ABV7]%0S8&.\RH
MSS?B[A,?9,/U.&DHQ#<<?8B$.)NP(PUH(C?3"-5S2_VY#?_1W)_9IN"?SL\E
M7:^!X^),E#FNKI1M<K;2S>3M!/%R4DD0T69.UG=H/_E#K$F"MTUH4&,)H](Y
M?Y`_+PYNX1!R[!/6\#XBKK!&U%+;K@F<RC+;AFK2+RVMK;O.FF+E,WD";2T&
M4;UN,6^]S#+@IA!_0Q8M,0UZ&K\L<8YV63EO^=@4+:EGN;!@/H*>^*7@B0L<
M,6AET5TT"=(%IE&""@</X6PA5I>5L\D5C%#R]Y58%N"PEK5EU5-G$^`8YVA+
MD.0=C*FE+(V3@34-HZVYUD+'E9QH"U`0L6TR9K'WX2JZ+[;V[1;9'MTR+-KC
MFZ^VV)8+K`9@/N((T[\`/?D\I"[L#LW5JV0*QJV/Q]^;@_D$^^G>TH@VD$__
M3+*_(CJK3WBN,_;!.6`8:35OZU@@1#Y2N/G`$48T@:&1!)FRT\+E%VJX"4%!
M',])@HC1LF>\H2*/03%K.A[F_3QP8T1\/OOE!_;+=HMW2^5=[_'YVAV*FJV\
M)2(67HMC9H,XT0$"%_RAA07:.)AVPP:/\E"*Y?<5">5P%9G!S4T:WF`Y&8=.
ML*F"DO-=(N2FKK<-RV,(SB+""^MLF\Q8APO-MC"C49I?7W\1SUB)F6[9;=,P
MI<<+;25A(@[]3F+XAMAML8^E^V9"N]0;@O->\1NZ:?R'S,]4S_41+%8E;+'I
MK/+O15/78@Y*/MX#W6U%.X=9\)U(%RF::#SO<TLED.7F#EPXU&P4MUDKA/)=
MPF*:MVZ?*W:)/*AVG]2!HK3+DMRJ[+(J1`N)F*-3LQ9^OP5TMKE:3OV4"O]3
MB757,2ISZ7'$ZZ;KR+9Y3&2IP5RVJSOS#.#-LAZU,"9CW(]'Z.#(+L=7^;C)
M)-Z^P>WV'<_IF;[B>5X?#.ZNI;B>[BH=R]9TO^]I=E?_\0QN?3L&-YT@DI1\
MAL_6Z"99,613)*F,>!X'H(+,1"@Q`DU,&"<L8L$JBY_N+VZ]X2_ZA5]KT?]X
M=IN&K&:7ILCR"4&@EN"(]]6O8XJK3AT2F#((FB=8R[PI#%D"I*&R)C-#ZDK`
MYMU1,)55-^?](JA?\W16]'19-FC^K-(Y[7??+]OMW'5?16@4D\Z<6^U"`R(C
M&?L3#=E4.F!D`^PBC$R`'O2QG3/<4TUEEAWUI,)5/BO_@[$`V>C!!1]:HX1T
MS]SVGDP$6ZQL@DXBF<'#162$N#8"17`@M4Q`:ZRE#*YI4JN<:11SG1W(,KB1
M6F^72*YN&=E-@-W:J?R>!VBXAL*=#3%N'AT26"Q/1B6&PH,)"5]02($%8^<?
MDC*L$?)4NKB%;!![P-F13$G.[0<ZZF3*4Q%XV3M&[L?4_"$?KTHNUDRLS]TI
M2U<1/Q-DP5M"U).X,,D";D,(P'`85@0;'@9<LQ(!(WHAV6@X*XIZ&.31,O'F
MAQ`,-SYH8^E%-:A?'\II*J:'==A&#Z;;9O6$ASDJV!^`FH`$(]Y5ZM_SN#S/
M%]53SN#J&1LYSV;4S0%T";AY56R13KDB#L9U(-X/!DF8-H,15&[3?`IQ4G"+
M[$MQK_^)70WEW)7/Y>Y4_>^L0P7SB62L^Q<N\`%].L4V=)OG>"R,:<R;TQ17
M!;OGL/7IKMPP(I))&SOR2#0+*LV0P&)C8.$E">M'4E;I\'5(I8R3DHT%TI1"
MI'+#F\KJ198-6Z7X=?X+H.^?+,]IFZ;7+@`**/Y+K8!XII'>]ERO;8*Z3,B;
M8]R5Y=K@`FW+!`55M?!8:.2$"+LA<13!Q%$QPW$C283>!^:'7O%0M4T],U2'
MP_D=G\V)7=F&$9]-^],;VVFKCM5V7.U`+<+X1$N2KV3@J9K6)@=0<;(9$#GK
M[T+MV_`QUK^-3&[&:-"1+&:J"O=QWDGE@<YC@AU%LIGL*!#SAIE[8Q#<(>-[
MS^<U7P7I#$B%/,P+#O]_#MZ793$Y*Q`,+J;RYD4!38G_2:.(.-E90!_Y<!)L
M!(=,(4WF-X*3@-IPC]0_G02\LYZ8R1K-*AE;_*5&[M)B8QS%2XVVU^2=BV]D
M]+'X.OGV,\:?L:Y[<&>HO]`,_>SDIZ/&4L`2Y]Q0YW.9\Q$HPH;"E^3C+*BY
M8/F^2GUP:#S[7WC<0]Z>,)BMN@UDFC*_339'[T"4=X(,F8_XFIM38`_^FWDQ
M20GELI9Z>S&%B:;L")3EJ6_P$O/@_;'*7J+@.IJ@1Y<Z`;)1CB4E8XS#;UF>
MB^@#1"P,(*9KQM)%PN^W`74F@N/"8\S0J8LG52R/)'+-ICYS_Q^<!Q=^J$.E
M(O[#9_"0!5CLI,UFY>`1D6"+$\RUG*=YYRWRML&!Q-AMDC98I-.PR9T!Y0R)
ME"6XN;S36Y*A-O,-J3EFC?A9VR!TP+)^3&M":>-D.&?RD1GR7*.C";)RN*,\
M[)M[+4F5O)N&LXC$'B7E('FS6>&C>]YA2?2X/'LE+X.QJ3IL"C*6!VE(DSH7
M#KB4@<O.DDW`K3]S[EV3:88X9A+?L/1<1"73+<LSK+AF$WYC\%/O*PD<NLMI
M*(Y3/F/NZ<=^I'-R0A7`\J=9YE6-0YL-KA5?HV:43SC!S7(=B^P#9!_T@_QM
M/'<X;ZHEC9KGW5"QTQKRSQSIP0@[Z\YHYE8VGY*6M=2GRSD47B_.HTJ$BY;A
M!!MX\<N1U=^.@S,5LA_PWB/,8?A7Z9)SF2O8H3PC&RFIR"(!.O]W`BNUT*7%
M)'W"9C['-$6^7?1DY+.#B",4TXW:K1M,/XQ)"MZP9DXLZ(JO9!W7F.C*R:<J
M0"I7F_7N`IJCO+VEW(V1@'2*I/!-9B+=36B1^4PQ2I>>L>D__$1IK>IH<R!N
MUF(Q'Q;$2+-`+W\CTG7(.42.:1:VD9^N=+0MMR-F#)I^`:M,(I9I,`0&$LV*
M+KN3!(-/.;7?!]&$^4R3%CV&7?#P7,47Q;-\QG#&71KB5]+E..=-\B2!3@UM
M,QD&:=/YY4,B8WWSZ!BD1_!6DRN&D4P;I;5HO]86)`%6#_)YD.*L!2(A,<EJ
MM:AVGCE9'Z5A++,:8L)M2-T'1YA;1L;+1;4[,7J_&&8*F4G@L7:<,:AC&!=)
M*:-60B1B=G%`\S6S_24Y,$<ZPB&7893F#%X>V"U)IOFL$!?(:EF":$S6>WB3
MB/LA_YIR@#DA)L3],$LM"C=P;F_NM:YDD^$Q75`C9&8PL+PSU@6<ON1Y::)3
MU&[*PYZ0@F>^?F=HEF%(#O^-82KCI)M0=)L)C$]1]E>7KC7^:VLN?UT==#J6
MVU&ZUL!0S$'?4#S7T)2>W7'UOM]WNK9]%)GX)614D]4.V(\X$B*&LF7BUE_A
M`ZD08-*DQ.RXS8K_Y=E)Z)2#ZT\BMHTM#('CS*E-/PF^8/A7<,.=E,C(^O=)
M&EQ-YG"YZ9__C$:T!/L\31AS^Q*.1A6V=I7R]U+SS*IC!QG"'&]\><>2\V*%
M0[V!!Q\M93[]+?@WS=DM)V+5Q,JSF6CCRVP4T=<9F'K=)KD=_@2_/]LD]WN7
MA]%)M5%Y`V7NT8/M@$8P2NA\08X3.BJY\HJJL$1YSRORY!N$(5;Y!RN)."M6
MY%[?&E\1"VQ$V-UX$HB>NI4T?X<G.Y!+L<A=+,!NDJ*_@GE5N5R1%_*)90=B
MZ4JVJ]JC@=?I>W:_HW3\CJF8/==3_*ZO*X.N,;!,2^U[_M*LXN5=0;?/\$A`
M*)2>74IN.RSKHV`.UTVH7S=3F136?%B:BBFRE4*Y`?39*Z'B8Q:JB*7S_+XI
M]QI0>8_<0#V?GE4D.TJ.][Q--]..*%)#=3P\V$B_I;>2QQEO.T,M^V$I+8G?
M=&3JK"6YW)*=H,ZB&5-6TWLPB$3L!7;(?!SYN\)0,/Y,/,P'![>+-%(@9W)7
M4<R+&?<\W';/BUO+>V=<*2UF5).^"5QI')(7#F<KE3+J.(P\+9/,D'(\C[PK
M6"^68X,'L5@5%T-"Z8CK\(5J8PRLHVB2O["%8G8)"4PX.VKH?LVL8C(^BN&H
MYZT_PQ;HVC0V^1HT4RPQPS33('>XX"`<\3<HG.0@8I8]=K$.A64E#Z$(TE!^
M9?F%B#B&)L'X2GB1LQ1K<$2$*M*<\;@4.JZ"%@4=\HPR05*8JX<YA65R(NW_
M!AZ<\,(S`0S^A/*96.?NVDT!?O%0PUDS)MV(]U94]<)Q[^>1</H%6`S;Y]=]
M6^T8?4=7+%/O*,"@!XK?<VU0Q&VW;^N>V5&7CLUXN4DIQI:J0*0@3'&8L(HX
MSV>;H)*#^"D<DJ._Q2PQ"4S,&8[AWRP@<GB;(@UYF)[5-\A9)O(^Q;P@=`F-
MQTPA1!]SH;AG(;(#49>+'(1'D*@\%C@FJH+(\-)0KK.%1>A;G$(.*N-PUEHU
MS+HVB:.A4W-'-N(?S/O3YS,(#G^B/(THSQBIS1Q@"0?(R=%&(MF#6E;A`\JD
M-)A\$+D8M,!G:0-)W'$5@GD;B3*XA912WH`TDP&E7Y:%W#&$DT_0DRE2!D;Y
MS"0FF8=BH-)LZ:^8IB)/&*G7UB@F]"W$S)QLZ=:*@2UD$N7FET3A[&=<"&)2
M"5QK/AB$9;"PF0]L;`/J2$7<*$<<+UHJVF'@;`U23-D3--<^'$]$S7=5#2UE
M?Z1<C:W1DMJD`HA)F2C.>=<DN=!<+LH6-=CMO,P\GYJ!>E(QO48X-?./V-2<
M9'X]&\\G@H,<^E9BDXG6OX06E)<LM2Z*27J'OZB+JEJ]CP*#:GD:5S%EE!PR
M02,G@F1M"X<NT,,#$[O<<,$&+,Q*B%*YATX<D)I_V//\'<0*63BC%NOZQ5()
MD48/?XYR)I&HY+@I-ISF&^83AQ#+WY(6>N^(5>4S@M#-45J1)FQE0MVO#)?B
MDI),H9P,6"003#.ANTN+%]8A6&-Y#XC"-"S-*)P5$YL(,,I0Q>87^92GF$PW
MD`$H[D6-215N"6QNM[+&&M3'8QB6=\+&#]&;`.20S!2D9S!=:!)5V;<D!G@)
M=/"@5X$-F557_9`_Z4;;T33>6,)INYHNH9;"YWRX&2OF6'6><FA23J.35REM
M,LP]8=EM&(H,Y779E*L[6JSI9W'J8'/J8'/J8/,C=;#9ZXV7'<>\L4=+ZOMQ
M8&7K=U$DT2;O,9H]1)JR]BS<R')EJRAY9HY2[D9N2[HTOY`@8.E>,*>R2"@!
MZKH#[9YW)62,I^0L%J8N\P'*2I_L?YT]3#$S"DAI+E)A6IU)`!O_/+Q%DL0;
M3AE.=\DHG)PO]S3GOD9NS%?*(OG8/.$XQOF2U&Y0C!8ESW2>$[6HO-9@D\]Z
MY!YN9B=1%0681F>O:O%??ET4K\J-$PO3MEGIL2B(87KP"#@RZC_,9YM[VD6:
M7FY,E:L=VCRZ2O%0=D1,"<XAY3@Z>Y5G!Y?1SH%9Z=L7MC9Z]Q_MVX=%YAEE
MMI-*5OCVY?A&#>'2A$U!M^(D!.6NC@=0A<ZJ@$!C3O2]YA)_+U]BJ7/U\C;*
MIPC9*4)VBI"=(F3/,T*V5SU-'O%W'$X3*G="%)).TQ(Z#<M2PW0B4FT^H&K#
M3&K0A89409J[9=E,WLJYXMKYI-8B"H'.A5P#.O!A?`3SYCU6SUP!%5&&WF&/
MA5=-H?A8*`]=3.LI<F>1T4B-D@C9S!<^39"5LC(*2F6EB='1L!7R7HKX(L;(
M)&<W)8NV6]=@,+-N3]^Y2T7D9A&[FQ=%L6QI5A?(:^OR==O<ZQ^)R!4?(5V4
M72,/8WFV]R2'Y'G0A:])A`R*5U"5;BVNSHJ.(#6-ODN"E952"SKE%;.%YZ$H
M,\G5KM)V6]2$DD=06%M-L;^S5P42\D@'_IOV0%.VE]<"?ZQ;),HXXM$KEHG[
M]XWW>6X%K-%S*Z:!!&1?$1)8`*+4E48BEP/?03XANR6-R#X>WI@+L=S)F15W
M(*]Q$%Y:E/,H;+$S&K-,,6D7N]31A0!2%!Z.X1R.X0X+%9E^!`>;]Q%`09LK
M#'QE=)_=1M,I4@;UZ)3"96E)*<P;[Z5A='<]3S,2ZT4<@M49LTK87-Y.HK%4
M#2Y\-"2Q:]^7.U5IH_5OPNN-_("*(N`I\=;#E\`(M[444Z,(6I1Q%SXEY'+,
MYV$X$585[>>H=C-@#0='\V$E-$!*-C69D]XR#&+RKB..(\#60QZ6'!7J^BV8
MRTE*I5A2&0+L[Z\X^4;DA7Z!2ICB+HABK#]@VV'.?LKFX7%AFG>>4UW&-$+Q
MH*!>8(]8]2?<>TR]0S4>*0.A)D<F]?VBF&16-!,5$8E\8&\I*LS?P'T1'&2F
MW?*O[Z.,CVW($8Z%6\P9.Y(\M7@TD3!NYE,*KMY1OX&`&O/(SJ,H'@'`Z0/N
M)9#O*0<<ZWPHA+<$Y:@*\_`R;:G--L0;NM"]06<(`Z3D>RV%?1`PK$^,PPE6
MW+2HUHWYK2BCB.T#Y1ZO,&';>6`E+V4JY'6.[9*;E%?MH*U`C2^02?QY&TW*
M`E2JM^4&%/\]%A#RP(_<;H_QE2!+XB*JB7Y5((*`:1'\!/+2%#P"47(XC-+A
M_`Y%#%7O8,<FTLU9;!Z?1GLD-XH+B;AL#:XT\.:>',?%]1'BE1QH`>O,(D70
M$7'I37@-"BZ]#VM,STMZQE6:=("Z`R-/G6\QG0A>,9GD.BZ0(*;I\"TS6ZBL
MF3&]JZ`C"B\*H,L@E=0MX23/POQYXAFX'.,:(@1R8(%]JLDXU62<:C*>3TU&
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MS9B4?O*/>1P67^EYGZ=O%`!9B?<RUC75;GN>*=!.IDB!>//<-DN(![F#H!6]
M[/*>IJ7P-Y.!HO5NZ:N:PV*]FRANQ0O3L3$6B\_6/0ZB[RX"/?BQASR_`3-'
MPIZYM5..6YJVX3&7#])LUW0/.EO5(+96U&YWELT@#X7ELUV.K9#>>/W.LE5K
MB[-L:H"N8#6?<]OG(=?/+-ZTY,T3.!CZU^7X4^YP8PM3_=0.QK@.;-6T!K;2
M[7<-Q71]5^G8GJYXAJFKO9[7[W<WFYBW!T_I:&E*/%U"L*7S`#?O)"AW6.8A
MV0!5?'):_;I!LL&ZK>N2-;M<`3P:K<[3"Q5M2")AE8XGU#K[Y\;SHL5O5OQD
M6Y^?7KW75Z^<2=^$9MVRXV?MW/,&P#?X1?G2B7LLQKIK4^P9.8E&KQ?P"K<2
M+E1,X^86;TQNCWQ!!X4T(H<<%,7???14T,-IZRW?V0I=OZ&)=$(81YC^`R#L
M8Q2?".Q`^-HR?3V9AW*Y?P.H2$#P_Q=./QX,EK!5=*34*3E?^O_S1;GXV.M_
M_/)K2]'"NX;ZV_O^`'Y0/+^HO7U:DM:[Z%+<">']U$A@\C^IXH=^IKE&6[/=
M1C^.DV]I,/W[:_;?ZCZW?56V"*-JM5WKA<-HN6W+L5XVC)K==G1[MS!NATT=
M"U/ZO+Z*8$_\:;-?U!Q^V["LMO9<2/RIX-J>T;8,X\<`5FN;MM6V//7'`-<S
MU;;IZ0?D8XL!O.7`[@R-52[(E6+R/Q4:\7>N$=>\8U.FM=,7[H.43E@[8>V$
MM5UA[:4;J%]HF"@5I;46HPF/4P/AFW&"DU<6A(OP>%8PCD]O(E8>:RJ`\N2V
M#?,P"M2Q8L7QO+;A:2><E"C%ULVV9A_&KCA>K*B6T]:U'3M-7H:2:H!$PGYA
MDW!?,O#Q;SPFU>&$MQ/>3GC;AK*ZD-99DQ>UJ^R<<A+0'QF^(6^KN;7,'5/3
M+<>V%=OOJXKIJCW%[0_ZBF</-+VCN_[`](]BPL:I>^JI>^JI>VJ#[JF+'*K,
M.LILY3*]"6*>6MH%"D/[/^#SD>3!2)?CO#7JYQPUO9R8=E!ZT?.LGFGV%!_X
MD6+JW8[B&9JC=%W;-QW@3IZ^-*5P96:<^,=O+53YE3$-7?UU@1G0EQGPYE]K
MT^+D-+AJFES#8@>IOJ%9E8*VKMA!_N6"/R1?1C[R50NND80YE[T+TILH5N`]
MOQ*3Y7\SB?XK<=$R,E=B7F#L$CL$Q%C[UKJ(A^>M-\A$J;26ZHN1Q[!'V/>_
MT(A<W%J>`M[];:%HK/<;%JO*CWP+Y6]_H;9\P#22%'@0%6Q2)Y&/R3T;N*IY
MGOU;ZS;Y!FPL;4N#S/B`96Q>09.V63="O+;49Q76@)]ZY]5"0)KTF;<_8J7=
ML/)#NSH!C5BUZ&^8IX(#JZ<"BI"7RDEC;*L-)6"!ZS3!;AQ8KY'.[Z@]A*@O
M!+0`T[L-@\GLMEU,7,NCF^P;7`,^&$?-^,ZV>4N9<_5Y8Q!0G4C3VM5$'MW3
MU(ZCNTJW[QJ*V;4TQ7=L3['L[L"Q'-_HJ]Y1:$BG)C&G)C&G)C$-^-(:SE%F
M,]@?GMK#2UQ*Z@W/?KL]K<?N:&;?,A1@*@YH/;V!TC']OF+;MFEJ9D\?6)L5
M4IS:YC_;MOF+A-N(%LODR[L624V+>KPGCNAGM"W2[0XZ@X$Q,!6[[VN*J?4Z
MBF]V7=#:NUW']X!V5?4H2/<T(>`T(>`T(>`)$P(6&=-:+E/+E)[@Q<QK.Z,L
M,77-^?K'YYY<X%G#GES?T+NJH?@##]B3#XS*'0PZ2L?J]SS#-KN^IWXUD#U9
MGF.:W@)P%<<)&)WH4PH!C?3?B_B*]<D0D/>9;`!;YQ(OD,^\:WN$>*#U>K9G
M:@I`.%!,4"L4UQQT%=?R7%?7M;X]P.85FO;ZG:)9FFMK!<R/@ZZ,H=]3T/BN
M:!;]$1ZT_OJ=81BF)1VTM.&%LT[N0K2M!F`R=,EE.@>.<)DW`N^$.+^</?<E
M^!YF_>^S-`"6`F(Z?;B`JYA]3&+$0II0XO"%J"`_/LQH)A*$[KE`.UZ))':%
MA"IW$%7UE^-2T?D17AX=+H]G.ZXKLXLEVZ\X7O':`#IR%Q+#VS'2`UP5S30M
M51H>OV3WU6N#;;`1%>S;(Z9Y#T"T5,^5R;U^\V40WQ>!$A_#-.%(.T(J-?`$
M+4<U)`Y?L_,*@9:/ECQ+QW=P#O(J0S-LUW(D\ES<>Y4TV6E>86.K(SPP4$/@
MU25R+#:\3A$1K<D^D=Y+1NOQ@>CAP:F>YJQ2.A8A*<.^R(&X7G*$E*H9R$8=
MTY!.=>G^*V"&LZ.^A)I=JS&4MKV.:,4(KFB_9D%3)5E%"$W5M:U5]"H!48:7
MMWW)OB3^D.+^H&;"P<\>KB;8[BX>]>%3%NPY0N#A>#7'EFVBYO`T95:\XQK\
MU&?.-4E`'2-.0*0JNJL:EM&$@:V";N&N=X/L]HI/"^H\_)&%HXMX('JF^2S0
M>)Q8T2V06YYJ.HY58@,-(5I4'RF!XD^<#]+#H._Q08SZAV[B>\NJ8WGC9<`P
MS>MR_'N2C++/Z`0[0H;^^IUN&YXG=;FJ;'K=M=Z:EWEW-]C`HW-TQUUU@5?Z
ML>HS_(X05F3@MFYJLO2JWWP9P%XX34,,.+*@O2_WH3L^*('YV*9JZ@6,*_9?
MN9+`H.`!_$^_B/^PK,PJ41PAY#HI8+;EJHXDI#<!JH(.UBF=LC%@A??),)A\
M";YSY;3#<D".D6\!XP*\F!(.FD!2;QL>L2FADO/26S0/:\T'D+S#,!R1W^X"
M;'V,%ER.NQ1!9U5K1TC1!FH2AN>JD@Q:"T@C58IY=HY=E=+(LU'6NIL#5/6H
ML@XZ<`%Z15K9\=*W";=8=SU;,V6WZ@H8EM.[[(W]E,^Q1"P^$XT:<&$#&1CU
MMV`C\);X]_HBB>'X"`'U%L-$QZ5=X]P3&Z\H9:PS"Y_DBU*_U)7E>*D>U!=+
M`PFN2@I,,V#JHE4[%]??L^C7.)K\_?4,[-E'2S+K=>LMVWYR$\:_=B=!!J3,
MAP_VOV.^*Y]KN9<FP*[G6?V!KRL]`$`Q;;NG=`8=N*2NX78\W1[T].Y71U7)
M\-.I%NEO;U?M7(+M\_SN+D@?\F?XQ7SX@IZ![>>M]GK=@=X=^(K7=73%[,`Q
M=#2GH]A:S],,I^_:MGO`GKQ^*V/XD*HFBBQJD4OX`#R?#^:HS5=@"0UZ7BVQ
MV3P/'-V$62*G%KZ._8@6OHZS>0M?ZW#-;'?^ZF?0S/:P3327S)1]B?U"_^1I
MS/1!T1349TG-E4]Q=NW*62.GIJ!5\='A26]%)J_QV_*4-NU1A<C[:WZVV"?"
M4.VVX;[PUIK>N6;N%L+GUW326$'TO[.$X&='S'K;,_6VZNWXL(^E#:%V[CK/
M@:P/R]U7$7IN/CT[4B_DD?GH?3S_&W!8++PLIM^G&H?G=Q/>:'K;4A_=>?:7
MYT#G;^SS'4%XP`9>IVZ6^^&Q.W_N)6@)V[,!]<=QT,DFC02?UE+PR39C6S>L
MMN?NN`'VH3HN/AD]Y]:.NY:^+,7C2=;F,[HV1ZFR'_UM>@DJ_HLU@)_1[7NC
MJRI.C]^GG7#TETL[MW8\LN-EB:HGV<C/ZK*X;MM]?%C@15Z6-YKW!(?KR0H_
M6>$G*WS;5OBZ8:$OF4GK;<=T#A;MVCF[?FRP]WS7\S%>&K-^25W5GRN[7M'_
M?8.<SO4)KB)=B.<'B<\I,6B[B;M?IV'Z=3$95E_('W4ZOJ.J`T?1W*Z'?4]=
MQ;<ZCD(O]WJVK?J=/!46#9;5B;"K(%R!']+KCS#]UWW]#G1Q%QN_+-_W.KB>
M]:D#!DCQ7H6`IH=>5/!@64\X8JUC6:7:5<!Z'@Z25.0/BG6.L%[#P"X/JBV0
M\DC`)-Q\I/:GE^,>=?CK%1WX_HQFMT4K0];)$(M`6#_YIV.F.\^`2X;INCMC
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M*GE6HN=4R7.JY#DZ9?6YWJ:7H.*_6`/X&=V^4R7/J9+G5,G3^+*<*GEJ'`VG
M2IZ3%7ZRPH_)"C]5\IPJ>:HJS:F2YU3)\]S8=;/,2,SVVV)JY&7<^D<0SX/T
M8<&):;1^3Z/Q.(J!PP[G*9L_<1$/SUMAWO6>&U2P4#+&I,@H;4W3\#Y*YMGD
M@6<)%VG$:9C-)Y1XS`?#1WQ$"OP:EM!4NZU;:HM5@>"*R3QM#:E"`5"1#/]:
M3#C>!XXPW3J'(9G/LED08U+CRD'V?(Q]&I[2/EE*I&MND/:Y[%YM^OFR_$Q3
M/5QNZ.[?O?ODT%)J8D6*+C_DJD!8F@KY6^O/B]Z7__ZU9;KG#5+!*SM?E2LI
MG%W%C:E+B'Q"['O;`GV?>;)2FNAEP>8JN'G9Z"#O#HW?*S;2"V;AEO.(#V.H
MK5:GY4J/#=R#]+/=91'M/<_"<K2V9GL',:@."+;SUE#?:L\BEW#[1*ZO2ZUY
M:42NMS5';7NZ]:.1N?%6-]YJ.P;[&7%W]4>C?.LI`<#G"K0))/_VH/4/N_")
M;?NY4T!D6QZVH_>U[4;U6,M(M_/0*5:QZUC%$Q%U6&(^L=H?*YQQ],QV78NR
MY4U`I$XA7\+A;0SJ\,V#/QR&638(PZL@&EW$4@<C/QYUD_@^3&<1O/!C,H-'
M'JC/6?(98PJWR604IL?8D^GU.UN59_5N#]K*Z.GZ1D_T?,8^'R3IQR0>!MDM
MK)Y%HY"YPQZ+M:^>KGF6^5W3;-/1'?C3U3WX4]=5QW8W[G\V<'W=MM2.TK/[
MIF+:AJ=XCNXJCNI9O;[>L3H=ZZN&W;\TFLSM$DZ?#OX&:`3U@;YZ=,.G+:.L
M:_9]S>CUE)XS,!33[?243K?;57QUT+%]1W--UV8H4Q%EG`PW`W7Y>/L+'N*[
M'$NDNW/,-)]\WA@Y^NMWAE=!SEI`RWCIA=>SBSB;I?.[,)Y]"&8857U`]_(3
M$&*XIL,0XKH+X%F]7F_@FQW%-WQ?,3M=5?%4>Z`X'=U2K:YN>SV/@4?3PC53
M435%DR!<OF6)-Y<?\N\28$G_2]>&$<OAH;->O[O2U`^<NZ[;[[Y.S3,T1S<?
M!Y8N>CS2H=F*;A[9H3T9.!O/3#NZ,[-,Q]`6P-([KF]UW*ZBJKV.8JI=7_$=
M756<KMGQ#0`,%("<C^"JBJ8KAM;\S/8%V0)/?8P`IO,SG@8H29A.D(4C;'47
MQME3U1!'U:SO`)UG&X^1%&[7[6H]4U?Z/;L+DL)QE([CF(IN=T&1T[JN;ZIX
MPM164;-<R[$D*5H+S%X`-G13,W<&L(X`HZIEVI;EJ<T@I@O]/AK"IZ%_DX8A
M4L(329@1+0H*RUX`17,]M^]T/*7?\8!H>QY(>:OC*\:@!S@:&*9F>;D*!""I
MQ%%%-]"ZG:X!9!"-9[?^'6L+=W"@+'X355/1O!5`R;M>"V":S8X&0$V<FJ=H
MUDH`BUVO`S"9IT=TA"9!"$<(_-19!:&\[34@?@X!K-'1@$B"4=45U2$-M-FV
MUX#XY39*CP="0T#H*?HJ,I5W+0%X!5_%,_Z#(E'E2YC>'1XVFWB,TYK=ILG\
MYA;3'P6K6;'O/<@#5UWL(6YJ7=72^JK2[P(PIM_3%;?;&2BZ;^M@`SJ^I9F%
M2>QYKJ+"_\SCD0=/`^H9R(.G`?@<Y,'3('P6\N!I(#X'>?`T"+<B#Z@)?7\\
M#K&?<7@1#T-J_7T<[-,A]ND@F>;L<^VVEX!(=;?'`1;SNUAH):A.#5CY5NM!
M&423213?'`<L-AW14EBDO4K`^*-1A,<53#XE#\%D]G`5/""U=N$FTA?^#1#P
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M`\7L]%W%,RU5L;N&[]JF[1C]3DFKS^]10^@DA/`G_^\\2&=A.GEXMJC0&4OA
MF%@/EHP#G%@Q>>B*,3!(.@LL9Q#N0$XW]CPWOS(5/#0$;9$BEM%.U@^&MU65
M_)G0"+HNU`4BV0A2F>4FJ!("&@?S&?"\#]$DS&9)G/_\RVVZ!9IY?"#?[MA=
M4QOT@%(ZIF)J5E?I`*4H`[=CF';/,C5?S6E&4TMJ2R/8-L#%9?P\,*%6];<&
M@.W:8[<D[&CH`]OR!YHR&%BV8MHZ@-?I6$K/L'JVW=4=SY<C..C<\A1CE=M@
M=6[9']-Q"I!L2RH\_C0;Q5L-#OC:)+(R6)M<[V_)LR!IC>O:S>_VMT06!\%W
M9)(LI>!+TH5?=-(0...NZ'K0L0W;!D+N=DU=,7LFB#JG9RB.T^_"T7JFUB_"
M(U>VVA/<?-E&2[*-P_HA##"M$N%]<F['2FB:GQ/81%=&`<W2G2Y1^C^&L\\!
M_*8'#]V'(\R_PK\OQU=I,IH/P9!B^O'V:;:J\-<F*38^5+7D;G@,A$>0WUE@
MRMU\H*W=Z9IJKV<J5E_M*::OJXK?&[A*W^QU@./[`TOMY[@R#4\W=6M["9V[
ME6-N35)%W^EV')!>?5,#<`T?P+4L7]$MN!UJQ^AV/$N68SKYY58YAVNY5TY&
M8$GCX+N+^!XN&/ZDZ.7R)2D^!1-30MGV::')K>EZW8ZE]S7%`_`5T[(=Q1L`
M?DS?=AS'[1M^1_]J,RLYOS+;`GD)G\E-*KAUXVBV%W:S$G&+_@6WKQI.Q_04
MU=%,1)NN>+9K*(:G^7U?!^:#&3HYL]'KW"X;@KD.6=Q'<1%W@TSV7B3I]FRH
MG6**:,RJ8\N;P%A&$[`EQJ+^O(V&MWQ\:S>(XV2&D?`HAKN\=4MS*1=JB@F4
MTYK^H<#$8\!X.B+^E4SF<`)I-'FZ#^_).$%-3'.?B!,)HB77"9/G&(OJ_P=,
M]B^)F-',/@2YMIV,>ADK7S%KU^`9U^JF>D\C#FYP]Z]>=[TV@OEH\;;*0?QH
MO.D<;UH=`W\1>-.-7>#-%/3V<O%F[@)O%L>;\3+O*;I@=\+?1'BKUJI[!-Z$
MJ2.FO/*QKJ4?2MVZX`W1T(]'O6@RGVVFRIN(-WVAV''1CJLIHW)]0^^JAN(/
M/,",/P"+=S#H*!VKW_,,V^SZG@HW47,Q4]QR7--T"R/N<9`U29[WL;#TAN1M
MYZ%XA/M^_&]!.KJDM).,!I!D%[R8I+(C^I*RJ8(H_5<PF6^DZ"]!J^3\^CH-
MTZ^+:%[48+O^P-9[AJWHF%1C.@-/<6VCK_0LW[4UW?)-MXMH!BS#Q5V7C+\S
M[)2/YF,X`QWY%FR(>["^1YV'/^`E%_'EE"SQ^,9G@]BCS0HFUV-U"Y6Y<)O-
MU^\4`V6Z7,[1'*0R*OI!&L/7&>!1X'O+E_515-7P\CJ`"O7<L0L\K(%GEU?T
M]S3)MD$P#6MHFUT\$7);6P?S)*C+:.6&Z%XO3T.*`71X*CRO%^@0NRW#<!$/
MTQ`0T`O9?P'<-)P&T:@7CL,T#4?][U.RGN+1Y>PV3/TL"V='R2Z`]2KPO"DQ
MW\<!5T80G3MSSASA.8-!;.JV;4F<0=KPPE$G=^%[^!;=2UV`)8KGP$,X[P2*
M[X3C)`W9<U^"[Z`J?9^E09*"#H!NO5EXEZ%#%WZ9)I0M=(%M/,/L&#%#XD/3
M-%6S=;5$$KM"0I4Y3$7H%O2I)"5_!%9@'N'=T>'N>)ZEF3*W6++]*DT)IRY#
MV!$3A/?ZG:-Y)>Y0O_<RA.^CX#J:D$8![&%^%XZT(SQ!0Z>>&YY\A#4[+X.6
M*TW%I3C"<T/=1U--T]1,B<O5[+U*F>PT,>'U&`\,@TP`I4R.Q88K33WX3?P4
M3D#7'WU)@"W]&<UNL<T,8`!,UZ<7,.^+TR"=ZH[N267ICP5OG2+C#X?)G-8=
MAM']ID&B/2$$N)*BJ[IMK=):%B&IV'E)G)3O`U=LCO`Z:P9`;%N.Z4BL:BD`
M"_;L4;,JS:[5.4K;7D>U*)7B69(>J5&N(H2>9:]6LR4@%GMHL-99&=Q@WD0+
M#7BIO0A0^E&*6%`H->!=EN;9Y9X:30!JRJQ$ZGT\@D_2>3B2I/@1(D73F72V
M++L)`UL%72/7U2#"S-EC=UWI%O8A42T'3/"UKJL:D,JHZ";9['+\>Y*,LL\@
M$H^1[X$5ZIB6+M%`9=/KR%\8Y-Q)<81GBG(+KK_K>*L(O0+'MMO,[`E6+$P$
MZM4U=[,^.KUPFL+;F9\-"X.+5E%'""5<4LMR9(MPQ?XK5Q+N,3:!A/_T_S,'
ME6Q")63D**P2Q1%"KN,!:Y9KJ[(!L@E0%73,@>;CV><9Z.^PPOMD&$Q`B><Z
M7">,P^/TGJ'/4(.WRDAH`DJ]I7G$.C<FJ%NF+4NCRJYWV$9R7T1-#-K3#-.4
MO-X;]HG\%&9AD`[Q'O2`A4^2*>IPQWNR)CJU#(RORZZ[%3`L/V?9XX<M;1^3
M6;DO60Q6LVZMZ`BZ#)9FT`,"9VDT!#4>>>$S43G1.M%50[:J'PW?$C<A)Z%C
MM+Q)8W$=U57U&A^AV'@9+EF\7X[1D,,^V&BG7*7A7;19*X`]'3.<LND:EB4I
MH6O!J"BAK,[[=Y!D:3!!+6=T%\414$2`[4".E]6!N@;4K:JZ=,+-@%E^ZZ4N
MWL<:F@'1[5C+.5T%@KJ(W\XUL>]9]&L<3?[^>@8F_:-U%.MUZZW<))<3\66\
MK+_Z($G%",7-BR?VY32RB@O[6+`DI(@$K7^&#Y_GT^DD"M-M<&.QUKI<#->S
M/:WG=Q2][UJ*Z>B^XF&Q>-?HJYJG:JZJ#5CR@>@X5+?A4F<>EK8DRR32R@`)
MXS#:5V).;259PP,&R9.GMZZ%YN!3%?9%]H`4QW-55=OQ5`5_].\YB^%F7Y*B
M!PY?.YA&LV#";]/3>$2Y_[VUNXD4(."^&MB\R[5`FY$LTXU!W:7S:7]-G5EJ
MEV8[LG=Q/TV=:P'>>5-G<J=ZIFIZ^H8`KZK(+&(4E^,_8.\;B`U#8UG=\/&J
M>]",K>J^YG8TQU,\W>PHIM;I@`CQ':7K&Y[N]4W?Q08CE$>KVKK5=!S&`G@2
MI^U.@@RL'GXWQ!CJ#3C!(1"0-XC@#'0)$#MSVQBV3=2OZ0CTHUK)].U^KVL,
M%-<;^(JI#UR@=TU3.IK1=X#YJ6IGP$IK^.23S:=[U&(&&P!N<KC+`&UVG*[G
M6?V!KRL]N,"*:=L]I3/H`(]W#;?CZ?:@IW>_FKQEFX9.BR4'2MM>!U8E_UN0
M`37MVN[9-DYA=H!X577@*)K;]12S:[F*;W4<A5[N]6Q;]3LY`NSSU?"O@F\I
M;BA/%R-IFW98V-O18S]5SP1)8M8"7P&@*:#/FA@P#^C<=9K@8SU1[*M0Q]-W
M7*>C4YV.;CB>8:B2C^=%U^DLP^K.RG0,5F6^NUJ!#<MTME:;LE5,-J175IHB
M1Y:>3VE*\_O\Z,H45G-]U$4I#:AF*ZP-55K;U.7ZP_J:E$>57.P+"M;#3G,E
M[GS<%1?[0@P57.B697EF*<R\IWJ+IU<B[`M1WNMWEFV6$GZ;%"(\*5M_7[`Y
ME,[LV99CU,3AEF7!;B%_>6]4CNG+I@6?2&QLM^G+>P/-KKO`*Y*7'YV8N#>(
M@%?;IBI'2U?F)3[59?ADN)KY"%$&.9YGR$4431R$6T[3VMLIPC$")@Z4I+4W
M*#%J9ME@^S7,T=I2JM*^X#.I1ZJNNH]*5'I"#LJ^`,0Q7)IG.W;S#)1MYV+L
M"U1*;P<A;YE/2\5X<GY"(X"WD)Z@+Z0G/"T2OVS?6PW$Z\T"\3L1?ON+#[((
M@FJYUH;)ZKN!=^?A0=)J;,^PC+5=9@[A'#5VYQS5F'/4L33+</0?RCFZB-6=
M.4>UE^T<W1(F&](K<XX:YO-UCC:YSX]VCFK/Q3FZDFJVPMK0.0HLW3%WZ!S=
M/134A<+SY&GDS\$YNGO$D',4E`/+U,UG[!S=/:*\U^^,2IW2GIRCNX?-$30@
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M]E'`\,OQ0!M]/!YH+5@-1RCRT=+T=S3"3\;`IUK9\!;V^??7M[/9]->W;[]]
M^W:>A</SF^3^;??BGZ_?P8LTS3$]$W2+XF?%4EEX0S."_O;].IV,HE_#[\#_
MAM'L0X@\L36*X%LLJ?G[Z[PN8Q+$'X.[T/\>9:_?L<J^;\F7VV2>!?'HR[=P
M`A+M/W/8,(@P?.%]B#]A"_[M;>U[WOWMK=@(!_EM">:_38NL>+;M69"R^6ML
MVJBC(/$7G^8/AJ`_%8^QH:3B,_$J:?&_O>4G][1C+#&\HSQ%IEZ0D8"_1"N!
M*)\.=3.])?L1CY;)[N=[M"OMBQ_H0'=^A,\3._4A[>=+[H?G9'JSH]7W?K0G
M3O8R#O2X.-D18*=2U7ALZ-$:H0?^9VB[0<^JBO:C8@>C,/KU?7@33/JT&\GP
M^#V-QN,H+D8,`\?8K?+2Y-3HL1V=VLJ.%$=U:L]//C>[D;MC6"O;JSS?LSV@
M@#ZZ$STQV>=W;,]4<]@E>C:8\7I41"Y8$N9KL%0K(/`AD'3GX6,PFZ?48$9\
M+-\!EH$4W02LX=;'\%LOG=_X&"QB+&_-A6B\LR\/4]B$Y("6-O$^@*U=1\DL
M&O:'QZ'G')K&V/SEET%C@RC-9I_"F_DDF"7I`Q!7FMP'D\OQ)>9(Q]$04RA'
M\^'L1&L'H[4CU<,>06NH;E^.B>9.S.UH"4[U7@C!=8'>@)HFGV?ST</5;9"%
M7[XE)[HZ&%V]%,6LAJYNTW"=67FBK&U2UG&2TNGHUAZ=?:1<8-71@0[,#B[[
M44^.#.LCU0M6G=P?<43]>6</H'=.DC0:!<(U.$CF\8A4S??1<`\Y)<=ZLK;I
MJOKS.]G/=X#(3^%T$@SIJR^W81I,'W[4,W0L^_F=X8?Y91S"_^`JIO\O3-?I
MYB_M\$YAM)=^MJ<PVLLY4<,UG>^>93J&]BP4VL^W23K[$J9W.)\)N;!LP1;S
M3D"WO8NR+$D?:&#=/HS8'UF=EJCH!R*;EWF*AG:T@:`EIRB^[D5I.)PE:0:,
M_7(\!OLGS<1(](>+.)NG./GB1SQ4TJ6/-82\ZF[R.-T/?XI2MHMSU')Z>?++
M13Q+P^_["8']L++XN#)LC@`].",*$W-5^$>U*O`KMB%1311YEN<<USW:;8U@
M<]X\O\["_\S1/+I'=]2"S*T\L-.[!@?;A)C@,<W=!S'IMJV2PN3:YHFT-B4M
M7E)]!8?Y\`68>!8,69.N!_F;,K5U;Z-PW/\>#N>X&Z[CG6A]?[2N.[:FGVA]
M;[3.Q\EC[MJ)UO=.ZYIFG6A]'[3^+Z#MJS3,"`$G&M\;C6NJY6B>>R+R71(Y
M;R135EJVYI(^47D#*C=TUSJI+;NG\H])W+^;3I*',,R=L2="WP6AJU)!-A*V
MI=N@L1BF>:24W$V(0%DCYD]1]E?GH>X$6<^XA8>W>Y91C%,,9J6R</'9SHY(
M=U0+>(_F.)9VI$&R7C@.TS0<\5;IDFNUXI7_?1[04&%X%*</9)?C3^%LGFZY
M,]4!CNG@[M-]PJP='\S:KF&&CW3KN&`F*:%;.X7YY/Q^?AI'E410D=@YB51<
MVD=/(2<G\M'0C'`-OUR:>9G.V,/2#'.QODB:>8%.S;W22M')]V3</O*(>%[%
MSH_H5,1XM.=Q;`EB!T[?.LQQG'P_S^*8;-,`I<2Q]&--8_^$AR(=!OV]OOW#
M,T*^K>KV<T+^9;SE5.0#(A^4<]-UCJR;WFK2;]"AXEG@_U2&]0Q2OP].&C\0
M+3R+HSE59?S`5_.X8D@[AOG4=[?Q6>A[.HMCHK^=PVRHMGXJ4MT.=[05?:<G
M9:CNJ?+T<4<#_]O(HX[3_>A<IO,TS'%\%P:PU_`=?OBWM^(O]G/\1>6W\AS%
MZA+\NU_ANP8K\1F#U478QYOMY"L`_;6RWBBZAW,O<(>_^SB_P^&W24$'37;/
M\%K_>UJV%\:@K<;+%JZ#J%AS\<=_>ROMO1;T?X7Q*$D74$>DR+Y[!/[^#%`/
MFQTA`@DNOKUMHO%C$G\5&:A?<U9;C];Z9QN@N3O/9@E`7;^L^+;!0OD@WMJ%
MQ+=+%F(<"/[Q_P%02P,$%`````@`,$!90\`9F@(+"P``Y)```!4`'`!O9V5N
M+3(P,3,P.3,P7V-A;"YX;6Q55`D``YQ=:E*<76I2=7@+``$$)0X```0Y`0``
M[5UM;]LX$OZ^P/X'G1<X[`'GMZ3;VP3-+O):&,C5AN-NB_M2,!)M$Y5)+RDE
M]OWZ&\JR9=FB1-E2*'GO2],H?'F>T9`SY`S%#[\O9J[U@KD@C%XUNJU.P\+4
M9@ZADZO&YZ?F]=-MK]?X_;<??_CPMV;3&@ZM.T8I=EV\M+[:V,4<>=@:H06C
M;+:T;I%K^R[RH#7KD=#OSTC@?UKR7\>"1U]OAH_66:MK65//FU^VVZ^OKRW.
MG763+9O-VE:SN>[NCQ6P2^M]ZPRP;?UER'SJ7%KOMA[=<KSJV`%(E]99IWO>
M['::9^]&G<YE]]UEY_U_MDNS^9*3R=2S?K;_`84[OS1E#6O8&K:V./[=>F)4
M0.G9'-&E=>VZUE#6$M80"\Q?L-,*&W5#NA9(E(JKQA;#Q3-W6XQ/VM#->7M=
ML/'C#]:J\.5"D%B%U_-U\6[[Z[\?G^PIGJ$FH<)#U(Y5E(TE5>U>7%RT@[^N
M2@MR*8)6'ID=2$D#H*4L(7]KKHLUY:-F]ZQYWFTMA-/X37;X@3,7#_'8"C!<
M>LLYOFH(,IN[N!$^FW(\OFJP"::!Y#L7YQU9_Z<[9OLS3(&J<T\]XBU[=,SX
M+$#=L&2[GX>]#7S&$;1`;!'HCA<J8EL6:Z>VU#X6YQ!J?GOR0-ED'_WQ`Z'P
M=@AR!TP0V<6MBX0@8X*=?+`UVWQ+`@/$<4[AYVC8FV*/V,@MGE(/YK(9/AAX
M6+UP6+=(3!]<]BIZU"$<V][!"/=;*A_L<<J0W%QQ*G!'A.TRX7-\@P01_?&`
MPTP-DX!4O&O'"100N8=/*OG;+Y#3$YE0&#@VHMZU;8,1],!2#YA+;()%H>P.
MZ*E(GAZSO]](OT&:7DQ%T$/RT_N%_"]T:3.`_-^\TVU1G9;.OMC7FZ.+`IE]
M09R#1HDG?S9#?-D?AP^N;8^\@(4^E$YFNR5P*/1]I#?Z!F]`]'U/^I?2]2_Z
M+<3:+G*<3!GW/,QGGYB'Q0`MT;.+BQTF^CT4R.N645B3>03ZDOV&W8[8TQ1L
MY92Y#N:%LCRXOT(YSV;$DSZ"N*8P*07V!M:B1=NUW/T4J:_^L\!_^M#W_0LN
M>@;1:[P8]S`8#2.V<>PW_IWH\PD">QAT!L(5X#`X*]-"G6U/:6M5$%6.R(SP
MPKMQP43ED\8;XBI;D#>^(!0+<8>%S<D\A)K@<Q8NJ@-Z+EL8J<YHX0+0[*T:
MI-</WI;\IM>RA1`-/5@Z;GFJ0^Q"$9B_!4"69BKP9<%R!;4*5XEC851<3"-I
M[PM3H6+`E"VRT#<MT>:D]&".7+&O.K.?TB=)Z:"/P$&_P\]>\98@N?6R23TR
M.BF-4W+C95-*<;M+'($Y>RU=67=<].+U5=E!2,V.`G0R/A>C"&4Q=>3VV>JI
M[.OX.,NJW_9.QR6BT0R?!`@``T@GUJ\K`V2,Q]]TV&T0!1LC\1R$PGS1G"`T
M;TL-:&/7$^LG@4XT.]TP(O93^/A;Z$]MMA&H`T^XCYU'@IZ)"PBQN/6YW`Y?
M=^^B9^Q>-0YIH6V0X1#;F+Q(B)^PIT<IL8H1#IMU\P`1IT=OT9QXR%7!5Y0V
M@EP([`D5T-4?S>'*4(-8&1,H96!*&@GX<?^G#ZKH!F;#NP479PEFXP_D^EB!
M7J^N$59@`<,81BJ!W6)FL,:V(=>S7+KB9%0RP>,.CS'T[@PQ&&$_`[^BL`G<
M/2J=!L:7,`,KT,:*F,"X9>A@P`4*N]J@%G+@R0!2(N[,:H:YI.M(1:S[@(>Z
MFCF=))4TA'@.9CD,UL*;[WM3S'7LD4Y-,XS8'*:[Y<"5&W3@<(/ZSJ6WJQZS
MJ55,<!ABX7%BRZV@(VQNWE;,,/40H=BY1YP"$`'.KC_S@UTPF/>)353O3*.B
M"3Z;_9!/C-X@^OV1(2HGU&W+JV"D5=4()UT;DF8UME:RUSP.'7%[W2#\-[:,
MW<^L#$NTA8R@R]::!!:SZ_ICSF9['OVZ,Z9RIBW&`7*0W?N^TVE8KUAFL`:_
MPV]S3A@'+E>-LX;E"P#'YJL%3579I4^!$=E_U8WLCD7:YJPY44;DNR=$/K>]
MB,1P=D)B2-]<B3B?GQ#G^)(DXOCNA#AJ.:D1]5_J0UUWL;8MC:1%T89\MT;C
M^1#R2:4B\C4R:.JE;=*,IK4A'HV`7T]-#GIN=22`BU,30-;.7S0&.J=&7;59
M&%&ND2NG-\LE[B-%?&ODO^CQW=^#C\C6R)'1(ZL,GT6<:^3!Z''6V>:)Z!^R
M"*]>`#U^;,LDR/"4GI&`E8#^/S+FB"?0$66$*E[*2&AM958"J8%C(4\!NR.T
M"-<<-YB"FBHC;%IU3;#ZR)D0`\[4V+=+F`FI2=U\!!`/,*^L$I!\F"+Z<WER
M'D:$N,%CQO&J'$@5B_N%QQ',%C#T^+('2B[`*[2A)N@]X)OTJ(<Y%NH(77D]
MFI.@KJZJ2IM!OA);"$6).%[*5.!7!&ER*_EEJIBBN`GLG[`7J;P"<+R,$91@
MNE8#4`XG"25=*]3E3:#OKZ&$(%1RWB]G%&VF7B25-()8;OCMOW(5:D5I0Z%<
M#/ZTW)2_@P6LRX)`3+INI]<QPR)8>ZO49/-G(^%)'-C@CV#(.'+E%IDS(Y0(
M3[[[EXQI1+.RT256@A,77UNMWTTM@UL9[/96$(K05;/:+-_`S=V66N(,7\O`
M[QL++L4-J66,)='YB\</2Y1O+;<L-466L.!2;%I6?&K*]+QWP\W)"Z%:1I]R
M<M]9KBKB3:?TOC6WQ13AIU.2A'()4LLXE'+!NI-6E+9VJ66RB19QW25%+7-.
M4E;_VS*(^>6US)W2))J@$8I\4-WIS%"89_]3AR:.LLT8]\+/R/3'\@BU/$<L
MDU@&',^(OWE7N\?;,NM5Y\C;`(,&.*!5'".![_#JIRHXE*<),X>QYJ`L9/VM
MG^T7H:"45L-0!"0FQA[5R9M2!T@.::Q:O*,,V-PLMZI6@]-._H\VH=UZU6"S
MSM?-HX#;=:K!(LS(78LX,3-7FYY68T:/>WX!<X_OV*MJ0DPH:"C2)\T,.&TO
M!'R)F^5G@<'&A#DJ=!)^ZU.M>CD:J!"_U9[$$?R2&J@0OXV#>BB_I`;^'XE6
M'B`-/[<5?HQKQ$9H\85X4YGD!C)\8#SZ--?VQ[L4A`YNSB3W$;NVP5GE6'F4
M+(.M1@.&#@?;&#OKO>YU2K5<;J@(I=0PS:`GA"_ONP@^(K=.H-7@D5S/-)LA
M>`$KY>F/-8[+:E6M$J?X(3U]HWQX>V8R!2*$L8_#*5,'5.7-'-_.,;,7,F_O
M?R)-/ODVPO:4,I=-EK`NPT(\8!QFBT<C=O7!MJSO4N^`+[IUHSM\AVS/Q**]
M.1RN6H9_2Q)0HL==RR,;)0DH<7;?".BL1H&B_&O*G2\1:-CW6AY\*4XP>X[H
M<2=A:BF/%+=!<;RWZK'EX]3CX#5H)*U?_SK2REX316*IT='@<N9>C75(9*EJ
M=)HX_^Y@THC3V?E0I+75<XRE["[N.#K)N:3U]V4R)%#X>JR6']\Y3GLTL@)J
MF6)RG%12(^^US*XZ3AZ9/DV=TJR.$T52Z+&67ZD[5@PZ&0Z*@PTG;8\S,@L4
MV=A_,9'HI2G4-(V[I(&5GC)5R^\,%2VJO8RDXU+`JY(N:OB#)0?<&VT0XP&W
M/YM$>]3%S94#7CGY9MZN7`%LM1%:[#)DD[JG?[6Q090'7TUL%'/.*X9-:H'6
MK<%O#O`-+_*M$+>;_#?O5@B]YK6YM4.\N>NV0LB/O8_V=*B$]XQ6B%#*M:^U
M0%D]B2JN8:T0PN1+52L$,.=-J!5"KK[35`GR0UMV_@SS!?SR/U!+`P04````
M"``P0%E#JDA(9&H;```%G`$`%0`<`&]G96XM,C`Q,S`Y,S!?9&5F+GAM;%54
M"0`#G%UJ4IQ=:E)U>`L``00E#@``!#D!``#M75MOXSB6?A]@_H,W`RQF@4WE
M4M6]6X6N&3BW1K"I.)NXJAKSTE`DVN:V++I(*8G[U^^A))N235&43)FTDY?N
ME,S+^0YOY\;#7_[Y,@U[3X@R3*+/!R?OC@]Z*/))@*/QYX.O#X?]A_/KZX-_
M_N.O?_GEWPX/>_?WO0L212@,T;SWFX]"1+T8]8;>"XG(=-Z[0",<X1@:Z]W@
MZ(]'CZ'_[/'_!CWX]-O9_4WO]-U)KS>)X]FGHZ/GY^=WE`:+%M_Y9'K4.SQ<
M]/8MH^M3[^=WIT!:X9=[DD3!I]Z'PJ=SBKRTXP`H^M0[/3YY?WAR?'CZ87A\
M_.GDPZ?CG_]5+$UF<XK'D[CW=_\_H/#Q3X>\1N_^W?V[`L1_[SV0B$'IZ<R+
MYKU^&/;N>2W6NT<,T2<4O,L;#7.X/6!HQ#X?%!"^/-+P':'C(^CF_=&BX,%?
M_]++"G]Z8;A4X?G]HOC)T6]?;A[\"9IZASABL1?YI8J\,5G5DX\?/QZEOQ9+
M`QU!O"Q>).NGH^S'K#3#GUC:YPWQ4YYJP.E5EN#_.EP4.^2?#D].#]^?O'MA
MP<$_>(>_4!*B>S3JI11_BN<S]/F`X>DL1`?YMPE%H\\'9(RB=)R./[X_YO7_
M=D'\9(HB8$QP&<4XGE]'(T*G*=4'/=[NU_OK)?F$>M`"]EDZT^)\UA[Q8D?*
MEHXVI?,>:O[^$,/4Y'T,1E<X@K'$7GA'6+I>SD./,3S"*&A&MF:;VP1PYU'4
MD/D-&HXG*,:^%YJ'=`T;WQ2U)CRO;IRL<X]-KD+RS*ZC`%/DQZTI7&^I>V(W
MFPSRYLQ-@0O,_)"PA*(SCV$V&-U1V-=A$^`3KQ\$Z03TPO:;2O/V#6)ZP.,(
M%H[O17'?]^'(C.%8OR,A]C%B1M&UZ,DDSICX?YQQ*8,?U"AB:0_RKY<O_$_H
MTB=`\I]-MUM3G7:.WNSP-NC"(++O'J4PH]A#,IUZ=#X8Y1_Z?HR?X(1N"Z>V
MW0XP&!T/=:-;&`$V2&(NC7(]P?0HE-HVN4XFA,8QHM-;$B-VY\V]QQ"972;Z
M/1C$=4XB4.!B#'WQ?O-NA^1A`F?EA(0!HD91MN[/*.;I%,=<1F#]"#:E]+P!
MQ=7TN=:X'Y/S-7EDZ$<"?5\^(=,[B%[C9L3#=#4,R5*P7\IW;$#''IR':6?`
M7`8"0Y`=+5%0E)0*6H&H+,`,T4M\%L(1U8P;6Z2K:T:>)0Q'B+$+Q'R*9SFI
M$IG3.*M:]-PU,Y3"J'$&:/;F!NC%A^V"7_;:-1/$T@/5L2"IWJ,0BL#^S8!D
M?DRELBR<7&DMXU-B4S(<9].0G_?&II`98KIF62Z;=GCF*'JP!\[L4-?VT_DF
MR07T(0CH%^@Q-G\2R%OO&M0-B<:=89(WWC4DA=C=X0ILV&OGDW5%1#<_7RL[
MR*%YU-=%5^']6?B5N-OGIQ2T%X8'O;SA(H1E+1S%1P&>'N5ECGB%#NF!KN#$
M@?/F,$`C+PGC9M2M5]\.K63JX:@UJ5GM+BE->SB<HNDCH@W)+%7MD,8)-$']
MY!$=+CG3C%)9`SF]P=(/SMW@)9IAD:$HX';G["MO:G,'9=;M4;G?[FC1]#HZ
M2579A62/Q-Q?:(^`=7=@VBUT#(=`J;>0QP$0*EUHZ?(8>>PQ72,).QQ[WNR(
M'W1'*(S9XDMZ]!T>G^2._[_EGW_O!_^7L.S0'1)AA;KS<'`=G7LS''MA+C=>
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MX$%4Y3LL3`SI@=^ZF?8CP)#_;DR>0$;#&?/ACU6>PZ??,['\(M?-2E2O_6R$
MF[]2/`(1\0'YL,+X]@`;Y9=<YUIGFJ*TC=FYNJE?1[D+8>DYAPGH^Q3&[@9[
MCSA,::Z8N"T;<PLW2&D(#K['L.J,U*KJ!J8+-$*4HN`>/:&H4J*IK^<&&GXJ
M1]!;DPE8K.,&BJ5DG^M#-9))@P;<P`=R_0STO<44RJ/N8.4/0-VG?<90K#]\
M6HW9P1TC"C(B5VTKT12*V*$QF_OS[W#2H`OR7"5P2`IV?T[?H+$79J=Q_P6O
M3@E9"1L\+)Q3,-M`F`RJA%!921L4WZ)89E"0J#$50!HTX#:^FIVU14,.X14J
M:LOQE#7@-KYVXZEJR"&\$H-?,YRR!MS&UVX\7;.,EHRYU5`*98QHG0L3SF!T
M#].;8C]&06KM`9U[A.`8EZKL&K5L\'`14)2'&PW)T'OYCN,)MR+`2`-Q(OBH
M&)Y4P>[6S=G$/B1]_T>"*8()#U,\GM^%/*`O"K@A=L:+U*#5:,`*/DI\A`)V
M1<FT$+7.;795@!0U;"/@9BQ^_S<-DUL86#5PR.O91G,/VE4V>0:CXG4)#4"5
M55W")#:YU,"O+0*W;\\&^B*%I?"W"G35Y6U0WVAG=VC?7OKP;W"$KN'/JLDD
M*6B5WJ%BA:\4LD)G,IN%*0U>N'#+%8)L:H1&W=I&9+`A\B<1"<EXWO=]Q-@5
M0GFH@]CCLR#&NKM:,EG-8.M+M"*8I4_+N#WJ+XC(0ZN:1HGEM4>P9W8<`+$@
MG)CG5(]0^%^:A.7GX^.#WHQB0G$\_WQP>M!+&#"%S+*@ECUFZK*?^J`/P:[_
M>O7L4GIZ!:/^^]4SJNK(%SSZ^.IY)#/>+_ES<OS&GP:.-<&W$V?Y9BJPJ<@C
MJ?-BR8Q3=R>1269L&%DEV/6ZYHY^2);@T.FKX%#[$"K!J?>OAU,ZAFK!F`^O
M@C'2PU(O[EZPZB?G6%45?K><"ZI0.2'\N;O1-H_F48LLLI@S,<#N*@JF^5"*
M[!(,<%<+,,T`O:"I)6?>NRNZ=;5$U.&H@C.O9_-8"^X43+`EB*U=C5T]'2J"
MOCC0]<-#G`CN3O?VT4C%P=7SR8GQ=5=\-,^/-9^Q8(.[PJ(9-B@<>X()[HF!
MAN="Z]@0P2-W3?GFUTM%A()@AKN&^FXW4XU@`,$D=V5O,TQJ$B4LN.*N0-X^
MBE2VU^C$8@DU9>=VEX9<:1*!++BR<]M,0P?$2MRG$%9W3CAKZA7NQ,,C^+=S
M4EWSB:,=`"ZX8DG,2S-%R7A1'?Y4\O2N!!TM\!P?YTI=E@_H$[>5HN#S04S3
M6XKY1Q+%Z"6^S.)Y/A\P-,ZV7B<GAQY#VDPAX;YTU\&R$7KE>230N[NQ;H1>
M*;D)].YNBWKHFV4G$;C=U6\WP;V6:T8`=E><U-SS=0,X!61WM2W],=[,-RAX
M84G'DB;B4W*D%$>\L."N&7AWP8C;,.2X;)8OW@,78/5.:C<RSDER\>UF@I:.
MJ?G]=&\2QNS7)?VWJQB:,Z\^IU-5NJ:W&)*F'M!%(N,==X&:=.G"!FH?T9M%
MPXSL*]U0F@I`>RO&;D^R:_&ZI34*6[Q0:2/7K4;(T7E":?65_"8M&#G894,?
M!<M'_91\KQ*:##9L':-,T#+4J)4LN"3R@5R:O=&#V1]G\R'T*1'1=6HX@8!3
M(]7"=&KL/(+&JJ6IW+0Z^2%=R`:Y0D.?BQWC[/Q63WR-BN[A44XCK:I[B,F8
M^27QN,R*H#<\GF2107%"(X4)1EW#:FY'[C[(GVICB#XI4J-65C#"U=N$\X+?
M$N=65!#Y8HH?$ZC-8_6J&"@5.5JV9!3%_Z!Y:A3&B"II+)4S2L$WD+4)91QS
M?CG@S`N7<7TS+YJKZ-*H;2=/3TJ+]'J#6J+6J6DM6PF,_MK9+MU-=&MMR_1A
M7G=86@8,2.M[:%KID.%M-V#[-M-MLZM2^K5NO;+&"I4XX7)DXQ;64UD4<#E,
ML=LITL@J9CUNT1J;M$0<EY-,;6%)Z<BVUA-+U7H2S!HE2^%$*O.>=0>:1<;H
M6(%R_IRZX#*5^8`;V'"5<Z)H4[$^)]1N8O.0G?`DZR0-J3<2KX5.JK1)^QG2
M]":WOKE6?WGOV&3OC@6[,OF;V(-%>$^-=;9I'D4K;FY^Y7;M0K+\:RXH\GM4
M<"+^N7BO>;M6K,OI+"1SA!Y`Y<,^DE^H[H<I!9CG`A7D9@'\YX3%E8[DKGJQ
M]-X5F2(1&9/3JG!`J6HXA$#IGE'7V0L4ECRPW,P"6RJ_(7(!VV1(TMO%^::@
MM"'KU+1B$?<G*$A"T.7,K'=EC&PG?5GA&@JAS?&O*$+4"[EQ)9C""<52&?`)
MY</*U%Z%1FWL?*[_+86%=G0VEL3^;I;,'OI/MCDHM4FJW8PQ;R"IK.074QVH
M]O4-+:7+).A=4;.T1*%R6BD-F<-E7UAKY`U/6>N>+_UH]BZ%+HT5LSM!\G(M
MW)G8\]>@B5=$/BU6WS+16_9NR[-'`VD,EK*\E>BFT(MNO:DJ&K54Q":-2D5Y
MI=".T&E)@W_3=\UI@@43\=E<%,G3LJ5+>Y`>(2Q/'@\;.KN.,D2-U,C->MI%
MCOV:7=3+(?Q*JU^K[:*GW>?8=\3]$2CH/R$N:*0_7L#!<^5AFN=PV0(WZZFP
MQNG'>HR/%1B_(0:8%N$A:5'EY#3=E1'YI?5`9T1P<<9/Y9@SE'Z67]#OH!<[
M*1"D3_%D1*8_YN.U>(FG<GMOWI"9MQ^?R7!"$N9%P?`9A:`\_DA`U[E.'?>@
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MY<L,9[D8N)M5&HQ<5?1-K7),_C3,J%J!8Q<<FH9X43K`=\$;V5"UKMP.K/L5
M#2N5$M'`ODJIY^);DV;6\*SKDO81*9Q[NH!VQ:TG$9>6"VQ5JMD%DU4MGH+4
M8MWX9`1/4?YK:I"Q<N-O0F@<(SJ]);!;+])7=N:KNT"/\77$0#1*0R>FT#G^
M,VU>>DU%KXZ==/Y%HJX\'P%A266&[LKB]FE?/-)Y#\=U>G65N\AYG`!,'RTT
MR@;LX_OBQ=Q6.N?BB!:>4@4K]*</CQ+*>(+4T0AD9\H6>63G0&=">3I0I5;=
MJ`DCZN`=)4'BQYIT:E6Q>V$QW1F'L#/RV:%W[U!2Q<Z%HP(9=0;0BL+6Z5[-
M`Z@B>UG6":J5MW*K2ENE_)9$9U[TQPWQ(KYA%$6!.ABJJK;U.9VU7([9ELX_
MZXI#]:.<RH4NOU0D8\4>6[(:L$AK->R"UJ6/N5J*W05MK"U.M<1KWXUN`KFF
MMK4+!MBVPUP6_.V;7+4L6DH92'E8N1.7WW!(%?F.:Y4*Z\9E,V#;:7Y-;Y;8
ML"]E468QAL.3'Z3Y.3HD:0S:A(2`H,/(<-$YS*0I9HS0>7J>5RNEM77L6S3>
MK$WN6IOJU.VJTO8IWT$[68D<E8E&5M()6\%KM'!L23FN69?5<N/^*\6M62/7
M$-W5A%L#U541W56.6T.O4IM<S_*J.`UVP<CWIAXV5P_KY?NF]@T[*M)TBF,^
M:;G:!YCX:V\HXF^]=:<:B9;OR=P+XWF>S0"ZSW[HC\<4C6$/6/Q>):9OW)P1
M]V,M`<O/./@"@SE-IJUP2)HQ0_^"/WFK_2A*O/`+S'J87USISPF1$JU;UPRE
M6>M95V4NL3O"8CZ=>=BG%^:V1BG)C1NQ(?@6$G]DGH#(*SS3!7\QST\3S2A]
M\4U;>35(3<7[GT,1['OA0YP$\[N)Q^K"\-45NJ))%:"O*FZ&GN4ALWK&5%DL
MM*MU3)],K]>J8HBN-Q.B8R9$6X8J9U-,7&$H,QZ,KC!E,7^LGL5X[&5BS"UZ
MOJ#)N,^?3LV2X53/VU;M&$(`/=ZC<1+R*G/HA9(G+QR,!@L).O<$J8AOUH01
MNJ^CF*(7%4]72ACJM?40;W54;SR8ZH^8Q-B_]!5)3Z3E=C_=2157L,^S\/5!
M9D_E(LDV5EVN,PJN\"B>]*<E7;:.FE*=#BF#A=V8LD*=[B@C"6W.M%*ESFA[
M0#ZHK`UI*U?JC+;A!-.FI)7JV)!!;@AC)2'S;'[+Y0HT&(G/LHVD10/V\>6D
M*1T]JAH[C\"4;OK%>^$F#F'N&HSN*.:Y0K*CF,]OD<UE2,3714KE+'^/;)T8
M:]LP4DR"(3D'5IY1Y/D3->FKA<W0@D-`2OAE.8^;6#GFZ@M&BM*&J%&:Y=@E
MX%[=\^1TMFC')(+_33P:(QK.]>R2&K7,4`=+>!+.S[W0Y])_FM%JS8!XA:12
MEG9=,Y0F@XC?X>1"P+\051B$*DJ:N:H#YREW":8S1=S7Y@X7&2FJX@;IR3(&
MC$:(IRQ%/%7M;'&+O)HJ527CM''H2(<>4=`T#:"B<QU=@XAB23-4%(X9GFLW
M3WG]`_:B(2F_`G!%*%]#)$H3T$D);=V8<2RW*'[PX`"X@!W_"057E$SYO_E9
MFMH+*F["M&_'.(+E!@L]C7"\*9"FS76'YQX]H2B!97T.4P3F0_(8IKL0H<IS
MLG5;QI'D3^JF^4\6=ZM9[NZJHUQ9USRE"W[PYP%23N5]7B^??QV,="EOTI8I
M)""M93DNOT^P/^%YP+T(CO4H(FDD`8Y@(]01LMHV91/'-Q(FP'N*PZJQV;15
M,^@(/YU`K+I*N**U%+L7\BN(.U+R-:IMA;[42=B&PJSB=FA\)JTHA&JFKH%G
MEERF-/G*BMFP&0`=/D(!XZ<;5X:Y;I(I`'+A1;^>G4!=$)C2`Z."[$(!)P*)
M7V/X\ZY1;LH2]C`%2>P>S4+/S^)!)HAZLWGU'J&NX%SJ^>P[:"NW)/(]!H=L
MQ'"`J"P&RD"#SN&_1<_I3ZU2[HO*1N;:$/F3B(1D/._[/F+L"J&OLQ$E4:PP
M5]57,D1;)F_!(-[R$Q!5&R:KBMH8>[XA#$:%""_%WBTO:X1[7R.<9JV/YX/1
M54@H#KQ[Q)!'_<D52:+`RZ)T,^VC>F]ITXR]>.B6T7G+..DJL^,R.OJ#N['@
MFV*O.78$"]R]`+\I"UJM&<$8=V]6;\H8>8"*0&[I0;0M()>J:4O@/[F2Z*9I
MZ&KA9DA-..D>WNYKS2QY1)++]_N,0BT'&+E\M\\H[)4((>L7_;:%NQQ]Y'("
M'+.SO!RL9C\=SM96]T@*VSVIIC5LI3_?_O/#G2%>]XA;?\NV8[!5X1$"]\?]
MQ%T(O5AB/7%/:6V/5=MI+.#OD5C6WA,MV+%'XII^0)N`OT=26XL;QH(/>R3&
MM;K3+CBQ1X+=1MD*!$?V2.9K%U,L6+%'PJ!^Z@0!?X_$0YW8;`%\G^3#5D&<
M2U:<[I'X6.E3%&CW2%I4W#01>/=('-3P9@O<^R$'FHBX$#S9#YFP04J^T_V0
M_1HEJ#O=#^FN::R-P+\?(ITLEE%@W`^YK4'TJ8"^3Y*;3B#X$OG[/1+4M,*W
M!?(]$MHT@^L%]CT2X%37D07@_9#<-K^=)CBR'W+;AO?;!#OV0Z@S=M%),&8_
M)+_-;K();NR''+CIG6/!C_V0&5<L'YMF$Q'LL217UN;UUHOC6Q>J*P+5K>>]
M[@QPD\Q$.1=.]X\+ZKSN[_<'L#1U70[S@XM9W:MR8BYWM=4LBB(`VY;^H\S%
MK\@=N!B?,ESK6T\!#QIY21B7`;5/<5:]#:VDWW*)!8KG%3KCP.^G+O"@_EZ!
M1@ZUPK+53$,JUK-[*FX;X,K<W@*L>^J:(;#%Y.H"KGMJ1QNX[7(I"RZX9Z5M
MQX6&^9C%U2'[1[;JB-N']W.V\E#0KAQ8'3P5],&6Y5EO"BLO8A='MO$=0?OC
MK36UNV)`FREOX[VHA^21H1\)8+A\2J%M_DB4F10!YQ.,1I<OR$_X%87\_6+E
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M#`F_X[-8!7KDMFO#RDB4E9R;BD<*:XL[0+M2?Y"7=8!JV;.+RJ(NT%R34K2B
MM".4JY-S5I;?:>I-)1<=/I/AA"0,5+3A,PJ?T.6/!,=SH=2`/%ZMK3:H;8/;
MW_B%+MB-<5"WF\A*6K75R12Z4@3\BC)EWP19;W*6*X#BME:#J>AR+HMZO:PX
MD$K;G\MI65K`K#(0NIR:HQE,Z8[C<JH-/7BUADR7TVDT@%AI,[:?)D//Q]7<
MLE*<O3(.V3]8M,Y+T\"=<..NI?745?)*?FJI>K*':3R;,,>D+\3E?)\;\:2!
M[\3EY)^M%HV&/<OEQ)^-Q[VY?<SE!*#-X1LQ8KN<&[35*FAER78Y5>CV)H:^
MY\=ZHM':FQ8ZEDZ5R+%ZJ<3ANT1-H3:1.]V_0]04?=E*9?W*D&XLJ]KX73.3
M=TPQ,@'6"66H^:XNCVJM<38US0B\O4#&-.AV2)9&M(<8]I<L[0<=>U&>TI/G
M<B(ASMXFZ4<!MT9Q@9[_<S"25!;QD4,@[2SDEX"=07:6,#B:&;M`S*=XEF."
MPQ8S?H-70'.0]@<\CO`(^R``]'V?)YKB@C2,37H[<5?I77QPAVXQ@5,U?BFD
MY0?P.6&`;55&<W$`-@22GM(.C<OW-&@\=GI_J:;1-6Z6[VNXQ\F%;<A1\L0]
M<;9Z4=SI";IZ9Z&>Q%^.>-^/L$7`/_X?4$L#!!0````(`#!`64,K=*<[S$T`
M`*D"!``5`!P`;V=E;BTR,#$S,#DS,%]L86(N>&UL550)``.<76I2G%UJ4G5X
M"P`!!"4.```$.0$``-1=Z6_D-I;_/L#\#US/8F<&\%%2W3W)#'QT!]YUMPW;
MF60W6#1DB5761"76DBJW*W_]DM2M$B5*)9'*AR2.BGR7WN_I\7K\[A_O&P^\
M04Q<Y']_8IR/3@#T;>2X_OK[DQ^?SBZ?KF]O3_[Q]S_^X;M_.SL#CX_@!OD^
M]#RX!S_;T(/8"B!XMMZ1CS9[<&>]0(^`.]?_]<4B\!2P?SL`^>#GJ\<[8)X;
M`+P&P?;#Q<6W;]_.,79B:N<VVER`L[.8TS]#F3Z`V;E)Q<K\\HAVOO,!3#*/
MKC&T`MH:.%2:#\`<&>,S8W1F3IY'HP_&Y,-H]C_9UFB[Q^[Z-0!_L?]*&X^F
M9ZP'>#Q_/,^H]Q_@"?F$MMYL+7\/+CT//+)>!#Q"`O$;=,XCHEZD+J#&],GW
M)QD-WU^P=X[P^H*R&5_$#4_^^`<0-O[P3MQ<AV_CN+EQ\?/GNR?[%6ZL,]<G
M@>7;N8Z,6%E78[E<7O!?P];$_4`XE3MD<RM)"`B$+=C_G<7-SMBC,\,\&QOG
M[\0Y^3MC^!U&'GR$*\!E^!#LM_#[$^)NMAX\B9Z]8K@JE\+#^(+UO_#AFKY+
MAW%8,@[&C''X4_28^]D)8"U_?+P5*K3,T0H[781">NQ_F)_FQ(3O`?0=Z,2"
MLNX5YN+4N:4Y4486V3F"'K,YPJ6*<UHKB[QP@CMRMK:L[05SQ0OH!21^PIWS
M;&1$1OY3]/CKI6U3)`04J0_(<VT7DLL7$F#+#F)N7,?O3R0Z7"3RLRXY#3`D
M:(=MV,@DX>MI*,57[X5UVGBT"PL_T#_[\>D$N,[W)Z[SU32,L6$LOB[-Q7*^
M^&I\-4[^GM(",3'P2TSN?[\+Y>A6M8#&)7C7OWYF._TN<=[_+&S'<M(_:Q2,
M6ES8B(::;7"6>XTKC#92OA3S1](VN="''O)@[:T7#U[Z#GV"=S1*N-:+Z[D!
M%?)ZAS'T:^`D14$]OF3$DG3(\=1<SG.`(R"B#BAY$-$'&08@XJ`5@IV;P,R9
M8!N9P*(FL"(3P/<M]`DD`X!F$\\NP:JT\72"]Q':T'UC8GZ!@1Q:2[MH@&>9
M'++.N)B/1@4\IN0`I3<,^!VM8AYO."%'3H$/2Y53C;$J!RP#E=`D6E#D."X;
M#UC>@^4ZM_ZUM74#2_A6!:U58J=<!%F?&L_-<02;A!!@E,"M#R):FA#3@6)F
M0;$MI43'C<`6*Z8,+=6.E@-*A26:802MJ;F8YX^6XQ'W>_8DP^`1[2TOV-/O
MW(:B\!KYX0^7ZS7FX\7X=TC?MA]8:UAX>4>3ZQ@Y#K)WC#4?XW<LJYPG&L9L
M,EL:7\<%5\0A.98Q,7[`CAD"*^:8MDEXGO>"Q;+XHM8ZQ0@4D0,1/Y`P!`G'
MM$W"4VV@4FLA'LJ>49"X#AM1.#L(`@1^_/3X24<LZRIXL&#7B3751,/DL>M\
M=GUWL]NT\HP2,H.+?H<R-O%:LT'42W^AN<<FY#6T:'>L->2C7/H+M4;$:XC1
M[5B+\*AV[\.SP-U`8(D=Y1O:>0YX@3SD?7N%/HU[+!92!]]YU+_?8!H6AQL*
MQ9%#/@0*3*YGL/2O'0F8=.09";+4GRR,+3^X)627+B$<I/I-Z2@=8#443G:$
M,C$F\91]R@(\(R`>B8&($0@YZ1J8]6D0'A$^62X&&PO_"@/P9GD4\F@%@E<(
MYG/CU)@MP;>0/@$NY\"2H!^PNUK1L=T3M'>8S\B=4LO9Y\`BP`(8.CN;AU;:
MA']CTF$@8!#FE-AR(F-EH\V&-B4!LG_5.TAL";#\\+'-^](>3QXA,Y#+9X7H
M>T0;>(<(?7YMD=<'C-Y<!SI7^Q\)I%K<;]F:N^NO+^D[?N,OOV[=KP]6NJ)2
M1_++KL4M34'@2N3@\ZVA)(")PGYDPH!8&G"U!TP>%ML2B4`JDOX52]WV-8OV
MI2$.)_;UJ7T]9ECZE/UM,^/NF$%I6$.)0:U$A@^#"6,=XUH8Z;I\:=V,*^.Q
M:Y2V7?K^SO(^6ZX?0)]]>:),KS01E^VK?`0I*9CLL&`^-^?C:-B8S/1$PT%@
M<>(T,4BHQ^,#U2/%7K0V\EI'M$%('&2HQP-&'2/"7C0WF[YO?4.\AB!.QW5-
M#-<^^2+0/E^CMPL'NF'>1?\HIEOTT==+RLMA_#YYUKKPH@]_5Y#8'#"5_5H:
MRTF\$2/N#EA_M>`X3GQ33OR^/5SH&,R+RS74,DS8(!RXO_%OTOWJ!KX$-R[A
M:\D/&&[<@^E8^7XJ$_@Z820=:#*:3V:Q_Z<DP?T*,*(@I@HBLIK2Z4ZUC?=`
M8,A5I0-V)]:2_J^/`ICN1*(),GFU,'Q%G@.QUBQ8UFUS*:V4X;K)3\,O4OAY
MRD\^D@=$@FNTV4!LNY87R5.:'S0FHCQC;2IADQGM692Z1HE+E,<4)K.I<U(^
M?)(IQTAU$MNO(8R,(>)4MK#@00#C`PX8Z<AK^S4&CUB,SMG!6Q=ZB;X<MVT@
M2)/=5M;4DDNP><\UY))=^LX7Y%OIDV?Z%['XM#'Y##<O$(L^;PVIJ,PSFHDF
M.U<_FLWC[989!GSK<YX%R/(`OX1<=$WJ]6@+\\`65FB+,[$Q;A`;VNH]L]#.
M_W,I2@NK:H$Z(3`@(M<(?U0)3,Y1>N^OL8@_J;Q?/P!B2^J5`&HN\RS=MV0)
M)5?F[3D7R#EQJID^WZQ;L\HW4NZKC<]L3::CK,_J7]1IKX99#3VU#ERY!G*H
MHSZ'KCE^DFNCW)T;GKZ8&P5O[O4\B5PD;J-")B#;8??!!.:JPR('^FKW:JEH
M76RKR\N;!KV9,9F6>?M`8O@Q6O%0?IUS?;VKXU5.)<1`]^O35Q9QR?WJ@;ZV
M>/Z,IO-/N\W&POO[U9.[]MV5:UN4]\'1Y3O7A[<!W!33ZPX)JYXG[$1JR5FB
MT=B83R;AW"'GRZ;OLYSYP#KBS7[+<`>E!^*9!("+T`].A;.*&LQF_'[,5CT)
MJ<%VIC+;*9FZ[#2&)=.9W;T7[8'ZF2V*=>U[(='?4X#F$LM.X=.\>6QV&9PY
M]]]17&YAK0YC<H_6ZB\<MS!9AZ%8;++!1^%<@.HD`J>O0L>0\6I'Z!>`D!M(
M;.QN(\E+]'F&[\$5%>17P<"G!2&%@\WFTDGOAI[.HO/!,0^08<*A40Z:7Q@K
MP'EI&JOV;)1,P$!YW74.9]L[?':LV])T.A#.-I13V=A_/O[?SGVS/+X2%EQ;
M&.]I'/HG.\`D\!"YO@IQ+"60]`*0N8AV-?/#'PRJ_(\,97`9@)@VX,1[@>H6
M8A<Y'WVG"J[=ZSY)=&>+P?R0!LSH;@4`TN<4O*%\/:K^%%@X4*O\M%;Y%[AV
M?9^]^7Y-4!NHNU?>K%1>9WQN%*ZR(5G>2,.)P@_<J6Y]&T.+P!L8_K>1%PA(
M:(_)Y7)).^DL+I<F#LTA!Q"S`#$//2M>O5F!+XBQ`XMNK.A?G(C.7\-3PK\;
M%%>[>SV8*ZRI"].?//3M"[4'_?/6?X.$G]+SG4\N.S23.[''-D9[B.PPK%F9
M.YJL8NP?(ZOL@&(Z'4TR\8"Q!!%/D##E82)AFSVNFS+6OD"HU&+\,\\V^7%#
MN8FA6+A8)88:R#'<KN!4C"-'6UM+;'EUX>KC.[1WK'C,_6KEVA!7;O*MZJ$R
M(HC%D/WL&8M9#'9&#"340$1.\S[=KE3DZ+S!Y^`_T:L/KI"_<M>>BRJU4P;&
M>O_+X:S&)-H@%*'<\J0A).BA&D+E8LA&__G,,+,02J@-"4(=J,@A]-FU7ZG0
M3SO/HYFB/QS\5#O?`7XJ[-')PNRU9Q%ROXJ*Z5"T8MLE!U6O*INJ7D05R"'I
M(_/Y;#$/5T:_[)@MV41.4IL)QM1XS24^M%!\Q*T+[4*0,T)LA2$NP)70TK`N
MV856'-<_';RI;K4INVJFK[<TR2IT6OU^E"R"U@2#9&FS2OL^H])/D%W<!)W+
M-XBM-8R?/V#7+MT@TH;,0*)9E8SRYSCGHZB*<TP.6"&]!#Y@RRC^/F)@=S:I
M"9`@,5?$*OD)<&;#":#=F<3,N4FL-R<TX-`D$Q'JPE:M#7L):5L7RZ5984/=
M88E+T<2CS(H<BQ,;3'1IH9HH?G!2@TA(VBAUD(\(U=$"^1QBA*!.%>\/ML?F
M(?5$!@'WKCXNXS8YR`!C1'?VJ(P?:K./8^)+AP:95*<?`XQ$1Z4><N;K(8+]
MP/[%ZH>&ZZ;UK[K806]D*DC3Q,DFPH1D'1(=2+`Y2L7RP!*19)6+'S1L6>I:
M23.?IT2T!A(=!``31((R._2/^N/RER;$!A4MNOI<39OG,X,.,=W913+\#'Y^
MI3<#5<ZR##J0'9'N-+6FEH7AG,3W^)')F!,M^9%$OXKJ,K4BI7(IN85\LGL8
MS.54E(3<8\!I%;">:4*2-CW5BJI=@>[;,AS^];%.V8+T$4Z?6ZEN:[?!(/U.
M4`Q"LI-N]-XU.TF_'!N3A6@6(L&IOLH"/>AJIKJB5%<DJZM61!XX9RWV[HXX
MP=\CRNYW`0DLWW']8OU^Z6ZZD9:11?K@X\00;<E(L)8AJ_$P69<*%Q<3.`7P
M8GGLX@BMI\:ZU'*:U_(J.1W6IZ+MXF9;%?/;;FH<56N<+`DOM9&R:)7!Q,JR
MJB<2'73'QP9%));F8CRIC8Q::FETK&)=\J&O]H6\"]8BJ6W-"JD)S`Q,CYN\
ME"6D=^)24DK)N2?3-"9M)BU1*H76Z<I>K"$(.RDK+9.4E7F:*M-4K\5J3^14
MF6%:90:I3$_#K&W#0"F8L6UBSXZBO>N[MN4]!3MG__!J$?A,V\/2DSD2'=1'
M[PIIFJP0+,(H'=,#A!$$6T81!(RD\D#<F6)&3C%.$'"*@)/4=/BH:RU-H99C
MK6>0Y%&6"0EU5ND+^M]0(^`GS0<`^UB6)EZSK`+]-Z0?\NV4J@#\M^H#K>KA
MWDY#,=C-08*]B*LJJ.<LT@W0T6;C\JNN614/Q`L>0K^V%+=,-^7`KY=)MJ:Q
M.1O/XP"04`V+VV3I:BR/W;FRAGYE:P)$UQJ;1VNL)F3((S0-'9*VZCF$"(M$
MUW493NAH4G]W9,RG2ZFPH:-P<Z<Z2D0+;>66.U54(DAH+I(L"3^)V*"WP'$J
M%RD*)E^1JQ$-E<LR3023OB]R-#&*2"0E'CJDHEJ]V<$LVL%J;P=E"SQM7#ZW
MYM/8G(-%=EW9\H9$AH;MQI6YQ\OEJ"FXM1<J[]$4]?@>/)(K"Y6W,%UGV3OR
MGP)*]):0'71N=IA=>L"7>QXLS*OQ?D(XWFP2KS6(,J]6M'3D^VT$;3`391CI
M0`#Y@#!>P.7,@,.Y18=.P-;"X(TQ!"N$#RM^J)YI5&(:(V,:S@N$S$#(+3Z2
M0OF%Q=P!Y9CN2(]Y:AI<]&\>'NP>$K]`*V"7N!%S%U8LTV-W621;!C*;!;2.
M28X)*KG!2FMSZ\IU(H&I>/?X*6`GN+F85.BG5PL+]X])]%2<U=2(([W7>SXI
M0SSS[WL,0L(1S"EIP&GKRU^Z5-HL?@%.TVBO.UV1]-)BCB)C'LW`XX*0RUWP
MBK#[VT%!'YD>>H!6%$-Z`#R;STH`%I(#*3WMH#I*P1(PD5!#JU)##:`2>:``
M3*5F&02(PH^N[(N-6NL$3RB"=.WU^6PL!DY(:R"@::&8&#"N4#-M8,E[6B50
M,J88!$@D3E!5==$)EQ;G3\;3Q4*,F;[/3#4'3EL5Q>A!`SEN(^&'E3@:Q#&;
M5*C*^^V*S?2`IM']7=/98EH"E/XNIVN"C>::E.#AWT?GHY&1#FG^!J:CT]&(
M_W.8F_T-C$>GQFQQ.C/&?/;6G)^.%^;I8CS*?Y?XCQF0L2O>GB@8^-8G1@0P
M9^*M;J`=/37X4_,44#I;R&X*@=Y^(/`47X56]D(TP7`+?<(G3!^AQX9UUX@$
MA-]]NY=8FY'JK1:T,B))#T`6DW330T(81)0!)QW>F[P?QC),Y\IS^'-//;NR
M"-<Y9:(99TU<MP`_:3OI0275W@]P**!+?KW:/U.>E^^NL"1&10^EZ!.*(>UT
M4S.9T\@0`XP:N-H#1@_\PBAJ`UDW.IH"'6L45`>O6A_,0ZK:*H.`T36&CANP
MOV3?;::'3ABE8DB[V'R\%,(H),?_'@B&6BIXB"'-NP%J':X2,P4K#`(S#,4W
M:&.YQ05UF1XZ,9.*(7UAU3)=H1:$Y9#@4+X\+56L_O)4J*@-1X=.6(FC@ETT
MX>@-XL!]\>`7%$#R8.W9+MOK'<945/$+KNJD%DT5DLC/'R27W*7T`"<((HH@
M(JD-45VI:1;5]"E!L(VT#%`XU?&*/`=BS=B2<,P"O.J,U-&.M(3/`Q79)03A
M/>=8<0"UKH_Z'6;5`DGZU'0R'R<;R5*?VB8DN7L1Y7O$.E3N("ZD)*,0H?-4
M:I>:'H2&@J8#.)XJ";W,_BP)^^CY[I+@?O4#0@YYHK%6&/?SK91^67.L9;\Q
M\\4L^922@%7)X20`HZ'KV]E>$3-1!*T`L3S=F[A+?2;_#3Q4MKU[$VB?K]';
MA0/=T+/I'T6'IH^^1I_83RZQ+>^_H84_^LZ-%107RRJ;*G#M*OZR`Q/*(:Y5
M'5("(2G`:+$Z1X!14^OIG>EEMM&K;^^7<3`&@5HK:`GSH4!\(^*E[]Q13MZS
M]?[QG<WKPROHPY4K'&5)]57Y29`12#:^+N;3`I`X77Z"B%,&E#2(:(.(N.I;
MK'K4G-=+"Q5]V1'79WOD`^M=Z_>EB;/FOCK2YM&!P1OX$H1Y(*&#H2@C9#=+
MD`#S0=+E!NW\P!"\>^GN"I$H*Y/TS$`RH\@H@Y0T2&B#E#@(J0-#3T+7B_*9
ML0_7FQ]I$4R2L(T=EFWC';^;A\H+:8(8H.0,3+2QA+;2>="EK?MG@=W(U+JP
M+7WZ7M!8,6Y;GR,W%\DY%8[2`1V;[T`OL[E>*A$D=]Z]P@Z=3#TR^CGPT?#T
M&Y_C$]_,6-M']=1CG4"R!5!&QG(65;/A?N.F'R@K0U3/W6G=*IF"/O\53I74
M=D5CMXJ&N[A>*9$SRG83SAZG'][#UZIM*E(6BLE4I)2A='U#4\$^638,O^H5
ML;ZTN>+O:)D,TBG?=#XM!Q6C%>6W^CZE1ZO&862+%V3BC<PT::78`@&T7WWD
MH?6>Y;5L)+J"_<QA48%>D`(#&&6!)(XCNG.)*K`5LPFA)?1'BMMHZ/-(1_WA
M25L:R-@&!VLM.B;1@("V:%(EE6Q&.QE/S?+X$E,'C'Q\MCQE,(28TYD!.`83
MA3%3F`^/<Z`<#AAE_%D,SUJKZ0?L7<U]A:+6VJ!XU_#6/G.R-(URW.F_E[`+
MU<PVJNE!TX&SB:%SI_WBP;P\GZU@A]U@7[*$*=%!&UJR4LAZU6P\$7RH8FH:
MUC,[5H^#YI/K6QY+`+ER#O\6K8K?HJH$47WJV_Y]<HV3%Q@K6YS/'DZL*`.<
M.%P<V$5_Q*BZ=Z^LI;88T>@:NHDQ&0N^ICKOUSM6HW!H:+]"9^=Q8-PA?QT&
M@8*>6HLG2WB:&"-Z2R7?P!7$&#J/\`WZPC/SQ59*09%C+3VU8,Y&,2!"`B"B
MH`L)[=7@*(@Z`B=69^<[$(/USF++EI`^P/S>=882#&G8]0%?T5Q##@^]L"CU
ML3PD#LTS`#A<IA:L.2TKT5$?:$JDD3[=,YHNRW$$,E3U'Z'M6&/S6(TU8:O"
M82O@)K+6\!!8>6Q0JNM@4-CPE)VYF$OC4.N1PLZU+L?B$`X5-O%5>?AI/F98
M$*[Z>*&@L3Z0-3UG-Q&EB7I/$7:@51XV6)S\:D)+Q?'`"NWU(&*+H>WR#0"7
MOI/=#R!\?>(>2K$A%$-Z!_1TNH@!DA+C6[^SY'2AI!O]S`/]^+[1&OW4X:;6
M_?+@J3:*%@2Y5"1*F]U'<;]:N39]LW>N]>)Z;K"_]<D.LRNV2\_DMB*A$F,-
MY)(O^&U&!RX2ZAQQ,7V0,``)!TU'6WLW@YDSPY\Y,F,&?RXU!%L_\&U6[$_G
M(=AC7#\'YZ:&U8/O>"/M_4I4"8T7"GUA]=X>PJ4=4K<'_#BB2F/`,9+*5RXW
MXB%@NNWZ?@4JR@BF3$',5?\&='7&,@O&0E7&.@VM==;(7.JB2!<`R\>5HU_#
MH"/-55;LNJJCQU(=8JPI%U6Z;K4QF[4)-N"J`!_M%4Q5&FRPE4T[@DVK`%)A
MUVY.VE!!V%[;>Y]5"XE*"3VCI[0X4N96I]);*%J347X>I[F,#6X+,T?1$9V(
M"]L"6E%R*G_'7+A-7?71G;[M8>3L<>^'Q77B0F//"&18Y2^6TW'CAQJ;F$?Z
MB+YS0.T#17HTJ*5UNXET47R@0\&/?L#'?]2^FW"JIWPP)=]/>2R3$$JV)I9A
MCN91[(JH\GD"R.D"-R6L.CYUK:.1TY'-"85T08:PMA%>/RJ;QZNL)KHT`&<:
M3F2MU7]EJ%B4L")/>-#Q$WU6W/%2W591;2BA`/)%E(QE`4U1%:7HOEA.37UQ
MJ&X4,]LHIJ(Z5*V3Q>6AJNV@&@VL/I4<%M*66I"0L)=U%V,YGY3C@%<3&P0*
MVBE5BH%JI=0CX,"QROT_;P%UWA_B3EPBL+R=8L_/,9=WD44Q_D?Q45]AP.,5
M,ILJI-+C2YVIZ.^'NJOS=K;YJN*U\)\5^S;CV<`#BJ&<==?GQXV%-Z6$5^FS
M69<HNFJBGHYUD(\6]EU_3>++LJ\LXMIT%''C>KM`>,UN72^%ZQ@UHLCZ#9MX
M#YT^)IA>_`XX33YDC*CJ68'H4E4.D5`O-L/AA"2`#P/@(4)8J9UP_DWG:H.D
M<V97$V1L-`2<R=UB6-=+(\Y:7MQG+)9S(<X&<UMAE\IRI'VAN+ICN$J4'1*N
M).XEE+&(%EQMMA[:0_@$\9MKPW2A,+N4>.EQ">A?]ZM':*.USRY_#5-$OKYX
M5U,FHVLN*G';K>BRKF\NY]&Z?RP`B"3(K>_GM@&D4K`=`JD<\0`DW!Z@OZR'
M3I.:8I-&.XZR0IQF;8K:VU198.H'S;E`UL/+ZW]H&4[J7T-VE9AWZSOP_;_@
MOF3(5-Y.T6"SE+G\P"U)#,)EF8@.X(0`I:1^`'J\0F93A50,2BN=*1Z=BG57
MYNWI3>0<I>0^O7]=_+*J.JG%084D\HLP<:V>V(?">N.<ZO]W]VW-;>/8NG\%
M;W-.57J71-WW?G+BN$_J=,>9Q-U==>:)EB"9-3*I(2D[GE]_<",)4@`(7H0%
M3]7T)+')=>/Z/MRQ..MG2)(+!I&Q?`TTOGZP=-8A?"RRLX&EMB"Y`I;R\//%
MKYV"I=MQWNEF-:G!`N:D\B#S`TOSW67TY3ECI8.NLO0N.N+T4YCC0Y+JNSKU
MIYSF;$VU_;=?+&JIRZ2@0@Q4`O?W)>CDB[ML5J9//:DOG7:5V]_Q(:*;<N+\
M:_BL6BM2/N8TN^NZ[5-B5N_%5V(0E0.5WP.\";IYXR[#U4E43W&%WR"S=/\Z
M$V-:SNDU'G(Y1U;3;#T?,UL6N<[>!S\1-\"-P-H-9U-!RI2IS>1<NCO*[NC/
M/_'VG$<ON#@FJZ_QK'O4]1YHC1VVA3@6J^EFS?<]EY)0(D0YWNH\BBO3NBOE
M>7?`LLVC^!7T\,O)IN46S)3[E$U1&`F\K`!A)DZ//21LO'WS&J:[YN).^_/N
M8:PWQC)1@F"R6LX++'-Q*!7G*^F9&C9S%#*1SI$]EG?3FG?%Z5%ZBHIYQT6"
M8'PL#QG0JTLIV"$441=5^IB8-]A13(L.4$(X$=F`'-`./8D(6D(%T4V]"Z/T
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MKNE(;TJ7=%MPYA'"4%9*HT-MQPPSED=3V:-*&ND,;"%)8RSW`KU[_P5/!.UX
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M@RI[4&40XA8A\32S"=6,XN>=4-VLLEH[3)?`ET"S+@:+\",/8\3#F%.-D-T-
M!Q"6NR_7_AYP+,@*UK,KX\R[\G1/.V>?"Q.LBW^M%Y,:<Y22P'?LC>%9T,,S
MMVC5IMHETM2A\``EOXGSH(;2G:8WX-`BFV%?NG*ZT""F$`=:I',L%]70L7`1
M"#^J)#1@Z"(N'N'(6(#3_`X\ECH=]YI--Y-I*YI`2VV.YV8;HCPHMFF5D!:H
M`BZO6?8XQ4ZZCSC&^@E:W=/.L71A@F5ZS2?K8%-#$9&$A"@D9$&B9YAC,F[(
M&(N,NK0.N<6)-L$N$:*.`!`V4AQF^!;S/[_$-UMVVWXF+MJG]0RWV_2,=\4>
MVP@;NG5]A+E%5@\+;7E]N9G,2N`Q^:A0A+[$J%!5%K-@)3VY-B2I`\/FM4/#
MH%M&H2A?P0I_BBB(G=O0\R8#(-$`>]^0^L4%W_$61R_4XL[)([WJ!<XK>^Q+
M.R_F-JBN)(\+X`UW-\8'NOV_'X3[>CVO(38MI7R@UU_Z"=++7+6#9"-$?@"P
M49;;^KLWWP.%7L,8ZSK1TZ+XIA)WS>KQOK2:0[SUKH"\=4::,::*B1\`HQN=
M8Z*M2Z=6?@<46)(AUK2^DF;X+T$E2?2G$>OMYIS[R=]^\[#-4F2?&4C-4/@!
M(K'$%Q\^A:<H#X_MZV2V`D#AI;/*=N*<]*!,P\%2/!+R?5ACNT8(6*OVZ8D\
MR+8%HZ1T/,PR3/J5=`1XK`9`_^T72-NRVXQ88P3]@.^W%)_":%<TTF)FBHQ-
M[_,GG-ZP;V2=,5;"0&%M8Z'U#I!@NC1`7*BJ^JK%+"R=^6'J$-?G3V,[?G18
M*UQ$HIC@89A/6`2V9Z*(EH_41@(.^UV@8>8!Z[C"<`+?:".LTB9+_2FG**ZI
MMAY4;8*R!>8""@3"`6Z`(_.:)UCOB3O`*/.FCH1+AR%3_!L!8<NW88\`)#?5
M:SW`"1:;1F;3UZ'ZC3T="&H.G#0.N,YF.454J5RZ.<H)#2(UQ3]--S@TGG!]
M`J.NOLM9,U$@NA#@^'C%$+NGLMV09R>&.!%8.^'D8(0ZT<N#$`I/8=H),5WT
M%>OG+Z1'G+83E5[KCL-J6BY>B;?15_4TF(MVHJ<#@6\3>9<Y4F\H&GZ")K)=
M_33MXQ`)WJ^(6+!>S)?-9/>F4-HHSM6!X`4&+"JB&5T'Q0:]SXMU?+[C#*<O
MAD4@[0L0^+BPPKK7O9[.F@@IA:%"&C!`AGE7APA*N0QT]^7NW@N\:%-.B1AU
M+$`Q\U<:Y?@V>=5O2;]X$`(CI7;;[%FM9D$3&TP(HE*`,='/&X8%[D.RW]-3
MTOCG*:(3T9%7;<A%2BFQ4(_!2(/OWO<J^GJ5XLB7XY%NQWI=C..]NRWQ*LY.
M5<[Z=B'B53P/1O'<T6Q"OVL.KW>SX7C-;)93A/.C`JVW)F@>=]SDJFRP;:KF
M\_E$!AT[""5.>%SWC@&;YG>P9_5);GX[`'2K:\JP9MNK#<`H+?!O89Q'CU&2
M1]O/6\/-><KG7+>M*B,ZW%:_GO"&5!*#/G_ZY+C-'.[$],*)+>C->,,]"A2?
M!;Z-,V&C;-"TSE^_0MMO^!`>>?4LQ6%_U1..ZK(UU':HTB<FRYD`5-2<!#B_
M/]2+H(,7+NJP:5*E*,&F<A6B]R4=P[J)=ZS0QE-RW)&OQ$MH:?H)K:\Y[(VU
MV6*_A7HEAD*21+9Q39:)N%"8*Z!&=97=X_1`5<I[4=D^M8S6(!:2_R9*R4#V
MX&RS5.[)6<7*1\BU;":W?MTC"';>13U;VT,1?!?Y5;P/FMY37/ZHX5+/1+[@
MTK1SO%/4H'&:962<M)M:)$#Q)!#ZA'KK\?IZNE$`C4M!4W@\]?&'0>=CDJ;)
M:Q0?,G2.25:1-BU)<T24/Z,XR7%U''^?I.A4WZWM"Z8:::>#CQPD8*1\XGO;
MV[]L\2`,3H1VZ[0*BFN:9)@((>!=P3[.2)V_XCB"U`GT)/\;R:1)?]E]/[+?
MO@?7?`$4#5W[*9O5>J5%A4^]LB'^\;-\EQ`!/;/7GG)FK(Q?&/NW:,N.]QQ2
MS&Y"NPWSYJD:_7/.9[451M@66UY/YC-1?4J(06$A!^V((->3VX-]F<J^E'(0
M%00QM3W8GT#ISP=TGT:'B*[OZCQS,\5M`$HUQ:T+PM6P>A?M\Z<;\J\=;IX6
MLGO'!PS+!G4X.3`+3'A&>RH5A5RL!^CN[Z4!Z8A)14*L)[CO[VE@^SV]X@$5
M"(V<<!&@*_)#FN6=^4%ZQP]^J`SJDD^S%GZ@E0=]XH>^7IKY@7KI&S_T]53-
M#Q_D;UE^8,\HXA*'+131B-'U*()\\>Y]B-I+7I"$;%&7K#*."M">B?6))OK[
M:>0)[J=G1-'?5RU32-_34ZI0X=',%1=ANAI9_,#$I5U'LJB_Y`-9U"SJDE@+
M(UED3*Q'9#'`3Q-9<+&>D<4`7W5D(7]//\E"B4<C65R&Z6ID\?`4I5VYHO:.
M#U0A&]0EJY9&ILBI5(^(HK^7)IY@4CVCB?Z>ZEA"^I9^DH0*AT:.N(@1R/I<
M$A\></I\BQ_SMDL!U,^Z7)53&6!]8GZZ+MI;(@91.8@*\N`R@.%^\86X)'[!
M:1[1?1M?$\(,166)/)$W1X&NS9G2K;8LIPT)#$JRC->P)&#>1CC[^/8US,\I
MOM]7/U;M>N\AP"F>;*VRKF6UFA6KWK0&:DTX^OB&N'A:B%I2`%H2[THQ"!0Q
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MEE4!\$(8>JZDB=1QC>^1_)K6_9*D";A#X'LDWX*V;P:'[58X5>`V!V,D=,>4
M0&[B^!P>?R<#NQS'(?'@6_A&U66?"9<T%PO4'ZZ''/>,T-U(Z[R;SB?3@BN8
M&A0R/>BY4D2/,3)-B'(T.C:7E9PSR;7C,97CP?4@21$J-"&J"ETL*((PT+5C
M$MCE""6JRPP!Y*W^1"$Q6L_@CLEU?S^'*<F!X]NE`8:$,+T%Q&,&DVS'WJM5
ML)K76>M?A5154L(0U&B.UNBHE*IB)#CF&<U9QC-_-WU-.N;YX^[[G3AT'\59
M'AZ/G'R(!FBNL0!JDUG:@C<.CR1Q_G1\^Q0>M^<C`RE=9WI^QNDV"H_1O]F/
M[K#R2*7UN\XYQ=*P+FV=N%!0B$;;2C:=I]LVI:,]=GT@\SI>3V6O)=E\G;GI
M-1$/P397\9QQSGV,?\FC9ZS^PN@U.1]WZ!&CW1DC\C,ZX2*.<L1Q]$*LII.]
M)$'X#RLA*`N/<'NLNJ*^HJ8ND1Z'H,[D$Y#_T2WB_P^GB?[>4LV3SLE':4:'
M!82%V'CY^Q]3DH>N260$ZSEEG!$1P_ZCLA`5!GESZ1B.!=5G@;^RU`R,"K%Z
MOR'VCGS%^:<P>_J6)B_1#N\^OOV1X=V7^"ZBW9LH/MQL\^B%K?9H-CAT$.!P
M9XF]5=95)>8+L1!+9",J'!72Z68O*I_6/2XUH$H%S+U`5PK!L@C!EH;@5(3@
M\8TTJ87KH=%U5QM2NJ>VO#^E8_C\QF[+/40]!'F)Y<[W*RZ+#G5G3(/?:G3E
MJ/!-UC0B^V/RFB$*+27"0:\_ZH^`?E`'OXI28ZHH[=&_N58)@(>XPBK;MFH3
M;`(+:)<:?&VNAX:@WER?,U8`2VQJ\KZI-J2U!7YUH?,;M_V::I,@+W'<N5&:
M!XN>>/:UJ1XK*LJF6H5P'YMJ"P3T@[JO3?7]":?AD*9:)0`>X@JKK`_UK6<V
M376IX>I-=4\\#PU!A>.BF4ZXQ"3VJT\RU%%UGR0IOZ_7?1(#?BV(2A<ZOPFJ
M7Y_$),A+PNK8^LXFF\FF)W'YVB<9*RK*/HD*X3[V22P0T`_J/O1)>#5#>OI.
MGQG2,VZ!6BFV+F"T+&X,H1@4I3.I`#!8]?0A*'PX7LUXB^:^I_'+-N,=(OHR
MP1M@;?@(@\/7F^TV.;/CKX0X8O+7+=N1F'U+CM'VC?]_VR4EG<4X17,WVZQ/
M0R^"<K3PBBH5J*X#<?'%'_#WGEPU'HP\OF-Z:._X)DYWZF,#"]!^F5_'<(]0
MCK+YY6L2?WX^'9,WC&^C%&_)>YE^`XSA:=>;8/2FV%ZI/PO6"W$].A'V"Q;2
MT*X0YWACS%@>385'J)"&2G&0VV/&<B\H/AC"W?QSLF>F'4_EOIF6@("TXH1Y
MBDX^[U1\YE7#=$V`]GF7[;+."/L.7[`L45,-Z437^[.^;IJ##NPHODD5L9+\
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MJ0X@`AC;^08M"/&\DR$4(*%!''6E.@`)8^P`!/9?'YQ5["%]P36688.8ERA7
M[,7X3;="?OF<PWF'"^66`^_Y9+D6!]BJ#2F%#)CINF&NR--TI4/8X)"K201M
M&LF3!FK?O<CZEEDX_?.0*.@\#57NW;I$`_ADVSC>!77O"FB`3K"U)IL1(^#[
MI^[K\WR&752J)R'PT7U#SWQ=7!EPWYR,OMZ^*NNFHJ<_R_+Z?'DGHF9CM7,P
MF+<LZ7P'`4!Z"&-QK<@G$K[D&.W8/V[B'>G.9<6PZ7XO3D^&QQ_D)WQS1EO#
M,HILER`;PV!K2E\7!Z!DM:BF%Q'%2-9,1TJE;E0IAV_AG(<N:(;N0R-V83-V
M2:_8.2./,9%8HYO1/LV[(ZC;*-L>$WH=;MO.R]'5O!?:4MAN72MJO5B/QV"5
M(1YL[@0-Z06SO5M:,N!O-(;211N$K.@.B,OM`[HDTSSMDCK4)EAWQ6?%?2M\
M[X=BPPL0?D?PZV)/"R@,S9E50Y/!]U'6@;Z%Z9_A\8SI.C!=*-[F>/<C)[B[
M2](]CG)U>2V+MURO^[2;U&'A<"76>XA0]$*E\NT!A5R44<%H7TAVO,HSMJO3
MPE4FE>\1*5UE@E$I&6!-9VQW@XLO6WY(_F'!5G#LP5BNW%@&9R2NR`D"Q37M
MGW^>(CY-0ZOCJK^;_G'W[*"UI4ORS`I:H-+*._IQ*0^13'YVS@8CN3:57"L*
M,E3R6)UJ$/2/Y%Y0N9>I/AUP>1@+<$F@-\=D1+2S76*?]WM,STGC+\P'HHJ6
MC==_+=-+,,@W6-0EB^8U_+.=@P@74FG/DHM%9,3C^D+SD?V4R8`)1:545(I%
M5"X8)XSFJ\0,TM?<:7QSR`86X&MP0EM,1F<&2C[8A@VJ!R$9H+2B2X8L5*AG
MDJ"!WM,=!;BY.Q[@N:=+@>D+>0'C"Z0HH5MW?VRXWD5'\OS!`J_RDX"`E<SH
MD@]+!6+W7!0P9'L[=(E9(<H#T/9VZA*U\E?R`;8*Q*APVXP`Q(1U44OM.SX2
M,W8/R4/XD^[D?$J..V+;79*R*M`?PPSOZ&Y.,GA007"P.(=3WGUMM#YR/-N4
MR!/U"H4J6A&9*$.2-CI)QFNX(Z80R1K'!>B&AR;&!VJ+:?+<383F4HCHA)HX
M-YJ'/W&&PBQ+MA$+&MLOS2=/'UF(MBTA<C4E/Q0[\IS]H)!#$L=#<K/]UYGT
M/[ZE=+TA?_M&OGU^$^\^DY^>%&42>P@`((=VJVR3?;F8SAMT0&A`2$>%>,3D
ML\7R4@,T_,>.`0<\,?B)9#%%_*EPGN[4P2:W74/:/JM5(+8,W#@==9S22Z+"
M`[[?4W9@-)$11>'Q(2F.:/`?$A*AE<22F,WU*[MGO84Y[^[WM;1#7W,M*A)6
MNFC2TC8(94PRS=GP2.MBQN4I'_&;/6G6MTPK;[I<#Q[<A&?:",_]GO5B>(<F
M0TP?9;OJ%)CX#>WU<*U\K1!B*.(F1,%E!ETDBRAO6>1*E592,.'&-4,)IAKZ
M#(KXZ&PI*;@_YUE.&B%Z,B%,8[S[@Y:X_2V)#W1YA,Z(QG1JE-#Y(0W5ZY:C
M"(9DT=Y6=ZGY.5,Q:BWWDTHWPDRYJ#=\).K94BE;,F$&T`X$M0"07!U%34&T
M,GTB23?BRA'3CJAZM@J+2@.0L`"8<QU%3L&_C'71@5UI89%=7C#O8+)2LO"P
M;S`Z(W_%^8_PB+-;G!)5NSL2"OKO^SW1NCMO\XQTL,/'HWH:NH\<2+ZU-=+^
MS/DZ4-)KC'-6"SE#.ZZ*GYBB/Q*#,*:.EGFG^@#)]#HA47`GO=B::4)"%:*Z
MV(_HKPMU2.@#9LKKA$4F1NGR"9H&M!&N98X7%-B5'92,URF6HQ/<W\]A2K[[
M\8UHVT?Y4)[K*@Z2[CK:VF60-56QWK\*?93@B$+OR>^J`5)P8*D/<87O@@JO
M&J1F5['&B+&448]A%F4%21Y2>@B9)YD7/-F39)1TV2?>UV/-[_@%QV?\)?X4
M9N3G/\Z/?$MFDMX<4HP5BPW#9'G!EQ:&=DGSP$R6*==&RW=MQ2Q]5FE$8:'2
M!Z(</3)&EA3::/TGJH]-9DJ1*57ZPI"C1X=7@.*<^#="?T3>06Q@3]!S^$],
MB9(MYK(F-CP>RVQ*\19+C6]A"AEK^L68'0C&3)>VP1^=*W]@MJ?D6TK4"5*^
MR;XG;^$Q5U[*9_TN)!>:#.N2P\KA<<:%DQ:<2"_Z@2C,4,H5`#+=>'XKF$T(
M1TQZT;U#-QD2"H!Y;#S?C;Q%^W:,E$Z&I*@&"E[0E0W&E?34&M/QZ8A.M?[*
M9UH'K:G8"P(E*ELK.UPDN5&N0G><PX8DL>O$1,5H+"9"E??K'U>*RW_(>D=G
MXE`37J<8C\]^1;</9Z)#*%CW2WRSVT7\1@O;SED76:`<V,'0+@WY7$F#E;)R
ML%%TX<@0-A0*V4E\^.[<U2*C(D,I,L70M>CDD2%LH9`=W/>CPW>UZ-AU`"W&
MJYXLA/2A%34]=@WY6`P9);O;<TJZHG\]1=LG\6D^A7&<Y)2=HSC,L3BIW#:S
MUTL4`#_VL;-+FB]*>B2:T(ZI0J]45SF/O67:6*O/U)4'V@%G]:X?EJD4%JX*
M,5W%A?.(:T.ENO(>`^`IO>N')AB>,9"$.(1%9#[L'6A(.OPS.9X)XZ314==U
M'"KUG9"D9'*7[%^.P9?HI5+^/KBS=[1&H%$D*7\_E-H[8B.PJYQ?[XUI%00U
ME'2;GP+DW!OY]%_#9WSS,]+=%%][Q.79-4FO[<FLR;JHFD#?1O1U]`\J`.C>
MU=X^!+8^.#M*IDB4VF&QIJ>0V7R;/(>1]E!W_2&`C.::K>_0G97M594/7`1P
M5O?PHYG7!C]<9W8]:52Y+?D[3E\YH9<G1.'Q[IR?4_Q[=,19GL2X.'AY'ZOW
M3%J\YKRWVVZ397=C,I^L9VO1G2VDHCT3BYX+N<7FC`R1?[CNJX[MZ[3N*Q>+
M2KFH/&E-)$/T-,?VEY%`Y5[XG)!^4#G1G:B==-,YM$=DU?NS#(\3RG@@;_<B
M#?ZB;[3!K+)-KLD\F'0@CIS*]HPZ>OAK31Y,MH?TT<-G,X'D.D>]H)`:0JU)
MI`J2&QIY37I]2O*:=Q3RFMA.=,S6D_6J`X&\)K[11U=?[<GC-?&1.KKZVT(<
M:B?]H(T*D?:D(<(#,A0GLG":BIO8OR;%)>VZ(:7N<9?#<XT-MF6\9O.B>GPI
M29QG_YJ@LK8`T)!]#-^"NF_LAH,/!#VBC`#H(+XEW6K#>5,LX+'"KPRY.>=/
M21K]^Z+XB.5+8+AI6F*;89O%?*)&C[ADIQ+I`X0&N:D&DK@^)S3Z"0,H74[J
M8:6,CR_@^I)EYT[`$B\`@XI;83O?&FQFFN9(`(J+\P=,/=PS`BG2^@<)HGKN
MM0%(BHDOX)&N5NGP<>6W@&$DF6++VLOI/#!B29+I#Z#Z.FI$56+V%!):BLQL
MPU<S1/`@LQ\E`0^0NHP?9K/)8J$&D#>#HN[^J'$2)]60Z']0,/DPF;#_+OMW
M_T.>C;%HI]BML5Z"RW(@!3Z&.H71[O//$]MC$^]8V<B;+,-Y]NE,C-3?W&SQ
MIEN0M9ECFZ2;Q:8"'16*A%1V,3,O!<H%(R$9#(>CNAS(+C^&Y`U^ZO4%Q[LD
M59YZ&.SD"TX?$[=N3FM^8BXVXSS"ONV6"Z6WSQ,5P(1BB\X&P5A%;)PUD31Y
MC)(\VF:?M]O?,;V_53DGK7C,^9K'I0T=CE4NBT724@KZ_.F3ZZ6,H2Y,FRYL
MM^@?7)#C;5'C^!-<?A*C/VY6)?28J%8A-)[#]`*2+<:[C%[I]"F)"2GGT>,1
MW^)'?>NO?\-IJZ\UP[)-F$_60=G:<V'\[C-)'*+RH-KX<1QD,/F8I&GR2CK)
MF3C_O95\S#!I]TA_.D[RZO1LGO#N-RU`@E/8IK`U1>M-H#ENT"BC$U2T?U6[
M?=<B!]3O`2%.:8QM7VR]V<Q5N"N$-F^WAL??<'<9"G\MK@KD3O-[9]+HA9[]
M.!W#+2Y*(<DWHL-UOD?]W"P`]-[=NOM1\<TMO(8@'"-:=;2C#Q<T^7S'Q6:<
M^_U70O>:FV8[O0I$03I[K!O'>7GRI<9"E5QV4S25#'/YZ=6<5O<(WD'KWY:]
M.CP:H^83)+_C+$^C;8YWG\+LZ2Z*"8N03W1#"S-'>82U)\YZR_,`O*U&6B?W
M<KIL1W2ECM[C^81*A:C2Z!?0QPT00[\4A"T-0HJ/F)86]!'IUJ"P@;]=+,>:
M'J-7!OX6A8_1,<K?OL39.:7=`N-4F?$5@&DSDSU=SD-74VA4(CH6(E%4R'0_
MGS:>;U/9MU(D*F4"3[2-YV@PQ%%7,W`VL)-GXUK#`]1'4->.)(,H?0.B?\5M
M2Z^UPW[N:CDM8:4MD4HKN8`UUN/X&-1\K%5"_4`KL``WR:TYV&AUS4&!`-)W
M\@U,US54OW<(D5*I]3ZC^4R</F&O@E[2T,_XP,9X5YE]D11R&M?]`\M993]1
M]83KO.W2<:#7<TS7M<P%Z0H-=4#.7@_N8%`DR$4&]^[`:`8T3.A];!B_-)YP
M/5RIJ[?\O,M)L!05I/CG=7\_P@"[)5P1`9##C`%.2-B:P@\@U&E>CA<4?HZ'
M+G9JN05?\C,@"),,L#V%/IVO5PL99!!W"0PS7D(:DP&.M=Z>2'";>0(W1=[7
M`==T=D3(O29M@"N?@(%;H=Z24U>+8%9KT-P?NQ]@MPRSUP0>9+V<D!`6^(*P
M9IHW\%7S$V3(@X]ACG??PC1_,UY'IWC0Y0#H0KOU^;MI((Y$"1F("0&^FFZ@
M/T$W?YP-C[3)5!LEJ7V'SOZ'-(RS<$L;A>SCF_P;TRR6O0`@M)BMLIY*6DY6
M*A3)TM%'6JZQEI.0LV77B8$*>?#3:IW36(='BTC!X+1:2_[QE*3LLF+#;FG]
M\TY1J#'"^O#><KDI0"?OI6#">'FM\3=*;[AC,3[03V]&V"C^S=E*3'5-)LJH
MK%]8E:R8[0,[Z?>!N4-82P+6`64*#`Q^,DR\?;J)=[?X!1\3MCPDSBMI/Z_I
M':<X,AAB?1)M7C5@7!Q;TI0$%H<.H9JKL9P,:D[2E<U=)1`60Q9)6,=16TR\
MPY)Y\<CB35]PU6GX':PWRYD=NJ#7H4;V^1)L77WV`GV&)2W+@`$A4=I52"RD
M?]#-#R_AD;:^-_FG,$W?HOA@NJRBJQ2W".UBFFTSL5K.UR5::[MR*6C97R0E
MZ"9'A1K(6S"N&0S5[EQ@L/;)[`9P.X<+!L1Y&,5X]SE,8WHNXF:[/3^?V;CS
M%N^C;:0?X[6^Z!2J;=;8)N1BOBCFXX5,5`A%DE0DQ$*!<51W&?YDYW9ZY]QA
MT#8QZ["S"@P,TEBQT>]XFQQB5F;T5MR+(WZC_=9M[SG%68LQ'>;1)P7,>/E9
M228JA!9%?*%0-J:S_##L.62%N:EKT>&)SKC0PSGY.8UAP6:9FW6LV83'#ZA]
M2X[1]NT!_\P_'O4GS]O?`X5:PQC;D=(\6&ST4.-"T3^H6,3D@HT-Q_0WT/CK
M%\HT:6E&F2HL@"C3K\V)7[O'C'41/?)''1I`AR![V2VGN/;0Q&#;+2Y-Z!=U
MV?P,'7",4];W?'PK:H5Z@%7-BIWD+P3R?FR?\.Y\Q/?[S\^G8_*&\0^<OD1;
MS&XK_4C/M-+:HCC.V":KFR.SA1>VYSSR;[SCY4@_)5F>/1AN0[B.+H><<!4'
M;-NBQ7(BMK\49M`5Q,(0)"SAUP,C9@N2C4&5-?P4=V$/$B5VF46D\:8V`;7;
M\/$-:O%-=/']Y?$BOA_D`">]`NR*D*Z*>9G=KO<]_R.HLF4(<3U][YDR.W;A
M9]-U<:G%=6D3>LSC1Z`Y?]+KFGY1Q+)81:L4_D?1H&GL==W/`TN'M9TQ=AU`
MQ2L@I'1IAW6ZKXJ%<IE7&ANZ?.E.#73SHE?TH]K8U>:F>S3KTU$-2$UP@#%%
M.93?'I;1M;[\C5Z\]5>8TCG?[#[E4[[V78BN\F#0V,U(ZUF\S4HQ<I*5(:Z-
MW5:'"GWH/BUFUGUJWJ\9)`[T\_-SF+Y1G%>A\*-,Q&!\:!B@1TA!Z`$?B<S#
MKVR"ZW@3[VYVSU$<97E*N@HOV+P+U/)EE\"WLLC^,IBIV!<JY"(AF.V%J8N&
MW2%Z!;\#R>\/8@;TR':QA379H.#ME+TUI-H'S%]89L8=I=UD>`?2K-N-(,%\
M.N^*U0QXP^GU`E$'[Z\2>/M$PB\X9_H-J=T#"@)NY?A<ER/JAUW"56F!]57C
M\Y78L::;#P/"WG"OI)DI/GF_E6>F\!7[`Q;+GF-\->;@0Y(3ZN!U[B[=!*4+
M(XYJO*`/AC\$<$/'!@=6<.#C6_6(./UV\QJFN_L3.WQYEZ1['.5G6ELUYC-X
MG;)@F"9PZAEDOO4LU6(:F'D+27;0X\WR<\(6Q(Q!PAHDF8.^Q&*ZWR?Z<Q?9
MBCM1(J*SYR*!9_"O!\UV0AH>_O?(9K^R*9'"#5:0Y4I)J]+TCMA,8;[M5-QF
M,5F.S6;<G(K($+/H?=+9T-`JZ.S`ME*_:S(S('-,,M,%?Y0+Q<8U[B'Y>J9C
MQ_O];93B+3&BR56.E+J^]NSJ'G4H-+F>\ZO4.$4IAEZA1&6/;[QLCGA.7+Z`
M0D9E-:QF*(K1B5-9GJ"864B7+':%C8ZO;/,LYM=N/AX2Q"VD2VFEC0"WS'D6
M=UZFK<S&.(E_P<5>HYTI3$YNLG/&K^7E>&X^S_OO2?^%Z1HCWMV\X#0\8/;+
MVS#'=V&4FLZ\N[;BW?;`6UVSOBUBMEA=G5X+:Y$PES^!J,&(6@QY?-_G[\+H
MMQ#Y2RB"QWH,:$>#MZ?!>]$%[WWV]:VYXWKC`+NO"$;3C^U^/FK\_!-GQ*^B
MV6&/&F<\QE;EFG!'MM\6O;/E3%YYNCQ?H2351P.G<FND7BHW")`S(4.KF/-X
M83+!:?!*V+S@NFM$'W;2@QM"U\GIY3`/R4?,?HR;ZTO7TO)NIC6T+EB/[::S
MS4::QU`M(5O/8[#?9&S)F5U1E"?H$?/?X=U[F;48*:0C]:.Y-:@PA\Y.?,1(
M6/2>)B5&"BN_($35Z_U@3K_W-S/12H+#IR+,'P6V#:#6_,H7+T9-1%GNN^%Y
MR6A[O,PWH\U0<RB)M:3WPN2]@S82=W.N_E6_`.<K5_<.7&..>'\^'M]$;[Q@
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MT2W$*#R="(/3,_<H)^%ZE<*5/!ZC`U,)WZSUA,D%XOO$&H8;I"L1?B,?[TN.
MG_7+7LJ'G>);98'UGM!@5FZW;=S>064A)@SJT.%PSX+2,_G"CA;/W*'+E&AU
M_&@C`8Z0UFLXU`]#(:3[U4[3]4:#$/B+,89[)B&$>?:5U2K[!E^KS)QD6G1X
M<%%%S1RBS5!X4_TL&#:$`=9C\_5\I88&E01:-W.X7ZJFXT.;8S#@:.28'AMR
M'+R`AK%6L^YI2'ATJG),$FEE!`AH\>8Q?#.!Q(-*SBWY9@0*<$WGTIZO2?PQ
MC/_Y6Q+&V4V\8^VS:)[;/JSI50@0&>RQOO-\LYA<((K(150P8I+9['AK-\8A
MOL9RNP(;NBPKRV84]E$<QELZ@1#%V3DE?\?H1*>)HROM_;.ZWF'LK]\D'6_*
MZW;!K))[VD($0D31(8[VT3:,\YOM-CG'.<FO;R*I6@=_=B^[)",KBZR'4)-R
M<%C)195@5$CV8;`XON>!A>>@@.R4NS5(V@=KG#U0SV&:?\>G8[AEJYD/3S@-
M3V_*:],L7G"^:\EDC>4&D>EROIX$8CL2E8?22B"=/*<276\L&L^O:>67)!`)
MB4#WNXWM9-#?23<;=VQ@5NW(:0T,2(-,8,C,:5V;N'S094-[H=UZ]6RQ*OKX
MA0P?5B.&^1-T\\=9"ZE-IEIKJ/8=-/OO][04\-TQ><UN'NF]B5M=B5WC*Q"(
M4-AA?6?F:K%L8N-^SZM=,X'H'X5(:)P,];*!F*2#E\[18TA&)8YTL0%&U!V?
M/PB/WY*,U4BT1Y;^51B$:>VQOA-^N9DID%;*185@GQ`WCM>7R.OL-0`"6Y-7
M@T1SS$`1::PG4W\(`F6=2LPM5^7UNE4O"+1"3'\WFITY#RK`*%-&F?'`55XN
MRDUH/\_%@TYSO*G=MN\R7ZZ+P?YED97K9#J]]]B<Z8.<65:7*[,-QD+2WQ#6
M^N0N[7795$]]I?]^I']K%TO[`B@<NG8L%M/U4@L+#[I0H_@7E%NA&QCY;[]`
M8NX9&4,!!IHO67;&N]MS2B?BV;T[?%?QIR1^(:;2<S+[/^(HU\^&=1+B&ES6
MEMF7I)PO),`AK@!Q#<556V+;?J6$#G&8&D`<7B<4@71,@8QHMLGS,W$W8[&)
M>&S.)U8-`:?;*&.E_EY%%2QP]'9._@M$=PNJ=RCG/[]+TJ\D8F'V1,S.HATM
M=6\XF=-?H"_H-UIIW32MYX$M$XC?T>,Z0B6JZ?20%L:+$:.(3Y?$X"W\K5!A
M307M@?2.%K[B5_:K7HU^];(O<"\MLIXH7Z]FMM`FPOGO?6S;^WE>`)8>J?M;
M5F_3Q5G8C/1DO<7O1?I:8[4>+^]P>4^W:_3)`_ZB+WADUE@?Q0XF&ULL,L$>
MPK"[PY=M)N!M6MUSTQIP562\`QO[I;BM\;,8O6C+;'47Y`L8E=;9-A>3Y7)M
M"T[^1'&5:JG*0[@.#XGB:E1L<M@+!!L3WAK1^N"-LZ.STOV0?`ZW3\6M_7:M
M93\9SO=]=C2PPUUAY590>88F3Q`F6LH;P-".`U@40Q%]OH2J<KU3]*J1N&2N
MAP11+67Y$6_Z&0ZBP4B+7Z`7GDYI\E+=K_&8D)_";2_MB?EJQVF?N(%T2,Z/
M&?[7F7##YQ>;K:BZQUUV+C0V6&^-F:R*+D0I"3%1/NQ.'<.YH)=SSKH$+2E7
M:_A-X?``+\IS'>9GX9#2K:K[=+%9Z6`"6\-^L%<:?/A0C]Z47@9@0!]EJ%O3
MNI%;]S@<-KIN;0X6J_)P0R.1/-BZ/89O2I!XLV&[)>$,4/%@HW;#H-;#M]KG
M`?'2]:!IL%E,-UK`P!^J'<4]-69\`HKYL*PQ"!Y`Q;B/6O4H'$"Z;$:>35;3
MF:ZO!;JU>JA/FIZ6!_NL#8EE@`3PGNN&,2UWDFF>!L1$M_N[9L%B,M?``OYB
MLA%<4Z/#EZO)S,EF`@GX]627]I@O*-,^#XN5;A=Y;:H]).J4@KVE;!3W3(CQ
MX9ZRML1K04WON\IT:U?GY^<P?;O?_\4WP-YL\^@ERM]8,Z8;=G1YT_DZE959
MMG==3%8K\B=?G>*"I<W"*!2R72]`7<'%J>SB_1X)T:B0C9APP&'8U3P/&A^W
MZ3G<$E,G:%8+2_8Q@FEY3Z<C.YT8'HN3\5_B?9(^AS;'T"W?=MHJ6YED/2B:
MSXO#LY+@ZD($),GV8!IQ?-^#"]]W4;8])MDY92<UV$[U/8U$5&F"/775+:7K
M+;Q]`,'0&N'T4\(*$O$-XM^C[)\MRUKFMURC4V^*]16X\_+^:R$0U20B*A)\
MU6L\5X,AKCK%77MR7N"M)4:C]*L?\/8I3H[)X>UFN\59=H<Q+8KR)>8;:-GN
MCYMXQ\]DY1%IFND5H.(&T(=$.EFJZ@>-*-UU_WP\TSOL)%I/>!^^4D[Z[E0[
MVF.,3K244137#Q6$,2V/6AK!KIXM;^#-$_E\O./N/U0$IXT(<NV(J.?%H+[$
M2.P.Y]O7Z.7,DA'LHN;BGF:ZJ4TR!&`H`17%X'IY"#92&9_LRM',R)_I6MS^
MQXF$(\Y%L4K+?&N\Y`$3URVR'4?/9O.)D6#/7&Q11AJ>+X?X::!!(;:H6>H'
MJPWQE9'5'Z=?N%NYZN/Z1#IJ%)JX1!&<D2@B?8YB!CW"1]$6\_V\ZD^F?M0]
M'2CML$V8Z7*Z*DF@E$2;JXB6)F"RG`-_!(^F38^X*+'['@3B(W@5&+\3(*:-
ML)&0K(\!Q#1).:W:,GUY^9S#J9`+Y=8[8H/B7$HU^P\^]3C,FZ"3-ZXF-+1I
M)$]AJ!T?I]5Z31Z>DG-&QAP/K_CX@OFM4+5BY/HZ!1W>=MZV69MF2:.3^328
MST1S]YJ@7$A'.1,O[@(C@SFA`)V(.-?-WY6<GA9.%](1%U_<\%8J0%0#9+F#
M:T6`L0>!3]##93?M:&<@5TUKMYB!M+9$P?W^AJYN'MC:B6&+F_I9EZVNR@#[
M>Q<V8GL;V\!ROT>2(-#-;</="DJWDKI;(2OJ%O\22C][('_-Z'8+>FP=?N>;
M,0-KC;4V3*,TV'_$$;O2+7^[W]\=DS3:A=]QAHDG3W?).=ZQ!O$WTC^.,YSI
M6^X^8EPWX3ULM!T2K1?S]8:WY7_<?;]#1RX%A8<4LX^6.6ZYK^XKHY1*"[OM
MGNM!A2)4:4*%*LBV_.HQ"<KO+Z2@F_+[P[?H`Y!>-NU]0PC1QO^1$=[\G.71
M<YAK[WQK/.2P5:]KMK^=="$N:B7O4]"5$F`:\0%>!(4728L7KIID=<+(;;'"
M6XC,_I-.5Y'/&>UPR^EPU9,.<URAWK:#MYI.1:+_R>9*"RG`.V2&>L22_C;]
M+_1[F.91C/X/Z:KN(WS<>;$=QI!8,@QT01BE0RKVG-Z6._:,6\@-3[ON7NI-
ML>U%K%:+V8+W(H4PQ[W&L5R82BZ@2AKTWN^QW`LD]T!:+$N@E-VV%L?'Q"TK
M>_MF@]GFDT!X;9AAGPG!R@>L#C*_AE,NR1.,#G++*WQJ`-'$ILKA,7&9??YY
MBOAFU5O%>,CX*!`RFW9TJ"X<3&K0I/=4%J+0CLJ"`>LPCZ8UCRI1Z-;]^&\\
MKQA8;9QQ"5H=6IJH5;H^*FSY_7ZFZ(LGH$#*U5L.@M:+S63>@":_K1,(D#VL
MK\/PB[;H@R/P]?`@4,0?'''U1+\`FN0FQ)3+7S@Z/.5X=_."T_"`OY[IH/=^
MSS8'WY_S+"?C^"@^?`RS:'L3[VZCXSG7WJO=4YC#B9M^%MK/A)0P$GJ04(2X
M)CJQR70A21EBVMB9`*$/9@K(06SD\E/GC%]EO$V>3T00>F11H"N<.RX9Q3A'
M9%B7T:UW?#,_Y!S2,*3(TTP#`LVA(L+P&Q%,_DW^1?Y"PH?)/_X_4$L#!!0`
M```(`#!`64,@W:<G,R4``$R8`@`5`!P`;V=E;BTR,#$S,#DS,%]P<F4N>&UL
M550)``.<76I2G%UJ4G5X"P`!!"4.```$.0$``.U=6W/C.'9^3U7^@]-;E4JJ
MXG:W>W:3[IK9+?G6Y8K'<F3U]&9?IF@*DI"A"`]`VM;\^@"\B*0$@``)"A3$
ME]T>&9=S/N)RSL&Y_/BWMU5P\@(P@2C\Z=W']Q_>G8#01S,8+GYZ]^WQ=/1X
M>7O[[F]__>=_^O%?3D]/)I.3*Q2&(`C`^N3O/@@`]B)P,O7>4(A6ZY,'#`@(
M(R^BPYW<P?"W)X^`_SAA_SL[H3_]_6)R=W+^_N/)R3**GK^<G;V^OK['>):/
M^=Y'J[.3T]-\OE]2RKZ<_.7].26N])<)BL/9EY,?2C]=8I!./*,T?3DY__#Q
MT^G'#Z?G/TP_?/CR\8<O'_[RCW)K]+S&<+&,3O[-_W?:^,.?3UF/D\G[R?L2
MD_]Z\HA"0ENOGKUP?3(*@I,)ZT5.)I15_`)F[[-!@XS=$PII2'YZ5^+P[0D'
M[Q%>G-%I/IWE#=_]\S^=I(V_O!%8Z?#Z*6_^\>SO/]\]^DNP\DYA2"(O]"L=
MV6"\KA\_?_Y\EOPU;4W@%Y*,<H?\!"4%`D^$+=A_G>;-3ME/IQ_/3S]]?/]&
M9N_^RB;\$:,`3,#\)*'A2[1^!C^](W#U'(!WV6]+#.8_O4,+$";(?_C\Z0/K
M_Z<KY,<KMHK"V748P6A]&\X17B54OSMAXWZ;W&[(1]BC(T"?)&LGRE;B&6MV
M)AWIK"V=$]KSUT>ZV`&;8SR_@2'].M`+'A"!;(K+P",$SB&8Z9&M..8^&7CP
M,-`$7V/@:`DBZ'N!>99NZ6&V`HT)S[H;)^O2(\N;`+V2VW`&,?"CQA3NCM0]
ML>T6`W\X<TO@"A(_0"3&X,(CD(SGY4MI-)LE"]`+FA\J^N,;Y.D1+D*Z<7PO
MC$:^3R_!B%[5#RB`/@3$*'<-9C+)9X3\WRZ8W,"N7A"29`;^K]=O[)]T2A]1
MDO_0/6Y-3=HY]V8_K\84!CG[[F%,5Q1YC%<K#Z_'\^R'D1_!%WI#-V6G=MP.
M>##Z/>2#[N$+D'$<,?F2R?ZFOT)E;)/[9(EP%`&\ND<1(`_>VGL*@-EMHCZ#
M0;XN44B5L@C2N=B\V;13]+BD=^42!3.`C7+9>#ZC/*]6,&(R`AF%]%!*[ANJ
MC)J^U[3G,;E>XR<"?H_IW-<OP/0)HC:X&?$PV0U3M!'L-_(=&>.%1^_#9#(*
M+J$"PRR]6L)965(J:05%YX*9*7B++@)Z1>FAL4>ZN@;R(B8P!(1<`>)C^)R1
MRI$YC4/58.:NP9`*H\8!4)RM'TSG/^R7^<VL78-0;#VJ.I8DU0D(:!-Z?A-*
M,KNF$EF6WEQ)+^-+HBT9/8=IRNY[8TO(##%=0Y;)IAW>.9(9[#%G]E/7SM/Y
M(<D$]"D5T*_`4V3^)N"/WC53=RA<=,83?_"N69*(W1WN0,U9.U^L6R*Z^?4J
MG"!C[;DDOK$'N@J/M#$(9\Q^EO[*)FO_T)),3*>F9%1F"]A+%,)52+/)DN<F
M`OSW"_1R-@/PC*',_I'`??KA8_;8]"?ZTZ\C.O6,37\3>(M\N,![`L%/[W;_
M?M8Y/9<Q9A;M&[K`O.!_@8>OP]D5_4(<TH1-]:C<78CLEU_SSS+B?);1$XFP
MQUX>*D2I]^L>QYR,%)T'@"&:W=#?"`=(<=M]T\F^HAJ51<O]T9@B(UZ0_';[
MHV]*AY60E?RY>VK257]))\3,>C(#;_\-UARR^.WV1A^]W++GB42:KEIP1<3*
M.NV+\AL8`'Q)5]8"83&NU5;[HFT"%I`=<6%T[ZUX:Y';;$-=^8(=X2JE'O;S
M\>@_*[?KKH]%UN+L.7D>/?67,-A<S'.,5CIG=4X%XNRF$X1G`"?./Q\_?'AW
M0AF8`WHKS>Y2EH4$)M1%`!.0M&0](<*4@I_>G;\[B0EE#CVG!LC#@F=+GBCP
M.1_PD=PE!4Z?!IRD<D&!U`\#4C627H'5GP>LQ+=4`=-?!I@D(ER!TW\..,F5
MU0*J_QJ@$LJN!4J?!Y14=9,-:%3B[!:T'\^V+5Y=VL$4/7<;:S)SCSPE:,3D
M=.%YSZDZ`X*(Y+]LZS79S[]F3WD;#Y9P1G_!,84<>D\PH!0"DAT%6RI/DQ&:
MZVKM.9P`'\`71N(]B-18XG:QPL/&9>/!@[/;\-)[AA%=RP+R!:VM4$X(B+9-
M7EM_M$>7P-@I:&2/SIKE6FECG4HE4+?;VJ":>9RSUQ_Z?]>_QW2C!\E[4'3I
M8;RF]]$O7A!O&WKT^EKAJKAAI0QL-[-#:\6_,+]#Y,N]II,-/JXR.64"7D`8
MU]`O:&R#[MN0O092>97>;P)J*TULT%@2(^B&2Q9LZGE*V,:+MLW$RMWZR$O-
MT:G<W3)O\O7?$[EPEPQU]/MP>SWDRE'M4<]K:8GB9RJ09A$R=`6/HR7`*A*.
M2D\['*%G>A6M'P(O58;I-GQF>I[X/)5VL<'#!-!%#'WF?]="'M(=Q0ZGD0=#
M,+OV<$@)(53-BU=QXGI([V3H0]$W4^AH@Y^-$]H]"B^\\+<[Y(7L8BA+10*.
ME+I:X4EB*:DYGY6ZVN%)46;IB92B+9>H2")[-%'*=7QFCZS16S=FR'.W7G;5
M@9%?;`4^;KWHZBZ<,A)-7FQ1Y`6'@(1`/BX#HB@[%`9^MWQ*M/'2EKH*Y%P^
MDQ20D]OS"YA</IH48*J:=@I8W/(LT89%20<MT&K@6_("\!-R!B\A,DW<2?I_
MW^D:Z,I0R0Q*!6YNN9>8P$W6NL#-+5\3P^M-8!@OT&OB@W)0NU5#<%!R=7#5
M^;D9=&J6IE8.T0=Q;>JA5O>ZZ:IC=#.T1&^HKCI%-T-)?E8U<87N_S&O8Q/>
ME5UY9KVNO0L/"R=U(:1`T,U;44\`X[[`NNIPWPRB76<D5QWMF^$C=.QTU<F^
M&4PJ+[>N.MPW0TRN#C:Y_W3DA#YZUU?3"=MUS*2TC'%"]BPY%A\`3J(AZGTU
MA3TMNYJFP1RC.**:8IIJMXZ3G1Z]X."6D%B=^JQU+R@7!_DK=;'OPG:/Z.)6
M]V,K-;=/N^+RK^G4%SZDFT#2H2_TUV^%NEY.NSX=D&HJ/B%<-]":06SW7'(U
M:T47N.7GH.N&6I.8\>-Y';7=-@5.215P-<.%0?!DQYNKYC=#H.V>;:[:XPP!
M)CC8NC;/63.E9#6NK*BVA,[_%:$9>42!6!FOMK*BA*=/<`EJHW#&:N@%4^\M
M\RZ[`"&8"X-*U/K:X"JWLN97$<OP[U,2KV`01T*]L*Z7#4Z^8D3(`T;BKU!N
M82<"E^VR.TK$#3VVTD3$,85Q_,Q*:-*]32[`'&&0MJ/K`Y#K-WIHT0.(GF9X
M?4NW*[E']*]A1'<PI6]Q&](#!A!Q0&]W,]I#<'-PU6C*HM;V*%<]+T2M[5">
M?O",%"'%U5:V(MQ)DN@[Q:]V<PB:VZ#]'D3%9A407&UCA4HJ/J1'!SL(&"GR
M52%NWROJ:\Z1^GXVN!GG)&7$B%;-;KM>4%N#N;B]5>IK]RBOI16*6:C#[L(5
M42UH;2E&'5"5C\5)78$7$*`D%E%^SLC[V.$B\6P4+9/-GZT\/H!$DOM*A0KL
M!<PW>K:"89)*-((O-4>Z8F<;?'T'K"H[F(U>`%-[[^/5$\#C>:*AE#1Z-16G
MX6`VS1\UTG'5R29?GJY;'C5`V;%%N&Y@U,"FHEVWLR/VWPE9`Q>)7..Z6U\3
ME,KR4SLG/J=6D8)FLK]TN8>+5MN<`TZMJ4ZMC>TR%#B(,\>RYWIZ`IT=6[5N
MM<M0X-3JJ7U_:96?P*U5U%2_:Y?(H/\0*MLUMW.&\(WEKGO;-81KZQ6DF6_=
MYQ2E$"R8$Y"#."F^DC?SLG,>/:'5UG7GNMKG@:U\6C(+L>OY5[2P4K7UNIY\
M10LTSM/:_M*K6',"8UGI;@+T2FZI&(4!A<9*]9/_BU.QA$R1(&(VJS<OC5S1
M'\=.K9<2E1-`56T?)CGN"FUIBMAW><#H!=+O>['^1@#E8+-"1S[=QFDX?TTI
MCBZFLH+9"N$(_I'L@_&<%;!G5=Q9MI\'#%8P7HD`J.TWU"4Y&*Y^/>\17VFM
M2KJ/,/`(N`+I_VNQ)QC"%H_L&F"F/_K/5$]DVS^<94[5Y:.`[:$`D1C7.=&T
M'E8/"U:Z+N'PP^=/'Q+^DF)V)4_O]-B_BC&=.(4_#SB[03B[&LCU&\`^W/F8
M[<:R4[7F*4IS5!$6*9]FJV+'.T4W+>^W8D?A1\'74^YNAS<J&_DP%2>IA%LZ
MZ(7LB'L866?YU3(.63:P+!G8%"6FJC130VEA<`69QL/LJT;Z%5IY<!O@G3\;
M0?,KAO,Y#!^!3W<8.Q[H0?DS8-8_'FB2UI8\?RN'^FVHDIQ0[!C<9+!^\5UD
M<];FLM2U'SQM9;)39FB[7S^XR1-)ZRS`<I]^<+'16#(]KSY,0'6`?O"7Y;7.
MEQ`WO[4RKTJ#V8P[8"I[3=!!TL1J3;WO]*8!5^A5)'!P&G9_3]^!A1>DM_'H
M#6XO"5X+VW7RJ`2S`C.1$,IK:2E6@V<HX:@QXD`.U0'ZS5]=X(3^0#WBMU!1
M&WY/W@#]YJ_9]Y0-U"-^.89,/3YY`_2;OV;?LV\6WZYCXP1:9V["&<^+`CZ)
MM8?JW',`=T,'5'M929WEK1/;_P0DF32G:.J]?8?1DED1Z)>FQ.7N1V!VB59,
M")094!H/9Y/W*1KYO\<0`V'%LQIN%0:P5)G4!V"6^WGF>>B9S4[$D*2';0Z8
M&8N*!W0#E0RL"GSP^]GF9D*UJW3QC.<*M3J5NO:)IVIM,W41N/EX=J+Y"@HW
M]3$D^TO<WD[M6(V3O4?G]L8WX0Z&('%'%]&\V]!R4L>-+X5Z,L?=+E9YF,HJ
M"E<;6:$S?GX.$AJ\($?N-IPCO/)4<F@J]C8B1TZ!OPQ1@!;KD>\#0FX`R-Q0
MBGN*O0A7*\CP'GMX\J;!T:T6J>O0$X:Y=AG_$J['AG;]03;SU+OSN)ZV;E]0
M2]_)78]6W1?((F'+]9(5^\*7]^3B>FSL_K!5?TIUO;JW*3<X4?&MS5.7ZY7*
M3`+9TH?/]9)F7:Q9=<?!`ETWL\T;7\B-G`0+E-V,*C>.LLHS3@&JF^%U71P,
M#2)U"IC=BF47.<5NUJ#,@=7U<&M]_SRY2,KS(BT6EH[R>DCAQ*91K'AZ%O#I
MZ*;'#)^:"^8&UT\ZHOTQXZKF&E_@.AR9*JCN.*D7`+HEJDN\7AE"N_=T<?FZ
MJ7PW=^6LUGY2<6@H%I6;FHEY+'><=0H(W=1#S$`H\<8H`-31,`[IQC6T"AN[
M`Q8(Z[Q['B'"]2YM!90-WC7IP?&$CF._M_`]*R!V\U73#,`Z`2T%HFYF[6T>
M+,$[7U5<C@OM^\A.5$U,=<)T"DS=S%#>/`1$)2VKHZ5OS8#6S6.\ZPG^C"U8
MY<BN=H4M^G\$B+VCFR'&<^UPRSID!#GII>5ZRN]6R$F%TG8IP5U!3B^_6+O4
MX*Z<<(JYYEHE`7].O@"E!T='`]FOYRU3Z::@78<]5T[4(%..-W$]D:[Z"FOG
M<-(NX>X!X2@)%JLLP*W`+-=?KOB!:/DKWLXC7P['A^/#0[8S-["XBXM>(""O
MID.:8:I908<F0/4GP_=#`N\21-"GU`V)(SM('.E6LJXA)-O%D&S![JG/3RM*
M/3OXW@Y^4+T`0DUKX:[V_<D#@P+2:WST%)#C@Z,O^L=^Q>K"9L'J#9+Q_*'\
M33;A,"55Q$8YG2-(A=AI:D`S5([QP@NS3`N7*"0H@+,\"T-YV8SGF7',"S:;
MJ4Y<-3.V[91BAY_T;0(B*DF!65[0=>3[\2I.O"NOP!SZ4)PKK+:C'7Z26`'1
MIMK\V6I1-Y/[JNIAG#/?2D,X"!_-SD`4>A>Y*4]WB6,#IQ<W'1`ZW/'UQ[?K
M/EJ=@:OC"]_(6^L0U(1'N`@A74G,_S>-<F1)2RC&/G.$Z8O"P"&MIJZDN(.5
MZI`*`:19C6HY0THC&#&S\O3'</88KU8>7H_GTG4C,L,;'-@ZCSRSMZ%!K=17
M1/3T"Y/ZRRB<0/+;Q7I*Y^0\^JCTZ`4'C!KNJYY*#SL5`U6J=O6A1M<6#2-F
MHUZD=CCYHE'HV#]^I(M(J:N99^/88T\!5&29P,4R#36+8AQ*GH[E/:S6IF+>
M?.G&H^<D?I&4=A-V,(+J?<RP8#E>F:_&%:M!#Y]BVIL%GHH`Y%YL#4<RRL5_
M@W7B>@*I["FCL=+.*`6_4(D48<)XSM*17'C!1K1^]L*UC"Z%WG:,@@DMW(0J
M<KE-I:>U3.7TZ^_<@=S31+67U72DM3K"YE'5@-SGZL.:>=E_@WK3D]95=XAN
MH!8*DZY:.KN%42:ON&K6W,,94)537#5A=KLTM8Q*^[-DN@2QDMSG:LV-/1P#
M*LJ"JW4VS%H@*V%.,EN>LR$IW>&I8NW*81T4@EI839XK[D<2*1CFI7N_;,!T
M56G5>`+8B9Z5V4!<KXZC;L97/PZ/9:WI/!D441\U)OS]E;NRYF_`'"MV$CCR
M?\W$;I;-B-X&?]!Y;3P-;4A/9=*<N"Q'Y24B$4FR4CXQ\O,,:S7N"2T'M6$P
MOEX]!V@-P"/`+]`'_$2<HR"A(/'&*3Y;FBDD84KD&=#5+':>N)A[81%WD-$J
M>165]>@1!])W4'D?.[["!-#SG.44N:*'=("2S(;9H2)]YE#I:>71QE^"61S0
M0\/,/I&&;G8REQ740$#'7'P%(<!>P,QDLQ4,V?,#I?<%9)^5R!^^M,8X^'+:
M-N0I(_=L1;SO9K>X+MAV=-'K52-U-:Q!03;8*IHANXA=7XI*<DC57U[ARG?U
M(;0Q:IH7I*O/GGN1LA1VM^-V^KW#;/Q".X;P<;Y%IC<!(8-5YGBL,@*'T_Q:
MVA2+29;LZ-7#,Z[KJ[2]%:?2P`OOO97,7;[2Q":-4M//5J/!,G(PEA$^P<53
MQL6Z:)*==\F&&2>7%,EJ%=,#D]R&*4=:!H=V,QTB8E_39$X9"U^Q.#](%S,=
M/F+?`7LW`[,1U?:I&)/\\8H>YS<>Q%E*[3V@64^%-:2?ZGE\$O#X"R"4I]PU
M*VDJ79RFIS(B%33^T"D13$CP$^G@`B0_\S,,=C"+G1R.5`)*,\M=Q9AYV*09
MY1,BDS]FW^OZ#6`?DATP6@QDY&M/7]%TB6+BA;/I*PA>`$L<'ZUO$W\.^`*8
M9"(.C]/H/5C&!\NX/<MX2_G"U0":@_TN"E*,ZT;J?7TSX_*0Z];O`]A,7+73
MU1BB?7Z7!N*@JW%%>X!=P8KI:FC1OM#M0AMT-1Y)9I:NQ,1MF81=E_KY)O#-
M$M-10??GWNWXDVYUC0Y/Y<-3N<6G\KQ$PR9X+?LARX"ZUGL?%UBZ+@./D,W0
M(GN<M*D1BYM@\"V--O_]`=-5I$&C=)A.Z'^&6`W%M&%W-+1%L'Z0#FA/+!<L
M[2_W\4^A0_<TM<-59S`K20\KU(YQ$E8VCB,247F$:G`">WUM-X=X^?6\BU56
MFJ#="E,=R`$>M+^$(1^I1""O\?W::F15*>;26PGRKMTIK4S^!U-76HR4REWE
MO(E=!QVN24_'POTYQ24$"V;'<@J93$9L9F%V`Q>-R[:=2?A`RK-KK2#E>[:5
MN?<H3FU5_-PTS38[T54Q<],FV>2L5T5,)RN,&_=`*^&_0.YC`UN@]LU@VQYH
M(%BF+\;`#A7\G<<[%?7^SFJ"#RY)LH@!28?N2[A?=U;>O@?J>:MZ"I(2W+L;
M2=*Z^V\HJ)I=^HS;+7KG3GR)0GHKD.35Z%L((Z%KN=X@5M/-*9UG.@JWF_Z9
MZC@U74FNFW+J;YS:"N#./HZK8:.Z%MU-*"J2!8KDA)+[T'FOUV:6+\<#'R2B
M1W[>5%?4_H"PK=QM.WN0\O-+7W22B@)>(C7]JY;&53=4;_0P5_1)EQ[Q]ZX;
M]UD;-93<DGDP2S)'%'^W1IT\Q6:IA1%M/AEP'/)GY;4P-^N4-JF;M]S&X,RO
MJ&[>30LCL^;G?F(H3].*>=%.F+BT:>]T!:DFVNQ>=3T8R1".`I<5-R.)-*U%
MPIWF>DR0GCY?N@<'2\=@Z1B4>F5T=B3(G6VU:_QQ&(FJ'+4YAK?%2M=M];58
ME$1.UZWN]5B4!?_]F4BMY01=(AQ12E?WB$HB>=G)WJ0$!4]106M=JD]^8R,Z
M$AO[-J0CQDDX\8J"!O](8!%'R=3VL:'%5XFZ\7Q`"8N%I<Z%S>W3?AO290M(
M-*$B=))OF84KL@!=NNR5N)$.8)^_G[V(O=FLF8J@Q$^E@Q7Z(08^'9NPHJKS
M.=6C,<GKUJXIG3%F94"E)B2M(8SL[`>,9K$?*=*IU,5NLM3D1)_2$YVM#K6<
MIYPN=I(=ELBHL_D+&ENG>[O*GHSL3=M>4"W-!RQJ;97R>Q1>>.%O=\@+V8%1
M%F'JV)!UM5N"4";Q\!/^\7:\Z_J=RGE7S4_%W:/.VY=:X714EB7Y[</%2'K^
MN&Y54,=+K'.TLC8<1'&HIBC)M1O77;?J45/4REU_M&NZO*K*I>O/=%(!72HE
M'$M"M!IE8+/C:K5EUU\R%8!J9@[97YRK+5-SZN,?02H=,4DI$Y2F*(D`6**`
M\M]A>%TQ.5W#*T@(PNM$8!/;>6K[V#(2[M<D/AB>C\OP7&=Y$[6V3_D!FLPK
MY,BLM;R6O3`;'J.QL]>&0>Z:<EV`K3G"=,T1KM:J;@R3JCW"3:^1QK")]&PW
MS3:2VVRPQ2O#(UQL1V:#'PPU+0PU]?KN_DRC]@P.JQ6,TLIIX8PB$L&0=O,A
MZ#"/3S'R!*V](%IG)2CH].D?1HL%3A)&Y7\7*8^MAS/B'U-+P.9G./L9AG`5
MKQKQP1G&#/TY/MFHHS",O>!GNF?H^F(&N(P0+M&J?<U0FHZ>3E5%B3P@$K'E
MS&*4O"![Y."2K#V(#76L5*TE?3@-O>*7*?T7H;H-)8YOG&LZBJ%TRQ1;WPL>
MHWBV?EAZI"Y44-ZA*YID082RYF;HV1R\V^>NR+:DW*UC^G@6&*4N5N*RQ?>;
MLH58;PQ#Z#MDBG?#I&W+<&H_WYU@C=Y`VF8QGM]`3"C;+X!$<.&E`LP]>+W"
M\6+T_!S`M&:.>-TV&L<0!W3&"5C$`>NRIK-@].(%X_DXEYVSMUP9\7I#&*'[
M-HPP>)-ANM7"T*R-/_%>O^J=1Y?Z$T01]*]]269#;KO#SVDH0@7ZK.#BB$KK
MB>S'.<;$[3JCX`;.H^5H5=%BZZBI].F0,KJQM2DK]>F.,A1C?=`JG3JC[1'X
M5%G5I*W:J3/:IDN(=4FK]+$A@]PA0BH2Y\7ZGLD58#PO?N8=)`T&L,]?1IKT
MX5'6P\C:^=E[8X:!PD@TGC]@R+*>I=<86QM%LL`I*G[-JV6G&3QY:\S8V(8Y
MA6@V19<4R`L,/'\I)WV[L1E:8$`Y12SBW&/Z%.-9'#<J:6V(&JDQBUQ3OK?/
M"SZ=#<8QR<'_Q!Z.``[6:M8\A5YFJ*,;>!FL+[W`9Y)SDM-VQ^QV`[@2BG)?
M,Y3&XY`E0F`7Z#\`EIB,!"W-1&#2NXB]<R4KI4B-PQXY>*3(FAND)TT*-9\#
M5O$3L-*_SWG"'C%5LD[&:4OJ6JC04S0T30-5;YE^JT!$N:49*DK7#"MGFU7W
M_IV>15-T'[/EF5\K-PBS/83")`4UE]#&@QGGY1Y$CQZ]`*[HB?\"9C<8K=A_
ML[LTT;4%`8[-QS'.P>:`I3/-8=26$=WANN-G`EY`&--M?4F7"%T/\5.0G$((
M2^_)QF,9Y^01))LP27&7I_H@V2-1'>72ON8IS?$`)$,JF_,VS%\2QW-5RG7&
M,L4)E=;2+/??E]!?LE+;7DBO]3!$R>L]#.E!J")D-1W*)A^_H""FV&,8B+Y-
MVU'-<(?8[43%JIN8J5D;L3N77ZFXPR5?H=M>Z$N>$9M0F';<#XVOJ!&%M)NI
M[!ZI%91(S:6\9C8L!I0.'X`98;<;4X:9;I(J`'SA1;V?':=K*C#QR@US&O3"
M*?P87=G;[*['%95F)N`Y\/S4YV()L/>\%N\S>8?>U3=*?Z<2_ST*?8_0BRHD
M<`8PS_O&P("]X_\>O"9_:E37J>AL9*U-@;\,48`6ZY'O`T)N`/CV/,<HC"0F
MG_I.AFA+91;Z$>_9+0+$QCU14QO?GAT'XWG)BTIR_O';&D'O6PB3VD_1>CR_
M"1"&,V\""/"PO[Q!<3C+_$-3"5Y\MC09QJ8G;T,?N(V'K\AXM_'K_<%-#^BV
MN-5<6@5\;F:,:`M?H]U:@.IF5H"VH/+=.@K4W"SCW!8UKG*W`>W/;AU_NHZU
MQ=KB.L>XFIW**$Q5/QE7@QR-0K;E).-JQ*-1S*K..ZZFK#*[,ZM^8JXFL#)\
MFLVYD+DEDC6&3.J&L+_L3`>%UJX30`&46S*K":!$WB0%9I\'S"1>+AN</@ZB
MO>;;?@'=(.ZW=#8HH!S4`$U_QP*Z01M(^C0(^2XP'-2#%,,F"0H*%`>%00U%
M6=J*`LU!EVCA8E_`."@9Z:)4SMU10#>H'<HA$@5H@][1P@][`^/YH);(W2$*
MI`8MI"Y(K<!J4#-4'8`*S`;]PH2#6X'GH&MH9(\]'W0*K6RHYPVTAEYGV^UL
MOY8<,@OT!F6!YW!>X#-H!!KA!05L@TZ@'B6T0>W3H`*HQP45J`WJ@$[$5X';
MH!IDQ@YQ?HT"K$$G:!^J7:`Y:`0M`\4+*`=UP5BT<0'J\!+1+A2]0'+0+]HF
M'"FP''21+;MGVS1D!;1'I:\(BX<(8OJ<K:W2%">=W(,Y>,X5%6D*7DT!G_-C
MQXF;"C='Y].QHZ-^:[A?\*A1"G\%$!VO^B?*";]!9CN+>!%*Z9:I29)T.S^(
MJCBYNB*:YQ062P5;&7N/"SINNN+2_E+,EU]L/+?,;TU`DY;I*8!RRQQD"*AR
MC:4"*K=,$TV@:E:HI$#0+:VY&8*:A5**#`-NR1)#$4Z+13A_<.LI3RG%5'DM
M:><"V=\:LU6^]#%^(N#WF$YQ_9+`TKYFJ9F\89=+".;7;\"/63#K>#Z'/L#2
M2HVR'E8JYS%Z;B!SAX?LJ%?D0-##2!:T;70DF<Y$38W007?>]>HY0&L`KB`&
M/NTG(472VGA.Z-*3RCB.2.2%,WJ_7WLX!+-O=*_A.Q0NV*G,PJM#A@\]=!?8
MXU<1,#*P^;S7[''C*SWNHI8\J0]D)<]MX(7WWDJ6<+72Q":-TO2J6XULT#D!
M5'`%LP</"RHD2AK:IK=\L5^LRW^1K`R-`<QDN65;B;WXSMC;.:#SI0+41CRY
M6!=-,E>MT:N'9^-$CB#)+B2W81[ED;\5;PY,WE[N?E*[V$S117X\&66_/*ZU
MG->$Q1K?(#SUWK[#:+E$`;M0Z`]\M@3KO-%0O<LA/(Z60J%*H:.955K,,T4L
M]C;?!6KD-AO#RI>HJ@QWVPX8V_B+FO>`=JDTSF_;`ZI)3;EM8?,>T,ZK?2YM
MV@>::[+V"UKWA')YYGYA>S,YRU_1=(EB0I6=Z2L(7L#U[S&,UH5Z0"5;L=ZG
MT=L&UK^PH&-Z$L-9W4G":VG38,;3C"HA/%M:B>NF5KX65@0%:ZQB5].'U2N"
MY04D-=ZYFKVO`40BZZ"KF=3T(.(>L*YF1E.#IM9ZZFKV,PUXA$9N5[.:-3=Z
ME7<;#UG7+_XZ598;E]'BB<#5A/BM\-1XCG`U.[X.?CH&,5<SXVNO-WWCG*L9
M\O6A,V)]=S5Y?J.=V\A\[VHN_?TM2/6G,E<S\:L:E"NKE6O`/3+)4!RE)C(5
M.QL,J8N0CE;B;!"D+FA5"ZVS,8\M=]O=,47QU3Q*U1Q*1ZK1\_VF:UZ#]U<J
M9;]>OXE3^!1MC,Z/=(+4&7J,%UZ89?]GZ3E1`-,:FZ-P]E"B93SG="Z<B:>4
MM(N`9:.P\!PW\GV6(I-I<Y1\%I57\TPNZ6#C.='X-^!S;7P:J\4]:[]Y>;N;
M1WA_]KR^G!07,:&7+B%7@/@8/F?H454+$I9>I2!F.`M:T-\`93Y?#08ZG/W<
M!*7CV[&/<!'".?2],-J%=]BE;9RMU)`5>%ZI=3Z<W:B*QK`#^<CD/PP[L4&H
M7<D0G%F5+A%AY<TH<>NZK:C:VPYGR2-H6BQA`LEOEW2KP(C]2\B-N(<-#MC#
M.%TGY`&D3QMJWZ2NEPU.;CR(?_&"&)04A*+N0+9<!/RH];7!%<OG$+*D!&H?
M1MC<!NWWX+5T$F%Z&L=T\9<05>-)>Q@[(6U)OM\)\!&]3MCFOLINSNPO`N;J
M^_6#&[5/5=_/6D#6SI/D.%=)*I["\G.BR4@V./[&<DY?DPBNZ'4IBHS8:F0D
MI.![DK(ADJ\66<O#D:CU3S?7_<OT\-M>HZY[C^FAHRC-N.Y"I@>:PB7LNN.8
M'F!BZ=)UCS!-ZTD3"<)UES`]")6-`*Y[=ZG!)I6F7(_1TEM9M2:,_7D,'`)<
M"KJ=ZV&2NB>7Q,BWOUC`OMC+BZ?V)-B&>ZCO>/C:?<I2)OFI3'*-D;WEH#;,
M`FT_74L@!*/:/`G,K(Q*N=NV&!_?"UQ+R!)_5"L/<\.YDJE'_A+,8E8M,(]\
M?@3X!?I`$`P2)+0DOER9&/('Y20)^$C8JWV=[VP^M\ZB#K_+\9U2F3+6$W_:
MS>0UI\EN.Y-V_GK'UKK65C-3BS#<5L`'[]*:'6#O"BZ.N"2(F`5J4FC3%$",
MDXQF,L83N%CJ7"VZXYE)4QBO6`G$\3R;9^1'\(5.G0`LW6.*/6V(!P;.JEZ>
M#JH?R_5W/RE2!C;J_EX&^W+25JM+6#6=4`+$9>BV51=^8SL^'UP$16X=W,96
ME0$I[N(2+,<LG^29:89-TY!N/H!\LOEM#V/+"/@\OAVC5'O4ZE9J5!UUUX-<
M8PQ+'O(ZWZ$%F_W8JHUKWC8%[/BV]G82&:N[V*$4Z?46!&'['F5>T,DIU".S
M[X]GC%AF_Z;_\?]02P,$%`````@`,$!90Y%;53(C#P``#Y8``!$`'`!O9V5N
M+3(P,3,P.3,P+GAS9%54"0`#G%UJ4IQ=:E)U>`L``00E#@``!#D!``#M'6MO
MVSCR^P+['W3^<.@"ZSA.VNXU2';AO`KCTCKGN.UBORQH:6P3)Y->DDKB_?4W
MI"2;LF1:LMU6.1@(`DF<&<Z+Y'#X\/EOS]/0>P0A*6<7C?;1<<,#YO.`LO%%
MX]-#L_-PU>TV?OOUQQ_._]%L>OV^=\T9@S"$N?>[#R$(HL`;D&?.^'3N/?@3
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MM%CZ0(F6KJB%0$V$`D%]&W4S7@Y'PP1J@68K^DTK+K2@?71+)>99<`G^T9@_
MMI+"8B7XD1#8UM:A)J4:]R2'&P`M1L."XMK@V9\4H^B28AS*'D&J8JRXK!A/
MJIDHQM(E&J=MX2@BQJ`^DBG(&?&AC%]@OS,%IFZYF%[#B$0A,OE71$(ZHA`T
M/**4H,-(008@8DN07S65<\(85Z8',>_ZRVQ&V8@GK_A!-Y,SP4,8H+-X^N%3
MO[N&197T@BT-UKKF?J29)"RX88JJ>1<)BZFIKN'1X*+AA%BPD#(1P(@R:IAM
M'[>]II>BVX](RHMI>1:Q\]8JA57B$7;7/?:K>?9)Z$>A0;S#]P0Y@7`AS@1V
MD$QM@;GD;#U>\C6UQ3Y,]("\&D?JC6XIPQZ7DO">2\/(54BD3/Q)&ZN/"'^6
M1'#;[A0-MB"$SY<DU)V]]S`!4/)@JUUL=4^PTU034!0U4]EP!GN#]5X[K>>]
MRG#PT\&:&ZW9Q7!S"L6V2LK<%GFS8I'%L_3XR.O-=(B*D(>6M=D65T1.;D/^
M)+LLH`)\56R6/)C;0F^=%M+4/$/N8*'J%BK1XQ7C;+#9+R5M=NCQRMGP(U<@
M!WPQ^BSUV1-CPNC?1I0K[*=X2`/STF'!O26F-70MD:^I]$,N(P$#>%:7(??_
M:SG!-ZS4[4W_TD'J`@M?[/H/+E/592XC21E(>0W2%W26V.V22"I[(]M\U9QB
M"[)NL[];-;NAI3L0F]K!_E7M_T#'#"-6GS#5\4V2@;+Q/;9AGR)&)9N7).6T
M<_MXU<X656])UDOI'BQ>U>)+[>)XSJ<S8-*(U0=4#`177*(I)S@27^K,ZSV9
M&ZQJKK!K'6X?:>=\1"%2T]#R[.H.SE'5.;X0(;"E;1L+.-#=)CU9-6E"Z="^
MJ_?H$R[4`'2Z<J@J]N#%J&[3G>9:HZ;2U&0\4Y6'[9L,0SB8LJHI[S@;;V?)
M8DRW(5^O&A*C^4<0BJ+MC"530WJ*>Z;WGO`P`'&P:U6[XA@UI<H\8E2,:M8A
M#3`=SVS;\U8DZ?:$-WE/6%`W"P,9^@?[5^ZBHZ&$OR)\O'FL'ERMQW9;]6VN
MHUX0\F)*!TM^G>E3^F&/TZ@%2;?-?ZDXG?)>I4^']-NWGED-]-A:SD?V4Y/;
M=7*)MG6S+.]53._@,7N<;E5PAHU$W';.9=;2J=?!KIOV92RT5I#8[`2!X8B$
M^=T:U?&<)CS))<T*DZ/X?4G<WM3AO;H&1>AAQ66SH9V#<RF3;T'!;?Q\-FS#
M$']P@]W=0`^%9B2T!\+BKS?/^A'ZX'.TR]_I+J!]$7,[1RZOMG80=Q0EE7K+
M6@^NLJ.KE.LJ*J"ZW2"?HUOO!H?.84>+I_'30S2=$C'OC9(/'5_11ZKFJV;>
M".^V;2YMMXC?]`S?D-210/+52ZD>#%K9H*4:K1O8;<I<WLTRY:%9?J5F*7N1
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M$H(C0H'@UPLR+T3ND`PA+"DRPA:(?*<IO!!I5YMY":$1I4#HS#I"@>SG+?N\
M*[YES\.>H^@8#'LL=S37<63=BT_%WW'?$'*@Z+=FBM?4GYKMD^9I^^A9!@F+
M53A8:KH:!RE>50X*SX67K3M%T)6^*56=\V3]NFI-E85'^5L0*KF@U5S2JJ[]
MW%'Z4DI8Q=*:>*?5WWZ["PO6+0`5V>#LXW:<N*Y*V,$P^DM5NVRZ?,#)3A%>
M^K(;(P57&93CQ$9<O#679*KSLG(_0BDV4AS]L),B5F]:*%7[`LD\[51__LZ&
M4AQ8:,GS3ERLW@%1BH<%DGEJ+M'M^I-K(0P#%XUES-[G<Q*J>;*C!J=N<4%G
M/!8P)@K2<A"^'B['R6ED/<3^N1.5.(3`#NEL%G_M*ICJX+KAD:%4@OCJHC$B
MH8D/]*4P&H[R8&#P@D@DLQY&PU`G'BX:2D1ZA,,I"H[QD2Y]+W@TNVC$Z!3I
M;ZF-Q6<:?,#H<!I-JVBA"#N6/F9LRAE.E<1\2P7$9</XK#T6P)"J_:@EM5["
M=8>QB(0?"&4*])X=2`2U=5$:Y44H(.8^%B5K7'G/I=*)#_1=2L+DM*:MB>JX
M+T$E1?M[6+!837#N!<$H&[0\TE+3GNC9JD,U(5"1XF*IOW)GLHM$9GO:GK23
MT/K&F@G4V62N._1H:&Q3K"-SK<AB[>GF63<$F>XC,9*OA<C(H_/,\ON-&VN8
M_`+Z3C0(.H^@TWOI]WN,GV&SB&[LS*AI\NSU$7]&A=.&27F=+6A8W-)^)7#K
M:[WW^A\$779OZELK9@ZNOM9<874KJU:B45_K6DOP6ZFA-/Z.*H@S7ON)5*Y"
MC+U\O:T\"N;W$R)A,!$`'V`Z!)&1U`F72&2N63P+^!1#V>\66A2P^L3+"+2$
MJI4XBW7#U67)HDBQ%'2-XL#U_*Y&>1LAZQG#(=?)IMZNE!$$UY'F+.XH[XGX
M3,)(7S*9[@-*>XH5P;<C\?6F2CX.XGN:*UE;).X%GU(IN9B;C3/Y-KL1M$X-
M5Y_![F)7+<S%FITI1\[C26PN>M@,:ILRY?+[C9MZM5M/I'ILW>X9RQ]CI[6E
MW0;[)4S[TTM4.P77L782#FT]E`*O46>-/8N/\(_0&^%\&D2^A:Z%J%/#3,XU
MR.34)'J>[EL[3T0$,B.+"^PE^.,MQ2!GK"]@$Q+[%YUWIV,29V$_PM.UB,:=
MV2RD<=H\9\SMT.MD:<-Y'\9ZCP8.%<BMX(\D[(UZZ8XB'$>"R%<%LE?$K)/8
M[P7%YL<>L"T*JC<1=)F?D]`%5"MA(F*FEQ#$E^CW1GU0D<B[ZR;`.@G594K`
M<T&;6RVH%]-5>Y`7V6G<H1/1(>6*^C=^OMT4%]=*`!QY<>#JC'&"KC]?X_!E
M"U!8G`DP\<OW"RZ+^+NE(S7IX%N0B20W@]9=+!QERHIE@]9<+!Z)TN;*PM9;
M,!PL.0O*";8"6V_!!A,J2LJ5!:V/6!_(LUY$7FZ>T"N"5"\!QJ.0!ET&.P.^
M_-H;/<0I^=6)ZOY(UF@;QU(H39]?Z>LH!!!_4BAX#J9>B8@/-$2-X_3K`Q"]
M^5X7Y;(K+J"ZB>/<#R)OT`2K;3(CZ#;H+V$FFTCV'PSQ%8AP[MQ>4P;X10C-
MF9J$<^N0@;GU*;LAYA;LV*X\RHM00-1C@'\Z1O@#1'X19QU`G:+QCYS=3&<A
MGP-<F]].X`5Y,Q=0K82)-$^]T;4>#\-K*N.?R>+B"U63=1-P.ZFV+0';775K
M'H/X?MUT*L2_8?X0Z<DLB"(9L\6UE.`SAG'H:EKY]P)FA`;)KQ'%]\L1-B^0
MJPS2KM+N<XT[72/3[J3]S5<0F%SN+1<C0#P[6"@#7*<M#/<8=#.5C.IF>XVA
MK2\!SDCE@"JWPO`MQ3'-_V8T`GUI"731M<Q/2:PD,DK`UF=Z8C-K-D$YA+'*
M:RG`+5)#+UDO00:@1B)8$SE]!U(\1[O1/^HXX&GO%G_$UFZMN]M2;D^C1I-`
M6PJ+1VL'TPT1#()/.,L7Z:7BNFTQW<CN!1\+,EVCE1WH[::AO8X9ED`?03T0
MG$)>8UV/$-P*/M7O.AE@EH#2VT/6Z*,\>DT=9#&10H9'5&VIALI4ZJZ-/CP"
MBW#$N<)N`-M\-`S-^,I%T=Q\>Q(UU<,#F#[>;&E,K\^1R1&.-7*[4>HJI^[+
MDQVNVW2'%?#KV?TMO%)OA3#^FMBNN[B3$(-EM^$KD:B7(R#A>,/=EPGU)\D$
MY\H<=-=6I`Q#&D=.;FL*]<I,;BG&9QY&Z`."AO/==9(A5C/U<!W[4A+>1BH2
ML,@XIYG7'LL,BV6@7T*";I,@9H]X!<$3^/\+T9]X%<$U](L06_!X[X,LVAM1
M6%JG_&429-Y1,J2AV7$ID3SJJ$@4-V2=Q.H3-M9Y\)P4JP6U8[KXM$F^J'Z,
M%YPI62VH$]/+GP7)7"JM-UF/#=SE//?+(6:O:\^DT^3[>#<V2]>$%XG\=+G"
MTL,WJ*M6V?2MY4V21\\S\,T.XTLPGS,)Z:]!/)/Q_<['$;>63TN4S*OVH:X,
MN5HI:$J$ZL,L)+[Y/)B`(+-YKO?9`%>KSFAYF&G`]:Z$M&7;1YMB_^VI25;*
MRJ@[VG*?T^IU5[V;$VPKOP872UL2(6-<E7[_?CX[`'_">,C'\X[O@Y2W`/IB
MERZSDL/Q,;Y-U_!:RM@GT9<0:Q?(^VDV$IRI_)Z7$K!?3^0]G@9,)_^(\5%/
M)""WFVLMQ,X9@7VV=(P"!Q,>2<*"P1.$CW#S5V1F$6G.#U67Z\&K(-6I.__$
MD#DAD=7>Z#;D@@:D#Q*(\">W/&*!J2G)YN3WOFR%72?Q-_UXMI'2!52WWCOA
MU=R1,W<(DP.HJ2!RN>-!+TG+O"1YB)U6K??9DZP]1NLZ(?MMXYSS5GP!'S[^
M#U!+`0(>`Q0````(`#!`64/N#TS,+W(``+R5`P`1`!@```````$```"D@0``
M``!O9V5N+3(P,3,P.3,P+GAM;%54!0`#G%UJ4G5X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`#!`64/`&9H""PL``.20```5`!@```````$```"D@7IR``!O
M9V5N+3(P,3,P.3,P7V-A;"YX;6Q55`4``YQ=:E)U>`L``00E#@``!#D!``!0
M2P$"'@,4````"``P0%E#JDA(9&H;```%G`$`%0`8```````!````I('4?0``
M;V=E;BTR,#$S,#DS,%]D968N>&UL550%``.<76I2=7@+``$$)0X```0Y`0``
M4$L!`AX#%`````@`,$!90RMTISO,30``J0($`!4`&````````0```*2!C9D`
M`&]G96XM,C`Q,S`Y,S!?;&%B+GAM;%54!0`#G%UJ4G5X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`#!`64,@W:<G,R4``$R8`@`5`!@```````$```"D@:CG
M``!O9V5N+3(P,3,P.3,P7W!R92YX;6Q55`4``YQ=:E)U>`L``00E#@``!#D!
M``!02P$"'@,4````"``P0%E#D5M5,B,/```/E@``$0`8```````!````I($J
M#0$`;V=E;BTR,#$S,#DS,"YX<V155`4``YQ=:E)U>`L``00E#@``!#D!``!0
52P4&``````8`!@`:`@``F!P!````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants - Additional Information (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2013

</div>
          <div>Griffin Securities Inc. [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantExercised', window );">Warrants exercised</a></td>
        <td class="nump">200,000<span></span></td>
        <td class="nump">200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Shares of common stock issued upon exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">106,250<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ClassOfWarrantExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants exercised in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ClassOfWarrantExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_SummaryOfWarrantActivityTableTextBlock', window );">Summary of Warrant Activity</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 A summary of warrant activity for the year ended December&#xA0;31,
 2012 and the nine months ended September&#xA0;30, 2013 is as
 follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br />
 Average<br />
 Price</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance &#x2013; December&#xA0;31, 2011</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">306,388</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19.14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,942,094</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,500</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6.00</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance &#x2013; December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,235,982</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Granted</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Exercised</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(200,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Expired</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(288,888</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19.87</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance &#x2013; September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,747,094</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.91</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Outstanding</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The warrants outstanding as of September&#xA0;30, 2013 are as
 follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center">
 <tr>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="40%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="40%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 48.6pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" align="center"><b>Exercise&#xA0;Price</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Warrants<br />
 Outstanding</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Expiration&#xA0;Dates</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">$</td>
 <td valign="top" align="right">1.50</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">571,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7/30/17</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">$</td>
 <td valign="top" align="right">2.00</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,170,925</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3/23/15</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">$</td>
 <td valign="top" align="right">10.00</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4/15/14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="top"></td>
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,747,094</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_SummaryOfWarrantActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Summary of warrant activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_SummaryOfWarrantActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Note Payable to Shareholder - Additional Information (Detail) (Convertible Promissory Note [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Promissory Note [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Short-term note payable</a></td>
        <td class="nump">$ 1,956,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on short-term note</a></td>
        <td class="nump">3.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Final payment date of short-term note payable</a></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENLAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Short-term Notes Payable - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Product Liability Insurance [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 08, 2013

</div>
          <div>Product Liability Insurance [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Directors' and Officers' Liability Insurance Financing [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 20, 2013

</div>
          <div>Directors' and Officers' Liability Insurance Financing [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermNonBankLoansAndNotesPayable', window );">Short term notes payable for financing insurance policies</a></td>
        <td class="nump">$ 108,220<span></span></td>
        <td class="nump">$ 47,977<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Short-term note payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 50,037<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 106,994<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on short-term note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6.57%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4.64%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_DebtInstrumentAmortizationPeriod', window );">Short-term notes payable amortization period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">11 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Final payment date of short-term note payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 10,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jun. 24,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_DebtInstrumentAmortizationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt instrument amortization period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_DebtInstrumentAmortizationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermDebtLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermNonBankLoansAndNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount at the balance sheet date of borrowings from a creditor other than a bank, not elsewhere specified in the taxonomy, with a maturity within one year (or within one operating cycle if longer) from the date of borrowing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermNonBankLoansAndNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E4EAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Warrants - Summary of Warrants Outstanding (Detail)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
        <td class="nump">2,747,094<span></span></td>
        <td class="nump">3,235,982<span></span></td>
        <td class="nump">306,388<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
        <td class="nump">571,169<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_WarrantsExpirationDates', window );">Expiration Dates</a></td>
        <td class="text">Jul. 30,
				 2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">2.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
        <td class="nump">2,170,925<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_WarrantsExpirationDates', window );">Expiration Dates</a></td>
        <td class="text">Mar. 23,
				 2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Range 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise Price</a></td>
        <td class="nump">10.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants Outstanding</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_WarrantsExpirationDates', window );">Expiration Dates</a></td>
        <td class="text">Apr. 15,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_WarrantsExpirationDates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants expiration dates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_WarrantsExpirationDates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3H">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical) (Griffin Securities Inc. [Member])<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Griffin Securities Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_WarrantsIssued', window );">Warrants issued</a></td>
        <td class="nump">771,169<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_WarrantsIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_WarrantsIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><b>2.</b></td>
 <td valign="top" align="left"><b>Basis of Presentation</b></td>
 </tr>
 </table>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The accompanying unaudited interim financial statements as of
 September&#xA0;30, 2013 and December&#xA0;31, 2012 (audited) and
 for the three and nine months ended September&#xA0;30, 2013 and
 2012 have been prepared in accordance with accounting principles
 generally accepted in the United States of America
 (&#x201C;GAAP&#x201D;) for interim financial information and with the
 instructions to Form 10-Q and Article 10 of Regulation S-X.
 Accordingly, they do not include all of the information and
 footnotes required by GAAP for complete financial statements. In
 the opinion of management, the accompanying financial statements
 include all adjustments, consisting of normal recurring accruals,
 necessary for a fair presentation of the financial condition,
 results of operations and cash flows for the periods presented. The
 results of operations for the interim period September&#xA0;30,
 2013 are not necessarily indicative of the results that may be
 expected for the year ending December&#xA0;31, 2013 or any future
 period.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 These financial statements should be read in conjunction with the
 audited financial statements and notes thereto for the year ended
 December&#xA0;31, 2012, which are included in our Annual Report on
 Form 10-K filed with the Securities and Exchange Commission on
 March&#xA0;26, 2013. The Company has incurred recurring losses and
 negative cash flows from operations since inception. To date the
 Company has not generated significant revenues from operations. The
 Company generated revenues of $597,449, incurred a net loss of
 $12,989,419, and used cash of $5,545,205 in its operating
 activities during the nine months ended September&#xA0;30, 2013. As
 of September&#xA0;30, 2013, the Company had an accumulated deficit
 of $(67,075,781).</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During 2012 and 2011, a significant source of debt and equity
 funding was provided to the Company by its largest shareholder, the
 Koski Family Limited Partnership (the &#x201C;KFLP&#x201D;). In 2012
 the Company raised $13,000,000 in gross proceeds through the
 private placement sale of its common stock. In 2013 the company
 raised $3,900,000 in gross proceeds through the private placement
 of its common stock. The Company expects to incur substantial
 expenditures to further develop each of its technologies. The
 Company believes the working capital at September&#xA0;30, 2013
 will be sufficient to meet the business objectives as presently
 structured through December 2014.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s ability to continue operations after its
 current cash resources are exhausted depends on its ability to
 obtain additional financing or achieve profitable operations, as to
 which no assurances can be given. Cash requirements may vary
 materially from those now planned because of changes in the
 Company&#x2019;s focus and direction of its research and development
 programs, competitive and technical advances, or other
 developments. Additional financing will be required to continue
 operations after the Company exhausts its current cash resources
 and to continue its long-term plans for clinical trials and new
 product development. There can be no assurance that any such
 financing can be realized by the Company, or if realized, what the
 terms thereof may be, or that any amount that the Company is able
 to raise will be adequate to support the Company&#x2019;s working
 capital requirements until it achieves profitable operations.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company intends to seek additional funding through sublicensing
 arrangements, joint venturing or partnering, sales of rights to
 technology, government grants and public or private financings. The
 Company&#x2019;s future success depends on its ability to raise
 capital and ultimately generate revenue and attain profitability.
 The Company cannot be certain that additional capital, whether
 through selling additional debt or equity securities or obtaining a
 line of credit or other loan, will be available to it or, if
 available, will be on terms acceptable to the Company. If the
 Company issues additional securities to raise funds, these
 securities may have rights, preferences, or privileges senior to
 those of its common stock, and the Company&#x2019;s current
 shareholders may experience dilution. If the Company is unable to
 obtain funds when needed or on acceptable terms, the Company may be
 required to curtail their current development programs, cut
 operating costs and forego future development and other
 opportunities.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_WarrantDisclosureTextBlock', window );">Warrants</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><b>5.</b></td>
 <td valign="top" align="left"><b>Warrants</b></td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 A summary of warrant activity for the year ended December&#xA0;31,
 2012 and the nine months ended September&#xA0;30, 2013 is as
 follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="77%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Warrants</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted<br />
 Average<br />
 Price</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance &#x2013; December&#xA0;31, 2011</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">306,388</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">19.14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,942,094</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.87</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(12,500</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6.00</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance &#x2013; December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,235,982</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.53</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Granted</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Exercised</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(200,000</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Expired</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(288,888</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(19.87</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance &#x2013; September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,747,094</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.91</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On January&#xA0;31, 2013 Griffin Securities Inc. exercised 200,000
 of their previously issued warrants resulting in the issuance of
 106,250 shares of our common stock.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The warrants outstanding as of September&#xA0;30, 2013 are as
 follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center">
 <tr>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="40%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="40%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom" colspan="2" nowrap="nowrap" align="center">
 <p style="BORDER-BOTTOM: #000000 1pt solid; WIDTH: 48.6pt; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt" align="center"><b>Exercise&#xA0;Price</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Warrants<br />
 Outstanding</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Expiration&#xA0;Dates</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">$</td>
 <td valign="top" align="right">1.50</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">571,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7/30/17</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">$</td>
 <td valign="top" align="right">2.00</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,170,925</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3/23/15</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">$</td>
 <td valign="top" align="right">10.00</td>
 <td valign="top" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,000</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4/15/14</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="top"></td>
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,747,094</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_WarrantDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_WarrantDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><b>3.</b></td>
 <td valign="top" align="left"><b>Significant Accounting
 Policies</b></td>
 </tr>
 </table>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Recently Issued Accounting Pronouncements</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 There are no new accounting pronouncements issued or effective
 during the second quarter of 2013 that have had or are expected to
 have an impact on the Company&#x2019;s financial statements.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Use of Estimates</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and disclosure of
 contingent assets and liabilities at the date of the financial
 statements, as well as the reported amounts of revenues and
 expenses during the reporting period. Actual results could differ
 from those estimates. The principal areas of estimation reflected
 in the financial statements are stock-based compensation, valuation
 of warrants, inventory obsolescence reserve, sales returns and
 allowances and the allowance for doubtful accounts.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Fair Value of Financial Instruments</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The fair value of the Company&#x2019;s cash and cash equivalents,
 accounts payable and accrued expenses approximate their carrying
 values due to their short-term nature.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Guaranteed Rights of Return</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has granted guaranteed rights of return to two dental
 distributors. The Company defers recognition of revenue on these
 accounts until either the distributor provides notification to the
 Company that the product has been sold to the end consumer or the
 guaranteed right of return period expires. Once notification has
 been received and verified, the Company records revenue in that
 accounting period. The Company had $23,711 and $27,812 of revenue
 deferred under guaranteed rights of return arrangements included in
 deferred revenue in the balance sheets as of September&#xA0;30,
 2013 and December&#xA0;31, 2012, respectively.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Inventory</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Inventory is stated at the lower of cost or market. Cost, which
 includes material, labor and overhead, is determined on a first-in,
 first-out basis. On a quarterly basis, we analyze our inventory
 levels and reserve for inventory that is expected to expire prior
 to being sold, inventory that has a cost basis in excess of its
 expected net realizable value, inventory in excess of expected
 sales requirements, or inventory that fails to meet commercial sale
 specifications. Expired inventory is disposed of and the related
 costs are written off to the reserve for inventory obsolescence.
 The inventory reserve was approximately $22,000 and $253,000 as of
 September&#xA0;30, 2013 and December&#xA0;31, 2012,
 respectively.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Stock-Based Payment Arrangements</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Generally, all forms of stock-based payments, including stock
 option grants, warrants, and restricted stock grants are measured
 at their fair value on the awards&#x2019; grant date typically using
 a Black-Scholes pricing model. Stock-based compensation awards
 issued to non-employees for services rendered are recorded at the
 fair value of the stock-based payment. The expense resulting from
 stock-based payments are recorded in research and development
 expense or selling, general and administrative expense in the
 statement of operations, depending on the nature of the services
 provided. Stock-based payment expense is recorded over the
 requisite service period in which the grantee provides services to
 us. To the extent the stock option grants, warrants, or restricted
 stock grants do not vest at the grant date they are subject to
 forfeiture.</p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Stock-Based Compensation</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 GAAP requires all share-based payments to employees, including
 grants of employee stock options, to be recognized in the financial
 statements based on their fair values as of the grant date.
 Stock-based compensation expense is recorded over the requisite
 service period in which the grantee provides services to us, to the
 extent the options do not vest at the grant date and are subject to
 forfeiture. For performance-based awards that do not include
 market-based conditions, we record share-based compensation expense
 only when the performance-based milestone is deemed probable of
 achievement. We utilize both quantitative and qualitative criteria
 to judge whether milestones are probable of achievement. For awards
 with market-based performance conditions, we recognize the
 grant-date fair value of the award over the derived service period
 regardless of whether the underlying performance condition is
 met.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Warrants</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company used the Black Scholes Option Pricing Model in
 calculating the relative fair value of any warrants that have been
 issued.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Net Loss Per Share</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During all periods presented, the Company had securities
 outstanding that could potentially dilute basic earnings per share
 in the future, but were excluded from the computation of diluted
 net loss per share, as their effect would have been antidilutive.
 Because the Company reported a net loss for all periods presented,
 shares associated with the stock options and warrants are not
 included because they are antidilutive. Basic and diluted net loss
 per share amounts are the same for the periods presented. Net loss
 per share is computed using the weighted average number of shares
 of common stock outstanding.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Revenue Recognition</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognizes revenues from the sales of product when
 title and risk of loss pass to the customer, which is generally
 when the product is shipped. Grant revenues are recognized as the
 reimbursable expenses are incurred over the life of the related
 grant. Grant revenues are deferred when reimbursable expenses have
 not been incurred.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company records allowances for discounts and product returns at
 the time of sale as a reduction of revenues as such allowances can
 be reliably estimated based on historical experience or known
 trends. The Company maintains a return policy that allows customers
 to return product within a specified period of time prior to and
 subsequent to the expiration date of the product. The estimate of
 the provision for returns is analyzed quarterly and is based upon
 many factors, including industry data of product return rates,
 historical experience of actual returns, analysis of the level of
 inventory in the distribution channel, if any, and reorder rates.
 If the history or product returns changes, the reserve will be
 adjusted. While the Company believes that the reserves it has
 established are reasonable and appropriate based upon current facts
 and circumstances, applying different judgments to the same facts
 and circumstances would result in the estimated amounts for sales
 returns and chargebacks to vary. Because the ProBiora3 products are
 still relatively new to the market, the Company could experience
 different circumstances in the future and these differences could
 be material.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Concentrations</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company is dependent on key suppliers to provide probiotics,
 blending, warehousing and packaging of its EvoraPlus, EvoraKids,
 EvoraPro, and Teddy&#x2019;s Pride products. The Company had four
 key suppliers during the three and nine months ended
 September&#xA0;30, 2013 and 2012. The majority of the
 Company&#x2019;s cost of sales are from these key suppliers during
 the three and nine months ended September&#xA0;30, 2013 and 2012.
 Accounts payable and accrued expenses for these vendors totaled
 approximately $-0- and $99,000 as of September&#xA0;30, 2013 and
 December&#xA0;31, 2012, respectively. As of September&#xA0;30,
 2013, the Company had a prepaid balance of approximately $27,000
 with one of these vendors.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYIAK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from private placement of common stock</a></td>
        <td class="nump">$ 3,939,800<span></span></td>
        <td class="nump">$ 11,913,442<span></span></td>
        <td class="nump">$ 13,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Promissory Note [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">convertible promissory note issued to pay technology access fee</a></td>
        <td class="nump">1,956,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date of convertible note</a></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">MU1140 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDate', window );">License Agreement, Original Date</a></td>
        <td class="text">Jun. 22,
				 2000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateFirstAmended', window );">License agreement, first amendment date</a></td>
        <td class="text">Sep. 15,
				 2000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateSecondAmended', window );">License agreement, second amendment date</a></td>
        <td class="text">Jul. 10,
				 2002<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateThirdAmended', window );">License agreement, third amendment date</a></td>
        <td class="text">Sep. 25,
				 2002<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateFourthAmended', window );">License agreement, fourth amendment date</a></td>
        <td class="text">Mar. 17,
				 2003<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateFifthAmended', window );">License agreement date fifth amended</a></td>
        <td class="text">Apr. 19,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PatentLicenseExpirationTerm', window );">Patents license expiration period</a></td>
        <td class="text">2017 through 2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Smart Replacement Therapy [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDate', window );">License Agreement, Original Date</a></td>
        <td class="text">Aug.
				04,
				 1998<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateFirstAmended', window );">License agreement, first amendment date</a></td>
        <td class="text">Sep. 15,
				 2000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateSecondAmended', window );">License agreement, second amendment date</a></td>
        <td class="text">Jul. 10,
				 2002<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateThirdAmended', window );">License agreement, third amendment date</a></td>
        <td class="text">Sep. 25,
				 2002<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateFourthAmended', window );">License agreement, fourth amendment date</a></td>
        <td class="text">Mar. 17,
				 2003<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDateFifthAmended', window );">License agreement date fifth amended</a></td>
        <td class="text">Apr. 19,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PatentRightFillingDate', window );">Patent right filling date</a></td>
        <td class="text">Jun.
				07,
				 1995<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PatentRightEffectiveInceptionDate', window );">Patent effective date</a></td>
        <td class="text">Mar.
				04,
				 1997<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PatentRightExpireDate', window );">Patent right expire date</a></td>
        <td class="text">Jun.
				07,
				 2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">UFRF License Agreements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfSellingPricePayableAsRoyalty', window );">Company's obligation to pay from percentage of selling price of product</a></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty', window );">Company's obligation to pay from all revenue received from sublicenses</a></td>
        <td class="nump">22.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_MonthlyCalculationOfCommercializationFee', window );">One-time commercialization fee would be due on the first anniversary of first commercial sale</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization', window );">Post-commercialization minimum royalty payments</a></td>
        <td class="nump">50,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum', window );">One-time additional royalty payment would be due when total cumulative royalties</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage', window );">Total royalties due to UFRF</a></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement', window );">Minimum annual maintenance payment per license agreement</a></td>
        <td class="nump">10,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_AggregateMinimumAnnualMaintenancePayment', window );">Aggregate minimum annual maintenance payment</a></td>
        <td class="nump">20,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_MinimumQuarterlyMaintenancePayment', window );">Quarterly maintenance payment to UFRF under installment plan</a></td>
        <td class="nump">5,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lantibiotic ECC [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDate', window );">License Agreement, Original Date</a></td>
        <td class="text">Jun.
				05,
				 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_TerminationNoticePeriod', window );">Termination notice period</a></td>
        <td class="text">90 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration', window );">Common stock issued</a></td>
        <td class="nump">4,392,425<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable', window );">Percentage company pay on quarterly basis out of gross profit</a></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement', window );">Company's obligation to make payment from all revenue received from sublicensing</a></td>
        <td class="nump">50.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily', window );">Period during which company cannot terminate license agreement voluntarily</a></td>
        <td class="text">18 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement', window );">Period during which company cannot terminate license agreement</a></td>
        <td class="text">12 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued', window );">Maximum percentage of primary investment securities to investment of shares issued</a></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lantibiotic ECC [Member] | Investigational New Drug Application [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock', window );">Percentage of number of shares of common stock equal to Base Shares</a></td>
        <td class="nump">1.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lantibiotic ECC [Member] | Clinical Study Phase 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock', window );">Percentage of number of shares of common stock equal to Base Shares</a></td>
        <td class="nump">1.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lantibiotic ECC [Member] | Clinical Study Phase 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock', window );">Percentage of number of shares of common stock equal to Base Shares</a></td>
        <td class="nump">2.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lantibiotic ECC [Member] | Filing of First Investigational New Drug Application [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock', window );">Percentage of number of shares of common stock equal to Base Shares</a></td>
        <td class="nump">2.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lantibiotic ECC [Member] | First Regulatory Approval of Oragenics Product [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock', window );">Percentage of number of shares of common stock equal to Base Shares</a></td>
        <td class="nump">3.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Probiotics ECC [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_LicenseAgreementDate', window );">License Agreement, Original Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable', window );">Percent of company pay out of net sales</a></td>
        <td class="nump">10.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_TerminationNoticePeriod', window );">Termination notice period</a></td>
        <td class="text">90 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_MaximumPeriodToCureBreach', window );">Maximum period to cure the breach</a></td>
        <td class="text">60 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_TechnologyAccessFeeUpfrontPayment', window );">Up-front technology access fee</a></td>
        <td class="nump">6,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PotentialFutureMilestonePaymentsOne', window );">Milestone amount payable one</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PotentialFutureMilestonePaymentsTwo', window );">Milestone amount payable two</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PotentialFutureMilestonePaymentsThree', window );">Milestone amount payable three</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_MilestoneMeasurementPeriod', window );">Milestone measurement period</a></td>
        <td class="text">30 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Probiotics ECC [Member] | Intrexon [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration', window );">Common stock issued</a></td>
        <td class="nump">1,348,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Company's common stock shares sold</a></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Per shares price</a></td>
        <td class="nump">$ 3.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from private placement of common stock</a></td>
        <td class="nump">3,900,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Probiotics ECC [Member] | Convertible Promissory Note [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">convertible promissory note issued to pay technology access fee</a></td>
        <td class="nump">$ 1,956,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date of convertible note</a></td>
        <td class="text">Dec. 31,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional royalty payment condition aggregate royalty percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_AdditionalRoyaltyPaymentConditionAggregateRoyaltyPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional royalty payment condition royalty paid minimum.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_AdditionalRoyaltyPaymentConditionRoyaltyPaidMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_AggregateMinimumAnnualMaintenancePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate minimum annual maintenance payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_AggregateMinimumAnnualMaintenancePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Annual minimum royalty payments post commercialization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_AnnualMinimumRoyaltyPaymentsPostCommercialization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_CommitmentAndContingenciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_CommitmentAndContingenciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_LicenseAgreementDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License agreement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_LicenseAgreementDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_LicenseAgreementDateFifthAmended">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License agreement date fifth amended.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_LicenseAgreementDateFifthAmended</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_LicenseAgreementDateFirstAmended">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License agreement date first amended.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_LicenseAgreementDateFirstAmended</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_LicenseAgreementDateFourthAmended">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License agreement date fourth amended.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_LicenseAgreementDateFourthAmended</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_LicenseAgreementDateSecondAmended">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License agreement date second amended.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_LicenseAgreementDateSecondAmended</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_LicenseAgreementDateThirdAmended">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License agreement date third amended.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_LicenseAgreementDateThirdAmended</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of primary investment securities to investment of shares issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_MaximumPercentageOfPrimaryInvestmentSecuritiesToInvestmentOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_MaximumPeriodToCureBreach">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum period to cure breach.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_MaximumPeriodToCureBreach</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_MilestoneMeasurementPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Milestone measurement period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_MilestoneMeasurementPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum annual maintenance payments each license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_MinimumAnnualMaintenancePaymentsEachLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_MinimumQuarterlyMaintenancePayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum quarterly maintenance payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_MinimumQuarterlyMaintenancePayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_MonthlyCalculationOfCommercializationFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Monthly calculation of commercialization fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_MonthlyCalculationOfCommercializationFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PatentLicenseExpirationTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Patent license expiration term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PatentLicenseExpirationTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PatentRightEffectiveInceptionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Patent right effective inception date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PatentRightEffectiveInceptionDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PatentRightExpireDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Patent right expire date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PatentRightExpireDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PatentRightFillingDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Patent right filling date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PatentRightFillingDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of base shares equal to number of shares for common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PercentageOfBaseSharesEqualToNumberOfSharesForCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of net sales derived from sale of products payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PercentageOfNetSalesDerivedFromSaleOfProductsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of quarterly profit derived from sale of products payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PercentageOfQuarterlyProfitDerivedFromSaleOfProductsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of quarterly revenue in case of sublicensor agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PercentageOfQuarterlyRevenueInCaseOfSublicensorAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PercentageOfSellingPricePayableAsRoyalty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of selling price payable as royalty.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PercentageOfSellingPricePayableAsRoyalty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of sublicenses revenue payable in addition of royalty.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PercentageOfSublicensesRevenuePayableInAdditionOfRoyalty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period during which company cannot terminate license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period during which company cannot terminate license agreement voluntarily.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PeriodDuringWhichCompanyCannotTerminateLicenseAgreementVoluntarily</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PotentialFutureMilestonePaymentsOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential future milestone payments one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PotentialFutureMilestonePaymentsOne</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PotentialFutureMilestonePaymentsThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential future milestone payments three.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PotentialFutureMilestonePaymentsThree</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PotentialFutureMilestonePaymentsTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Potential future milestone payments two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PotentialFutureMilestonePaymentsTwo</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_TechnologyAccessFeeUpfrontPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Technology access fee upfront payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_TechnologyAccessFeeUpfrontPayment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_TerminationNoticePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Termination notice period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_TerminationNoticePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584090&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentFaceAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for noncash consideration for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForNoncashConsideration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>28
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0F%L86YC95]3:&5E
M=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"86QA
M;F-E7U-H965T<U]087)E;G1H971I8V%L/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`S+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT<U]O9E]/<&5R871I;VYS/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1A=&5M96YT
M<U]O9E]#87-H7T9L;W=S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1A=&5M96YT<U]O9E]#87-H7T9L;W=S7U!A<F5N/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T:6]N
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0F%S:7-?
M;V9?4')E<V5N=&%T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4VEG;FEF:6-A;G1?06-C;W5N=&EN9U]0;VQI8VEE/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#
M;VUP96YS871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3`N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y787)R86YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-H;W)T5&5R;5].;W1E<U]087EA8FQE/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$R
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N=F5R=&EB;&5?3F]T95]087EA
M8FQE7W1O7U-H/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97,\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6)S97%U96YT7T5V96YT<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-I9VYI9FEC
M86YT7T%C8V]U;G1I;F=?4&]L:6-I93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=&]C:T)A<V5D7T-O;7!E;G-A=&EO;E]486)L
M97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y787)R
M86YT<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y"87-I<U]O9E]0<F5S96YT871I;VY?061D:71I;VX\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3:6=N:69I8V%N=%]!8V-O
M=6YT:6YG7U!O;&EC:64R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VM"87-E9%]#;VUP96YS871I;VY?4W1O8VM"/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#(Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"87-E9%]#
M;VUP96YS871I;VY?061D:71I/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^5V%R<F%N='-?4W5M;6%R>5]O9E]787)R86YT7T%C/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#(S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^5V%R<F%N='-?
M061D:71I;VYA;%]);F9O<FUA=&EO/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^5V%R<F%N='-?4W5M;6%R>5]O9E]787)R86YT<U]/
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4VAO<G1T
M97)M7TYO=&5S7U!A>6%B;&5?061D:71I/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^0V]N=F5R=&EB;&5?3F]T95]087EA8FQE7W1O
M7U-H,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O
M;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S7T%D9&ET
M:6]N86Q?23PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE
M<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z
M06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T
M<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T
M96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC
M96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\
M8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@
M36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$X.#DR9C`Q7S9B-C=?-#(X
M-E]A-S8S7V(W8V4W,34X-C4Q-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]A.#@Y,F8P,5\V8C8W7S0R.#9?83<V,U]B-V-E-S$U.#8U,38O5V]R
M:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,4%!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`R-2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$;V-U;65N="!!;F0@16YT:71Y($EN9F]R;6%T:6]N(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C
M=6UE;G0@5'EP93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`M
M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-"@D),C`Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE
M;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E$S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4F5G:7-T
M<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y/4D%'
M14Y)0U,@24Y#/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C`P,#$Q-S0Y-#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES
M8V%L(%EE87(@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/BTM,3(M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N
M>3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PU,#8L-C@U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15!9044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^0F%L86YC92!3:&5E=',@*%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A
M;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PR-C<L
M.#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Y+#DR-2PY-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C$L-S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE
M<RP@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU."PX-S@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M.2PW.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=F5N=&]R>2P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,C,L,S$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(T+#$W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@
M;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R-RPP,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,C$L.#,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-S<W+#`Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#0P
M,RPU-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L,3DX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#0L-3DQ/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#@Q-2PR.3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,"PT.#@L,3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S
M('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,S8T+#DV.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,34W+#4R,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAO<G0M=&5R
M;2!N;W1E<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,#@L,C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#<L.3<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!N;W1E('!A>6%B;&4@=&\@
M<VAA<F5H;VQD97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M.34V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C,L-S$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3`L.3@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PT-3(L
M.#DY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PR-38L-#@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E:&]L9&5R<R<@97%U:71Y.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VLL(&YO('!A<B!V86QU93L@,C`L,#`P+#`P,"!S:&%R97,@
M875T:&]R:7IE9#L@;F]N92!I<W-U960@86YD(&]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:RP@)#`N,#`Q('!A<B!V86QU93L@-3`L,#`P
M+#`P,"!S:&%R97,@875T:&]R:7IE9#L@,S`L,38X+#8Q,R!A;F0@,C<L,S@R
M+#@S,"!S:&%R97,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!A="!397!T96UB
M97(@,S`L(#(P,3,@86YD($1E8V5M8F5R(#,Q+"`R,#$R+"!R97-P96-T:79E
M;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#$V.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#,X
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<Q+#0P."PP,#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPR.3`L-C(U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U;75L
M871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V
M-RPP-S4L-S@Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4T+#`X-BPS-C(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<VAA<F5H;VQD97)S)R!E
M<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S8R+#,Y
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/CDL,C,Q+#8T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S(&%N9"!S:&%R96AO;&1E
M<G,G(&5Q=6ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X
M+#@Q-2PR.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$P+#0X."PQ,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W
M,34X-C4Q-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A.#@Y,F8P
M,5\V8C8W7S0R.#9?83<V,U]B-V-E-S$U.#8U,38O5V]R:W-H965T<R]3:&5E
M=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%-DY!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY"86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A;"D@*%531"`D*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4W1A=&5M96YT($]F($9I;F%N8VEA;"!0;W-I=&EO;B!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R
M<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A
M=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@:7-S=65D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,"PQ-C@L-C$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L
M,S@R+#@S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#$V."PV,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPS.#(L
M.#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M15)/04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1A=&5M96YT<R!O9B!/
M<&5R871I;VYS("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!3
M=&%T96UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2979E;G5E+"!N970\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C4S+#,W-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C8T+#(T.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3DW+#0T.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M.3`Q+#$X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]S="!O9B!S86QE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3$S+#,X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V-"PP-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C,L.3DP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<T+#4R-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S
M('!R;V9I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,Y+#DY
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P,"PQ.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,S,L-#4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-#(V+#8U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@97AP
M96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPY,#<L,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C`P+#(P.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C@Y+#8Q-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,3,P
M+#<X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V5L;&EN9RP@9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-34X+#(P-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3DV+#4U
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L,3@P+#<P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-S0P+#`R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]P97)A=&EN9R!E>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT-C4L-#4U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ
M.38L-S8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,L-#<P+#,Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#@W,"PX,#(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T
M:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PS,C4L-#8U
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L,#DV+#4W,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,RPQ,S8L.#4W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#0T-"PQ-#8I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T
M:&5R(&EN8V]M92`H97AP96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&EN8V]M93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV,3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#8T-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U+#`Y.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,3DS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#4T-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@T-38L,C,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,L,S,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#8U-"PV,3$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;V-A;"!B=7-I;F5S
M<R!T87@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L,#(T*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#@L
M-S<V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#@L.#(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$P+#`U-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&EN8V]M93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,30T+#4P,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]T:&5R(&EN8V]M
M92`H97AP96YS92DL(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T-3DL,S8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$T-RPT,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V-3<L-#<T*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@8F5F;W)E(&EN
M8V]M92!T87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PS
M,C4L-#(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(L-34U+#DT,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,BPY.#DL-#$Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#$P,2PV,C`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O
M;64@=&%X(&)E;F5F:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B0@*#DL,S(U+#0R-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#(L-34U+#DT,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$R+#DX.2PT,3DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,2PQ
M,#$L-C(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%S:6,@86YD(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,S0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C$Q
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,"XT-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#`N-S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@=7-E9"!T;R!C;VUP=71E(&)A<VEC
M(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C<L-3$U+#,W,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(S+#<Y,RPS,#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-RPT.38L
M-C<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,30L-3<X+#0T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?83@X.3)F,#%?-F(V-U\T,C@V7V$W-C-?8C=C93<Q-3@V-3$V
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$X.#DR9C`Q7S9B-C=?
M-#(X-E]A-S8S7V(W8V4W,34X-C4Q-B]7;W)K<VAE971S+U-H965T,#4N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5$04)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T871E
M;65N=',@;V8@0V%S:"!&;&]W<R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R
M;VT@;W!E<F%T:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#$R+#DX.2PT,3DI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q,2PQ,#$L-C(P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@=&\@
M;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&5C:&YO;&]G
M>2!A8V-E<W,@9F5E('!A:60@:6X@8V]M;6]N('-T;V-K(&%N9"!C;VYV97)T
M:6)L92!N;W1E('!A>6%B;&4@=&\@<VAA<F5H;VQD97(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-SDX+#`P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<F5T
M:6]N(&]F(&1I<V-O=6YT(&]N(&YO=&5S('!A>6%B;&4@=&\@<VAA<F5H;VQD
M97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X,RPU-3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV-"PP-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-2PW.3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E
M;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#8R-"PQ-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#`U-RPR,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=R:71E(&]F9B!O9B!E>'!I<F5D(&EN
M=F5N=&]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C0P+#`P
M-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N9"!L
M:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L92P@;F5T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PY,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PR-C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>2P@
M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#`L.#8U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DU
M+#8T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U,2PX-C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PX
M-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(X,"PS-3,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`T+#4U-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(W+#(W."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,3(L.#<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I
M;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-2PU-#4L,C`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#,L-#<P+#DW-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M
M(&EN=F5S=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0=7)C:&%S92!O9B!P<F]P97)T>2!A;F0@
M97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-RPV
M-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!I;G9E<W1I;F<@86-T:79I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L-C0Y*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#87-H(&9L;W=S(&9R;VT@9FEN86YC:6YG(&%C=&EV:71I97,Z/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)O<G)O=VEN
M9W,@=6YD97(@;F]T92!P87EA8FQE('1O('-H87)E:&]L9&5R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#4P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)O<G)O=VEN9W,@
M=6YD97(@8V]N=F5R=&EB;&4@<V5C=7)E9"!N;W1E('!A>6%B;&4@=&\@<VAA
M<F5H;VQD97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!A>6UE;G1S(&]N('-H;W)T+71E<FT@;F]T97,@<&%Y86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.38L-S@X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DY+#4Q-"D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A
M>6UE;G0@;V8@:6YC;VUE('1A>&5S(&%S<V]C:6%T960@=VET:"!S=&]C:R!B
M87-E9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$R-RPR.3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@<')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M.3,Y+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$Q+#DQ,RPT-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:"!R96QE87-E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$L-S8S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(P+#,W-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#DP-"PW-S4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PP-3<L
M,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&EN8W)E87-E("AD96-R96%S92D@:6X@8V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PV-3@L,#<Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$Q+#4X-BPP,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',@870@8F5G:6YN:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.2PY,C4L.38W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<Q+#<S.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E
M<75I=F%L96YT<R!A="!E;F0@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX+#(V-RPX.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PW-3<L-S<U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M<'!L96UE;G1A;"!D:7-C;&]S=7)E(&]F(&-A<V@@9FQO=R!I;F9O<FUA=&EO
M;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YT97)E<W0@<&%I9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPQ,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#DS-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY.;VXM8V%S:"!I;G9E<W1I;F<@86YD(&9I
M;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y";W)R;W=I;F=S('5N9&5R('-H;W)T('1E<FT@
M;F]T97,@<&%Y86)L92!F;W(@<')E<&%I9"!E>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3<L,#,Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,T+#DQ-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%R('9A;'5E
M(&]F(&-O;6UO;B!S=&]C:R!I<W-U960@9F]R(&-A<VAL97-S(&5X97)C:7-E
M(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;G9E<G-I;VX@;V8@8V]N=F5R=&EB;&4@;F]T92!P87EA8FQE(&%N
M9"!A8V-R=65D(&EN=&5R97-T('1O(&-O;6UO;B!S:&%R97,@86YD('=A<G)A
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PR-S4L,3DV
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$:7-C;W5N="!O;B!N;W1E('!A>6%B;&4@=&\@<VAA<F5H;VQD97(@9F]R
M('=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-#@S+#4U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&%R('9A;'5E(&]F(&9O<F9E:71E9"!S=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<FEF9FEN(%-E8W5R
M:71I97,@26YC+B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DYO;BUC87-H(&EN=F5S=&EN9R!A;F0@9FEN86YC
M:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9A:7(@;6%R:V5T('9A;'5E(&]F('1H92`W-S$L,38Y
M('=A<G)A;G1S(&ES<W5E9"!T;R!'<FEF9FEN(%-E8W5R:71I97,L($EN8RX@
M87,@82!R961U8W1I;VX@:6X@<&%I9"!I;B!C87!I=&%L(&9R;VT@:7-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$L.#4P+#@P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?83@X.3)F,#%?-F(V-U\T,C@V7V$W-C-?8C=C93<Q-3@V
M-3$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$X.#DR9C`Q7S9B
M-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q-B]7;W)K<VAE971S+U-H965T,#8N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4S2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY3=&%T
M96UE;G1S(&]F($-A<V@@1FQO=W,@*%!A<F5N=&AE=&EC86PI("A'<FEF9FEN
M(%-E8W5R:71I97,@26YC+B!;365M8F5R72D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W)I9F9I;B!396-U<FET
M:65S($EN8RX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW-S$L,38Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D]R9V%N
M:7IA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<F=A;FEZ
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@
M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313I#3TQ,05!313L@9F]N
M="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT+7-I>F4Z,3!P="<@8F]R
M9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H
M/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-"4@=F%L:6=N/3-$=&]P
M(&%L:6=N/3-$;&5F=#X\8CXQ+CPO8CX\+W1D/@T*(#QT9"!A;&EG;CTS1&QE
M9G0@=F%L:6=N/3-$=&]P/CQB/D]R9V%N:7IA=&EO;CPO8CX\+W1D/@T*(#PO
M='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P=#L@
M;6%R9VEN+6)O='1O;3HP<'0[(&9O;G0M<VEZ93HQ,'!T.R!F;VYT+69A;6EL
M>3I4:6UE<R!.97<@4F]M86XG/@T*($]R86=E;FEC<RP@26YC+B`H9F]R;65R
M;'D@:VYO=VX@87,@3W)A9V5N+"!);F,N*2`H=&AE#0H@)B-X,C`Q0SM#;VUP
M86YY)B-X,C`Q1#L@;W(@)B-X,C`Q0SMW928C>#(P,40[*2!W87,@:6YC;W)P
M;W)A=&5D(&EN#0H@3F]V96UB97(@,3DY-CL@:&]W979E<BP@;W!E<F%T:6YG
M(&%C=&EV:71Y(&1I9"!N;W0@8V]M;65N8V4@=6YT:6P-"B`Q.3DY+B!4:&4@
M0V]M<&%N>2!I<R!F;V-U<V5D(&]N('1H92!D:7-C;W9E<GDL(&1E=F5L;W!M
M96YT(&%N9`T*(&-O;6UE<F-I86QI>F%T:6]N(&]F(&$@=F%R:65T>2!O9B!T
M96-H;F]L;V=I97,@87-S;V-I871E9"!W:71H#0H@8G)O860@<W!E8W1R=6T@
M86YT:6)I;W1I8W,L(&]R86P@:&5A;'1H+"!A;F0@;W1H97(@9V5N97)A;"!H
M96%L=&@-"B!B96YE9FET<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D)A<VES(&]F(%!R97-E;G1A=&EO;CQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@
M4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"87-I<R!O9B!0<F5S96YT871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'1A8FQE('-T>6QE
M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-
M"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$
M;&5F=#X\8CXR+CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX]
M,T1L969T/CQB/D)A<VES(&]F(%!R97-E;G1A=&EO;CPO8CX\+W1D/@T*(#PO
M='(^#0H@/"]T86)L93X-"B`\(2TM('AB<FPL8F]D>2`M+3X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B!4:&4@86-C;VUP86YY:6YG('5N875D:71E9"!I;G1E<FEM(&9I;F%N8VEA
M;"!S=&%T96UE;G1S(&%S(&]F#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@
M86YD($1E8V5M8F5R)B-X03`[,S$L(#(P,3(@*&%U9&ET960I(&%N9`T*(&9O
M<B!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C
M>$$P.S,P+"`R,#$S(&%N9`T*(#(P,3(@:&%V92!B965N('!R97!A<F5D(&EN
M(&%C8V]R9&%N8V4@=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,-"B!G96YE
M<F%L;'D@86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE<FEC
M80T*("@F(W@R,#%#.T=!05`F(W@R,#%$.RD@9F]R(&EN=&5R:6T@9FEN86YC
M:6%L(&EN9F]R;6%T:6]N(&%N9"!W:71H('1H90T*(&EN<W1R=6-T:6]N<R!T
M;R!&;W)M(#$P+5$@86YD($%R=&EC;&4@,3`@;V8@4F5G=6QA=&EO;B!3+5@N
M#0H@06-C;W)D:6YG;'DL('1H97D@9&\@;F]T(&EN8VQU9&4@86QL(&]F('1H
M92!I;F9O<FUA=&EO;B!A;F0-"B!F;V]T;F]T97,@<F5Q=6ER960@8GD@1T%!
M4"!F;W(@8V]M<&QE=&4@9FEN86YC:6%L('-T871E;65N=',N($EN#0H@=&AE
M(&]P:6YI;VX@;V8@;6%N86=E;65N="P@=&AE(&%C8V]M<&%N>6EN9R!F:6YA
M;F-I86P@<W1A=&5M96YT<PT*(&EN8VQU9&4@86QL(&%D:G5S=&UE;G1S+"!C
M;VYS:7-T:6YG(&]F(&YO<FUA;"!R96-U<G)I;F<@86-C<G5A;',L#0H@;F5C
M97-S87)Y(&9O<B!A(&9A:7(@<')E<V5N=&%T:6]N(&]F('1H92!F:6YA;F-I
M86P@8V]N9&ET:6]N+`T*(')E<W5L=',@;V8@;W!E<F%T:6]N<R!A;F0@8V%S
M:"!F;&]W<R!F;W(@=&AE('!E<FEO9',@<')E<V5N=&5D+B!4:&4-"B!R97-U
M;'1S(&]F(&]P97)A=&EO;G,@9F]R('1H92!I;G1E<FEM('!E<FEO9"!397!T
M96UB97(F(WA!,#LS,"P-"B`R,#$S(&%R92!N;W0@;F5C97-S87)I;'D@:6YD
M:6-A=&EV92!O9B!T:&4@<F5S=6QT<R!T:&%T(&UA>2!B90T*(&5X<&5C=&5D
M(&9O<B!T:&4@>65A<B!E;F1I;F<@1&5C96UB97(F(WA!,#LS,2P@,C`Q,R!O
M<B!A;GD@9G5T=7)E#0H@<&5R:6]D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`Q,G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE<V4@
M9FEN86YC:6%L('-T871E;65N=',@<VAO=6QD(&)E(')E860@:6X@8V]N:G5N
M8W1I;VX@=VET:"!T:&4-"B!A=61I=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&%N9"!N;W1E<R!T:&5R971O(&9O<B!T:&4@>65A<B!E;F1E9`T*($1E8V5M
M8F5R)B-X03`[,S$L(#(P,3(L('=H:6-H(&%R92!I;F-L=61E9"!I;B!O=7(@
M06YN=6%L(%)E<&]R="!O;@T*($9O<FT@,3`M2R!F:6QE9"!W:71H('1H92!3
M96-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S:6]N(&]N#0H@36%R8V@F
M(WA!,#LR-BP@,C`Q,RX@5&AE($-O;7!A;GD@:&%S(&EN8W5R<F5D(')E8W5R
M<FEN9R!L;W-S97,@86YD#0H@;F5G871I=F4@8V%S:"!F;&]W<R!F<F]M(&]P
M97)A=&EO;G,@<VEN8V4@:6YC97!T:6]N+B!4;R!D871E('1H90T*($-O;7!A
M;GD@:&%S(&YO="!G96YE<F%T960@<VEG;FEF:6-A;G0@<F5V96YU97,@9G)O
M;2!O<&5R871I;VYS+B!4:&4-"B!#;VUP86YY(&=E;F5R871E9"!R979E;G5E
M<R!O9B`D-3DW+#0T.2P@:6YC=7)R960@82!N970@;&]S<R!O9@T*("0Q,BPY
M.#DL-#$Y+"!A;F0@=7-E9"!C87-H(&]F("0U+#4T-2PR,#4@:6X@:71S(&]P
M97)A=&EN9PT*(&%C=&EV:71I97,@9'5R:6YG('1H92!N:6YE(&UO;G1H<R!E
M;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,RX@07,-"B!O9B!397!T96UB
M97(F(WA!,#LS,"P@,C`Q,RP@=&AE($-O;7!A;GD@:&%D(&%N(&%C8W5M=6QA
M=&5D(&1E9FEC:70-"B!O9B`D*#8W+#`W-2PW.#$I+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`Q,G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@1'5R:6YG(#(P,3(@86YD(#(P,3$L(&$@<VEG;FEF:6-A;G0@<V]U<F-E
M(&]F(&1E8G0@86YD(&5Q=6ET>0T*(&9U;F1I;F<@=V%S('!R;W9I9&5D('1O
M('1H92!#;VUP86YY(&)Y(&ET<R!L87)G97-T('-H87)E:&]L9&5R+"!T:&4-
M"B!+;W-K:2!&86UI;'D@3&EM:71E9"!087)T;F5R<VAI<"`H=&AE("8C>#(P
M,4,[2T9,4"8C>#(P,40[*2X@26X@,C`Q,@T*('1H92!#;VUP86YY(')A:7-E
M9"`D,3,L,#`P+#`P,"!I;B!G<F]S<R!P<F]C965D<R!T:')O=6=H('1H90T*
M('!R:79A=&4@<&QA8V5M96YT('-A;&4@;V8@:71S(&-O;6UO;B!S=&]C:RX@
M26X@,C`Q,R!T:&4@8V]M<&%N>0T*(')A:7-E9"`D,RPY,#`L,#`P(&EN(&=R
M;W-S('!R;V-E961S('1H<F]U9V@@=&AE('!R:79A=&4@<&QA8V5M96YT#0H@
M;V8@:71S(&-O;6UO;B!S=&]C:RX@5&AE($-O;7!A;GD@97AP96-T<R!T;R!I
M;F-U<B!S=6)S=&%N=&EA;`T*(&5X<&5N9&ET=7)E<R!T;R!F=7)T:&5R(&1E
M=F5L;W`@96%C:"!O9B!I=',@=&5C:&YO;&]G:65S+B!4:&4-"B!#;VUP86YY
M(&)E;&EE=F5S('1H92!W;W)K:6YG(&-A<&ET86P@870@4V5P=&5M8F5R)B-X
M03`[,S`L(#(P,3,-"B!W:6QL(&)E('-U9F9I8VEE;G0@=&\@;65E="!T:&4@
M8G5S:6YE<W,@;V)J96-T:79E<R!A<R!P<F5S96YT;'D-"B!S=')U8W1U<F5D
M('1H<F]U9V@@1&5C96UB97(@,C`Q-"X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!#
M;VUP86YY)B-X,C`Q.3MS(&%B:6QI='D@=&\@8V]N=&EN=64@;W!E<F%T:6]N
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M;B!B92!N;R!A<W-U<F%N8V4@=&AA="!A;GD@<W5C:`T*(&9I;F%N8VEN9R!C
M86X@8F4@<F5A;&EZ960@8GD@=&AE($-O;7!A;GDL(&]R(&EF(')E86QI>F5D
M+"!W:&%T('1H90T*('1E<FUS('1H97)E;V8@;6%Y(&)E+"!O<B!T:&%T(&%N
M>2!A;6]U;G0@=&AA="!T:&4@0V]M<&%N>2!I<R!A8FQE#0H@=&\@<F%I<V4@
M=VEL;"!B92!A9&5Q=6%T92!T;R!S=7!P;W)T('1H92!#;VUP86YY)B-X,C`Q
M.3MS('=O<FMI;F<-"B!C87!I=&%L(')E<75I<F5M96YT<R!U;G1I;"!I="!A
M8VAI979E<R!P<F]F:71A8FQE(&]P97)A=&EO;G,N/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
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M92!#;VUP86YY)B-X,C`Q.3MS(&-U<G)E;G0-"B!S:&%R96AO;&1E<G,@;6%Y
M(&5X<&5R:65N8V4@9&EL=71I;VXN($EF('1H92!#;VUP86YY(&ES('5N86)L
M92!T;PT*(&]B=&%I;B!F=6YD<R!W:&5N(&YE961E9"!O<B!O;B!A8V-E<'1A
M8FQE('1E<FUS+"!T:&4@0V]M<&%N>2!M87D@8F4-"B!R97%U:7)E9"!T;R!C
M=7)T86EL('1H96ER(&-U<G)E;G0@9&5V96QO<&UE;G0@<')O9W)A;7,L(&-U
M=`T*(&]P97)A=&EN9R!C;W-T<R!A;F0@9F]R96=O(&9U='5R92!D979E;&]P
M;65N="!A;F0@;W1H97(-"B!O<'!O<G1U;FET:65S+CPO<#X-"B`-"B`-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q-@T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A.#@Y,F8P,5\V8C8W7S0R.#9?83<V
M,U]B-V-E-S$U.#8U,38O5V]R:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QT86)L92!S='EL93TS1"="
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@/'1R
M/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0T)2!A;&EG;CTS1&QE9G0^
M/&(^,RX\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F
M=#X\8CY3:6=N:69I8V%N="!!8V-O=6YT:6YG#0H@4&]L:6-I97,\+V(^/"]T
M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"$M+2!X8G)L+&)O9'D@+2T^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@/&(^4F5C96YT;'D@27-S=65D($%C8V]U;G1I;F<@4')O;F]U
M;F-E;65N=',\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H97)E(&%R92!N;R!N97<@
M86-C;W5N=&EN9R!P<F]N;W5N8V5M96YT<R!I<W-U960@;W(@969F96-T:79E
M#0H@9'5R:6YG('1H92!S96-O;F0@<75A<G1E<B!O9B`R,#$S('1H870@:&%V
M92!H860@;W(@87)E(&5X<&5C=&5D('1O#0H@:&%V92!A;B!I;7!A8W0@;VX@
M=&AE($-O;7!A;GDF(W@R,#$Y.W,@9FEN86YC:6%L('-T871E;65N=',N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B`\8CY5<V4@;V8@17-T:6UA=&5S/"]B/CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B!4:&4@<')E<&%R871I;VX@;V8@9FEN86YC:6%L('-T871E;65N
M=',@:6X@8V]N9F]R;6ET>2!W:71H($=!05`-"B!R97%U:7)E<R!M86YA9V5M
M96YT('1O(&UA:V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<R!T:&%T(&%F
M9F5C=`T*('1H92!R97!O<G1E9"!A;6]U;G1S(&]F(&%S<V5T<R!A;F0@;&EA
M8FEL:71I97,@86YD(&1I<V-L;W-U<F4@;V8-"B!C;VYT:6YG96YT(&%S<V5T
M<R!A;F0@;&EA8FEL:71I97,@870@=&AE(&1A=&4@;V8@=&AE(&9I;F%N8VEA
M;`T*('-T871E;65N=',L(&%S('=E;&P@87,@=&AE(')E<&]R=&5D(&%M;W5N
M=',@;V8@<F5V96YU97,@86YD#0H@97AP96YS97,@9'5R:6YG('1H92!R97!O
M<G1I;F<@<&5R:6]D+B!!8W1U86P@<F5S=6QT<R!C;W5L9"!D:69F97(-"B!F
M<F]M('1H;W-E(&5S=&EM871E<RX@5&AE('!R:6YC:7!A;"!A<F5A<R!O9B!E
M<W1I;6%T:6]N(')E9FQE8W1E9`T*(&EN('1H92!F:6YA;F-I86P@<W1A=&5M
M96YT<R!A<F4@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N+"!V86QU871I;VX-
M"B!O9B!W87)R86YT<RP@:6YV96YT;W)Y(&]B<V]L97-C96YC92!R97-E<G9E
M+"!S86QE<R!R971U<FYS(&%N9`T*(&%L;&]W86YC97,@86YD('1H92!A;&QO
M=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U;G1S+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
M/&(^1F%I<B!686QU92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\+V(^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(%1H92!F86ER('9A;'5E(&]F('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',L#0H@86-C;W5N=',@
M<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<R!A<'!R;WAI;6%T92!T:&5I
M<B!C87)R>6EN9PT*('9A;'5E<R!D=64@=&\@=&AE:7(@<VAO<G0M=&5R;2!N
M871U<F4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CY'=6%R86YT965D(%)I9VAT<R!O
M9B!2971U<FX\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P
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M>2!R96-O<F1S(')E=F5N=64@:6X@=&AA=`T*(&%C8V]U;G1I;F<@<&5R:6]D
M+B!4:&4@0V]M<&%N>2!H860@)#(S+#<Q,2!A;F0@)#(W+#@Q,B!O9B!R979E
M;G5E#0H@9&5F97)R960@=6YD97(@9W5A<F%N=&5E9"!R:6=H=',@;V8@<F5T
M=7)N(&%R<F%N9V5M96YT<R!I;F-L=61E9"!I;@T*(&1E9F5R<F5D(')E=F5N
M=64@:6X@=&AE(&)A;&%N8V4@<VAE971S(&%S(&]F(%-E<'1E;6)E<B8C>$$P
M.S,P+`T*(#(P,3,@86YD($1E8V5M8F5R)B-X03`[,S$L(#(P,3(L(')E<W!E
M8W1I=F5L>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/DEN=F5N=&]R>3PO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@26YV96YT;W)Y(&ES('-T871E9"!A="!T:&4@;&]W97(@
M;V8@8V]S="!O<B!M87)K970N($-O<W0L('=H:6-H#0H@:6YC;'5D97,@;6%T
M97)I86PL(&QA8F]R(&%N9"!O=F5R:&5A9"P@:7,@9&5T97)M:6YE9"!O;B!A
M(&9I<G-T+6EN+`T*(&9I<G-T+6]U="!B87-I<RX@3VX@82!Q=6%R=&5R;'D@
M8F%S:7,L('=E(&%N86QY>F4@;W5R(&EN=F5N=&]R>0T*(&QE=F5L<R!A;F0@
M<F5S97)V92!F;W(@:6YV96YT;W)Y('1H870@:7,@97AP96-T960@=&\@97AP
M:7)E('!R:6]R#0H@=&\@8F5I;F<@<V]L9"P@:6YV96YT;W)Y('1H870@:&%S
M(&$@8V]S="!B87-I<R!I;B!E>&-E<W,@;V8@:71S#0H@97AP96-T960@;F5T
M(')E86QI>F%B;&4@=F%L=64L(&EN=F5N=&]R>2!I;B!E>&-E<W,@;V8@97AP
M96-T960-"B!S86QE<R!R97%U:7)E;65N=',L(&]R(&EN=F5N=&]R>2!T:&%T
M(&9A:6QS('1O(&UE970@8V]M;65R8VEA;"!S86QE#0H@<W!E8VEF:6-A=&EO
M;G,N($5X<&ER960@:6YV96YT;W)Y(&ES(&1I<W!O<V5D(&]F(&%N9"!T:&4@
M<F5L871E9`T*(&-O<W1S(&%R92!W<FET=&5N(&]F9B!T;R!T:&4@<F5S97)V
M92!F;W(@:6YV96YT;W)Y(&]B<V]L97-C96YC92X-"B!4:&4@:6YV96YT;W)Y
M(')E<V5R=F4@=V%S(&%P<')O>&EM871E;'D@)#(R+#`P,"!A;F0@)#(U,RPP
M,#`@87,@;V8-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,BP-"B!R97-P96-T:79E;'DN/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B`\8CY3=&]C:RU"87-E9"!087EM96YT($%R<F%N9V5M96YT<SPO8CX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@1V5N97)A;&QY+"!A;&P@9F]R;7,@;V8@<W1O8VLM
M8F%S960@<&%Y;65N=',L(&EN8VQU9&EN9R!S=&]C:PT*(&]P=&EO;B!G<F%N
M=',L('=A<G)A;G1S+"!A;F0@<F5S=')I8W1E9"!S=&]C:R!G<F%N=',@87)E
M(&UE87-U<F5D#0H@870@=&AE:7(@9F%I<B!V86QU92!O;B!T:&4@87=A<F1S
M)B-X,C`Q.3L@9W)A;G0@9&%T92!T>7!I8V%L;'D@=7-I;F<-"B!A($)L86-K
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M('1H97D@87)E('-U8FIE8W0@=&\-"B!F;W)F96ET=7)E+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q.'!X.R!-05)'24XM0D]45$]-.B`P<'@[
M($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]B/CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!'
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M<FQY:6YG('!E<F9O<FUA;F-E(&-O;F1I=&EO;B!I<PT*(&UE="X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#QB/E=A<G)A;G1S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@
M0V]M<&%N>2!U<V5D('1H92!";&%C:R!38VAO;&5S($]P=&EO;B!0<FEC:6YG
M($UO9&5L(&EN#0H@8V%L8W5L871I;F<@=&AE(')E;&%T:79E(&9A:7(@=F%L
M=64@;V8@86YY('=A<G)A;G1S('1H870@:&%V92!B965N#0H@:7-S=65D+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@/&(^3F5T($QO<W,@4&5R(%-H87)E/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B!$=7)I;F<@86QL('!E<FEO9',@<')E<V5N=&5D+"!T:&4@
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M;W(@86QL('!E<FEO9',@<')E<V5N=&5D+`T*('-H87)E<R!A<W-O8VEA=&5D
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M=71S=&%N9&EN9RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/E)E=F5N=64@4F5C;V=N
M:71I;VX\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@
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M;W0@8F5E;B!I;F-U<G)E9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
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M86PN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B`\8CY#;VYC96YT<F%T:6]N<SPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@5&AE($-O;7!A;GD@:7,@9&5P96YD96YT(&]N(&ME>2!S
M=7!P;&EE<G,@=&\@<')O=FED92!P<F]B:6]T:6-S+`T*(&)L96YD:6YG+"!W
M87)E:&]U<VEN9R!A;F0@<&%C:V%G:6YG(&]F(&ET<R!%=F]R85!L=7,L($5V
M;W)A2VED<RP-"B!%=F]R85!R;RP@86YD(%1E9&1Y)B-X,C`Q.3MS(%!R:61E
M('!R;V1U8W1S+B!4:&4@0V]M<&%N>2!H860@9F]U<@T*(&ME>2!S=7!P;&EE
M<G,@9'5R:6YG('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD960-"B!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q,BX@5&AE(&UA:F]R:71Y
M(&]F('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@8V]S="!O9B!S86QE<R!A<F4@
M9G)O;2!T:&5S92!K97D@<W5P<&QI97)S(&1U<FEN9PT*('1H92!T:')E92!A
M;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@
M86YD(#(P,3(N#0H@06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E
M;G-E<R!F;W(@=&AE<V4@=F5N9&]R<R!T;W1A;&5D#0H@87!P<F]X:6UA=&5L
M>2`D+3`M(&%N9"`D.3DL,#`P(&%S(&]F(%-E<'1E;6)E<B8C>$$P.S,P+"`R
M,#$S(&%N9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3(L(')E<W!E8W1I=F5L
M>2X@07,@;V8@4V5P=&5M8F5R)B-X03`[,S`L#0H@,C`Q,RP@=&AE($-O;7!A
M;GD@:&%D(&$@<')E<&%I9"!B86QA;F-E(&]F(&%P<')O>&EM871E;'D@)#(W
M+#`P,`T*('=I=&@@;VYE(&]F('1H97-E('9E;F1O<G,N/"]P/@T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83@X
M.3)F,#%?-F(V-U\T,C@V7V$W-C-?8C=C93<Q-3@V-3$V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W
M8V4W,34X-C4Q-B]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS
M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY$:7-C;&]S=7)E($]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O
M<W1S(%-H87)E8F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!#
M;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD
M:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXT+CPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1T;W`@86QI9VX],T1L969T/CQB/E-T;V-K+6)A<V5D($-O;7!E
M;G-A=&EO;CPO8CX\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\(2TM('AB
M<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!R96-O9VYI>F5D
M('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!O;B!A;&P@96UP;&]Y964@86YD
M#0H@;F]N+65M<&QO>65E(&%W87)D<R!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L
M:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^
M#0H@/'1D('=I9'1H/3-$-#8E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^5&AR964F(WA!,#M-;VYT:',F(WA!,#M%;F1E
M9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4:')E928C>$$P.TUO;G1H<R8C
M>$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3(\+V(^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DYI;F4F(WA!,#M-
M;VYT:',F(WA!,#M%;F1E9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R
M,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY.:6YE
M)B-X03`[36]N=&AS)B-X03`[16YD960\8G(@+SX-"B!397!T96UB97(F(WA!
M,#LS,"P@,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M
M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@
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M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(%-E;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,2PS-34L,3<U/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C8Y,RPU,S,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2PT-C4L-3DP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CDT,"PT.3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1O=&%L(%-T
M;V-K(&)A<V5D(&-O;7!E;G-A=&EO;CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-3,X+#,T
M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XW.3DL,SDQ/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L-C(T+#$V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`U-RPR,3@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q
M<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@5&AE($-O;7!A;GD@9W)A;G1E9"`M,"T@86YD(#,U+#`P,"!S
M=&]C:R!O<'1I;VYS+"!W:71H(&$-"B!W96EG:'1E9"UA=F5R86=E(&=R86YT
M(&1A=&4@9F%I<B!V86QU92!O9B`M,"T@86YD("0S+C0Q('!E<B!S:&%R92P-
M"B!D=7)I;F<@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T
M96UB97(F(WA!,#LS,"P@,C`Q,RP-"B!R97-P96-T:79E;'DN(%1H92!#;VUP
M86YY(&=R86YT960@+3`M(&%N9"`Q,#`L,#`P('-T;V-K(&]P=&EO;G,L#0H@
M=VET:"!A('=E:6=H=&5D+6%V97)A9V4@9W)A;G0@9&%T92!F86ER('9A;'5E
M(&]F("0P(&%N9"`D,2XP,R!P97(-"B!S:&%R92P@9'5R:6YG('1H92!T:')E
M92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L#0H@
M,C`Q,BP@<F5S<&5C=&EV96QY+B!$=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N
M9&5D(%-E<'1E;6)E<B8C>$$P.S,P+`T*(#(P,3,L(#4P+#4S,R!S=&]C:R!O
M<'1I;VYS('!R979I;W5S;'D@9W)A;G1E9"!H879E('9E<W1E9"P@-38L,#4P
M#0H@<W1O8VL@;W!T:6]N<R!W97)E(&9O<F9E:71E9"!A;F0@,S$L-3,S(&EN
M8VQU9&5D(&EN(&]U='-T86YD:6YG#0H@<W1O8VL@;W!T:6]N<R!W97)E(&5X
M97)C:7-E9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN8VQU9&5D(&EN('1H92!R97-U
M;'1S(&9O<B!T:&4@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@<75A<G1E<B!I
M<PT*(&$@;&EA8FEL:71Y(&%N9"!E>'!E;G-E(&EN('1H92!A;6]U;G0@;V8@
M)#$L-#@W+#@P,2!R96QA=&EN9R!T;PT*('!R;V)A8FQE(&%W87)D<R!U;F1E
M<B!T:&4@0V]M<&%N>28C>#(P,3D[<R`R,#$R($5Q=6ET>2!);F-E;G1I=F4-
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M#0H@9W)A;G0@9&%T92!F86ER('9A;'5E(&]F('1H92`T,C(L,S4Y('-H87)E
M<R!E>'!E8W1E9"!T;R!B92!A=V%R9&5D#0H@=6YD97(@=&AE(#(P,3(@4&QA
M;BX@4V5E($YO=&4@."`F(W@R,#$S.R!3=6)S97%U96YT($5V96YT<RX\+W`^
M#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E=A<G)A
M;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^5&5X="!";&]C:R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QT86)L92!S='EL93TS1"="
M3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@/'1R
M/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0T)2!A;&EG;CTS1&QE9G0^
M/&(^-2X\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F
M=#X\8CY787)R86YT<SPO8CX\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B!!('-U;6UA<GD@;V8@=V%R<F%N="!A8W1I=FET>2!F;W(@=&AE
M('EE87(@96YD960@1&5C96UB97(F(WA!,#LS,2P-"B`R,#$R(&%N9"!T:&4@
M;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@:7,@
M87,-"B!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0W-R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY787)R86YT<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(^/&(^5V5I9VAT960\8G(@+SX-"B!!=F5R86=E/&)R("\^#0H@4')I
M8V4\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($)A;&%N8V4@)B-X,C`Q
M,SL@1&5C96UB97(F(WA!,#LS,2P@,C`Q,3PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
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M/C$Y+C$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!'<F%N=&5D/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY-#(L,#DT/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N.#<\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5X97)C:7-E9#PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%>'!I<F5D
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$R+#4P,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8N,#`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F%L86YC92`F
M(W@R,#$S.R!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XS+#(S-2PY.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS
M+C4S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!'<F%N=&5D/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%>&5R
M8VES960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,#`L,#`P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$N-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M($5X<&ER960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R.#@L.#@X/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@Q.2XX-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!"86QA;F-E("8C>#(P
M,3,[(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR+#<T-RPP.30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XY,3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($]N($IA;G5A<GDF(WA!,#LS,2P@,C`Q,R!'<FEF9FEN
M(%-E8W5R:71I97,@26YC+B!E>&5R8VES960@,C`P+#`P,`T*(&]F('1H96ER
M('!R979I;W5S;'D@:7-S=65D('=A<G)A;G1S(')E<W5L=&EN9R!I;B!T:&4@
M:7-S=6%N8V4@;V8-"B`Q,#8L,C4P('-H87)E<R!O9B!O=7(@8V]M;6]N('-T
M;V-K+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@5&AE('=A<G)A;G1S(&]U='-T86YD:6YG
M(&%S(&]F(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%R92!A<PT*(&9O;&QO
M=W,Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-
M"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0X-"4@86QI9VX],T1C96YT97(^#0H@/'1R/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0T,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-#`E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@;F]W<F%P/3-$;F]W<F%P(&%L:6=N/3-$8V5N=&5R/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M.R!724142#H@-#@N-G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<@86QI9VX],T1C96YT97(^/&(^17AE<F-I<V4F
M(WA!,#M0<FEC93PO8CX\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/E=A<G)A;G1S/&)R("\^#0H@3W5T<W1A;F1I;F<\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D5X
M<&ER871I;VXF(WA!,#M$871E<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/C$N-3`\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3<Q+#$V.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+S,P+S$W/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^,BXP
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#$W,"PY,C4\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,R\R,R\Q-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1'1O<"!A;&EG;CTS1')I9VAT/C$P+C`P/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$=&]P(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,#`P/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C0O,34O,30\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(L-S0W+#`Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$X.#DR9C`Q7S9B-C=?-#(X-E]A
M-S8S7V(W8V4W,34X-C4Q-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]A.#@Y,F8P,5\V8C8W7S0R.#9?83<V,U]B-V-E-S$U.#8U,38O5V]R:W-H
M965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4VAO<G0M5&5R;2!.;W1E<R!087EA8FQE/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5B="!$:7-C
M;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VAO<G0M5&5R;2!.;W1E<R!087EA8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U3
M25I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\<#X\(2TM('AB<FPL;B`M+3X\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O<"!W
M:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXV+CPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1T;W`@86QI9VX],T1L969T/CQB/E-H;W)T+71E<FT@3F]T97,@
M4&%Y86)L93PO8CX\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\(2TM('AB
M<FPL8F]D>2`M+3X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!!<R!O9B!397!T96UB97(F(WA!,#LS
M,"P@,C`Q,R!A;F0@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@=&AE#0H@0V]M
M<&%N>2!H860@)#$P."PR,C`@86YD("0T-RPY-S<@<F5S<&5C=&EV96QY+"!I
M;B!S:&]R="UT97)M(&YO=&5S#0H@<&%Y86)L92!F;W(@=&AE(&9I;F%N8VEN
M9R!O9B!V87)I;W5S(&EN<W5R86YC92!P;VQI8VEE<RX@3VX-"B!-87)C:"8C
M>$$P.S@L(#(P,3,L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A('-H;W)T
M+71E<FT@;F]T90T*('!A>6%B;&4@9F]R("0U,"PP,S<@8F5A<FEN9R!I;G1E
M<F5S="!A="`V+C4W)2!T;R!F:6YA;F-E('1H90T*('!R;V1U8W0@;&EA8FEL
M:71Y(&EN<W5R86YC92X@4')I;F-I<&%L(&%N9"!I;G1E<F5S="!P87EM96YT
M<R!O;@T*('1H:7,@;F]T92!B96=A;B!!<')I;"8C>$$P.S$P+"`R,#$S(&%N
M9"!A<F4@;6%D92!E=F5N;'D@8F%S960@;VX@80T*('-T<F%I9VAT(&QI;F4@
M86UO<G1I>F%T:6]N(&]V97(@82`Q,"UM;VYT:"!P97)I;V0@=VET:"!T:&4@
M9FEN86P-"B!P87EM96YT(&1U92!O;B!*86YU87)Y)B-X03`[,3`L(#(P,30N
M($]N($IU;F4F(WA!,#LR,"P@,C`Q,RP@=V4-"B!E;G1E<F5D(&EN=&\@82!S
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M(WA!,#LR-"P@,C`Q,R!A;F0@87)E(&UA9&4@979E;FQY(&)A<V5D(&]N(&$-
M"B!S=')A:6=H="!L:6YE(&%M;W)T:7IA=&EO;B!O=F5R(&%N(#$Q+6UO;G1H
M('!E<FEO9"!W:71H('1H92!F:6YA;`T*('!A>6UE;G0@9'5E(&]N($IU;F4F
M(WA!,#LR-"P@,C`Q-"X\+W`^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/D-O;G9E<G1I8FQE($YO=&4@4&%Y86)L92!T;R!3:&%R
M96AO;&1E<CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1E8G0@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M($YO=&4@4&%Y86)L92!T;R!3:&%R96AO;&1E<CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52
M+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\
M=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-"4@86QI9VX],T1L969T/CQB/C<N
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!A;&EG;CTS1&QE9G0^/&(^
M0V]N=F5R=&EB;&4@3F]T92!087EA8FQE(%1O#0H@4VAA<F5H;VQD97(\+V(^
M/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"$M+2!X8G)L+&)O9'D@+2T^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@3VX@4V5P=&5M8F5R(#,P+"`R,#$S+"!T:&4@0V]M<&%N
M>2!E;G1E<F5D(&EN=&\@86X@=6YS96-U<F5D#0H@<VAO<G0M=&5R;2!#;VYV
M97)T:6)L92!0<F]M:7-S;W)Y($YO=&4@:6X@=&AE('!R:6YC:7!A;"!A;6]U
M;G0@;V8-"B`D,2PY-38L,#`P(&)E87)I;F<@:6YT97)E<W0@870@,RXP,"4@
M87,@<&%R=&EA;"!C;VYS:61E<F%T:6]N(&9O<@T*('1H92!496-H;F]L;V=Y
M($%C8V5S<R!&965S(&%S<V]C:6%T960@=VET:"!T:&4@4')O8FEO=&EC($5#
M0PT*("AD:7-C=7-S960@8F5L;W<I(&5N=&5R960@:6YT;R!W:71H($EN=')E
M>&]N($-O<G!O<F%T:6]N+B!4:&4-"B!#;VYV97)T:6)L92!0<F]M:7-S;W)Y
M($YO=&4@:7,@<&%Y86)L92P@870@=&AE($-O;7!A;GDF(W@R,#$Y.W,-"B!O
M<'1I;VXL(&EN(&-A<V@@;W(@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X,C`Q
M.3MS(&-O;6UO;B!S=&]C:RX-"B!0<FEN8VEP86P@86YD(&%C8W)U960@:6YT
M97)E<W0@87)E(&1U92!O;B!$96-E;6)E<B`S,2P@,C`Q,RX\+W`^#0H@#0H@
M#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S
M(&%N9"!#;VYT:6YG96YC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O;G1I;F=E
M;F-I97,@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UI=&UE;G1S(&%N9"!#;VYT
M:6YG96YC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!V86QI9VX],T1T;W`@=VED
M=&@],T0T)2!A;&EG;CTS1&QE9G0^/&(^."X\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\8CY#;VUM:71M96YT<R!A;F0-"B!#
M;VYT:6YG96YC:65S/"]B/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PA
M+2T@>&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QI/E1H92!5;FEV97)S:71Y
M(&]F($9L;W)I9&$@4F5S96%R8V@@1F]U;F1A=&EO;B!,:6-E;G-E<SPO:3X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@:&]L9',@97AC;'5S:79E(&QI
M8V5N<V5S(&9R;VT@=&AE(%5N:79E<G-I='D@;V8@1FQO<FED80T*(%)E<V5A
M<F-H($9O=6YD871I;VXL($EN8RX@*"8C>#(P,4,[54921B8C>#(P,40[*2!F
M;W(@:71S(%--85)4#0H@4F5P;&%C96UE;G0@5&AE<F%P>2!A;F0@354Q,30P
M('!R;V1U8W0@8V%N9&ED871E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@/&D^354Q,30P("8C>#(P,3,[/"]I/B!4:&4@0V]M<&%N>2!H
M87,@97AC;'5S:79E;'D@;&EC96YS960@=&AE#0H@:6YT96QL96-T=6%L('!R
M;W!E<G1Y(&9O<B!O=7(@354Q,30P(&QA;G1I8FEO=&EC('1E8VAN;VQO9WD@
M9G)O;0T*('1H92!51E)&+B!4:&4@;W)I9VEN86P@;&EC96YS92!A9W)E96UE
M;G0@=V%S(&1A=&5D($IU;F4F(WA!,#LR,BP-"B`R,#`P(&%N9"!W87,@<W5B
M<V5Q=65N=&QY(&%M96YD960@;VX@4V5P=&5M8F5R)B-X03`[,34L#0H@,C`P
M,"PF(WA!,#M*=6QY)B-X03`[,3`L(#(P,#(L)B-X03`[4V5P=&5M8F5R)B-X
M03`[,C4L#0H@,C`P,BPF(WA!,#M-87)C:"8C>$$P.S$W+"`R,#`S(&%N9"!!
M<')I;"8C>$$P.S$Y+"`R,#$S+B!4:&4@86UE;F1E9`T*(&QI8V5N<V4@86=R
M965M96YT('!R;W9I9&5S('1H92!#;VUP86YY('=I=&@@86X@97AC;'5S:79E
M('=O<FQD=VED90T*(&QI8V5N<V4@=&\@;6%K92P@=7-E(&%N9"!S96QL('!R
M;V1U8W1S(&%N9"!P<F]C97-S97,@8V]V97)E9"!B>0T*(%!A=&5N="!.;RXF
M(WA!,#LU+#DS,BPT-CD@96YT:71L960@)B-X,C`Q0SM!;G1I;6EC<F]B:6%L
M#0H@4&]L>7!E<'1I9&4L($YU8VQE:6,@06-I9"!A;F0@365T:&]D<R!O9B!5
M<V4F(W@R,#%$.R!A;F0@:6YC;'5D97,-"B!5+E,N('!A=&5N="!N=6UB97)S
M(#8L.38T+#<V,#L@-RPP-C<L,3(U.R`V+#,Y,2PR.#4[(#8L-#<U+#<W,2!A
M;F0-"B!F;W)E:6=N('!A=&5N=',N(%1H92!#;VUP86YY)B-X,C`Q.3MS(&QI
M8V5N<V4@:7,@9F]R('1H92!P97)I;V0@;V8-"B!T:&4@<&%T96YT<RP@=VAI
M8V@@97AP:7)E(&9R;VT@,C`Q-R!T:')O=6=H(#(P,3DL('-U8FIE8W0@=&\@
M=&AE#0H@<&5R9F]R;6%N8V4@;V8@=&5R;7,@86YD(&-O;F1I=&EO;G,@8V]N
M=&%I;F5D('1H97)E:6XN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QI/E--85)4(%)E<&QA8V5M96YT(%1H97)A<'D@)B-X,C`Q,SL\+VD^
M(%1H92!#;VUP86YY(&AA<PT*(&5X8VQU<VEV96QY(&QI8V5N<V5D('1H92!I
M;G1E;&QE8W1U86P@<')O<&5R='D@9F]R(&ET<R!R97!L86-E;65N=`T*('1H
M97)A<'D@=&5C:&YO;&]G>2!F<F]M('1H92!51E)&+B!4:&4@;W)I9VEN86P@
M;&EC96YS92!A9W)E96UE;G0-"B!W87,@9&%T960@075G=7-T)B-X03`[-"P@
M,3DY."!A;F0@=V%S('-U8G-E<75E;G1L>2!A;65N9&5D(&]N#0H@4V5P=&5M
M8F5R)B-X03`[,34L(#(P,#`L)B-X03`[2G5L>28C>$$P.S$P+`T*(#(P,#(L
M)B-X03`[4V5P=&5M8F5R)B-X03`[,C4L(#(P,#(L)B-X03`[36%R8V@F(WA!
M,#LQ-RP@,C`P,R!A;F0-"B!!<')I;"8C>$$P.S$Y+"`R,#$S+B!4:&4@86UE
M;F1E9"!L:6-E;G-E(&%G<F5E;65N="!P<F]V:61E<R!T:&4-"B!#;VUP86YY
M('=I=&@@86X@97AC;'5S:79E('=O<FQD=VED92!L:6-E;G-E('1O(&UA:V4L
M('5S92!A;F0@<V5L;`T*('!R;V1U8W1S(&%N9"!P<F]C97-S97,@8V]V97)E
M9"!B>2!0871E;G0@3F\N)B-X03`[-2PV,#<L-C<R+`T*(&5N=&ET;&5D("8C
M>#(P,4,[4F5P;&%C96UE;G0@5&AE<F%P>2!F;W(@1&5N=&%L($-A<FEE<R8C
M>#(P,40[+"!W:&EC:`T*('=A<R!F:6QE9"!I;B!T:&4@52Y3+B!05$\@;VX@
M2G5N928C>$$P.S<L(#$Y.34@86YD(&UA9&4@969F96-T:79E#0H@;VX@36%R
M8V@F(WA!,#LT+"`Q.3DW+B!4:&4@<&%T96YT('=I;&P@97AP:7)E(&]N($IU
M;F4F(WA!,#LW+"`R,#$U+@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS(&QI8V5N
M<V4@:7,@9F]R('1H92!P97)I;V0@;V8@=&AE('!A=&5N="P-"B!S=6)J96-T
M('1O('1H92!P97)F;W)M86YC92!O9B!T97)M<R!A;F0@8V]N9&ET:6]N<R!C
M;VYT86EN960-"B!T:&5R96EN+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B`\:3Y!9&1I=&EO;F%L(%1E<FUS(&]F(%5&4D8@3&EC96YS92!!
M9W)E96UE;G1S("8C>#(P,3,[/"]I/B!);B!T:&4-"B!A;65N9&5D(&QI8V5N
M<V4@86=R965M96YT<R!F;W(@4TUA4E0@4F5P;&%C96UE;G0@5&AE<F%P>2!A
M;F0-"B!-53$Q-#`L('1H92!#;VUP86YY(&ES(&]B;&EG871E9"!T;R!P87D@
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M=6)L:6-E;G-E<RP@97AC;'5D:6YG(&UO;FEE<R!R96-E:79E9`T*('-O;&5L
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M("0U+#`P,"!P97(@;6]N=&@@8F5T=V5E;@T*($UA>28C>$$P.S$L(#(P,3,@
M86YD('1H92!M;VYT:"!O9B!T:&4@9FER<W0@86YN:79E<G-A<GD@;V8@80T*
M(&-O;6UE<F-I86P@<V%L92X@5&AE('!O<W0M8V]M;65R8VEA;&EZ871I;VX@
M;6EN:6UU;2!R;WEA;'1Y#0H@<&%Y;65N=',@;V8@)#4P+#`P,"!A;FYU86QL
M>2!W;W5L9"!B92!D=64@9F]L;&]W:6YG('!A>6UE;G0@;V8@80T*(&-O;6UE
M<F-I86QI>F%T:6]N(&9E92X@5&AE(&]N92UT:6UE(&%D9&ET:6]N86P@<F]Y
M86QT>2!P87EM96YT#0H@=V]U;&0@8F4@9'5E('=H96X@=&]T86P@8W5M=6QA
M=&EV92!R;WEA;'1I97,@<&%I9"!T;R!51E)&(&5X8V5E9`T*("0R+C`@;6EL
M;&EO;BP@=7!O;B!W:&EC:"!W92!W;W5L9"!B92!O8FQI9V%T960@=&\@;6%K
M92!A(&]N92UT:6UE#0H@861D:71I;VYA;"!P87EM96YT('1O(%5&4D8@;V8@
M,3`E(&]F('1H92!T;W1A;"!R;WEA;'1I97,@9'5E('1O#0H@54921B!I;B!T
M:&4@8V%L96YD87(@>65A<B!I;B!W:&EC:"!C=6UU;&%T:79E(')O>6%L=&EE
M<R!E>&-E961E9`T*("0R+C`@;6EL;&EO;BX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)
M6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!#;VUP86YY
M(&ES(')E<75I<F5D('1O(&UA:V4@;6EN:6UU;2!A;FYU86P@;6%I;G1E;F%N
M8V4@<&%Y;65N=',-"B!T;R!T:&4@54921B!F;W(@=&AE('1E<FT@;V8@=&AE
M(&%M96YD960@;&EC96YS92!A9W)E96UE;G1S(&EN('1H90T*(&%M;W5N="!O
M9B`D,3`L,#`P(&9O<B!E86-H(&QI8V5N<V4@86=R965M96YT(&%N9"`D,C`L
M,#`P(&EN#0H@86=G<F5G871E+B!4:&4@86=G<F5G871E(&UI;FEM=6T@86YN
M=6%L('!A>6UE;G1S(&%R92!R97%U:7)E9"!T;R!B90T*('!A:60@:6X@861V
M86YC92!O;B!A('%U87)T97)L>2!B87-I<R`H:2YE+B`D-2PP,#`@<&5R('%U
M87)T97(I(&9O<@T*(&)O=&@@;&EC96YS97,N(%1H92!#;VUP86YY(&UU<W0@
M86QS;R!P87D@86QL('!A=&5N="!C;W-T<R!A;F0-"B!E>'!E;G-E<R!I;F-U
M<G)E9"!B>2!T:&4@54921B!F;W(@=&AE('!R97!A<F%T:6]N+"!F:6QI;F<L
M#0H@<')O<V5C=71I;VXL(&ES<W5A;F-E(&%N9"!M86EN=&5N86YC92!O9B!T
M:&4@<&%T96YT<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QI/E1H92!%>&-L=7-I=F4@
M0VAA;FYE;"!#;VQL86)O<F%T:6]N("@F(W@R,#%#.T5#0R8C>#(P,40[*0T*
M($%G<F5E;65N=',@=VET:"!);G1R97AO;B!#;W)P;W)A=&EO;@T*("@F(W@R
M,#%#.TEN=')E>&]N)B-X,C`Q1#LI/"]I/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!/;B!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,RP@=&AE($-O;7!A;GD@96YT97)E9"!I
M;G1O(&%N($5#0PT*($%G<F5E;65N="`H=&AE("8C>#(P,4,[4')O8FEO=&EC
M<R!%0T,F(W@R,#%$.RD@=VET:"!);G1R97AO;B!T:&%T#0H@9V]V97)N<R!A
M("8C>#(P,4,[8VAA;FYE;"!C;VQL86)O<F%T:6]N)B-X,C`Q1#L@87)R86YG
M96UE;G0@:6X@=VAI8V@-"B!T:&4@0V]M<&%N>2!W:6QL('5S92!);G1R97AO
M;B8C>#(P,3D[<R!P<F]P<FEE=&%R>2!T96-H;F]L;V=Y#0H@<F5L871I;F<@
M=&\@=&AE(&ED96YT:69I8V%T:6]N+"!D97-I9VX@86YD('!R;V1U8W1I;VX@
M;V8-"B!G96YE=&EC86QL>2!M;V1I9FEE9"!C96QL<RP@1$Y!('9E8W1O<G,@
M86YD(&EN('9I=F\@8V]N=')O;"!O9@T*(&5X<')E<W-I;VX@*'1H92`F(W@R
M,#%#.U1E8VAN;VQO9WDF(W@R,#%$.RD@9F]R('1H92!D979E;&]P;65N="!A
M;F0-"B!C;VUM97)C:6%L:7IA=&EO;B!O9B!P<F]B:6]T:6-S+"!S<&5C:69I
M8V%L;'D@=&AE(&1I<F5C=`T*(&%D;6EN:7-T<F%T:6]N('1O(&AU;6%N<R!O
M9B!G96YE=&EC86QL>2!M;V1I9FEE9"!P<F]B:6]T:6-S(&9O<B!T:&4-"B!T
M<F5A=&UE;G0@;V8@9&ES96%S97,@;V8@=&AE(&]R86P@8V%V:71Y+"!T:')O
M870L('-I;G5S(&%N9`T*(&5S;W!H86=U<RP@:6YC;'5D:6YG+"!B=70@;F]T
M(&QI;6ET960@=&\L(&%P:'1H;W5S('-T;VUA=&ET:7,@86YD#0H@0F5H8V5T
M)B-X,C`Q.3MS(&1I<V5A<V4@*&-O;&QE8W1I=F5L>2P@=&AE("8C>#(P,4,[
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M<&5R='D@;6%T=&5R<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!0<F]B:6]T:6-S
M($5#0R!G<F%N=',@=&AE($-O;7!A;GD@86X@97AC;'5S:79E('=O<FQD=VED
M90T*(&QI8V5N<V4@=&\@=71I;&EZ92!);G1R97AO;B8C>#(P,3D[<R!496-H
M;F]L;V=Y('1O(&1E=F5L;W`@86YD#0H@8V]M;65R8VEA;&EZ92!P<F]B:6]T
M:6-S+"!S<&5C:69I8V%L;'D@=&AE(&1I<F5C="!A9&UI;FES=')A=&EO;B!T
M;PT*(&AU;6%N<R!O9B!G96YE=&EC86QL>2!M;V1I9FEE9"!P<F]B:6]T:6-S
M(&9O<B!T:&4@=')E871M96YT(&]F#0H@9&ES96%S97,@;V8@=&AE(&]R86P@
M8V%V:71Y+"!T:')O870L('-I;G5S(&%N9"!E<V]P:&%G=7,-"B`H)B-X,C`Q
M0SM#;VUP86YY(%!R;V1U8W1S)B-X,C`Q1#LI+B!3=6-H(&QI8V5N<V4@:7,@
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M4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!5;F1E
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M<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@1D].5"U&
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M9`T*('1O('!A>2!);G1R97AO;B!A('!E<F-E;G1A9V4@;V8@<F5V96YU92!O
M8G1A:6YE9"!F<F]M(&$@<W5B;&EC96YS964-"B!I;B!T:&4@979E;G0@;V8@
M82!S=6)L:6-E;G-I;F<@87)R86YG96UE;G0N(%1H92!P97)C96YT86=E(&]F
M('1H90T*(')E=F5N=64@=&\@8F4@<&%I9"!W:6QL(&)E(&1E=&5R;6EN960@
M870@=&AE('1I;64@=&AA="!A('-U8FQI8V5N<V4-"B!A9W)E96UE;G0@:7,@
M;F5G;W1I871E9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!#;VUP86YY(&UA>2!V
M;VQU;G1A<FEL>2!T97)M:6YA=&4@=&AE(%!R;V)I;W1I8W,@14-#('5P;VX@
M.3`-"B!D87ES('=R:71T96X@;F]T:6-E('1O($EN=')E>&]N+B!);G1R97AO
M;B!M87D@86QS;R!T97)M:6YA=&4@=&AE#0H@4')O8FEO=&EC<R!%0T,@:68@
M=&AE($-O;7!A;GD@8G)E86-H97,@=&AE(%!R;V)I;W1I8W,@14-#(&%N9"!F
M86EL<PT*('1O(&-U<F4@=&AE(&)R96%C:"!W:71H:6X@-C`@9&%Y<R!O<B!T
M:&4@0V]M<&%N>2!D;V5S(&YO="!P=7)S=64-"B!D979E;&]P;65N="!O9B!T
M:&4@4W5P97)I;W(@5&AE<F%P>2!U;F1E<B!T:&4@<')O8FEO=&EC<R!I9&5N
M=&EF:65D#0H@8GD@26YT<F5X;VX@=&AA="!I<R!A("8C>#(P,4,[4W5P97)I
M;W(@5&AE<F%P>28C>#(P,40[(&%S(&1E9FEN960@:6X-"B!T:&4@4')O8FEO
M=&EC<R!%0T,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!5<&]N('1E<FUI;F%T:6]N(&]F
M('1H92!0<F]B:6]T:6-S($5#0RP@=&AE($-O;7!A;GD@;6%Y(&-O;G1I;G5E
M('1O#0H@9&5V96QO<"!A;F0@8V]M;65R8VEA;&EZ92!A;GD@0V]M<&%N>2!0
M<F]D=6-T('1H870L(&%T('1H92!T:6UE(&]F#0H@=&5R;6EN871I;VXL('-A
M=&ES9FEE<R!A="!L96%S="!O;F4@;V8@=&AE(&9O;&QO=VEN9R!C<FET97)I
M83H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T)SX-"B`F(WA!,#L\+W`^#0H@
M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX],T1L969T
M/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#YC
M;VUM97)C:6%L:7IE9"!B>2!T:&4@0V]M<&%N>3L\+W1D/@T*(#PO='(^#0H@
M/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0G/@T*("8C>$$P.SPO<#X-
M"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@
M=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE
M9G0^)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q
M)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T
M/F%P<')O=F5D(&)Y(')E9W5L871O<GD-"B!A=71H;W)I=&EE<SL\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0G/@T*("8C
M>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U
M)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A
M;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI
M9VX],T1L969T/F$@<W5B:F5C="!O9B!A;B!A<'!L:6-A=&EO;B!F;W(-"B!R
M96=U;&%T;W)Y(&%P<')O=F%L('1H870@:7,@<&5N9&EN9R!B969O<F4@=&AE
M(&%P<&QI8V%B;&4-"B!R96=U;&%T;W)Y(&%U=&AO<FET>3L@;W(\+W1D/@T*
M(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0G/@T*("8C
M>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C
M;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U
M)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A
M;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@
M=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI
M9VX],T1L969T/G1H92!S=6)J96-T(&]F(&%T(&QE87-T(&%N(&]N9V]I;F<-
M"B!0:&%S92`Q+"!0:&%S92`R(&]R(%!H87-E(#,@8VQI;FEC86P@=')I86P@
M:6X@=&AE(&9I96QD(&]F('1H90T*(%!R;V)I;W1I8W,@4')O9W)A;2X\+W1D
M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-
M"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P="<^#0H@26X@861D:71I;VXL(&EN('!A<G1I
M86P@8V]N<VED97)A=&EO;B!F;W(@96%C:"!P87)T>28C>#(P,3D[<PT*(&5X
M96-U=&EO;B!A;F0@9&5L:79E<GD@;V8@=&AE(%!R;V)I;W1I8W,@14-#+"!O
M;B!397!T96UB97(F(WA!,#LS,"P-"B`R,#$S('1H92!#;VUP86YY(&5N=&5R
M960@:6YT;R!A(%-T;V-K(%!U<F-H87-E(&%N9"!)<W-U86YC90T*($%G<F5E
M;65N="!A;F0@82!&:7)S="!!;65N9&UE;G0@=&\@=&AE(%-T;V-K(%!U<F-H
M87-E(&%N9"!)<W-U86YC90T*($%G<F5E;65N="`H8V]L;&5C=&EV96QY('1H
M92`F(W@R,#%#.U-024$F(W@R,#%$.RD@=VET:"!);G1R97AO;BX-"B!0=7)S
M=6%N="!T;R!T:&4@4U!)02P@=&AE($-O;7!A;GD@<&%I9"!);G1R97AO;B!A
M;B!U<"UF<F]N=`T*('1E8VAN;VQO9WD@86-C97-S(&9E92!O9B`D-BPP,#`L
M,#`P("AT:&4@)B-X,C`Q0SM496-H;F]L;V=Y($%C8V5S<PT*($9E928C>#(P
M,40[*2!I;B!C;VYS:61E<F%T:6]N(&9O<B!T:&4@97AE8W5T:6]N(&]F('1H
M92!0<F]B:6]T:6-S#0H@14-#+B!4:&4@5&5C:&YO;&]G>2!!8V-E<W,@1F5E
M('=A<R!P86ED('1O($EN=')E>&]N(&)Y('1H92!#;VUP86YY#0H@=&AR;W5G
M:"!T:&4@*&DI)B-X03`[:7-S=6%N8V4@;V8@,2PS-#@L,#`P('-H87)E<R`H
M870@)#,N,#`@<&5R#0H@<VAA<F4I(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M(&-O;6UO;B!S=&]C:R`H=&AE("8C>#(P,4,[5&5C:&YO;&]G>0T*($%C8V5S
M<R!3:&%R97,F(W@R,#%$.RDL(&%N9"`H:6DI)B-X03`[82!C;VYV97)T:6)L
M92!P<F]M:7-S;W)Y(&YO=&4-"B!I;B!T:&4@86UO=6YT(&]F("0Q+#DU-BPP
M,#`@=VAI8V@@:7,@<&%Y86)L92P@870@=&AE#0H@0V]M<&%N>28C>#(P,3D[
M<R!O<'1I;VXL(&EN(&-A<V@@;W(@<VAA<F5S(&]F($-O;7!A;GD@8V]M;6]N
M('-T;V-K#0H@*'1H92`F(W@R,#%#.T-O;G9E<G1I8FQE($YO=&4F(W@R,#%$
M.RDN(%1H92!#;VYV97)T:6)L92!.;W1E(&UA='5R97,-"B!O;B!$96-E;6)E
M<B8C>$$P.S,Q+"`R,#$S(&%N9"!R97%U:7)E<R!T:&4@0V]M<&%N>2!T;R!O
M8G1A:6X-"B!S:&%R96AO;&1E<B!A<'!R;W9A;"!P<FEO<B!T;R!C;VYV97)S
M:6]N(&]F('1H92!#;VYV97)T:6)L92!.;W1E+@T*(%1H92!C;VYV97)S:6]N
M('!R:6-E(&ES(&5Q=6%L('1O('1H92!C;&]S:6YG('!R:6-E('!E<B!S:&%R
M92!O9B!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!O;B!T
M:&4@;&%S="!T<F%D:6YG(&1A>2!I;6UE9&EA=&5L>0T*('!R:6]R('1O('1H
M92!D871E(&]F(&-O;G9E<G-I;VXN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!/;B!397!T
M96UB97(F(WA!,#LS,"P@,C`Q,R!T:&4@0V]M<&%N>2!A;'-O('-O;&0@=&\@
M26YT<F5X;VX-"B`Q+#,P,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&-O;6UO;B!S=&]C:R!A="!A('!R:6-E('!E<@T*('-H87)E(&]F
M("0S+C`P(&9O<B!G<F]S<R!P<F]C965D<R!O9B`D,RPY,#`L,#`P+B!4:&4@
M0V]M<&%N>0T*(&EN=&5N9',@=&\@=7-E('1H92!P<F]C965D<R!F<F]M('1H
M:7,@<V%L92!O9B!C;VUM;VX@<W1O8VL@=&]W87)D<PT*(&1E=F5L;W!M96YT
M(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&ME>2!I;FET:6%T:79E<R!R96QA
M=&EN9R!T;R!T:&4-"B!0<F]B:6]T:6-S(%!R;V=R86TL(&%N9"!G96YE<F%L
M(&-O<G!O<F%T92!P=7)P;W-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
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M('!A>6%B;&4-"B!A<F4@87,@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@-G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%
M4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@
M/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P
M('=I9'1H/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#XD,BPP,#`L,#`P('=I=&AI;B!T:&ER
M='D-"B`H,S`I)B-X03`[9&%Y<R!O9B!T:&4@9&]S:6YG(&]F(&$@<&%T:65N
M="!B>2!O<B!O;B!B96AA;&8@;V8@=&AE#0H@0V]M<&%N>2P@;W(@86X@069F
M:6QI871E("AA<R!T:&%T('1E<FT@:7,@9&5F:6YE9"!I;B!T:&4@4')O8FEO
M=&EC<PT*($5#0RD@;W(@<&5R;6ET=&5D('-U8FQI8V5N<V5E(&]F('1H92!#
M;VUP86YY+"!I;B!A('!H87-E($E)#0H@8VQI;FEC86P@=')I86PL('=H971H
M97(@<W5C:"!O8V-U<G,@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE<FEC
M80T*('5N9&5R('1H92!J=7)I<V1I8W1I;VX@;V8@=&AE(%5N:71E9"!3=&%T
M97,@1F]O9"!A;F0@1')U9PT*($%D;6EN:7-T<F%T:6]N("@F(W@R,#%#.T9$
M028C>#(P,40[*2!O<B!E;'-E=VAE<F4@=6YD97(@=&AE#0H@:G5R:7-D:6-T
M:6]N(&]F(&$@9F]R96EG;B!R96=U;&%T;W)Y(&%G96YC>2P@9F]R(&$@0V]M
M<&%N>0T*(%!R;V1U8W0[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@-G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$=&]P('=I9'1H/3-$,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#XD-2PP,#`L,#`P('=I
M=&AI;B!T:&ER='D-"B`H,S`I)B-X03`[9&%Y<R!O9B!T:&4@9FER<W0@;65E
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M<V1I8W1I;VX@;V8@82!F;W)E:6=N(')E9W5L871O<GD@86=E;F-Y+`T*(&9O
M<B!A($-O;7!A;GD@4')O9'5C=#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`V<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@
M<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(]
M,T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q
M,#`E/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R
M,CL\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/B0Q,"PP,#`L
M,#`P('=I=&AI;B!T:&ER='D-"B`H,S`I)B-X03`[9&%Y<R!O9B!T:&4@9FER
M<W0@=&\@;V-C=7(@;V8@*&$I)B-X03`[=&AE($9I<G-T#0H@0V]M;65R8VEA
M;"!386QE("AA<R!T:&%T('1E<FT@:7,@9&5F:6YE9"!I;B!T:&4@4')O8FEO
M=&EC<R!%0T,I(&]F#0H@82!#;VUP86YY(%!R;V1U8W0L(&]R("AB*28C>$$P
M.W1H92!A<'!R;W9A;"!O9B!A($YE=R!$<G5G#0H@07!P;&EC871I;VX@*&%S
M('1H870@=&5R;2!I<R!D969I;F5D(&EN('1H92!0<F]B:6]T:6-S($5#0RD@
M9F]R(&$-"B!#;VUP86YY(%!R;V1U8W0@8GD@=&AE($9$02!O<B!E<75I=F%L
M96YT(')E9W5L871O<GD@86-T:6]N(&EN(&$-"B!F;W)E:6=N(&IU<FES9&EC
M=&EO;BX\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`Q,G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@3F]N
M92!O9B!T:&4@4')O8FEO=&EC($5#0R!M:6QE<W1O;F5S(&AA9"!B965N(&%C
M:&EE=F5D(&%S(&]F#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,N/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B!/;B!*=6YE)B-X03`[-2P@,C`Q,BP@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&%N($5#0R!!9W)E96UE;G0-"B`H=&AE("8C>#(P,4,[
M3&%N=&EB:6]T:6,@14-#)B-X,C`Q1#LI('=I=&@@26YT<F5X;VX@=&AA="!G
M;W9E<FYS(&$-"B`F(W@R,#%#.V-H86YN96P@8V]L;&%B;W)A=&EO;B8C>#(P
M,40[(&%R<F%N9V5M96YT(&EN('=H:6-H('1H90T*($-O;7!A;GD@=VEL;"!U
M<V4@26YT<F5X;VXF(W@R,#$Y.W,@861V86YC960@=')A;G-G96YE(&%N9"!C
M96QL#0H@96YG:6YE97)I;F<@<&QA=&9O<FUS(&9O<B!T:&4@9&5V96QO<&UE
M;G0@86YD('!R;V1U8W1I;VX@;V8-"B!L86YT:6)I;W1I8W,L(&$@8VQA<W,@
M;V8@<&5P=&ED92!A;G1I8FEO=&EC<R!T:&%T(&%R92!N871U<F%L;'D-"B!P
M<F]D=6-E9"!I;B!'<F%M+7!O<VET:79E(&)A8W1E<FEA(&%N9"!C;VYT86EN
M('1H92!C:&%R86-T97)I<W1I8PT*('!O;'EC>6-L:6,@=&AI;V5T:&5R(&%M
M:6YO(&%C:61S(&QA;G1H:6]N:6YE(&%N9"!M971H>6QL86YT:&]N:6YE#0H@
M*&-O;&QE8W1I=F5L>2P@=&AE("8C>#(P,4,[3&%N=&EB:6]T:6-S(%!R;V=R
M86TF(W@R,#%$.RDN(%1H90T*($QA;G1I8FEO=&EC($5#0R!E<W1A8FQI<VAE
M<R!C;VUM:71T965S(&-O;7!R:7-E9"!O9B!#;VUP86YY(&%N9`T*($EN=')E
M>&]N(')E<')E<V5N=&%T:79E<R!T:&%T('=I;&P@9V]V97)N(&%C=&EV:71I
M97,@<F5L871E9"!T;R!T:&4-"B!,86YT:6)I;W1I8W,@4')O9W)A;2!I;B!T
M:&4@87)E87,@;V8@<')O:F5C="!E<W1A8FQI<VAM96YT+`T*(&-H96UI<W1R
M>2P@;6%N=69A8W1U<FEN9R!A;F0@8V]N=')O;',@;6%T=&5R<RP@8VQI;FEC
M86P@86YD#0H@<F5G=6QA=&]R>2!M871T97)S+"!C;VUM97)C:6%L:7IA=&EO
M;B!E9F9O<G1S(&%N9"!I;G1E;&QE8W1U86P-"B!P<F]P97)T>2!M871T97)S
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
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M;F9E8W1I;W5S#0H@9&ES96%S92`H)B-X,C`Q0SM/<F%G96YI8W,@4')O9'5C
M=',F(W@R,#%$.RDN(%-U8V@@;&EC96YS92!I<PT*(&5X8VQU<VEV92!W:71H
M(')E<W!E8W0@=&\@86YY(&-L:6YI8V%L(&1E=F5L;W!M96YT+"!S96QL:6YG
M+`T*(&]F9F5R:6YG(&9O<B!S86QE(&]R(&]T:&5R(&-O;6UE<F-I86QI>F%T
M:6]N(&]F($]R86=E;FEC<R!0<F]D=6-T<RP-"B!A;F0@;W1H97)W:7-E(&ES
M(&YO;BUE>&-L=7-I=F4N(%-U8FIE8W0@=&\@;&EM:71E9"!E>&-E<'1I;VYS
M+"!T:&4-"B!#;VUP86YY(&UA>2!N;W0@<W5B;&EC96YS92!T:&4@<FEG:'1S
M(&1E<V-R:6)E9"!W:71H;W5T#0H@26YT<F5X;VXF(W@R,#$Y.W,@=W)I='1E
M;B!C;VYS96YT+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@56YD97(@=&AE($QA;G1I8FEO
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M9"!C;&EN:6-A;"!D979E;&]P;65N=`T*(&]F(&-A;F1I9&%T92!L86YT:6)I
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M;G1R97AO;B8C>#(P,3D[<R!P871E;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`Q,G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@4W5B
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M=&\@<&%Y($EN=')E>&]N(&]N(&$@<75A<G1E<FQY#0H@8F%S:7,@-3`E(&]F
M(')E=F5N=64@;V)T86EN960@:6X@=&AA="!Q=6%R=&5R(&9R;VT@82!S=6)L
M:6-E;G-O<B!I;@T*('1H92!E=F5N="!O9B!A('-U8FQI8V5N<VEN9R!A<G)A
M;F=E;65N="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@
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M90T*($QA;G1I8FEO=&EC($5#0R!W:71H;W5T($EN=')E>&]N)B-X,C`Q.3MS
M(&-O;G-E;G0N($9O;&QO=VEN9R!T:&4-"B!F:7)S="`Q,B!M;VYT:',@;V8@
M=&AE(&%G<F5E;65N="P@26YT<F5X;VX@;6%Y(&%L<V\@=&5R;6EN871E('1H
M90T*($QA;G1I8FEO=&EC($5#0R!I9B!T:&4@0V]M<&%N>2!F86EL<R!T;R!U
M<V4@9&EL:6=E;G0@969F;W)T<R!T;PT*(&1E=F5L;W`@86YD(&-O;6UE<F-I
M86QI>F4@3W)A9V5N:6-S(%!R;V1U8W1S(&]R(&EF('1H92!#;VUP86YY#0H@
M96QE8W1S(&YO="!T;R!P=7)S=64@=&AE(&1E=F5L;W!M96YT(&]F(&$@3&%N
M=&EB:6]T:6-S(%!R;V=R86T-"B!I9&5N=&EF:65D(&)Y($EN=')E>&]N('1H
M870@:7,@82`F(W@R,#%#.U-U<&5R:6]R(%1H97)A<'DF(W@R,#%$.R!A<PT*
M(&1E9FEN960@:6X@=&AE($QA;G1I8FEO=&EC($5#0RX@1F]L;&]W:6YG('1H
M92!F:7)S="`Q."!M;VYT:',@;V8-"B!T:&4@86=R965M96YT+"!T:&4@0V]M
M<&%N>2!M87D@=F]L=6YT87)I;'D@=&5R;6EN871E('1H90T*($QA;G1I8FEO
M=&EC($5#0R!A="!A;GD@=&EM92!U<&]N(#DP(&1A>7,@=W)I='1E;B!N;W1I
M8V4@=&\-"B!);G1R97AO;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
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M92!O9B!T97)M:6YA=&EO;CH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T)SX-
M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H
M/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P
M(&%L:6=N/3-$;&5F=#YC;VUM97)C:6%L:7IE9"!B>2!T:&4@0V]M<&%N>3L\
M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`V<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@]
M,T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T
M;W`@86QI9VX],T1L969T/F%P<')O=F5D(&)Y(')E9W5L871O<GD-"B!A=71H
M;W)I=&EE<SL\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`V<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1T;W`@86QI9VX],T1L969T/F$@<W5B:F5C="!O9B!A;B!A<'!L
M:6-A=&EO;B!F;W(-"B!R96=U;&%T;W)Y(&%P<')O=F%L('1H870@:7,@<&5N
M9&EN9R!B969O<F4@=&AE(&%P<&QI8V%B;&4-"B!R96=U;&%T;W)Y(&%U=&AO
M<FET>3L@;W(\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`V<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]2
M1$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1T
M;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1T;W`@86QI9VX],T1L969T/G1H92!S=6)J96-T(&]F(&%T(&QE
M87-T(&%N(&]N9V]I;F<-"B!0:&%S92`Q+"!0:&%S92`R(&]R(%!H87-E(#,@
M8VQI;FEC86P@=')I86P@:6X@=&AE($9I96QD("AI;B!T:&4-"B!C87-E(&]F
M(&$@=&5R;6EN871I;VX@8GD@26YT<F5X;VX@9'5E('1O(&%N('5N8W5R960@
M;6%T97)I86P@8G)E86-H#0H@8GD@=&AE($-O;7!A;GD@;W(@82!V;VQU;G1A
M<GD@=&5R;6EN871I;VX@8GD@=&AE($-O;7!A;GDI+CPO=&0^#0H@/"]T<CX-
M"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>28C>#(P,3D[<R!O
M8FQI9V%T:6]N('1O('!A>2`R-24@;V8@9W)O<W,@<')O9FET<R!O<@T*(')E
M=F5N=64@9&5S8W)I8F5D(&%B;W9E('=I=&@@<F5S<&5C="!T;R!T:&5S90T*
M("8C>#(P,4,[<F5T86EN960F(W@R,#%$.R!P<F]D=6-T<R!A<R!W96QL(&%S
M('1O('5S92!D:6QI9V5N="!E9F9O<G1S#0H@=&\@9&5V96QO<"!A;F0@8V]M
M;65R8VEA;&EZ92!T:&5S92`F(W@R,#%#.W)E=&%I;F5D)B-X,C`Q1#L@3W)A
M9V5N:6-S#0H@4')O9'5C=',@=VEL;"!S=7)V:79E('1E<FUI;F%T:6]N(&]F
M('1H92!,86YT:6)I;W1I8R!%0T,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!A9&1I
M=&EO;BP@:6X@<&%R=&EA;"!C;VYS:61E<F%T:6]N(&9O<B!E86-H('!A<G1Y
M)B-X,C`Q.3MS#0H@97AE8W5T:6]N(&%N9"!D96QI=F5R>2!O9B!T:&4@3&%N
M=&EB:6]T:6,@14-#+"!T:&4@0V]M<&%N>2!E;G1E<F5D#0H@:6YT;R!A(%-T
M;V-K($ES<W5A;F-E($%G<F5E;65N="!W:71H($EN=')E>&]N+B!0=7)S=6%N
M="!T;R!T:&4-"B!3=&]C:R!)<W-U86YC92!!9W)E96UE;G0L('1H92!#;VUP
M86YY(&ES<W5E9"!T;R!);G1R97AO;B`T+#,Y,BPT,C4-"B!S:&%R97,@;V8@
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M:'1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@56YD97(@=&AE(%-T;V-K($ES<W5A;F-E
M($%G<F5E;65N="!A;F0@87,@<&%R="!O9B!T:&4@3&%N=&EB:6]T:6,-"B!%
M0T,L('1H92!#;VUP86YY(&AA<R!A;'-O(&%G<F5E9"!T;R!M86ME(&-E<G1A
M:6X@<&%Y;65N=',@=&\-"B!);G1R97AO;B!U<&]N('1H92!#;VUP86YY)B-X
M,C`Q.3MS(&%C:&EE=F5M96YT(&]F(&1E<VEG;F%T960-"B!M:6QE<W1O;F5S
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M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL
M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^
M#0H@/'1R/@T*(#QT9"!W:61T:#TS1#@E/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1'1O<"!W:61T:#TS1#4E(&%L:6=N/3-$;&5F=#XH:2D\+W1D/@T*
M(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/G5P;VX@9FEL:6YG(&]F
M('1H92!F:7)S=`T*($EN=F5S=&EG871I;VYA;"!.97<@1')U9R!A<'!L:6-A
M=&EO;B!W:71H('1H92!5+E,N($9O;V0@86YD($1R=6<-"B!!9&UI;FES=')A
M=&EO;B!F;W(@86X@3W)A9V5N:6-S(%!R;V1U8W0L('1H870@;G5M8F5R(&]F
M('-H87)E<PT*(&5Q=6%L('1O('1H92!N=6UB97(@;V8@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!C;VUP<FES:6YG(#$N,"4@;V8-"B!T:&4@0F%S92!3:&%R
M97,@*&%S(&1E9FEN960@8F5L;W<I.SPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE
M/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!W:61T:#TS1#$P,"4^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#@E/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#4E(&%L:6=N/3-$
M;&5F=#XH:6DI/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F
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M"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#9P="<^#0H@)B-X03`[/"]P
M/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
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M96YI8W,@4')O9'5C="P@=&AA=`T*(&YU;6)E<B!O9B!S:&%R97,@97%U86P@
M=&\@=&AE(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K#0H@8V]M
M<')I<VEN9R`R)2!O9B!T:&4@0F%S92!3:&%R97,[/"]T9#X-"B`\+W1R/@T*
M(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$."4^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$-24@86QI9VX],T1L
M969T/BAI=BD\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T
M/G5P;VX@=&AE(&9I;&EN9R!O9B!T:&4@9FER<W0@3F5W($1R=6<-"B!!<'!L
M:6-A=&EO;B`H)B-X,C`Q0SM.1$$F(W@R,#%$.RD@;W(@0FEO;&]G:6-S($QI
M8V5N<V4@07!P;&EC871I;VX-"B`H)B-X,C`Q0SM"3$$F(W@R,#%$.RD@=VET
M:"!T:&4@52Y3+B!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T:6]N(&9O<@T*
M(&%N($]R86=E;FEC<R!0<F]D=6-T+"!O<B!A;'1E<FYA=&EV96QY('1H92!F
M:6QI;F<@;V8@=&AE(&9I<G-T#0H@97%U:79A;&5N="!R96=U;&%T;W)Y(&9I
M;&EN9R!W:71H(&$@9F]R96EG;B!R96=U;&%T;W)Y(&%G96YC>2P@=&AA=`T*
M(&YU;6)E<B!O9B!S:&%R97,@97%U86P@=&\@=&AE(&YU;6)E<B!O9B!S:&%R
M97,@;V8@0V]M;6]N(%-T;V-K#0H@8V]M<')I<VEN9R`R+C4E(&]F('1H92!"
M87-E(%-H87)E<SL@86YD/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@-G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-
M"B`\='(^#0H@/'1D('=I9'1H/3-$."4^)B-X03`[/"]T9#X-"B`\=&0@=F%L
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M;7!R:7-I;F<@,R4@;V8@=&AE#0H@0F%S92!3:&%R97,N/"]T9#X-"B`\+W1R
M/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@
M,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($)A<V4@4VAA<F5S(&ES(&1E9FEN
M960@:6X@=&AE(%-T;V-K($ES<W5A;F-E($%G<F5E;65N="!T;R!M96%N#0H@
M*&DI)B-X03`[=&AE(&YU;6)E<B!O9B!S:&%R97,@;V8@0V]M<&%N>2!C;VUM
M;VX@<W1O8VL@=&]G971H97(@=VET:`T*(&%N>2!S96-U<FET:65S(&]R(&EN
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M;VUP86YY(&ES<W5E9`T*('1O(&EN=F5S=&]R<R!I;B!C;VYN96-T:6]N('=I
M=&@@82!D96)T(&]R(&5Q=6ET>2!I;G9E<W1M96YT(&EN('1H90T*($-O;7!A
M;GD@=&AA="!A<F4@:7-S=65D(&EN(&%D9&ET:6]N('1O('1H92!P<FEM87)Y
M(&EN=F5S=&UE;G0-"B!S96-U<FET:65S(&%N9"!I;B!A;B!A;6]U;G0@;F]T
M('1O(&5X8V5E9"`Q,"4@;V8@=&AE(&]V97)A;&P@;G5M8F5R#0H@;V8@<VAA
M<F5S(&ES<W5E9"!I;B!T:&4@:6YV97-T;65N="`H;VX@86X@87,M8V]N=F5R
M=&5D('1O(&-O;6UO;@T*('-T;V-K(&)A<VES*2X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M($YO;F4@;V8@=&AE($QA;G1I8FEO=&EC($5#0R!M:6QE<W1O;F5S(&AA9"!B
M965N(&%C:&EE=F5D(&%S(&]F#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,N
M/"]P/@T*(`T*(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?83@X.3)F,#%?-F(V-U\T,C@V7V$W-C-?8C=C93<Q
M-3@V-3$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$X.#DR9C`Q
M7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q-B]7;W)K<VAE971S+U-H965T
M,34N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3
M=6)S97%U96YT($5V96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5B<V5Q=65N="!%=F5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('9A;&EG;CTS
M1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXY+CPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQB/E-U8G-E<75E;G0@
M179E;G1S/"]B/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PA+2T@>&)R
M;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]N($]C=&]B97(F(WA!,#LQ."P@,C`Q
M,RP@=&AE($-O;7!E;G-A=&EO;B!#;VUM:71T964@;V8@=&AE($)O87)D#0H@
M;V8@1&ER96-T;W)S("AT:&4@)B-X,C`Q0SM";V%R9"8C>#(P,40[*2!O9B!T
M:&4@0V]M<&%N>2!M970@86YD#0H@9&5T97)M:6YE9"!T:&%T(&]N92!O9B!T
M:&4@<&5R9F]R;6%N8V4@9V]A;',@97-T86)L:7-H960@:6X@=&AE#0H@0V]M
M<&%N>28C>#(P,3D[<R!,;VYG(%1E<FT@26YC96YT:79E(%!R;V=R86US("@F
M(W@R,#%#.TQ425`F(W@R,#%$.RD-"B!A<R!P87)T(&]F(&5X96-U=&EV92!C
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M)B-X03`[2F]H;B!";VYF:6=L:6\L('1H92!#;VUP86YY)B-X,C`Q.3MS($-H
M:65F($5X96-U=&EV90T*($]F9FEC97(L($UI8VAA96P@4W5L;&EV86XL('1H
M92!#;VUP86YY)B-X,C`Q.3MS($-H:65F($9I;F%N8VEA;`T*($]F9FEC97(L
M(&%N9"!$<BXF(WA!,#M-87)T:6X@2&%N9&9I96QD+"!T:&4@0V]M<&%N>28C
M>#(P,3D[<R!6:6-E#0H@4')E<VED96YT(&]F(%)E<V5A<F-H(&%N9"!$979E
M;&]P;65N="P@=V5R92!E;G1I=&QE9"!T;R!A=V%R9',@;V8-"B`P+C4P)2P@
M,"XQ."4L(&%N9"`P+C$W)2!R97-P96-T:79E;'D@;V8@=&AE($-O;7!A;GDF
M(W@R,#$Y.W,@8V]M;6]N#0H@<W1O8VL@;W5T<W1A;F1I;F<@870@=&AE('1I
M;64@;V8@=&AE($-O;7!E;G-A=&EO;B!#;VUM:71T964F(W@R,#$Y.W,-"B!D
M971E<FUI;F%T:6]N('1H870@<W5C:"!G;V%L(&AA9"!B965N(&UE="X@06-C
M;W)D:6YG;'DL#0H@1'(N)B-X03`[0F]N9FEG;&EO+"!-<BXF(WA!,#M3=6QL
M:79A;BP@86YD($1R+B8C>$$P.TAA;F1F:65L9"!W97)E#0H@87=A<F1E9"`Q
M-3`L.#0S+"`U-"PS,#0@86YD(#4Q+#(X-R!S:&%R97,@;V8@0V]M<&%N>2!C
M;VUM;VX@<W1O8VL-"B!U;F1E<B!T:&4@0V]M<&%N>28C>#(P,3D[<R`R,#$R
M($5Q=6ET>2!);F-E;G1I=F4@4&QA;B`H=&AE#0H@)B-X,C`Q0SLR,#$R(%!L
M86XF(W@R,#%$.RDL(')E<W!E8W1I=F5L>2X@06QS;R!O;B!/8W1O8F5R)B-X
M03`[,3@L#0H@,C`Q,R!T:&4@0F]A<F0@;65T(&%N9"!D971E<FUI;F5D('1H
M870@82!S:6UI;&%R('!E<F9O<FUA;F-E(&=O86P-"B!U;F1E<B!T:&4@<')E
M=FEO=7-L>2!E<W1A8FQI<VAE9"!,;VYG(%1E<FT@26YC96YT:79E(%!R;V=R
M86T@9F]R#0H@=&AE(&-O;7!E;G-A=&EO;B!O9B!N;VXM96UP;&]Y964@9&ER
M96-T;W)S(&AA9"!B965N(&UE="X@07,@80T*(')E<W5L="P@=&AE($)O87)D
M(&%P<')O=F5D('1H92!A=V%R9"!O9B`S,RPQ.#4@<VAA<F5S(&]F(&-O;6UO
M;@T*('-T;V-K('5N9&5R('1H92!0;&%N+"!T;R!E86-H(&]F('1H92!#;VUP
M86YY)B-X,C`Q.3MS(&1I<F5C=&]R<R!W:&\-"B!W97)E(&YO="!E;7!L;WEE
M9"!B>2!T:&4@0V]M<&%N>2P@:6YC;'5D:6YG($9R961E<FEC:R!496QL:6YG
M+`T*($-H87)L97,@4&]P92P@06QA;B!$=6YT;VXL($-H<FES=&EN92!+;W-K
M:2!A;F0@4F]B97)T($MO<VMI+B!);@T*(&%D9&ET:6]N+"!T:&4@0F]A<F0@
M9&5T97)M:6YE9"!T;R!A;65N9"!I=',@;F]N+65M<&QO>65E(&1I<F5C=&]R
M#0H@8V]M<&5N<V%T:6]N('!R;V=R86TN($EN(&-O;FYE8W1I;VX@=VET:"!E
M86-H(&%N;G5A;"!M965T:6YG(&]F#0H@<VAA<F5H;VQD97)S(&-O;6UE;F-I
M;F<@=VET:"!T:&4@,C`Q,R!!;FYU86P@365E=&EN9RP@96%C:`T*(&-O;G1I
M;G5I;F<@;F]N+65M<&QO>65E(&1I<F5C=&]R('=I;&P@8F4@9W)A;G1E9"!A
M;B!A=V%R9"!O9B`Q,"PP,#`-"B!F=6QL>2!V97-T960@<VAA<F5S(&]F('1H
M92!#;VUP86YY)B-X,C`Q.3MS(&-O;6UO;B!S=&]C:R!U;F1E<B!T:&4-"B!#
M;VUP86YY)B-X,C`Q.3MS(#(P,3(@4&QA;BX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H
M92!A9V=R96=A=&4@<VAA<F5S(&%W87)D960@=6YD97(@=&AE(#(P,3(@4&QA
M;B!O9B`T,C(L,S4Y#0H@8V]N<VES=&5D(&]F(&$@=&]T86P@;V8@,38U+#DR
M-2!S:&%R97,@=&\@;F]N+65M<&QO>65E(&1I<F5C=&]R<PT*(&%N9"`R-38L
M-#,T('-H87)E<R!T;R!E>&5C=71I=F4@;V9F:6-E<G,N($]F('1H92!A9V=R
M96=A=&4@-#(R+#,U.0T*('-H87)E<R!A=V%R9&5D('5N9&5R('1H92!,5$E0
M+"`H:2DF(WA!,#LQ-3`L.#0S('-H87)E<R!W97)E(&%W87)D960-"B!T;R!$
M<BXF(WA!,#M";VYF:6=L:6\@;V8@=VAI8V@@-3`L,#`P('-H87)E<R!W97)E
M(')E=&%I;F5D(&)Y('1H90T*($-O;7!A;GD@9F]R(&%P<&QI8V%B;&4@=&%X
M('=I=&AH;VQD:6YG(&]B;&EG871I;VYS+`T*("AI:2DF(WA!,#LU-"PS,#0@
M<VAA<F5S('=E<F4@87=A<F1E9"!T;R!-<BXF(WA!,#M3=6QL:79A;B!O9B!W
M:&EC:`T*(#$Y+#`P,"!S:&%R97,@=V5R92!R971A:6YE9"!B>2!T:&4@0V]M
M<&%N>2!F;W(@87!P;&EC86)L92!T87@-"B!W:71H:&]L9&EN9R!O8FQI9V%T
M:6]N+"`H:6EI*28C>$$P.S4Q+#(X-R!S:&%R97,@=V5R92!A=V%R9&5D('1O
M#0H@1'(N)B-X03`[2&%N9&9I96QD(&]F('=H:6-H(#$U+#(X-R!S:&%R97,@
M=V5R92!R971A:6YE9"!B>2!T:&4-"B!#;VUP86YY(&9O<B!A<'!L:6-A8FQE
M('1A>"!W:71H:&]L9&EN9R!O8FQI9V%T:6]N+"!A;F0-"B`H:78I)B-X03`[
M,S,L,3@U('-H87)E<R!W97)E(&%W87)D960@=&\@96%C:"!O9B!T:&4@9FEV
M90T*(&YO;BUE;7!L;WEE92!D:7)E8W1O<G,N/"]P/@T*(`T*(`T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83@X
M.3)F,#%?-F(V-U\T,C@V7V$W-C-?8C=C93<Q-3@V-3$V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W
M8V4W,34X-C4Q-B]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5$
M3$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-I9VYI9FEC86YT($%C8V]U
M;G1I;F<@4&]L:6-I97,@*%!O;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I
M97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y296-E;G1L>2!)<W-U960@06-C;W5N=&EN9R!0<F]N;W5N
M8V5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B`\8CY296-E;G1L>2!)<W-U960@06-C;W5N=&EN9R!0<F]N
M;W5N8V5M96YT<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M-G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE<F4@87)E(&YO(&YE
M=R!A8V-O=6YT:6YG('!R;VYO=6YC96UE;G1S(&ES<W5E9"!O<B!E9F9E8W1I
M=F4-"B!D=7)I;F<@=&AE('-E8V]N9"!Q=6%R=&5R(&]F(#(P,3,@=&AA="!H
M879E(&AA9"!O<B!A<F4@97AP96-T960@=&\-"B!H879E(&%N(&EM<&%C="!O
M;B!T:&4@0V]M<&%N>28C>#(P,3D[<R!F:6YA;F-I86P@<W1A=&5M96YT<RX\
M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y5<V4@;V8@17-T:6UA=&5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CY5<V4@;V8@
M17-T:6UA=&5S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@<')E<&%R871I;VX@
M;V8@9FEN86YC:6%L('-T871E;65N=',@:6X@8V]N9F]R;6ET>2!W:71H($=!
M05`-"B!R97%U:7)E<R!M86YA9V5M96YT('1O(&UA:V4@97-T:6UA=&5S(&%N
M9"!A<W-U;7!T:6]N<R!T:&%T(&%F9F5C=`T*('1H92!R97!O<G1E9"!A;6]U
M;G1S(&]F(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@86YD(&1I<V-L;W-U<F4@
M;V8-"B!C;VYT:6YG96YT(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@870@=&AE
M(&1A=&4@;V8@=&AE(&9I;F%N8VEA;`T*('-T871E;65N=',L(&%S('=E;&P@
M87,@=&AE(')E<&]R=&5D(&%M;W5N=',@;V8@<F5V96YU97,@86YD#0H@97AP
M96YS97,@9'5R:6YG('1H92!R97!O<G1I;F<@<&5R:6]D+B!!8W1U86P@<F5S
M=6QT<R!C;W5L9"!D:69F97(-"B!F<F]M('1H;W-E(&5S=&EM871E<RX@5&AE
M('!R:6YC:7!A;"!A<F5A<R!O9B!E<W1I;6%T:6]N(')E9FQE8W1E9`T*(&EN
M('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!A<F4@<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N+"!V86QU871I;VX-"B!O9B!W87)R86YT<RP@:6YV96YT;W)Y
M(&]B<V]L97-C96YC92!R97-E<G9E+"!S86QE<R!R971U<FYS(&%N9`T*(&%L
M;&]W86YC97,@86YD('1H92!A;&QO=V%N8V4@9F]R(&1O=6)T9G5L(&%C8V]U
M;G1S+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@5F%L=64@;V8@1FEN86YC:6%L($EN
M<W1R=6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B`\8CY&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T
M<G5M96YT<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE(&9A:7(@=F%L=64@;V8@
M=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V%S:"!A;F0@8V%S:"!E<75I=F%L96YT
M<RP-"B!A8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S(&%P
M<')O>&EM871E('1H96ER(&-A<G)Y:6YG#0H@=F%L=65S(&1U92!T;R!T:&5I
M<B!S:&]R="UT97)M(&YA='5R92X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'=6%R86YT965D
M(%)I9VAT<R!O9B!2971U<FX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/D=U87)A;G1E960@4FEG:'1S(&]F
M(%)E='5R;CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@:&%S(&=R
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M(%1H92!#;VUP86YY(&AA9"`D,C,L-S$Q(&%N9"`D,C<L.#$R(&]F(')E=F5N
M=64-"B!D969E<G)E9"!U;F1E<B!G=6%R86YT965D(')I9VAT<R!O9B!R971U
M<FX@87)R86YG96UE;G1S(&EN8VQU9&5D(&EN#0H@9&5F97)R960@<F5V96YU
M92!I;B!T:&4@8F%L86YC92!S:&5E=',@87,@;V8@4V5P=&5M8F5R)B-X03`[
M,S`L#0H@,C`Q,R!A;F0@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@<F5S<&5C
M=&EV96QY+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^26YV96YT
M;W)Y/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);G9E;G1O<GD@:7,@<W1A=&5D(&%T
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M8V5S<R!O9B!E>'!E8W1E9`T*('-A;&5S(')E<75I<F5M96YT<RP@;W(@:6YV
M96YT;W)Y('1H870@9F%I;',@=&\@;65E="!C;VUM97)C:6%L('-A;&4-"B!S
M<&5C:69I8V%T:6]N<RX@17AP:7)E9"!I;G9E;G1O<GD@:7,@9&ES<&]S960@
M;V8@86YD('1H92!R96QA=&5D#0H@8V]S=',@87)E('=R:71T96X@;V9F('1O
M('1H92!R97-E<G9E(&9O<B!I;G9E;G1O<GD@;V)S;VQE<V-E;F-E+@T*(%1H
M92!I;G9E;G1O<GD@<F5S97)V92!W87,@87!P<F]X:6UA=&5L>2`D,C(L,#`P
M(&%N9"`D,C4S+#`P,"!A<R!O9@T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M(&%N9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R+`T*(')E<W!E8W1I=F5L>2X\
M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!087EM96YT($%R<F%N9V5M96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M="<^#0H@/&(^4W1O8VLM0F%S960@4&%Y;65N="!!<G)A;F=E;65N=',\+V(^
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*($=E;F5R86QL>2P@86QL(&9O<FUS(&]F('-T;V-K
M+6)A<V5D('!A>6UE;G1S+"!I;F-L=61I;F<@<W1O8VL-"B!O<'1I;VX@9W)A
M;G1S+"!W87)R86YT<RP@86YD(')E<W1R:6-T960@<W1O8VL@9W)A;G1S(&%R
M92!M96%S=7)E9`T*(&%T('1H96ER(&9A:7(@=F%L=64@;VX@=&AE(&%W87)D
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M9&5D(&EN(')E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*(&5X<&5N<V4@;W(@
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M9`T*('-T;V-K(&=R86YT<R!D;R!N;W0@=F5S="!A="!T:&4@9W)A;G0@9&%T
M92!T:&5Y(&%R92!S=6)J96-T('1O#0H@9F]R9F5I='5R92X\+W`^#0H@#0H@
M#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!#;VUP96YS871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^4W1O
M8VLM0F%S960@0V]M<&5N<V%T:6]N/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!'04%0
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M:6YG('!E<F9O<FUA;F-E(&-O;F1I=&EO;B!I<PT*(&UE="X\+W`^#0H@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@/&(^5V%R<F%N=',\+V(^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%1H92!#;VUP86YY('5S960@=&AE($)L86-K(%-C:&]L97,@3W!T:6]N
M(%!R:6-I;F<@36]D96P@:6X-"B!C86QC=6QA=&EN9R!T:&4@<F5L871I=F4@
M9F%I<B!V86QU92!O9B!A;GD@=V%R<F%N=',@=&AA="!H879E(&)E96X-"B!I
M<W-U960N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@4&5R(%-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\
M8CY.970@3&]S<R!097(@4VAA<F4\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#9P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
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M9&EL=71E9`T*(&YE="!L;W-S('!E<B!S:&%R92P@87,@=&AE:7(@969F96-T
M('=O=6QD(&AA=F4@8F5E;B!A;G1I9&EL=71I=F4N#0H@0F5C875S92!T:&4@
M0V]M<&%N>2!R97!O<G1E9"!A(&YE="!L;W-S(&9O<B!A;&P@<&5R:6]D<R!P
M<F5S96YT960L#0H@<VAA<F5S(&%S<V]C:6%T960@=VET:"!T:&4@<W1O8VL@
M;W!T:6]N<R!A;F0@=V%R<F%N=',@87)E(&YO=`T*(&EN8VQU9&5D(&)E8V%U
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M"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E=F5N=64@4F5C;V=N:71I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/E)E=F5N=64@
M4F5C;V=N:71I;VX\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
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M=F4-"B!N;W0@8F5E;B!I;F-U<G)E9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
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M;6%T97)I86PN/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N8V5N=')A=&EO;G,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB
M/D-O;F-E;G1R871I;VYS/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N
M>2!I<R!D97!E;F1E;G0@;VX@:V5Y('-U<'!L:65R<R!T;R!P<F]V:61E('!R
M;V)I;W1I8W,L#0H@8FQE;F1I;F<L('=A<F5H;W5S:6YG(&%N9"!P86-K86=I
M;F<@;V8@:71S($5V;W)A4&QU<RP@179O<F%+:61S+`T*($5V;W)A4')O+"!A
M;F0@5&5D9'DF(W@R,#$Y.W,@4')I9&4@<')O9'5C=',N(%1H92!#;VUP86YY
M(&AA9"!F;W5R#0H@:V5Y('-U<'!L:65R<R!D=7)I;F<@=&AE('1H<F5E(&%N
M9"!N:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M(&%N9"`R,#$R+B!4:&4@;6%J;W)I='D@;V8@=&AE#0H@0V]M<&%N>28C>#(P
M,3D[<R!C;W-T(&]F('-A;&5S(&%R92!F<F]M('1H97-E(&ME>2!S=7!P;&EE
M<G,@9'5R:6YG#0H@=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q,BX-"B!!8V-O=6YT<R!P
M87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S(&9O<B!T:&5S92!V96YD;W)S
M('1O=&%L960-"B!A<'!R;WAI;6%T96QY("0M,"T@86YD("0Y.2PP,#`@87,@
M;V8@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@86YD#0H@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,BP@<F5S<&5C=&EV96QY+B!!<R!O9B!397!T96UB97(F(WA!
M,#LS,"P-"B`R,#$S+"!T:&4@0V]M<&%N>2!H860@82!P<F5P86ED(&)A;&%N
M8V4@;V8@87!P<F]X:6UA=&5L>2`D,C<L,#`P#0H@=VET:"!O;F4@;V8@=&AE
M<V4@=F5N9&]R<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1I<V-L
M;W-U<F4@3V8@0V]M<&5N<V%T:6]N(%)E;&%T960@0V]S=',@4VAA<F5B87-E
M9"!087EM96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;B!%
M>'!E;G-E(%)E8V]G;FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@<F5C;V=N:7IE9"!S
M=&]C:RUB87-E9"!C;VUP96YS871I;VX@;VX@86QL(&5M<&QO>65E(&%N9`T*
M(&YO;BUE;7!L;WEE92!A=V%R9',@87,@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG
M;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-#8E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5&AR964F(WA!
M,#M-;VYT:',F(WA!,#M%;F1E9#QB<B`O/@T*(%-E<'1E;6)E<B8C>$$P.S,P
M+"`R,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4
M:')E928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D/&)R("\^#0H@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/DYI;F4F(WA!,#M-;VYT:',F(WA!,#M%;F1E9#QB<B`O/@T*(%-E
M<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CY.:6YE)B-X03`[36]N=&AS)B-X03`[16YD960\8G(@
M+SX-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,CPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:
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M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(%-E;&QI;F<L(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T
M:79E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PS-34L,3<U/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8Y,RPU,S,\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,2PT-C4L-3DP/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CDT,"PT.3(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%1O=&%L(%-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$L-3,X+#,T,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW.3DL,SDQ/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$L-C(T+#$V-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`U
M-RPR,3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)&/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E=A<G)A;G1S("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5&5X="!"
M;&]C:R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@5V%R<F%N="!!8W1I=FET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=CX-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!!
M('-U;6UA<GD@;V8@=V%R<F%N="!A8W1I=FET>2!F;W(@=&AE('EE87(@96YD
M960@1&5C96UB97(F(WA!,#LS,2P-"B`R,#$R(&%N9"!T:&4@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@:7,@87,-"B!F;VQL
M;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^
M#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED
M=&@],T0W-R4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY7
M87)R86YT<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M5V5I9VAT960\8G(@+SX-"B!!=F5R86=E/&)R("\^#0H@4')I8V4\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($)A;&%N8V4@)B-X,C`Q,SL@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!'<F%N=&5D/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY-#(L,#DT/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$N.#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5X97)C:7-E9#PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%>'!I<F5D/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$R+#4P,#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#8N,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F%L86YC92`F(W@R,#$S.R!$
M96-E;6)E<B8C>$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XS+#(S-2PY.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C4S/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E
M;3L@1D].5"U325I%.B`Q,'!T)SX-"B!'<F%N=&5D/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%>&5R8VES960\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,#`L,#`P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$N-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5X<&ER960\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R.#@L.#@X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B@Q.2XX-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@1D].5"U325I%.B`Q,'!T)SX-"B!"86QA;F-E("8C>#(P,3,[(%-E<'1E
M;6)E<B8C>$$P.S,P+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M+#<T-RPP.30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XY,3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/"]D:78^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=6UM87)Y(&]F(%=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#$R<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@=V%R
M<F%N=',@;W5T<W1A;F1I;F<@87,@;V8@4V5P=&5M8F5R)B-X03`[,S`L(#(P
M,3,@87)E(&%S#0H@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#@T)2!A;&EG;CTS1&-E;G1E<CX-
M"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0P)3X\+W1D/@T*(#QT9#X\
M+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0T,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!N;W=R87`],T1N;W=R87`@
M86QI9VX],T1C96YT97(^#0H@/'`@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60[(%=)1%1(.B`T."XV<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)R!A;&EG;CTS1&-E
M;G1E<CX\8CY%>&5R8VES928C>$$P.U!R:6-E/"]B/CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5V%R<F%N=',\8G(@
M+SX-"B!/=71S=&%N9&EN9SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^17AP:7)A=&EO;B8C>$$P.T1A=&5S/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG
M:'0^,2XU,#PO=&0^#0H@/'1D('9A;&EG;CTS1'1O<"!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU-S$L
M,38Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<O,S`O
M,3<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/B0\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@
M86QI9VX],T1R:6=H=#XR+C`P/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(L,3<P+#DR-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XS+S(S+S$U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$<FEG:'0^
M,3`N,#`\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PP,#`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"\Q-2\Q-#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)
M6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPW-#<L,#DT/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83@X
M.3)F,#%?-F(V-U\T,C@V7V$W-C-?8C=C93<Q-3@V-3$V#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W
M8V4W,34X-C4Q-B]7;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5%
M1D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D)A<VES(&]F(%!R97-E;G1A
M=&EO;B`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ871I
M;VX@0V]N<V]L:61A=&EO;B!!;F0@4')E<V5N=&%T:6]N($]F($9I;F%N8VEA
M;"!3=&%T96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5V96YU97,@9V5N97)A=&5D(&)Y(&-O
M;7!A;GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4S+#,W
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,C8T+#(T.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-3DW+#0T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@.3`Q+#$X,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DL,S(U+#0R-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#4U-2PY-#$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3(L.3@Y+#0Q.2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q,2PQ,#$L-C(P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!U<V5D(&EN(&]P97)A=&EO
M;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4L-30U+#(P-2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M+#0W,"PY-S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@V-RPP-S4L-S@Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8W+#`W-2PW.#$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-30L,#@V
M+#,V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D=R;W-S('!R;V-E961S(&9R;VT@<')I=F%T92!P;&%C96UE;G0@
M;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,L.3,Y+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3$L.3$S+#0T,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83@X.3)F,#%?-F(V
M-U\T,C@V7V$W-C-?8C=C93<Q-3@V-3$V#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q
M-B]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5#4D%'/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L
M:6-I97,@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/E-U<'!L:65R/&)R/E9E;F1O<CQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/E-U<'!L
M:65R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L
M(#(P,3,\8G(^4W5P<&QI97(\8G(^0W5S=&]M97(\8G(^5F5N9&]R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M4W5P<&QI97(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY"87-I<R!/9B!0<F5S96YT871I;VX@06YD(%-U;6UA<GD@
M3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(&1E;G1A;"!D:7-T<FEB=71O<B!W:71H(&=U87)A;G1E960@
M<FEG:'1S(&]F(')E='5R;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=F5N=&]R>2!R97-E<G9E($9)1D\\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,BPP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(U,RPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!K97D@<W5P<&QI97)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X
M<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,V-"PY
M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#,V-"PY-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#$U-RPU,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@8F%L86YC92!O9B!V96YD
M;W)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C<L,#`X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(W
M+#`P.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(R,2PX,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!V96YD;W)S('=I=&@@<')E<&%I9"!B
M86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1W5A
M<F%N=&5E9"!2:6=H=',@;V8@4F5T=7)N(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0F%S:7,@3V8@4')E<V5N
M=&%T:6]N($%N9"!3=6UM87)Y($]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@
M4&]L:6-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@9&5F97)R960@=6YD97(@9W5A
M<F%N=&5E9"!R:6=H=',@;V8@<F5T=7)N(&%R<F%N9V5M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L-S$Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,L-S$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<L.#$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=7!P;&EE<B!#;VYC96YT<F%T:6]N(%)I<VL@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"87-I<R!/9B!0<F5S
M96YT871I;VX@06YD(%-U;6UA<GD@3V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C
M<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R97!A:60@8F%L86YC92!O9B!V96YD;W)S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15I/044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N
M("T@4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N($5X<&5N<V4@4F5C;V=N:7IE
M9"`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE
M92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO
M;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M4W1O8VL@8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$L-3,X+#,T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-SDY+#,Y,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PV,C0L,38U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M+#`U-RPR,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL
M($%L;&]C871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(%-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@S+#$V.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-2PX-3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3@L-3<U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$V
M+#<R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V5L;&EN9RP@1V5N97)A;"!A;F0@061M:6YI<W1R871I=F4@17AP
M96YS97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E
M;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T
M<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5&]T86P@4W1O8VL@8F%S960@8V]M<&5N<V%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L,S4U+#$W-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-CDS
M+#4S,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PT-C4L-3DP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Y-#`L-#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P13-8044^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N("T@061D:71I;VYA;"!)
M;F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D($-O;7!E;G-A=&EO;BP@
M06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO9"!#;W-T<R!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VL@;W!T:6]N<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+6%V97)A9V4@
M9W)A;G0@9&%T92!F86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,N-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N,#,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@=F5S
M=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PU,S,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T
M;V-K(&]P=&EO;G,@9F]R9F5I=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU-BPP-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&]P=&EO;G,@97AE<F-I<V5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,2PU,S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3(@17%U:71Y
M($EN8V5N=&EV92!0;&%N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^16UP;&]Y964@4V5R=FEC92!3:&%R92UB
M87-E9"!#;VUP96YS871I;VXL($%L;&]C871I;VX@;V8@4F5C;V=N:7IE9"!0
M97)I;V0@0V]S=',@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI86)I;&ET>2!A;F0@97AP96YS92!R
M96QA=&5D('1O(&5Q=6ET>2!I;F-E;G1I=F4@<&QA;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#0X-RPX,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT(&1A=&4@9F%I
M<B!V86QU92P@<VAA<F5S(&5X<&5C=&5D('1O(&)E(&%W87)D960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R,BPS-3D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$X.#DR9C`Q7S9B-C=?-#(X
M-E]A-S8S7V(W8V4W,34X-C4Q-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]A.#@Y,F8P,5\V8C8W7S0R.#9?83<V,U]B-V-E-S$U.#8U,38O5V]R
M:W-H965T<R]3:&5E=#(S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%24-!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY787)R86YT<R`M(%-U;6UA<GD@;V8@5V%R<F%N="!!
M8W1I=FET>2`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%<75I
M='D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<RP@0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C,U+#DX,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-BPS.#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#DT,BPP.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S+"!%>&5R8VES960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(P,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<RP@17AP:7)E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@X+#@X."D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPU
M,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT<RP@16YD:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-S0W+#`Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C,U+#DX,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@
M079E<F%G92!0<FEC92P@0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,RXU,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3DN,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V
M97)A9V4@4')I8V4L($=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XX-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!0<FEC92P@17AE<F-I
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@079E<F%G92!0<FEC92P@17AP:7)E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XD("@Q.2XX-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E
M(%!R:6-E+"!%;F1I;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+CDQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`S+C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15I"04,^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^5V%R<F%N=',@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*86XN(#,Q+"`R,#$S/&)R/D=R:69F:6X@4V5C=7)I=&EE<R!);F,N(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-L87-S(&]F(%=A<G)A;G0@;W(@4FEG:'0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S(&5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!O9B!C;VUM;VX@<W1O8VL@:7-S
M=65D('5P;VX@97AE<F-I<V4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P-BPR-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W
M8V4W,34X-C4Q-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A.#@Y
M,F8P,5\V8C8W7S0R.#9?83<V,U]B-V-E-S$U.#8U,38O5V]R:W-H965T<R]3
M:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%-$5!1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY787)R86YT<R`M(%-U;6UA<GD@;V8@5V%R<F%N=',@3W5T<W1A;F1I
M;F<@*$1E=&%I;"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@5V%R<F%N="!O
M<B!2:6=H="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-S0W+#`Y-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C,U+#DX,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P
M-BPS.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E)A;F=E(#$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!787)R86YT(&]R(%)I9VAT
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!/=71S=&%N9&EN9SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<Q+#$V.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP:7)A=&EO;B!$
M871E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^2G5L(#,P+`T*
M"0DR,#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y286YG92`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@5V%R<F%N="!O<B!2:6=H
M="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#$W,"PY,C4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER871I;VX@
M1&%T97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DUA<B`R,RP-
M"@D),C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F%N9V4@,R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%=A<G)A;G0@;W(@4FEG
M:'0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A;F1I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!I<F%T:6]N($1A
M=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!<'(@,34L#0H)
M"3(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q-@T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A.#@Y,F8P,5\V8C8W7S0R.#9?83<V
M,U]B-V-E-S$U.#8U,38O5V]R:W-H965T<R]3:&5E=#(V+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%3DQ!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY3:&]R="UT97)M($YO
M=&5S(%!A>6%B;&4@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^4')O9'5C="!,:6%B:6QI='D@
M26YS=7)A;F-E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,#@L(#(P,3,\8G(^4')O9'5C="!,:6%B:6QI='D@26YS
M=7)A;F-E(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^1&ER96-T;W)S)R!A;F0@3V9F:6-E<G,G
M($QI86)I;&ET>2!);G-U<F%N8V4@1FEN86YC:6YG(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,C`L(#(P,3,\8G(^
M1&ER96-T;W)S)R!A;F0@3V9F:6-E<G,G($QI86)I;&ET>2!);G-U<F%N8V4@
M1FEN86YC:6YG(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H;W)T+71E<FT@1&5B="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4VAO<G0@=&5R;2!N;W1E<R!P87EA8FQE(&9O<B!F:6YA;F-I;F<@:6YS=7)A
M;F-E('!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$P."PR,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#0W+#DW-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAO<G0M=&5R;2!N;W1E('!A>6%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-3`L,#,W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,#8L.3DT
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1E<F5S="!R871E(&]N('-H;W)T+71E<FT@;F]T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BXU-R4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+C8T)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAO<G0M=&5R;2!N
M;W1E<R!P87EA8FQE(&%M;W)T:7IA=&EO;B!P97)I;V0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C$P(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$Q(&UO;G1H<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1FEN86P@
M<&%Y;65N="!D871E(&]F('-H;W)T+71E<FT@;F]T92!P87EA8FQE/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*86X@,3`L#0H)"3(P,30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y*=6X@
M,C0L#0H)"3(P,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q-@T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A.#@Y,F8P,5\V8C8W7S0R
M.#9?83<V,U]B-V-E-S$U.#8U,38O5V]R:W-H965T<R]3:&5E=#(W+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%4T=!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYV97)T
M:6)L92!.;W1E(%!A>6%B;&4@=&\@4VAA<F5H;VQD97(@+2!!9&1I=&EO;F%L
M($EN9F]R;6%T:6]N("A$971A:6PI("A#;VYV97)T:6)L92!0<F]M:7-S;W)Y
M($YO=&4@6TUE;6)E<ETL(%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!0<F]M:7-S;W)Y($YO=&4@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$96)T($EN<W1R=6UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H;W)T+71E<FT@;F]T
M92!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M.34V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YT97)E<W0@<F%T92!O;B!S:&]R="UT97)M(&YO=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:6YA;"!P87EM
M96YT(&1A=&4@;V8@<VAO<G0M=&5R;2!N;W1E('!A>6%B;&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83@X.3)F,#%?-F(V
M-U\T,C@V7V$W-C-?8C=C93<Q-3@V-3$V#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q
M-B]7;W)K<VAE971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5924%+/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC
M:65S("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G0@06YD($-O;G1I;F=E;F-I
M97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=R;W-S('!R;V-E961S(&9R;VT@<')I=F%T92!P;&%C
M96UE;G0@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,L.3,Y+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,3$L.3$S+#0T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3,L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]N=F5R=&EB;&4@4')O;6ES<V]R>2!.;W1E(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N="!!
M;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^8V]N=F5R=&EB;&4@<')O;6ES
M<V]R>2!N;W1E(&ES<W5E9"!T;R!P87D@=&5C:&YO;&]G>2!A8V-E<W,@9F5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DU-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA
M='5R:71Y(&1A=&4@;V8@8V]N=F5R=&EB;&4@;F]T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*"0DR,#$S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-53$Q-#`@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#;VUM:71M96YT($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E
M;G-E($%G<F5E;65N="P@3W)I9VEN86P@1&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^2G5N(#(R+`T*"0DR,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&%G<F5E
M;65N="P@9FER<W0@86UE;F1M96YT(&1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/E-E<"`Q-2P-"@D),C`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!A9W)E96UE
M;G0L('-E8V]N9"!A;65N9&UE;G0@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^2G5L(#$P+`T*"0DR,#`R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&%G<F5E;65N
M="P@=&AI<F0@86UE;F1M96YT(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/E-E<"`R-2P-"@D),C`P,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!A9W)E96UE;G0L
M(&9O=7)T:"!A;65N9&UE;G0@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^36%R(#$W+`T*"0DR,#`S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6-E;G-E(&%G<F5E;65N="!D
M871E(&9I9G1H(&%M96YD960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D%P<B`Q.2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&%T96YT<R!L:6-E;G-E(&5X<&ER871I
M;VX@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$W
M('1H<F]U9V@@,C`Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4VUA<G0@4F5P;&%C96UE;G0@5&AE<F%P>2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-O;6UI=&UE;G0@06YD($-O;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N
M<V4@06=R965M96YT+"!/<FEG:6YA;"!$871E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y!=6<@-"P-"@D),3DY.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!A9W)E96UE
M;G0L(&9I<G-T(&%M96YD;65N="!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y397`@,34L#0H)"3(P,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@86=R965M96YT
M+"!S96-O;F0@86UE;F1M96YT(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/DIU;"`Q,"P-"@D),C`P,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!A9W)E96UE;G0L
M('1H:7)D(&%M96YD;65N="!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y397`@,C4L#0H)"3(P,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@86=R965M96YT+"!F
M;W5R=&@@86UE;F1M96YT(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/DUA<B`Q-RP-"@D),C`P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&EC96YS92!A9W)E96UE;G0@9&%T
M92!F:69T:"!A;65N9&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y!<'(@,3DL#0H)"3(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!A=&5N="!R:6=H="!F:6QL:6YG(&1A=&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;B`W+`T*"0DQ.3DU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0871E;G0@969F96-T:79E(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/DUA<B`T+`T*"0DQ.3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0871E;G0@<FEG:'0@97AP:7)E
M(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;B`W+`T*
M"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y51E)&($QI8V5N<V4@06=R965M96YT<R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE
M;G0@06YD($-O;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!A;GDG<R!O8FQI
M9V%T:6]N('1O('!A>2!F<F]M('!E<F-E;G1A9V4@;V8@<V5L;&EN9R!P<FEC
M92!O9B!P<F]D=6-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<&%N>2=S(&]B;&EG871I;VX@=&\@<&%Y(&9R;VT@86QL(')E
M=F5N=64@<F5C96EV960@9G)O;2!S=6)L:6-E;G-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C(N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/;F4M=&EM92!C;VUM97)C:6%L
M:7IA=&EO;B!F964@=V]U;&0@8F4@9'5E(&]N('1H92!F:7)S="!A;FYI=F5R
M<V%R>2!O9B!F:7)S="!C;VUM97)C:6%L('-A;&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0;W-T+6-O;6UE<F-I86QI>F%T:6]N
M(&UI;FEM=6T@<F]Y86QT>2!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y/;F4M=&EM92!A9&1I=&EO;F%L(')O>6%L
M='D@<&%Y;65N="!W;W5L9"!B92!D=64@=VAE;B!T;W1A;"!C=6UU;&%T:79E
M(')O>6%L=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!R;WEA;'1I97,@9'5E('1O(%5&4D8\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!A;FYU86P@
M;6%I;G1E;F%N8V4@<&%Y;65N="!P97(@;&EC96YS92!A9W)E96UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E
M(&UI;FEM=6T@86YN=6%L(&UA:6YT96YA;F-E('!A>6UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^475A<G1E<FQY(&UA:6YT
M96YA;F-E('!A>6UE;G0@=&\@54921B!U;F1E<B!I;G-T86QL;65N="!P;&%N
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&%N=&EB
M:6]T:6,@14-#(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N="!!;F0@0V]N=&EN9V5N8VEE<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&EC96YS92!!9W)E96UE;G0L($]R:6=I;F%L($1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;B`U+`T*"0DR,#$R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M97)M:6YA=&EO;B!N;W1I8V4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XY,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#,Y,BPT,C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A
M9V4@8V]M<&%N>2!P87D@;VX@<75A<G1E<FQY(&)A<VES(&]U="!O9B!G<F]S
M<R!P<F]F:70\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M<&%N>2=S(&]B;&EG871I;VX@=&\@;6%K92!P87EM96YT(&9R;VT@
M86QL(')E=F5N=64@<F5C96EV960@9G)O;2!S=6)L:6-E;G-I;F<\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R:6]D(&1U<FEN
M9R!W:&EC:"!C;VUP86YY(&-A;FYO="!T97)M:6YA=&4@;&EC96YS92!A9W)E
M96UE;G0@=F]L=6YT87)I;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C$X(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4&5R:6]D(&1U<FEN9R!W:&EC:"!C;VUP86YY(&-A
M;FYO="!T97)M:6YA=&4@;&EC96YS92!A9W)E96UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C$R(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!P97)C96YT
M86=E(&]F('!R:6UA<GD@:6YV97-T;65N="!S96-U<FET:65S('1O(&EN=F5S
M=&UE;G0@;V8@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,86YT:6)I;W1I8R!%0T,@6TUE;6)E<ET@?"!)
M;G9E<W1I9V%T:6]N86P@3F5W($1R=6<@07!P;&EC871I;VX@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E
M(&]F(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&5Q=6%L('1O
M($)A<V4@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&%N=&EB:6]T:6,@14-#(%M-96UB97)=('P@0VQI;FEC86P@4W1U
M9'D@4&AA<V4@,B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G0@06YD($-O;G1I;F=E;F-I97,@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@;G5M8F5R(&]F('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@97%U86P@=&\@0F%S92!3:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$N-3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,86YT:6)I;W1I8R!%0T,@6TUE
M;6)E<ET@?"!#;&EN:6-A;"!3='5D>2!0:&%S92`S(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N
M="!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!N
M=6UB97(@;V8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!E<75A;"!T;R!"87-E
M(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BXP,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQA;G1I8FEO=&EC($5#0R!;365M8F5R72!\($9I;&EN9R!O9B!&:7)S="!)
M;G9E<W1I9V%T:6]N86P@3F5W($1R=6<@07!P;&EC871I;VX@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM
M:71M96YT($%N9"!#;VYT:6YG96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E
M(&]F(&YU;6)E<B!O9B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&5Q=6%L('1O
M($)A<V4@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+C4P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&%N=&EB:6]T:6,@14-#(%M-96UB97)=('P@1FER<W0@4F5G=6QA
M=&]R>2!!<'!R;W9A;"!O9B!/<F%G96YI8W,@4')O9'5C="!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI
M=&UE;G0@06YD($-O;G1I;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@
M;V8@;G5M8F5R(&]F('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@97%U86P@=&\@
M0F%S92!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F]B:6]T:6-S($5#0R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G0@06YD($-O;G1I
M;F=E;F-I97,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQI8V5N<V4@06=R965M96YT+"!/<FEG:6YA
M;"!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y397`@,S`L
M#0H)"3(P,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!E<F-E;G0@;V8@8V]M<&%N>2!P87D@;W5T(&]F(&YE="!S
M86QE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M97)M:6YA=&EO;B!N;W1I8V4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XY,"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M('!E<FEO9"!T;R!C=7)E('1H
M92!B<F5A8V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8P(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5P+69R;VYT('1E8VAN;VQO9WD@86-C97-S(&9E93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@86UO
M=6YT('!A>6%B;&4@;VYE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUI;&5S=&]N92!A;6]U;G0@<&%Y86)L92!T=V\\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EL97-T
M;VYE(&%M;W5N="!P87EA8FQE('1H<F5E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@;65A<W5R96UE;G0@
M<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XS,"!D87ES
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]B:6]T:6-S($5#0R!;365M8F5R72!\($EN=')E>&]N(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M
M;6ET;65N="!!;F0@0V]N=&EN9V5N8VEE<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PS
M-#@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUP86YY)W,@8V]M;6]N('-T;V-K('-H87)E<R!S;VQD/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<B!S
M:&%R97,@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1W)O<W,@<')O8V5E9',@9G)O;2!P<FEV871E('!L86-E;65N="!O9B!C
M;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')O8FEO=&EC<R!%0T,@6TUE;6)E<ET@?"!#;VYV97)T:6)L
M92!0<F]M:7-S;W)Y($YO=&4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT($%N9"!#;VYT:6YG
M96YC:65S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#YC;VYV97)T:6)L92!P<F]M:7-S;W)Y(&YO=&4@
M:7-S=65D('1O('!A>2!T96-H;F]L;V=Y(&%C8V5S<R!F964\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PY-38L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-871U<FET>2!D
M871E(&]F(&-O;G9E<G1I8FQE(&YO=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/D1E8R`S,2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?83@X.3)F,#%?-F(V-U\T,C@V7V$W-C-?
M8C=C93<Q-3@V-3$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$X
M.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q-B]7;W)K<VAE971S
M+U-H965T,CDN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5(6D%'/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G1S("T@061D:71I;VYA;"!);F9O<FUA
M=&EO;B`H1&5T86EL*2`H4W5B<V5Q=65N="!%=F5N="!;365M8F5R72D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`Q."P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q,B!%<75I
M='D@26YC96YT:79E(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VL@87=A<F1E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#(R+#,U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^07=A<F0@87!P<F]V960@8GD@=&AE(&)O
M87)D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPQ.#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!F=6QL>2!V97-T960@<VAA<F5S(&=R86YT960@87,@87=A<F0@
M=&\@;F]N+65M<&QO>65E(&1I<F5C=&]R/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1R+B!*;VAN($)O;F9I9VQI;R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M8G-E<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@<VAA<F4@
M9W)A;G1E9"!U;F1E<B!L;VYG('1E<FT@:6YC96YT:79E('!R;V=R86T\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N-3`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$<BX@2F]H;B!"
M;VYF:6=L:6\@6TUE;6)E<ET@?"`R,#$R($5Q=6ET>2!);F-E;G1I=F4@4&QA
M;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E-U8G-E<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:R!A=V%R9&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L
M.#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y2971A:6YE9"!B>2!T:&4@0V]M<&%N>2!F;W(@87!P;&EC86)L92!T
M87@@=VET:&AO;&1I;F<@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^36EC:&5L(%-U;&QI=F%N(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B
M<V5Q=65N="!%=F5N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!S:&%R92!G
M<F%N=&5D('5N9&5R(&QO;F<@=&5R;2!I;F-E;G1I=F4@<')O9W)A;3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XQ."4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI8VAE;"!3=6QL
M:79A;B!;365M8F5R72!\(#(P,3(@17%U:71Y($EN8V5N=&EV92!0;&%N(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W5B<V5Q=65N="!%=F5N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&%W
M87)D960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T+#,P-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5T86EN960@8GD@=&AE($-O;7!A;GD@9F]R(&%P<&QI8V%B;&4@=&%X('=I
M=&AH;VQD:6YG(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1R+B!-87)T:6X@2&%N9&9I96QD(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B
M<V5Q=65N="!%=F5N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!S:&%R92!G
M<F%N=&5D('5N9&5R(&QO;F<@=&5R;2!I;F-E;G1I=F4@<')O9W)A;3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XQ-R4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1R+B!-87)T:6X@
M2&%N9&9I96QD(%M-96UB97)=('P@,C`Q,B!%<75I='D@26YC96YT:79E(%!L
M86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=6)S97%U96YT($5V96YT(%M,:6YE($ET96US73PO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VL@87=A<F1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$L
M,C@W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y2971A:6YE9"!B>2!T:&4@0V]M<&%N>2!F;W(@87!P;&EC86)L92!T
M87@@=VET:&AO;&1I;F<@;V)L:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U+#(X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+2!E;7!L;WEE92!$:7)E8W1O<G,@
M6TUE;6)E<ET@?"`R,#$R($5Q=6ET>2!);F-E;G1I=F4@4&QA;B!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U
M8G-E<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!A=V%R9&5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C4L.3(U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@;F]N+65M<&QO>65E(&1I<F5C=&]R<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AE8W5T:79E($]F9FEC97)S(%M-96UB97)=
M('P@,C`Q,B!%<75I='D@26YC96YT:79E(%!L86X@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S97%U96YT
M($5V96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@87=A<F1E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4V+#0S-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83@X.3)F,#%?-F(V-U\T,C@V
M7V$W-C-?8C=C93<Q-3@V-3$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q-B]7;W)K
M<VAE971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C
M:&5M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN
M1FEL92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#(Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C,N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(T+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(W+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R."YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,CDN:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]
M7TYE>'1087)T7V$X.#DR9C`Q7S9B-C=?-#(X-E]A-S8S7V(W8V4W,34X-C4Q
%-BTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>61</ContextCount>
  <ElementCount>176</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/StatementOfIncome</Role>
      <ShortName>Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Organization</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock</Role>
      <ShortName>Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock</Role>
      <ShortName>Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Short-Term Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsShortTermDebtTextBlock</Role>
      <ShortName>Short-Term Notes Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Convertible Note Payable to Shareholder</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsLongTermDebtTextBlock</Role>
      <ShortName>Convertible Note Payable to Shareholder</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlockTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation</Role>
      <ShortName>Basis of Presentation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseRecognized</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Warrants - Summary of Warrant Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantActivity</Role>
      <ShortName>Warrants - Summary of Warrant Activity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation</Role>
      <ShortName>Warrants - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Warrants - Summary of Warrants Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureWarrantsSummaryOfWarrantsOutstanding</Role>
      <ShortName>Warrants - Summary of Warrants Outstanding (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Short-term Notes Payable - Additional Information (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureShorttermNotesPayableAdditionalInformation</Role>
      <ShortName>Short-term Notes Payable - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Convertible Note Payable to Shareholder - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureConvertibleNotePayableToShareholderAdditionalInformation</Role>
      <ShortName>Convertible Note Payable to Shareholder - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://oragenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 103 - Statement - Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - Statements of Cash Flows</Log>
    <Log type="Info">	Process Flow-Through: Removing column '12 Months Ended
Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 107 - Statement - Statements of Cash Flows (Parenthetical)</Log>
  </Logs>
  <InputFiles>
    <File>ogen-20130930.xml</File>
    <File>ogen-20130930.xsd</File>
    <File>ogen-20130930_cal.xml</File>
    <File>ogen-20130930_def.xml</File>
    <File>ogen-20130930_lab.xml</File>
    <File>ogen-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNoParValue', window );">Preferred stock, par value</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">20,000,000<span></span></td>
        <td class="nump">20,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">50,000,000<span></span></td>
        <td class="nump">50,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">30,168,613<span></span></td>
        <td class="nump">27,382,830<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">30,168,613<span></span></td>
        <td class="nump">27,382,830<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNoParValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockNoParValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><b>8.</b></td>
 <td valign="top" align="left"><b>Commitments and
 Contingencies</b></td>
 </tr>
 </table>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>The University of Florida Research Foundation Licenses</i></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company holds exclusive licenses from the University of Florida
 Research Foundation, Inc. (&#x201C;UFRF&#x201D;) for its SMaRT
 Replacement Therapy and MU1140 product candidates.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>MU1140 &#x2013;</i> The Company has exclusively licensed the
 intellectual property for our MU1140 lantibiotic technology from
 the UFRF. The original license agreement was dated June&#xA0;22,
 2000 and was subsequently amended on September&#xA0;15,
 2000,&#xA0;July&#xA0;10, 2002,&#xA0;September&#xA0;25,
 2002,&#xA0;March&#xA0;17, 2003 and April&#xA0;19, 2013. The amended
 license agreement provides the Company with an exclusive worldwide
 license to make, use and sell products and processes covered by
 Patent No.&#xA0;5,932,469 entitled &#x201C;Antimicrobial
 Polypeptide, Nucleic Acid and Methods of Use&#x201D; and includes
 U.S. patent numbers 6,964,760; 7,067,125; 6,391,285; 6,475,771 and
 foreign patents. The Company&#x2019;s license is for the period of
 the patents, which expire from 2017 through 2019, subject to the
 performance of terms and conditions contained therein.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>SMaRT Replacement Therapy &#x2013;</i> The Company has
 exclusively licensed the intellectual property for its replacement
 therapy technology from the UFRF. The original license agreement
 was dated August&#xA0;4, 1998 and was subsequently amended on
 September&#xA0;15, 2000,&#xA0;July&#xA0;10,
 2002,&#xA0;September&#xA0;25, 2002,&#xA0;March&#xA0;17, 2003 and
 April&#xA0;19, 2013. The amended license agreement provides the
 Company with an exclusive worldwide license to make, use and sell
 products and processes covered by Patent No.&#xA0;5,607,672,
 entitled &#x201C;Replacement Therapy for Dental Caries&#x201D;, which
 was filed in the U.S. PTO on June&#xA0;7, 1995 and made effective
 on March&#xA0;4, 1997. The patent will expire on June&#xA0;7, 2015.
 The Company&#x2019;s license is for the period of the patent,
 subject to the performance of terms and conditions contained
 therein.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>Additional Terms of UFRF License Agreements &#x2013;</i> In the
 amended license agreements for SMaRT Replacement Therapy and
 MU1140, the Company is obligated to pay 5% of the selling price of
 any products developed from the licensed technologies that the
 Company may sell as royalty to the UFRF. In addition, if the
 Company sublicenses any rights granted by the amended license
 agreements, the Company is obligated to pay the UFRF 22% of all
 revenues received from the sublicenses, excluding monies received
 solely for development costs. The Company is also obligated to make
 the following payments to UFRF as follows: a one-time
 commercialization fee, post-commercialization minimum royalty
 payments, and a one-time cumulative royalty payment. The one-time
 commercialization fee would be due on the first anniversary of
 first commercial sale and is calculated at $5,000 per month between
 May&#xA0;1, 2013 and the month of the first anniversary of a
 commercial sale. The post-commercialization minimum royalty
 payments of $50,000 annually would be due following payment of a
 commercialization fee. The one-time additional royalty payment
 would be due when total cumulative royalties paid to UFRF exceed
 $2.0 million, upon which we would be obligated to make a one-time
 additional payment to UFRF of 10% of the total royalties due to
 UFRF in the calendar year in which cumulative royalties exceeded
 $2.0 million.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company is required to make minimum annual maintenance payments
 to the UFRF for the term of the amended license agreements in the
 amount of $10,000 for each license agreement and $20,000 in
 aggregate. The aggregate minimum annual payments are required to be
 paid in advance on a quarterly basis (i.e. $5,000 per quarter) for
 both licenses. The Company must also pay all patent costs and
 expenses incurred by the UFRF for the preparation, filing,
 prosecution, issuance and maintenance of the patents.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>The Exclusive Channel Collaboration (&#x201C;ECC&#x201D;)
 Agreements with Intrexon Corporation
 (&#x201C;Intrexon&#x201D;)</i></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On September&#xA0;30, 2013, the Company entered into an ECC
 Agreement (the &#x201C;Probiotics ECC&#x201D;) with Intrexon that
 governs a &#x201C;channel collaboration&#x201D; arrangement in which
 the Company will use Intrexon&#x2019;s proprietary technology
 relating to the identification, design and production of
 genetically modified cells, DNA vectors and in vivo control of
 expression (the &#x201C;Technology&#x201D;) for the development and
 commercialization of probiotics, specifically the direct
 administration to humans of genetically modified probiotics for the
 treatment of diseases of the oral cavity, throat, sinus and
 esophagus, including, but not limited to, aphthous stomatitis and
 Behcet&#x2019;s disease (collectively, the &#x201C;Probiotics
 Program&#x201D;). The Probiotics ECC establishes committees
 comprised of Company and Intrexon representatives that will govern
 activities related to the Probiotics Program in the areas of
 project establishment, chemistry, manufacturing and controls
 matters, clinical and regulatory matters, commercialization efforts
 and intellectual property matters.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Probiotics ECC grants the Company an exclusive worldwide
 license to utilize Intrexon&#x2019;s Technology to develop and
 commercialize probiotics, specifically the direct administration to
 humans of genetically modified probiotics for the treatment of
 diseases of the oral cavity, throat, sinus and esophagus
 (&#x201C;Company Products&#x201D;). Such license is exclusive with
 respect to any clinical development, selling, offering for sale or
 other commercialization of Company Products, and otherwise is
 non-exclusive. Subject to limited exceptions, the Company may not
 sublicense the rights described without Intrexon&#x2019;s written
 consent.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Under the Probiotics ECC, and subject to certain exceptions, the
 Company is responsible for, among other things, funding the further
 anticipated development of probiotics toward the goal of
 commercialization, conducting preclinical and clinical development
 of candidate probiotics, as well as for other aspects of
 manufacturing and the commercialization of the product(s). Among
 other things, Intrexon is responsible for technology discovery
 efforts, cell-engineering development, and certain aspects of the
 manufacturing process.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company will pay Intrexon 10% of the net sales derived from the
 sale of products developed from the exclusive channel collaboration
 relating to the Probiotics Program. The Company has likewise agreed
 to pay Intrexon a percentage of revenue obtained from a sublicensee
 in the event of a sublicensing arrangement. The percentage of the
 revenue to be paid will be determined at the time that a sublicense
 agreement is negotiated.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company may voluntarily terminate the Probiotics ECC upon 90
 days written notice to Intrexon. Intrexon may also terminate the
 Probiotics ECC if the Company breaches the Probiotics ECC and fails
 to cure the breach within 60 days or the Company does not pursue
 development of the Superior Therapy under the probiotics identified
 by Intrexon that is a &#x201C;Superior Therapy&#x201D; as defined in
 the Probiotics ECC.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upon termination of the Probiotics ECC, the Company may continue to
 develop and commercialize any Company Product that, at the time of
 termination, satisfies at least one of the following criteria:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">commercialized by the Company;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">approved by regulatory
 authorities;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">a subject of an application for
 regulatory approval that is pending before the applicable
 regulatory authority; or</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">the subject of at least an ongoing
 Phase 1, Phase 2 or Phase 3 clinical trial in the field of the
 Probiotics Program.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In addition, in partial consideration for each party&#x2019;s
 execution and delivery of the Probiotics ECC, on September&#xA0;30,
 2013 the Company entered into a Stock Purchase and Issuance
 Agreement and a First Amendment to the Stock Purchase and Issuance
 Agreement (collectively the &#x201C;SPIA&#x201D;) with Intrexon.
 Pursuant to the SPIA, the Company paid Intrexon an up-front
 technology access fee of $6,000,000 (the &#x201C;Technology Access
 Fee&#x201D;) in consideration for the execution of the Probiotics
 ECC. The Technology Access Fee was paid to Intrexon by the Company
 through the (i)&#xA0;issuance of 1,348,000 shares (at $3.00 per
 share) of the Company&#x2019;s common stock (the &#x201C;Technology
 Access Shares&#x201D;), and (ii)&#xA0;a convertible promissory note
 in the amount of $1,956,000 which is payable, at the
 Company&#x2019;s option, in cash or shares of Company common stock
 (the &#x201C;Convertible Note&#x201D;). The Convertible Note matures
 on December&#xA0;31, 2013 and requires the Company to obtain
 shareholder approval prior to conversion of the Convertible Note.
 The conversion price is equal to the closing price per share of the
 Company&#x2019;s common stock on the last trading day immediately
 prior to the date of conversion.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On September&#xA0;30, 2013 the Company also sold to Intrexon
 1,300,000 shares of the Company&#x2019;s common stock at a price per
 share of $3.00 for gross proceeds of $3,900,000. The Company
 intends to use the proceeds from this sale of common stock towards
 development of the Company&#x2019;s key initiatives relating to the
 Probiotics Program, and general corporate purposes.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Under the SPIA and as part of the Probiotics ECC, the Company has
 also agreed to make certain payments to Intrexon upon the
 Company&#x2019;s achievement of designated milestones. The milestone
 payments are each payable to Intrexon, at the Company&#x2019;s
 election (subject to an election right of Intrexon if the milestone
 is achieved by a sublicensee), either in cash or in shares of
 Company common stock (using the fair market value of the shares to
 calculate the number of shares to be issued to Intrexon in lieu of
 cash). The Commercialization Milestone Events and amounts payable
 are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">$2,000,000 within thirty
 (30)&#xA0;days of the dosing of a patient by or on behalf of the
 Company, or an Affiliate (as that term is defined in the Probiotics
 ECC) or permitted sublicensee of the Company, in a phase II
 clinical trial, whether such occurs in the United States of America
 under the jurisdiction of the United States Food and Drug
 Administration (&#x201C;FDA&#x201D;) or elsewhere under the
 jurisdiction of a foreign regulatory agency, for a Company
 Product;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">$5,000,000 within thirty
 (30)&#xA0;days of the first meeting of the primary endpoint by or
 on behalf of the Company, or an Affiliate or permitted sublicensee
 of the Company, in a phase III clinical trial, whether such occurs
 in the United States of America under the jurisdiction of the FDA
 or elsewhere under the jurisdiction of a foreign regulatory agency,
 for a Company Product;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">$10,000,000 within thirty
 (30)&#xA0;days of the first to occur of (a)&#xA0;the First
 Commercial Sale (as that term is defined in the Probiotics ECC) of
 a Company Product, or (b)&#xA0;the approval of a New Drug
 Application (as that term is defined in the Probiotics ECC) for a
 Company Product by the FDA or equivalent regulatory action in a
 foreign jurisdiction.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 None of the Probiotic ECC milestones had been achieved as of
 September&#xA0;30, 2013.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On June&#xA0;5, 2012, the Company entered into an ECC Agreement
 (the &#x201C;Lantibiotic ECC&#x201D;) with Intrexon that governs a
 &#x201C;channel collaboration&#x201D; arrangement in which the
 Company will use Intrexon&#x2019;s advanced transgene and cell
 engineering platforms for the development and production of
 lantibiotics, a class of peptide antibiotics that are naturally
 produced in Gram-positive bacteria and contain the characteristic
 polycyclic thioether amino acids lanthionine and methyllanthonine
 (collectively, the &#x201C;Lantibiotics Program&#x201D;). The
 Lantibiotic ECC establishes committees comprised of Company and
 Intrexon representatives that will govern activities related to the
 Lantibiotics Program in the areas of project establishment,
 chemistry, manufacturing and controls matters, clinical and
 regulatory matters, commercialization efforts and intellectual
 property matters.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Lantibiotic ECC grants the Company an exclusive worldwide
 license to use patents and other intellectual property of Intrexon
 in connection with the research, development, use, importing,
 exporting, manufacture, sale, and offer for sale of drug products
 involving the direct administration to humans or companion animals
 of a lantibiotic for the prevention or treatment of infectious
 disease (&#x201C;Oragenics Products&#x201D;). Such license is
 exclusive with respect to any clinical development, selling,
 offering for sale or other commercialization of Oragenics Products,
 and otherwise is non-exclusive. Subject to limited exceptions, the
 Company may not sublicense the rights described without
 Intrexon&#x2019;s written consent.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Under the Lantibiotic ECC, and subject to certain exceptions, the
 Company is responsible for, among other things, funding the further
 anticipated development of lantibiotics toward the goal of
 commercialization, conducting preclinical and clinical development
 of candidate lantibiotics, as well as for other aspects of
 manufacturing and the commercialization of the product(s). Among
 other things, Intrexon is responsible for technology discovery
 efforts, cell-engineering development, certain aspects of the
 manufacturing process, and costs of filing, prosecution and
 maintenance of Intrexon&#x2019;s patents.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Subject to certain expense allocations and other offsets provided
 in the Lantibiotic ECC, the Company will pay Intrexon on a
 quarterly basis 25% of gross quarterly profits derived in that
 quarter from the sale of products developed from the Lantibiotic
 ECC, calculated on an Oragenics Product-by-Oragenics Product basis.
 The Company has likewise agreed to pay Intrexon on a quarterly
 basis 50% of revenue obtained in that quarter from a sublicensor in
 the event of a sublicensing arrangement.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During the first 18 months of the agreement, neither the Company
 nor Intrexon may terminate the ECC Agreement, except under limited
 circumstances, including in the event of a material breach by the
 other party and Intrexon may terminate the Lantibiotic ECC under
 certain circumstances if the Company assigns its rights under the
 Lantibiotic ECC without Intrexon&#x2019;s consent. Following the
 first 12 months of the agreement, Intrexon may also terminate the
 Lantibiotic ECC if the Company fails to use diligent efforts to
 develop and commercialize Oragenics Products or if the Company
 elects not to pursue the development of a Lantibiotics Program
 identified by Intrexon that is a &#x201C;Superior Therapy&#x201D; as
 defined in the Lantibiotic ECC. Following the first 18 months of
 the agreement, the Company may voluntarily terminate the
 Lantibiotic ECC at any time upon 90 days written notice to
 Intrexon.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upon termination of the Lantibiotic ECC, the Company may continue
 to develop and commercialize any Oragenics Product that has been,
 at the time of termination:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">commercialized by the Company;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">approved by regulatory
 authorities;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">a subject of an application for
 regulatory approval that is pending before the applicable
 regulatory authority; or</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">the subject of at least an ongoing
 Phase 1, Phase 2 or Phase 3 clinical trial in the Field (in the
 case of a termination by Intrexon due to an uncured material breach
 by the Company or a voluntary termination by the Company).</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s obligation to pay 25% of gross profits or
 revenue described above with respect to these
 &#x201C;retained&#x201D; products as well as to use diligent efforts
 to develop and commercialize these &#x201C;retained&#x201D; Oragenics
 Products will survive termination of the Lantibiotic ECC.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In addition, in partial consideration for each party&#x2019;s
 execution and delivery of the Lantibiotic ECC, the Company entered
 into a Stock Issuance Agreement with Intrexon. Pursuant to the
 Stock Issuance Agreement, the Company issued to Intrexon 4,392,425
 shares of the Company&#x2019;s common stock as an initial technology
 access fee, in consideration for the execution and delivery of the
 Lantibiotic ECC and granted Intrexon certain equity participation
 rights and registration rights.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Under the Stock Issuance Agreement and as part of the Lantibiotic
 ECC, the Company has also agreed to make certain payments to
 Intrexon upon the Company&#x2019;s achievement of designated
 milestones in the form of shares of Company common stock or, at the
 Company&#x2019;s option, make a cash payment to Intrexon (based upon
 the fair market value of the shares otherwise required to be
 issued). The milestone events and amounts payable are as
 follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="5%" align="left">(i)</td>
 <td valign="top" align="left">upon filing of the first
 Investigational New Drug application with the U.S. Food and Drug
 Administration for an Oragenics Product, that number of shares
 equal to the number of shares of common stock comprising 1.0% of
 the Base Shares (as defined below);</td>
 </tr>
 </table>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="5%" align="left">(ii)</td>
 <td valign="top" align="left">upon the dosing of the first patient
 in the first Phase 2 clinical study with an Oragenics Product, that
 number of shares equal to the number of shares of common stock
 comprising 1.5% of the Base Shares;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="5%" align="left">(iii)</td>
 <td valign="top" align="left">upon the dosing of the first patient
 in the first Phase 3 clinical study with an Oragenics Product, that
 number of shares equal to the number of shares of common stock
 comprising 2% of the Base Shares;</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="5%" align="left">(iv)</td>
 <td valign="top" align="left">upon the filing of the first New Drug
 Application (&#x201C;NDA&#x201D;) or Biologics License Application
 (&#x201C;BLA&#x201D;) with the U.S. Food and Drug Administration for
 an Oragenics Product, or alternatively the filing of the first
 equivalent regulatory filing with a foreign regulatory agency, that
 number of shares equal to the number of shares of Common Stock
 comprising 2.5% of the Base Shares; and</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="8%">&#xA0;</td>
 <td valign="top" width="5%" align="left">(v)</td>
 <td valign="top" align="left">upon the granting of the first
 regulatory approval of an Oragenics Product, that number of shares
 equal to the number of shares of Common Stock comprising 3% of the
 Base Shares.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Base Shares is defined in the Stock Issuance Agreement to mean
 (i)&#xA0;the number of shares of Company common stock together with
 any securities or instruments convertible or exercisable for shares
 of common stock issued and outstanding at the time of the
 applicable milestone event, (ii)&#xA0;minus any shares issuable
 upon conversion of Capital Inducement Securities. Capital
 Inducement Securities is defined in the Stock Issuance Agreement to
 mean warrants or other convertible securities of the Company issued
 to investors in connection with a debt or equity investment in the
 Company that are issued in addition to the primary investment
 securities and in an amount not to exceed 10% of the overall number
 of shares issued in the investment (on an as-converted to common
 stock basis).</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 None of the Lantibiotic ECC milestones had been achieved as of
 September&#xA0;30, 2013.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDABG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (12,989,419)<span></span></td>
        <td class="num">$ (11,101,620)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder', window );">Technology access fee paid in common stock and convertible note payable to shareholder</a></td>
        <td class="nump">6,000,000<span></span></td>
        <td class="nump">5,798,001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Accretion of discount on notes payable to shareholder</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">483,559<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">64,042<span></span></td>
        <td class="nump">55,793<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">1,624,165<span></span></td>
        <td class="nump">1,057,218<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write off of expired inventory</a></td>
        <td class="num">(240,005)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
        <td class="nump">10,917<span></span></td>
        <td class="nump">20,265<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
        <td class="nump">140,865<span></span></td>
        <td class="nump">195,643<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">151,861<span></span></td>
        <td class="nump">11,843<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="num">(280,353)<span></span></td>
        <td class="num">(104,556)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(27,278)<span></span></td>
        <td class="nump">112,879<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(5,545,205)<span></span></td>
        <td class="num">(3,470,975)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
        <td class="num">(17,649)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(17,649)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable', window );">Borrowings under note payable to shareholder</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Borrowings under convertible secured note payable to shareholder</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Payments on short-term notes payable</a></td>
        <td class="num">(96,788)<span></span></td>
        <td class="num">(99,514)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of income taxes associated with stock based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(127,291)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
        <td class="nump">3,939,800<span></span></td>
        <td class="nump">11,913,442<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities', window );">Restricted cash released</a></td>
        <td class="nump">61,763<span></span></td>
        <td class="nump">120,374<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">3,904,775<span></span></td>
        <td class="nump">15,057,011<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
        <td class="num">(1,658,079)<span></span></td>
        <td class="nump">11,586,036<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">9,925,967<span></span></td>
        <td class="nump">171,739<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">8,267,888<span></span></td>
        <td class="nump">11,757,775<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
        <td class="nump">3,108<span></span></td>
        <td class="nump">2,936<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Borrowings under short term notes payable for prepaid expense</a></td>
        <td class="nump">157,031<span></span></td>
        <td class="nump">134,914<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise', window );">Par value of common stock issued for cashless exercise of warrants</a></td>
        <td class="nump">106<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible note payable and accrued interest to common shares and warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,275,196<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_DiscountOnNotePayableToShareholderForWarrantsIssued', window );">Discount on note payable to shareholder for warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">483,559<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ParValueOfRestrictedStockForfeited', window );">Par value of forfeited stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Griffin Securities Inc. [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair market value of the 771,169 warrants issued to Griffin Securities, Inc. as a reduction in paid in capital from issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,850,806<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock issued during period par value for warrants exercise.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_CommonStockIssuedDuringPeriodParValueForWarrantsExercise</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_DiscountOnNotePayableToShareholderForWarrantsIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Discount on note payable to shareholder for warrants issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_DiscountOnNotePayableToShareholderForWarrantsIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ParValueOfRestrictedStockForfeited">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Par value of restricted stock forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ParValueOfRestrictedStockForfeited</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Technology access fee paid in common stock and convertible note payable to shareholder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_TechnologyAccessFeePaidInCommonStockAndConvertibleNotePayableToShareholder</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 470<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Warrant<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentAmount1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInInventories</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4542-108314<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryWriteDown</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of liabilities assumed in noncash investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAssumed1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromConvertibleDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from cash and cash items that are not available for withdrawal or usage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromRepaymentsOfRestrictedCashFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfShortTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 8,267,888<span></span></td>
        <td class="nump">$ 9,925,967<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">61,763<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables, net</a></td>
        <td class="nump">58,878<span></span></td>
        <td class="nump">69,795<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
        <td class="nump">223,318<span></span></td>
        <td class="nump">124,178<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">227,008<span></span></td>
        <td class="nump">221,838<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">8,777,092<span></span></td>
        <td class="nump">10,403,541<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">38,198<span></span></td>
        <td class="nump">84,591<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">8,815,290<span></span></td>
        <td class="nump">10,488,132<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">2,364,968<span></span></td>
        <td class="nump">1,157,520<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermNonBankLoansAndNotesPayable', window );">Short-term notes payable</a></td>
        <td class="nump">108,220<span></span></td>
        <td class="nump">47,977<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible note payable to shareholder</a></td>
        <td class="nump">1,956,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">23,711<span></span></td>
        <td class="nump">50,989<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">4,452,899<span></span></td>
        <td class="nump">1,256,486<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, no par value; 20,000,000 shares authorized; none issued and outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 50,000,000 shares authorized; 30,168,613 and 27,382,830 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively</a></td>
        <td class="nump">30,169<span></span></td>
        <td class="nump">27,383<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">71,408,003<span></span></td>
        <td class="nump">63,290,625<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(67,075,781)<span></span></td>
        <td class="num">(54,086,362)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
        <td class="nump">4,362,391<span></span></td>
        <td class="nump">9,231,646<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
        <td class="nump">$ 8,815,290<span></span></td>
        <td class="nump">$ 10,488,132<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermNonBankLoansAndNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount at the balance sheet date of borrowings from a creditor other than a bank, not elsewhere specified in the taxonomy, with a maturity within one year (or within one operating cycle if longer) from the date of borrowing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermNonBankLoansAndNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHZAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) (Subsequent Event [Member])<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Oct. 18, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2012 Equity Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock awarded</a></td>
        <td class="nump">422,359<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_StockIssuedToEachDirectorDuringPeriodSharesOther', window );">Award approved by the board</a></td>
        <td class="nump">33,185<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted', window );">Number of fully vested shares granted as award to non-employee director</a></td>
        <td class="nump">10,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Dr. John Bonfiglio [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram', window );">Percentage of share granted under long term incentive program</a></td>
        <td class="nump">0.50%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Dr. John Bonfiglio [Member] | 2012 Equity Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock awarded</a></td>
        <td class="nump">150,843<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Retained by the Company for applicable tax withholding obligations</a></td>
        <td class="nump">50,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Michel Sullivan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram', window );">Percentage of share granted under long term incentive program</a></td>
        <td class="nump">0.18%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Michel Sullivan [Member] | 2012 Equity Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock awarded</a></td>
        <td class="nump">54,304<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Retained by the Company for applicable tax withholding obligations</a></td>
        <td class="nump">19,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Dr. Martin Handfield [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram', window );">Percentage of share granted under long term incentive program</a></td>
        <td class="nump">0.17%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Dr. Martin Handfield [Member] | 2012 Equity Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock awarded</a></td>
        <td class="nump">51,287<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Retained by the Company for applicable tax withholding obligations</a></td>
        <td class="nump">15,287<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Non- employee Directors [Member] | 2012 Equity Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock awarded</a></td>
        <td class="nump">165,925<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors', window );">Number of non-employee directors</a></td>
        <td class="nump">5<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Executive Officers [Member] | 2012 Equity Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Common stock awarded</a></td>
        <td class="nump">256,434<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of common stock outstanding earned under long term incentive program.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PercentageOfCommonStockOutstandingEarnedUnderLongTermIncentiveProgram</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of share granted under long term incentive program.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_PercentageOfShareGrantedUnderLongTermIncentiveProgram</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options grants in period to number of directors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodToNumberOfDirectors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award to be granted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardToBeGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_StockIssuedToEachDirectorDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued to each director during period shares other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_StockIssuedToEachDirectorDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EICAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Warrants - Summary of Warrant Activity (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, Beginning balance</a></td>
        <td class="nump">3,235,982<span></span></td>
        <td class="nump">306,388<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantGrantedInPeriod', window );">Warrants, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,942,094<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantExercised', window );">Warrants, Exercised</a></td>
        <td class="num">(200,000)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantExpired', window );">Warrants, Expired</a></td>
        <td class="num">(288,888)<span></span></td>
        <td class="num">(12,500)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, Ending balance</a></td>
        <td class="nump">2,747,094<span></span></td>
        <td class="nump">3,235,982<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice', window );">Weighted Average Price, Beginning balance</a></td>
        <td class="nump">$ 3.53<span></span></td>
        <td class="nump">$ 19.14<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Price, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.87<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice', window );">Weighted Average Price, Exercised</a></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice', window );">Weighted Average Price, Expired</a></td>
        <td class="num">$ (19.87)<span></span></td>
        <td class="num">$ (6.00)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice', window );">Weighted Average Price, Ending balance</a></td>
        <td class="nump">$ 1.91<span></span></td>
        <td class="nump">$ 3.53<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ClassOfWarrantExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants exercised in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ClassOfWarrantExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of warrants exercised in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ClassOfWarrantExercisedWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ClassOfWarrantExpired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants expired in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ClassOfWarrantExpired</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of warrants expired in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ClassOfWarrantExpiredWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ClassOfWarrantGrantedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants granted in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ClassOfWarrantGrantedInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of warrants granted in period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ClassOfWarrantGrantedInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average exercise price of warrants outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ClassOfWarrantOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Note Payable to Shareholder<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Convertible Note Payable to Shareholder</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><b>7.</b></td>
 <td valign="top" align="left"><b>Convertible Note Payable To
 Shareholder</b></td>
 </tr>
 </table>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On September 30, 2013, the Company entered into an unsecured
 short-term Convertible Promissory Note in the principal amount of
 $1,956,000 bearing interest at 3.00% as partial consideration for
 the Technology Access Fees associated with the Probiotic ECC
 (discussed below) entered into with Intrexon Corporation. The
 Convertible Promissory Note is payable, at the Company&#x2019;s
 option, in cash or shares of the Company&#x2019;s common stock.
 Principal and accrued interest are due on December 31, 2013.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LongTermDebtTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Recently Issued Accounting Pronouncements</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 There are no new accounting pronouncements issued or effective
 during the second quarter of 2013 that have had or are expected to
 have an impact on the Company&#x2019;s financial statements.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Use of Estimates</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The preparation of financial statements in conformity with GAAP
 requires management to make estimates and assumptions that affect
 the reported amounts of assets and liabilities and disclosure of
 contingent assets and liabilities at the date of the financial
 statements, as well as the reported amounts of revenues and
 expenses during the reporting period. Actual results could differ
 from those estimates. The principal areas of estimation reflected
 in the financial statements are stock-based compensation, valuation
 of warrants, inventory obsolescence reserve, sales returns and
 allowances and the allowance for doubtful accounts.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Fair Value of Financial Instruments</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The fair value of the Company&#x2019;s cash and cash equivalents,
 accounts payable and accrued expenses approximate their carrying
 values due to their short-term nature.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDeferredRevenue', window );">Guaranteed Rights of Return</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Guaranteed Rights of Return</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has granted guaranteed rights of return to two dental
 distributors. The Company defers recognition of revenue on these
 accounts until either the distributor provides notification to the
 Company that the product has been sold to the end consumer or the
 guaranteed right of return period expires. Once notification has
 been received and verified, the Company records revenue in that
 accounting period. The Company had $23,711 and $27,812 of revenue
 deferred under guaranteed rights of return arrangements included in
 deferred revenue in the balance sheets as of September&#xA0;30,
 2013 and December&#xA0;31, 2012, respectively.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Inventory</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Inventory is stated at the lower of cost or market. Cost, which
 includes material, labor and overhead, is determined on a first-in,
 first-out basis. On a quarterly basis, we analyze our inventory
 levels and reserve for inventory that is expected to expire prior
 to being sold, inventory that has a cost basis in excess of its
 expected net realizable value, inventory in excess of expected
 sales requirements, or inventory that fails to meet commercial sale
 specifications. Expired inventory is disposed of and the related
 costs are written off to the reserve for inventory obsolescence.
 The inventory reserve was approximately $22,000 and $253,000 as of
 September&#xA0;30, 2013 and December&#xA0;31, 2012,
 respectively.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Payment Arrangements</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Stock-Based Payment Arrangements</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Generally, all forms of stock-based payments, including stock
 option grants, warrants, and restricted stock grants are measured
 at their fair value on the awards&#x2019; grant date typically using
 a Black-Scholes pricing model. Stock-based compensation awards
 issued to non-employees for services rendered are recorded at the
 fair value of the stock-based payment. The expense resulting from
 stock-based payments are recorded in research and development
 expense or selling, general and administrative expense in the
 statement of operations, depending on the nature of the services
 provided. Stock-based payment expense is recorded over the
 requisite service period in which the grantee provides services to
 us. To the extent the stock option grants, warrants, or restricted
 stock grants do not vest at the grant date they are subject to
 forfeiture.</p>


 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Stock-Based Compensation</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 GAAP requires all share-based payments to employees, including
 grants of employee stock options, to be recognized in the financial
 statements based on their fair values as of the grant date.
 Stock-based compensation expense is recorded over the requisite
 service period in which the grantee provides services to us, to the
 extent the options do not vest at the grant date and are subject to
 forfeiture. For performance-based awards that do not include
 market-based conditions, we record share-based compensation expense
 only when the performance-based milestone is deemed probable of
 achievement. We utilize both quantitative and qualitative criteria
 to judge whether milestones are probable of achievement. For awards
 with market-based performance conditions, we recognize the
 grant-date fair value of the award over the derived service period
 regardless of whether the underlying performance condition is
 met.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_WarrantPolicyTextBlock', window );">Warrants</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Warrants</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company used the Black Scholes Option Pricing Model in
 calculating the relative fair value of any warrants that have been
 issued.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Net Loss Per Share</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During all periods presented, the Company had securities
 outstanding that could potentially dilute basic earnings per share
 in the future, but were excluded from the computation of diluted
 net loss per share, as their effect would have been antidilutive.
 Because the Company reported a net loss for all periods presented,
 shares associated with the stock options and warrants are not
 included because they are antidilutive. Basic and diluted net loss
 per share amounts are the same for the periods presented. Net loss
 per share is computed using the weighted average number of shares
 of common stock outstanding.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Revenue Recognition</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognizes revenues from the sales of product when
 title and risk of loss pass to the customer, which is generally
 when the product is shipped. Grant revenues are recognized as the
 reimbursable expenses are incurred over the life of the related
 grant. Grant revenues are deferred when reimbursable expenses have
 not been incurred.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company records allowances for discounts and product returns at
 the time of sale as a reduction of revenues as such allowances can
 be reliably estimated based on historical experience or known
 trends. The Company maintains a return policy that allows customers
 to return product within a specified period of time prior to and
 subsequent to the expiration date of the product. The estimate of
 the provision for returns is analyzed quarterly and is based upon
 many factors, including industry data of product return rates,
 historical experience of actual returns, analysis of the level of
 inventory in the distribution channel, if any, and reorder rates.
 If the history or product returns changes, the reserve will be
 adjusted. While the Company believes that the reserves it has
 established are reasonable and appropriate based upon current facts
 and circumstances, applying different judgments to the same facts
 and circumstances would result in the estimated amounts for sales
 returns and chargebacks to vary. Because the ProBiora3 products are
 still relatively new to the market, the Company could experience
 different circumstances in the future and these differences could
 be material.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Concentrations</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company is dependent on key suppliers to provide probiotics,
 blending, warehousing and packaging of its EvoraPlus, EvoraKids,
 EvoraPro, and Teddy&#x2019;s Pride products. The Company had four
 key suppliers during the three and nine months ended
 September&#xA0;30, 2013 and 2012. The majority of the
 Company&#x2019;s cost of sales are from these key suppliers during
 the three and nine months ended September&#xA0;30, 2013 and 2012.
 Accounts payable and accrued expenses for these vendors totaled
 approximately $-0- and $99,000 as of September&#xA0;30, 2013 and
 December&#xA0;31, 2012, respectively. As of September&#xA0;30,
 2013, the Company had a prepaid balance of approximately $27,000
 with one of these vendors.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_WarrantPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_WarrantPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2126999<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197196<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2228939<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Short-Term Notes Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">Short-Term Notes Payable</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p><!-- xbrl,n --></p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><b>6.</b></td>
 <td valign="top" align="left"><b>Short-term Notes Payable</b></td>
 </tr>
 </table>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 As of September&#xA0;30, 2013 and December&#xA0;31, 2012, the
 Company had $108,220 and $47,977 respectively, in short-term notes
 payable for the financing of various insurance policies. On
 March&#xA0;8, 2013, the Company entered into a short-term note
 payable for $50,037 bearing interest at 6.57% to finance the
 product liability insurance. Principal and interest payments on
 this note began April&#xA0;10, 2013 and are made evenly based on a
 straight line amortization over a 10-month period with the final
 payment due on January&#xA0;10, 2014. On June&#xA0;20, 2013, we
 entered into a short-term note payable for $106,994 bearing
 interest at 4.64% to finance a portion of the directors&#x2019; and
 officers&#x2019; liability insurance and employment practices
 liability insurance premiums. Principal and interest payments on
 this note began August&#xA0;24, 2013 and are made evenly based on a
 straight line amortization over an 11-month period with the final
 payment due on June&#xA0;24, 2014.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for short-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 13<br><br> -Article 9<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShortTermDebtTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr>
 <td width="4%" valign="top" align="left"><b>1.</b></td>
 <td align="left" valign="top"><b>Organization</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Oragenics, Inc. (formerly known as Oragen, Inc.) (the
 &#x201C;Company&#x201D; or &#x201C;we&#x201D;) was incorporated in
 November 1996; however, operating activity did not commence until
 1999. The Company is focused on the discovery, development and
 commercialization of a variety of technologies associated with
 broad spectrum antibiotics, oral health, and other general health
 benefits.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues generated by company</a></td>
        <td class="nump">$ 253,374<span></span></td>
        <td class="nump">$ 264,248<span></span></td>
        <td class="nump">$ 597,449<span></span></td>
        <td class="nump">$ 901,182<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(9,325,424)<span></span></td>
        <td class="num">(2,555,941)<span></span></td>
        <td class="num">(12,989,419)<span></span></td>
        <td class="num">(11,101,620)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(5,545,205)<span></span></td>
        <td class="num">(3,470,975)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(67,075,781)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(67,075,781)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(54,086,362)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from private placement of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,939,800<span></span></td>
        <td class="nump">$ 11,913,442<span></span></td>
        <td class="nump">$ 13,000,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td valign="top" width="4%" align="left"><b>9.</b></td>
 <td valign="top" align="left"><b>Subsequent Events</b></td>
 </tr>
 </table>
 <!-- xbrl,body -->
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On October&#xA0;18, 2013, the Compensation Committee of the Board
 of Directors (the &#x201C;Board&#x201D;) of the Company met and
 determined that one of the performance goals established in the
 Company&#x2019;s Long Term Incentive Programs (&#x201C;LTIP&#x201D;)
 as part of executive compensation and non-employee director
 compensation had been achieved. The performance goal met was the
 goal related to the broadening of the Intrexon relationship to
 include a new area outside of lantibiotics. As a result of the
 Compensation Committee&#x2019;s determination, and pursuant to the
 LTIP, Dr.&#xA0;John Bonfiglio, the Company&#x2019;s Chief Executive
 Officer, Michael Sullivan, the Company&#x2019;s Chief Financial
 Officer, and Dr.&#xA0;Martin Handfield, the Company&#x2019;s Vice
 President of Research and Development, were entitled to awards of
 0.50%, 0.18%, and 0.17% respectively of the Company&#x2019;s common
 stock outstanding at the time of the Compensation Committee&#x2019;s
 determination that such goal had been met. Accordingly,
 Dr.&#xA0;Bonfiglio, Mr.&#xA0;Sullivan, and Dr.&#xA0;Handfield were
 awarded 150,843, 54,304 and 51,287 shares of Company common stock
 under the Company&#x2019;s 2012 Equity Incentive Plan (the
 &#x201C;2012 Plan&#x201D;), respectively. Also on October&#xA0;18,
 2013 the Board met and determined that a similar performance goal
 under the previously established Long Term Incentive Program for
 the compensation of non-employee directors had been met. As a
 result, the Board approved the award of 33,185 shares of common
 stock under the Plan, to each of the Company&#x2019;s directors who
 were not employed by the Company, including Frederick Telling,
 Charles Pope, Alan Dunton, Christine Koski and Robert Koski. In
 addition, the Board determined to amend its non-employee director
 compensation program. In connection with each annual meeting of
 shareholders commencing with the 2013 Annual Meeting, each
 continuing non-employee director will be granted an award of 10,000
 fully vested shares of the Company&#x2019;s common stock under the
 Company&#x2019;s 2012 Plan.</p>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The aggregate shares awarded under the 2012 Plan of 422,359
 consisted of a total of 165,925 shares to non-employee directors
 and 256,434 shares to executive officers. Of the aggregate 422,359
 shares awarded under the LTIP, (i)&#xA0;150,843 shares were awarded
 to Dr.&#xA0;Bonfiglio of which 50,000 shares were retained by the
 Company for applicable tax withholding obligations,
 (ii)&#xA0;54,304 shares were awarded to Mr.&#xA0;Sullivan of which
 19,000 shares were retained by the Company for applicable tax
 withholding obligation, (iii)&#xA0;51,287 shares were awarded to
 Dr.&#xA0;Handfield of which 15,287 shares were retained by the
 Company for applicable tax withholding obligation, and
 (iv)&#xA0;33,185 shares were awarded to each of the five
 non-employee directors.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3XAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">35,000<span></span></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value</a></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 3.41<span></span></td>
        <td class="nump">$ 1.03<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock options vested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,533<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock options forfeited</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">56,050<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,533<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">2012 Equity Incentive Plan [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ExpensesRelatedToStockAwards', window );">Liability and expense related to equity incentive plan</a></td>
        <td class="nump">$ 1,487,801<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded', window );">Grant date fair value, shares expected to be awarded</a></td>
        <td class="nump">422,359<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ExpensesRelatedToStockAwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenses related to stock awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ExpensesRelatedToStockAwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share-based compensation arrangement by share based payment award shares expected to be awarded.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesExpectedToBeAwarded</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ECRAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Supplier

</div>
          <div>Vendor</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Supplier</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Supplier

</div>
          <div>Customer

</div>
          <div>Vendor</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Supplier</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns', window );">Number of dental distributor with guaranteed rights of returns</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory reserve FIFO</a></td>
        <td class="nump">$ 22,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 22,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 253,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_NumberOfKeySuppliers', window );">Number of key suppliers</a></td>
        <td class="nump">4<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">2,364,968<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,364,968<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,157,520<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid balance of vendors</a></td>
        <td class="nump">227,008<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">227,008<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">221,838<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_NumberOfVendorsWithPrepaidBalanceOfCompany', window );">Number of vendors with prepaid balance</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Guaranteed Rights of Return [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Revenue deferred under guaranteed rights of return arrangements</a></td>
        <td class="nump">23,711<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">23,711<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">27,812<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Supplier Concentration Risk [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">99,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid balance of vendors</a></td>
        <td class="nump">$ 27,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 27,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of dental distributor with guaranteed rights of returns.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_NumberOfDentalDistributorWithGuaranteedRightsOfReturns</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_NumberOfKeySuppliers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of key suppliers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_NumberOfKeySuppliers</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_NumberOfVendorsWithPrepaidBalanceOfCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of vendors with prepaid balance of company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_NumberOfVendorsWithPrepaidBalanceOfCompany</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of valuation reserve for inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SX 210.12-09)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.BB)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 09<br><br> -Article 12<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InventoryValuationReserves</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 25, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ogen_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ORAGENICS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001174940<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,506,685<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ogen_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>ogen_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>ogen_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total Stock based compensation</a></td>
        <td class="nump">$ 1,538,343<span></span></td>
        <td class="nump">$ 799,391<span></span></td>
        <td class="nump">$ 1,624,165<span></span></td>
        <td class="nump">$ 1,057,218<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total Stock based compensation</a></td>
        <td class="nump">183,168<span></span></td>
        <td class="nump">105,858<span></span></td>
        <td class="nump">158,575<span></span></td>
        <td class="nump">116,726<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Selling, General and Administrative Expenses [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total Stock based compensation</a></td>
        <td class="nump">$ 1,355,175<span></span></td>
        <td class="nump">$ 693,533<span></span></td>
        <td class="nump">$ 1,465,590<span></span></td>
        <td class="nump">$ 940,492<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
